PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Booth, V; Koth, CM; Edwards, AM; Arrowsmith, CH				Booth, V; Koth, CM; Edwards, AM; Arrowsmith, CH			Structure of a conserved domain common to the transcription factors TFIIS, elongin A, and CRSP70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR TFIIS; RNA-POLYMERASE-II; CORRELATION SPECTROSCOPY; NMR-SPECTROSCOPY; PROTEINS; SPECTRA; SENSITIVITY; RESTRAINTS; ALIGNMENT; HOMOLOGY	TFIIS is a transcription elongation factor that consists of three domains. We have previously solved the structures of domains II and III, which stimulate arrested polymerase II elongation complexes in order to resume transcription. Domain I is conserved in evolution from yeast to human species and is homologous to the transcription factors elongin A and CRSP70. Domain I also interacts with the transcriptionally active RNA polymerase II holoenzyme and therefore, may have a function, unrelated to the previously described transcription elongation activity of TFIIS. We have solved the structure of domain I of yeast TFIIS using NMR spectroscopy. Domain I is a compact four-helix bundle that is structurally independent of domains II and III of the TFIIS. Using the yeast structure as a template, we have modeled the homologous domains from elongin A and CRSP70 and identified a conserved positively charged patch on the surface of all three proteins, which may be involved in conserved functional interactions with the transcriptional machinery.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250; Koth, Christopher/0000-0003-3939-8856				Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gronenborn AM, 1996, PROTEIN SCI, V5, P174; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P133; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labhart P, 1998, GENOMICS, V52, P278, DOI 10.1006/geno.1998.5449; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; PASCAL S, 1994, J MAGN RESON, V101, P197; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; REINES D, 1994, RAV S MOL C, V3, P263; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437	31	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31266	31268		10.1074/jbc.M002595200	http://dx.doi.org/10.1074/jbc.M002595200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10811649	hybrid			2022-12-25	WOS:000089762700073
J	Greene, AL; Lalli, MJ; Ji, Y; Babu, GJ; Grupp, I; Sussman, M; Periasamy, M				Greene, AL; Lalli, MJ; Ji, Y; Babu, GJ; Grupp, I; Sussman, M; Periasamy, M			Overexpression of SERCA2b in the heart leads to an increase in sarcoplasmic reticulum calcium transport function and increased cardiac contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT; MOUSE HEARTS; CA2+-ATPASE; ATPASE; GENE; ISOFORMS; BRAIN; PUMPS; CELLS; PHOSPHOLAMBAN	The sarcoplasmic reticulum calcium ATPase SERCA2b is an alternate isoform encoded by the SERCA2 gene. SERCA2b is expressed ubiquitously and has a higher Ca2+ affinity compared with SERCA2 a. We made transgenic mice that overexpress the rat SERCA2b cDNA in the heart. SERCA2b mRNA level was approximately similar to 20-fold higher than endogenous SERCA2b mRNA in transgenic hearts. SERCA2b protein was increased 8-10-fold in the heart, whereas SERCA2a mRNA/protein level remained unchanged. Confocal microscopy showed that SERCA2b is localized preferentially around the T-tubules of the SR, whereas SERCA2a isoform is distributed both transversely and longitudinally in the SR membrane. Calcium-dependent calcium uptake measurements showed that the maximal velocity of Ca2+ uptake was not changed, but the apparent pump affinity for Ca2+ (K-0.5) was increased in SERCA2b transgenic mice (0.199 +/- 0.011 mu M) compared with wild-type control mice (0.269 +/- 0.012 mu M, p < 0.01). Work-performing heart preparations showed that SERCA2b transgenic hearts had a higher rates of contraction and relaxation, shorter time to peak pressure and half-time for relaxation than wild-type hearts. These data show that SERCA2b is associated in a subcompartment within the sarcoplasmic reticulum of cardiac myocytes. Overexpression of SERCA2b leads to an increase in SR calcium transport function and increased cardiac contractility, suggesting that SERCA2b plays a highly specialized role in regulating the beat-to-beat contraction of the heart.	Univ Cincinnati, Coll Med, Dept Internal Med, Mol Cardiol Lab, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Periasamy, M (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Mol Cardiol Lab, 231 Bethesda Ave,ML 0542, Cincinnati, OH 45267 USA.		Babu, Gopal/AAB-7787-2021; Sussman, Mark/H-2284-2014	Babu, Gopal/0000-0001-7833-5300; Sussman, Mark/0000-0002-0104-4799; Periasamy, Muthu/0000-0001-8834-5975				Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Cambon Natalie, 1997, Methods in Cell Science, V19, P83, DOI 10.1023/A:1009738012742; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Inesi G, 1998, AM J PHYSIOL-CELL PH, V274, pC645, DOI 10.1152/ajpcell.1998.274.3.C645; Ji Y, 1999, AM J PHYSIOL-HEART C, V276, pH89, DOI 10.1152/ajpheart.1999.276.1.H89; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Loukianov E, 1998, CIRC RES, V83, P889; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; STEWART PS, 1976, J BIOL CHEM, V251, P712; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	29	55	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24722	24727		10.1074/jbc.M001783200	http://dx.doi.org/10.1074/jbc.M001783200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816568	hybrid			2022-12-25	WOS:000088683300067
J	Shi, CS; Sinnarajah, S; Cho, H; Kozasa, T; Kehrl, JH				Shi, CS; Sinnarajah, S; Cho, H; Kozasa, T; Kehrl, JH			G(13)alpha-mediated PYK2 activation - PYK2 is a mediator of G(13)alpha-induced serum response element-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TYROSINE KINASE PYK2; TERNARY COMPLEX FACTORS; N-TERMINAL KINASE; NEURITE RETRACTION; LYSOPHOSPHATIDIC ACID; ANGIOTENSIN-II; P115 RHOGEF; G-ALPHA(12); PATHWAYS	G(12)alpha/G(13)alpha transduces signals from G-protein-coupled receptors to stimulate growth-promoting pathways and the early response gene c-fos, Within the c-fos promoter lies a key regulatory site, the serum response element (SRE). Here we show a critical role for the tyrosine kinase PYK2 in muscarinic receptor type 1 and G12 alpha/G(13)alpha signaling to an SRE reporter gene. A kinase-inactivate form of PYK2 (PYR2 KD) inhibits muscarinic receptor type 1 signaling to the SRE and PYK2 itself triggers SRE reporter gene activation through a RhoA-dependent pathway. Placing PYK2 downstseam of G-protein activation but upstream of RhoA, the expression of PYK2 KD blocks the activation of an SRE reporter gene by GTPase-deficient forms of G(12)alpha or G(13)alpha but not by RhoA The GTPase-deficient form of G(13)alpha triggers PYK2 kinase activity and PYK2 tyrosine phosphorylation, and co-expression of the RGS domain of p115 Rho-GEF inhibits both responses. Finally, we show that in vivo G(13)alpha, although not G(12)alpha, readily associates with PYK2. Thus, G-protein-coupled receptors via G(13)alpha activation can use PYR2 to link to SRE-dependent gene expression.	NIAID, Cell Mol Immunol Sect B, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kehrl, JH (corresponding author), NIAID, Cell Mol Immunol Sect B, Immunoregulat Lab, NIH, Bldg 10,Rm 11B08,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.		Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739, ZIAAI000739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berts A, 1999, MOL PHARMACOL, V55, P296, DOI 10.1124/mol.55.2.296; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LEFFERS H, 1993, EXP CELL RES, V209, P165, DOI 10.1006/excr.1993.1298; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACHIDE M, 1995, ONCOGENE, V11, P619; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	34	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24470	24476		10.1074/jbc.M908449199	http://dx.doi.org/10.1074/jbc.M908449199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821841	hybrid			2022-12-25	WOS:000088683300032
J	Naccache, PH; Levasseur, S; Lachance, G; Chakravarti, S; Bourgoin, SG; McColl, SR				Naccache, PH; Levasseur, S; Lachance, G; Chakravarti, S; Bourgoin, SG; McColl, SR			Stimulation of human neutrophils by chemotactic factors is associated with the activation of phosphatidylinositol 3-kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-DERIVED CELLS; HUMAN INTERLEUKIN-8 RECEPTOR; PEPTIDE-INDUCED ACTIVATION; G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; WORTMANNIN; INHIBITION	The activation of human polymorphonuclear neutrophil leukocytes (neutrophils) is associated with an increased synthesis of the highly phosphorylated phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3). The aims of the present investigation were to determine whether the newly described, G protein-dependent phosphatidylinositol 3-kinase (PI3K), p110 gamma, was involved in the responses to chemotactic factors interacting with G protein-coupled receptors. The presence of p110 gamma in neutrophils was first established both at the protein and the mRNA level. Stimulation of the cells with fMet-Leu-Phe or interleukin-8 increased the PI3K activity in p110 gamma, but not p85, immunoprecipitates. The time course of this effect (threshold within less than 5 s, maximal activation at 10-15 s) was consistent with that of the generation of PtdIns(3,4,5)P-3. Wortmannin, a PI3K inhibitor, abrogated the effects of Met-Leu-Phe, which were also significantly inhibited by pertussis toxin. Finally, fMet-Leu-Phe also induced a significant translocation of p110 gamma to a particulate fraction derived from these cells. These data indicate that p110 gamma represent the major PI3K activated by fMet-Leu-Phe and interleukin-8 at very early time points following the stimulation of human neutrophils.	Univ Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Physiol & Med, Quebec City, PQ G1V 4G2, Canada; Univ Adelaide, Dept Microbiol & Immunol, Adelaide, SA 5005, Australia	Laval University; Laval University; University of Adelaide	Naccache, PH (corresponding author), CHUQ, CHUL, Ctr Rech Rhumatol & Immunol, Rm T 1-49,2705 Blvd, Quebec City, PQ G1V 4G2, Canada.	paul.naccache@crchul.ulaval.ca		Bourgoin, Sylvain/0000-0001-9779-0368				Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; Bernstein HG, 1998, CELL MOL BIOL, V44, P973; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; Capodici C, 1998, J IMMUNOL, V160, P1901; Coffer PJ, 1998, BIOCHEM J, V329, P121; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; EBERLE M, 1990, J BIOL CHEM, V265, P16725; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; Hanna AN, 1999, J BIOL CHEM, V274, P12722, DOI 10.1074/jbc.274.18.12722; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kodama T, 1999, BIOCHEM J, V337, P201, DOI 10.1042/0264-6021:3370201; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; NACCACHE PH, 1993, LAB INVEST, V69, P19; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; OKADA T, 1994, J BIOL CHEM, V269, P3563; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; Pellegatta F, 1998, J BIOL CHEM, V273, P27768, DOI 10.1074/jbc.273.43.27768; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; ROLLET E, 1994, J IMMUNOL, V153, P353; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sotsios Y, 1999, J IMMUNOL, V163, P5954; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; Stephens L, 1996, PHILOS T R SOC B, V351, P211, DOI 10.1098/rstb.1996.0018; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tessier PA, 1997, J IMMUNOL, V159, P3595; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YUSOFF P, 1994, GROWTH FACTORS, V10, P181, DOI 10.3109/08977199409000236	54	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23636	23641		10.1074/jbc.M001780200	http://dx.doi.org/10.1074/jbc.M001780200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816567	hybrid			2022-12-25	WOS:000088564200033
J	Mitchell-Felton, H; Hunter, RB; Stevenson, EJ; Kandarian, SC				Mitchell-Felton, H; Hunter, RB; Stevenson, EJ; Kandarian, SC			Identification of weight-bearing-responsive elements in the skeletal muscle sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RESPONSE; CALCIUM-PUMP GENE; G-RICH-BOX; SARCOPLASMIC-RETICULUM; MESSENGER-RNA; CA-2+-ATPASE GENE; MOLECULAR-CLONING; CA2+-ATPASE GENE; REGULATORY ELEMENTS; MULTIPLE ELEMENTS	skeletal muscle sarco(endo)plasmic reticulum calcium ATPase (SERCA1) gene is transactivated as early as 2 days after the removal of weight-bearing (Peters, D. G., Mitchell-Felton, H., and Kandarian, S. C. (1999) Am. J. Physiol, 276, C1218-C1225), but the transcriptional mechanisms are elusive. Here, the rat SERCA1 5' flank and promoter region (-3636 to +172 base pairs) was comprehensively examined using in vivo somatic gene transfer into rat soleus muscles (n = 804) to identify region(s) that are both necessary and sufficient for sensitivity to weight-bearing. In all, 40 different SERCA1 reporter plasmids were constructed and tested. Several different regions of the SERCA1 5' flank were sufficient to confer a transcriptional response to 7 days of muscle unloading when placed upstream of a heterologous promoter, Two of these regions were analyzed further because they were necessary for the unloading response of -3636 to +172, as demonstrated using internal deletion constructs. Deletion analysis of these regions (-1373 to -1158 and -330 to +172) suggested that unloading responsiveness corresponded to CACC sites and E-boxes, Mutagenesis of cis-elements in the first region showed that a specific CACC box (-1262) was involved in SERCA1 transactivation and a nearby E-box (-1248) was also implicated. Constructs containing trimerized CACC sites and E-boxes showed that the presence of both elements is required to activate transcription. This is the first identification of specific cis-elements required for the regulation of a Ca2+ handling gene by changes in muscle loading condition.	Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA	Boston University	Kandarian, SC (corresponding author), Boston Univ, Dept Hlth Sci, 635 Commonwealth Ave,4th Floor, Boston, MA 02215 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041705, R29AR041705] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41705] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BASSANI JWM, 1994, CIRC RES, V74, P991, DOI 10.1161/01.RES.74.5.991; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; Cadre BM, 1998, J MOL CELL CARDIOL, V30, P2247, DOI 10.1006/jmcc.1998.0788; Calvo S, 1999, MOL CELL BIOL, V19, P515; CHULTE LM, 1993, AM J PHYSIOL, V264, pC1308; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; FEO S, 1995, MOL CELL BIOL, V15, P5991; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARTONG R, 1994, J BIOL CHEM, V269, P13021; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; Hu P, 1998, BBA-GENE STRUCT EXPR, V1395, P121, DOI 10.1016/S0167-4781(97)00135-8; KANDARIAN S, 1992, J APPL PHYSIOL, V72, P2510, DOI 10.1152/jappl.1992.72.6.2510; KANDARIAN SC, 1994, AM J PHYSIOL, V266, pC1190, DOI 10.1152/ajpcell.1994.266.5.C1190; Kandarian SC, 1996, AM J PHYSIOL-CELL PH, V270, pC1588, DOI 10.1152/ajpcell.1996.270.6.C1588; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kataoka H, 2000, NUCLEIC ACIDS RES, V28, P626, DOI 10.1093/nar/28.2.626; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SAYEN MR, 1992, MOL CELL ENDOCRINOL, V87, P87, DOI 10.1016/0303-7207(92)90236-Y; SIMONIDES WS, 1990, FEBS LETT, V274, P73, DOI 10.1016/0014-5793(90)81332-I; Simonides WS, 1996, J BIOL CHEM, V271, P32048, DOI 10.1074/jbc.271.50.32048; Thelen MHM, 1998, BIOCHEM J, V329, P131; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; Wheeler MT, 1999, AM J PHYSIOL-CELL PH, V276, pC1069, DOI 10.1152/ajpcell.1999.276.5.C1069; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZARAINHERZBERG A, 1994, J BIOL CHEM, V269, P1460	53	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23005	23011		10.1074/jbc.M003678200	http://dx.doi.org/10.1074/jbc.M003678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811813	hybrid			2022-12-25	WOS:000088419400055
J	Schwamborn, K; Weil, R; Courtois, G; Whiteside, ST; Israel, A				Schwamborn, K; Weil, R; Courtois, G; Whiteside, ST; Israel, A			Phorbol esters and cytokines regulate the expression of the NEMO-related protein, a molecule involved in a NF-kappa B-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE COMPLEX; ALPHA PROTEOLYSIS; IKK COMPLEX; ACTIVATION; PHOSPHORYLATION; DEGRADATION; SIGNAL; BETA; IDENTIFICATION; INHIBITOR	The NF-kappa B signaling pathway plays a crucial role in the immune, inflammatory, and apoptotic responses. Recently, we identified the NF-kappa B Essential Modulator (NEMO) as an essential component of this pathway. NEMO is a structural and regulatory subunit of the high molecular kinase complex (IKK) responsible for the phosphorylation of NF-kappa B inhibitors. Data base searching led to the isolation of a cDNA encoding a protein we called NRP (NEMO-related protein), which shows a strong homology to NEMO. Here we show that NRP is present in a novel high molecular weight complex, that contains none of the known members of the IKK complex. Consistently, we could not observe any effect of NRP on NF-kappa B signaling. Nonetheless, we could demonstrate that treatment with phorbol esters induces NRP phosphorylation and decreases its half-life. This phosphorylation event could only be inhibited by K-252a and stauroporin. We also show that de novo expression of NRP can be induced by interferon and tumor necrosis factor cy and that these two stimuli have a synergistic effect on NRP expression. In addition, we observed that endogenous NRP is associated with the Golgi apparatus. Analogous to NEMO, we find that NRP is associated in a complex with two kinases, suggesting that NRP could play a similar role in another signaling pathway.	Inst Pasteur, URA 1773 CNRS, Unite Biol Mol Express Gen, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Israel, A (corresponding author), Inst Pasteur, URA 1773 CNRS, Unite Biol Mol Express Gen, 25 Rue Dr Roux, F-75724 Paris 15, France.			Schwamborn, Klaus/0000-0001-9702-6036; COURTOIS, Gilles/0000-0003-3117-9595; Weil, Robert/0000-0001-5235-0932				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Weil R, 1997, J BIOL CHEM, V272, P9942; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	34	91	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22780	22789		10.1074/jbc.M001500200	http://dx.doi.org/10.1074/jbc.M001500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807909	hybrid			2022-12-25	WOS:000088419400027
J	Yang, J; Hurley, TD; DePaoli-Roach, AA				Yang, J; Hurley, TD; DePaoli-Roach, AA			Interaction of inhibitor-2 with the catalytic subunit of type 1 protein phosphatase - Identification of a sequence analogous to the consensus type 1 protein phosphatase-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; GLYCOGEN-METABOLISM; SMOOTH-MUSCLE; SYNERGISTIC PHOSPHORYLATION; PHOSPHOPROTEIN PHOSPHATASE; REGULATORY SUBUNITS; CELLULAR-REGULATION	Inhibitor-8 (I-2) is the regulatory subunit of a cytosolic type 1 Ser/Thr protein phosphatase (PP1) and potently inhibits the activity of the free catalytic subunit (CS1). Previous work from the laboratory had proposed that the interaction of I-2 with CS1 involved multiple sites (Park, I. K., and DePaoli-Roach, A. A. (1994) J. Biol. Chem. 269, 28919-28928). The present study refines the earlier analysis and arrives at a more detailed model for the interaction between I-2 and CSI. Although the NH2-terminal I-2 regions containing residues 1-35 and 1-64 have no inhibitory activity on their own, they increase the IC50, for I-2 by similar to 30-fold, indicating the presence of a CS1-interacting site. Based on several experimental approaches, we have also identified the sequence Lys(144) Leu-His-Tyr(147) as a second site of interaction that corresponds to the RVXF motif present in many CS1-binding proteins. The peptide I-2(135-151) significantly increases the IC50 for I-2 and attenuates CS1 inhibition. Replacement of Leu and Tyr with Ala abolishes the ability to counteract inhibition by I-2, The I-2(135-151) peptide, but not I-2(1-35), also antagonizes inhibition of CS1 by DARPP-32 in a pattern similar to that of I-2. Furthermore, a peptide derived from the glycogen-binding subunit, R-GL/G(M)(61-80), which contains a consensus CS1-binding motif, completely counteracts CS1 inhibition by I-2 and DARPP-32. The NH2-terminal 35 residues of I-2 bind to CS1 at a site that is specific for I-2, whereas the KLHY sequence interacts with CS1 at a site shared with other interacting proteins. Other results suggest the presence of yet more sites of interaction. A model is presented in which multiple "anchoring interactions" serve to position a segment of I-2 such that it sterically occludes the catalytic pocket but need not make high affinity contacts itself.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	DePaoli-Roach, AA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	adepaoli@iupui.edu		HURLEY, THOMAS/0000-0002-5942-1163	NIDDK NIH HHS [DK36569] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; CANNON JF, 1994, GENETICS, V136, P485; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Fischer EH, 1997, BIOFACTORS, V6, P367, DOI 10.1002/biof.5520060307; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Helps NR, 1999, FEBS LETT, V463, P72, DOI 10.1016/S0014-5793(99)01573-2; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; Hirano K, 1997, BBA-PROTEIN STRUCT M, V1339, P177, DOI 10.1016/S0167-4838(97)00048-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Ernest Y. C., 1999, Frontiers in Bioscience, V4, pD270, DOI 10.2741/Lee; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; NIMMO GA, 1978, EUR J BIOCHEM, V87, P353, DOI 10.1111/j.1432-1033.1978.tb12384.x; Oliver Carey J., 1998, Frontiers in Bioscience, V3, pD961; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scott JD, 1997, SOC GEN PHY, V52, P227; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Yang J, 1998, FASEB J, V12, pA1407; YANG SD, 1981, J BIOL CHEM, V256, P231; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	62	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22635	22644		10.1074/jbc.M003082200	http://dx.doi.org/10.1074/jbc.M003082200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807923	hybrid			2022-12-25	WOS:000088419400008
J	Chang, Q; Su, KH; Baker, JR; Yang, XY; Paterson, AJ; Kudlow, JE				Chang, Q; Su, KH; Baker, JR; Yang, XY; Paterson, AJ; Kudlow, JE			Phosphorylation of human glutamine : fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE LEVELS; EIF-2 ALPHA-SUBUNIT; O-GLYCOSYLATION; FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; RETICULOCYTE LYSATE; INSULIN-RESISTANCE; 67-KDA POLYPEPTIDE; GENE-TRANSCRIPTION; CDNA SEQUENCE; GROWTH-FACTOR	Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme in glucosamine synthesis. Prior studies from our laboratory indicated that activation of adenylate cyclase was associated with depletion of O-GlcNAc modification. This finding and evidence that human GFAT (hGFAT) might be regulated by cAMP-dependent protein kinase (PKA) led us to investigate the role of PKA in hGFAT function. We confirmed that adenylate cyclase activation by forskolin results in diminished O-GlcNAc modification of several cellular proteins which can be overcome by exposure of the cells to glucosamine but not glucose, suggesting the PKA activation results in depletion of UDP-GlcNAc for O-glycosylation, To determine if GFAT is indeed regulated by PKA, we expressed the active form of the enzyme using a vaccinia virus expression system and showed that the activity of the enzyme was to decrease to undetectable levels by PKA phosphorylation. We mapped the PKA phosphorylation sites with the aid of matrix-assisted laser desorption ionization mass spectroscopy and showed that the protein was stoichiometrically phosphorylated at serine 205 and also phosphorylated, to a lesser extent at serine 235, Mutagenesis studies indicated that the phosphorylation of serine 205 by PKA was necessary for the observed inhibition of enzyme activity while serine 235 phosphorylation played no observable role. The activity of GFAT is down-regulated by cAMP, thus placing regulation on the hexosamine pathway that is in concert with the energy requirements of the organism. During starvation, hormones acting through adenylate cyclase could direct the flux of glucose metabolism into energy production rather than into synthetic pathways that require hexosamines.	Univ Alabama, Dept Med Endocrinol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med Endocrinol, 1808 7th Ave S,Rm 756, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055262] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55262] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Cooksey RC, 1999, ENDOCRINOLOGY, V140, P1151, DOI 10.1210/en.140.3.1151; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; Depre C, 1998, EUR J BIOCHEM, V258, P277, DOI 10.1046/j.1432-1327.1998.2580277.x; GOMEZCUADRADO A, 1995, MOL CELL BIOL, V15, P6670; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HEBERT LF, 1996, J CLIN INVEST, V98; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Konrad RJ, 2000, BIOCHEM BIOPH RES CO, V267, P26, DOI 10.1006/bbrc.1999.1895; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; KORNFELD S, 1966, EXP CELL RES, V41, P592, DOI 10.1016/S0014-4827(66)80109-X; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Oki T, 1999, GENOMICS, V57, P227, DOI 10.1006/geno.1999.5785; PATERSON AJ, 1995, ENDOCRINOLOGY, V136, P2809, DOI 10.1210/en.136.7.2809; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roos MD, 1996, AM J PHYSIOL-CELL PH, V270, pC803, DOI 10.1152/ajpcell.1996.270.3.C803; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Sayeski PP, 1997, NUCLEIC ACIDS RES, V25, P1458, DOI 10.1093/nar/25.7.1458; SAYESKI PP, 1994, GENE, V140, P289, DOI 10.1016/0378-1119(94)90560-6; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Shaw P, 1996, ONCOGENE, V12, P921; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Zhou JX, 1998, DIABETES, V47, P1836, DOI 10.2337/diabetes.47.12.1836	42	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21981	21987		10.1074/jbc.M001049200	http://dx.doi.org/10.1074/jbc.M001049200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806197	hybrid			2022-12-25	WOS:000088363800033
J	Schmidtke, G; Emch, S; Groettrup, M; Holzhutter, HG				Schmidtke, G; Emch, S; Groettrup, M; Holzhutter, HG			Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICATALYTIC PROTEINASE COMPLEX; SENSITIVE NEUTRAL ENDOPEPTIDASE; I ANTIGEN PRESENTATION; RAT-LIVER; ACTIVE-SITES; LACTACYSTIN; INHIBITOR; ACIDOPHILUM; SPECIFICITY	The 20 S proteasome is an endoprotease complex that preferentially cleaves peptides C-terminal of hydrophobic, basic, and acidic residues. Recently, we showed that these specific activities, classified as chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide-hydrolyzing (PGPH) activity, are differently affected by Ritonavir, an inhibitor of human immunodeficiency virus-1 protease, Ritonavir competitively inhibited the chymotrypsin-like activity, whereas the trypsin-like activity was enhanced. Here we demonstrate that the Ritonavir-mediated up-regulation of the trypsin-like activity is not affected by specific active site inhibitors of the chymotrypsin-like and PG:PH activity. Moreover, we show that the mutual regulation of chymotrypsin-like and PGPH activities by their substrates as described previously by a "cyclical bite-chew" model is not affected by selective inhibitors of the respective active sites. These data challenge the bite-chew model and suggest that effecters of proteasome activity can act by binding to non-catalytic sites. Accordingly, we propose a kinetic "two-site modifier" model that assumes that the substrate (or effector) may bind to an active site as well as to a second noncatalytic modifier site. This model appears to be valid as it describes the complex kinetic effects of Ritonavir very well. Since Ritonavir partially inhibits major histocompatibility complex class I restricted antigen presentation, the postulated modifier site may be required to coordinate the active centers of the proteasome for the production of class I peptide ligands.	Kantonsspital St Gallen, Lab Forsch Abt, Res Dept, CH-9007 St Gallen, Switzerland; Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany	Kantonsspital St. Gallen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Groettrup, M (corresponding author), Kantonsspital St Gallen, Lab Forsch Abt, Res Dept, Haus 09, CH-9007 St Gallen, Switzerland.							Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEMENA IR, 1993, BIOCHEM J, V296, P93, DOI 10.1042/bj2960093; DJABALLAH H, 1992, BIOCHEMISTRY-US, V31, P4133, DOI 10.1021/bi00131a033; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HOLZHUTTER HG, 1990, COMPUT APPL BIOSCI, V6, P23; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; Salzmann U, 1999, FEBS LETT, V454, P11, DOI 10.1016/S0014-5793(99)00768-1; Schmidtke G, 1998, J EXP MED, V187, P1641, DOI 10.1084/jem.187.10.1641; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; TANAKA K, 1986, J BIOL CHEM, V261, P5197; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; Wilk S, 1997, MOL BIOL REP, V24, P119, DOI 10.1023/A:1006851428691; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x	33	78	79	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22056	22063		10.1074/jbc.M002513200	http://dx.doi.org/10.1074/jbc.M002513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806206	hybrid, Green Published			2022-12-25	WOS:000088363800044
J	Schepens, I; Johansson, K; Decottignies, P; Gillibert, M; Hirasawa, M; Knaff, DB; Miginiac-Maslow, M				Schepens, I; Johansson, K; Decottignies, P; Gillibert, M; Hirasawa, M; Knaff, DB; Miginiac-Maslow, M			Inhibition of the thioredoxin-dependent activation of the NADP-malate dehydrogenase and cofactor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COENZYME SPECIFICITY; STRUCTURAL BASIS; ALCOHOL-DEHYDROGENASE; CHLOROPLAST ENZYME; BINDING; RESIDUE; IDENTIFICATION; AUTOINHIBITION; REDUCTION	The chloroplastic NADP-malate dehydrogenase is activated by reduction of its N- and C-terminal disulfides by reduced thioredoxin. The activation is inhibited by NADP(+), the oxidized form of the cofactor. Previous studies suggested that the C-terminal disulfide was involved in this process. Recent structural data pointed toward a possible direct interaction between the C terminus of the oxidized enzyme and the cofactor. In the present study, the relationship between the cofactor specificity for catalysis and for inhibition of activation has been investigated by changing the cofactor specificity of the enzyme by substitution of selected residues of the cofactor-binding site. An NAD-specific thiol-regulated MDH was engineered. Its activation was inhibited by NAD(+) but no longer by NADP(+). These results demonstrate that the oxidized cofactor is bound at the same site as the reduced cofactor and support the idea of a direct interaction between the negatively charged C-terminal end of the enzyme and the positively charged nicotinamide ring of the cofactor, in agreement with the structural data. The structural requirements for cofactor specificity are modeled and discussed.	Univ Paris Sud, Inst Biotechnol Plantes, CNRS, UMR 8618, Orsay, France; BMC, Dept Mol Biol, S-75124 Uppsala, Sweden; Lab Enzymol & Biochim Struct, CNRS, UPR 9063, F-91198 Gif Sur Yvette, France; Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Texas Tech University System; Texas Tech University	Miginiac-Maslow, M (corresponding author), Univ Paris Sud, Inst Biotechnol Plantes, CNRS, UMR 8618, Batiment 630, Orsay, France.			Schepens, Isabelle/0000-0002-6718-9608				ASHTON AR, 1983, ARCH BIOCHEM BIOPHYS, V227, P416, DOI 10.1016/0003-9861(83)90471-X; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Carugo O, 1997, PROTEINS, V28, P29, DOI 10.1002/(SICI)1097-0134(199705)28:1<29::AID-PROT3>3.3.CO;2-C; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CLERMONT S, 1993, BIOCHEMISTRY-US, V32, P10178, DOI 10.1021/bi00089a038; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; Hirasawa M, 2000, BIOCHEMISTRY-US, V39, P3344, DOI 10.1021/bi9916731; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krimm I, 1999, J BIOL CHEM, V274, P34539, DOI 10.1074/jbc.274.49.34539; LAUVERGEAT V, 1995, BIOCHEMISTRY-US, V34, P12426, DOI 10.1021/bi00038a041; Levy HR, 1996, ARCH BIOCHEM BIOPHYS, V326, P145, DOI 10.1006/abbi.1996.0058; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NISHIYAMA M, 1993, J BIOL CHEM, V268, P4656; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; Ruelland E, 1997, J BIOL CHEM, V272, P19851, DOI 10.1074/jbc.272.32.19851; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SANGER F, 1977, P NATL ACAD SCI US, V74; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIBE R, 1983, PLANTA, V157, P148; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	28	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20996	21001		10.1074/jbc.M002066200	http://dx.doi.org/10.1074/jbc.M002066200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801830	hybrid			2022-12-25	WOS:000088230600006
J	Eby, MT; Jasmin, A; Kumar, A; Sharma, K; Chaudhary, PM				Eby, MT; Jasmin, A; Kumar, A; Sharma, K; Chaudhary, PM			TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION; JNK ACTIVATION; PROTEIN; DOMAIN; LIGAND; INDUCTION; EFFECTOR; LYMPHOCYTES	We have isolated a novel member of the TNFR family, designated TAJ, that is highly expressed during embryonic development. TAJ possesses a unique cytoplasmic domain with no sequence homology to the previously characterized members of the TNFR family. TAJ interacts with the TRAF family members and activates the JNK pathway when overexpressed in mammalian cells. Although it lacks a death domain, TAJ is capable of inducing apoptosis by a caspase-independent mechanism. Based on its unique expression profile and signaling properties, TAJ may play an essential role in embryonic development.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Washington, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	pchaud@mednet.swmed.edu	Chaudhary, Preet/E-1970-2018; Kumar, Arvind/B-6094-2009					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Deas O, 1998, J IMMUNOL, V161, P3375; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Drenou B, 1999, J IMMUNOL, V163, P4115; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Frade JM, 1996, NATURE, V383, P166; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Heibein JA, 1999, J IMMUNOL, V163, P4683; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pettersen RD, 1998, J IMMUNOL, V160, P4343; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stefanis L, 1999, J NEUROSCI, V19, P6235; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	48	98	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15336	15342		10.1074/jbc.275.20.15336	http://dx.doi.org/10.1074/jbc.275.20.15336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809768	hybrid			2022-12-25	WOS:000087128300076
J	Luberto, C; Yoo, DS; Suidan, HS; Bartoli, GM; Hannun, YA				Luberto, C; Yoo, DS; Suidan, HS; Bartoli, GM; Hannun, YA			Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF-INDUCED APOPTOSIS; PROTEIN-KINASE-C; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; FACTOR-ALPHA; ACID SPHINGOMYELINASE; CERAMIDE; PATHWAY	The precise role of ceramide in NF-kappa B signaling remains unclear. The recent observation of differential sphingomyelin synthase (SMS) activity in normal (low SMS) versus SV40-transformed thigh SMS) WI38 human lung fibroblasts provides an opportunity to assess the involvement of ceramide and SMS in NF-kappa B activation. Treatment of normal WI38 fibroblasts with bacterial sphingomyelinase resulted in a 4-fold elevation of ceramide and blocked NF-kappa B activation by serum stimulation. Such inhibition was not observed in SV40-transformed fibroblasts. Under regular growth conditions, after sphingomyelinase was washed out, normal WI38 did not show SM re-synthesis nor NF-kappa B activation. In SV40-WI38, on the other hand, sphingomyelinase washout induced resynthesis of SM due to the action of SMS on ceramide generated at the plasma membrane. NF-kappa B activation correlated with SM resynthesis. This activation was abrogated by D609, which inhibited SM resynthesis but not the initial formation of ceramide. The differential activity of SMS may explain the effects of ceramide in NF-kappa B signaling: in the absence of significant SIMS activity, ceramide inhibits NF-kappa B, whereas with high SMS, the conversion of the ceramide signal to a diacylglycerol signal by the action of SMS stimulates NF-kappa B. These results also suggest a role for SMS in regulating NF-kappa B.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA; Univ Cattolica Sacro Cuore, Inst Gen Pathol, I-00168 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	Medical University of South Carolina; Duke University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250780,114 Doughty St, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zhang P, 1997, J BIOL CHEM, V272, P9609	31	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14760	14766		10.1074/jbc.275.19.14760	http://dx.doi.org/10.1074/jbc.275.19.14760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799564	hybrid			2022-12-25	WOS:000087006900100
J	Boulanger, MJ; Kukimoto, M; Nishiyama, M; Horinouchi, S; Murphy, MEP				Boulanger, MJ; Kukimoto, M; Nishiyama, M; Horinouchi, S; Murphy, MEP			Catalytic roles for two water bridged residues (Asp-98 and His-255) in the active site of copper-containing nitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-XYLOSOXIDANS NCIMB-11015; ZINC SUPEROXIDE-DISMUTASE; FAECALIS STRAIN S-6; X-RAY STRUCTURE; ACHROMOBACTER-CYCLOCLASTES; DISSIMILATORY NITRITE; MUTANT FORMS; WILD-TYPE; PROTEIN; CENTERS	Two active site residues, Asp-98 and His-255, of copper-containing nitrite reductase (NIR) from Alcaligenes faecalis have been mutated to probe the catalytic mechanism. Three mutations at these two sites (D98N, H255D, and H255N) result in large reductions in activity relative to native NIR, suggesting that both residues are involved intimately in the reaction mechanism. Crystal structures of these mutants have been determined using data collected to better than 1.9-Angstrom resolution, In the native structure, His-255 N epsilon 2 forms a hydrogen bond through a bridging water molecule to the side chain of Asp-98, which also forms a hydrogen bond to a water or nitrite oxygen ligated to the active site copper. In the D98N mutant, reorientation of the Asn-98 side chain results in the loss of the hydrogen bond to the copper ligand water, consistent with a negatively charged Asp-98 directing the binding and protonation of nitrite in the native enzyme. An additional solvent molecule is situated between residues 255 and the bridging water in the H255N and H255D mutants and likely inhibits nitrite binding, The interaction of His-255 with the bridging water appears to be necessary for catalysis and may donate a proton to reaction intermediates in addition to Asp-98.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 113, Japan	University of British Columbia; University of British Columbia; University of Tokyo; University of Tokyo	Murphy, MEP (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	memurphy@interchange.ubc.ca	Kukimoto-Niino, Mutsuko/C-6704-2017; Murphy, Michael/R-6805-2017	Kukimoto-Niino, Mutsuko/0000-0002-4178-1611; Murphy, Michael/0000-0003-2589-0014; Nishiyama, Makoto/0000-0001-8143-8052				ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; JACKSON MA, 1991, FEBS LETT, V291, P41, DOI 10.1016/0014-5793(91)81099-T; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; Kataoka K, 2000, J BIOCHEM-TOKYO, V127, P345, DOI 10.1093/oxfordjournals.jbchem.a022613; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHALSKI WP, 1985, BIOCHIM BIOPHYS ACTA, V828, P130; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, J BIOL CHEM, V272, P28455, DOI 10.1074/jbc.272.45.28455; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NISHIYAMA M, 1993, J GEN MICROBIOL, V139, P725, DOI 10.1099/00221287-139-4-725; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; Olesen K, 1998, BIOCHEMISTRY-US, V37, P6086, DOI 10.1021/bi971603z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Strange RW, 1999, J MOL BIOL, V287, P1001, DOI 10.1006/jmbi.1999.2648; STRANGE RW, 1995, NAT STRUCT BIOL, V2, P287, DOI 10.1038/nsb0495-287; Suzuki E, 1999, BIOCHEM BIOPH RES CO, V255, P427, DOI 10.1006/bbrc.1998.9932; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Veselov A, 1998, BIOCHEMISTRY-US, V37, P6095, DOI 10.1021/bi971604r; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; ZHANG H, 2000, IN PRESS J PHYS CHEM	36	108	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23957	23964		10.1074/jbc.M001859200	http://dx.doi.org/10.1074/jbc.M001859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811642	hybrid			2022-12-25	WOS:000088564200076
J	Song, DH; Sussman, DJ; Seldin, DC				Song, DH; Sussman, DJ; Seldin, DC			Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; APC TUMOR-SUPPRESSOR; BETA-CATENIN; CASEIN KINASE; MAMMALIAN-CELLS; XENOPUS EMBRYOS; NUCLEAR-LOCALIZATION; CONSENSUS SEQUENCES; CELLULAR-REGULATION; NEGATIVE REGULATOR	Protein kinase CK2 (formerly casein kinase II) is a serine/threonine kinase overexpressed in many human tumors, transformed cell lines, and rapidly proliferating tissues. Recent data have shown that many cancers involve inappropriate reactivation of Wnt signaling through ectopic expression of Wnts themselves, as has been seen in a number of human breast cancers, or through mutation of intermediates in the Wnt pathway, such as adenomatous polyposis coli or beta-catenin, as described in colon and other cancers. Wnts are secreted factors that are important in embryonic development, but overexpression of certain Wnts, such as Wnt-1, leads to proliferation and transformation of cells. We report that upon stable transfection of Wnt-1 into the mouse mammary epithelial cell line C57MG, morphological changes and increased proliferation are accompanied by increased levels of CK2, as well as of beta-catenin, CK2 and beta-catenin co-precipitate with the Dvl proteins, which are Wnt signaling intermediates. A major phosphoprotein of the size of beta-catenin appears in in vitro kinase reactions performed on the Dvl immunoprecipitates. In vitro translated beta-catenin, Dvl-2, and Dvl-3 are phosphorylated by CK2. The selective CK2 inhibitor apigenin blocks proliferation of Wnt-1-transfected cells, abrogates phosphorylation of beta-catenin, and reduces beta-catenin and Dvl protein levels. These results demonstrate that endogenous CK2 is a positive regulator of Wnt signaling and growth of mammary epithelial cells.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Med Ctr, Dept Chem, Boston, MA 02118 USA; Boston Med Ctr, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Boston, MA 02118 USA; Univ Maryland, Sch Med, Div Human Genet, Baltimore, MD 21201 USA	Boston Medical Center; Boston Medical Center; Boston Medical Center; Boston University; University System of Maryland; University of Maryland Baltimore	Seldin, DC (corresponding author), Evans Biomed Res Ctr, Dept Med, 650 Albany St,426A, Boston, MA 02118 USA.	dseldin@med-med1.bu.edu		Seldin, David C/0000-0003-0168-2333	NATIONAL CANCER INSTITUTE [R01CA071796, R01CA063929] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71796, R01 CA63929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHAUDHRY PS, 1989, ARCH BIOCHEM BIOPHYS, V271, P98, DOI 10.1016/0003-9861(89)90259-2; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Dale TC, 1998, BIOCHEM J, V329, P209; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; LEROY D, 1994, CELL MOL BIOL RES, V40, P441; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092-8674(00)80354-2; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wagner U, 1997, FEBS LETT, V411, P369, DOI 10.1016/S0014-5793(97)00733-3; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	81	156	165	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23790	23797		10.1074/jbc.M909107199	http://dx.doi.org/10.1074/jbc.M909107199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10806215	hybrid			2022-12-25	WOS:000088564200054
J	Cruickshank, J; Shire, K; Davidson, AR; Edwards, AM; Frappier, L				Cruickshank, J; Shire, K; Davidson, AR; Edwards, AM; Frappier, L			Two domains of the Epstein-Barr virus origin DNA-binding protein, EBNA1, orchestrate sequence-specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS E2 PROTEIN; NUCLEAR ANTIGEN EBNA-1; CRYSTAL-STRUCTURE; LATENT ORIGIN; RECOGNITION; REPLICATION; PURIFICATION; ENHANCER; COMPLEX	The EBNA1 (for Epstein-Barr nuclear antigen 1) protein of Epstein-Barr virus governs the replication and partitioning of the viral genomes during latent infection by binding to specific recognition sites in the viral origin of DNA replication. The crystal structure of the DNA binding portion of the EBNA1 protein revealed that this region comprises two structural motifs; a core domain, which mediates protein dimerization and is structurally homologous to the DNA binding domain of the papillomavirus E2 protein, and a flanking domain, which mediated all the observed sequence-specific contacts. To test the possibility that the EBNA1 core domain plays a role in sequence-specific DNA binding not revealed in the crystal structure, we examined the effects of point mutations in potential hydrogen bond donors located in an cu-helix of the EBNA1 core domain whose structural homologue in E2 mediates sequence-specific DNA binding. We show that these mutations severely reduce the affinity of EBNA1 for its recognition site, and that the core domain, when expressed in the absence of the flanking domain, has sequence-specific DNA binding activity. Flanking domain residues were also found to contribute to the DNA binding activity of EBNA1, Thus, both the core and flanking domains of EBNA1 play direct roles in DNA recognition.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Frappier, L (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Edwards, Aled/0000-0002-4782-6016				AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Bochkarev A, 1998, J MOL BIOL, V284, P1273, DOI 10.1006/jmbi.1998.2247; Chamberlin M J, 1992, Harvey Lect, V88, P1; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; Summers H, 1997, J BIOL CHEM, V272, P26434, DOI 10.1074/jbc.272.42.26434; Yates J.L, 1996, DNA REPLICATION EUKA, P751; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Yates JL, 1996, VIROLOGY, V222, P1, DOI 10.1006/viro.1996.0392; YATES JL, 1988, CANCER CELL, V6, P197; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j	31	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22273	22277		10.1074/jbc.M001414200	http://dx.doi.org/10.1074/jbc.M001414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801810	hybrid			2022-12-25	WOS:000088363800071
J	Pascal, A; Wacker, U; Irrgang, KD; Horton, P; Renger, G; Robert, B				Pascal, A; Wacker, U; Irrgang, KD; Horton, P; Renger, G; Robert, B			Pigment binding site properties of two photosystem II antenna proteins - A resonance Raman investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEXES; CHLOROPHYLL BINDING; SPECTRAL FORMS; SPECTROSCOPY; CP29; RECONSTITUTION; POLYPEPTIDE; MEMBRANES; BACTERIA; SPINACH	Two light-harvesting proteins associated with photosystem II of higher plants, namely the major antenna complex LHCIIb and the minor Lhcb4 protein (CP29), have been investigated by resonance Raman spectroscopy. One of the two chlorophylls b and up to five of the six chlorophylls a present in Lhcb4 are shown to adopt similar binding conformations to the (presumably) corresponding molecules in LHCIIb, whereas at least two chlorophylls in the former protein assume unique conformations relative to the bulk complex. The overall conformation of bound xanthophyll molecules is identical in the two antenna proteins, although some small differences are apparent. The pigment binding properties of these two LHCs are discussed, with particular reference to possible structural motifs within this extended family of proteins.	Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10623 Berlin, Germany; Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2UH, S Yorkshire, England	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Technical University of Berlin; University of Sheffield	Pascal, A (corresponding author), Univ Verona, Fac Sci MMFFNN, Strada Grazie, I-37134 Verona, Italy.	andypascal@yahoo.com	Robert, Bruno/D-1264-2012; pascal, andrew a/B-6186-2014; Horton, Peter/A-3958-2012	Robert, Bruno/0000-0001-5999-4538; pascal, andrew a/0000-0002-1844-6065; Horton, Peter/0000-0002-6095-1460				ALBRECHT AC, 1961, J CHEM PHYS, V34, P1476, DOI 10.1063/1.1701032; BASSI R, 1990, PHOTOCHEM PHOTOBIOL, V52, P1187, DOI 10.1111/j.1751-1097.1990.tb08457.x; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; FEILER U, 1994, PHOTOSYNTH RES, V41, P175, DOI 10.1007/BF02184158; FUJIWARA M, 1986, J PHYS CHEM-US, V90, P5646, DOI 10.1021/j100280a033; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gruszecki WI, 1997, BBA-BIOENERGETICS, V1319, P267, DOI 10.1016/S0005-2728(96)00167-3; HENRYSSON T, 1989, BIOCHIM BIOPHYS ACTA, V977, P301, DOI 10.1016/S0005-2728(89)80084-2; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JENNINGS RC, 1993, BIOCHEMISTRY-US, V32, P3203, DOI 10.1021/bi00064a002; KOYAMA Y, 1983, PHOTOBIOCH PHOTOBIOP, V5, P139; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LIAAENJENSEN S, 1990, NEW J CHEM, V14, P747; LUTZ M, 1977, BIOCHIM BIOPHYS ACTA, V460, P408, DOI 10.1016/0005-2728(77)90081-0; Lutz M., 1984, ADV INFRARED RAMAN S, V11, P211; Naveke A, 1997, J RAMAN SPECTROSC, V28, P599, DOI 10.1002/(SICI)1097-4555(199708)28:8<599::AID-JRS136>3.0.CO;2-C; Pascal A, 1999, EUR J BIOCHEM, V262, P817, DOI 10.1046/j.1432-1327.1999.00457.x; Pascal AA, 1998, BIOCHEMISTRY-US, V37, P2450, DOI 10.1021/bi9719657; PICHERSKY E, 1991, MOL GEN GENET, V227, P277, DOI 10.1007/BF00259681; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; ROBERT B, 1999, PHOTOCHEMISTRY CAROT, P189; ROBERT B, 1996, THESIS, P161; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; RUBAN AV, 1995, BIOCHEMISTRY-US, V34, P2333, DOI 10.1021/bi00007a029; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; THORNBER JP, 1993, BIOCHEM SOC T, V21, P15, DOI 10.1042/bst0210015; THORNBER JP, 1988, LIGHT ENERGY TRANSDU, P137; ZADOROZH.BA, 1965, OPT SPECTROSC-USSR, V19, P306	32	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22031	22036		10.1074/jbc.M000658200	http://dx.doi.org/10.1074/jbc.M000658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806192	hybrid			2022-12-25	WOS:000088363800041
J	Sano, H; Chiba, H; Iwaki, D; Sohma, H; Voelker, DR; Kuroki, Y				Sano, H; Chiba, H; Iwaki, D; Sohma, H; Voelker, DR; Kuroki, Y			Surfactant proteins A and D bind CD14 by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; A-DEFICIENT MICE; SOLUBLE CD14; II CELLS; ALVEOLAR MACROPHAGES; LIPOPOLYSACCHARIDE LPS; BACTERIAL LIPOPOLYSACCHARIDES; PHOSPHOLIPID SECRETION; SPECIFICALLY BINDS; CELLULAR-RESPONSE	Surfactant proteins A (SP-A) and D (SP-D) are lung collectins that are constituents of the innate immune system of the lung. Recent evidence (Sano, H,, Sohma, H,, Muta, T., Nomura, S., Voelker, D. R., and Kuroki, Y. (1999) J. Immunol. 163, 387-395) demonstrates that SP-A modulates lipopolysaccharide (LPS)-induced cellular responses by direct interaction with CD14. In this report we examined the structural elements of the lung collectins involved in CD14 recognition and the consequences for CD14/LPS interaction. Rat SP-A and SP-D bound CD14 in a concentration-dependent manner. Mannose and EDTA inhibited SP-D binding to CD14 but did not decrease SP-A binding. The SP-A binding to CD14 was completely blocked by a monoclonal antibody that binds to the SP-A neck domain but only partially blocked by an antibody that binds to the SP-A lectin domain. SP-A but not SP-D bound to deglycosylated CD14, SP-D decreased CD14 binding to both smooth and rough LPS, whereas SP-A enhanced CD14 binding to rough LPS and inhibited binding to smooth LPS. SP-A also altered the migration profile of LPS on a sucrose density gradient in the presence of CD14. From these results, we conclude that 1) lung collectins bind CD14, 2) the SP-A neck domain and SP-D lectin domain participate in CD14 binding, 3) SP-A recognizes a peptide component and SP-D recognizes a carbohydrate moiety of CD14, and 4) lung collectins alter LPS/CD14 interactions.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Sapporo Medical University; National Jewish Health	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp			NHLBI NIH HHS [HL 45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1992, CURRENT PROTOCOLS MO; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BORRONP, 2000, AM J PHYSIOL, V278, pL840; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; FERRERO E, 1990, J IMMUNOL, V145, P331; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GRIFFISS JM, 1988, REV INFECT DIS, V10, pS287; Hailman E, 1996, J IMMUNOL, V156, P4384; HANCOCK REW, 1994, N COMP BIOC, V27, P263, DOI DOI 10.1016/S0167-7306(08)60415-9; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAZIOT A, 1994, J IMMUNOL, V152, P5868; Honna T, 1997, BIOCHEMISTRY-US, V36, P7176, DOI 10.1021/bi962967e; Horowitz AD, 1996, AM J PHYSIOL-LUNG C, V270, pL69, DOI 10.1152/ajplung.1996.270.1.L69; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1991, BIOCHEM J, V279, P115, DOI 10.1042/bj2790115; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SIMMONS DL, 1989, BLOOD, V73, P284; Stelter F, 1996, EUR J BIOCHEM, V236, P457, DOI 10.1111/j.1432-1033.1996.00457.x; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; VANIWAARDEN JF, 1990, J BIOL CHEM, V2, P91; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	69	160	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22442	22451		10.1074/jbc.M001107200	http://dx.doi.org/10.1074/jbc.M001107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801802	hybrid			2022-12-25	WOS:000088363800093
J	Wakino, S; Kintscher, U; Kim, S; Yin, F; Hsueh, WA; Law, RE				Wakino, S; Kintscher, U; Kim, S; Yin, F; Hsueh, WA; Law, RE			Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G(1) -> S transition in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; IN-VITRO; REGULATORY MOTIF; CDK INHIBITORS; PPAR-GAMMA; CYCLIN D1; GROWTH; P27(KIP1); EXPRESSION; PROTEIN	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear receptor superfamily that is activated by binding certain fatty acids, eicosanoids, and insulin-sensitizing thiazolidinediones (TZD). The TZD troglitazone (TRO) inhibits vascular smooth muscle cell proliferation and migration both in vitro and in vivo, The precise mechanism of its antiproliferative activity, however, has not been elucidated. We report here that PPAR gamma ligands inhibit rat aortic vascular smooth muscle cell proliferation by blocking the events critical for G(1) --> S progression. Flow cytometry demonstrated that both TRO and another TZD, rosiglitazone, prevented G(1) --> S progression induced by platelet-derived growth factor and insulin. Movement of cells from G(1) --> S was also inhibited by the non-TZD, natural PPAR gamma ligand 15-deoxy-(12,14)Delta prostaglandin J(2) (15d-PGJ(2)), and the mitogen-activated protein kinase pathway inhibitor PD98059. Inhibition of G(1) --> S exit by these compounds was accompanied by a substantial blockade of retinoblastoma protein phosphorylation, TRO and rosiglitazone attenuated both the mitogen-induced degradation of p27(kip1) and the mitogenic induction of p21(cip1). 15d-PGJ(2) and PD98059 inhibited both the degradation of p27(kip1) and the induction of cyclin D1 in response to mitogens. These effects resulted in the inhibition of mitogenic stimulation of cyclin-dependent kinases activated by cyclins D1 and E. These data demonstrate that PPAR gamma ligands are antiproliferative drugs that act by modulating cyclin-dependent kinase inhibitors; they may provide a new therapeutic approach for proliferative vascular diseases.	Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Humboldt Univ, Klinikum Rudolf Virchow, Dept Med Cardiol, D-13353 Berlin, Germany; German Heart Inst, D-13353 Berlin, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin	Law, RE (corresponding author), Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, Warren Hall,2nd Floor,Suite 24-130,900 Vet Ave,Bo, Los Angeles, CA 90095 USA.	rlaw@med1.medsch.ucla.edu		Ponka, Prem/0000-0001-5835-1477; Kintscher, Ulrich/0000-0001-7386-0990	NHLBI NIH HHS [HL58328-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Goalstone ML, 1998, ENDOCRINOLOGY, V139, P4067, DOI 10.1210/en.139.10.4067; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Graf K, 1997, FEBS LETT, V400, P119, DOI 10.1016/S0014-5793(96)01371-3; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; HARPER JW, 1993, CELL, V75, P805; Hsueh WA, 1999, AM J CARDIOL, V84, p21J; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kubota T, 1998, CANCER RES, V58, P3344; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; LI Y, 1994, ONCOGENE, V9, P2261; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; MICHIELI P, 1994, CANCER RES, V54, P3391; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rao GN, 1999, BBA-MOL CELL RES, V1448, P525, DOI 10.1016/S0167-4889(98)00149-9; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takahashi A, 1999, CIRC RES, V84, P543, DOI 10.1161/01.RES.84.5.543; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZWOLAK RM, 1987, J VASC SURG, V5, P126, DOI 10.1067/mva.1987.avs0050126	54	196	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22435	22441		10.1074/jbc.M910452199	http://dx.doi.org/10.1074/jbc.M910452199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801895	hybrid			2022-12-25	WOS:000088363800092
J	Watanabe, T; Ihara, N; Itoh, T; Fujita, T; Sugimoto, Y				Watanabe, T; Ihara, N; Itoh, T; Fujita, T; Sugimoto, Y			Accelerated publication - Deletion mutation in Drosophila ma-l homologous, putative molybdopterin cofactor sulfurase gene is associated with bovine xanthinuria type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLASES; DEFICIENCY	Defective xanthine dehydrogenase (XDH) activity in humans results in xanthinuria and xanthine calculus accumulation in kidneys. Bovine xanthinuria was demonstrated in a local herd and characterized as xanthinuria type II, similar to the Drosophila ma-l mutations, which lose activities of molybdoenzymes, XDH, and aldehyde oxidase, although sulfite oxidase activity is preserved. Linkage analysis located the disease locus at the centromeric region of bovine chromosome 24, where a ma-l homologous, putative molybdopterin cofactor sulfurase gene (MCSU) has been physically mapped, We found that a deletion mutation at tyrosine 257 in MCSU is tightly associated with bovine xanthinuria type II.	Shirakawa Inst Anim Genet, Fukushima 9618061, Japan; Ohita Prefecture Livestock Expt Stn, Naoiri, Ohita 8780201, Japan		Sugimoto, Y (corresponding author), Shirakawa Inst Anim Genet, Fukushima 9618061, Japan.							Amrani L, 1999, MOL MICROBIOL, V31, P1065, DOI 10.1046/j.1365-2958.1999.01242.x; BOGAART AM, 1981, BIOCHEM GENET, V19, P929, DOI 10.1007/BF00504258; FELSTED RL, 1973, J BIOL CHEM, V248, P2580; FINNERTY V, 1979, MOL GEN GENET, V172, P37, DOI 10.1007/BF00276213; Hirano T, 1996, ANIM GENET, V27, P365, DOI 10.1111/j.1365-2052.1996.tb00980.x; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; Kappes SM, 1997, GENOME RES, V7, P235, DOI 10.1101/gr.7.3.235; KOJIMA T, 1984, CLIN CHIM ACTA, V137, P189; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; MIZOGUCHI H, 1997, LIVESTOCK TECHNOL, V509, P2; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; REITER S, 1990, CLIN CHIM ACTA, V187, P221, DOI 10.1016/0009-8981(90)90107-4; SIMMONDS JA, 1995, METABOLIC MOL BASES, P1781; Takeda H, 1998, ANIM GENET, V29, P216, DOI 10.1111/j.1365-2052.1998.00325.x; WADA M, 1994, NUCLEIC ACIDS RES, V22, P1651, DOI 10.1093/nar/22.9.1651; WAHL RC, 1982, J BIOL CHEM, V257, P3958	19	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21789	21792		10.1074/jbc.C000230200	http://dx.doi.org/10.1074/jbc.C000230200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801779	hybrid			2022-12-25	WOS:000088363800004
J	Fanara, P; Hodel, MR; Corbett, AH; Hodel, AE				Fanara, P; Hodel, MR; Corbett, AH; Hodel, AE			Quantitative analysis of nuclear localization signal (NLS)-importin alpha interaction through fluorescence depolarization - Evidence for auto-inhibitory regulation of NLS binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTIN-ALPHA; PROTEIN IMPORT; KARYOPHERIN-ALPHA; SUBSTRATE; SEQUENCE; IDENTIFICATION; DOMAIN; BETA; NUCLEOPORINS; RECOGNITION	We have developed a quantitative in vitro steady-state fluorescence depolarization assay to measure the interaction of a nuclear localization signal (NLS) substrate with its receptors, This assay relies on the change in fluorescence depolarization of an NLS fused to the green fluorescent protein upon binding to receptor. No binding is observed in the absence of a functional NLS, and binding affinities measured correlate with previous in vivo studies of NLS function. We have used this assay to test an auto-inhibitory model for the interaction of an NLS with the NLS receptor complex. This model suggests that NLS binding to importin alpha is modulated by an auto-inhibitory sequence within the N terminus of importin alpha, which is displaced by importin beta binding. Consistent with this model, NLS substrates bind tightly to an N-terminally truncated importin alpha lacking the autoinhibitory domain (K-d similar to 10 nM), but measurable binding to full-length importin alpha is only observed upon addition of importin beta, Our quantitative results support the autoinhibitory model and suggest a mechanism for a switch between a cytoplasmic, high affinity and a nuclear, low affinity NLS receptor. This predicted mode of interaction would facilitate binding of substrate in the cytoplasm and its subsequent release into the nucleus.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Hodel, AE (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NIGMS NIH HHS [GM-58728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENENKEL C, 1996, P NATL ACAD SCI USA, V93, P1286; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kohler M, 1999, MOL CELL BIOL, V19, P7782; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7735; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Perrin F, 1926, J PHYS-PARIS, V7, P390, DOI 10.1051/jphysrad:01926007012039000; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Wittmayer PK, 1996, BIOCHEMISTRY-US, V35, P1076, DOI 10.1021/bi952363v	23	83	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21218	21223		10.1074/jbc.M002217200	http://dx.doi.org/10.1074/jbc.M002217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10806202	hybrid			2022-12-25	WOS:000088230600036
J	Haddad, JJE; Olver, RE; Land, SC				Haddad, JJE; Olver, RE; Land, SC			Antioxidant/pro-oxidant equilibrium regulates HIF-1 alpha and NF-kappa B redox sensitivity - Evidence for inhibition by glutathione oxidation in alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; TRANSCRIPTION FACTOR; REACTIVE OXYGEN; LUNG INJURY; ACTIVATION; ALPHA; DIETHYLDITHIOCARBAMATE; PHOSPHORYLATION; TRANSLOCATION; SULFOXIMINE	The O-2 and redox-sensitive transcription factors hypoxia inducible factor-1 alpha (HIF-1 alpha) and nuclear factor-kappa B (NF-kappa B) are differentially regulated in the alveolar epithelium over fetal to neonatal oxygen tensions. We have used fetal alveolar type II epithelial cells to monitor their regulation in association with redox responsiveness to antioxidant pretreatment in vitro. N-Acetyl-L-cysteine, a glutathione (GSH) precursor and a potent scavenger of reactive oxygen species, induced HIF-1 alpha and ameliorated NF-kappa B nuclear abundance and DNA binding activity, respectively, in a dose-dependent manner. Analysis of variations in glutathione homeostasis at ascending Delta pO(2) regimen with N-acetyl-(L)-cysteine reveals increased GSH at the expense of the oxidized form of glutathione (GSSG;), thereby shifting GSH/GSSG into reduction equilibrium. Pyrrolidine dithiocarbamate (PDTC), which exerts both antioxidant and pro-oxidant effects, provoked a substantial increase in HIF-1 alpha nuclear abundance, with no apparent effect on its activation. PDTC reduced NF-kappa B nuclear abundance and its inhibitory effects on binding activity are dose-dependent. Assessment of glutathione homeostasis with PDTC shows increasing levels of GSSG at the expense of GSH, lowering GSH/GSSG in favor of an oxidative equilibrium. Our results indicate the hypoxic activation of HIF-1 alpha and the hyperoxic induction of NF-kappa B in the fetal epithelium is redox-sensitive and, thus, tightly regulated by the GSH/GSSG equilibrium. This highlights glutathione as a key regulatory component for determining genetic responsiveness to oxidant/antioxidant imbalance in normal lung development and pathophysiological conditions.	Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Oxygen Signaling Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Lung Membrane Transport Grp, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Land, SC (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Fac Med,Tayside Inst Child Hlth, Ctr Res Human Dev,Oxygen Signaling Grp, Dundee DD1 9SY, Scotland.	s.c.land@dundee.ac.uk		Land, Stephen/0000-0001-9216-5969				ATKINSON DR, 1977, CELLULARENERGY METAB; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V2, P509; BERNARD GR, 1991, AM J MED, V91, pS54, DOI 10.1016/0002-9343(91)90284-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRIGHAM KL, 1986, CHEST, V89, P859, DOI 10.1378/chest.89.6.859; Chabot F, 1998, EUR RESPIR J, V11, P745; Cotton RB, 1998, FETAL NEONATAL PHYSL, P1165; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DROGE W, 1994, FASEB J, V8, P1131; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; HADDAD JJ, 1999, J PHYSIOL-LONDON, V517, P91; Haddad JJE, 2000, AM J PHYSIOL-LUNG C, V278, pL492, DOI 10.1152/ajplung.2000.278.3.L492; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KELLY GS, 1998, ALTERN MED REV, V3, P144; Liu JK, 1996, FREE RADICAL RES, V24, P461, DOI 10.3109/10715769609088045; MANKHETKORN S, 1994, FREE RADICAL BIO MED, V17, P517, DOI 10.1016/0891-5849(94)90091-4; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Meister A, 1979, Ciba Found Symp, P135; MENON SD, 1993, J BIOL CHEM, V268, P26805; MOLDEUS P, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195086; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; RUSAKOW LS, 1995, J APPL PHYSIOL, V79, P1769, DOI 10.1152/jappl.1995.79.5.1769; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wild AC, 1999, BIOCHEM J, V338, P659, DOI 10.1042/0264-6021:3380659	40	211	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21130	21139		10.1074/jbc.M000737200	http://dx.doi.org/10.1074/jbc.M000737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801793	hybrid			2022-12-25	WOS:000088230600025
J	Beranger, F; Mejean, C; Moniot, B; Berta, P; Vandromme, M				Beranger, F; Mejean, C; Moniot, B; Berta, P; Vandromme, M			Muscle differentiation is antagonized by SOX15, a new member of the SOX protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; CAMPOMELIC DYSPLASIA; HMG BOX; CARTILAGE FORMATION; GENE-EXPRESSION; SRY; MUTATIONS; MYOD; ENHANCER; CELLS	SOX proteins belong to a multigenic family characterized by a unique DNA binding domain, known as the high mobility group box, that is related to that of the testis determining gene SRY, cDNA sequences for more than 30 SOX genes have been identified, and some are known to have diverse roles in vertebrate differentiation and development. Here, we report the isolation and characterization of mouse Sox15 that was uncovered during a screen for high mobility group box containing transcription factors that are expressed at different levels during skeletal muscle differentiation. Sox15 cDNAs were found at a much higher frequency in myoblasts prior to their differentiation into myotubes, Electrophoretic mobility shift assays indicated that recombinant SOX15 protein was capable of binding to a consensus DNA binding site for SOX proteins. When overexpressed in C2C12 myoblasts, wild type SOX15, but not a C-terminal truncated form or the related protein SOX11, specifically inhibited activation of muscle-specific genes and expression of the basic helix-loop-helix myogenic factors myogenin and MyoD, resulting in a failure of the cells to differentiate into myotubes, These results suggest a specific and repressive role for SOX15, requiring the C-terminal domain, during myogenesis.	Inst Human Genet, CNRS, UPR 1142, Cell Biol Unit,Human Mol Genet Grp, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Beranger, F (corresponding author), Inst Human Genet, CNRS, UPR 1142, Cell Biol Unit,Human Mol Genet Grp, 141 Rue Cardonille, F-34396 Montpellier 5, France.	beranger@igh.cnrs.fr	Vandromme, Marie M/N-6615-2018; Vandromme, Marie/ABC-3003-2021; Beranger, Florence/R-7581-2019	vandromme, Marie/0000-0002-5675-7999				Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bondurand N, 1998, FEBS LETT, V432, P168, DOI 10.1016/S0014-5793(98)00843-6; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cremazy F, 1998, FEBS LETT, V438, P311, DOI 10.1016/S0014-5793(98)01294-0; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Emerson CP, 1993, CURR OPIN CELL BIOL, V5, P1057, DOI 10.1016/0955-0674(93)90092-5; Foster JW, 1996, ACTA PAEDIATR JAPON, V38, P405; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GOLDSBOROUGH AS, 1994, P NATL ACAD SCI USA, V91, P12696, DOI 10.1073/pnas.91.26.12696; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Hiraoka Y, 1998, BBA-GENE STRUCT EXPR, V1396, P132, DOI 10.1016/S0167-4781(97)00186-3; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kucharczuk KL, 1999, DEVELOPMENT, V126, P1957; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; Miller JB, 1999, CURR TOP DEV BIOL, V43, P191; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; Soullier S, 1999, J MOL EVOL, V48, P517, DOI 10.1007/PL00006495; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Vujic M, 1998, MAMM GENOME, V9, P1059; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	40	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16103	16109		10.1074/jbc.275.21.16103	http://dx.doi.org/10.1074/jbc.275.21.16103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821863	hybrid			2022-12-25	WOS:000087291400068
J	Derocq, JM; Jbilo, O; Bouaboula, M; Segui, M; Clere, C; Casellas, P				Derocq, JM; Jbilo, O; Bouaboula, M; Segui, M; Clere, C; Casellas, P			Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60 - Possible involvement of the CB2 receptor in cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MEDIATED IMMUNE MODULATION; ZINC-FINGER PROTEIN; GENE-EXPRESSION; SELECTIVE ANTAGONIST; PHORBOL ESTERS; DELTA(9)-TETRAHYDROCANNABINOL; IDENTIFICATION; MIGRATION; PATHWAY	The function of the peripheral cannabinoid receptor (CB2), which is mainly expressed on hematopoietic cells, remains an enigma. In an attempt to decipher its role, we used Affymetrix(TM) DNA chips to investigate the gene expression profile of the promyelocytic cells HL-60 transfected with the CB2 receptor and activated with the cannabinoid agonist CP 55,940, Agonist exposure of these cells led to an activation of a mitogen-activated protein kinase cascade and a receptor desensitization, indicating a functional coupling of the transfected receptors. At the genomic level, activation of the CB2 receptors induced an up-regulation of nine genes involved in cytokine synthesis, regulation of transcription, and cell differentiation. A majority of them are under the control of the transcription factor NF-kappa B, whose nuclear translocation was demonstrated. Many features of the transcriptional events, reported here for the first time, appeared to be related to an activation of a cell differentiation program, suggesting that CB2 receptors could play a role in the initialization of cell maturation. Moreover, we showed that CB2-activated wild-type HL-60 cells developed properties usually found in host defense effector cells such as an enhanced release of chemotactic cytokines and an increased motility, characteristic of more mature cells of the granulocytic-monocytic lineage.	Sanofi Synthelabo, F-34184 Montpellier 04, France	Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Synthelabo, 371 Rue Prof Joseph Blayac, F-34184 Montpellier 04, France.	pierre.casellas@sanofi-synthelabo.com						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Bouaboula M, 1999, J BIOL CHEM, V274, P20397, DOI 10.1074/jbc.274.29.20397; BOUABOULA M, 1996, EUR J BIOCHEM, V214, P173; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; Casale TB, 1999, INFLAMM RES, V48, P22, DOI 10.1007/s000110050379; Cross AK, 1997, CYTOKINE, V9, P521, DOI 10.1006/cyto.1996.0196; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; GALLAGHER R, 1979, BLOOD, V54, P713; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; Itoh K, 1998, BLOOD, V92, P1432, DOI 10.1182/blood.V92.4.1432.416k13_1432_1441; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KLEIN TW, 1995, P SOC EXP BIOL MED, V209, P205; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LUO YD, 1992, INT J IMMUNOPHARMACO, V14, P49, DOI 10.1016/0192-0561(92)90104-S; LYNN AB, 1994, J PHARMACOL EXP THER, V268, P1612; Marchand J, 1999, CYTOMETRY, V35, P227, DOI 10.1002/(SICI)1097-0320(19990301)35:3<227::AID-CYTO5>3.0.CO;2-4; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAHAS GG, 1991, ADV EXP MED BIOL, V288, P25; Neyns B, 1996, ONCOGENE, V12, P1247; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Portier M, 1999, J PHARMACOL EXP THER, V288, P582; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; Shimizu M, 1998, TOXICOL SCI, V45, P204, DOI 10.1093/toxsci/45.2.204; SHIVERS SC, 1994, LIFE SCI, V54, P1281, DOI 10.1016/0024-3205(94)00856-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Tiffany HL, 1998, J IMMUNOL, V160, P1385; Watson A, 1998, CURR OPIN BIOTECH, V9, P609, DOI 10.1016/S0958-1669(98)80138-9; ZHU WG, 1994, J PHARMACOL EXP THER, V270, P1334	52	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15621	15628		10.1074/jbc.275.21.15621	http://dx.doi.org/10.1074/jbc.275.21.15621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821843	hybrid			2022-12-25	WOS:000087291400005
J	Ghohestani, RF; Hudson, BG; Claudy, A; Uitto, J				Ghohestani, RF; Hudson, BG; Claudy, A; Uitto, J			The alpha 5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; PEMPHIGOID ANTIGEN; IDENTIFICATION; SKIN; PROTEIN; AUTOANTIGEN; GOODPASTURE; ANTIBODIES; SERA	We describe a novel autoimmune disease characterized by severe subepidermal bullous eruptions and renal insufficiency with IgG autoantibodies directed against the NC1 domain of the alpha 5(TV) collagen chain. In vivo deposits of IgG and C3 were found along the dermal-epidermal junction of skin lesions. The identity of the target antigen was determined by immunochemical analyses of candidate antigens using the patients' autoantibodies. The patients' IgG autoantibodies reacted with a 185-kDa polypeptide that was distinguished from the known autoantigens of the extracellular matric including type XVII collagen, type VII collagen, or the alpha 3, beta 3, and gamma 2 chains of laminin 5. Preincubation of the serum with recombinant alpha 5(IV)NC1 domain of type IV collagen abolished immunoreactivity with the 185-kDa antigen. The serum reacted specifically with the alpha 5(IV)NC1, among the six NC1 domains of type IV collagen, by Western blot and enzyme-linked immunosorbent assay analyses. The patients' autoantibodies reacted with normal skin and renal glomerulus but not with skin and glomerulus of a patient with Alport syndrome in which the basement membranes are devoid of the alpha 5(IV) collagen chain. This study provided for the first time unambiguous evidence for the alpha 5(IV) collagen chain as the target antigen in a novel autoimmune disease characterized by skin and renal involvement.	Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Immunodermatol Unit, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Lyon 1, E Herriot Hosp, Dept Dermatol, F-69437 Lyon, France	Jefferson University; Jefferson University; University of Kansas; University of Kansas Medical Center; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ghohestani, RF (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Immunodermatol Unit, BLSB 419,233 S 10th St, Philadelphia, PA 19107 USA.	ghohestani@mail.tju.edu		Hudson, Billy/0000-0002-5420-4100	NIAMS NIH HHS [P01-AR38923] Funding Source: Medline; NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P1983, DOI 10.1093/oxfordjournals.ndt.a027085; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; GAUCHERAND M, 1995, BRIT J DERMATOL, V132, P190; Ghohestani R, 1997, BRIT J DERMATOL, V137, P774; Ghohestani RF, 1996, J INVEST DERMATOL, V107, P136, DOI 10.1111/1523-1747.ep12298424; Ghohestani RF, 1998, J CLIN IMMUNOL, V18, P202, DOI 10.1023/A:1020531005776; Ghohestani RF, 1997, J INVEST DERMATOL, V108, P854, DOI 10.1111/1523-1747.ep12292581; Ghohestani RF, 1997, ARCH DERMATOL, V133, P1102, DOI 10.1001/archderm.133.9.1102; GUBLER MC, 1995, KIDNEY INT, V47, P1142, DOI 10.1038/ki.1995.163; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; PEYRON E, 1994, J IMMUNOL, V153, P1333; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rhys C, 1997, KIDNEY INT, V52, P208, DOI 10.1038/ki.1997.321; ROSS EA, 1989, AM J KIDNEY DIS, V14, P225, DOI 10.1016/S0272-6386(89)80076-9; ROSS JB, 1985, ARCH DERMATOL, V121, P1442, DOI 10.1001/archderm.121.11.1442; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; Tyagi S, 1996, P NATL ACAD SCI USA, V93, P14714, DOI 10.1073/pnas.93.25.14714; WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602	23	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16002	16006		10.1074/jbc.275.21.16002	http://dx.doi.org/10.1074/jbc.275.21.16002			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821854	hybrid			2022-12-25	WOS:000087291400054
J	Kovalenko, M; Denner, K; Sandstrom, J; Persson, C; Gross, S; Jandt, E; Vilella, R; Bohmer, F; Ostman, A				Kovalenko, M; Denner, K; Sandstrom, J; Persson, C; Gross, S; Jandt, E; Vilella, R; Bohmer, F; Ostman, A			Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; PDGF RECEPTOR; INTACT-CELLS; KINASE; EXPRESSION; IDENTIFICATION; ASSOCIATION; SUBSTRATE	Ligand stimulation of PDGF P-receptors leads to autophosphorylation of the regulatory tyrosine 857 and of tyrosine residues that in their phosphorylated form serve as docking sites for Src homology 2 domain-containing proteins. Regulation of the PDGF beta-receptor by protein-tyrosine phosphatases is poorly understood. We have investigated PDGF beta-receptor dephosphorylation by receptor-like protein-tyrosine phosphatase DEP-1 using a cell line with inducible DEP-1 expression and by characterizing in vitro dephosphorylation of the PDGF beta-receptor and of receptor-derived phosphopeptides by DEP-1. After DEP-1 induction PDGF beta-receptor DEP-1 complexes and reduced receptor tyrosine phosphorylation were observed. Phosphopeptide analysis of the PDGF P-receptors from DEP-1-expressing cells and of the receptors dephosphorylated in vitro by DEP-1 demonstrated that dephosphorylation of autophosphorylation sites of the receptor differed and revealed that the regulatory Tyr(p)(857) was not a preferred site for DEP-1 dephosphorylation, When dephosphorylation of synthetic receptor-derived peptides was analyzed, the selectivity was reproduced, indicating that amino acid sequence surrounding the phosphorylation sites is the major determinant of selectivity. This notion is supported by the observation that the poorly dephosphorylated Tyr(P)(562) and Tyr(P)(857), in contrast to other analyzed phosphorylation sites, are surrounded by basic amino acid residues at positions -4 and +3 relative to the tyrosine residue. Our study demonstrates that DEP-1 dephosphorylation of the PDGF beta-receptor is site-selective and may lead to modulation, rather than general attenuation, of signaling.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Univ Jena, Mol Cell Biol Res Unit, D-07747 Jena, Germany; Hosp Clin Barcelona, Serv Immunol, E-08036 Barcelona, Spain	Ludwig Institute for Cancer Research; Friedrich Schiller University of Jena; University of Barcelona; Hospital Clinic de Barcelona	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	Arne.Ostman@licr.uu.se						Ahmad F, 1997, J BIOL CHEM, V272, P448; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Borges LG, 1996, CIRC RES, V79, P570, DOI 10.1161/01.RES.79.3.570; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224	46	119	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16219	16226		10.1074/jbc.275.21.16219	http://dx.doi.org/10.1074/jbc.275.21.16219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821867	hybrid			2022-12-25	WOS:000087291400083
J	Jang, SI; Karaman-Jurukovska, N; Morasso, MI; Steinert, PM; Markova, NG				Jang, SI; Karaman-Jurukovska, N; Morasso, MI; Steinert, PM; Markova, NG			Complex interactions between epidermal POU domain and activator protein 1 transcription factors regulate the expression of the profilaggrin gene in normal human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLUCRIN PROMOTER ACTIVITY; DNA-BINDING; TERMINAL DIFFERENTIATION; RESPONSE ELEMENT; FLEXIBILITY; FAMILY; OCT-1; AP-1; CELLS; RECOGNITION	The human profilaggrin gene is expressed in the granular layer during the late stages of the epidermal differentiation. The proximal promoter region of the gene confers high levels of keratinocyte-specific transcription via interactions with c-Jun/c-Fos heterodimers, Here we provide evidence for another level of complexity in the regulation of the profilaggrin promoter activity. The POU domain proteins Oct1, Skn1a/i, and Oct6, which are abundantly expressed in the epidermal cells, act to both stimulate and repress transcription in a general and a cell type-specific mode. While binding to specific recognition elements within the promoter region, they exert their effects by either stimulating or antagonizing the c-Jun-dependent activity of the promoter. The response of the promoter to forced expression of the POU domain proteins reflects the effect of these transcription factors on the endogenous profilaggrin mRNA synthesis and suggests that the latter requires a fine balance in the amounts and the activities of the individual activator protein 1 and POU domain proteins.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; SUNY Stony Brook, Living Skin Bank, Stony Brook, NY 11794 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Markova, NG (corresponding author), SUNY Stony Brook, Sch Dent Med, Dept Oral Biol & Pathol, Living Skin Bank, Westchester Hall,Rm 1112, Stony Brook, NY 11790 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041085] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abdulkadir SA, 1998, J LEUKOCYTE BIOL, V64, P681, DOI 10.1002/jlb.64.5.681; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; Cleary MA, 1997, P NATL ACAD SCI USA, V94, P8450, DOI 10.1073/pnas.94.16.8450; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; Delhase M, 1996, J BIOL CHEM, V271, P32349, DOI 10.1074/jbc.271.50.32349; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; KIM MK, 1993, J BIOL CHEM, V268, P23366; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sambrook J., 2002, MOL CLONING LAB MANU; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; SUZUKI N, 1990, EMBO J, V8, P2543; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; YUKAWA K, 1993, GENE, V133, P163; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	59	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15295	15304		10.1074/jbc.275.20.15295	http://dx.doi.org/10.1074/jbc.275.20.15295			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809764	hybrid			2022-12-25	WOS:000087128300071
J	Kong, AM; Speed, CJ; O'Malley, CJ; Layton, MJ; Meehan, T; Loveland, KL; Cheema, S; Ooms, LM; Mitchell, CA				Kong, AM; Speed, CJ; O'Malley, CJ; Layton, MJ; Meehan, T; Loveland, KL; Cheema, S; Ooms, LM; Mitchell, CA			Cloning, and characterization of a 72-kDa inositol-polyphosphate 5-phosphatase localized to the Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; HUMAN-PLATELETS; SACCHAROMYCES-CEREVISIAE; PROTEIN; IDENTIFICATION; 3-KINASE; POLYPHOSPHATE-5-PHOSPHATASE	The inositol-polyphosphate B-phosphatase enzyme family removes the B-position phosphate from both inositol phosphate and phosphoinositide signaling molecules. We have cloned and characterized a novel B-phosphatase, which demonstrates a restricted substrate specificity and tissue expression. The 3.9-kb cDNA predicts for a 72-kDa protein with an N-terminal proline rich domain, a central B-phosphatase domain, and a C-terminal CAAX motif. The 3.9-kilobase mRNA showed a restricted expression but was abundant in testis and brain. Antibodies against the sequence detected a 72-kDa protein in the testis in the detergent-insoluble fraction. Indirect immunofluorescence of the Tera-1 cell line using anti-peptide antibodies to the 72-kDa 5-phosphatase demonstrated that the enzyme is predominantly located to the Golgi. Expression of green fluorescent protein-tagged 72-kDa 5-phosphatase in COS-7 cells revealed that the enzyme localized predominantly to the Golgi, mediated by the N-terminal proline-rich domain, but not the C-terminal CAAX motif. In vitro, the protein inserted into microsomal membranes on the cytoplasmic face of the membrane. Immunoprecipitated recombinant 72-kDa B-phosphatase hydrolyzed phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,5-bisphosphate, forming phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol S-phosphate, respectively. We propose that the novel 5-phosphatase hydrolyzes phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,5-bisphosphate on the cytoplasmic Golgi membrane and thereby may regulate Golgi-vesicular trafficking.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3168, Australia; Monash Med Ctr, Monash Inst Reprod & Dev, Clayton, Vic 3168, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia	Monash University; Monash University; Monash University; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.		Ooms, Lisa/AGZ-7420-2022; Loveland, Kate L/X-4404-2019	Loveland, Kate L/0000-0002-5750-8046; O'Malley, Cindy/0000-0003-1779-5105; Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932				Asano T, 1999, BIOCHEM BIOPH RES CO, V261, P188, DOI 10.1006/bbrc.1999.0998; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; AUGER KR, 1990, METHODS INOSITIDE RE, P163; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; Chaudhary A, 1998, J BIOL CHEM, V273, P8344, DOI 10.1074/jbc.273.14.8344; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOVE SK, 1999, SIGNAL TRANSDUCTION, P255; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Gleeson PA, 1996, J CELL SCI, V109, P2811; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kisseleva MV, 2000, J BIOL CHEM, V275, P20110, DOI 10.1074/jbc.M910119199; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; KOOY J, 1992, J BIOL CHEM, V267, P20255; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; MADISON EL, 1992, GENE, V121, P179, DOI 10.1016/0378-1119(92)90179-S; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Matzaris M, 1998, J BIOL CHEM, V273, P8256, DOI 10.1074/jbc.273.14.8256; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; Meinhardt A, 1998, J REPROD FERTIL, V112, P233, DOI 10.1530/jrf.0.1120233; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SPEED CJ, 1995, EUR J BIOCHEM, V234, P216, DOI 10.1111/j.1432-1033.1995.216_c.x; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574	50	75	77	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24052	24064		10.1074/jbc.M000874200	http://dx.doi.org/10.1074/jbc.M000874200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10806194	hybrid			2022-12-25	WOS:000088564200089
J	Lok, CN; Ponka, P				Lok, CN; Ponka, P			Identification of an erythroid active element in the transferrin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON REGULATORY PROTEIN-2; TRANSCRIPTIONAL REGULATION; INCREASED EXPRESSION; FUNCTIONAL-ANALYSIS; PROMOTER REGION; BINDING PROTEIN; CELLS; DIFFERENTIATION; STABILIZATION; METABOLISM	Hemoglobin synthesis consumes most of the iron that is taken up by cells from plasma transferrin, and this process requires very high expression of transferrin receptors (TfR) at the membranes of erythroid cells. Studies in our and other laboratories indicate that a dramatic increase in TfR levels during erythroid differentiation occurs at the transcriptional level. In this study, we investigated the transcriptional regulation of the TfR in terms of its promoter activity and DNA-protein binding in murine erythroleukemia cells. Reporter gene assays revealed that the TfR promoter activity was stimulated 6-8-fold in murine erythroleukemia cells induced to differentiate into hemoglobin-synthesizing cells by either Me2SO or N,N'-hexamethylene-bis-acetamide, A minimal region (-118 to +14) was required for the differentiation-induced promoter activity. Mutation of either an Ets-binding site or an activator protein-1/cyclic AMP-response element-like motif within this region, but not disruption of the adjacent GC-rich/specificity protein-1 sequence, inhibited the inducible promoter activity. Electrophoresis mobility shift assays suggest that the cyclic AMP-response element-binding proteins/activating transcription factor-like factors and Ets-like factors bind constitutively to this bipartite element. Upon induction of differentiation, a shift in the pattern of the cyclic AMP-response element-binding protein/activating transcription factor-like binding factors was observed. Our data indicate that the TfR gene promoter contains an erythroid active element that stimulates the receptor gene transcription upon induction of hemoglobin synthesis.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Ponka, P (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK49219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; Busfield SJ, 1997, EUR J BIOCHEM, V249, P77, DOI 10.1111/j.1432-1033.1997.t01-1-00077.x; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; Clausen PA, 1997, LEUKEMIA, V11, P1224, DOI 10.1038/sj.leu.2400735; Fleming MD, 1998, J LAB CLIN MED, V132, P464, DOI 10.1016/S0022-2143(98)90123-8; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; GUO B, 1994, J BIOL CHEM, V269, P24252; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Iler N, 1999, BLOOD CELL MOL DIS, V25, P47, DOI 10.1006/bcmd.1999.0226; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lok CN, 1996, EUR J BIOCHEM, V236, P614, DOI 10.1111/j.1432-1033.1996.00614.x; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Ponka P, 1997, BLOOD, V89, P1; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SETH A, 1993, ONCOGENE, V8, P1783; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	34	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24185	24190		10.1074/jbc.M000944200	http://dx.doi.org/10.1074/jbc.M000944200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811637	hybrid			2022-12-25	WOS:000088564200104
J	Abraham, D; Podar, K; Pacher, M; Kubicek, M; Welzel, N; Hemmings, BA; Dilworth, SM; Mischak, H; Kolch, W; Baccarini, M				Abraham, D; Podar, K; Pacher, M; Kubicek, M; Welzel, N; Hemmings, BA; Dilworth, SM; Mischak, H; Kolch, W; Baccarini, M			Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; SMALL-T-ANTIGEN; SIGNAL-TRANSDUCTION; IN-VITRO; MONOCLONAL-ANTIBODIES; NEGATIVE REGULATION; SIMIAN VIRUS-40; OKADAIC ACID; RAF-1 KINASE; RAS	The Raf-1 kinase plays a key role in relaying proliferation signals elicited by mitogens or oncogenes, Raf-1 is regulated by complex and incompletely understood mechanisms including phosphorylation, A number of studies have indicated that phosphorylation of serines 259 and 621 can inhibit the Raf-1 kinase, We show that both serines are hypophosphorylated during early mitogenic stimulation and that hypophosphorylation correlates with peak Raf-1 activation. Concentrations of okadaic acid that selectively inhibit protein phosphatase 2A (PP2A) induce phosphorylation of these residues and prevent maximal activation of the Raf-1 kinase. This effect is mediated via phosphorylation of serine 259. The PP2A core heterodimer forms complexes with Raf-1 in vivo and in vitro. These data identify PP2A as a positive regulator of Raf-1 activation and are the first indication that PP2A may support the activation of an associated kinase.	Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Friedrich Miescher Inst, CH-4056 Basel, Switzerland; Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, Dept Metab Med, London W12 0NN, England; Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Vienna Biocenter (VBC); Friedrich Miescher Institute for Biomedical Research; Imperial College London; Hannover Medical School; Beatson Institute	Baccarini, M (corresponding author), Vienna Bioctr, Inst Microbiol & Genet, Dr Bohr Gasse 9, A-1030 Vienna, Austria.		Admin, SBI/HGB-2738-2022; Mischak, Harald/E-8685-2011; Podar, Klaus/ABD-1112-2020; Kolch, Walter/ABF-2102-2021; Baccarini, Manuela/B-6481-2014	Podar, Klaus/0000-0002-7414-3632; Baccarini, Manuela/0000-0002-3033-391X; Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016; Abraham, Dietmar/0000-0001-6337-0058				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baccarini M, 1991, Receptor, V1, P243; Baek KH, 1996, DEV BIOL, V175, P191, DOI 10.1006/dbio.1996.0107; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1990, ONCOGENE, V5, P713; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	51	183	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22300	22304		10.1074/jbc.M003259200	http://dx.doi.org/10.1074/jbc.M003259200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801873	hybrid			2022-12-25	WOS:000088363800075
J	Mizutani, T; Yamada, K; Minegishi, T; Miyamoto, K				Mizutani, T; Yamada, K; Minegishi, T; Miyamoto, K			Transcriptional regulation of rat scavenger receptor class B type I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; STEROIDOGENIC FACTOR-I; BOVINE CYP11A GENE; PROTEIN STAR GENE; APOPROTEIN-A-I; SR-BI; PROMOTER ACTIVITY; BINDING PROTEIN; ADRENAL-GLAND; EXPRESSION	The scavenger receptor class B type I (SR-BI) mediates the selective transport of lipids from high density lipoprotein to cells and plays an important role in the reverse uptake of cholesterol to the liver and in the delivery of substrates for steroidogenesis in steroidogenic organs. We report here on the isolation and characterization of the upstream promoter region of the rat SR-BI gene. The transcription start site for rat SR-BI was mapped, and DNA sequence analysis revealed the presence of binding sites for the Sp1 family in the proximal 5'-flanking region. Analysis of deletion mutants with different 5' lengths revealed that the region between -121 and -90 base pairs from the transcription start site is essential for the efficient transcription of SR-BI. Both Sp1 and Sp3 bind to three GC boxes in the region (-141 to -1 base pairs) in a sequence-specific manner, Mutations in any of the GC boxes decreased efficient transcription from this promoter in MA-10 mouse Leydig tumor cells, The overexpression of Sp1 or Sp3 protein enhanced the rat SR-BI promoter activity. These results indicate that Sp1 family members of transcription factors are essential for transcription of the rat SR-BI gene.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan; Gunma Univ, Sch Med, Dept Obstet & Gynecol, Maebashi, Gumma 371, Japan	University of Fukui; Gunma University	Miyamoto, K (corresponding author), Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAGENBUCHLE O, 1985, J MOL BIOL, V185, P285, DOI 10.1016/0022-2836(85)90404-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	43	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22512	22519		10.1074/jbc.M001631200	http://dx.doi.org/10.1074/jbc.M001631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801817	hybrid			2022-12-25	WOS:000088363800101
J	Kawabe, Y; Seki, M; Seki, T; Wang, WS; Imamura, O; Furuichi, Y; Saitoh, H; Enomoto, T				Kawabe, Y; Seki, M; Seki, T; Wang, WS; Imamura, O; Furuichi, Y; Saitoh, H; Enomoto, T			Covalent modification of the Werner's syndrome gene product with the ubiquitin-related protein, SUMO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME GENE; DNA HELICASE; CONJUGATING ENZYME; MOLECULAR-CLONING; SYNDROME CELLS; S-PHASE; MUTATIONS; HOMOLOG; RECQ; P53	Werner's syndrome is a potential model of accelerated human aging. The gene responsible for Werner's syndrome encodes a protein that has a helicase domain homologous to Escherichia coli RecQ. To identify binding partners that regulate the function in concert with Wrn, we screened for proteins using the yeast two-hybrid system with mouse Wrn as bait and found three. One was a novel protein, and the other two were mouse Ubc9 and SUMO-1. Ubc9 also interacted with the mouse homologue of the Bloom's syndrome gene product, another eukaryotic RecQ-type helicase, but not mouse DNA helicase Q1/RecQL (RecQL1). Deletion experiments indicated that both proteins interacted with the N-terminal segment of Wrn (amino acid 272-514). The interaction between Wrn and SUMO-1 was weaker than that between Wrn and Ubc9. Positive interaction was observed in the heterogeneous combination of Wrn and yeast Ubc9 (yUbc9), as well as yUbc9 and SUMO-1, in the two-hybrid system. The interaction between yUbc9 and SUMO-1 was abolished by deleting the C-terminal Gly residue of SUMO-1, which is reportedly required for the formation of Ubc9-SUMO-1 thioester linkage. The interaction of Wrn and SUMO-1 was also abolished by deleting the Gly residue, indicating that the interaction of Wrn and SUMO-1 is mediated by yUbc9 in the two-hybrid system. Finally, we confirmed by immunoblotting with an anti-SUMO-l antibody that Wrn was covalently attached with SUMO-1.	Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan; AGENE Res Inst, Kamakura, Kanagawa 247, Japan; Picower Inst Med Res, Manhasset, NY 11030 USA	Tohoku University; Northwell Health	Enomoto, T (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan.							ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Goto M, 1997, HUM GENET, V99, P191, DOI 10.1007/s004390050336; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; MARTIN GM, 1977, AM J PATHOL, V89, P484; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; ONG L, 1997, J BIOL CHEM, V272, P28198; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schulz VP, 1996, HUM GENET, V97, P750; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Seki T, 1998, BBA-GENE STRUCT EXPR, V1398, P377, DOI 10.1016/S0167-4781(98)00066-9; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; WANG WS, 1998, IOCH BIOPHYS ACTA, V1443, P198; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	46	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20963	20966		10.1074/jbc.C000273200	http://dx.doi.org/10.1074/jbc.C000273200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10806190	hybrid			2022-12-25	WOS:000088230600002
J	Kobayashi, H; Hirashima, Y; Sun, GW; Fujie, M; Nishida, T; Takigawa, M; Terao, T				Kobayashi, H; Hirashima, Y; Sun, GW; Fujie, M; Nishida, T; Takigawa, M; Terao, T			Identity of urinary trypsin inhibitor-binding protein to link protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE NASAL CARTILAGE; TUMOR-CELL INVASION; HYALURONAN-BINDING; MONOCLONAL-ANTIBODIES; PLASMINOGEN-ACTIVATOR; BASEMENT-MEMBRANES; KERATAN SULFATE; PROTEOGLYCAN; IDENTIFICATION; CHONDROSARCOMA	Urinary trypsin inhibitor (UTI), a Kunitz-type protease inhibitor, directly binds to some types of cells via cell-associated UTI-binding proteins (UTI-BPs). Here we report that the 40-kDa protein (UTI-BP40) was purified from the cultured human chondrosarcoma cell line HCS-2/8 by UTI affinity chromatography. Purified UTI-BP40 was digested with trypsin, and the amino acid sequences of the peptide fragments were determined. The sequences of six tryptic fragments of UTI-BP40 were identical to subsequences present in human link protein (LP). Authentic bovine LP and UTI-BP40 displayed identical electrophoretic and chromatographic behavior. The UTI-binding properties of UTI-BP40 and LP were indistinguishable. Direct binding and competition studies strongly demonstrated that the NH2-terminal fragment is the UTI-binding part of the LP molecule, that the COOH-terminal UTI fragment (HI-8) failed to bind the NH2-terminal subdomain of the LP molecule, and that LP and UTI-BP40 exhibited significant hyaluronic acid binding. These results demonstrate that UTI-BP40 is identical to LP and that the NH2-terminal domain of UTI is involved in the interaction with the NH2-terminal fragment of LP, which is bound to hyaluronic acid in the extracellular matrix.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Equipment Ctr, Shizuoka 4313192, Japan; Okayama Univ, Sch Dent, Dept Biochem & Mol Dent, Okayama 7008525, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Okayama University	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handacho 3600, Shizuoka 4313192, Japan.							BANSAL MK, 1987, BIOCHIM BIOPHYS ACTA, V928, P152, DOI 10.1016/0167-4889(87)90116-9; BERTHEIM U, 1994, BRIT J PLAST SURG, V47, P483, DOI 10.1016/0007-1226(94)90031-0; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; BONNET F, 1978, BIOCHIM BIOPHYS ACTA, V532, P242, DOI 10.1016/0005-2795(78)90578-0; BONNET F, 1983, BIOCHIM BIOPHYS ACTA, V743, P82, DOI 10.1016/0167-4838(83)90420-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEZHU J, 1994, JPN J CANCER RES, V85, P364; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; ENGSTROMLAURENT A, 1985, ANN RHEUM DIS, V44, P83, DOI 10.1136/ard.44.2.83; ENOMOTO M, 1992, BIOL REGULATION CHON, P321; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GUESDON JL, 1992, J IMMUNOL METHODS, V150, P33, DOI 10.1016/0022-1759(92)90063-Y; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Hirashima Y, 1997, EUR J OBSTET GYN R B, V73, P79, DOI 10.1016/S0301-2115(96)02689-9; HOEDTSCHMIDT S, 1993, HISTOCHEMISTRY, V99, P391, DOI 10.1007/BF00717052; Kobayashi H, 1996, EUR J CELL BIOL, V71, P380; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; Kobayashi H, 1996, J BIOL CHEM, V271, P11362, DOI 10.1074/jbc.271.19.11362; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kobayashi H, 1999, AM J OBSTET GYNECOL, V180, P141, DOI 10.1016/S0002-9378(99)70164-X; Kobayashi H, 1998, PFLUG ARCH EUR J PHY, V436, P16, DOI 10.1007/s004240050599; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIU J, 1992, J ORTHOPAED RES, V10, P621, DOI 10.1002/jor.1100100504; Manilal SB, 1996, BIOCHEM MOL BIOL INT, V39, P711; MCCARTHY MT, 1989, J CELL PHYSIOL, V141, P191, DOI 10.1002/jcp.1041410127; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neame P J, 1994, EXS, V70, P53; NEAME PJ, 1985, J BIOL CHEM, V260, P2402; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; PERRY JK, 1994, BBA-MOL CELL RES, V1221, P145, DOI 10.1016/0167-4889(94)90006-X; POOLE AR, 1984, J BIOL CHEM, V259, P4849; RAUCH U, 1991, J BIOL CHEM, V266, P14785; REICH R, 1988, CANCER RES, V48, P3307; Reuning U, 1998, INT J ONCOL, V13, P893; RHODES C, 1991, NUCLEIC ACIDS RES, V19, P1933, DOI 10.1093/nar/19.8.1933; ROBERTS CR, 1991, AM J PHYSIOL, V261, pL92, DOI 10.1152/ajplung.1991.261.2.L92; TAKIGAWA M, 1989, CANCER RES, V49, P3996; Takigawa M, 1997, ENDOCRINOLOGY, V138, P4390, DOI 10.1210/en.138.10.4390; TAKIGAWA M, 1997, CLIN PEDIAT ENDO S10, V6, P169; TANG LH, 1979, J BIOL CHEM, V254, P523; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; VIJAYAGOPAL P, 1985, BIOCHIM BIOPHYS ACTA, V839, P110, DOI 10.1016/0304-4165(85)90188-6; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Yamasaki F, 1996, PFLUG ARCH EUR J PHY, V433, P9, DOI 10.1007/s004240050242	55	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21185	21191		10.1074/jbc.M907862199	http://dx.doi.org/10.1074/jbc.M907862199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801881	hybrid			2022-12-25	WOS:000088230600031
J	Ichida, M; Hakamata, Y; Hayakawa, M; Ueno, E; Ikeda, U; Shimada, K; Hamamoto, T; Kagawa, Y; Endo, H				Ichida, M; Hakamata, Y; Hayakawa, M; Ueno, E; Ikeda, U; Shimada, K; Hamamoto, T; Kagawa, Y; Endo, H			Differential regulation of exonic regulatory elements for muscle-specific alternative splicing during myogenesis and cardiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SYNTHASE GAMMA-SUBUNIT; GREEN FLUORESCENT PROTEIN; SR-PROTEINS; PREMESSENGER RNA; ENHANCER COMPLEX; BINDING; EXPRESSION; SELECTION; DISTINCT	Muscle-specific isoform of the mitochondrial ATP synthase gamma subunit (F(1)gamma) was generated by alternative splicing, and exon 9 of the gene was found to be lacking particularly in skeletal muscle and heart tissue. Recently, we reported that alternative splicing of exon 9 was induced by low serum or acidic media in mouse myoblasts, and that this splicing required de novo protein synthesis of a negative regulatory factor (Ichida, M., Endo, H., Ikeda, U., Matsuda, C., Ueno, E., Shimada, K., and Kagawa, Y. (1998) J. Biol. Chem. 273, 8492-8501; Hayakawa, M, Endo, H., Hamamoto, T., and Kagawa, Y. (1998) Biochem Biophys. Res. Commun. 251, 603-608). In the present report, we identified a cis-acting element on the muscle-specific alternatively spliced exon of F(1)gamma gene by an in vivo splicing system using cultured cells and transgenic mice. We constructed a F(1)gamma wild-type minigene, containing the full-length gene from exon 8 to exon 10, and two mutants; one mutant involved a pyrimidine-rich substitution on exon 9, whereas the other was a purine-rich substitution, abbreviated as F(1)gamma Pudel and F(1)gamma Pu-rich mutants, respectively. Based on an in vivo splicing assay using low serum- or acid-stimulated splicing induction system in mouse myoblasts, Pudel mutation inhibited exon inclusion, indicating that a Pu-del mutation would disrupt an exonic splicing enhancer. On the other hand, the Pu-rich mutation blocked muscle-specific exon exclusion following both inductions. Next, we produced transgenic mice bearing both mutant minigenes and analyzed their splicing patterns in tissues. Based on an analysis of F(1)gamma Pu-del mini-gene transgenic mice, the purine nucleotide of this element was shown to be necessary for exon inclusion in non-muscle tissue. In contrast, analysis of F(1)gamma Pu-rich minigene mice revealed that the F(1)gamma Pu-rich mutant exon had been excluded from heart and skeletal muscle of these transgenic mice, despite the fact mutation of the exon inhibited muscle-specific exon exclusion in myotubes of early embryonic stage. These results suggested that the splicing regulatory mechanism underlying F(1)gamma pre-mRNA differed between myotubes and myofibers during myogenesis and cardiogenesis.	Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Cardiol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Expt Med Lab, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University	Endo, H (corresponding author), Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan.		Hakamata, Yoji/AAF-7759-2020	Hayakawa, Morisada/0000-0002-1869-2450; Hakamata, Yoji/0000-0002-0138-6692				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; ENDO H, 1994, J BIOL CHEM, V269, P12488; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hanamura A, 1998, RNA, V4, P430; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; Hayakawa M, 1998, BIOCHEM BIOPH RES CO, V251, P603, DOI 10.1006/bbrc.1998.9525; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HOGAN B, 1986, MANIPULATING MOUSE E, P153; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; Ichida M, 1998, J BIOL CHEM, V273, P8492, DOI 10.1074/jbc.273.14.8492; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Kimata Y, 1997, BIOCHEM BIOPH RES CO, V232, P69, DOI 10.1006/bbrc.1997.6235; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WANG Z, 1995, RNA, V1, P21; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	40	24	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15992	16001		10.1074/jbc.275.21.15992	http://dx.doi.org/10.1074/jbc.275.21.15992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821853	hybrid			2022-12-25	WOS:000087291400053
J	Scandella, E; Nagl, UO; Oehl, B; Bergmann, F; Gschwentner, M; Furst, J; Schmarda, A; Ritter, M; Waldegger, S; Lang, F; Deetjen, P; Paulmichl, M				Scandella, E; Nagl, UO; Oehl, B; Bergmann, F; Gschwentner, M; Furst, J; Schmarda, A; Ritter, M; Waldegger, S; Lang, F; Deetjen, P; Paulmichl, M			The promoter for constitutive expression of the human ICln gene CLNS1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL I-CLN; CHLORIDE CHANNEL; CELL-VOLUME; MOLECULAR-CLONING; CILIARY EPITHELIUM; MESSENGER-RNA; PI(CLN); CONDUCTANCE; PROTEIN; REGION	The ICln protein is expressed ubiquitously in mammals. Experiments designed to knock down the ICln protein in NIH 3T3 fibroblasts as well as in epithelial cells led to the conclusion that this protein is crucially involved in volume regulation after cytoplasmic swelling. Reconstitution of the ICln protein in lipid bilayers revealed the ion channel nature of ICln, Here we describe a new human promoter sequence, composed of 89 nucleotides, which is responsible for a highly constitutive expression of the ICln protein. The promoter sequence lacks a TATA box, and the transcription can be effected at multiple sites. In addition to the starting sites, upstream sequence elements are mandatory for an efficient transcription of the ICln gene (CLNS1A). These new nucleotide elements were defined by site-directed mutagenesis.	Univ Innsbruck, Dept Physiol, A-6020 Innsbruck, Austria; Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany	University of Innsbruck; Eberhard Karls University of Tubingen	Paulmichl, M (corresponding author), Univ Innsbruck, Dept Physiol, Fritz Pregal Str 3, A-6020 Innsbruck, Austria.	markus.paulmichl@uibk.ac.at	Ritter, Markus/AAG-4987-2020	Ritter, Markus/0000-0001-7346-7750				ABE T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P353, DOI 10.1016/0167-4781(93)90138-4; ALEXANDER SPH, 1998, TRENDS PHARM SCI S, P82; ANGUITA J, 1995, BIOCHEM BIOPH RES CO, V208, P89, DOI 10.1006/bbrc.1995.1309; Buyse G, 1996, BIOCHEM BIOPH RES CO, V218, P822, DOI 10.1006/bbrc.1996.0146; Chen LX, 1999, AM J PHYSIOL-CELL PH, V276, pC182, DOI 10.1152/ajpcell.1999.276.1.C182; Chen S, 1998, BIOCHEM BIOPH RES CO, V246, P59, DOI 10.1006/bbrc.1998.8571; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU S, 1998, AM J PHYSIOL, V276, pL614; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; FRANCIS F, 1994, GENET ANAL-BIOMOL E, V11, P148, DOI 10.1016/1050-3862(94)90035-3; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gschwentner M, 1996, BRIT J PHARMACOL, V118, P41, DOI 10.1111/j.1476-5381.1996.tb15364.x; Gschwentner M, 1998, INT CONGR SER, V1160, P131; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Hall JA, 1996, AM J PHYSIOL-CELL PH, V271, pC579, DOI 10.1152/ajpcell.1996.271.2.C579; JACKSON PS, 1995, J GEN PHYSIOL, V105, P643, DOI 10.1085/jgp.105.5.643; Jackson PS, 1996, AM J PHYSIOL-CELL PH, V270, pC57, DOI 10.1152/ajpcell.1996.270.1.C57; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; KOH J, 1993, J BIOL CHEM, V268, P15912; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; KWON HM, 1992, J BIOL CHEM, V267, P6297; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; Lang F., 1990, Comparative Physiology, V4, P1; Lewis RA, 1996, J MEMBRANE BIOL, V149, P103, DOI 10.1007/s002329900011; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Maniatis T., 1982, MOL CLONING LAB MANU; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; Nagl UO, 1996, GENOMICS, V38, P438, DOI 10.1006/geno.1996.0651; Nagl UO, 1998, GENE, V209, P59, DOI 10.1016/S0378-1119(98)00002-X; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PAULMICHL M, 1995, BIOPHYS J, V68, P242; Reeves RE, 1998, CURR EYE RES, V17, P861, DOI 10.1076/ceyr.17.9.861.5140; Schwartz RS, 1997, BIOCHEM J, V327, P609; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; TAKENAKA M, 1995, P NATL ACAD SCI USA, V92, P1072, DOI 10.1073/pnas.92.4.1072; Uchida S, 1998, AM J PHYSIOL-RENAL, V274, pF602, DOI 10.1152/ajprenal.1998.274.3.F602; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Wickman K, 1997, GENOMICS, V40, P402, DOI 10.1006/geno.1996.4600; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1	43	3	3	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15613	15620		10.1074/jbc.275.21.15613	http://dx.doi.org/10.1074/jbc.275.21.15613			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821842	hybrid			2022-12-25	WOS:000087291400004
J	Seah, SYK; Labbe, G; Nerdinger, S; Johnson, MR; Snieckus, V; Eltis, LD				Seah, SYK; Labbe, G; Nerdinger, S; Johnson, MR; Snieckus, V; Eltis, LD			Identification of a serine hydrolase as a key determinant in the microbial degradation of polychlorinated biphenyls	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN LB400; 2-HYDROXY-6-KETO-NONA-2,4-DIENE-1,9-DIOIC ACID 5,6-HYDROLASE; 2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID; CHLORINE SUBSTITUTION; DIOXYGENASE; METABOLISM; PURIFICATION; PATHWAY; 2,3-DIHYDROXYBIPHENYL; CHLOROBIPHENYLS	The ability of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate (HOPDA) hydrolase (BphD) of Burkholderia cepacia LB400 to hydrolyze polychlorinated biphenyl (PCB) metabolites was assessed by determining its specificity for monochlorinated HOPDAs. The relative specificities of BphD for HOPDAs bearing chlorine substituents on the phenyl moiety were 0.28, 0.38, and 1.1 for 8-Cl, 9-Cl, and 10-Cl HOPDA, respectively, versus HOPDA (100 mM phosphate, pH 7.5, 25 degrees C). In contrast, HOPDAs bearing chlorine substituents on the dienoate moiety were poor substrates for BphD, which hydrolyzed 3-Cl, 4-Cl, and 5-Cl HOPDA at relative maximal rates of 2.1 x 10(-3), 1.4 x 10(-4), and 0.36, respectively, versus HOPDA. The enzymatic transformation of 3-, 5-, 8-, 9-, and 10-Cl HOPDAs yielded stoichiometric quantities of the corresponding benzoate, indicating that BphD catalyzes the hydrolysis of these HOPDAs in the same manner as unchlorinated HOPDA. HOPDAs also underwent a nonenzymatic transformation to products that included acetophenone. In the case of 4-Cl HOPDA, this transformation proceeded via the formation of 4-OH HOPDA (t(1/2) = 2.8 h; 100 mM phosphate, pH 7.5, 25 degrees C). 3-Cl HOPDA (t(1/2) = 504 h) was almost 3 times more stable than 4-OH HOPDA. Finally, 3-Cl, 4-Cl and 4-OH HOPDAs competitively inhibited the BphD-catalyzed hydrolysis of HOPDA (K-ic values of 0.57 +/- 0.04, 3.6 +/- 0.2, and 0.95 +/- 0.04 mu M, respectively). These results explain the accumulation of HOPDAs and chloroacetophenones in the microbial degradation of certain PCB congeners. More significantly, they indicate that in the degradation of PCB mixtures, BphD would be inhibited, thereby slowing the mineralization of all congeners. BphD is thus a key determinant in the aerobic microbial degradation of PCBs.	Univ Laval, Dept Biochem, Ste Foy, PQ G1K 7P4, Canada; Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada	Laval University; Queens University - Canada	Eltis, LD (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300,6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Labbé, Geneviève/N-4531-2017; Eltis, Lindsay D/J-8272-2015	Labbé, Geneviève/0000-0001-9720-7574; Eltis, Lindsay D/0000-0002-6774-8158				AHMAD D, 1995, GENE, V156, P69, DOI 10.1016/0378-1119(95)00073-F; BAXTER RM, 1984, ENVIRON SCI TECHNOL, V18, P608, DOI 10.1021/es00126a008; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1103, DOI 10.1128/AEM.53.5.1103-1112.1987; Bruhlmann F, 1999, BIOTECHNOL BIOENG, V63, P544, DOI 10.1002/(SICI)1097-0290(19990605)63:5<544::AID-BIT4>3.0.CO;2-6; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; DIAZ E, 1995, J BIOL CHEM, V270, P6403, DOI 10.1074/jbc.270.11.6403; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; FOCHT DD, 1995, CURR OPIN BIOTECH, V6, P341, DOI 10.1016/0958-1669(95)80057-3; FURUKAWA K, 1979, APPL ENVIRON MICROB, V38, P301, DOI 10.1128/AEM.38.2.301-310.1979; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; Head IM, 1998, MICROBIOL-UK, V144, P599, DOI 10.1099/00221287-144-3-599; Henderson IMJ, 1997, BIOCHEMISTRY-US, V36, P12252, DOI 10.1021/bi971116j; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; Hurtubise Y, 1998, J BACTERIOL, V180, P5828, DOI 10.1128/JB.180.22.5828-5835.1998; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; KNOX WE, 1957, J BIOL CHEM, V225, P675; KOSTER R, 1965, LIEBIGS ANN CHEM, V689, P40; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; Lam WWY, 1997, BIOCHEMISTRY-US, V36, P12242, DOI 10.1021/bi971115r; March J., 1992, ADV ORG CHEM, P939; MCFARLAND VA, 1989, ENVIRON HEALTH PERSP, V81, P225, DOI 10.2307/3430833; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; Nerdinger S, 1999, CHEM COMMUN, P2259, DOI 10.1039/a907279i; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OMORI T, 1986, AGR BIOL CHEM TOKYO, V50, P931, DOI 10.1080/00021369.1986.10867489; Pollard JR, 1997, CHEM COMMUN, P1885; Seah SYK, 1998, J BIOL CHEM, V273, P22943, DOI 10.1074/jbc.273.36.22943; Seeger M, 1999, APPL ENVIRON MICROB, V65, P3614; SEEGER M, 1995, APPL ENVIRON MICROB, V61, P2654, DOI 10.1128/AEM.61.7.2654-2658.1995; Seto M, 1996, BIOTECHNOL LETT, V18, P1193, DOI 10.1007/BF00128591; Tiedje James M., 1993, Biodegradation, V4, P231, DOI 10.1007/BF00695971; Vaillancourt FH, 1998, J BIOL CHEM, V273, P34887, DOI 10.1074/jbc.273.52.34887	35	82	89	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15701	15708		10.1074/jbc.275.21.15701	http://dx.doi.org/10.1074/jbc.275.21.15701			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821847	hybrid			2022-12-25	WOS:000087291400016
J	Beerens, N; Berkhout, B				Beerens, N; Berkhout, B			In vitro studies on tRNA annealing and reverse transcription with mutant HIV-1 RNA templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMER-BINDING-SITE; NUCLEOCAPSID PROTEIN; SECONDARY STRUCTURE; TYPE-1 RNA; GENOMIC RNA; LEADER RNA; RICH LOOP; U5 REGION; INITIATION	The human immunodeficiency virus type 1 (HIV-1) RNA genome encodes a semistable stem-loop structure, the US-PBS hairpin, which occludes part of the tRNA primer binding site (PBS). In previous studies, we demonstrated that mutations that alter the stability of the U5-PBS hairpin inhibit virus replication. A reverse transcription defect was measured in assays with the virion-extracted RNA-tRNA complexes. We now extend these studies with in vitro synthesized wild-type and mutant RNA templates that were tested in primer annealing and reverse transcription assays. The effect of annealing temperature and the presence of the viral nucleocapsid protein on reverse transcription was analyzed for the templates with a stabilized or destabilized U5-PBS hairpin, and in reactions initiated by tRNA or DNA primers. The results of this in vitro assay are consistent with the in vivo findings, in that both tRNA annealing and initiation of reverse transcription are sensitive to stable template RNA structure. Reverse transcription initiated by a DNA primer is less hindered by secondary structure in the RNA template than tRNA primed reactions. The inhibitory effect of template structure on tRNA-primed reverse transcription is more pronounced in this in vitro assay compared with the in vivo material, indicating that the heat-annealed RNA-tRNA complex differs from the virion-extracted viral RNA-tRNA complex.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, POB 22700, NL-1100 DE Amsterdam, Netherlands.							AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; DAS AT, 1995, J VIROL, V69, P3090, DOI 10.1128/JVI.69.5.3090-3097.1995; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Essink BBO, 1999, J BIOMED SCI, V6, P121; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; ESSINK BBO, 1995, J BIOL CHEM, V270, P23867, DOI 10.1074/jbc.270.40.23867; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585; Huang Y, 1998, J VIROL, V72, P3907, DOI 10.1128/JVI.72.5.3907-3915.1998; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Kang SM, 1996, VIROLOGY, V222, P401, DOI 10.1006/viro.1996.0437; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; Leis J, 1993, REVERSE TRANSCRIPTAS; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Morris S, 1999, J VIROL, V73, P6307, DOI 10.1128/JVI.73.8.6307-6318.1999; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; Telesnitsky A., 1997, P121; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	48	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15474	15481		10.1074/jbc.275.20.15474	http://dx.doi.org/10.1074/jbc.275.20.15474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809779	hybrid			2022-12-25	WOS:000087128300094
J	Desrosiers, RR; Gauthier, F; Lanthier, J; Beliveau, R				Desrosiers, RR; Gauthier, F; Lanthier, J; Beliveau, R			Modulation of Rho and cytoskeletal protein attachment to membranes by a prenylcysteine analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; ACTIN CYTOSKELETON; LOCALIZATION; EXCHANGE; GTPASES; DISEASE; DOMAIN; CELLS	The GTPases Rho regulate the assembly of polymerized actin structures. Their C-terminal sequences end with the CAAX motif that undergo a lipidation of the cysteine residue. Analogs to the C-terminal ends of Rho proteins, N-acetyl-S-all-trans, trans-farnesyl-L-cysteine and N-acetyl-S-all-trans-geranylgeranyl-L- were used to analyze the role of prenylation in their membrane association. Silver-stained gels indicated that Nacetyl-S-all-trans-geranylgeranyl-L-cysteine treatment released only a few proteins of 20, 46, and 60 kDa, Western blot analysis showed that N-acetyl-S-all-trans-geranylgeranyl-L-cysteine released RhoB (10%), RhoA (28%), and Cdc42 (95%) from membranes, whereas N-acetyl-S-all-trans and trans-farnesyl-L-cyseeine did not. Rab1, which possesses two geranylgeranyl groups, was also strongly extracted by N-acetyl-S-all-trans-geranylgeranyl-L-cysteine, whereas Ras, which is farnesylated, was not. Furthermore, N-acetyl-S-all-trans-geranylgeranylL-cysteine was very efficient (95%) in dissociating actin and tubulin from membranes but not integral membrane protein P-glycoprotein and sodium/phosphate cotransporter NaPi-2. The extraction of Rho and cytoskeletal proteins occurred below the critical micellar concentration of N-acetyl-S-all-trans-geranylgeranyl-Lcysteine, Membrane treatments with 0.7 M KI, totally extracted actin, whereas 70% of Cdc42 was released. Actin was, however, insoluble in Triton X-100-treated membranes, whereas this detergent extracted (80%) Cdc42. These data show that Rho proteins and actin are not physically bound together and suggest that their extraction from membranes by N-acetyl-S-all-trans-geranylgeranyl-L-cysteine likely occurs via different mechanisms.	Univ Quebec, Mol Med Lab, Hop St Justine, Montreal, PQ H3C 3P8, Canada	Universite de Montreal; University of Quebec; University of Quebec Montreal	Desrosiers, RR (corresponding author), Univ Quebec, Mol Med Lab, Hop St Justine, CP 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BEAUREGARD G, 1983, ANAL BIOCHEM, V132, P362, DOI 10.1016/0003-2697(83)90021-0; Boivin D, 1996, CAN J PHYSIOL PHARM, V74, P801, DOI 10.1139/cjpp-74-7-801; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Booth A G, 1974, Biochem J, V142, P575; Boyer CJC, 1996, BBA-BIOMEMBRANES, V1281, P117, DOI 10.1016/0005-2736(96)00033-8; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Demeule M, 1997, J BIOL CHEM, V272, P6647, DOI 10.1074/jbc.272.10.6647; Desrosiers RR, 1998, BIOCHEM CELL BIOL, V76, P63, DOI 10.1139/bcb-76-1-63; GEORGE SG, 1973, BIOCHEM J, V134, P43, DOI 10.1042/bj1340043; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; KELLY MH, 1970, CLIN BIOCHEM, V3, P33, DOI 10.1016/S0009-9120(70)80053-4; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER J, 1993, BIOCHIM BIOPHYS ACTA, V1225, P1, DOI 10.1016/0925-4439(93)90115-H; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Lim L, 1996, SEMIN CELL DEV BIOL, V7, P699, DOI 10.1006/scdb.1996.0086; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACKAY DJG, 1996, CURR BIOL, V6, P1256; Michiels F, 1999, BIOCHEM SOC SYMP, V65, P125; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	39	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14949	14957		10.1074/jbc.275.20.14949	http://dx.doi.org/10.1074/jbc.275.20.14949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809740	hybrid			2022-12-25	WOS:000087128300026
J	Shi, Y; Kong, W; Nakayama, K				Shi, Y; Kong, W; Nakayama, K			Human lactoferrin binds and removes the hemoglobin receptor protein of the periodontopathogen Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBACTERIAL ACTIVITY; POLYMORPHONUCLEAR LEUKOCYTES; BACTEROIDES-GINGIVALIS; HAEMOPHILUS-INFLUENZAE; CYSTEINE PROTEINASE; ENCODING GENES; IRON; IDENTIFICATION; DOMAIN; LIPOPOLYSACCHARIDE	Porphyromonas gingivalis possesses a hemoglobin receptor (HbR) protein on the cell surface as one of the major components of the hemoglobin utilization system in this periodontopathogenic bacterium. HbR is intragenically encoded by the genes of an arginine-specific cysteine proteinase (rgpA), lysine-specific cysteine proteinase (kgp), and a hemagglutinin (hagA). Here, we have demonstrated that human lactoferrin as well as hemoglobin have the abilities to bind purified HbR and the cell surface of P. gingivalis through HbR. The interaction of lactoferrin with HbR led to the release of HbR from the cell surface of P. gingivalis. This lactoferrin-mediated HbR release was inhibited by the cysteine proteinase inhibitors effective to the cysteine proteinases of P. gingivalis. P. gingivalis could not utilize lactoferrin for its growth as an iron source and, in contrast, lactoferrin inhibited the growth of the bacterium in a rich medium containing hemoglobin as the sole iron source. Lactoferricin B, a 25-amino acid-long peptide located at the N-lobe of bovine lactoferrin, caused the same effects on P. gingivalis cells as human lactoferrin, indicating that the effects of lactoferrin might be attributable to the lactoferricin region. These results suggest that lactoferrin has a bacteriostatic action on P. gingivalis by binding HbR, removing it from the cell surface, and consequently disrupting the iron uptake system from hemoglobin.	Kyushu Univ, Fac Dent, Dept Microbiol, Fukuoka 8128582, Japan	Kyushu University	Nakayama, K (corresponding author), Kyushu Univ, Fac Dent, Dept Microbiol, Fukuoka 8128582, Japan.	knak@dent.kyushu-u.ac.jp						ADONOGIANAKI E, 1993, J CLIN PERIODONTOL, V20, P26, DOI 10.1111/j.1600-051X.1993.tb01755.x; AMBRUSO DR, 1981, J CLIN INVEST, V67, P352, DOI 10.1172/JCI110042; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; Bhogal PS, 1997, MICROBIOL-SGM, V143, P2485, DOI 10.1099/00221287-143-7-2485; BRAMANTI TE, 1990, BIOCHEM BIOPH RES CO, V166, P1146, DOI 10.1016/0006-291X(90)90986-W; BROXMEYER HE, 1978, J EXP MED, V148, P1052, DOI 10.1084/jem.148.4.1052; CURTIS MA, 1993, J GEN MICROBIOL, V139, P949, DOI 10.1099/00221287-139-5-949; DeCarlo AA, 1997, ORAL MICROBIOL IMMUN, V12, P47, DOI 10.1111/j.1399-302X.1997.tb00366.x; DEVET BJCM, 1978, ACTA MED SCAND, V203, P197; EATON JW, 1982, SCIENCE, V215, P691, DOI 10.1126/science.7036344; FRIEDMAN SA, 1983, J PERIODONTOL, V54, P347, DOI 10.1902/jop.1983.54.6.347; FUJIMURA S, 1995, FEMS IMMUNOL MED MIC, V10, P109; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; GIBBONS RJ, 1960, J BACTERIOL, V80, P164, DOI 10.1128/JB.80.2.164-170.1960; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; Haffajee A D, 1994, Periodontol 2000, V5, P78, DOI 10.1111/j.1600-0757.1994.tb00020.x; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; HITCHCOCK PJ, 1983, EUR J BIOCHEM, V133, P685, DOI 10.1111/j.1432-1033.1983.tb07517.x; KALFAS S, 1991, ORAL MICROBIOL IMMUN, V6, P350, DOI 10.1111/j.1399-302X.1991.tb00506.x; KISHORE AR, 1992, J MED MICROBIOL, V37, P341, DOI 10.1099/00222615-37-5-341; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NISHIKATA M, 1989, MICROBIOL IMMUNOL, V33, P75, DOI 10.1111/j.1348-0421.1989.tb01499.x; Odell EW, 1996, FEBS LETT, V382, P175, DOI 10.1016/0014-5793(96)00168-8; OSEAS R, 1981, BLOOD, V57, P939; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PEREZ GIP, 1985, INFECT IMMUN, V47, P353, DOI 10.1128/IAI.47.2.353-359.1985; Pike RN, 1996, J BACTERIOL, V178, P2876, DOI 10.1128/jb.178.10.2876-2882.1996; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; POULSEN K, 1989, INFECT IMMUN, V57, P3097, DOI 10.1128/IAI.57.10.3097-3105.1989; Qiu JZ, 1998, P NATL ACAD SCI USA, V95, P12641, DOI 10.1073/pnas.95.21.12641; REITER B, 1983, INT J TISSUE REACT, V5, P87; Reiter B, 1998, ADV EXP MED BIOL, V443, P175; Schryvers AB, 1998, ADV EXP MED BIOL, V443, P123; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; SHAH HN, 1979, BIOCHEM J, V180, P45, DOI 10.1042/bj1800045; Sharp L, 1998, MICROBIOL-SGM, V144, P3019, DOI 10.1099/00221287-144-11-3019; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; SHIZUKUISHI S, 1995, FEMS MICROBIOL LETT, V131, P313; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; Smalley JW, 1998, BIOCHEM J, V331, P681, DOI 10.1042/bj3310681; VAARA M, 1994, ANTIMICROB AGENTS CH, V38, P2498, DOI 10.1128/AAC.38.10.2498; VALENTI P, 1982, ANTIMICROB AGENTS CH, V21, P840, DOI 10.1128/AAC.21.5.840; YAMAUCHI K, 1993, INFECT IMMUN, V61, P719, DOI 10.1128/IAI.61.2.719-728.1993	47	37	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30002	30008		10.1074/jbc.M001518200	http://dx.doi.org/10.1074/jbc.M001518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10811640	hybrid			2022-12-25	WOS:000089577900013
J	Warner, GJ; Berry, MJ; Moustafa, ME; Carlson, BA; Hatfield, DL; Faust, JR				Warner, GJ; Berry, MJ; Moustafa, ME; Carlson, BA; Hatfield, DL; Faust, JR			Inhibition of selenoprotein synthesis by selenocysteine tRNA([Ser]Sec) lacking isopentenyladenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA MODIFICATION; HAMSTER OVARY CELLS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TRANSFER RNA<SER>SEC; MAMMALIAN-CELLS; CODON; GENE; IDENTIFICATION; UGA	A common posttranseriptional modification of tRNA is the isopentenylation of adenosine at position 37, creating isopentenyladenosine (i(6)A), The role of this modified nucleoside in protein synthesis of higher eukaryotes is not well understood. Selenocysteyl (Sec) tRNA (tRNA([Ser]Sec)) decodes specific UGA codons and contains i(6)A. To address the role of the modified nucleoside in this tRNA, we constructed a site-specific mutation, which eliminates the site of isopentenylation, in the Xenopus tRNA([Ser]Sec) gene. Transfection of the mutant tRNA([Ser]Sec) gene resulted in 80% and 95% reduction in the expression of co-transfected selenoprotein genes encoding type I and II iodothyronine deiodinases, respectively. A similar decrease in type I deiodinase synthesis was observed when transfected cells were treated with lovastatin, an inhibitor of the biosynthesis of the isopentenyl moiety, Neither co-transfection with the mutant tRNA gene nor lovastatin treatment reduced type I deiodinase mRNA levels. Also, mutant tRNA expression did not alter initiation of translation or degradation of the type I deiodinase protein. Furthermore, isopentenylation of tRNA([Ser]Sec) was not required for synthesis of Sec on the tRNA, We conclude that isopentenylation of tRNA([Ser]Sec) is required for efficient translational decoding of UGA and synthesis of selenoproteins.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Harvard Inst Med,Dept Med,Thyroid Div, Boston, MA 02115 USA; NCI, Div Basic Sci, Basic Res Lab, Bethesda, MD 20892 USA	Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Faust, JR (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.		Moustafa, Mohamed E/E-9002-2018; Moustafa, Mohamed/AAM-2211-2021	Moustafa, Mohamed/0000-0003-1308-6221	NATIONAL CANCER INSTITUTE [ZIABC005317, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBARESE E, 1995, J CELL SCI, V108, P2781; BARTZ JK, 1970, BIOCHEM BIOPH RES CO, V40, P1481, DOI 10.1016/0006-291X(70)90035-5; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BOUADLOUN F, 1986, J BACTERIOL, V166, P1022, DOI 10.1128/jb.166.3.1022-1027.1986; BROWN T, 1997, CURRENT PROTOCOLS MO, V1; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Chittum HS, 1997, BBA-MOL CELL RES, V1359, P25, DOI 10.1016/S0167-4889(97)00092-X; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; DIAZ I, 1991, J MOL BIOL, V222, P1161, DOI 10.1016/0022-2836(91)90599-2; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; EISENBERG SP, 1979, J MOL BIOL, V135, P111, DOI 10.1016/0022-2836(79)90343-7; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GEFTER ML, 1969, J MOL BIOL, V39, P145, DOI 10.1016/0022-2836(69)90339-8; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAGERVALL TG, 1990, BIOCHIM BIOPHYS ACTA, V1050, P263, DOI 10.1016/0167-4781(90)90178-5; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1972, P NATL ACAD SCI USA, V69, P3014, DOI 10.1073/pnas.69.10.3014; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; JANNER F, 1980, J MOL BIOL, V139, P207, DOI 10.1016/0022-2836(80)90305-8; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATEN H, 1978, NUCLEIC ACIDS RES, V5, P4329, DOI 10.1093/nar/5.11.4329; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; Liu G, 1996, TRENDS CELL BIOL, V6, P168, DOI 10.1016/0962-8924(96)20013-3; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL RE, 1967, SCIENCE, V155, P820, DOI 10.1126/science.155.3764.820; Moustafa ME, 1998, RNA, V4, P1436, DOI 10.1017/S1355838298981043; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; Ohama T, 1995, BIOCHEM MOL BIOL INT, V36, P421; ONEILL VA, 1985, J BIOL CHEM, V260, P2501; PETRULLO LA, 1983, MOL GEN GENET, V190, P289, DOI 10.1007/BF00330653; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; vanStralen PGJ, 1996, J CLIN ENDOCR METAB, V81, P244, DOI 10.1210/jc.81.1.244; Warner GJ, 1998, NUCLEIC ACIDS RES, V26, P5533, DOI 10.1093/nar/26.23.5533; WILSON RK, 1989, P NATL ACAD SCI USA, V86, P409, DOI 10.1073/pnas.86.2.409; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	47	114	119	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28110	28119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10821829				2022-12-25	WOS:000089197100077
J	Eto, H; Yoon, SS; Bode, BP; Kamidono, S; Makino, K; Saya, H; Nakamura, H; Tanabe, KK				Eto, H; Yoon, SS; Bode, BP; Kamidono, S; Makino, K; Saya, H; Nakamura, H; Tanabe, KK			Mapping and regulation of the tumor-associated epitope recognized by monoclonal antibody RS-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITIONAL CELL CARCINOMAS; O-LINKED GLYCOSYLATION; BREAST-CANCER; INTERMEDIATE FILAMENTS; EXPRESSION PATTERNS; MOLECULAR-CLONING; HUMAN KERATIN-18; CYTOKERATIN; ANTIGEN; PHOSPHORYLATION	We have previously described a rat monoclonal antibody, RS-ll, which recognizes a tumor-associated antigen common to several species. In the present study, we have cloned and characterized the antigen recognized by RS-11, We screened a phage expression library prepared from HeLa cDNA and identified a clone that reacts with RS-ll, DNA sequence analysis revealed that this clone contains sequences of keratin 18 (nucleotides 568-1196). We constructed several glutathione S-transferase fusion proteins and synthetic peptides based on this DNA sequence analysis and examined their reactivity with RS-ll to accurately map the RS-ll epitope. We determined that the epitope resides within a region of seven amino acids on the alpha-helix 2B domain of keratin 18 in which two amino acids (Leu(366) and Lys(370)) are completely conserved among intermediate filaments as well as other keratin members that are immunoreactive with RS-ll, These two residues are sequentially discontinuous but spatially adjacent, The RS-ll epitope is constitutively present in human primary cultured hepatocytes; however, its immunoreactivity with RS-11 is upregulated by malignant transformation or stimulation with either epidermal growth factor or transforming growth factor alpha.	Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Kobe Univ, Sch Med, Dept Urol, Kobe, Hyogo 650, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Kobe University; Kumamoto University	Tanabe, KK (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, Cox 626, Boston, MA 02114 USA.				NCI NIH HHS [CA71345, CA64454] Funding Source: Medline; NIDDK NIH HHS [DK43351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064454, T32CA071345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE T, 1989, JPN J CANCER RES, V80, P271, DOI 10.1111/j.1349-7006.1989.tb02304.x; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; BAUMAN PA, 1994, P NATL ACAD SCI USA, V91, P5311, DOI 10.1073/pnas.91.12.5311; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CONEY LR, 1991, CANCER RES, V51, P6125; DITZEL H, 1993, CANCER RES, V53, P5920; ERB K, 1992, HYBRIDOMA, V11, P121, DOI 10.1089/hyb.1992.11.121; ETO H, 1989, INT J CANCER, V44, P454, DOI 10.1002/ijc.2910440313; FRANKE WW, 1987, EXP CELL RES, V173, P17, DOI 10.1016/0014-4827(87)90328-4; FRANKE WW, 1983, J CELL BIOL, V97, P1255, DOI 10.1083/jcb.97.4.1255; HAREUVENI M, 1990, EUR J BIOCHEM, V189, P475, DOI 10.1111/j.1432-1033.1990.tb15512.x; HAZAN R, 1986, LAB INVEST, V54, P543; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; HOTTA H, 1988, CANCER RES, V48, P2955; Karsten U, 1998, CANCER RES, V58, P2541; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Minamizuka Toshio, 1992, Archiv fuer Japanische Chirurgie, V61, P413; MOLL R, 1988, AM J PATHOL, V132, P123; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; Nilsson O, 1997, BRIT J CANCER, V75, P789, DOI 10.1038/bjc.1997.142; Nishibori H, 1996, CANCER RES, V56, P2752; OKUDA Y, 1989, MED J KOBE U, V50, P1; OSHIMA RG, 1986, DIFFERENTIATION, V33, P61, DOI 10.1111/j.1432-0436.1986.tb00411.x; PAREKH HK, 1995, CANCER RES, V55, P5203; PFAFF M, 1988, CANCER RES, V50, P5192; SCHAAFSMA HE, 1991, AM J PATHOL, V139, P1389; SCHAAFSMA HE, 1993, J PATHOL, V170, P77, DOI 10.1002/path.1711700113; SCHAAFSMA HE, 1990, AM J PATHOL, V136, P329; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SKALETSKY E, 1988, HYBRIDOMA, V7, P367, DOI 10.1089/hyb.1988.7.367; Sundstrom B. E., 1994, International Journal of Biological Markers, V9, P102; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Wells MJ, 1997, J BIOL CHEM, V272, P28574, DOI 10.1074/jbc.272.45.28574	42	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27075	27083						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10801882				2022-12-25	WOS:000089144800056
J	Busch, E; Hohenester, E; Timpl, R; Paulsson, M; Maurer, P				Busch, E; Hohenester, E; Timpl, R; Paulsson, M; Maurer, P			Calcium affinity, cooperativity, and domain interactions of extracellular EF-hands present in BM-40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MATRIX PROTEIN BM-40; CRYSTAL-STRUCTURE; BINDING-SITES; CA2+ BINDING; 2 SERIES; CAENORHABDITIS-ELEGANS; CA2+-BINDING PROTEINS; REGULATORY DOMAIN; POINT MUTATIONS	The structure and function of cytosolic Ca2+-binding proteins containing EF-hands are well understood. Recently, the presence of EF-hands in an extracellular protein was for the first time proven by the structure determination of the EC domain of BM-40 (SPARC (for secreted protein acidic and rich in cysteine)/osteonectin) (Hohenester, E., Maurer, P., Hohenadl, C., Timpl, R., Jansonius, J. N., and Engel, J. (1996) Not. Struct. Biol. 3, 67-73). The structure revealed a pair of EF-hands with two bound Ca2+ ions. Two unusual features were noted that distinguish the extracellular EF-hands of BM-40 from their cytosolic counterparts. An insertion of one amino acid into the loop of the first EF-hand causes a variant Ca2+ coordination, and a disulfide bond connects the helices of the second EF-hand. Here we show that the extracellular EF-hands in the BM-40 EC domain bind Ca2+ cooperatively and with high affinity. The EC domain is thus in the Ca2+-saturated form in the extracellular matrix, and the EF-hands play a structural rather than a regulatory role. Deletion mutants demonstrate a strong interaction between the EC domain and the neighboring FS domain, which contributes about 10 kJ/mol to the free energy of binding and influences cooperativity. This interaction is mainly between the FS domain and the variant EF-hand 1. Certain mutations of Ca2+-coordinating residues changed affinity and cooperativity, but others inhibited folding and secretion of the EC domain in a mammalian cell line. This points to a function of EF-hands in extracellular proteins during biosynthesis and processing in the endoplasmic reticulum or Golgi apparatus.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BZ, England; Univ London Imperial Coll Sci Technol & Med, Div Med, London SW7 2BZ, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Cologne; Imperial College London; Imperial College London; Max Planck Society	Maurer, P (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.				Wellcome Trust [054334] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; Damjanovski S, 1997, J HISTOCHEM CYTOCHEM, V45, P643, DOI 10.1177/002215549704500502; DELANY A, 1998, BONE, V23, pS199; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; EBERHARD M, 1990, COMPUT APPL BIOSCI, V6, P213; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Fitzgerald MC, 1998, CURR BIOL, V8, P1285, DOI 10.1016/S0960-9822(07)00540-4; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; LINSE S, 1995, PROTEIN SCI, V4, P1038, DOI 10.1002/pro.5560040602; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; Maurer P, 1997, MATRIX BIOL, V15, P569, DOI 10.1016/S0945-053X(97)90033-0; MAURER P, 1992, EUR J BIOCHEM, V205, P233, DOI 10.1111/j.1432-1033.1992.tb16773.x; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; NICHOLSON C, 1980, FED PROC, V39, P1519; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; POCHET R, 1990, CA2PLUS BINDING PROT; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; PURCELL L, 1993, J EXP ZOOL, V265, P153, DOI 10.1002/jez.1402650207; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHWARZBAUER JE, 1993, MOL BIOL CELL, V4, P941, DOI 10.1091/mbc.4.9.941; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; SZEBENYI DM, 1981, NATURE, V294, pS327; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Vannahme C, 1999, J NEUROCHEM, V73, P12, DOI 10.1046/j.1471-4159.1999.0730012.x; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; [No title captured]	55	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25508	25515		10.1074/jbc.M001770200	http://dx.doi.org/10.1074/jbc.M001770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10801822	hybrid			2022-12-25	WOS:000088849400062
J	Vilaboa, NE; Galan, A; Troyano, A; de Blas, E; Aller, P				Vilaboa, NE; Galan, A; Troyano, A; de Blas, E; Aller, P			Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENE; MDR1 GENE; CELL-LINES; PROMOTER ACTIVITY; BINDING-PROTEIN; DRUG-RESISTANCE; SODIUM-BUTYRATE; HUMAN CANCER; ACTIVATION; AMPLIFICATION	Infection of HeLa cells with adenovirus-carrying HSF1(+) cDNA, which encodes a mutated form of HSF1 with constitutive transactivation capacity, increased multidrug resistance 1. (MDR1) mRNA level and P-glycoprotein (P-gp) cell surface content and stimulated rhodamine 123 accumulation and vinblastine efflux activity. On the other hand, infection with adenovirus-carrying HSP70 and HSP27 cDNAs did not increase MDR1/P-gp expression. HSF1 regulates MDR1/P-gp expression at the transcriptional level, since HSF1+ bound the heat-shock consensus elements (HSEs) in the MDR1 gene promoter and also activated the expression of an MDR1 promoter-driven reporter plasmid (pMDR1 (-1202)). In addition, heat-shock increased pMDR1(-1202) promoter activity but not the activity of a similar reporter plasmid with point mutations at specific HSEs, and the heat-induced increase was totally inhibited by co-transfection with an expression plasmid carrying HSF1(-), a dominant negative mutant of HSF1. The stress inducers arsenite, butyrate, and etoposide also increased pMDR1(-1202) promoter activity, but the increase was not inhibited (in the case of butyrate) or was only partially inhibited (in the case of arsenite and etoposide) by HSF1(-). These results demonstrate that HSF1 regulates MDR1 expression, and that the HSEs present in the -315 to -285 region mediate the heat-induced activation of the MDR1 promoter. However, other factors may also participate in MDR1 induction by stressing agents.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Aller, P (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Vilaboa, Nuria/L-1727-2014; Vilaboa, Nuria/S-2794-2019	Vilaboa, Nuria/0000-0003-4473-4498				ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BATES SE, 1989, MOL CELL BIOL, V9, P4337, DOI 10.1128/MCB.9.10.4337; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; FROMMEL TO, 1993, INT J CANCER, V55, P297, DOI 10.1002/ijc.2910550221; GARCIABERMEJO L, 1995, LEUKEMIA RES, V19, P713, DOI 10.1016/0145-2126(95)00045-P; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim SH, 1998, EXP MOL MED, V30, P87, DOI 10.1038/emm.1998.13; Kim SH, 1997, CANCER LETT, V115, P9, DOI 10.1016/S0304-3835(97)04725-3; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Li ZH, 1997, CANCER LETT, V119, P177, DOI 10.1016/S0304-3835(97)00267-X; Martin JL, 1997, CIRCULATION, V96, P4343; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; Rohlff C, 1998, INT J ONCOL, V12, P383; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; RONINSON IB, 1992, MUTAT RES, V276, P151, DOI 10.1016/0165-1110(92)90005-T; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHUETZ YJ, 1992, P NATL ACAD SCI USA, V88, P6911; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Sonneveld Pieter, 1997, Current Opinion in Oncology, V9, P543, DOI 10.1097/00001622-199711000-00009; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; VILABOA NE, 1995, J CELL SCI, V108, P2877; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Xia WL, 1999, CELL STRESS CHAPERON, V4, P8, DOI 10.1054/csac.1998.0113; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	43	112	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24970	24976		10.1074/jbc.M909136199	http://dx.doi.org/10.1074/jbc.M909136199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816597	hybrid, Green Published			2022-12-25	WOS:000088683300098
J	Xu, YS; Kantorow, M; Davis, J; Piatigorsky, J				Xu, YS; Kantorow, M; Davis, J; Piatigorsky, J			Evidence for gelsolin as a corneal crystallin in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-REGULATORY PROTEIN; MAJOR SOLUBLE-PROTEIN; ALDEHYDE DEHYDROGENASE; BOVINE CORNEA; F-ACTIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SEVERING PROTEINS; LENS CRYSTALLINS; PLASMA GELSOLIN; BINDING DOMAIN	We have shown that gelsolin is one of the most prevalent water-soluble proteins in the transparent cornea of zebrafish. There are also significant amounts of actin. In contrast to actin, gelsolin is barely detectable in other eye tissues (iris, lens, and remaining eye) of the zebrafish, Gelsolin cDNA hybridized intensely in Northern blots to RNA from the cornea but not from the lens, brain, or headless body. The deduced zebrafish gelsolin is similar to 60% identical to mammalian cytosolic gelsolin and has the characteristic six segmental repeats as well as the binding sites for actin, calcium, and phosphatidylinositides. In situ hybridization tests showed that gelsolin mRNA is concentrated in the zebrafish corneal epithelium. The zebrafish corneal epithelium stains very weakly with rhodamine-phalloidin, indicating little F-actin in the cytoplasm, In contrast, the mouse corneal epithelium contains relatively little gelsolin and stains intensely with rhodamine-phalloidin, as does the zebrafish extraocular muscle. We propose, by analogy with the diverse crystallins of the eye lens and with the putative enzyme-crystallins (aldehyde dehydrogenase class 3 and other enzymes) of the mammalian cornea, that gelsolin and actin-gelsolin complexes act as water-soluble crystallins in the zebrafish cornea and contribute to its optical properties.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 6 Ctr Dr,MSC 2730,Bldg 6,Rm 201, Bethesda, MD 20892 USA.				NATIONAL EYE INSTITUTE [Z01EY000126] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6; BOCK D, 1994, EUR J BIOCHEM, V225, P727, DOI 10.1111/j.1432-1033.1994.00727.x; Bohnke M, 1999, PROG RETIN EYE RES, V18, P553, DOI 10.1016/S1350-9462(98)00028-7; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; COOPER DL, 1993, ADV EXP MED BIOL, V328, P169; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; Danjo Y, 1998, J CELL SCI, V111, P3323; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; EDELHAUSER HF, 1968, J FISH RES BOARD CAN, V25, P863, DOI 10.1139/f68-081; Eisen JS, 1996, CELL, V87, P969, DOI 10.1016/S0092-8674(00)81792-4; FARRELL RA, 1994, PRINCIPLES PRACTICE, P64; GIPSON IK, 1994, PRINCIPLES PRACTICE, P3; HALTIA M, 1992, AM J MED GENET, V42, P357, DOI 10.1002/ajmg.1320420321; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; HERRMANNSDOERFER AJ, 1993, AM J PHYSIOL, V265, pG1071, DOI 10.1152/ajpgi.1993.265.6.G1071; HOLT WS, 1973, INVEST OPHTH VISUAL, V12, P114; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jester JV, 1999, J CELL SCI, V112, P613; JOYCE NC, 1994, PRINCIPLES PRACTICE, P17; Kelly GM, 1997, BIOCHEM CELL BIOL, V75, P623, DOI 10.1139/bcb-75-5-623; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUZAK JR, 1994, PRINCIPLES PRACTICE, P82; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Langer M, 1998, COMP BIOCHEM PHYS B, V119, P697, DOI 10.1016/S0305-0491(98)00045-5; LENA JY, 1994, INT J DEV NEUROSCI, V12, P375, DOI 10.1016/0736-5748(94)90021-3; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; LIND SE, 1988, AM REV RESPIR DIS, V138, P429, DOI 10.1164/ajrccm/138.2.429; Lu M, 1997, J CELL BIOL, V138, P1279, DOI 10.1083/jcb.138.6.1279; LUCK A, 1995, BIOCHEM J, V305, P767; Marks PW, 1998, J CELL SCI, V111, P2129; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MAURICE DM, 1957, J PHYSIOL-LONDON, V136, P263, DOI 10.1113/jphysiol.1957.sp005758; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Ohtsuka Y, 1998, BBA-PROTEIN STRUCT M, V1383, P219, DOI 10.1016/S0167-4838(97)00211-2; OLSEN BR, 1994, PRINCIPLES PRACTICE, P38; Pearson DS, 1996, DNA CELL BIOL, V15, P263, DOI 10.1089/dna.1996.15.263; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RABAEY M, 1981, C EUR SOC OPHTH, P41; Robbens J, 1998, MOL CELL BIOL, V18, P4589, DOI 10.1128/MCB.18.8.4589; RODRIGUES MM, 1993, AM J OPHTHALMOL, V115, P644, DOI 10.1016/S0002-9394(14)71464-3; RousseauxPrevost R, 1997, MOL REPROD DEV, V48, P63, DOI 10.1002/(SICI)1098-2795(199709)48:1<63::AID-MRD8>3.0.CO;2-N; SAX CM, 1996, J BIOL CHEM, V271, P36568; SILVERMAN B, 1981, EXP EYE RES, V33, P19, DOI 10.1016/S0014-4835(81)80078-4; STELLA MC, 1994, J CELL BIOL, V125, P607, DOI 10.1083/jcb.125.3.607; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; TANAKA J, 1993, DEV BRAIN RES, V76, P268, DOI 10.1016/0165-3806(93)90217-X; TEUBNER A, 1994, CELL TISSUE RES, V276, P535, DOI 10.1007/BF00343950; UBELS JL, 1983, CURR EYE RES, V2, P613, DOI 10.3109/02713688208996362; VERHAGEN C, 1991, EXP EYE RES, V53, P283, DOI 10.1016/0014-4835(91)90085-S; Vouyiouklis DA, 1997, J NEUROCHEM, V69, P995; WANG FS, 1991, J CELL SCI, V100, P61; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; Wieland T, 1977, Curr Probl Clin Biochem, V7, P11; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YU FX, 1992, J BIOL CHEM, V267, P14616	85	42	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24645	24652		10.1074/jbc.M001159200	http://dx.doi.org/10.1074/jbc.M001159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818094	hybrid			2022-12-25	WOS:000088683300057
J	del Pino, MMS; Corrales, FJ; Mato, JM				del Pino, MMS; Corrales, FJ; Mato, JM			Hysteretic behavior of methionine adenosyltransferase III - Methionine switches between two conformations of the enzyme with different specific activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; NITROSYLATION	Methionine adenosyltransferase III (MATIII) catalyzes S-adenosylmethionine (AdoMet) synthesis and, as part of its reaction mechanism, it also hydrolyzes tripolyphosphate. Tripolyphosphatase activity was linear over time and had a slightly sigmoidal behavior with an affinity in the low micromolar range. On the contrary, AdoMet synthetase activity showed a lag phase that was independent of protein concentration but decreased at increasing substrate concentrations. Tripolyphosphatase activity, which appeared to be slower than AdoMet synthesis, was stimulated by preincubation with ATP and methionine so that it matched AdoMet synthetase activity. This stimulation process, which is probably the origin of the lag phase, represents the slow transition between two conformations of the enzyme that could be distinguished by their different tripolyphosphatase activity and sensitivity to S-nitrosylation. Tripolyphosphatase activity appeared to be the rate-determining reaction in AdoMet synthesis and the one inhibited by S-nitrosylation. The methionine concentration necessary to obtain half-maximal stimulation was in the range of physiological methionine fluctuations. Moreover, stimulation of MAT activity by methionine was demonstrated in vivo. We propose that the hysteretic behavior of MATIII, in which methionine induces the transition to a higher specific activity conformation, can be considered as an adaptation to the specific functional requirements of the liver.	Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Navarra, Spain	University of Navarra	del Pino, MMS (corresponding author), Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Navarra, Spain.		MATO, JOSE/A-5187-2011; del Pino, Manuel M. Sánchez/I-3977-2015	MATO, JOSE/0000-0003-1264-3153; del Pino, Manuel M. Sánchez/0000-0001-9696-7600; Corrales, Fernando/0000-0002-0231-5159				Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CHOU T, 1972, BIOCHEMISTRY-US, V11, P1065, DOI 10.1021/bi00756a019; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; Graham DE, 2000, J BIOL CHEM, V275, P4055, DOI 10.1074/jbc.275.6.4055; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOMBARDINI JB, 1970, MOL PHARMACOL, V6, P481; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MATO JM, 2000, HOMOCYSTEINE HLTH DI; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017	19	25	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23476	23482		10.1074/jbc.M002730200	http://dx.doi.org/10.1074/jbc.M002730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811651	hybrid			2022-12-25	WOS:000088564200012
J	Veenhoff, LM; Geertsma, ER; Knol, J; Poolman, B				Veenhoff, LM; Geertsma, ER; Knol, J; Poolman, B			Close approximation of putative alpha-helices II, IV, VII, X, and XI in the translocation pathway of the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ESCHERICHIA-COLI; MELIBIOSE CARRIER; CATION SPECIFICITY; CHARGED RESIDUES; SUBSTRATE RECOGNITION; MEMBRANE TOPOLOGY; SUGAR-TRANSPORT; PERMEASE; MUTANTS	The lactose transport protein (LacS) of Streptococcus thermophilus belongs to a family of transporters in which putative alpha-helices II and TV have been implicated in cation binding and the coupled transport of the substrate and the cation, Here, the analysis of site-directed mutants shows that a positive and negative charge at positions 64 and 71 in helix II are essential for transport, but not for lactose binding. The conservation of charge/side-chain properties is less critical for Glu-67 and Ile-70 in helix II, and Asp-133 and Lys-139 in helix TV, but these residues are important for the coupled transport of lactose together with a proton. The analysis of second-site suppressor mutants indicates an ion pair exists between helices II and IV, and thus a close approximation of these helices can be made. The second-site suppressor analysis also suggests ion pairing between helix II and the intracellular loops 6-7 and 10-11, Because the C-terminal region of the transmembrane domain, especially helix XI and loop 10-11, is important for substrate binding in this family of proteins, we propose that sugar and proton binding and translocation are performed by the joint action of these regions in the protein. Indeed, substrate protection of maleimide labeling of single cysteine mutants confirms that cy-helices II and TV are directly interacting or at least conformationally involved in sugar binding and/or translocation, On the basis of new and published data, we reason that the helices II, IV, VII, X, and XI and the intracellular loops 6-7 and 10-11 are in close proximity and form the binding sites and/or the translocation pathway in the transporters of the galactosides-pentosides-hexuronides family.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Technol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Technol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Knol, Jan/A-2178-2010; Poolman, Bert/D-1882-2012; Knol, Jan/AAL-6487-2020	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961; Veenhoff, Liesbeth/0000-0002-0158-4728; Geertsma, Eric R./0000-0002-2789-5444				BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Cordat E, 1998, J BIOL CHEM, V273, P33198, DOI 10.1074/jbc.273.50.33198; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Franco PJ, 1999, J BACTERIOL, V181, P6377, DOI 10.1128/JB.181.20.6377-6386.1999; Franco PJ, 1996, BBA-BIOMEMBRANES, V1282, P240, DOI 10.1016/0005-2736(96)00062-4; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Gunnewijk MGW, 1999, J BACTERIOL, V181, P632, DOI 10.1128/JB.181.2.632-641.1999; Gwizdek C, 1997, BIOCHEMISTRY-US, V36, P8522, DOI 10.1021/bi970312n; HAMA H, 1994, J BIOL CHEM, V269, P1063; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; LOLKEMA JS, 1995, J BIOL CHEM, V270, P12670, DOI 10.1074/jbc.270.21.12670; Maehrel C, 1998, J BIOL CHEM, V273, P33192, DOI 10.1074/jbc.273.50.33192; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POURCHER T, 1993, J BIOL CHEM, V268, P3209; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SHIOTA S, 1984, J BACTERIOL, V160, P445, DOI 10.1128/JB.160.1.445-447.1984; SHUGAR D, 1976, BIOCHIM BIOPHYS ACTA, V447, P274, DOI 10.1016/0005-2787(76)90050-2; Spooner PJR, 1999, BIOCHEMISTRY-US, V38, P9634, DOI 10.1021/bi990745l; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; WILSON DM, 1995, BIOCHEM BIOPH RES CO, V209, P242, DOI 10.1006/bbrc.1995.1495; Wilson TH, 1998, BBA-BIOMEMBRANES, V1374, P77, DOI 10.1016/S0005-2736(98)00132-1; ZANI ML, 1994, J BIOL CHEM, V269, P24883; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23834	23840		10.1074/jbc.M001343200	http://dx.doi.org/10.1074/jbc.M001343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816556	Green Published, hybrid			2022-12-25	WOS:000088564200059
J	Walter, J; Schindzielorz, A; Hartung, B; Haass, C				Walter, J; Schindzielorz, A; Hartung, B; Haass, C			Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURITE OUTGROWTH; ALZHEIMERS-DISEASE; ECTOPROTEIN KINASE; SELECTIVE INHIBITOR; SULFATED GLYCOSAMINOGLYCANS; ECTODOMAIN PHOSPHORYLATION; ENDOTHELIAL-CELLS; HUMAN PLATELETS; FACTOR-VA; SECRETION	The beta-amyloid precursor protein (beta APP) is one of the rare proteins known to be phosphorylated within its ectodomain. We have shown previously that beta APP can be phosphorylated within secretory vesicles and at the cell surface (Walter, J,, Capell, A., Hung, A. Y,, Langen, H,, Schnolzer, M,, Thinakaran, G., Sisodia, S. S,, Selkoe, D, J,, and Haass, C. (1997) J. Biol. Chem. 272, 1896-1903). We have now specifically characterized the phosphorylation of cell surface-located beta APP and identified two ectoprotein kinases that phosphorylate beta APP at the outer face of the plasma membrane. By using selective protein kinase inhibitors and by investigating the usage of ATP and GTP as cosubstrates, we demonstrate that membrane-bound beta APP as well as secreted forms of beta APP can be phosphorylated by casein kinase (CK) 1- and CK2-like ectoprotein kinases, The ectodomain of beta APP was also phosphorylated by purified CK1 and CK2 in vitro, but not by protein kinases A and C, Phosphorylation of beta APP by ectoprotein kinases and by purified CK1 and CK2 occurred within an acidic domain in the N-terminal half of the protein, Heparin strongly inhibited the phosphorylation of cell-surface beta APP by ecto-CK1 and ecto-CK2, indicating a regulatory role of this extracellular matrix component in beta APP phosphorylation.	Univ Munich, Lab Alzheimers Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Walter, J (corresponding author), Univ Munich, Lab Alzheimers Dis Res, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	jwalter@pbm.med.uni-muenchen.de; chaass@pbm.med.uni-muenchen.de	Walter, Jochen/B-3677-2014; Wang, Caihong/T-5837-2019	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912				Ando K, 1999, J NEUROSCI, V19, P4421; Babinska A, 1996, AM J PHYSIOL-HEART C, V271, pH2134, DOI 10.1152/ajpheart.1996.271.5.H2134; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1990, J BIOL CHEM, V265, P15977; Chen W, 1996, P NATL ACAD SCI USA, V93, P8688, DOI 10.1073/pnas.93.16.8688; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; Ekdahl KN, 1999, J IMMUNOL, V162, P7426; ERIKSSON S, 1993, THROMB RES, V72, P315, DOI 10.1016/0049-3848(93)90140-J; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; JELINEK T, 1993, BIOTECHNIQUES, V15, P629; KALAFATIS M, 1993, BLOOD, V81, P704; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1993, BIOCHEM BIOPH RES CO, V197, P380, DOI 10.1006/bbrc.1993.2490; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, J BIOL CHEM, V257, P322; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MULTHAUP G, 1994, BIOCHIMIE, V76, P304, DOI 10.1016/0300-9084(94)90163-5; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V205, P1467, DOI 10.1006/bbrc.1994.2830; NAGASHIMA K, 1991, FEBS LETT, V293, P119, DOI 10.1016/0014-5793(91)81165-5; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; PAAS Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P780, DOI 10.1006/abbi.1995.1104; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Qi Z, 1998, FEBS LETT, V423, P227, DOI 10.1016/S0014-5793(98)00096-9; RAND MD, 1994, BLOOD, V83, P2180; Schindzielorz A, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P231; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; VOLONTE C, 1994, J NEUROCHEM, V63, P2028; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; [No title captured]	75	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23523	23529		10.1074/jbc.M002850200	http://dx.doi.org/10.1074/jbc.M002850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10806211	hybrid			2022-12-25	WOS:000088564200018
J	Korman, VL; Hatch, V; Dixon, KY; Craig, R; Lehman, W; Tobacman, LS				Korman, VL; Hatch, V; Dixon, KY; Craig, R; Lehman, W; Tobacman, LS			An actin subdomain 2 mutation that impairs thin filament regulation by troponin and tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN SUBFRAGMENT-1; 3-DIMENSIONAL RECONSTRUCTION; MUSCLE-CONTRACTION; F-ACTIN; STRUCTURAL DYNAMICS; CARDIAC TROPONIN; BINDING; MICROSCOPY; CALDESMON; RESIDUE	Striated muscle thin filaments adopt different quaternary structures, depending upon calcium binding to troponin and myosin binding to actin. Modification of actin subdomain 2 alters troponin-tropomyosin-mediated regulation, suggesting that this region of actin may contain important protein-protein interaction sites. We used yeast actin mutant D56A/E57A to examine this issue. The mutation increased the affinity of tropomyosin for actin 3-fold. The addition of Ca2+ to mutant actin filaments containing troponin-tropomyosin produced little increase in the thin filament-myosin S1 MgATPase rate. Despite this, three-dimensional reconstruction of electron microscope images of filaments in the presence of troponin and Ca2+ showed tropomyosin to be in a position similar to that found for muscle actin filaments, where most of the myosin binding site is exposed. Troponin-tropomyosin bound with comparable affinity to mutant and wild type actin in the absence and presence of calcium, and in the presence of myosin S1, tropomyosin bound very tightly to both types of actin. The mutation decreased actin-myosin S1 affinity 13-fold in the presence of troponin-tropomyosin and 2.6-fold in the absence of the regulatory proteins. The results suggest the importance of negatively charged actin subdomain 2 residues 56 and 57 for myosin binding to actin, for tropomyosin-actin interactions, and for regulatory conformational changes in the actin-troponin-tropomyosin complex.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA	University of Iowa; University of Iowa; University of Massachusetts System; University of Massachusetts Worcester; Boston University	Tobacman, LS (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200 Hawkins Dr,SE610,GH, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu		Lehman, William/0000-0002-9430-9521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036153, R01HL038834, R37HL036153, R29HL038834, R01HL036153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38834, HL-36153] Funding Source: Medline; NIAMS NIH HHS [AR-34711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; BONAFE N, 1994, BIOCHEMISTRY-US, V33, P2594, DOI 10.1021/bi00175a031; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; COOK RK, 1992, J BIOL CHEM, V267, P9430; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Hanein D, 1999, BIOPHYS J, V76, pA145; HILL LE, 1992, J BIOL CHEM, V267, P16106; HOLMES KC, 1995, BIOPHYS J, V68, pS2; JOHNSON P, 1978, BIOCHEM BIOPH RES CO, V82, P1013, DOI 10.1016/0006-291X(78)90884-7; Korman VL, 1999, J BIOL CHEM, V274, P22191, DOI 10.1074/jbc.274.32.22191; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kronert WA, 1999, J CELL BIOL, V144, P989, DOI 10.1083/jcb.144.5.989; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; McArdle K, 1998, J CELL BIOL, V143, P1201, DOI 10.1083/jcb.143.5.1201; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MIKI M, 1989, J BIOCHEM-TOKYO, V106, P651, DOI 10.1093/oxfordjournals.jbchem.a122911; MIKI M, 1991, BIOCHEMISTRY-US, V30, P5625, DOI 10.1021/bi00236a042; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; Orlova A, 1997, J MOL BIOL, V265, P469, DOI 10.1006/jmbi.1996.0761; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POOLE KJV, 1995, BIOPHYS J, V68, pS348; Prochniewicz E, 1999, BIOCHEMISTRY-US, V38, P14860, DOI 10.1021/bi991343g; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Razzaq A, 1999, J BIOL CHEM, V274, P28321, DOI 10.1074/jbc.274.40.28321; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; ROSOL M, 2000, BIOPHYS J, V78, P339; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; VIBERT P, 1982, J MOL BIOL, V157, P299, DOI 10.1016/0022-2836(82)90236-4; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WERTMAN KF, 1992, GENETICS, V132, P337; Xu C, 1999, BIOPHYS J, V77, P985, DOI 10.1016/S0006-3495(99)76949-3	53	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22470	22478		10.1074/jbc.M002939200	http://dx.doi.org/10.1074/jbc.M002939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801864	hybrid			2022-12-25	WOS:000088363800096
J	Hoshino, H; Kobayashi, A; Yoshida, M; Kudo, N; Oyake, T; Motohashi, H; Hayashi, N; Yamamoto, M; Igarashi, K				Hoshino, H; Kobayashi, A; Yoshida, M; Kudo, N; Oyake, T; Motohashi, H; Hayashi, N; Yamamoto, M; Igarashi, K			Oxidative stress abolishes leptomycin B-sensitive nuclear export of transcription repressor Bach2 that counteracts activation of Maf recognition element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENTS; DNA-BINDING ACTIVITY; YA SUBUNIT GENE; FACTOR PAP1; CRM1; PROTEINS; SIGNAL; IDENTIFICATION; RESISTANCE; RECEPTOR	The mammalian transcription activator Nrf2 plays critical roles in executing oxidative stress response by binding to the regulatory DNA sequence Maf recognition element. Bach2 is an Nrf2-related transcription repressor and a tissue-specific partner of the Maf oncoprotein family. We show here how Bach2 is regulated by an oxidative stress-sensitive conditional nuclear export. In cultured cells, Bach2 was localized in cytoplasm through its C-terminal evolutionarily conserved cytoplasmic localization signal (CLS), The CLS directed leptomycin B-sensitive nuclear export of reporter proteins, suggesting its dependence on the nuclear exporter Crm1/exportin 1. However, the CLS sequence does not bear a resemblance to the leucine-rich class of nuclear export signal, and mutagenesis analysis indicated that a stretch of nonhydrophobic amino acids is essential for its activity. Oxidative stressors aborted the CLS activity and induced nuclear accumulation of Bach2, Whereas oxidative stress is known to activate MARE-dependent transcription, overexpression of Bach2 in cultured cells silenced the inducibility of MARE. The results suggest that Bach2 mediates nucleocytoplasmic communication to couple oxidative stress and transcription repression in mammalian cells.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Tohoku Univ, Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Tsukuba, Ctr Tsukuba Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Hiroshima University; Tohoku University; University of Tsukuba; University of Tsukuba; University of Tokyo	Igarashi, K (corresponding author), Hiroshima Univ, Sch Dent, Dept Biochem, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.		Kobayashi, Akira/AAN-8003-2020; Yamamoto, Masayuki/A-4873-2010; Kudo, Nobuaki/AAU-7196-2021; Yoshida, Minoru/C-8049-2014; Motohashi, Hozumi/AAZ-2628-2020	Yamamoto, Masayuki/0000-0002-9073-9436; Yoshida, Minoru/0000-0002-4376-5674; Kobayashi, Akira/0000-0001-9727-1218; Igarashi, Kazuhiko/0000-0002-2470-2475; Kudo, Nobuaki/0000-0001-8134-1242				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Camhi S L, 1995, New Horiz, V3, P170; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Oyake T, 1996, MOL CELL BIOL, V16, P6083; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU AL, 1993, J BIOL CHEM, V268, P18850; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416	41	84	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15370	15376		10.1074/jbc.275.20.15370	http://dx.doi.org/10.1074/jbc.275.20.15370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809773	hybrid			2022-12-25	WOS:000087128300081
J	Mouyna, I; Fontaine, T; Vai, M; Monod, M; Fonzi, WA; Diaquin, M; Popolo, L; Hartland, RP; Latge, JP				Mouyna, I; Fontaine, T; Vai, M; Monod, M; Fonzi, WA; Diaquin, M; Popolo, L; Hartland, RP; Latge, JP			Glycosylphosphatidylinositol-anchored glucanosyltransferases play an active role in the biosynthesis of the fungal cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE GAS1 PROTEIN; SERINE-RICH REGION; PH-REGULATED GENE; SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; ASPERGILLUS-FUMIGATUS; BETA-1,3-GLUCAN CONTENT; POLYACRYLAMIDE GELS; MEMBRANE-PROTEINS; PLASMA-MEMBRANE	A novel 1,3-beta-glucanosyltransferase isolated from the cell wall of Aspergillus fumigatus was recently characterized. This enzyme splits internally a 1,3-beta-glucan molecule and transfers the newly generated reducing end to the non-reducing end of another 1,3-beta-glucan molecule forming a 1,3-beta linkage, resulting in the elongation of 1,3-beta-glucan chains. The GEL1 gene encoding this enzyme was cloned and sequenced. The predicted amino acid sequence of Gellp was homologous to several yeast protein families encoded by GAS of Saccharomyces cerevisiae, PHR of Candida albicans, and EPD of Candida maltosa, Although the expression of these genes is required for correct morphogenesis in yeast, the biochemical function of the encoded proteins was unknown. The biochemical assays performed on purified recombinant Gas1p, Phr1p, and Phr2p showed that these proteins have a 1,3-beta-glucanosyltransferase activity similar to that of Gellp, Biochemical data and sequence analysis have shown that Gellp is attached to the membrane through a glycosylphosphatidylinositol in a similar manner as the yeast homologous proteins. The activity has been also detected in membrane preparations, showing that this 1,3-beta-glucanosyltransferase is indeed active in vivo. Our results show that transglycosidases anchored to the plasma membrane via glycosylphosphatidylinositols can play an active role in fungal cell wall synthesis.	Inst Pasteur, Lab Aspergillus, F-75724 Paris 15, France; Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; CHU Vaudois, Hop Beaumont, Serv Dermatol, Lab Mycol, CH-1011 Lausanne, Switzerland; Georgetown Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Washington, DC 20007 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Milan; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Georgetown University	Mouyna, I (corresponding author), Inst Pasteur, Lab Aspergillus, 25 Rue Dr Roux, F-75724 Paris 15, France.		Latge, Jean Paul/C-9846-2014; latge, jean paul/F-3581-2011; mouyna, isabelle/F-3578-2011; Fontaine, thierry/Q-2201-2018; Fontaine, Thierry/F-8227-2011; Mouyna, Isabelle/O-7697-2018; Popolo, Laura/B-1173-2017	Fontaine, thierry/0000-0002-8184-789X; Mouyna, Isabelle/0000-0003-3140-5927; Popolo, Laura/0000-0002-5590-0167				BEAUVAIS A, 1993, J GEN MICROBIOL, V139, P3071, DOI 10.1099/00221287-139-12-3071; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Borg-von Zepelin M, 1998, MOL MICROBIOL, V28, P543, DOI 10.1046/j.1365-2958.1998.00815.x; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; Fontaine T, 1997, BIOCHEM SOC T, V25, P194, DOI 10.1042/bst0250194; GATTI E, 1994, J BIOL CHEM, V269, P19695; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GHANNOUM MA, 1995, INFECT IMMUN, V63, P4528, DOI 10.1128/IAI.63.11.4528-4530.1995; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; Hartland RP, 1996, J BIOL CHEM, V271, P26843, DOI 10.1074/jbc.271.43.26843; HEARN VM, 1994, MICROBIOL-UK, V140, P789, DOI 10.1099/00221287-140-4-789; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kelly R, 1996, J BACTERIOL, V178, P4381, DOI 10.1128/jb.178.15.4381-4391.1996; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KOIZUMI K, 1989, J CHROMATOGR, V464, P365; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; LARRIBA G, 1995, FEMS MICROBIOL LETT, V125, P121; LATGE JP, 1991, NATO ASI SERIES H, V53, P143; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; Mouyna I, 1998, MICROBIOL-SGM, V144, P3171, DOI 10.1099/00221287-144-11-3171; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; Nakazawa T, 1998, J BACTERIOL, V180, P2079, DOI 10.1128/JB.180.8.2079-2086.1998; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; POPOLO L, 1993, CURR GENET, V24, P382, DOI 10.1007/BF00351845; Popolo L, 1998, J BACTERIOL, V180, P163, DOI 10.1128/JB.180.1.163-166.1998; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; Popolo L, 1997, J BACTERIOL, V179, P463, DOI 10.1128/jb.179.2.463-469.1997; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SANSEGUNDO P, 1993, J BACTERIOL, V175, P3823, DOI 10.1128/JB.175.12.3823-3837.1993; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vai M, 1996, YEAST, V12, P361, DOI 10.1002/(SICI)1097-0061(19960330)12:4<361::AID-YEA920>3.0.CO;2-T; VAI M, 1991, J BIOL CHEM, V266, P12242; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; vanderVaart JM, 1996, BBA-GEN SUBJECTS, V1291, P206, DOI 10.1016/S0304-4165(96)00067-0; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	43	275	289	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14882	14889		10.1074/jbc.275.20.14882	http://dx.doi.org/10.1074/jbc.275.20.14882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809732	hybrid, Green Published			2022-12-25	WOS:000087128300017
J	Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L				Bossu, P; Vanoni, M; Wanke, V; Cesaroni, MP; Tropea, F; Melillo, G; Asti, C; Porzio, S; Ruggiero, P; Di Cioccio, V; Maurizi, G; Ciabini, A; Alberghina, L			A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts	ONCOGENE			English	Article						CDC25(Mm); signal transduction therapy; fos-luciferase; oncogenes; GEF	TARGETING SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; DISEASE THERAPY; IN-VIVO; PROTEIN; GRB2; EXPRESSION; RECEPTOR; CLONING; FAMILY	Ras proteins are small GTPases playing a pivotal role in cell proliferation and differentiation, Their activation state depends on the competing action of GTPase Activating Proteins (GAP) and Guanine nucleotide Exchange Factors (GEF), A tryptophan residue (Trp1056 in CDC25(Mm)-GEF), conserved in all ras-specific GEFs identified so far has been previously shown to be essential for GEF activity. Its substitution with glutamic acid results in a catalytically inactive mutant, which is able to efficiently displace wild-ty pe GEF from p21(ras) and to originate a stable ras/GEF binary complex due to the reduced affinity of the nucleotide-free ras/GEF complex for the incoming nucleotide, We show here that this 'ras-sequestering property' can be utilized to attenuate ras signal transduction pathways in mouse fibroblasts transformed by oncogenic ras, In fact overexpression of the dominant negative GEF(W1056E), stable transfected cells strongly reduces intracellular ras GTP levels in k-ras transformed fibroblasts. Accordingly, the transfected fibroblasts revert to wild-type phenotype on the basis of morphology, cell cycle and anchorage independent growth. The reversion of the transformed phenotype is accompanied bar DNA endoreduplication, The possible use of dominant negative ras-specific GEFs as a tool to down-regulate tumor growth is discussed.	Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Ctr Ric Dompe, Laquila, Italy	University of Milano-Bicocca; Dompe	Alberghina, L (corresponding author), Univ Milan Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Di Cioccio, Vito/N-1296-2013; Bossù, Paola/E-4832-2014; Vanoni, Marco/AAA-3699-2021; Nacmias, Benedetta/J-5084-2018	Di Cioccio, Vito/0000-0002-8063-9650; Bossù, Paola/0000-0002-1432-0078; Vanoni, Marco/0000-0002-8690-2587; Nacmias, Benedetta/0000-0001-9338-9040; Alberghina, Lilia/0000-0003-1694-931X				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DHIN L, 1999, NATURE, V400, P468; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Downward J, 1997, CURR BIOL, V7, P258; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Guerrero C, 1996, ONCOGENE, V12, P1097; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Levitzki A, 1997, MED ONCOL, V14, P83, DOI 10.1007/BF02990952; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1994, INT J ONCOL, V4, P175; Zippel R, 1996, ONCOGENE, V12, P2697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	49	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2147	2154		10.1038/sj.onc.1203539	http://dx.doi.org/10.1038/sj.onc.1203539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815806				2022-12-25	WOS:000086728000008
J	Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F				Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F			Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation	ONCOGENE			English	Article						adenocarcinoma; epidermal growth factor receptor; mammary gland; transgenic mice; differentiation	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR-ALPHA; TGF-ALPHA; FUNCTIONAL-DIFFERENTIATION; BETA-LACTOGLOBULIN; GENE-EXPRESSION; EGF-RECEPTOR; HUMAN COLON; MICE	The epidermal growth factor receptor (EGFR) is overexpressed in about 48% of human breast cancer tissues. To analyse the role of the EGFR in mammary tumor development me generated transgenic mice expressing the human EGFR under the control of either the MMTV-LTR (MHERc) or the beta-lactoglobulin promoter (BLGHERc), The BLGHERc-transgene was expressed exclusively in the female mammary. gland, whereas the MHERc transgene was expressed more promiscuously in other organs, such as ovary, salivary gland and testis, Female virgin and lactating transgenic mice of both strains have impaired mammary gland development. Virgin EGFR transgenic mice developed mammary epithelial hyperplasias, whereas in lactating animals progression to dysplasias and tubular adenocarcinomas was observed. In both strains the number of dysplasias increased after multiple pregnancies. The transgene expression pattern mas heterogeneous, but generally restricted to regions of impaired mammary gland development. Highest EGFR transgene expression was observed in adenocarcinomas. By using a whole mount organ culture sa stem to study the differentiation potential of the mammary epithelium, we observed a reduced number of fully developed alveoli and a decrease in whey acidic protein expression. Taken together, EGFR overexpression results in a dramatic effect of impaired mammary gland development in vitro as well as in vitro, reducing the differentiation potential of the mammary epithelium and inducing epithelial cell transformation.	Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, D-10117 Berlin, Germany; Schering Res Labs, D-13342 Berlin, Germany; MDC Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Theuring, F (corresponding author), Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, Dorotheen Str 94, D-10117 Berlin, Germany.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ARCHIBALD AL, 1990, P NATL ACAD SCI USA, V87, P5178, DOI 10.1073/pnas.87.13.5178; BANERJEE MR, 1973, IN VITRO CELL DEV B, V9, P129, DOI 10.1007/BF02616011; BARASH I, 1994, TRANSGENIC RES, V3, P141, DOI 10.1007/BF01973981; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BORG A, 1991, ONCOGENE, V6, P137; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1989, ONCOGENE, V4, P831; FAN Z, 1993, CANCER RES, V53, P4322; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; GOLDENRING JR, 1993, REGUL PEPTIDES, V43, P37, DOI 10.1016/0167-0115(93)90405-W; GRAMLICH TL, 1994, AM J CLIN PATHOL, V101, P493; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HARRIS AL, 1987, REGULATORY MECHANISM, P93; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Hinrichs S H, 1991, Princess Takamatsu Symp, V22, P259; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Krane IM, 1996, ONCOGENE, V12, P1781; LEE PPH, 1995, ENDOCRINOLOGY, V136, P1718, DOI 10.1210/en.136.4.1718; LIU TH, 1995, CHINESE MED J-PEKING, V108, P653; Matsui Y., 1990, CELL, V61, P1137; MCCLENAGHAN M, 1995, BIOCHEM J, V310, P637, DOI 10.1042/bj3100637; MULLANEY BP, 1992, MOL ENDOCRINOL, V6, P2103, DOI 10.1210/me.6.12.2103; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; RIVERA EM, 1967, METHODS MAMMAL EMBRY, V31, P442; Salomon D S, 1991, Cancer Treat Res, V53, P107; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; YEE LD, 1989, SEMIN DIAGN PATHOL, V6, P110; YULL F, 1996, TRANSGENIC RES, V6, P7	42	58	61	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2129	2137		10.1038/sj.onc.1203520	http://dx.doi.org/10.1038/sj.onc.1203520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815804				2022-12-25	WOS:000086728000006
J	Podor, TJ; Shaughnessy, SG; Blackburn, MN; Peterson, CB				Podor, TJ; Shaughnessy, SG; Blackburn, MN; Peterson, CB			New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1 vitronectin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-B DOMAIN; PAI-1 BINDING-SITE; PLASMA VITRONECTIN; ANALYTICAL ULTRACENTRIFUGATION; STRUCTURAL REQUIREMENTS; CONFORMATIONAL-CHANGES; UROKINASE RECEPTOR; ESCHERICHIA-COLI; CELL ATTACHMENT; LIGAND-BINDING	Plasminogen activator inhibitor-type 1 (PAI-1) is the primary inhibitor of endogenous plasminogen activators that generate plasmin in the vicinity of a thrombus to initiate thrombolysis, or in the pericellular region of cells to facilitate migration and/or tissue remodeling. It has been shown that the physiologically relevant form of PAI-1 is in a complex with the abundant plasma glycoprotein, vitronectin, The interaction between vitronectin and PAI-1 is important for stabilizing the inhibitor in a reactive conformation. Although the complex is clearly significant, information is vague regarding the composition of the complex and consequences of its formation on the distribution and activity of vitronectin in vivo, Most studies have assumed a 1:1 interaction between the two proteins, but this has not been demonstrated experimentally and is a matter of some controversy since more than one PAI-1-binding site has been proposed within the sequence of vitronectin, To address this issue, competition studies using monoclonal antibodies specific for separate epitopes confirmed that the two distinct PAI-1-binding sites present on vitronectin can be occupied simultaneously. Analytical ultracentrifugation was used also for a rigorous analysis of the composition and sizes of complexes formed from purified vitronectin and PAI-1. The predominant associating species observed was high in molecular weight (M-r similar to 320,000), demonstrating that self-association of vitronectin occurs upon interaction with PAI-1, Moreover, the size of this higher order complex indicates that two molecules of PAI-1 bind per vitronectin molecule. Binding of PAI-1 to vitronectin and association into higher order complexes is proposed to facilitate interaction with macromolecules on surfaces.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON 18V 1C3, Canada; Hamilton Civ Hosp, Res Ctr, Hamilton, ON 18V 1C3, Canada; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA	University of Tennessee System; University of Tennessee Knoxville; McMaster University; McMaster University; GlaxoSmithKline	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	Cynthia_Peterson@utk.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS I, 1994, METHOD ENZYMOL, V240, P459; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Fay WP, 1996, ARTERIOSCL THROM VAS, V16, P1277, DOI 10.1161/01.ATV.16.10.1277; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Gibson AD, 1999, J BIOL CHEM, V274, P6432, DOI 10.1074/jbc.274.10.6432; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; Hill SA, 1996, BLOOD, V87, P5061, DOI 10.1182/blood.V87.12.5061.bloodjournal87125061; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KEIJER J, 1991, BLOOD, V78, P401; KOST C, 1992, J BIOL CHEM, V267, P12098; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PITT WG, 1989, J COLLOID INTERF SCI, V129, P231, DOI 10.1016/0021-9797(89)90435-9; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; POLLANEN J, 1991, ADV CANCER RES, V57, P273; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; Robbie LA, 1996, THROMB HAEMOSTASIS, V75, P127; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANE DC, 1991, THROMB HAEMOSTASIS, V66, P310; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; Seiffert D, 1997, J BIOL CHEM, V272, P9971; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; STEELE JG, 1993, J BIOMED MATER RES, V27, P927, DOI 10.1002/jbm.820270712; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; UNDERWOOD PA, 1993, J CELL SCI, V104, P793; VANLOON BJP, 1992, THROMB HAEMOSTASIS, V67, P101; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	53	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25402	25410		10.1074/jbc.M000362200	http://dx.doi.org/10.1074/jbc.M000362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10821827	Green Published, hybrid			2022-12-25	WOS:000088849400048
J	Nichols, A; Camps, M; Gillieron, C; Chabert, C; Brunet, A; Wilsbacher, J; Cobb, M; Pouyssegur, J; Shaw, JP; Arkinstall, S				Nichols, A; Camps, M; Gillieron, C; Chabert, C; Brunet, A; Wilsbacher, J; Cobb, M; Pouyssegur, J; Shaw, JP; Arkinstall, S			Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; MAP KINASE; TYROSINE-PHOSPHATASE; SELECTIVELY DEPHOSPHORYLATES; CRYSTAL-STRUCTURE; INTERACTION MOTIF; MAMMALIAN-CELLS; DOCKING SITES; GROWTH-FACTOR; HEAT-SHOCK	Mitogen-activated protein (MAP) kinase phosphatase-3 (MKP-3) is a dual specificity phosphatase that inactivates extracellular signal-regulated kinase (ERK) MAP kinases. This reflects tight and specific binding between ERR and the MKP-8 amino terminus with consequent phosphatase activation and dephosphorylation of the bound MAP kinase. We have used a series of p38/ERK chimeric molecules to identify domains within ERR necessary for binding and catalytic activation of MKP-3. These studies demonstrate that ERK kinase subdomains V-XI are necessary and sufficient for binding and catalytic activation of MKP-3. These domains constitute the major COOH-terminal structural lobe of ERK, p38/ERK chimeras possessing these regions display increased sensitivity to inactivation by MKP-3. These data also reveal an overlap between ERR domains interacting with MKP-3 and those known to confer substrate specificity on the ERK RAP kinase. Consistent with this, we show that peptides representing docking sites within the target substrates Elk-1 and p90(rsk) inhibit ERR-dependent activation of MKP-3. In addition, abolition of ERR-dependent phosphatase activation following mutation of a putative (k) under bar inase (i) under bar nteraction (m) under bar otif (KIM) within the MKP-3 NH2 terminus suggests that key sites of contact for the ERK COOH-terminal structural lobe include residues localized between the Cdc25 homology domains (CH2) found conserved between members of the DSP gene family.	Ares Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Nice, Ctr Biochim, CNRS UMR 6543, F-06108 Nice, France	Merck & Company; Serono International S.A.; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Arkinstall, S (corresponding author), Serono Reprod Biol Inst Inc, 280 Pond St, Randolph, MA 02368 USA.			Cobb, Melanie/0000-0003-0833-5473; Camps, Montserrat/0000-0002-9849-8657				Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King AG, 1995, ONCOGENE, V11, P2553; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	52	80	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24613	24621		10.1074/jbc.M001515200	http://dx.doi.org/10.1074/jbc.M001515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10811804	hybrid			2022-12-25	WOS:000088683300053
J	Zhao, Q; Morales, CR				Zhao, Q; Morales, CR			Identification of a novel sequence involved in lysosomal sorting of the sphingolipid activator protein prosaposin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR SULFATED GLYCOPROTEIN-1; MANNOSE 6-PHOSPHATE RECEPTOR; COMMON BACKBONE STRUCTURE; RAT SERTOLI CELLS; CYTOPLASMIC TAIL; SAPOSIN-B; METACHROMATIC LEUKODYSTROPHY; ENTAMOEBA-HISTOLYTICA; NONCILIATED CELLS; TARGETING SIGNAL	Prosaposin is synthesized as a 53-kDa protein, posttranslationally modified to a 65-kDa form and further glycosylated to a 70-kDa secretory product. The 65-kDa protein is associated to Golgi membranes and is targeted to lysosomes, where four smaller nonenzymatic saposins implicated in the hydrolysis of sphingolipids are generated by its partial proteolysis. The targeting of the 65-kDa protein to lysosomes is not mediated by the mannose B-phosphate receptor. The Golgi apparatus appears to accomplish the molecular sorting of the 65-kDa prosaposin by decoding a signal from its amino acid backbone. This investigation deals with the characterization of the sequence involved in this process by deleting the saposin functional domains A, B, C, and D and the highly conserved N and C termini of prosaposin. The truncated cDNAs were subcloned into expression vectors and transfected to COS-7 cells. The destination of the mutated proteins was assessed by immunocytochemistry. Deletion of the C terminus did not interfere with the secretion of prosaposin but abolished its transport to lysosomes, Deletion of saposins and the N-terminal domain did not affect the lysosomal or secretory routing of prosaposin, A chimeric construct of albumin and the C terminus of prosaposin was not directed to lysosomes, However, albumin connected to the C terminus and one or more functional domains of prosaposin reached lysosomes, indicating that the C terminus and at least one saposin domain are required for this process. In summary, we are reporting a novel sequence involved in the targeting of prosaposin to lysosomes.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University	Morales, CR (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	cxco@musica.mcgill.ca	Morales, Carlos R./H-1055-2011	Zhao, Qing/0000-0002-5757-5273				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Azuma N, 1998, BIOCHEM J, V330, P321, DOI 10.1042/bj3300321; AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Campana WM, 1999, J NEUROSCI RES, V57, P332; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GLEW RH, 1988, LAB INVEST, V58, P5; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HOOK GER, 1982, J BIOL CHEM, V257, P9211; IGDOURA SA, 1993, ANAT RECORD, V235, P411, DOI 10.1002/ar.1092350310; IGDOURA SA, 1995, MOL REPROD DEV, V40, P91, DOI 10.1002/mrd.1080400112; Igdoura SA, 1996, CELL TISSUE RES, V283, P385, DOI 10.1007/s004410050549; INUI K, 1983, P NATL ACAD SCI-BIOL, V80, P3074, DOI 10.1073/pnas.80.10.3074; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6917, DOI 10.1021/bi00242a015; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kolter T, 1998, BRAIN PATHOL, V8, P79; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KORNFELD S, 1985, HOSP PRACT, V20, P71; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LAMONTAGNE S, 1994, J BIOL CHEM, V269, P20528; Lefrancois S, 1999, J LIPID RES, V40, P1593; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; LYNCH EC, 1982, EMBO J, V1, P801, DOI 10.1002/j.1460-2075.1982.tb01250.x; MAILLET CM, 1993, EXP CELL RES, V208, P282, DOI 10.1006/excr.1993.1248; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MORIMOTO S, 1990, ANAL BIOCHEM, V190, P154, DOI 10.1016/0003-2697(90)90173-7; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MUNFORD RS, 1995, J LIPID RES, V36, P1653; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PONTING CP, 1994, PROTEIN SCI, V3, P359; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; POTIER M, 1990, BIOCHEM BIOPH RES CO, V173, P449, DOI 10.1016/S0006-291X(05)81079-4; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROSENTHAL AL, 1995, MOL REPROD DEV, V40, P69, DOI 10.1002/mrd.1080400110; Sandhoff K, 1997, CLIN CHIM ACTA, V266, P51, DOI 10.1016/S0009-8981(97)00166-6; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; SYLVESTER SR, 1989, BIOL REPROD, V41, P941, DOI 10.1095/biolreprod41.5.941; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Vielhaber G, 1996, J BIOL CHEM, V271, P32438, DOI 10.1074/jbc.271.50.32438; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Zhao Q, 1998, J ANDROL, V19, P165; ZHU Y, 1994, J BIOL CHEM, V269, P3846	76	41	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24829	24839		10.1074/jbc.M003497200	http://dx.doi.org/10.1074/jbc.M003497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818106	hybrid			2022-12-25	WOS:000088683300080
J	Das, AK; Bellizzi, JJ; Tandel, S; Biehl, E; Clardy, J; Hofmann, SL				Das, AK; Bellizzi, JJ; Tandel, S; Biehl, E; Clardy, J; Hofmann, SL			Structural basis for the insensitivity of a serine enzyme (palmitoyl-protein thioesterase) to phenylmethylsulfonyl fluoride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; STAPHYLOCOCCUS-HYICUS LIPASE; ACTIVE-SITE SERINE; PSEUDOMONAS-FLUORESCENS; SUBSTRATE-SPECIFICITY; PANCREATIC LIPASE; ESCHERICHIA-COLI; CARBOXYLESTERASE; PURIFICATION; INACTIVATION	Palmitoyl-protein thioesterase-1 (PPT1) is a newly de scribed lysosomal enzyme that hydrolyzes long chain fatty acids from lipid-modified cysteine residues in proteins, Deficiency in this enzyme results in a severe neurodegenerative storage disorder, infantile neuronal ceroid lipofuscinosis. Although the primary structure of PPT1 contains a serine lipase consensus sequence, the enzyme is insensitive to commonly used serine-modifying reagents phenylmethylsulfonyl fluoride (PMSF) and diisopropylfluorophosphate. In the current paper, we show that the active site serine in PPT1 is modified by a substrate analog of PMSF, hexadecylsulfonylfluoride (HDSF) in a specific and site-directed manner. The apparent K-t of the inhibition was 125 mu M (in the presence of 1.5 mM Triton X-100), and the catalytic rate constant for sulfonylation (k(2)) was 3.3/min, a value similar to previously described sulfonylation reactions. PPT1 was crystallized after inactivation with HDSF, and the structure of the inactive form was determined to 2.4 Angstrom resolution. The hexadecylsulfonyl was found to modify serine 115 and to snake through a narrow hydrophobic channel that would not accommodate an aromatic sulfonyl fluoride, Therefore, the geometry of the active site accounts for the reactivity of PPT1 with HDSF but not PMSF, These observations suggest a structural explanation as to why certain serine lipases are resistant to modification by commonly used serine-modifying reagents.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; So Methodist Univ, Dept Chem, Dallas, TX 75275 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Southern Methodist University; Cornell University	Hofmann, SL (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	hofmann@simmons.swmed.edu		Bellizzi, John/0000-0003-4833-2795	NCI NIH HHS [CA59021] Funding Source: Medline; NCRR NIH HHS [RR-01646] Funding Source: Medline; NINDS NIH HHS [NS35323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; BROCKLEHURST K, 1979, BIOCHEM J, V181, P775, DOI 10.1042/bj1810775; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CORNISH-BOWDEN A, 1979, European Journal of Biochemistry, V93, P383, DOI 10.1111/j.1432-1033.1979.tb12834.x; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLD AM, 1964, BIOCHEMISTRY-US, V3, P783, DOI 10.1021/bi00894a009; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; Hofmann SL, 1997, NEUROPEDIATRICS, V28, P27, DOI 10.1055/s-2007-973661; HONG KH, 1991, AGR BIOL CHEM TOKYO, V55, P2839, DOI 10.1080/00021369.1991.10871052; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P247, DOI 10.1111/j.1432-1033.1991.tb16008.x; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kim KK, 1997, STRUCTURE, V5, P1571, DOI 10.1016/S0969-2126(97)00306-7; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1994, MOSFLM; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; LUTHIPENG QQ, 1992, FEBS LETT, V299, P111, DOI 10.1016/0014-5793(92)80112-T; MALCOLM ADB, 1970, EUR J BIOCHEM, V15, P555, DOI 10.1111/j.1432-1033.1970.tb01040.x; MARAGANORE JM, 1986, TRENDS BIOCHEM SCI, V11, P497, DOI 10.1016/0968-0004(86)90076-9; MAYLIE MF, 1972, BIOCHIM BIOPHYS ACTA, V276, P162, DOI 10.1016/0005-2744(72)90017-4; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P230, DOI 10.1016/0003-9861(84)90064-X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; Szebenyi DME, 1997, J SYNCHROTRON RADIAT, V4, P128, DOI 10.1107/S0909049597000204; TJEENK ML, 1994, PROTEIN ENG, V7, P579, DOI 10.1093/protein/7.4.579; van Diggelen OP, 1999, MOL GENET METAB, V66, P240, DOI 10.1006/mgme.1999.2809; VANOORT MG, 1989, BIOCHEMISTRY-US, V28, P9278, DOI 10.1021/bi00450a007; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yu Lin, 1992, Bioorganic and Medicinal Chemistry Letters, V2, P1343	36	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23847	23851		10.1074/jbc.M002758200	http://dx.doi.org/10.1074/jbc.M002758200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801859	hybrid			2022-12-25	WOS:000088564200061
J	Fukuta, K; Abe, R; Yokomatsu, T; Omae, F; Asanagi, M; Makino, T				Fukuta, K; Abe, R; Yokomatsu, T; Omae, F; Asanagi, M; Makino, T			Control of bisecting GlcNAc addition to N-linked sugar chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-G; ACETYLGLUCOSAMINYLTRANSFERASE-III; WALDENSTROMS MACROGLOBULINEMIA; HIGH-EXPRESSION; OLIGOSACCHARIDES; IGM; GLYCOSYLATION; GLYCOPEPTIDES; PROTEIN; ENZYME	In the present study, experimental control of the formation of bisecting GlcNAc was investigated, and the competition between beta-1,4-GalT (UDP-galactose N-acetyl-glucosamine beta-1,4-galactosyltransferase) and GnT-III (UDP-N-acetylglucosamine:beta-D-mannoside beta-1,4-N--acetylglucosaminyltransferase) was examined. We isolated a beta-1,4-GalT-I single knockout human B cell clone producing monoclonal IgM and several transfectant clones that overexpressed beta-1,4-GalT-I or GnT-III. In the beta-1,4-GalT-I-single knockout cells, the extent of bisecting GlcNAc addition to the sugar chains of IgM was increased, where beta-1,4-GalT activity was reduced to about half that in the parental cells, and GnT-III activity was unaltered. In the beta-1,4-GalT-I, transfectants, the extent of bisecting GlcNAc addition was reduced although GnT-III activity was not altered significantly. In the GnT-III transfectants, the extent of bisecting GlcNAc addition increased along with the increase in levels of GnT-III activity. The extent of bisecting GlcNAc addition to the sugar chains of IgM was significantly correlated with the level of intracellular beta-1,4-GalT activity relative to that of GnT-III. These results were interpreted as indicating that beta-1,4-GalT competes with GnT-III for substrate in the cells.	Mitsui Chem Inc, Life Sci Lab, Chiba 2970017, Japan	Mitsui Chemicals	Makino, T (corresponding author), Mitsui Chem Inc, Life Sci Lab, 1144 Togo, Chiba 2970017, Japan.							AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BAZIN R, 1992, J IMMUNOL, V149, P3889; CAHOUR A, 1984, FEBS LETT, V170, P343, DOI 10.1016/0014-5793(84)81341-1; CHAPMAN A, 1979, J BIOL CHEM, V254, P816; FUJII S, 1990, J BIOL CHEM, V265, P6009; Fukuta K, 2000, ARCH BIOCHEM BIOPHYS, V378, P142, DOI 10.1006/abbi.2000.1806; Fukuta K, 2000, GLYCOBIOLOGY, V10, P421, DOI 10.1093/glycob/10.4.421; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HICKMAN S, 1972, J BIOL CHEM, V247, P2156; IHARA Y, 1995, GLYCOCONJ J, V12, P447; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; Leibiger H, 1998, GLYCOBIOLOGY, V8, P497, DOI 10.1093/glycob/8.5.497; MIYOSHI E, 1993, CANCER RES, V53, P3899; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; MONICA TJ, 1995, GLYCOBIOLOGY, V5, P175, DOI 10.1093/glycob/5.2.175; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; NEMANSKY M, 1995, FEBS LETT, V363, P280, DOI 10.1016/0014-5793(95)00336-8; NISHIURA T, 1990, CANCER RES, V50, P5345; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V269, P463, DOI 10.1016/0003-9861(89)90130-6; OOKA H, 1992, MICROBIOL IMMUNOL, V36, P1305, DOI 10.1111/j.1348-0421.1992.tb02132.x; PAREKH RB, 1988, LANCET, V1, P966; PUTNAM FW, 1973, SCIENCE, V182, P287, DOI 10.1126/science.182.4109.287; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHIMIZU A, 1971, NATURE-NEW BIOL, V231, P73, DOI 10.1038/newbio231073a0; Tokugawa K, 1996, GLYCOCONJUGATE J, V13, P53, DOI 10.1007/BF01049679; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; WRIGHT JF, 1990, J BIOL CHEM, V265, P10506; YABE N, 1986, IN VITRO CELL DEV B, V22, P363; Yamada E, 1997, GLYCOCONJUGATE J, V14, P401, DOI 10.1023/A:1018582930906; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOSHIMURA M, 1995, INT J CANCER, V60, P443, DOI 10.1002/ijc.2910600404	37	18	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23456	23461		10.1074/jbc.M002693200	http://dx.doi.org/10.1074/jbc.M002693200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816579	hybrid			2022-12-25	WOS:000088564200009
J	Ng, DC; Shafaee, S; Lee, D; Bikle, DD				Ng, DC; Shafaee, S; Lee, D; Bikle, DD			Requirement of an AP-1 site in the calcium response region of the involucrin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; C-FOS TRANSCRIPTION; HUMAN KERATIN-1 GENE; KINASE TYPE-II; MOUSE KERATINOCYTES; TERMINAL DIFFERENTIATION; CORNIFIED ENVELOPE; CYCLIC-AMP; EXPRESSION; CREB	Involucrin is a major protein of the cornified envelope of keratinocytes that provides much of the structural integrity of the skin. The gene expression of this differentiation marker is induced by elevated extracellular calcium in cultured human keratinocytes. A 3.7-kilobase fragment of this gene contains the necessary elements to drive a luciferase reporter in a calcium-dependent manner. We have sequenced the upstream region of the involucrin promoter and localized a calcium response element that contains an activating protein-1 (AP-1) site (TGAGTCA), Mutation of this site abolished the promoter activation by calcium. Compared with cells grown in 0.03 mar calcium, the binding activity of factors within nuclear extracts from keratinocytes for this AP-1 site was enhanced 3-fold in cells grown in 1.2 mM calcium. Immunoelectrophoretic mobility shift (supershift) assays identified JunD, Fra1, and Fra2 as the major factors that bind to the AP-1 element. Western analysis of the proteins in the nuclear extracts showed that the levels of c-Jun, JunB, JunD, FosB, and Fra2 increased and the levels of c-Fos and Fra1 decreased slightly with calcium treatment. The effect of calcium on the involucrin promoter was enhanced synergistically by phorbol 12-myristate: 13-acetate (PMA) in a protein kinase-dependent manner. In conclusion, calcium-regulated involucrin gene expression is mediated at least in part by AP-1 transcription factors.	Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ng, DC (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, 4150 Clement St,111N, San Francisco, CA 94121 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR038386] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39448, AR38386] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABMAYR SM, 1987, DNA PROTEIN INTERACT, V2; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; BARTHEL F, 1995, J NEUROCHEM, V64, P41; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; FLECKMAN P, 1985, J INVEST DERMATOL, V85, P507, DOI 10.1111/1523-1747.ep12277306; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jia MC, 1996, MOL CELL BIOCHEM, V156, P43; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; Ng Dean C., 1996, Frontiers in Bioscience (online), V1, pA16; PASSEGUE E, 1995, MOL CELL ENDOCRINOL, V107, P29, DOI 10.1016/0303-7207(94)03417-R; PILLAI S, 1993, J CELL PHYSIOL, V154, P101, DOI 10.1002/jcp.1041540113; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; SEBAG M, 1994, J INVEST DERMATOL, V103, P323, DOI 10.1111/1523-1747.ep12394802; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; SU MJ, 1994, J BIOL CHEM, V269, P14723; Takahashi H, 1998, J BIOL CHEM, V273, P17375, DOI 10.1074/jbc.273.28.17375; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614	41	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24080	24088		10.1074/jbc.M002508200	http://dx.doi.org/10.1074/jbc.M002508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816578	hybrid			2022-12-25	WOS:000088564200092
J	Summer, EJ; Mori, H; Settles, AM; Cline, K				Summer, EJ; Mori, H; Settles, AM; Cline, K			The thylakoid Delta pH-dependent pathway machinery facilitates RR-independent N-tail protein integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL COMPONENT; LUMENAL PROTEINS; SIGNAL PEPTIDE; TRANSLOCATION; MEMBRANE; SEC; TRANSPORT; EXPORT; CHLOROPLASTS; IMPORT	The thylakoidal Delta pH-dependent and bacterial twin arginine transport systems are structurally and functionally related protein export machineries. These recently discovered systems have been shown to transport folded proteins brit are not known to assemble integral membrane proteins. We determined the translocation pathway of a thylakoidal FtsH homologue, plastid fusion/protein translocation factor, which is synthesized with a chloroplast-targeting peptide, a hydrophobic signal peptide, and a hydrophobic membrane anchor. The twin arginine motif in its signal peptide and its sole integration requirement of a Delta pH suggested that plastid fusion/protein translocation factor employs the Delta pH pathway. Surprisingly, changing the twin arginine to twin lysine or deleting the signal peptide did not abrogate integration capability or characteristics. Nevertheless, three criteria argue that all three forms require the Delta pH pathway for integration. First, integration was competed by an authentic Delta pH pathway precursor. Second, antibodies to Delta pH pathway component Hcf106 specifically inhibited integration. Finally, chloroplasts from the hcf106 null mutant were unable to integrate Pftf into their thylakoids. Thus, Delta pH pathway machinery facilitates both signal peptide-directed and N-tail-mediated membrane integration and does not strictly require the twin arginine motif.	Univ Florida, Dept Hort Sci, Hort Sci & Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, Hort Sci & Plant Mol & Cellular Biol Program, Fifield Hall, Gainesville, FL 32611 USA.	kline@ufl.edu	Cline, Kenneth/J-6238-2013	Settles, A. Mark/0000-0002-5846-0996	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Asai T, 1999, J BIOL CHEM, V274, P20075, DOI 10.1074/jbc.274.29.20075; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Rojo EE, 1999, J BIOL CHEM, V274, P19617, DOI 10.1074/jbc.274.28.19617; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Summer EJ, 1999, PLANT PHYSIOL, V119, P575, DOI 10.1104/pp.119.3.1147; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6	37	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23483	23490		10.1074/jbc.M004137200	http://dx.doi.org/10.1074/jbc.M004137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816594	hybrid			2022-12-25	WOS:000088564200013
J	Zhang, WG; Trible, RP; Zhu, MH; Liu, SK; McGlade, J; Samelson, LE				Zhang, WG; Trible, RP; Zhu, MH; Liu, SK; McGlade, J; Samelson, LE			Association of Grb2 Gads, and phospholipase C-gamma 1 with phosphorylated LAT tyrosine residues - Effect of LAT tyrosine mutations on T cell antigen receptor-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; MOLECULAR-CLONING; ACTIVATION; KINASES; PLC-GAMMA-1; SLP-76; REQUIREMENT; EXCHANGE; DOMAIN; ZAP-70	The linker for activation of T cells (LAT) is a critical adaptor molecule required for T cell antigen receptor (TCR)-mediated signaling and thymocyte development. Upon T cell activation, LAT becomes highly phosphorylated on tyrosine residues, and Grb2, Gads, and phospholipase C (PLC)-gamma 1 bind LAT via Src homology-2 domains. In LAT-deficient mutant Jurkat cells, TCR engagement fails to induce ERK activation, Ca2+ flux, and activation of AP-1 and NF-AT. We mapped the tyrosine residues in LAT responsible for interaction with these specific signaling molecules by expressing LAT mutants with tyrosine to phenylalanine mutations in LAT-deficient cells. Our results showed that three distal tyrosines, Tyr(171), Tyr(191), and Tyr(226), are responsible for Grb2-binding; Tyr171, and Tyr(191), but not Tyr(226) necessary for Gads binding. Mutation of Tyr(132) alone abolished PLC-gamma 1 binding. Mutation of all three distal tyrosines also abolished PLC-gamma 1 binding, suggesting there might be multiple binding sites for PLC-gamma 1. Mutation of Tyr(132) affected calcium flux and blocked Erk and NF-AT activation. Since Grb2 binding is not affected by this mutation, these results strongly suggest that PLC-gamma activation regulates Ras activation in these cells. Mutation of individual Grb2 binding sites had no functional effect, but mutation of two or three of these sites, in combination, also affected Erk. and NF-AT activation.	NCI, Div Basic Sci, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Hosp Sick Children, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Duke Med Ctr, Dept Immunol, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Duke University	Samelson, LE (corresponding author), NCI, Div Basic Sci, Cellular & Mol Biol Lab, NIH, Bldg 37,Room 1E24,37 Convent Dr, Bethesda, MD 20892 USA.	samelson@helix.nih.gov		Liu, Stanley/0000-0001-6851-0857	NATIONAL CANCER INSTITUTE [Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Stoica B, 1998, J IMMUNOL, V160, P1059; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1984, J IMMUNOL, V133, P123; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	326	338	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23355	23361		10.1074/jbc.M000404200	http://dx.doi.org/10.1074/jbc.M000404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811803	hybrid			2022-12-25	WOS:000088419400104
J	Angata, T; Varki, A				Angata, T; Varki, A			Cloning, characterization, and phylogenetic analysis of Siglec-9, a new member of the CD33-related group of Siglecs - evidence for co-evolution with sialic acid synthesis pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; ACETYLGLUCOSAMINE 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; IMMUNOGLOBULIN SUPERFAMILY MEMBER; BIFUNCTIONAL ENZYME CATALYZES; SITE-DIRECTED MUTAGENESIS; NATURAL-KILLER-CELLS; FIRST 2 STEPS; MOLECULAR-CLONING; BINDING-SITE; SIALOADHESIN FAMILY	The Siglecs are a subfamily of I-type lectins (immunoglobulin superfamily proteins that bind sugars) that specifically recognize sialic acids. We report the cloning and characterization of human Siglec-9. The cDNA encodes a type 1 transmembrane protein with three extracellular immunoglobulin-like domains and a cytosolic tail containing two tyrosines, one within a typical immunoreceptor tyrosine-based inhibitory motif (ITIM). The N-terminal V-set Ig domain has most amino acid residues typical of Siglecs. Siglec-9 is expressed on granulocytes and monocytes, Expression of the full-length cDNA in COS cells induces sialic-acid dependent erythrocyte binding. A recombinant soluble form of the extracellular domain binds to alpha 2-3 and alpha 2-6-linked sialic acids. Typical of Siglecs, the carboxyl group and side chain of sialic acid are essential for recognition, and mutation of a critical arginine residue in domain 1 abrogates binding. The underlying glycan structure also affects binding, with Gal beta 1-4Glc[NAc] being preferred. Siglec-9 shows closest homology to Siglec-7 and both belong to a Siglec-3/CD33-related subset of Siglecs (with Siglecs-5, -6, and -8), The Siglec-9 gene is on chromosome 19q13.3-13.4, in a cluster with all Siglec-3/CD33-related Siglec genes, suggesting their origin by gene duplications. A homology search of the Drosophila melanogaster and Caenorhabditis elegans genomes suggests that Siglec expression may be limited to animals of deuterostome lineage, coincident with the appearance of the genes of the sialic acid biosynthetic pathway.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIGMS NIH HHS [R01-GM323373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CASTELLINO FJ, 1993, METHOD ENZYMOL, V223, P168; COLIGAN EC, CURRENT PROTOCOLS IM; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DAS HK, 1987, J BIOL CHEM, V262, P4787; DAVIS TR, 1995, IN VITRO CELL DEV-AN, V31, P659; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GORDON LA, 1995, GENOMICS, V30, P187, DOI 10.1006/geno.1995.9886; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; KARLSTROM RO, 1993, DEVELOPMENT, V118, P509; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; LAW CL, 1995, J IMMUNOL, V155, P3368; LeshkoLindsay L, 1997, DEVELOPMENT, V124, P169; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Mendoza HL, 1999, DEV COMP IMMUNOL, V23, P359, DOI 10.1016/S0145-305X(99)00017-8; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEIPER SC, 1988, BLOOD, V72, P314; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; SCHAUER R, 1999, GLYCONJUGATE, V16, pS32; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SGROI D, 1993, J BIOL CHEM, V268, P7011; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Tangye SG, 1999, J IMMUNOL, V162, P6981; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Vely F, 1997, J IMMUNOL, V159, P2075; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Yousef GM, 1999, ANTICANCER RES, V19, P2843; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	67	131	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22127	22135		10.1074/jbc.M002775200	http://dx.doi.org/10.1074/jbc.M002775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801860	hybrid			2022-12-25	WOS:000088363800054
J	Balsinde, J; Balboa, MA; Dennis, EA				Balsinde, J; Balboa, MA; Dennis, EA			Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D(1) macrophage-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PHOSPHOLIPASE A(2); PROTEIN-KINASE-C; MAST-CELLS; ENDOPEROXIDE SYNTHASE-2; ANTISENSE INHIBITION; D-2 GENERATION; DELAYED PHASE; ENZYMES; CYCLOOXYGENASE-2; EXPRESSION	Previous studies have demonstrated that P388D(1) macrophages are able to mobilize arachidonic acid (AA) and synthesize prostaglandins in two temporally distinct phases. The first phase is triggered by platelet-activating factor within minutes, but needs the cells to be previously exposed to bacterial lipopolysaccharide (LPS) for periods up to 1 h, It is thus a primed immediate phase. The second, delayed phase occurs in response to LPS alone over long incubation periods spanning several hours. Strikingly, the effector enzymes involved in both of these phases are the same, namely the cytosolic group IV phospholipase A(2) (cPLA(2)), the secretory group V phospholipase A(2), and cyclooxygenase-2, although the regulatory mechanisms differ. Here we report that P388D(1) macrophages mobilize AA and produce prostaglandins in response to zymosan particles in a manner that is clearly different from the two described above. Zymosan triggers an immediate AA mobilization response from the macrophages that neither involves the group v phospholipase A(2) nor requires the cells to be primed by LPS, The group VI Ca2+-independent phospholipase A(2) is also not involved. Zymosan appears to signal exclusively through activation of the cPLA(2), which is coupled to the cyclooxygenase-2, These results define a secretory PLA(2)-independent pathway for AA mobilization in the P388D(1) macrophages, and demonstrate that, under certain experimental settings, stimulation of the cPLA(2) is sufficient to generate a prostaglandin biosynthetic response in the P388D(1) macrophages.	Univ Calif San Diego, Dept Chem & Biochem, Revelle Coll, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Balsinde, J (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Revelle Coll, La Jolla, CA 92093 USA.		Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298	NICHD NIH HHS [HD26171] Funding Source: Medline; NIGMS NIH HHS [GM20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIZOLA E, 1998, J BIOL CHEM, V273, P30208; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, ADV EXP MED BIOL, V407, P99; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BALSINDE J, 1992, BIOCHIM BIOPHYS ACTA, V1136, P75, DOI 10.1016/0167-4889(92)90087-R; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dan P, 1998, BIOCHEMISTRY-US, V37, P6199, DOI 10.1021/bi972066l; Daniele JJ, 1999, PROSTAG OTH LIPID M, V57, P341, DOI 10.1016/S0090-6980(98)00084-7; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLASER KB, 1990, J BIOL CHEM, V265, P8658; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LISTER MD, 1989, J BIOL CHEM, V264, P8520; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tada K, 1998, J IMMUNOL, V161, P5008	41	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22544	22549		10.1074/jbc.M910163199	http://dx.doi.org/10.1074/jbc.M910163199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811815	hybrid, Green Published			2022-12-25	WOS:000088363800106
J	Fogarty, KE; Kidd, JF; Turner, A; Skepper, JN; Carmichael, J; Thorn, P				Fogarty, KE; Kidd, JF; Turner, A; Skepper, JN; Carmichael, J; Thorn, P			Microtubules regulate local Ca2+ spiking in secretory epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CAPACITATIVE CALCIUM-ENTRY; ACTIVATED PROTEIN-KINASE; ENDOPLASMIC-RETICULUM; INOSITOL TRISPHOSPHATE; EXOCRINE PANCREAS; XENOPUS-LAEVIS; RELEASE; CYTOSKELETON; CHANNELS	The role of the cytoskeleton in regulating Ca2+ release has been explored in epithelial cells. Trains of local Ca2+ spikes were elicited in pancreatic acinar cells by infusion of inositol trisphosphate through a whole cell patch pipette, and the Ca2+-dependent Cl- current spikes were recorded. The spikes were only transiently inhibited by cytochalasin B, an agent that acts on microfilaments, In contrast, nocodazole (5-100 mu M), an agent that disrupts the microtubular network, dose-dependently reduced spike frequency and decreased spike amplitude leading to total blockade of the response. Consistent with an effect of microtubular disruption, colchicine also inhibited spiking but neither Me2SO nor beta-lumicolchicine, an inactive analogue of colchicine, had any effect. The microtubule-stabilizing agent, taxol, also inhibited spiking. The nocodazole effects were not due to complete loss of function of the Ca2+ signaling apparatus, because supramaximal carbachol concentrations were still able to mobilize a Ca2+ response. Finally, as visualized by 2-photon excitation microscopy of ER-Tracker, nocodazole promoted a loss of the endoplasmic reticulum in the secretory pole region. We conclude that microtubules specifically maintain localized Ca2+ spikes at least in part because of the local positioning of the endoplasmic reticulum.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Univ Massachusetts, Sch Med, Dept Physiol, Biomed Imaging Grp, Worcester, MA 01650 USA; Univ Cambridge, Dept Anat, Multi Imaging Ctr, Cambridge CB2 3DY, England	University of Cambridge; University of Massachusetts System; University of Massachusetts Worcester; University of Cambridge	Thorn, P (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.		Thorn, Peter/F-7030-2010	Thorn, Peter/0000-0002-3228-770X	NCRR NIH HHS [R01-5RR09799] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009799] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; BERGHAHN R, 1986, Journal of Applied Ichthyology, V2, P11, DOI 10.1111/j.1439-0426.1986.tb00425.x; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; CRASKE, 1999, P NATL ACAD SCI US, V96, P4426; da Costa SR, 1998, J CELL SCI, V111, P1267; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Duesbery NS, 1996, ZYGOTE, V4, P21, DOI 10.1017/S0967199400002859; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Fogarty KE, 2000, BIOPHYS J, V78, P2298, DOI 10.1016/S0006-3495(00)76776-2; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Kidd JF, 1999, J PHYSIOL-LONDON, V520, P187, DOI 10.1111/j.1469-7793.1999.00187.x; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; KURIHARA H, 1987, HISTOCHEMISTRY, V87, P223, DOI 10.1007/BF00492413; Lane JD, 1999, MOL BIOL CELL, V10, P1909, DOI 10.1091/mbc.10.6.1909; LEE C, 1989, J CELL BIOL, V109, P2045, DOI 10.1083/jcb.109.5.2045; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; LEE YC, 1982, J BIOL CHEM, V257, P6306; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; OBrien ET, 1997, CELL MOTIL CYTOSKEL, V36, P125, DOI 10.1002/(SICI)1097-0169(1997)36:2<125::AID-CM3>3.0.CO;2-8; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; SALMON ED, 1984, J CELL BIOL, V99, P1066, DOI 10.1083/jcb.99.3.1066; SAMSON F, 1979, J PHARMACOL EXP THER, V208, P411; SARASTE J, 1991, J CELL SCI, V100, P415; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; TASAKA K, 1991, SKIN PHARMACOL, V4, P43; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Thorn P, 1996, CELL CALCIUM, V20, P203, DOI 10.1016/S0143-4160(96)90107-4; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; VANDECANDELAERE A, 1994, BIOCHEMISTRY-US, V33, P2792, DOI 10.1021/bi00176a007; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; WILSON L, 1985, BIOCHEMISTRY-US, V24, P5254, DOI 10.1021/bi00340a045	53	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22487	22494		10.1074/jbc.M909402199	http://dx.doi.org/10.1074/jbc.M909402199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801885	hybrid			2022-12-25	WOS:000088363800098
J	Ford, HL; Landesman-Bollag, E; Dacwag, CS; Stukenberg, PT; Pardee, AB; Seldin, DC				Ford, HL; Landesman-Bollag, E; Dacwag, CS; Stukenberg, PT; Pardee, AB; Seldin, DC			Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; DNA-BINDING; HOMEOBOX GENES; SITE; ACTIVATION; CK2; IDENTIFICATION; EXPRESSION; DROSOPHILA; TISSUE	Human SIX1 (HSIX1) is a member of the Six class of homeodomain proteins implicated in muscle, eye, head, and brain development. To further understand the role of HSIX1 in the cell cycle and cancer, we developed an HSIX1-specific antibody to study protein expression at various stages of the cell cycle. Our previous work demonstrated that HSIX1 mRNA expression increases as cells exit S phase and that overexpression of HSIX1 can attenuate a DNA damage-induced G(2) cell cycle checkpoint. Overexpression of HSIX1 mRNA was observed in 44% of primary breast cancers and 90% of metastatic lesions. Now wt? demonstrate that HSIX1 is a nuclear phosphoprotein that becomes hyperphosphorylated at mitosis in both MCF7 cells and in Xenopus extracts. The pattern of phosphorylation observed in mitosis is similar to that seen by treating recombinant HSIX1 with casein kinase II (CK2) in vitro, Apigenin, a selective CK2 inhibitor, diminishes interphase and mitotic phosphorylation of HSIX1. Treatment of MCF7 cells with apigenin leads to a dose-dependent arrest at the G(2)/M boundary, implicating CK2, like HSIX1, in the G(2)/M transition. HSIX1 hyperphosphorylated in vitro by CK2 loses its ability to bind the MEF3 sites of the aldolase A promoter (pM), and decreased binding to pM is observed during mitosis, Because CK2 and HSIX1 have both been implicated in cancer and in cell cycle control, we propose that HSIX1, whose activity is regulated by CK2, is a relevant target of CK2 in G(2)/M checkpoint control and that both molecules participate in the same pathway whose dysregulation leads to cancer.	Dana Farber Canc Inst, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Boston Univ, Med Ctr, Dept Med & Pathol, Boston, MA 02118 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University	Ford, HL (corresponding author), Dana Farber Canc Inst, Div Canc Biol, D610B,44 Binney St, Boston, MA 02115 USA.			Seldin, David C/0000-0003-0168-2333; Stukenberg, Todd/0000-0002-6788-2111	NCI NIH HHS [1F32 CA79197-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA079197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; BOURBON HM, 1995, J BIOL CHEM, V270, P11130, DOI 10.1074/jbc.270.19.11130; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Dong JL, 1998, EMBO J, V17, P2308, DOI 10.1093/emboj/17.8.2308; Fienberg AA, 1999, J EXP ZOOL, V285, P76, DOI 10.1002/(SICI)1097-010X(19990415)285:1<76::AID-JEZ9>3.0.CO;2-K; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; FORD HL, 1995, ONCOGENE, V10, P1597; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Harlow E., 1988, ANTIBODIES LABORATOR, P63; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Jackman MR, 1997, CANCER SURV, V29, P47; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; Lepley DM, 1996, CARCINOGENESIS, V17, P2367, DOI 10.1093/carcin/17.11.2367; Li C, 1999, MOL CELL, V3, P77, DOI 10.1016/S1097-2765(00)80176-8; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Ohto H, 1999, MOL CELL BIOL, V19, P6815; OLIVER G, 1995, DEVELOPMENT, V121, P693; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PYERIN W, 1992, ANN NY ACAD SCI, V659, P295; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Relaix F, 1999, GENE DEV, V13, P3171, DOI 10.1101/gad.13.24.3171; Sambrook J., 2002, MOL CLONING LAB MANU; SATO F, 1994, BIOCHEM BIOPH RES CO, V204, P578, DOI 10.1006/bbrc.1994.2498; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Seo HC, 1999, MECH DEVELOP, V83, P127, DOI 10.1016/S0925-4773(99)00045-3; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P8373, DOI 10.1073/pnas.91.18.8373; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Wilhelm H, 1997, METHOD ENZYMOL, V283, P12; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	45	100	103	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22245	22254		10.1074/jbc.M002446200	http://dx.doi.org/10.1074/jbc.M002446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801845	hybrid			2022-12-25	WOS:000088363800068
J	Hussaini, IM; Karns, LR; Vinton, G; Carpenter, JE; Redpath, GT; Sando, JJ; VandenBerg, SR				Hussaini, IM; Karns, LR; Vinton, G; Carpenter, JE; Redpath, GT; Sando, JJ; VandenBerg, SR			Phorbal 12-myristate 13-acetate induces protein kinase C eta-specific proliferative response in astrocytic tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE THYMOMA CELLS; HIGH-DOSE TAMOXIFEN; MALIGNANT GLIOMAS; SIGNAL-TRANSDUCTION; GLIAL-CELLS; GLUTAMINE-SYNTHETASE; GROWTH-RATE; EXPRESSION; LINES; ALPHA	Protein kinase C (PKC) activation has been implicated in cellular proliferation in neoplastic astrocytes, The roles for specific PKC isozymes in regulating this glial response, however, are not well understood. The aim of this study was to characterize the expression of PKC isozymes and the role of PKC-eta expression in regulating cellular proliferation in two well characterized astrocytic tumor cell lines (U-1242 MG and U-251 MG) with different properties of growth in cell culture. Both cell lines expressed an array of conventional (alpha, beta I, beta II, and gamma) and novel (theta and epsilon) PKC isozymes that can be activated by phorbol myristate acetate (PMA), Another novel PKC isozyme, PKC-eta, was only expressed by U-251 MG cells. In contrast, PKC-delta was readily detected in U-1242 MG cells but was present only at low levels in U-251 MG cells. PMA (100 nM) treatment for 24 h increased cell proliferation by over 2-fold in the U-251 MG cells, whereas it decreased the mitogenic response in the U-1242 MG cells by over 90%. When PKC-eta was stably transfected into U-1242 MG cells, PMA increased cell proliferation by 2.2-fold, similar to the response of U-251 MG cells. The cell proliferation induced by PMA in both the U-251 MG and U-1242-PKC-eta cells was blocked by the PKC inhibitor bisindolylmaleimide (0.5 mu M) and the MEK inhibitor, PD 98059 (50 mu M). Transient transfection of wild type U-251 with PKC-eta antisense oligonucleotide (1 mu M) also blocked the PMA-induced increase in [H-3]thymidine incorporation. The data demonstrate that two glioblastoma lines, with functionally distinct proliferative responses to PMA, express different novel PKC isozymes and that the differential expression of PKC-eta plays a determining role in the different proliferative capacity.	Univ Virginia, Dept Pathol Neuropathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hussaini, IM (corresponding author), Univ Virginia, Dept Pathol Neuropathol, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM31184] Funding Source: Medline; NINDS NIH HHS [NS35122] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035122, R29NS035122] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASOTRA K, 1994, J NEUROSCI RES, V39, P273, DOI 10.1002/jnr.490390305; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; BALTUCH GH, 1995, CAN J NEUROL SCI, V22, P264, DOI 10.1017/S0317167100039457; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; Basu A, 1998, MOL PHARMACOL, V53, P105, DOI 10.1124/mol.53.1.105; BENZIL DL, 1992, CANCER RES, V52, P2951; Bhat NR, 1995, DEV NEUROSCI-BASEL, V17, P267, DOI 10.1159/000111296; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; Chen CC, 1998, J BIOL CHEM, V273, P19424, DOI 10.1074/jbc.273.31.19424; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper SR, 1999, PHARMACOL THERAPEUT, V82, P427, DOI 10.1016/S0163-7258(99)00002-9; Couldwell WT, 1996, CLIN CANCER RES, V2, P619; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; COULDWELL WT, 1992, NEUROSURGERY, V31, P717; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dooley NP, 1998, NEUROREPORT, V9, P1727, DOI 10.1097/00001756-199806010-00011; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; Guizzetti M, 1998, EUR J PHARMACOL, V359, P223, DOI 10.1016/S0014-2999(98)00620-7; Hoffman J, 1996, J LIPID MEDIAT CELL, V13, P51, DOI 10.1016/0929-7855(95)00044-5; Hussaini IM, 1999, GLIA, V25, P71, DOI 10.1002/(SICI)1098-1136(19990101)25:1<71::AID-GLIA7>3.0.CO;2-0; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Livneh E, 1996, ONCOGENE, V12, P1545; Luo WH, 1997, CELL GROWTH DIFFER, V8, P1225; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSADA S, 1990, J BIOL CHEM, V265, P22434; Pollack IF, 1997, CLIN CANCER RES, V3, P1109; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Resnick MS, 1997, CANCER RES, V57, P2209; Sharif TR, 1999, INT J ONCOL, V14, P327; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Slevin M, 1998, LAB INVEST, V78, P987; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; TODO T, 1991, NEUROSURGERY, V108, P11; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Yu SM, 1996, MOL PHARMACOL, V50, P1000; Zellner A, 1998, CLIN CANCER RES, V4, P1797	50	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22348	22354		10.1074/jbc.M003203200	http://dx.doi.org/10.1074/jbc.M003203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806212	hybrid			2022-12-25	WOS:000088363800081
J	Moracci, M; Cobucci-Ponzano, B; Trincone, A; Fusco, S; De Rosa, M; van der Oost, J; Sensen, CW; Charlebois, RL; Rossi, M				Moracci, M; Cobucci-Ponzano, B; Trincone, A; Fusco, S; De Rosa, M; van der Oost, J; Sensen, CW; Charlebois, RL; Rossi, M			Identification and molecular characterization of the first alpha-xylosidase from an Archaeon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-FLAVUS MO-5; SULFOLOBUS-SOLFATARICUS; GLYCOSYL HYDROLASES; BETA-GALACTOSIDASE; PYROCOCCUS-FURIOSUS; PURIFICATION; GLYCOSIDASE; SEQUENCE; GLUCOSIDASE; CELLULOSE	We here report the first molecular characterization of an alpha-xylosidase (XylS) from an Archaeon. Sulfolobus solfataricus is able to grow at temperatures higher than 80 degrees C on several carbohydrates at acidic pH, The isolated xylS gene encodes a monomeric enzyme homologous to cu-glucosidases, alpha-xylosidases, glucoamylases and sucrase-isomaltases of the glycosyl hydrolase family 31. xylS belongs to a cluster of four genes in the S. solfataricus genome, including a beta-glycosidase, an hypothetical membrane protein homologous to the major facilitator superfamily of transporters, and an open reading frame of unknown function. The alpha-xylosidase was overexpressed in Escherichia coli showing optimal activity at 90 degrees C and a half-life at this temperature of 38 h. The purified enzyme follows a retaining mechanism of substrate hydrolysis, showing high hydrolytic activity on the disaccharide isoprimeverose and catalyzing the release of xylose from xyloglucan oligosaccharides. Synergy is observed in the concerted in vitro hydrolysis of xyloglucan oligosaccharides by the alpha-xylosidase and the beta-glycosidase from S. solfataricus. The analysis of the total S, solfataricus RNA revealed that all the genes of the cluster are actively transcribed and that xylS and orf3 genes are cotranscribed.	CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice Napoli, Italy; Univ Naples 2, Ist Farmacol & Tossicol, CRIB, I-80138 Naples, Italy; Agr Univ Wageningen, Dept Biomol Sci, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Univ Naples Federico II, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; Wageningen University & Research; International Business Machines (IBM); National Research Council Canada; University of Ottawa; University of Naples Federico II	Moracci, M (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via Marconi 10, I-80125 Naples, Italy.	moracci@dafne.ibpe.na.cnr.it	Cobucci Ponzano, Beatrice/G-8536-2013; Sensen, Christoph W./C-1798-2013; Cobucci-Ponzano, Beatrice/B-7654-2015; Trincone, Antonio/B-4323-2010; Moracci, Marco/B-8444-2015; van+der+Oost, John/Y-2548-2019; Cobucci-Ponzano, Beatrice/AAX-7630-2020	Sensen, Christoph W./0000-0001-9604-8962; Trincone, Antonio/0000-0003-4191-7280; Moracci, Marco/0000-0002-9846-2531; Cobucci-Ponzano, Beatrice/0000-0002-8211-2297; De Rosa, Mario/0000-0002-2976-0818				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer MW, 1998, CURR OPIN BIOTECH, V9, P141, DOI 10.1016/S0958-1669(98)80106-7; Bauer MW, 1999, J BACTERIOL, V181, P284, DOI 10.1128/JB.181.1.284-290.1999; BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaillou S, 1998, J BACTERIOL, V180, P2312, DOI 10.1128/JB.180.9.2312-2320.1998; Crombie HJ, 1998, PLANT J, V15, P27, DOI 10.1046/j.1365-313X.1998.00182.x; CUBELLIS MV, 1990, GENE, V94, P89, DOI 10.1016/0378-1119(90)90472-4; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; GROGAN DW, 1991, APPL ENVIRON MICROB, V57, P1644, DOI 10.1128/AEM.57.6.1644-1649.1991; Guagliardi A, 1997, J MOL BIOL, V267, P841, DOI 10.1006/jmbi.1996.0873; Gueguen Y, 1997, J BIOL CHEM, V272, P31258, DOI 10.1074/jbc.272.50.31258; Haseltine C, 1999, GENETICS, V152, P1353; Haseltine C, 1996, J BACTERIOL, V178, P945, DOI 10.1128/jb.178.4.945-950.1996; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Matsuo M, 1996, BIOSCI BIOTECH BIOCH, V60, P341, DOI 10.1271/bbb.60.341; MATSUSHITA J, 1985, J BIOCHEM, V98, P825, DOI 10.1093/oxfordjournals.jbchem.a135341; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; Moracci M, 1996, PROTEIN ENG, V9, P1191, DOI 10.1093/protein/9.12.1191; Moracci M, 1998, BIOCHEMISTRY-US, V37, P17262, DOI 10.1021/bi981855f; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PISANI FM, 1990, EUR J BIOCHEM, V187, P321, DOI 10.1111/j.1432-1033.1990.tb15308.x; PRISCO A, 1995, J BACTERIOL, V177, P1614, DOI 10.1128/jb.177.6.1614-1619.1995; QUARONI A, 1976, J BIOL CHEM, V251, P3250; ROLFSMEIER M, 1995, J BACTERIOL, V177, P482, DOI 10.1128/jb.177.2.482-485.1995; Sambrook J., 2002, MOL CLONING LAB MANU; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; Sunna A, 1997, EXTREMOPHILES, V1, P2, DOI 10.1007/s007920050009; VINCKEN JP, 1995, PLANT PHYSIOL, V108, P1579, DOI 10.1104/pp.108.4.1579; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X; YOSHIKAWA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1275, DOI 10.1271/bbb.57.1275; YOSHIKAWA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1281, DOI 10.1271/bbb.57.1281; ZILLIG W, 1980, ARCH MICROBIOL, V125, P259, DOI 10.1007/BF00446886	40	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22082	22089		10.1074/jbc.M910392199	http://dx.doi.org/10.1074/jbc.M910392199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801892	hybrid			2022-12-25	WOS:000088363800048
J	Zhang, H; Hoff, H; Sell, C				Zhang, H; Hoff, H; Sell, C			Insulin-like growth factor I-mediated degradation of insulin receptor substrate-1 is inhibited by epidermal growth factor in prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED DOWN-REGULATION; 3T3-L1 ADIPOCYTES; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PROTEIN; TISSUE EXPRESSION; DEPENDENT MANNER; IRS-1; PATHWAY	We have sought to determine whether insulin-like growth factor I (IGF-I) regulates the levels of insulin receptor substrate-1 (IRS-1) in prostate epithelial cells. Exposure of prostate epithelial cells to IGF-I in the absence of other growth factors leads to a reduction in IRS-1 levels. Ubiquitin content of IRS-1 is increased in the presence of ICE-I, and inhibitors of the proteasome prevented the reduction of IRS-1 levels seen following IGF-I exposure. These results imply that IRS-1 is targeted to the proteasome upon exposure to IGF-I. The addition of epidermal growth factor (EGF) maintained IRS-1 levels even in the presence of IGF-I and inhibits IGF-I-dependent ubiquitination of IRS-1. Thus, these two growth factors, IGF-I and EGF, had antagonistic effects on IRS-1 protein levels in prostate epithelial cells. This regulation of IRS-1 reveals a novel level of cross-talk between the IGF-I and EGF signal pathways, which may have implications in tumors that harbor activating mutations in the EGF receptor.	Lankennau Med Res Ctr, Wynnewood, PA 19096 USA; Med Coll Penn & Hahnemann Univ, Sch Med, Program Mol Biol, Philadelphia, PA 19129 USA; Thomas Jefferson Univ, Philadelphia, PA 19101 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Drexel University; Jefferson University	Sell, C (corresponding author), Lankennau Med Res Ctr, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	Sellc@mlhs.org			NATIONAL CANCER INSTITUTE [R29CA068923] Funding Source: NIH RePORTER; NCI NIH HHS [CA68923] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALDWIN D, 1980, P NATL ACAD SCI-BIOL, V77, P5975, DOI 10.1073/pnas.77.10.5975; BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BASERGA R, 1992, ANN NY ACAD SCI, V663, P154, DOI 10.1111/j.1749-6632.1992.tb38658.x; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bright RK, 1997, CANCER RES, V57, P995; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Gustafson T A, 1999, Rev Physiol Biochem Pharmacol, V137, P71; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; LAM K, 1994, J BIOL CHEM, V269, P20648; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu JL, 1998, MOL ENDOCRINOL, V12, P1452, DOI 10.1210/me.12.9.1452; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387	50	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22558	22562		10.1074/jbc.M000412200	http://dx.doi.org/10.1074/jbc.M000412200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811632	hybrid			2022-12-25	WOS:000088363800108
J	Zhong, SP; Ma, WY; Dong, ZG				Zhong, SP; Ma, WY; Dong, ZG			ERKs and p38 kinases mediate ultraviolet B-induced phosphorylation of histone H3 at serine 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PREMATURE CHROMOSOME CONDENSATION; INDUCED AP-1 ACTIVATION; MAP KINASE; CELL-CYCLE; GROWTH-FACTORS; OKADAIC ACID; MITOSIS; INDUCTION; PATHWAY	Histone H3 is the core protein of the nucleosome. Phosphorylation of H3 involves immediate early gene expression, chromatin remodeling, and chromosome condensation during mitosis. Very recently, Rsk2 or MSK1 kinase-mediated phosphorylation of H3 at serine 10 was reported. In the present study, we show that both ERKs and p38 kinase may mediate ultraviolet B-induced phosphorylation of H3 at serine 10. PD 98059, a MEK1 inhibitor, and SE 202190, a p38 kinase inhibitor, efficiently inhibited ultraviolet B-induced phosphorylation of H3. Phosphorylation of H3 was also inhibited in cells expressing dominant negative mutant (DNM) ERK2 and DNM p38 kinase. In contrast, no inhibition of H3 phosphorylation in Jnk1 or Jnk2 knockout cells (Jnk1(-/-) or Jnk2(-/-)) and cells expressing DNM JNK1 was observed. More importantly, incubation of active ERK2 or p38 kinase with H3 protein resulted in phosphorylation of H3 at serine 10 in vitro. These results suggest that ERK and p38 kinase are at least two important mediators of phosphorylation of H3 at serine 10.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net			NCI NIH HHS [CA81064, CA77646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081064, R37CA081064, R01CA077646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIRO K, 1985, J BIOL CHEM, V260, P5379; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; AJIRO K, 1983, J BIOL CHEM, V258, P4534; Ajiro K, 1996, EUR J BIOCHEM, V241, P923, DOI 10.1111/j.1432-1033.1996.00923.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Altheim BA, 1999, P NATL ACAD SCI USA, V96, P1345, DOI 10.1073/pnas.96.4.1345; BALHORN R, 1975, BIOCHEMISTRY-US, V14, P2504, DOI 10.1021/bi00682a033; Bianchini L, 1997, J BIOL CHEM, V272, P271; CANO E, 1995, J CELL SCI, V108, P3599; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Davie JR, 1999, J CELL BIOCHEM, P141; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dong ZG, 1998, ONCOGENE, V17, P1845, DOI 10.1038/sj.onc.1202084; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Oliver RH, 1999, BIOCHEM BIOPH RES CO, V263, P143, DOI 10.1006/bbrc.1999.1301; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PUMO DE, 1980, BIOCHEMISTRY-US, V19, P2362, DOI 10.1021/bi00552a013; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smalley KSM, 1999, BIOCHEM BIOPH RES CO, V263, P239, DOI 10.1006/bbrc.1999.1351; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TLKOO K, 1997, BIOCHEM J, V322, P281; VANHOLDE KE, 1988, CHROMATIN, P111; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7	49	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20980	20984		10.1074/jbc.M909934199	http://dx.doi.org/10.1074/jbc.M909934199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10806218	hybrid			2022-12-25	WOS:000088230600004
J	Hefferan, TE; Reinholz, GG; Rickard, DJ; Johnsen, SA; Waters, KM; Subramaniam, M; Spelsberg, TC				Hefferan, TE; Reinholz, GG; Rickard, DJ; Johnsen, SA; Waters, KM; Subramaniam, M; Spelsberg, TC			Overexpression of a nuclear protein, TIEG, mimics transforming growth factor-beta action in human osteoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE EARLY GENE; TGF-BETA; TRANSCRIPTION FACTOR; ESTROGEN REGULATION; FAMILY MEMBERS; BONE; EXPRESSION; RECEPTORS; APOPTOSIS; ACID	Although transforming growth factor-beta (TGF-beta) is a growth factor with many known regulatory activities in many different cell types, its intracellular signaling pathway is still not fully understood. A TGF-beta-inducible early gene (TIEG) was discovered and shown by this laboratory to be a 3-zinc finger transcription factor family member; its expression is rapidly induced in cells treated with TGF-beta. To ascertain whether TIEG plays a major role in the TGF-beta pathway, human osteosarcoma MG-63 cells were stably transfected either with an expression vector containing a TIEG cDNA or with the vector alone. Clones that contain only the vector express normal levels of TIEG mRNA and protein and display the same patterns of gene expression and levels of cell proliferation as the nontransfected, non-TGF-beta-treated parental cells. However, transfected cells that overexpress TIEG mRNA and protein (TIEG-6 and TIEG-7) display changes that mimic those of MG-63 cells treated with TGF-beta, i.e. increased alkaline phosphatase activity, decreased levels of osteocalcin mRNA and protein, and decreased cell proliferation. The degree of these changes correlated with the level of TIEG expressed in the cell lines. TGF-beta treatment of the overexpressed cells showed no added effects. These findings and other published reports support a primary role of TIEG as a transcription factor in the TGF-beta signaling pathway.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Chem Ind Inst Toxicol, Div Endocrine Reprod & Dev Toxicol, Res Triangle Pk, NC 27709 USA	Mayo Clinic	Spelsberg, TC (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 1601A Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.		Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Waters, Katrina/0000-0003-4696-5396	NATIONAL CANCER INSTITUTE [T32CA009441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043627] Funding Source: NIH RePORTER; NCI NIH HHS [CA09441] Funding Source: Medline; NIAMS NIH HHS [AR43627] Funding Source: Medline; NICHD NIH HHS [HD07108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENZ WW, 1997, EXP CELL RES, V108, P157; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CENTRELLA M, 1995, ENDOCRINE REV MONOGR, V4, P211; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Eisch AJ, 1999, NEUROSCIENCE, V94, P629, DOI 10.1016/S0306-4522(99)00302-4; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Fautsch MP, 1998, MAMM GENOME, V9, P838, DOI 10.1007/s003359900878; HEFFERAN TE, 2000, IN PRESS J CELL BIOC; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CANCER SURV, V27, P41; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Rickard DJ, 1996, J BONE MINER RES, V11, P312; Robinson JA, 1997, ENDOCRINOLOGY, V138, P2919, DOI 10.1210/en.138.7.2919; Robinson JA, 1996, ENDOCRINOLOGY, V137, P615, DOI 10.1210/en.137.2.615; Ruscetti FW, 1998, CYTOKINES, P415, DOI 10.1016/B978-012498340-3/50029-4; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; Yajima S, 1997, J NEUROSCI, V17, P8657	30	68	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20255	20259		10.1074/jbc.C000135200	http://dx.doi.org/10.1074/jbc.C000135200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10816551	hybrid			2022-12-25	WOS:000088084500007
J	Xia, CZ; Bao, ZM; Tabassam, F; Ma, WB; Qiu, MS; Hua, SB; Liu, MY				Xia, CZ; Bao, ZM; Tabassam, F; Ma, WB; Qiu, MS; Hua, SB; Liu, MY			GCIP, a novel human Grap2 and cyclin D interacting protein, regulates E2F-mediated transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATORS; KINASE-ACTIVITY; DNA-BINDING; EXPRESSION; E2F; GENE; RB	Regulation of mammalian cell growth and proliferation is governed through receptor-mediated signaling networks that ultimately converge on the cell cycle machinery. Adaptor proteins play essential roles in the formation of intracellular signaling complexes, relaying extracellular signals from the plasma membrane to the nucleus of a cell, The leukocyte-specific adaptor protein Grap2 is a central linker protein in immune cell signaling and activation Using Grap2 as bait protein, we identified a novel human protein, GCIP (Grap2 cyclin-D interacting protein.), We found that GCIP bound to Grap2 in both yeast two-hybrid assays and in mammalian cells through binding to the COOH-terminal unique domain and SH3 domain (designated QC domain) of Grap2, GCIP also associated with cyclin D both in vitro and in vivo. The expression of GCIP was found in all human tissues examined with the highest level of expression in the heart, muscle, peripheral blood leukocytes, and brain. Furthermore, phosphorylation of retinoblastoma protein by cyclin D-dependent protein kinase was reduced and E2F1-mediated transcription activity was inhibited in cells transfected with GCIP. High level expression of GCIP in terminally differentiated tissues and the inhibition of E2F1 transcription activation suggest that GCIP could play an important role in controlling cell differentiation and proliferation.	Univ Texas, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Inst Biosci & Technol,Dept Med Biochem & Genet, Houston, TX 77030 USA; Ocean Univ Qingdao, Qingdao 266003, Peoples R China; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Clontech Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; University of Texas Health Science Center Houston; Ocean University of China; University of Louisville	Liu, MY (corresponding author), Univ Texas, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Inst Biosci & Technol,Dept Med Biochem & Genet, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamu.edu						BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; CHOI KY, 1994, CELL, V78, P499; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DEED RW, 1993, ONCOGENE, V8, P599; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Hwang SY, 1997, DEV DYNAM, V209, P217, DOI 10.1002/(SICI)1097-0177(199706)209:2<217::AID-AJA7>3.0.CO;2-L; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Wang S, 1999, MOL CELL BIOL, V19, P7447; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	42	43	45	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20942	20948		10.1074/jbc.M002598200	http://dx.doi.org/10.1074/jbc.M002598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801854	hybrid			2022-12-25	WOS:000088084500101
J	Hochepied, T; Van Molle, W; Berger, FG; Baumann, H; Libert, C				Hochepied, T; Van Molle, W; Berger, FG; Baumann, H; Libert, C			Involvement of the acute phase protein alpha(1)-acid glycoprotein in nonspecific resistance to a lethal Gram-negative infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-1-ACID GLYCOPROTEIN; RECOMBINANT INTERLEUKIN-1; BACTERIAL-INFECTION; ALPHA1-ACID GLYCOPROTEIN; MICE; RECEPTOR; INFLAMMATION; EXPRESSION; PROTECTION	Resistance to Gram-negative infection can be induced by pretreating animals with several agents such as turpentine and interleukin (IL)-1. Because these agents are powerful inducers of acute phase proteins, we wondered whether these proteins, more particularly alpha(1)-acid glycoprotein (alpha(1)-AGP), are involved in nonspecific resistance to infection. Turpentine and IL-1 protect completely against a lethal challenge of Klebsiella pneumoniae when given 48 and 12-48 h before the challenge, respectively. alpha(1)-AGP induction in the serum reached peak values 48 h after turpentine and 12-48 h after IL-1 injection. Administration of rw,-AGP, 2 h before a challenge of It pneumoniae, significantly increased the survival. Numbers of bacteria cultured from blood and organs were significantly lower in mice pretreated with a protective dose of turpentine, IL-1, or alpha(1)-AGP, These data suggest that alpha(1)-AGP is a possible mediator in turpentine- or IL-1-induced protection because time points of maximal induction of alpha(1)-AGP by turpentine or IL-1 and of optimal protection by alpha(1)-AGP coincide. Transgenic overexpression of rat alpha(1)-AGP protected mice from a It pneumoniae infection. Bacterial counts in blood and organs were significantly lower in transgenic mice, and only in control mice were large necrotic areas, apoptosis, and blood clots observed in the spleen. Our data suggest that alpha(1)-AGP prevents Gram-negative infections and may be an essential component in nonspecific resistance to infection.	Univ Ghent, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Ghent University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Roswell Park Cancer Institute	Libert, C (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	claude@dmb.rug.ac.be	Libert, Claude/A-6504-2010					Abraham Edward, 1999, Molecular Medicine Today, V5, P56, DOI 10.1016/S1357-4310(98)01413-0; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1984, J BIOL CHEM, V259, P566; BAUMANN H, 1993, ACUTE PHASE PROTEINS, P409; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; Chan J, 1991, Protein Expr Purif, V2, P34, DOI 10.1016/1046-5928(91)90006-5; CHEDID L, 1977, P NATL ACAD SCI USA, V74, P2089, DOI 10.1073/pnas.74.5.2089; CHIU KM, 1977, IMMUNOLOGY, V32, P997; COSTELLO M, 1979, NATURE, V281, P677, DOI 10.1038/281677a0; CZUPRYNSKI CJ, 1988, J IMMUNOL, V140, P962; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; DEWEY MJ, 1990, J IMMUNOL, V144, P4392; Dinarello C A, 1989, Biotherapy, V1, P245, DOI 10.1007/BF02171000; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DINARELLO CA, 1991, BLOOD, V77, P1627; DONNELLY PB, 1965, LANCET, V1, P822; GAHMBERG CG, 1978, J EXP MED, V148, P507, DOI 10.1084/jem.148.2.507; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; HARALDSSON B, 1987, ACTA PHYSIOL SCAND, V129, P127, DOI 10.1111/j.1748-1716.1987.tb08047.x; Havenaar EC, 1998, GLYCOCONJUGATE J, V15, P389, DOI 10.1023/A:1006977903048; KOJ A, 1993, ACUTE PHASE PROTEINS, P275; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUNST MW, 1979, INFECTION, V7, P30, DOI 10.1007/BF01640554; KUSHNER I, 1993, ACUTE PHASE PROTEINS, P3; LAINE E, 1990, INFLAMMATION, V14, P1, DOI 10.1007/BF00914025; Leon LR, 1996, AM J PHYSIOL-REG I, V271, pR1668, DOI 10.1152/ajpregu.1996.271.6.R1668; LIBERT C, 1991, J IMMUNOL, V146, P2625; LIBERT C, 1994, J EXP MED, V180, P1571, DOI 10.1084/jem.180.4.1571; LIBERT C, 1998, TRANSGENIC RES, V7, P1; Muchitsch EM, 1996, ARCH INT PHARMACOD T, V331, P313; OLDENBURG HSA, 1995, CYTOKINE, V7, P510, DOI 10.1006/cyto.1995.0069; OZAKI Y, 1987, INFECT IMMUN, V55, P1436, DOI 10.1128/IAI.55.6.1436-1440.1987; PARANT M, 1975, ANN INST PASTEUR IMM, VC126, P319; PARANT M, 1994, INT J IMMUNOPHARMACO, V16, P445, DOI 10.1016/0192-0561(94)90034-5; PETERSDORF RG, 1977, HARRISONS PRINCIPLES, P770; Richards C, 1991, Eur Cytokine Netw, V2, P89; SARCIONE EJ, 1963, ARCH BIOCHEM BIOPHYS, V100, P516, DOI 10.1016/0003-9861(63)90120-6; Schmid K., 1975, PLASMA PROTEINS, P183; SHILO M, 1959, ANNU REV MICROBIOL, V13, P255, DOI 10.1146/annurev.mi.13.100159.001351; Sorensson J, 1999, AM J PHYSIOL-HEART C, V276, pH530, DOI 10.1152/ajpheart.1999.276.2.H530; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; TREUHEIT MJ, 1992, BIOCHEM J, V283, P105, DOI 10.1042/bj2830105; TURCK M, 1977, HARRISONS PRINCIPLES, P830; UCHIYAMA J, 1991, IMMUNOBIOLOGY, V184, P63, DOI 10.1016/S0171-2985(11)80572-3; van der Meer J W, 1988, Biotherapy, V1, P19; VANDERMEER JWM, 1989, EUR J IMMUNOL, V19, P413, DOI 10.1002/eji.1830190229; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VANDIJK W, 1993, ACUTE PHASE PROTEINS, P559; VanMolle W, 1997, J IMMUNOL, V159, P3555; VANTWOUT JW, 1988, EUR J IMMUNOL, V18, P1143, DOI 10.1002/eji.1830180728; VOGELS MTE, 1993, ANTIMICROB AGENTS CH, V37, P2527, DOI 10.1128/AAC.37.12.2527; VOGELS MTE, 1995, ANTIMICROB AGENTS CH, V39, P1744, DOI 10.1128/AAC.39.8.1744; Williams JP, 1997, AM J PHYSIOL-GASTR L, V273, pG1031, DOI 10.1152/ajpgi.1997.273.5.G1031	54	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14903	14909		10.1074/jbc.275.20.14903	http://dx.doi.org/10.1074/jbc.275.20.14903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809735	hybrid			2022-12-25	WOS:000087128300020
J	Ma, KY; Simantov, R; Zhang, JC; Silverstein, R; Hajjar, KA; McCrae, KR				Ma, KY; Simantov, R; Zhang, JC; Silverstein, R; Hajjar, KA; McCrae, KR			High affinity binding of beta(2)-glycoprotein I to human endothelial cells is mediated by annexin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; BETA-2-GLYCOPROTEIN-I APOLIPOPROTEIN-H; DEPENDENT PLASMINOGEN ACTIVATION; LOW-DENSITY-LIPOPROTEIN; BETA-2 GLYCOPROTEIN-I; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; PHOSPHOLIPID-BINDING; RECOGNIZE BETA(2)-GLYCOPROTEIN-I; CRYSTAL-STRUCTURE	beta(2)-Glycoprotein I (beta(2)GPI) is an abundant plasma phospholipid-binding protein and an autoantigen in the antiphospholipid antibody syndrome. Binding of beta(2)GPI to endothelial cells targets them for activation by anti-beta(2)GPI antibodies, which circulate and are associated with thrombosis in patients with the antiphospholipid antibody syndrome. However, the binding of beta(2)GPI to endothelial cells has not been characterized and is assumed to result from association of beta(2)GPI with membrane phospholipid, Here, we characterize the binding of beta(2)GPI to endothelial cells and identify the beta(2)GPI binding site. I-125-beta(2)GPI bound With high affinity (K-d similar to 18 nM) to human umbilical vein endothelial cells (HUVECs), Using affinity purification, we isolated beta(2)GPI-binding proteins of similar to 78 and similar to 36 kDa from HUVECs and EAHY.926 cells. Amino acid sequences of tryptic peptides from each of these were identical to sequences within annexin II. A role for annexin II in binding of beta(2)GPI to cells was confirmed by the observations that annexin II-transfected HEK 293 cells bound similar to 10-fold more I-125-beta(2)GPI than control cells and that anti-annexin II antibodies inhibited the binding of I-125 beta(2)GPI to HUVECs by similar to 90%. Finally, surface plasmon resonance studies revealed high affinity binding between annexin II and beta(2)GPI. These results demonstrate that annexin II mediates the binding of beta(2)GPI to endothelial cells.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY USA; Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Case Western Reserve University; Cornell University; Cornell University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB 3,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxm71@po.cwru.edu			NCRR NIH HHS [M01RR00047] Funding Source: Medline; NHLBI NIH HHS [HL50827] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], [No title captured]; Arnout J, 1998, THROMB HAEMOSTASIS, V79, P79; ARVIEUX J, 1991, J IMMUNOL METHODS, V143, P223, DOI 10.1016/0022-1759(91)90047-J; Balasubramanian K, 1997, J BIOL CHEM, V272, P31113, DOI 10.1074/jbc.272.49.31113; Bombeli T, 1997, THROMB HAEMOSTASIS, V77, P408; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; BREY RL, 1995, ARTHRITIS RHEUM, V314, P25; CABIEDES J, 1995, J RHEUMATOL, V22, P1899; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cines DB, 1998, BLOOD, V91, P3527; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Cotran RS, 1988, ENDOTHELIAL BIOL HLT, P335; DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179; DelPapa N, 1997, ARTHRITIS RHEUM-US, V40, P551; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ESMON CT, 1995, SEMIN CELL BIOL, V6, P259, DOI 10.1006/scel.1995.0035; Galli M, 1996, BRIT J HAEMATOL, V93, P1, DOI 10.1046/j.1365-2141.1996.390969.x; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; George J, 1999, CIRCULATION, V99, P2227, DOI 10.1161/01.CIR.99.17.2227; GLUECK HI, 1985, ARCH INTERN MED, V145, P1389, DOI 10.1001/archinte.145.8.1389; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; Hasunuma Y, 1997, CLIN EXP IMMUNOL, V107, P569, DOI 10.1046/j.1365-2249.1997.d01-948.x; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Horkko S, 1997, P NATL ACAD SCI USA, V94, P10356, DOI 10.1073/pnas.94.19.10356; HUNT J, 1994, J IMMUNOL, V152, P653; HUNT JE, 1992, LUPUS, V1, P75, DOI 10.1177/096120339200100204; Kandiah DA, 1998, ADV IMMUNOL, V70, P507, DOI 10.1016/S0065-2776(08)60393-4; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KATO H, 1991, BIOCHEMISTRY-US, V30, P11687, DOI 10.1021/bi00114a012; Kochl S, 1997, BLOOD, V90, P1482, DOI 10.1182/blood.V90.4.1482.1482_1482_1489; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LOFAS S, 1995, BIOSENS BIOELECTRON, V10, P9; Long M, 1995, BLOOD, V86, P2187; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MATSUURA E, 1994, J EXP MED, V179, P457, DOI 10.1084/jem.179.2.457; MATSUURA E, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91697-9; MCCRAE KR, 1991, BRIT J HAEMATOL, V79, P595, DOI 10.1111/j.1365-2141.1991.tb08087.x; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; NIMPF J, 1985, THROMB HAEMOSTASIS, V54, P397; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PENGO V, 1995, THROMB HAEMOSTASIS, V73, P29; POLZ E, 1979, BIOCHEM BIOPH RES CO, V90, P1305, DOI 10.1016/0006-291X(79)91178-1; POLZ E, 1980, INT J BIOCHEM, V11, P265, DOI 10.1016/0020-711X(80)90229-3; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; Puurunen M, 1996, CLIN IMMUNOL IMMUNOP, V80, P16, DOI 10.1006/clin.1996.0089; Rand JH, 1999, NEW ENGL J MED, V340, P1035, DOI 10.1056/NEJM199904013401310; Rand JH, 1998, BLOOD, V92, P1652, DOI 10.1182/blood.V92.5.1652.417k21_1652_1660; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Roden LD, 1996, BIOCHEM BIOPH RES CO, V225, P1073, DOI 10.1006/bbrc.1996.1297; ROSENBERG RD, 1984, J CLIN INVEST, V74, P1, DOI 10.1172/JCI111389; ROUBEY RAS, 1995, J IMMUNOL, V154, P954; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schinco P, 1997, CLIN EXP RHEUMATOL, V15, P5; SCHOUSBOE I, 1980, THROMB RES, V19, P225, DOI 10.1016/0049-3848(80)90421-1; SCHULTZE HE, 1961, NATURWISSENSCHAFTEN, V48, P719, DOI 10.1007/BF00620967; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Shapiro SS, 1996, ANNU REV MED, V47, P533; SHI W, 1993, THROMB HAEMOSTASIS, V70, P342; Simantov R, 1996, LUPUS, V5, P440, DOI 10.1177/096120339600500521; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; STEINKASSERER A, 1992, FEBS LETT, V313, P193, DOI 10.1016/0014-5793(92)81442-O; Swadzba J, 1997, J RHEUMATOL, V24, P1710; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; VANHEERDE WL, 1994, BIOCHEM J, V302, P305, DOI 10.1042/bj3020305; VIARD JP, 1992, AM J MED, V93, P181, DOI 10.1016/0002-9343(92)90049-H; WAGENKNECHT DR, 1993, THROMB HAEMOSTASIS, V69, P361; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; WURM H, 1982, METABOLISM, V31, P484, DOI 10.1016/0026-0495(82)90238-4; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; Yanase K, 1997, J CLIN INVEST, V100, P25, DOI 10.1172/JCI119517; ZINI JM, 1992, BLOOD, V79, P2917	84	181	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15541	15548		10.1074/jbc.275.20.15541	http://dx.doi.org/10.1074/jbc.275.20.15541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809787	hybrid			2022-12-25	WOS:000087128300103
J	Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G				Nicot, C; Mahieux, R; Opavsky, R; Cereseto, A; Wolff, L; Brady, JN; Franchini, G			HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300	ONCOGENE			English	Article						tax; c-Myb; transrepression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; CREB BINDING-PROTEIN; INDUCED TRANSCRIPTION ACTIVATION; NEGATIVE REGULATORY DOMAIN; NF-KAPPA-B; MESSENGER-RNA; V-MYB; PHOSPHORYLATION SITE; ABERRANT EXPRESSION	The c-Myb proto-oncogene is preferentially expressed in hematopoietic lineages, and highly expressed in several leukemia types. The Human T-cell Leukemia Virus Type I (HTLV-I) is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL), A previous report suggested that Tax, the viral transactivator, is able to suppress the transactivation potential of c-Myb protein by competing for recruitment of CBP, We tested whether such a competition could affect transcription from the c-Myb promoter in Tax expressing T-cells, Using several c-Myb promoter reporter constructs carrying mutations in various regions, we demonstrate that Tax suppression of c-Myb transactivation results in transrepression of the c-Myb promoter through the Myb responsive elements in Jurkat T-cells, The ability of Tax mutants M22, M47 and V89A to interact with the full-length CBP and p300 proteins in vitro, and their ability to repress the c-Myb promoter, was then evaluated. Although both M47 and M22 bind to CBP and p300 to a similar extent, only M47 was able to repress the c-Myb promoter, suggesting that competition for CBP/p300 binding was not the mechanism underlying Tax's effect. This concept was further supported by the fact that the Tax mutant V89A transrepresses the c-Myb promoter efficiently in spite of an impaired binding to CBP and p300, Therefore, Tax-mediated repression of the c-Myb promoter appears to be independent from a direct competition between c-Myb and Tax for recruitment of CBP/p300, Interestingly, a decreased transcription from the endogenous c-Myb promoter was observed in several HTLV-I transformed T-cell lines. Finally, the ability of Tax to directly repress the endogenous c-Myb promoter was demonstrated in a Jurkat cell line stably transfected with a tax gene driven by a cadmium-inducible promoter.	NCI, Div Basic Sci, Basic Res Lab, Bethesda, MD 20814 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20814 USA; NIH, Cellular Oncol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Nicot, C (corresponding author), NCI, Div Basic Sci, Basic Res Lab, 9000 Rockville Pike,Bldg 41,Room C303, Bethesda, MD 20814 USA.			Cereseto, Anna/0000-0003-4453-2597; mahieux, renaud/0000-0002-5129-6804	NATIONAL CANCER INSTITUTE [ZIABC005254, ZIABC005645, Z01BC005254, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CASTRON KM, 1992, J IMMUNOL, V148, P934; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATSUMOTO K, 1994, VIROLOGY, V200, P813, DOI 10.1006/viro.1994.1248; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Nicot C, 1997, VIROLOGY, V236, P47, DOI 10.1006/viro.1997.8720; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; NICOT C, IN PRESS BLOOD; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TATEWAKI M, 1995, BLOOD, V86, P3109; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; WATSON RJ, 1988, ONCOGENE, V2, P267; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728	71	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2155	2164		10.1038/sj.onc.1203536	http://dx.doi.org/10.1038/sj.onc.1203536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815807				2022-12-25	WOS:000086728000009
J	Bailer, SM; Balduf, C; Katahira, J; Podtelejnikov, A; Rollenhagen, C; Mann, M; Pante, N; Hurt, E				Bailer, SM; Balduf, C; Katahira, J; Podtelejnikov, A; Rollenhagen, C; Mann, M; Pante, N; Hurt, E			Nup116p associates with the Nup82p-Nsp1p-Nup159p nucleoporin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; POLY(A)(+) RNA; FUNCTIONAL-CHARACTERIZATION; MOLECULAR ARCHITECTURE; CYTOPLASMIC FIBRILS; CONDITIONAL ALLELE; GLFG NUCLEOPORIN; TRANSPORT FACTOR	Nup116p is a GLFG nucleoporin involved in RNA export processes. We show here that Nup116p physically interacts with the Nup82p-Nsp1p-Nup159p nuclear pore subcomplex, which plays a central role in nuclear mRNA export. For this association, a sequence within the C-terminal domain of Nup116p that includes the conserved nucleoporin RNA-binding motif was sufficient and necessary. Consistent with this biochemical interaction, protein A-Nup116p and the protein A-tagged Nup116p C-terminal domain, like the members of the Nup82p complex, localized to the cytoplasmic side of the nuclear pore complex, as revealed by immunogold labeling. Finally, synthetic lethal interactions were found between mutant alleles of NUP116 and all members of the Nup82p complex. Thus, Nup116p consists of three independent functional domains: 1) the C-terminal part interacts with the Nup82p complex; 2) the Gle2p-binding sequence interacts with Gle2p/Rae1p; and 3) the GLFG domain interacts with shuttling transport receptors such as karyopherin-beta family members.	Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.		Ed Hurt, Dr./AAE-8874-2019; Mann, Matthias/A-3454-2013; Podtelejnikov, Alexandre/B-6120-2017; Pante, Nelly/GVR-8478-2022	Ed Hurt, Dr./0000-0002-4535-8255; Mann, Matthias/0000-0003-1292-4799; Podtelejnikov, Alexandre/0000-0002-8124-6584; Katahira, Jun/0000-0001-5188-0368				Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; Del Priore V, 1997, J CELL SCI, V110, P2987; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Emtage JLT, 1997, J CELL SCI, V110, P911; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; HURT EC, 1988, EMBO J, V7, P4323, DOI 10.1002/j.1460-2075.1988.tb03331.x; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Maniatis T., 1982, MOL CLONING LAB MANU; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Vartanian JP, 1996, NUCLEIC ACIDS RES, V24, P2627, DOI 10.1093/nar/24.14.2627; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; Whalen WA, 1997, YEAST, V13, P1167, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1167::AID-YEA154>3.3.CO;2-F; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	60	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23540	23548		10.1074/jbc.M001963200	http://dx.doi.org/10.1074/jbc.M001963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801828	hybrid			2022-12-25	WOS:000088564200020
J	Fan, QR; Long, EO; Wiley, DC				Fan, QR; Long, EO; Wiley, DC			Cobalt-mediated dimerization of the human natural killer cell inhibitory receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-C; DIRECT BINDING; NK CELLS; ZINC; MOLECULES; P58; SPECIFICITIES; RECOGNITION; PROLACTIN; ALLOTYPES	Upon engagement of specific class I major histocompatibility complex (MHC) molecules on target cells, inhibitory receptors on natural killer (NK) cells deliver a negative signal that prevents the target cell lysis by NK cells. In humans, killer cell immunoglobulin-related receptors (KIR) with two immunoglobulin-like domains (KIR2D) modulate the lysis of target cells bearing specific HLA-C alleles (Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R., Barbaresi, M., Ciccone, E., and Moretta, L. (1993) J. Exp. Med. 178, 597-604). The transduction of inhibitory signals by KIR2D molecules is impaired by the zinc chelator, 1,10-phenanthroline, and mutation of a putative zinc-binding site (Rajagopalan, S., and Long, E. O. (1998) J. Immunol. 161, 1299-1305), but the mechanism by which zinc may affect the function of KIR remains unknown. In this study, the inhibitory NK receptor KIR2DL1 was discovered to dimerize in the presence of Co2+ as observed on native gel electrophoresis and by gel filtration column chromatography. Furthermore, Co2+-mediated KIR2DL1 dimer binds to HLA-Cw4 with higher affinity than the wild type KIR2DL1 monomer. Replacement of the amino-terminal His residue by Ala abolishes the ability of KIR2DL1 to bind Co2+, indicating that Co2+-mediated KIR2DL1 dimerization involves pairing of the D1 domain. Although not observed on native gels, the inhibitory receptor KIR2DL1 can be chemically cross-linked into dimers in the presence of Zn2+ and its related divalent metal ions, suggesting that Co2+-mediated dimerization of KIR2DL1 may mimic a weaker interaction between KIR2DL1 and zinc in vivo.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Wiley, DC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.		Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000525, ZIAAI000525] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Collman J.P., 1980, METAL ION ACTIVATION, P1; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DANDREA A, 1995, J IMMUNOL, V155, P2306; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; DAWSON RMC, 1986, DATA BIOCH RES, P408; Dohring C, 1996, IMMUNOGENETICS, V44, P227, DOI 10.1007/s002510050116; Fan QR, 1996, P NATL ACAD SCI USA, V93, P7178, DOI 10.1073/pnas.93.14.7178; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; FAN QR, 2000, IN PRESS EUR J IMMUN; Gray H. B., 1981, COPPER PROTEINS, P1; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOPPELMAN MCS, 1989, J CLIN ENDOCR METAB, V68, P215, DOI 10.1210/jcem-68-1-215; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; LENTNER C, 1981, GEIGY SCI TABLES, V3; Long EO, 1997, CURR OPIN IMMUNOL, V9, P344, DOI 10.1016/S0952-7915(97)80080-5; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; Rajagopalan S, 1998, J IMMUNOL, V161, P1299; RAJAGOPALAN S, 1995, J IMMUNOL, V155, P4143; SIDNEY J, 1995, J IMMUNOL, V154, P247; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1983, ZINC ENZYMES, P25; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1	29	21	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23700	23706		10.1074/jbc.M003318200	http://dx.doi.org/10.1074/jbc.M003318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816589	hybrid			2022-12-25	WOS:000088564200042
J	Ambrosetti, DC; Scholer, HR; Dailey, L; Basilico, C				Ambrosetti, DC; Scholer, HR; Dailey, L; Basilico, C			Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the Fibroblast growth factor-4 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; POU-DOMAIN; GROWTH-FACTOR-4 ENHANCER; FUNCTIONAL INTERACTION; REGULATORY ELEMENTS; MAMMALIAN EMBRYO; STEM-CELLS; PROTEIN; GENE; MOUSE	Fibroblast growth factor (FGF)-4 gene expression in the inner cell mass of the blastocyst and in EC cells requires the combined activity of two transcriptional regulators, Sox2 and Oct-3, which bind to adjacent sites on the FGF-4 enhancer DNA and synergistically activate transcription. Sox2 and Oct-3 bind cooperatively to the enhancer DNA through their DNA-binding, high mobility group and POU domains, respectively. These two domains, however, are not sufficient to activate transcription. We have analyzed a number of Sox2 and Oct-3 deletion mutants to identify the domains within each protein that contribute to the activity of the Sox2.Oct-3 complex. Within Oct-3, we have identified two activation domains, the N-terminal AD1 and the C-terminal AD2, that play a role in the activity of the Sox2.Oct-3 complex. AD1 also displays transcriptional activation functions in the absence of Sox2 while AD2 function was only detected within the Sox2.Oct-3 complex. In Sox2, we have identified three activation domains within its C terminus: R1, R2, and R3, RI and R2 can potentiate weak activation by Sox2 in the absence of Oct-3 but their deletion has no effect on the Sox2.Oct-3 complex. In contrast, R3 function is only observed when Sox2 is complexed with Oct-3. In addition, analysis of Oct-1/Oct-3 chimeras indicates that the Oct-3 homeodomain also plays a critical role in the formation of a functional Sox2.Oct-3 complex. Our results are consistent with a model in which the synergistic action of Sera and Oct-3 results from two major processes. Cooperative binding of the factors to the enhancer DNA, mediated by their binding domains, stably tethers each factor to DNA and increases the activity of intrinsic activation domains within each protein. Protein-protein and protein-DNA interactions then may lead to reciprocal conformational changes that expose latent activation domains within each protein. These findings define a mechanism that may also be utilized by other Sox.POU protein complexes in gene activation.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Univ Penn, New Bolton Ctr, Ctr Anim Transgenesis & Germ Cell Res, Kennett Sq, PA 19348 USA	New York University; University of Pennsylvania	Dailey, L (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	dailel01@med.nyu.edu; basilc01@med.nyu.edu	, HS/AAB-4434-2019	, HS/0000-0003-2643-5136	NATIONAL CANCER INSTITUTE [R01CA078925] Funding Source: NIH RePORTER; NCI NIH HHS [CA42568, CA78925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Ma Y, 1998, MECH DEVELOP, V73, P169, DOI 10.1016/S0925-4773(98)00050-1; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6481; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Soriano NS, 1998, DEVELOPMENT, V125, P3989; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	44	136	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23387	23397		10.1074/jbc.M000932200	http://dx.doi.org/10.1074/jbc.M000932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801796	hybrid			2022-12-25	WOS:000088419400108
J	Bradford, HN; Pixley, RA; Colman, RW				Bradford, HN; Pixley, RA; Colman, RW			Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; PROTEASE-ACTIVATED RECEPTOR-1; COAGULATION FACTOR-XII; AMINO-ACID-SEQUENCE; BETA-FACTOR-XIIA; HAGEMAN-FACTOR; HEAVY-CHAIN; MONOCLONAL-ANTIBODY; ALPHA-THROMBIN; SITE	Factor XII deficiency has been postulated to be a risk factor for thrombosis suggesting that factor XII is an antithrombotic protein. The biochemical mechanism leading to this clinical observation is unknown. We have previously reported high molecular weight kininogen (HK) inhibition of thrombin-induced platelet aggregation by binding to the platelet glycoprotein (GP) Ib-M-V complex. Although factor XII will bind to the intact platelet through GP Ib alpha (glycocalicin) without activation, we now report that factor XIIa (0.37 mu M), but not factor XII zymogen, is required for the inhibition of thrombin-induced platelet aggregation. Factor XIIa had no significant effect on SFLLRN-induced platelet aggregation. Moreover, an antibody to the thrombin site on protease-activated receptor-1 failed to block factor XII binding to platelets. Inhibition of thrombin-induced platelet aggregation was demonstrated with factor Wa but not with factor XII zymogen or factor XIIa indicating that the conformational exposure of the heavy chain following proteolytic activation is required for inhibition. However, inactivation of the catalytic activity of factor XIIa did not affect the inhibition of thrombin-induced platelet aggregation. Factor XII showed displacement of biotin-labeled HK (30 nM) binding to gel-filtered platelets and, at concentrations of 50 nM, was able to block 50% of the HX binding, suggesting involvement of the GP Ib complex. Antibodies to GP Ib and GP IX, which inhibited HK binding to platelets, did not block factor XII binding. However, using a biosensor, which monitors protein-protein interactions, both HX and factor XII bind to GP IB alpha. Factor XIII may serve to regulate thrombin binding to the GP Ib receptor by colocalizing with HK, to control the extent of platelet aggregation in vivo.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Colman, RW (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.			Bradford, Harlan/0000-0001-5582-278X	NHLBI NIH HHS [P0-1 HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; CHIEN P, 1988, J CLIN INVEST, V82, P1554, DOI 10.1172/JCI113765; CHIEN P, 1990, BLOOD, V76, P178; CLARKE BJ, 1989, J BIOL CHEM, V264, P11497; Colman RW, 1999, ARTERIOSCL THROM VAS, V19, P2245, DOI 10.1161/01.ATV.19.9.2245; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; COOL DE, 1985, J BIOL CHEM, V260, P3666; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; HARMON JT, 1988, BIOCHEMISTRY-US, V27, P2151, DOI 10.1021/bi00406a050; JANDROTPERRUS M, 1990, BRIT J HAEMATOL, V75, P385, DOI 10.1111/j.1365-2141.1990.tb04353.x; JIANG YP, 1992, J BIOL CHEM, V267, P3712; Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Khan MMH, 1999, ANN THORAC SURG, V68, P473, DOI 10.1016/S0003-4975(99)00551-2; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; PIXLEY RA, 1993, METHOD ENZYMOL, V222, P51; PIXLEY RA, 1987, J BIOL CHEM, V262, P10140; PURI RN, 1993, BLOOD COAGUL FIBRIN, V4, P465, DOI 10.1097/00001721-199306000-00012; PURI RN, 1991, BLOOD, V77, P500; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; RUAN CG, 1987, BLOOD, V69, P570; SAMUEL M, 1992, J BIOL CHEM, V267, P19691; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WACHTFOGEL YT, 1986, BLOOD, V67, P1731; WALSMANN P, 1974, PHARMAZIE, V29, P413; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMAMOTO K, 1986, THROMB HAEMOSTASIS, V55, P162	36	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22756	22763		10.1074/jbc.M002591200	http://dx.doi.org/10.1074/jbc.M002591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801853	hybrid			2022-12-25	WOS:000088419400024
J	Cohen, GB; Rangan, VS; Chen, BK; Smith, S; Baltimore, D				Cohen, GB; Rangan, VS; Chen, BK; Smith, S; Baltimore, D			The human thioesterase II protein binds to a site on HIV-1 Nef critical for CD4 down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACYL-COA THIOESTERASE; CELL-SURFACE CD4; CYCLOPHILIN-A; TYPE-1 NEF; ADAPTER COMPLEXES; TARGETING SIGNAL; ESCHERICHIA-COLI; T-LYMPHOCYTES; SH3 DOMAIN	A HIV-I Nef affinity column was used to purify a 35-kDa Nef-interacting protein from T-cell lysates. The 35-kDa protein was identified by peptide microsequence analysis as the human thioesterase II (hTE) enzyme, an enzyme previously identified in a yeast two-hybrid screen as a potential Nef-interacting protein. Immunofluorescence studies showed that hTE localizes to peroxisomes and that coexpression of Nef and hTE leads to relocalization of Nef to peroxisomes. Interaction of Nef and hTE was abolished by point mutations in Nef at residues Asp(108), Leu(112), Phe(121), Pro(122), and Asp(123). All of these mutations also abrogated the ability of Nef to down-regulate CD4 from the surface of HIV-infected cells. Eased on the x-ray and NMR structures of Nef, these residues define a surface on Nef critical for CD4 down-regulation. A subset of these mutations also affected the ability of Nef to down-regulate major histocompatibility complex class I. These results, taken together with previous studies, identify a region on Nef critical for most of its known functions. However, not all Nef alleles bind to hTE with high affinity, so the role of hTE during HIV infection remains uncertain.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr AIDS Res, Charlestown, MA 02129 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; MIT, Whitehead Inst, Dept Biol, Cambridge, MA 02139 USA; CALTECH, Off President, Pasadena, CA 91125 USA	Harvard University; Massachusetts General Hospital; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Massachusetts Institute of Technology (MIT); Whitehead Institute; California Institute of Technology	Baltimore, D (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr AIDS Res, Charlestown, MA 02129 USA.	baltimore@caltech.edu		Chen, Benjamin K/0000-0002-5404-1997				ANDERSON S, 1993, J VIROL, V67, P4923, DOI 10.1128/JVI.67.8.4923-4931.1993; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BERGE RK, 1980, FEBS LETT, V109, P194, DOI 10.1016/0014-5793(80)81084-2; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; CACCAVELLI L, 1994, NEUROENDOCRINOLOGY, V60, P314, DOI 10.1159/000126764; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Colgan J, 1996, J VIROL, V70, P4299, DOI 10.1128/JVI.70.7.4299-4310.1996; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; CRISE B, 1992, J BIOL CHEM, V267, P13593; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Lock M, 1999, EMBO J, V18, P2722, DOI 10.1093/emboj/18.10.2722; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MIURA S, 1992, J BIOL CHEM, V267, P14405; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Trono D, 1997, CHEM BIOL, V4, P13, DOI 10.1016/S1074-5521(97)90232-5; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x	61	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23097	23105		10.1074/jbc.M000536200	http://dx.doi.org/10.1074/jbc.M000536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807905	Green Accepted, hybrid			2022-12-25	WOS:000088419400067
J	Siviter, RJ; Coast, GM; Winther, AME; Nachman, RJ; Taylor, CAM; Shirras, AD; Coates, D; Isaac, RE; Nassel, DR				Siviter, RJ; Coast, GM; Winther, AME; Nachman, RJ; Taylor, CAM; Shirras, AD; Coates, D; Isaac, RE; Nassel, DR			Expression and functional characterization of a Drosophila neuropeptide precursor with homology to mammalian preprotachykinin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYKININ-RELATED PEPTIDES; CENTRAL-NERVOUS-SYSTEM; LEUCOPHAEA-MADERAE; URECHIS-UNICINCTUS; ECHIUROID WORM; CDNA SEQUENCE; SUBSTANCE-P; STABLE FLY; GENE; RECEPTOR	Peptides structurally related to mammalian tachykinins have recently been isolated from the brain and intestine of several insect species, where they are believed to function as both neuromodulators and hormones. Further evidence for the signaling role of insect tachykinin-related peptides was provided by the cloning and characterization of cDNAs for two tachykinin receptors from Drosophila melanogaster. However, no endogenous ligand has been isolated for the Drosophila tachykinin receptors to date. Analysis of the Drosophila genome allowed us to identify a putative tachykinin-related peptide prohormone (prepro-DTK) gene. A 1.5-kilobase pair cDNA amplified from a Drosophila head cDNA library contained an 870-base pair open reading frame, which encodes five novel Drosophila tachykinin-related peptides (called DTK peptides) with conserved C-terminal FXGXR-amide motifs common to other insect tachykinin-related peptides. The tachykinin-related peptide prohormone gene (Dtk) is both expressed and post-translationally processed in larval and adult midgut endocrine cells and in the central nervous system, with midgut expression starting at stage 17 of embryogenesis. The predicted Drosophila tachykinin peptides have potent stimulatory effects on the contractions of insect gut. These data provide additional evidence for the conservation of both the structure and function of the tachykinin peptides in the brain and gut during the course of evolution.	Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Stockholm, Dept Zool, S-10691 Stockholm, Sweden; USDA, So Plains Agr Res Ctr, College Stn, TX 77845 USA; Univ London Birkbeck Coll, Dept Biol, London WC1E 7HX, England	University of Leeds; Lancaster University; Stockholm University; United States Department of Agriculture (USDA); University of London; Birkbeck University London	Isaac, RE (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	r.e.isaac@leeds.ac.uk	Winther, Åsa/E-8842-2010	Shirras, Alan/0000-0002-1377-5134				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER M, 1989, DROSOPHILA LAB MANUA, P122; BAUTZ AM, 1979, ARCH ZOOL EXP GEN, V120, P183; Beerntsen BT, 1999, INSECT MOL BIOL, V8, P459, DOI 10.1046/j.1365-2583.1999.00141.x; CARTER MS, 1990, J NEUROSCI, V10, P2203; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; Coast GM, 1998, PEPTIDES, V19, P469, DOI 10.1016/S0196-9781(97)00461-0; Cook BJ, 1997, J ENTOMOL SCI, V32, P487, DOI 10.18474/0749-8004-32.4.487; ERSPAMER V, 1962, EXPERIENTIA, V18, P58, DOI 10.1007/BF02138250; ERSPAMER V, 1981, TRENDS NEUROSCI, V4, P267, DOI 10.1016/0166-2236(81)90084-9; Goldhill J, 1998, EUR J PHARMACOL, V363, P161, DOI 10.1016/S0014-2999(98)00797-3; Guerrero FD, 1997, PEPTIDES, V18, P1, DOI 10.1016/S0196-9781(96)00278-1; HARMAR AJ, 1990, FEBS LETT, V275, P22, DOI 10.1016/0014-5793(90)81429-R; HOLMAN GM, 1991, INSECT BIOCHEM, V21, P107, DOI 10.1016/0020-1790(91)90070-U; Holman GM, 1999, PEPTIDES, V20, P1, DOI 10.1016/S0196-9781(98)00150-8; Holzer P, 1997, PHARMACOL THERAPEUT, V73, P219, DOI 10.1016/S0163-7258(96)00196-9; Holzer P, 1997, PHARMACOL THERAPEUT, V73, P173, DOI 10.1016/S0163-7258(96)00195-7; IKEDA T, 1993, BIOCHEM BIOPH RES CO, V192, P1, DOI 10.1006/bbrc.1993.1373; Ikeda T, 1999, FEBS LETT, V461, P201, DOI 10.1016/S0014-5793(99)01457-X; KAGE R, 1988, J NEUROCHEM, V50, P1412, DOI 10.1111/j.1471-4159.1988.tb03024.x; Kawada T, 1999, BIOCHEM BIOPH RES CO, V263, P848, DOI 10.1006/bbrc.1999.1465; Kim MY, 1997, ARCH INSECT BIOCHEM, V34, P475, DOI 10.1002/(SICI)1520-6327(1997)34:4<475::AID-ARCH6>3.0.CO;2-R; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; LUNDQUIST CT, 1994, J COMP NEUROL, V341, P225, DOI 10.1002/cne.903410208; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; Meola SM, 1998, NEUROCHEM RES, V23, P189, DOI 10.1023/A:1022432909360; MONNIER D, 1992, J BIOL CHEM, V267, P1298; Muren JE, 1997, PEPTIDES, V18, P7, DOI 10.1016/S0196-9781(96)00243-4; Muren JE, 1996, REGUL PEPTIDES, V65, P185, DOI 10.1016/0167-0115(96)00092-4; Nachman RJ, 1999, PEPTIDES, V20, P23, DOI 10.1016/S0196-9781(98)00149-1; Nachman RJ, 1999, ANN NY ACAD SCI, V897, P388, DOI 10.1111/j.1749-6632.1999.tb07908.x; Nassel Dick R., 1998, Society for Experimental Biology Seminar Series, V65, P248; NASSEL DR, 1993, CELL TISSUE RES, V274, P27, DOI 10.1007/BF00327982; Nassel DR, 2000, J COMP NEUROL, V418, P81, DOI 10.1002/(SICI)1096-9861(20000228)418:1<81::AID-CNE6>3.0.CO;2-B; Nassel DR, 1999, PEPTIDES, V20, P141, DOI 10.1016/S0196-9781(98)00142-9; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Reese M.G., 1995, 7 INT GEN SEQ AN C H; Reese MG, 2000, GENOME RES, V10, P529, DOI 10.1101/gr.10.4.529; ROSAY P, 1995, MECH DEVELOP, V51, P329, DOI 10.1016/0925-4773(95)00382-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Veenstra JA, 2000, ARCH INSECT BIOCHEM, V43, P49, DOI 10.1002/(SICI)1520-6327(200002)43:2&lt;49::AID-ARCH1&gt;3.0.CO;2-M; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; Winther AME, 1998, PEPTIDES, V19, P445, DOI 10.1016/S0196-9781(97)00463-4; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	47	130	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23273	23280		10.1074/jbc.M002875200	http://dx.doi.org/10.1074/jbc.M002875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801863	Green Accepted, hybrid			2022-12-25	WOS:000088419400093
J	Baker, TL; Booden, MA; Buss, JE				Baker, TL; Booden, MA; Buss, JE			S-nitrosocysteine increases palmitate turnover on Ha-Ras in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE LOCALIZATION; PROTEIN ALPHA-SUBUNITS; NITRIC-OXIDE SYNTHASE; SIGNAL-TRANSDUCTION; CYSTEINE RESIDUES; POLYBASIC DOMAIN; FATTY ACYLATION; CAAX MOTIF; IN-VIVO; PALMITOYLATION	Ha-Res is modified by isoprenoid on Cys(186) and by reversibly attached palmitates at Cys(181) and Cys(184). Ha-Ras loses 90% of its transforming activity if Cys(181) and Cys(184) changed to serines, implying that palmitates make important contributions to oncogenicity, However, study of dynamic acylation is hampered by an absence of methods for acutely manipulating Ha-Ras palmitoylation in living cells. S-nitrosocysteine (SNC) and, to a more modest extent, S-nitrosoglutathione were found to rapidly increase [H-3]palmitate incorporation into cellular or oncogenic Ha-Ras in NIH 3T3 cells. In contrast, SNC decreased [H-3]palmitate labeling of the transferrin receptor and caveolin. SNC accelerated loss of [H-3]palmitate from Ha-Ras, implying that SNC stimulated deacylation and permitted subsequent reacylation of Ha-Ras. SNC also decreased Ha-Ras GTP binding and inhibited phosphorylation of the kinases ERK1 and ERK2 in NIH 3T3 cells. Thus, SNC altered two important properties of Ha-Res activation state and lipidation. These results identify SNC as a new tool for manipulating palmitate turnover on Ha-Ras and for studying requirements of repalmitoylation and the relationship be tween palmitate cycling, membrane localization, and signaling by Ha-Ras.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Iowa State Univ Sci & Technol, Dept Zool Genet, Ames, IA 50011 USA	Iowa State University; Iowa State University	Buss, JE (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	jbuss@iastate.edu		Buss, Janice/0000-0002-8086-265X	NCI NIH HHS [CA51890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1999, J BIOL CHEM, V274, P26337, DOI 10.1074/jbc.274.37.26337; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HESS DT, 1994, NEUROPHARMACOLOGY, V33, P1283, DOI 10.1016/0028-3908(94)90028-0; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Ji YB, 1999, METHOD ENZYMOL, V301, P145; Kato K, 1992, Semin Cancer Biol, V3, P179; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Liu L, 1999, J BIOL CHEM, V274, P3252; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MERY PF, 1993, J BIOL CHEM, V268, P26286; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Satoh S, 1997, J NEUROCHEM, V69, P2197; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yeh DC, 1999, J BIOL CHEM, V274, P33148, DOI 10.1074/jbc.274.46.33148; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	74	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22037	22047		10.1074/jbc.M001813200	http://dx.doi.org/10.1074/jbc.M001813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801823	hybrid			2022-12-25	WOS:000088363800042
J	Watanabe, K; Fujii, H; Takahashi, T; Kodama, M; Aizawa, Y; Ohta, Y; Ono, T; Hasegawa, G; Naito, M; Nakajima, T; Kamijo, Y; Gonzalez, FJ; Aoyama, T				Watanabe, K; Fujii, H; Takahashi, T; Kodama, M; Aizawa, Y; Ohta, Y; Ono, T; Hasegawa, G; Naito, M; Nakajima, T; Kamijo, Y; Gonzalez, FJ; Aoyama, T			Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; COENZYME-A DEHYDROGENASE; ENZYME GENE-EXPRESSION; PPAR-ALPHA; BETA-OXIDATION; PENTADECANOIC ACID; MOLECULAR-CLONING; KAPPA-B; RAT; MITOCHONDRIAL	The peroxisome proliferator-activated receptor alpha (PPAR alpha) is a member of the nuclear receptor superfamily and mediates the biological effects of peroxisome proliferators, To determine the physiological role of PPAR alpha in cardiac fatty acid metabolism, we examined the regulation of expression of cardiac fatty acid-metabolizing proteins using PPAR alpha-null mice. The capacity for constitutive myocardial beta-oxidation of the medium and long chain fatty acids, octanoic acid and palmitic acid, was markedly reduced in the PPAR alpha-null mice as compared with the wild-type mice, indicating that mitochondrial fatty acid catabolism is impaired in the absence of PPAR alpha. In contrast, constitutive beta-oxidation of the very long chain fatty acid, lignoceric acid, did not differ between the mice, suggesting that the constitutive expression of enzymes involved in peroxisomal beta-oxidation is independent of PPAR alpha. Indeed, PPAR alpha-null mice had normal levels of the peroxisomal beta-oxidation enzymes except the D-type bifunctional protein. At least seven mitochondrial fatty acid-metabolizing enzymes were expressed at much lower levels in the PPAR alpha-null mice, whereas other fatty acid-metabolizing enzymes were present at similar or slightly lower levels in the PPAR alpha-null, as compared with wild-type mice. Additionally, lower constitutive mRNA expression levels of fatty acid transporters were found in the PPAR alpha-null mice, suggesting a role for PPAR alpha in fatty acid transport and catabolism. Indeed, in fatty acid metabolism experiments in vivo, myocardial uptake of iodophenyl 9-methylpentadecanoic acid and its conversion to 3-methyl-nonanoic acid were reduced in the PPAR alpha-null mice. Interestingly, a decreased ATP concentration after exposure to stress, abnormal cristae of the mitochondria, abnormal caveolae, and fibrosis were observed only in the myocardium of the PPAR alpha-null mice. These cardiac abnormalities appeared to proceed in an age-dependent manner. Taken together, the results presented here indicate that PPAR alpha controls constitutive fatty acid oxidation, thus establishing a role for the receptor in cardiac fatty acid homeostasis, Furthermore, altered expression of fatty acid-metabolizing proteins seems to lead to myocardial damage and fibrosis, as inflammation and abnormal cell growth control can cause these conditions.	Niigata Coll Pharm, Dept Clin Pharmacol, Niigata 9502081, Japan; Niigata Univ, Sch Med, Dept Biochem 2, Niigata 9518510, Japan; Niigata Univ, Sch Med, Radioisotope Ctr, Niigata 9518510, Japan; Niigata Univ, Sch Med, Dept Med 1, Niigata 9518510, Japan; Niigata Univ, Sch Med, Dept Pathol 2, Niigata 9518510, Japan; Shinshu Univ, Sch Med, Dept Hyg & Med Genet, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Internal Med 2, Nagano 3908621, Japan; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Shinshu Univ, Sch Med, Dept Aging Biochem, Matsumoto, Nagano 3908621, Japan	Niigata University; Niigata University; Niigata University; Niigata University; Shinshu University; Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shinshu University	Watanabe, K (corresponding author), Niigata Coll Pharm, Dept Clin Pharmacol, Kamisin Ei Cho, Niigata 9502081, Japan.				NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BREMER J, 1984, FATTY ACID METABOLIS; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOURAQUI P, 1991, J NUCL MED, V32, P447; Cox GF, 1998, J PEDIATR-US, V133, P247, DOI 10.1016/S0022-3476(98)70228-8; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; ISEMANN I, 1990, NATURE, V347, P645; KAMIJO T, 1994, J CLIN INVEST, V93, P1740, DOI 10.1172/JCI117158; Kamijo T, 1997, PEDIATR RES, V42, P569, DOI 10.1203/00006450-199711000-00002; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KNAPP FF, 1995, EUR J NUCL MED, V22, P361, DOI 10.1007/BF00941855; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefer A M, 1987, Cardiovasc Clin, V18, P85; LEFER AM, 1985, FED PROC, V44, P275; LEFER DJ, 1987, ARCH INT PHARMACOD T, V287, P89; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; Nakajima K, 1998, NUCL MED COMMUN, V19, P839, DOI 10.1097/00006231-199809000-00004; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NAYLER WG, 1979, J MOL CELL CARDIOL, V11, P683, DOI 10.1016/0022-2828(79)90381-X; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; NIETH H, 1966, NATURE, V209, P1244, DOI 10.1038/2091244a0; Orii KE, 1996, BIOCHEM BIOPH RES CO, V219, P773, DOI 10.1006/bbrc.1996.0309; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; SAKAI K, 1995, EUR J BIOCHEM, V229, P201, DOI 10.1111/j.1432-1033.1995.tb20456.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHINDO Y, 1978, BIOCHEM PHARMACOL, V27, P2683; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Taegtmeyer H, 1994, CURR PROB CARDIOLOGY, V19, P57; Watanabe K, 1998, Ann Nucl Med, V12, P261; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	45	255	271	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22293	22299		10.1074/jbc.M000248200	http://dx.doi.org/10.1074/jbc.M000248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801788	hybrid			2022-12-25	WOS:000088363800074
J	Werbonat, Y; Kleutges, N; Jakobs, KH; van Koppen, CJ				Werbonat, Y; Kleutges, N; Jakobs, KH; van Koppen, CJ			Essential role of dynamin in internalization of M-2 muscarinic acetylcholine and angiotensin AT(1A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COATED VESICLE FORMATION; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE PHOSPHORYLATION; MEDIATED ENDOCYTOSIS; GTPASE ACTIVITY; MECHANISMS; SEQUESTRATION; STIMULATION	Most G protein-coupled receptors (GPCRs), including the M-1 muscarinic acetylcholine receptor (mAChR), internalize in clathrin-coated vesicles, a process that requires dynamin GTPase. The observation that some GPCRs like the M-2 mAChR and the angiotensin AT(1A) receptor (AT(1A)R) internalize irrespective of expression of dominant-negative K44A dynamin has led to the proposal that internalization of these GPCRs is dynamin-independent. Here, we report that, contrary to what is postulated, internalization of M-2 mAChR and AT(1A) HEK-293 cells is dynamin-dependent, Expression of N272 dynamin, which lacks the GTP-binding domain, or K535M dynamin, which is not stimulatable by phosphatidylinositol 4,5-bisphosphate, strongly inhibits internalization of M-1 and M-2 mAChRs and AT(1A)Rs. Expression of kinase-defective K298M c-Src or Y231F,Y597F dynamin (which cannot be phosphorylated by c-Src) reduces M-1 mAChR internalization. Similarly, c-Src inhibitor PP1 as well as the generic tyrosine kinase inhibitor genistein strongly inhibit M-1 aAChR internalization. In contrast, M-2 mAChR internalization is not (or is only slightly) reduced by expression of these constructs or treatment with PP1 or genistein, Thus, dynamin GTPases are not only essential for M-1 mAChR but also for M-2 mAChR and AT(1A)R internalization in HEK-293 cells. Our findings also indicate that dynamin GTPases are differentially regulated by c-Src-mediated tyrosine phosphorylation.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	van Koppen, CJ (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelanderstr 55, D-45122 Essen, Germany.							Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hunyady L, 1999, J AM SOC NEPHROL, V10, pS47; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	62	64	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21969	21974		10.1074/jbc.M001736200	http://dx.doi.org/10.1074/jbc.M001736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801820	hybrid			2022-12-25	WOS:000088363800031
J	Gao, QS; Kumar, A; Srinivasan, S; Singh, L; Mukai, H; Ono, Y; Wazer, DE; Band, V				Gao, QS; Kumar, A; Srinivasan, S; Singh, L; Mukai, H; Ono, Y; Wazer, DE; Band, V			PKN binds and phosphorylates human papillomavirus E6 oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-C; HUMAN FORESKIN KERATINOCYTES; ZIPPER-LIKE SEQUENCES; MIDDLE TUMOR-ANTIGEN; E7 PROTEIN; T-ANTIGEN; GENE-PRODUCT; TYROSINE PHOSPHORYLATION; MUTATIONAL ANALYSIS	The high risk human papillomaviruses (HPVs) are associated with carcinomas of cervix and other genital tumors. Previous studies have identified two viral oncoproteins E6 and E7, which are expressed in the majority of HPV-associated carcinomas. The ability of high risk HPV E6 protein to immortalize human mammary epithelial cells has provided a single gene model to study the mechanisms of EG-induced oncogenic transformation. In recent years, it has become clear that in addition to EG-induced degradation of p53 tumor suppressor protein, other targets of E6 are required for mammary epithelial cells immortalization, Using the yeast two-hybrid system, we have identified a novel interaction of HPV16 E6 with protein kinase PKN, a fatty acid- and Rho small G protein-activated serine/threonine kinase with a catalytic domain highly homologous to protein kinase C. We demonstrate direct binding of high risk HPV E6 proteins to PKN in wheat-germ lysate in vitro and in 293T cells in vivo. Importantly, E6 proteins of high risk HPVs but not low risk HPVs were able to bind PKN, Furthermore, all the immortalization-competent and many immortalization-non-competent E6 mutants bind PKN. These data suggest that binding to PKN may be required but not sufficient for immortalizing normal mammary epithelial cells, Finally, we show that PKN phosphorylates E6, demonstrating for the first time that HPV E6 is a phosphoprotein, Our finding suggests a novel link between HPV E6 mediated oncogenesis and regulation of a well known phosphorylation cascade.	Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan; Kobe Univ, Dept Biol, Fac Sci, Kobe, Hyogo 6578501, Japan	Tufts Medical Center; Tufts University; Kobe University; Kobe University	Band, V (corresponding author), Tufts Univ New England Med Ctr, Dept Radiat Oncol, 750 Washington St, Boston, MA 02111 USA.	vband@olifespan.org		Mukai, Hideyuki/0000-0002-0167-8695	NATIONAL CANCER INSTITUTE [R01CA070195, R01CA064823] Funding Source: NIH RePORTER; NCI NIH HHS [CA70195, CA64823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARBOSA MS, 1988, J VIROL, V62, P1088, DOI 10.1128/JVI.62.3.1088-1092.1988; Boyer SN, 1996, CANCER RES, V56, P4620; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Chatterjee A, 1997, J VIROL, V71, P6472, DOI 10.1128/JVI.71.9.6472-6478.1997; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; Cullere X, 1998, J VIROL, V72, P558; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Gao QS, 1999, MOL CELL BIOL, V19, P733; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Horikawa I, 1999, CANCER RES, V59, P826; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maesaki R, 1999, J STRUCT BIOL, V126, P166, DOI 10.1006/jsbi.1999.4114; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Oishi K, 1999, BIOCHEM BIOPH RES CO, V261, P808, DOI 10.1006/bbrc.1999.1116; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Takakura M, 1999, CANCER RES, V59, P551; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476; zur Hausen H, 1987, Appl Pathol, V5, P19; ZURHAUSEN H, 1987, PAPILLOMAVIRUSES PAP, V2	78	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14824	14830		10.1074/jbc.275.20.14824	http://dx.doi.org/10.1074/jbc.275.20.14824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809724	hybrid			2022-12-25	WOS:000087128300009
J	Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T				Kajino, S; Suganuma, M; Teranishi, F; Takahashi, N; Tetsuka, T; Ohara, H; Itoh, M; Okamoto, T			Evidence that de novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B	ONCOGENE			English	Article						carcinogenesis; NF-kappa B; apoptosis; TNF-alpha; cycloheximide	RHEUMATOID SYNOVIAL FIBROBLASTS; INDUCED CELL-DEATH; TUMOR PROMOTER; INHIBITION; ACTIVATION; ALPHA; INDUCTION; CANCER; AUROTHIOGLUCOSE; SUPPRESSION	The transcription factor NF-kappa B is a positive transcription factor for a number of genes and has been recognized as an anti-apoptotic regulator. However, the mechanism by which NF-kappa B blocks apoptosis is still controversial. Here, we demonstrate the evidence that NF-kappa B could attenuate the TNF-alpha-induced apoptosis without de novo protein synthesis using human pancreatic cancer cell lines, MIA PaCa-2 and Capan-2, The TNF-alpha-induced apoptosis was blocked by IL-1 beta, a potent inducer of NF-kappa B activation. This inhibitory effect of IL-1 beta was evident when cells were treated with protein synthesis inhibitors such as cycloheximide (CHS). Moreover, NF-kappa B decoy oligonucleotides could not block the anti-apoptotic effect of IL-1 beta at doses sufficient to block the NF-kappa B-dependent transcription induced by IL-1 beta, To confirm the role of NF-kappa B in blocking apoptosis we generated stable cell Lines expressing I kappa B Delta N, a highly stable form of I kappa B alpha, a cytoplasmic inhibitor of NF-kappa B. In these stable transfectants, the antiapoptotic effect of IL-1 beta was totally abolished, indicating that the anti-apoptotic action of IL-1 beta could be ascribed to the NF-kappa B action. These findings show that ne novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappa B and support the possibility that NF-kappa B could exert its anti-apoptotic action through protein-protein interaction.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; FUJIKI H, 1987, ADV CANCER RES, V49, P223, DOI 10.1016/S0065-230X(08)60799-X; Gilmore TD, 1996, ONCOGENE, V13, P1367; KOMORI A, 1993, CANCER RES, V53, P1982; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Suganuma M, 1996, CANCER RES, V56, P3711; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151	33	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2233	2239		10.1038/sj.onc.1203560	http://dx.doi.org/10.1038/sj.onc.1203560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822373				2022-12-25	WOS:000086974100008
J	Ye, FC; Zangenehpour, S; Chaudhuri, A				Ye, FC; Zangenehpour, S; Chaudhuri, A			Light-induced down-regulation of the rat class 1 dynein-associated protein robl/LC7-like gene in visual cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; AXONAL-TRANSPORT; EXPRESSION; KINESIN; FAMILY; BRAIN; FOS	Dynein and kinesin are the main microtubule-dependent motors that mediate intracellular movement in eukaryotic organisms. We have cloned a full-length cDNA encoding rat dynein light chain protein, robl/LC7-like (class 1), from visual cortex. We found that rat robl/LC7-like gene is highly expressed in neocortex and displays the unusual feature of being rapidly down-regulated by sensory stimulation. This effect was seen at both mRNA and protein levels in visual cortex, being detectable in as little as 45 min after the onset of visual stimulation. Down-regulation by sensory stimulation was also found within ocular dominance columns of area V1 in monocularly deprived monkeys. Our results suggest a high turnover rate of the robl/LC7-like protein and the presence of a repressor mechanism in neurons that is tightly coupled to synaptic stimulation.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada	McGill University	Chaudhuri, A (corresponding author), McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Bowman AB, 1999, J CELL BIOL, V146, P165; Chaudhuri A, 1997, NEUROREPORT, V8, pR5; CHAUDHURI A, 1995, VISUAL NEUROSCI, V12, P35, DOI 10.1017/S095252380000729X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Finkbeiner S, 1998, J NEUROBIOL, V37, P171, DOI 10.1002/(SICI)1097-4695(199810)37:1<171::AID-NEU13>3.0.CO;2-H; Gall CM, 1998, NEUROBIOL LEARN MEM, V70, P14, DOI 10.1006/nlme.1998.3835; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Kaczmarek L, 1997, BRAIN RES REV, V23, P237, DOI 10.1016/S0165-0173(97)00005-2; KING SM, 1995, J CELL SCI, V108, P3757; LEVITAN ES, 1995, J BIOL CHEM, V270, P6036, DOI 10.1074/jbc.270.11.6036; Liang F, 1996, EXP BRAIN RES, V110, P163; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Milisav I, 1998, CELL MOTIL CYTOSKEL, V39, P261, DOI 10.1002/(SICI)1097-0169(1998)39:4<261::AID-CM2>3.0.CO;2-6; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; SHARP FR, 1993, CRIT REV NEUROBIOL, V7, P205; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y	19	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27172	27176						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10816553				2022-12-25	WOS:000089144800068
J	Bao, J; Alroy, I; Waterman, H; Schejter, ED; Brodie, C; Gruenberg, J; Yarden, Y				Bao, J; Alroy, I; Waterman, H; Schejter, ED; Brodie, C; Gruenberg, J; Yarden, Y			Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGAND-INDUCED INTERNALIZATION; EGF-RECEPTOR; DOWN-REGULATION; JUXTAMEMBRANE DOMAIN; ENDOCYTIC PATHWAY; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; CBL; CELLS	Transregulation of the epidermal growth factor receptor (EGFR) by protein kinase C (PKC) serves as a model for heterologous desensitization of receptor tyrosine kinases, but the underlying mechanism remained unknown. By using c-Cbl-induced ubiquitination of EGFR as a marker for transfer from early to late endosomes, we provide evidence that PKC can inhibit this process. In parallel, receptor down-regulation and degradation are significantly reduced. The inhibitory effects of PKC are mediated by a single threonine residue (threonine 654) of EGFR, which serves as a major PKC phosphorylation site. Biochemical and morphological analyses indicate that threonine-phosphorylated EGFR molecules undergo normal internalization, but instead of sorting to lysosomal degradation, they recycle back to the cell surface. In conclusion, by sorting EGFR to the recycling endosome, heterologous desensitization restrains ligand-induced down-regulation of EGFR.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Univ Geneva, Dept Biochem, Geneva 4, Switzerland	Weizmann Institute of Science; Weizmann Institute of Science; Bar Ilan University; University of Geneva	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	41	142	146	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26178	26186		10.1074/jbc.M002367200	http://dx.doi.org/10.1074/jbc.M002367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10816576	hybrid			2022-12-25	WOS:000088999700042
J	Rosser, MFN; Nicchitta, CV				Rosser, MFN; Nicchitta, CV			Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94 I. Evidence for allosteric regulation of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR COMPLEXES; ENDOPLASMIC-RETICULUM; ATP-BINDING; MOLECULAR CHAPERONE; PEPTIDE-BINDING; STRESS PROTEINS; IMMUNOGLOBULIN-CHAINS; SIGNAL-TRANSDUCTION; T-CELLS	X-ray crystallographic studies of the N-terminal domain of Hsp90 have identified an unconventional ATP binding fold, thereby inferring a role for ATP in the regulation of the Hsp90 activity. In this report, N-ethyl-carboxamidoadenosine (NECA) was used to investigate the nucleotide binding properties of GRP94, the endoplasmic reticulum paralog of Hsp90. Whereas Hsp90 did not bind NECA, GRP94 bound NECA in a saturable manner with a K-d of 200 nM. NECA binding to GRP94 was efficiently blocked by geldanamycin and radicicol. Analysis of ligand binding stoichiometries by radioligand and calorimetric techniques indicated that GRP94 bound 1 mol of NECA/mol of GRP94 dimer. In contrast, GRP94 bound radicicol at a stoichiometry of 2 mol of radicicol/mol of GRP94 dimer. In [H-3]NECA displacement assays, GRP94 displayed binding interactions with ATP, dATP, ADP, AMP, cAMP, and adenosine, but not GTP, CTP, or UTP. To accommodate the 0.5 mol of NE-CA:mol of GRP94 binding stoichiometry observed for the native GRP94 dimer, a model for allosteric regulation (negative cooperativity) of ligand binding is proposed. A hypothesis on the regulation of GRP94 conformation and activity by adenosine-based ligand(s) other than ATP and ADP is presented.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.				NIDDK NIH HHS [DK53058] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07184-23] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOX IH, 1983, J BIOL CHEM, V258, P6952; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GUILBAULT GG, 1967, FLUORESCENCE THEORY; Heike M, 1996, J LEUKOCYTE BIOL, V60, P153, DOI 10.1002/jlb.60.2.153; HUTCHISON KA, 1989, J BIOL CHEM, V264, P19898; HUTCHISON KA, 1990, BIOCHEMISTRY-US, V29, P5138, DOI 10.1021/bi00473a020; HUTTEMANN E, 1984, N-S ARCH PHARMACOL, V325, P226, DOI 10.1007/BF00495948; Ishii T, 1999, J IMMUNOL, V162, P1303; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; *MICR INC, 1998, MICR SOFTW 1; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair S, 1999, J IMMUNOL, V162, P6426; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; Nemoto T, 1996, J BIOCHEM-TOKYO, V120, P249; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt W B, 1996, EXS, V77, P79; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; Riera M, 1999, MOL CELL BIOCHEM, V191, P97, DOI 10.1023/A:1006810311743; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SMITH DF, 1993, J BIOL CHEM, V268, P18365; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152	68	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22798	22805		10.1074/jbc.M001477200	http://dx.doi.org/10.1074/jbc.M001477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816561	hybrid			2022-12-25	WOS:000088419400029
J	Austin, C; Hinners, I; Tooze, SA				Austin, C; Hinners, I; Tooze, SA			Direct and GTP-dependent interaction of ADP-ribosylation factor 1 with clathrin adaptor protein AP-1 on immature secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; COP-COATED VESICLES; GOLGI MEMBRANES; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; ARF PROTEINS; CELLS; COATOMER; COMPLEX; TRANSPORT	ADP-ribosylation factor 1 (ARF1) mediates clathrin coat formation on PC12 immature secretory granules (ISGs). We have used two approaches to investigate whether ARF1 interacts directly with the clathrin adaptor protein, AP-1, Using an in vitro recruitment assay and co-immunoprecipitation, we could isolate an AP-1 .ARF1 complex. Then we used a site-directed photocross-linking approach to determine the components that act downstream of ARF1 in clathrin coat formation on ISGs. Myristoylated ARF1, with a photolabile phenylalanine analogue incorporated into its putative effector domain (switch 1), showed a specific, GTP dependent interaction with both the gamma- and beta-adaptin subunits of AP-1 on ISGs. These experiments provide evidence for a direct interaction of ARF1 with AP-1. On mature secretory granules myristoylated ARF1 does not bind, and hence clathrin coat formation cannot be initiated, supporting the hypothesis that molecules involved in coat recruitment are removed during ISG maturation.	Imperial Canc Res Fund, Secretory Pathway Lab, London WC2A 3PX, England	Cancer Research UK	Tooze, SA (corresponding author), Imperial Canc Res Fund, Secretory Pathway Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	tooze@icrf.icnet.uk		Tooze, Sharon/0000-0002-2182-3116				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Clairmont KB, 1997, CELL MOL LIFE SCI, V53, P611, DOI 10.1007/s000180050080; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Dittie AS, 1999, J CELL SCI, V112, P3955; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Schledzewski K, 1999, J MOL EVOL, V48, P770, DOI 10.1007/PL00006521; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Utsumi T, 1996, ARCH BIOCHEM BIOPHYS, V326, P179, DOI 10.1006/abbi.1996.0063; Utsumi T, 1998, ARCH BIOCHEM BIOPHYS, V349, P216, DOI 10.1006/abbi.1997.0468; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu YX, 1999, P NATL ACAD SCI USA, V96, P5013, DOI 10.1073/pnas.96.9.5013; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	50	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21862	21869		10.1074/jbc.M908875199	http://dx.doi.org/10.1074/jbc.M908875199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807927	hybrid			2022-12-25	WOS:000088363800017
J	Elliott, K; Watkins, H; Redwood, CS				Elliott, K; Watkins, H; Redwood, CS			Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ESCHERICHIA-COLI; CA2+ SENSITIVITY; THIN FILAMENT; T MUTATIONS; C-TERMINUS; TROPOMYOSIN; ACTIN; EXPRESSION; CALCIUM	Cardiac troponin I (cTnI) is the inhibitory component of the troponin complex and is involved in the calcium control of heart muscle contraction. Recently, specific missense mutations of the cTnI gene (TNNI3) have been shown to cause familial hypertrophic cardiomyopathy (HCM). We have analyzed the functional effects of two HCM mutations (R145G; and R162W) using purified recombinant cTnI, Both mutations gave reduced inhibition of actin-tropomyosin-activated myosin ATPase, both in experiments using cTnI alone and in those using reconstituted human cardiac troponin under relaxing conditions. Both mutant troponin complexes also conferred increased calcium sensitivity of ATPase regulation. Studies on wild type/R145G; mutant mixtures showed that the wild typo phenotype was dominant in that the inhibition and the calcium sensitivity conferred by a 50:50 mixture was more similar to wild type than expected. Surface plasmon resonance-based assays showed that R162W mutant had an increased affinity for troponin C in the presence of calcium. This observation may contribute to the increased calcium sensitivity found with this mutant and also corroborates recent structural data. The observed decreased inhibition and increased calcium sensitivity suggest that these mutations may cause HCM via impaired relaxation rather than the impaired contraction seen with some other classes of HCM mutants.	Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England	University of Oxford	Redwood, CS (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.			Watkins, Hugh/0000-0002-5287-9016				ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; BERS D, 1999, METHOD CELL BIOL, V40, P1; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Bottinelli R, 1998, CIRC RES, V82, P106; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Huang XP, 1999, CIRC RES, V84, P1; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Levine RJC, 1998, J STRUCT BIOL, V122, P149, DOI 10.1006/jsbi.1998.3980; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; McDonough JL, 1999, CIRC RES, V84, P9; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Redwood C, 2000, CIRC RES, V86, P1146; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; Reiffert SU, 1998, BIOCHEMISTRY-US, V37, P13516, DOI 10.1021/bi980280j; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Strauss JD, 1996, PFLUG ARCH EUR J PHY, V431, P853, DOI 10.1007/BF02332169; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VANEYK JE, 1993, FEBS LETT, V323, P223, DOI 10.1016/0014-5793(93)81344-Y; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593	43	121	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22069	22074		10.1074/jbc.M002502200	http://dx.doi.org/10.1074/jbc.M002502200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806205	hybrid			2022-12-25	WOS:000088363800046
J	Diamant, S; Ben-Zvi, AP; Bukau, B; Goloubinoff, P				Diamant, S; Ben-Zvi, AP; Bukau, B; Goloubinoff, P			Size-dependent disaggregation of stable protein aggregates by the DnaK chaperone machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; RNA-POLYMERASE; HSP70; GRPE; GROEL; ATPASE; CLPB; MECHANISMS; DISTINCT	Classic in vitro studies show that the Hsp70 chaperone system from Escherichia coli (DnaK-DnaJ-GrpE, the DnaK system) can bind to proteins, prevent aggregation, and promote the correct refolding of chaperone-bound polypeptides into native proteins. However, little is known about how the DnaK system handles proteins that have already aggregated. In this study, glucose-6-phosphate dehydrogenase was used as a model system to generate stable populations of protein aggregates comprising controlled ranges of particle sizes. The DnaK system recognized the glucose-6-phosphate dehydrogenase aggregates as authentic substrates and specifically solubilized and refolded the protein into a native enzyme. The efficiency of disaggregation by the DnaK system was high with small aggregates, but the efficiency decreased as the size of the aggregates increased. High folding efficiency was restored by either excess DnaK or substoichiometric amounts of the chaperone ClpB. We suggest a mechanism whereby the DnaK system can readily solubilize small aggregates and refold them into active proteins. With large aggregates, however, the binding sites for the DnaK system had to be dynamically exposed with excess DnaK or the catalytic action of ClpB and ATP. Disaggregation by the DnaK machinery in the cell can solubilize early aggregates that formed accidentally during chaperone-assisted protein folding or that escaped the protection of "holding" chaperones during stress.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Hebrew University of Jerusalem; University of Freiburg	Goloubinoff, P (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	pierre@vms.huji.ac.il	BEN-ZVI, ANAT/F-1674-2012	BEN-ZVI, ANAT/0000-0003-2477-6519; Goloubinoff, Pierre/0000-0002-4802-0807; Bukau, Bernd/0000-0003-0521-7199				Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bukau B., 1999, MOL CHAPERONES FOLDI, P3; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; Jaenicke R, 1999, MOL CHAPERONES FOLDI, P407; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mendoza JA, 1996, BIOCHEM BIOPH RES CO, V229, P271, DOI 10.1006/bbrc.1996.1791; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	31	192	195	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21107	21113		10.1074/jbc.M001293200	http://dx.doi.org/10.1074/jbc.M001293200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801805	hybrid			2022-12-25	WOS:000088230600022
J	Ogawa, S; Fujita, M; Ishii, Y; Tsurukami, H; Hirabayashi, M; Ikeda, K; Orimo, A; Hosoi, T; Ueda, M; Nakamura, T; Ouchi, Y; Muramatsu, M; Inoue, S				Ogawa, S; Fujita, M; Ishii, Y; Tsurukami, H; Hirabayashi, M; Ikeda, K; Orimo, A; Hosoi, T; Ueda, M; Nakamura, T; Ouchi, Y; Muramatsu, M; Inoue, S			Impaired estrogen sensitivity in bone by inhibiting both estrogen receptor alpha and beta pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; POSTMENOPAUSAL OSTEOPOROSIS; DEFICIENT MICE; OVARIECTOMIZED RATS; MOLECULAR-CLONING; THYROID-HORMONE; MESSENGER-RNA; 2ND DECADE; GENE; EXPRESSION	Although it is well established that estrogen deficiency causes osteoporosis among the postmenopausal women, the involvement of estrogen receptor (ER) in its pathogenesis still remains uncertain. In the present study, we have generated rats harboring a dominant negative ER alpha, which inhibits the actions of not only ER alpha but also recently identified ER beta. Contrary to our expectation, the bone mineral density (BMD) of the resulting transgenic female rats was maintained at the same level with that of the wild-type littermates when sham-operated. In addition, ovariectomy-induced bone loss was observed almost equally in both groups. Strikingly, however, the BMD of the transgenic female rats, after ovariectomized, remained decreased even if 17 beta-estradiol (E-2) was administrated, whereas, in contrast, the decrease of littermate BMD was completely prevented by E-2. Moreover, bone histomorphometrical analysis of ovariectomized transgenic rats revealed that the higher rates of bone turnover still remained after treatment with E-2. These results demonstrate that the prevention from the ovariectomy-induced bone loss by estrogen is mediated by ER pathways and that the maintenance of BMD before ovariectomy might be compensated by other mechanisms distinct from ER alpha and ER beta pathways.	Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Med Sch, Dept Biochem, Moroyama, Saitama 3500495, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed Surg, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; YS New Technol Inst Inc, Ishibashi, Tochigi 3290512, Japan	University of Tokyo; Saitama Medical University; University of Occupational & Environmental Health - Japan	Inoue, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Hirabayashi, Masumi/C-8935-2019	Hirabayashi, Masumi/0000-0002-1059-5883; Orimo, Akira/0000-0001-5330-7282				Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BENZ DJ, 1991, J BONE MINER RES, V6, P531; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Gustafsson JA, 1997, NAT MED, V3, P493, DOI 10.1038/nm0597-493; Hashimoto M, 1998, BIOCHEM BIOPH RES CO, V247, P401, DOI 10.1006/bbrc.1998.8799; Hiroi H, 1999, J MOL ENDOCRINOL, V22, P37, DOI 10.1677/jme.0.0220037; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; INCE BA, 1993, J BIOL CHEM, V268, P14026; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LINDSAY R, 1976, LANCET, V1, P1038; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MIYAZAKI J, 1989, GENE, V79, P269; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Nishida S, 1998, CALCIFIED TISSUE INT, V62, P227, DOI 10.1007/s002239900422; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Ogawa S, 1998, FEBS LETT, V423, P129, DOI 10.1016/S0014-5793(98)00079-9; Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Pan LC, 1997, J BONE MINER RES, V12, P126; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; TAKEUCHI M, 1995, BIOCHEM BIOPH RES CO, V210, P295, DOI 10.1006/bbrc.1995.1660; Westerlind KC, 1998, J BONE MINER RES, V13, P1023, DOI 10.1359/jbmr.1998.13.6.1023; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730	49	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21372	21379		10.1074/jbc.M909675199	http://dx.doi.org/10.1074/jbc.M909675199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10806217	hybrid			2022-12-25	WOS:000088230600056
J	Beer, HD; Vindevoghel, L; Gait, MJ; Revest, JM; Duan, DR; Mason, I; Dickson, C; Werner, S				Beer, HD; Vindevoghel, L; Gait, MJ; Revest, JM; Duan, DR; Mason, I; Dickson, C; Werner, S			Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; FACTOR FAMILY; NERVOUS-SYSTEM; CDNA CLONING; ACIDIC FGF; BASIC FGF; MEMBER; DOMAIN; GENE; GROWTH-FACTOR-10	Fibroblast growth factors (FGFs) transmit their signals through four transmembrane receptors that are designated FGFR1-4. Alternative splicing in the extracellular region of FGFR1-3 generates receptor variants with different ligand binding affinities. Thus two types of transmembrane receptors (IIIb and me isoforms) have been identified for FGFR2 and FGFR3, and the existence of analogous variants has been postulated for FGFR1 based on its genomic structure. However, only a single full-length transmembrane FGFR1 variant (FGFR1-IIIc) has been identified so far. Here we describe the cloning of a full-length cDNA encoding FGFR1-IIIb from a mouse skin wound cDNA library. This receptor isoform was expressed at the highest levels in a subset of sebaceous glands of the skin and in neurons of the hippocampus and the cerebellum. FGFR1-IIIb was expressed in L6 rat skeletal muscle myoblasts and used in cross-linking and receptor binding studies. FGF-1 was found to bind the receptor with high affinity, whereas FGF-2, -10, and -7 bound with significantly lower affinities. Despite their apparently similar but low affinities, FGF-10 but not FGF-7 induced the activation of p44/42 mitogen-activated protein kinase in FGFR1-IIIb-expressing L6 myoblasts and stimulated mitogenesis in these cells, demonstrating that this new receptor variant is a functional transmembrane receptor for FGF-10.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Kings Coll London, Dept Dev Neurobiol, London SE1 9RT, England; Imperial Canc Res Fund, London WC2A 3PX, England; Human Genome Sci Inc, Rockville, MD 20850 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of London; King's College London; Cancer Research UK; GlaxoSmithKline; Human Genome Sciences Inc	Werner, S (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch	Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050; Beer, Hans-Dietmar/0000-0002-8085-713X; Werner, Sabine/0000-0001-7397-8710				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANILENKO DM, 1995, AM J PATHOL, V147, P145; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; ECKENSTEIN FP, 1994, PROG BRAIN RES, V103, P55; Greene JM, 1998, EUR J NEUROSCI, V10, P1911, DOI 10.1046/j.1460-9568.1998.00211.x; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; Jimenez PA, 1999, J SURG RES, V81, P238, DOI 10.1006/jsre.1998.5501; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Madlener H, 1997, GENE, V202, P75, DOI 10.1016/S0378-1119(97)00456-3; MAHMOOD R, 1999, METHODS MOL BIOL MOL, P623; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; Shamim H, 1999, DEVELOPMENT, V126, P945; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; Yamasaki M, 1999, BIOCHEM BIOPH RES CO, V258, P109, DOI 10.1006/bbrc.1999.0594; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	47	68	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16091	16097		10.1074/jbc.275.21.16091	http://dx.doi.org/10.1074/jbc.275.21.16091			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821861	hybrid			2022-12-25	WOS:000087291400066
J	Klapstein, K; Bruinsma, R				Klapstein, K; Bruinsma, R			RecA force generation by hydrolysis waves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-STRAND EXCHANGE; PROMOTED ATP HYDROLYSIS; ESCHERICHIA-COLI; DUPLEX DNA; NUCLEOPROTEIN FILAMENTS; BRANCHED JUNCTIONS; HOLLIDAY JUNCTION; BINDING PROTEIN; SINGLE; MECHANISM	We present a simple theory of the dynamics of force generation by RecA during homologous strand exchange and a continuous, deterministic mathematical model of the proposed process. Calculations show that force generation is possible in this model for certain reasonable values of the parameters. We predict the shape of the force-velocity curve for the Holliday junction, which exhibits a distinctive kink at large retarding force, and suggest experiments which should distinguish between the proposed model and other models in the literature.	Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Klapstein, K (corresponding author), Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA.							Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; Drozdov AN, 1999, J CHEM PHYS, V110, P2159, DOI 10.1063/1.477826; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; Holbrook JA, 1999, BIOCHEMISTRY-US, V38, P8409, DOI 10.1021/bi990043w; JAIN SK, 1995, J BIOL CHEM, V270, P4943, DOI 10.1074/jbc.270.9.4943; Julicher F, 1997, REV MOD PHYS, V69, P1269, DOI 10.1103/RevModPhys.69.1269; JWANG K, 1990, P NATL ACAD SCI USA, V89, P7596; KIM JI, 1992, J BIOL CHEM, V267, P16444; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KURUMIZAKA H, 1994, NUCLEIC ACIDS RES, V22, P3387, DOI 10.1093/nar/22.16.3387; Landau L. D., 1976, MECHANICS, V1; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; Lilley DMJ, 1997, P NATL ACAD SCI USA, V94, P9513, DOI 10.1073/pnas.94.18.9513; LILLEY DMJ, 1993, Q REV BIOPHYS, V26, P131, DOI 10.1017/S0033583500004054; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; Lodish H., 1995, MOL CELL BIOL; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P3127; MOREL P, 1994, J BIOL CHEM, V269, P19830; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; Rehrauer WM, 1996, J BIOL CHEM, V271, P11996, DOI 10.1074/jbc.271.20.11996; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SEEMAN NC, 1994, ANNU REV BIOPH BIOM, V23, P53, DOI 10.1146/annurev.bb.23.060194.000413; Sha RJ, 1999, BIOCHEMISTRY-US, V38, P2832, DOI 10.1021/bi9823479; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shivashankar GV, 1999, P NATL ACAD SCI USA, V96, P7916, DOI 10.1073/pnas.96.14.7916; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; Voet D., 1995, BIOCHEMISTRY; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8845; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	56	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16073	16083		10.1074/jbc.275.21.16073	http://dx.doi.org/10.1074/jbc.275.21.16073			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821860	hybrid			2022-12-25	WOS:000087291400064
J	Stracke, JO; Hutton, M; Stewart, M; Pendas, AM; Smith, B; Lopez-Otin, C; Murphy, G; Knauper, V				Stracke, JO; Hutton, M; Stewart, M; Pendas, AM; Smith, B; Lopez-Otin, C; Murphy, G; Knauper, V			Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19 - Evidence for a role as a potent basement membrane degrading enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; N-TERMINAL DOMAIN; RHEUMATOID-ARTHRITIS; GELATINASE-A; STROMELYSIN-1; DEGRADATION; ACTIVATION; COLLAGEN; TIMP-1; REGION	We have recently cloned MMP-19 a novel matrix metalloproteinase, which, due to unique structural features, was proposed to represent the first member of a new MMP subfamily (Pendas, A.M., Knauper, V., Puente, X. S., Llano, E., Mattei, M. G., Apte, S., Murphy, G., and Lopez-Otin, C. (1997) J. Biol. Chem. 272, 4281-4286). A recombinant COOH-terminal deletion mutant of MMP-19 (pro Delta(260-508)MMP-19), comprising the propeptide and the catalytic domain, was expressed in Escherichia coli, refolded, and purified. Interestingly, we found that pro Delta(260-508)MMP-19 has the tendency to autoactivate, whereby the Lys(97)-Tyr(98) peptide bond is hydrolyzed, resulting in free catalytic domain. Mutation of two residues (Glu(88), Pro and Pro(90) --> Val) within the propeptide latency motif did not prevent autoactivation but the autolysis rate was somewhat reduced. Analysis of the substrate specificity revealed that the catalytic domain of MMP-19 was able to hydrolyze the general MMP substrate Mca-Pro-Leu-Gly-Dpa-Ala-Arg-NH, and, with higher efficiency, the stromelysin substrate Mca-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2. Kinetic analysis of the interactions of the catalytic domain of MMP-19 with the natural MMP inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), showed strong inhibition using TIMP-2, TIMP-3, and TIMP-4, while TIMP-1 was less efficient. We also demonstrated that synthetic hydroxamic acid-based compounds efficiently inhibited the enzyme. The catalytic domain of MMP-19 was able to hydrolyze the basement membrane components type TV collagen, laminin, and nidogen, as well as the large tenascin-C isoform, fibronectin, and type I gelatin in vitro, suggesting that MMP-19 is a potent proteinase capable of hydrolyzing a broad range of extracellular matrix components. Neither the catalytic domain nor the full-length MMP-19 was able to degrade triple-helical collagen. Finally, and in contrast to studies with other MMPs, MMP-19 catalytic domain was not able to activate any of the latent MMPs tested in vitro.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Celltech Ltd, Slough SL1 4EN, Berks, England	University of East Anglia; University of Oviedo; Celltech Group Ltd	Stracke, JO (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	j.stracke@uea.ac.uk	Pendas, Alberto M/L-1017-2014; López-Otín, Carlos/AAB-2106-2020	López-Otín, Carlos/0000-0001-6964-1904; Pendas, Alberto M/0000-0001-9264-3721; Knauper, Vera/0000-0002-3965-9924				APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holman CM, 1999, BIOCHEMISTRY-US, V38, P677, DOI 10.1021/bi9822170; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Knauper V, 1996, EUR J BIOCHEM, V235, P187, DOI 10.1111/j.1432-1033.1996.00187.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Kolb C, 1999, EXP CELL RES, V250, P122, DOI 10.1006/excr.1999.4493; Kolb C, 1997, IMMUNOL LETT, V57, P83, DOI 10.1016/S0165-2478(97)00057-6; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mayer U, 1998, ANN NY ACAD SCI, V857, P130, DOI 10.1111/j.1749-6632.1998.tb10113.x; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; PARK AJ, 1991, J BIOL CHEM, V266, P1584; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Quesada AR, 1997, CLIN EXP METASTAS, V15, P26; Reynolds JJ, 1997, PERIODONTOL 2000, V14, P144, DOI 10.1111/j.1600-0757.1997.tb00195.x; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Savarese JJ, 1996, J ORTHOPAED RES, V14, P273, DOI 10.1002/jor.1100140216; Sedlacek R, 1998, IMMUNOBIOLOGY, V198, P408, DOI 10.1016/S0171-2985(98)80049-1; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VONBREDOW DC, 1995, EXP CELL RES, V221, P83, DOI 10.1006/excr.1995.1355; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	46	114	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14809	14816		10.1074/jbc.275.20.14809	http://dx.doi.org/10.1074/jbc.275.20.14809			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809722	hybrid			2022-12-25	WOS:000087128300007
J	Sugiyama, K; Izawa, S; Inoue, Y				Sugiyama, K; Izawa, S; Inoue, Y			The Yap1p-dependent induction of glutathione synthesis in heat shock response of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; YAP-1 TRANSCRIPTIONAL REGULATION; ESCHERICHIA-COLI-B; HANSENULA-MRAKII; NUCLEAR EXPORT; BZIP PROTEINS; TARGET GENE; CTT1 GENE; YEAST	Glutathione is synthesized in two sequential reactions catalyzed by gamma-glutamylcysteine synthetase (GSH1 gene product) and glutathione synthetase (GSH2 gene product). The expression of GSH1 in Saccharomyces cerevisiae has been known to be up-regulated by Yap1p, a critical transcription factor for the oxidative stress response in yeast. The present study demonstrates that GSH2 expression is also regulated by Yap1p under oxidative stress-induced conditions. In addition to oxidative stress, expression of GSH1 and GSH2 was induced by heat shock stress in a Yap1p-dependent manner with subsequent increases in intracellular glutathione content. Oxygen respiration rate increased when cells were exposed to higher temperatures, and as a result, intracellular oxidation levels were increased. The heat shock-induced expression of GSH1 and GSH2 did not occur under anaerobic conditions. Furthermore, even under aerobic conditions, the heat shock response of these genes was not observed when cells were pretreated with KCN to block oxygen respiration. We speculate that heat shock stress enhances oxygen respiration, which in turn results in an increase in the generation of reactive oxygen species in mitochondria, This signal may be mediated by Yap1p, resulting in the elevation of intracellular glutathione levels.	Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan.	inoue@food2.food.kyoto-u.ac.jp		Izawa, Shingo/0000-0002-4920-2450				Braden M, 1976, Front Oral Physiol, V2, P1; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; GEIER BM, 1995, EUR J BIOCHEM, V227, P296, DOI 10.1111/j.1432-1033.1995.tb20388.x; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HEALY AM, 1992, ANN NY ACAD SCI, V663, P319, DOI 10.1111/j.1749-6632.1992.tb38675.x; HOFFMAN MZ, 1972, J AM CHEM SOC, V94, P7950, DOI 10.1021/ja00778a002; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Inoue Y, 1995, BBA-GEN SUBJECTS, V1245, P325, DOI 10.1016/0304-4165(95)00117-4; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Inoue Y, 1996, CLIN DIAGN LAB IMMUN, V3, P663, DOI 10.1128/CDLI.3.6.663-668.1996; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; Miller JH., 1972, EXPT MOL GENETICS; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Scandalios J.G., 1997, OXIDATIVE STRESS MOL; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRAN LT, 1993, BIOCHIM BIOPHYS ACTA, V1164, P166, DOI 10.1016/0167-4838(93)90244-L; WATANABE K, 1986, APPL MICROBIOL BIOT, V24, P375, DOI 10.1007/BF00294593; WATANABE K, 1986, AGR BIOL CHEM TOKYO, V50, P1925, DOI 10.1080/00021369.1986.10867700; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WIESER R, 1991, J BIOL CHEM, V266, P12406; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416	50	107	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15535	15540		10.1074/jbc.275.20.15535	http://dx.doi.org/10.1074/jbc.275.20.15535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809786	hybrid			2022-12-25	WOS:000087128300102
J	Lee, TA; Farnham, PJ				Lee, TA; Farnham, PJ			Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation	ONCOGENE			English	Article						E2F; Ras; Neu; NIH3T3; transformation; tumor suppressor	MAMMARY EPITHELIAL-CELLS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; DNA-BINDING; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; MEMBRANE-PROTEIN; FAMILY PROTEINS; NEU ONCOGENE; GENE FAMILY	To gain insight into the tumor suppressor properties of E2F1, we investigated growth inhibition by the E2F family of transcription factors using a tissue culture model system, We first show that exogenous E2F expression causes an 80% decrease in NIH3T3 colony formation and activated c-Ha-Ras-mediated focus formation. Inhibition of Ras-mediated transformation was dependent upon E2F DNA binding activity but did not require amino- or carboxy-terminal E2F1 protein interaction domains. Because E2F upregulation has been suggested to be associated with a neoplastic phenotype, it was possible that increased E2F activity would not be inhibitory to previously transformed cells. However, we found that exogenous E2F was also inhibitory to growth of NIH3T3 cells previously transformed by Ras or Neu. Further characterization revealed that exogenous E2F expression is inhibitory at very early times after transfection, causing dramatic losses in transfected cell populations. Interestingly, those few cells which do establish appear to be unaffected by the overexpressed E2F, Therefore, we propose that increased E2F activity may only be tolerated in a subset of cells which have acquired specific alterations that are dominant over E2F-mediated growth inhibition.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA09135, CA07175, CA22484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Maniatis T., 1982, MOL CLONING LAB MANU; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2257	2268		10.1038/sj.onc.1203556	http://dx.doi.org/10.1038/sj.onc.1203556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822376				2022-12-25	WOS:000086974100011
J	Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW				Stepanova, L; Yang, G; DeMayo, F; Wheeler, TM; Finegold, M; Thompson, TC; Harper, JW			Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia	ONCOGENE			English	Article						Cdc37; cyclin dependent kinase; chaperone; cancer; transgenic mice	ROUS-SARCOMA VIRUS; CELL-CYCLE MACHINERY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; CDK INHIBITORS; TYROSINE KINASE; FREE SYSTEM; HSP90; P27(KIP1); ARREST	The Cdc37 gene encodes a 50 kDa protein which targets intrinsically unstable oncoprotein kinases such as Cdk4, Raf-1, and src to the molecular chaperone Hsp90, This activity is thought to play an important role in the establishment of signaling pathways controlling proliferation. The budding yeast Cdc37 homolog is required for cell division and mammalian Cdc37 is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation, Here we report that human prostatic tumors, neoplasias and certain pre-malignant lesions display increased Cdc37 expression, suggesting an important and early role for Cdc37 in prostatic transformation. To test the consequences of increased Cdc37 levels, transgenic mice expressing Cdc37 in the prostate were generated, These mice displayed a wide range of growth-related abnormalities including prostatic epithelial cell hyperplasia and dysplasia. These data suggest that the expression of Cdc37 may promote inappropriate proliferation and may be an important early step in the development of human prostate cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Harper, JW (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Harper, Jeffrey/0000-0002-6944-7236	NIGMS NIH HHS [GM54137] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaltomaa S, 1999, PROSTATE, V38, P175; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Bangma CH, 1999, SEMIN ONCOL, V26, P422; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Bubendorf L, 1999, CANCER RES, V59, P803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Munoz MJ, 1999, MOL GEN GENET, V261, P242, DOI 10.1007/s004380050963; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sharma P, 1999, ONCOGENE, V18, P5349, DOI 10.1038/sj.onc.1203037; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STEPANOVA L, 2000, IN PRESS MOL CELL BI; Tamboli P, 1998, MODERN PATHOL, V11, P247; THOMPSON T, 1999, COMPREHENSIVE TXB GE; WALSH PC, 1992, CAMPBELLS UROLOGY, V1, P1007; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109	41	67	76	3	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2186	2193		10.1038/sj.onc.1203561	http://dx.doi.org/10.1038/sj.onc.1203561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822368				2022-12-25	WOS:000086974100003
J	Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB				Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB			p21(Waf1/Cip1/Sdi1)-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells	ONCOGENE			English	Article						p21; mitosis; endoreduplication; spindle checkpoint control; senescence	TERMINAL PROLIFERATION ARREST; CYCLIN-DEPENDENT KINASES; NORMAL HUMAN FIBROBLASTS; HUMAN TUMOR-CELLS; REPLICATIVE SENESCENCE; MAMMALIAN-CELLS; INHIBITOR P21; DNA-DAMAGE; EXPRESSION; CHECKPOINT	Induction of a cyclin-dependent kinase inhibitor p21(Wafl/) (Cip1/Sdi1) is an integral part of cell growth arrest associated with senescence and damage response, p21 overexpression from an inducible promoter resulted in senescence-like growth arrest in a human fibrosarcoma cell line. After release from p21-induced growth arrest, cells reentered the cell cycle but displayed growth retardation, cell death and decreased clonogenicity. The failure to form colonies was associated with abnormal mitosis and endoreduplication in the recovering cells and was correlated with the induced level of p21 and the duration of p21 induction. p21 induction was found to inhibit the expression of multiple proteins involved in the execution and control of mitosis, p21-induced depletion of the cellular pools of mitosis-control proteins nas followed by asynchronous resynthesis of such proteins after release from p21, which explains the observed mitotic abnormalities. Genetic destabilization in cells recovering from p21-induced growth arrest may conceivably play a role in carcinogenesis and tumor progression.	Univ Illinois, Dept Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NATIONAL CANCER INSTITUTE [R01CA062099, R37CA040333] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG BD, 1999, CANCER RES, V18, P4808; CHANG BP, 2000, IN PRESS P NATL ACAD; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; GARTEL AL, 1998, INHIBITORS CELL GROW, V20, P43; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hixon ML, 1998, MOL CELL BIOL, V18, P6224, DOI 10.1128/MCB.18.11.6224; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jordan MA, 1996, CANCER RES, V56, P816; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139	41	151	159	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2165	2170		10.1038/sj.onc.1203573	http://dx.doi.org/10.1038/sj.onc.1203573			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815808				2022-12-25	WOS:000086728000010
J	De Beeck, AO; Montserret, R; Duvet, S; Cocquerel, L; Cacan, R; Barberot, B; Le Maire, M; Penin, F; Dubuisson, J				De Beeck, AO; Montserret, R; Duvet, S; Cocquerel, L; Cacan, R; Barberot, B; Le Maire, M; Penin, F; Dubuisson, J			The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SCANNING MUTAGENESIS; RECOMBINANT VACCINIA VIRUS; INTEGRAL MEMBRANE-PROTEINS; ENDOPLASMIC-RETICULUM; 3-DIMENSIONAL STRUCTURE; HELIX INTERACTIONS; LACTOSE PERMEASE; ESCHERICHIA-COLI; ALPHA-HELICES; NMR	Oligomerization of viral envelope proteins is essential to control virus assembly and fusion. The transmembrane domains (TMDs) of hepatitis C virus envelope glycoproteins El and E2 have been shown to play multiple functions during the biogenesis of E1E2 heterodimer. This makes them very unique among known transmembrane sequences. In this report, we used alanine scanning insertion mutagenesis in the TMDs of El and E2 to examine their role in the assembly of E1E2 heterodimer. Alanine insertion within the center of the TMDs of El or E2 or in the N-terminal part of the TMD of El dramatically reduced heterodimerization, demonstrating the essential role played by these domains in the assembly of hepatitis C virus envelope glycoproteins. To better understand the alanine scanning data obtained for the TMD of El which contains GXXXG motifs, we analyzed by circular dichroism and nuclear magnetic resonance the three dimensional structure of the E1-(350-370) peptide encompassing the N-terminal sequence of the TMD of El involved in heterodimerization. Alanine scanning results and the three-dimensional molecular model we obtained provide the first framework for a molecular level understanding of the mechanism of hepatitis C virus envelope glycoprotein heterodimerization.	Inst Pasteur, CNRS UMR 8526, IBL, F-59021 Lille, France; IBCP, CNRS UMR 5086, F-69367 Lyon 07, France; Univ Sci & Tech Lille Flandres Artois, CNRS UMR 8576, F-59655 Villeneuve Dascq, France; CEA, CNRS URA 2096, F-91191 Gif Sur Yvette, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS UMR 8526, Equipe Hepatite C, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Cocquerel, Laurence/P-1951-2016; PENIN, Francois/A-7315-2008; Dubuisson, Jean/E-6813-2016	Cocquerel, Laurence/0000-0002-2136-5178; Dubuisson, Jean/0000-0003-1626-7693				BARSUKOV IL, 1990, EUR J BIOCHEM, V192, P321, DOI 10.1111/j.1432-1033.1990.tb19230.x; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; BRUNGER AT, 1998, XPLOR SYSTEM CRYSTAL; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Choukhi A, 1999, J GEN VIROL, V80, P3099, DOI 10.1099/0022-1317-80-12-3099; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; DOMS RW, 1990, METHOD ENZYMOL, V191, P841; DRILLIEN R, 1982, VIROLOGY, V119, P372, DOI 10.1016/0042-6822(82)90096-4; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Flint M, 1999, J VIROL, V73, P6782, DOI 10.1128/JVI.73.8.6782-6790.1999; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KMIECIK D, 1995, GLYCOBIOLOGY, V5, P483, DOI 10.1093/glycob/5.5.483; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Lambotte S, 1998, BIOCHEMISTRY-US, V37, P16, DOI 10.1021/bi9724671; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LI ZM, 1993, J BIOL CHEM, V268, P4584; LOMIZE AL, 1992, J BIOMOL NMR, V2, P361, DOI 10.1007/BF01874814; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; Marassi FM, 1998, CURR OPIN STRUC BIOL, V8, P640, DOI 10.1016/S0959-440X(98)80157-7; Mayo MA, 1998, J GEN VIROL, V79, P649, DOI 10.1099/0022-1317-79-4-649; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; Mingarro I, 1997, J MOL BIOL, V272, P633, DOI 10.1006/jmbi.1997.1276; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Monne M, 1999, J MOL BIOL, V293, P807, DOI 10.1006/jmbi.1999.3183; Montserret R, 1999, BIOCHEMISTRY-US, V38, P6479, DOI 10.1021/bi9900222; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Penin F, 1997, J MOL BIOL, V270, P496, DOI 10.1006/jmbi.1997.1123; PERVUSHIN KV, 1992, FEBS LETT, V308, P190, DOI 10.1016/0014-5793(92)81272-N; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RICE CM, 1996, FIELDS VIROLOGY, P931; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yi MK, 1997, VIROLOGY, V231, P119, DOI 10.1006/viro.1997.8516; [No title captured]; [No title captured]	74	131	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31428	31437		10.1074/jbc.M003003200	http://dx.doi.org/10.1074/jbc.M003003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10807921				2022-12-25	WOS:000089762700096
J	Vaiskunaite, R; Adarichev, V; Furthmayr, H; Kozasa, T; Gudkov, A; Voyno-Yasenetskaya, TA				Vaiskunaite, R; Adarichev, V; Furthmayr, H; Kozasa, T; Gudkov, A; Voyno-Yasenetskaya, TA			Conformational activation of radixin by G(13) protein alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN BINDING; PLASMA-MEMBRANE; G13 PROTEINS; ERM PROTEINS; IN-VIVO; PHOSPHORYLATION; G-ALPHA(13); FAMILY; KINASE; EZRIN	G(13) protein, one of the heterotrimeric guanine nucleotide-binding proteins (G proteins), regulates diverse and complex cellular responses by transducing signals from the cell surface presumably involving more than one pathway. Yeast two-hybrid screening of a mouse brain cDNA library identified radixin, a member of the ERM family of three closely related proteins (ezrin, radixin, and moesin), as a protein that interacted with G alpha(13). Interaction between radixin and G alpha(13) was confirmed by in vitro binding assay and by co-immunoprecipitation technique. Activated Ga,, induced conformational activation of radixin, as determined by binding of radixin to polymerized F-actin and by immunofluorescence in intact cells. Finally, two dominant negative mutants of radixin inhibited G alpha(13)-induced focus formation of Rat-1 fibroblasts but did not affect Ras-induced focus formation. Our results identifying a new signaling pathway for G alpha(13) indicate that ERM proteins can be activated by and serve as effecters of heterotrimeric G proteins.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Univ Illinois, Dept Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Stanford University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, 635 S Wolcott Ave, Chicago, IL 60612 USA.		Furthmayr, Heinz -/A-6295-2010					Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; FINLEY RL, 1995, DNA CLONING, V2, P169; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Panchenko M. P., 1993, Biokhimiya, V58, P438; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	30	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26206	26212		10.1074/jbc.M001863200	http://dx.doi.org/10.1074/jbc.M001863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10816569	hybrid			2022-12-25	WOS:000088999700045
J	Chiang, SY; Burli, RW; Benz, CC; Gawron, L; Scott, GK; Dervan, PB; Beerman, TA				Chiang, SY; Burli, RW; Benz, CC; Gawron, L; Scott, GK; Dervan, PB; Beerman, TA			Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE; DNA-BINDING; TRANSCRIPTION; RECOGNITION; PROTEIN; DOMAIN; DRUGS; INHIBITION; COMPLEXES; SEQUENCE	Three DNA binding polyamides (1-3) were synthesized that bind with high affinity (K-a = 8.7 . 10(9) m(-1) to 1.4 . 10(10) m(-1)) to two 7-base pair sequences overlapping the Ets DNA binding site (EBS; GAGGAA) within the regulatory region of the HER2/neu proximal promoter. As measured by electrophoretic mobility shift assay, polyamides binding to flanking elements upstream (1) or downstream (2 and 3) of the EBS were one to two orders of magnitude more effective than the natural product distamycin at inhibiting formation of complexes between the purified EBS protein, epithelial restricted with serine box (ESX), and the HER2/neu promoter probe, One polyamide, 2, completely blocked Ets-DNA complex formation at 10 nm ligand concentration, whereas formation of activator protein-2-DNA complexes was unaffected at the activator protein-2 binding site immediately upstream of the HER2/neu EBS, even at 100 nar ligand concentration. At equilibrium, polyamide 1 was equally effective at inhibiting Ets/DNA binding when added before or after in vitro formation of protein-promoter complexes, demonstrating its utility to disrupt endogenous Ets-mediated HER2/neu preinitiation complexes. Polyamide 2, the most potent inhibitor of Ets-DNA complex formation by electrophoretic mobility shift assay, was also the most effective inhibitor of HER2/neu promoter-driven transcription measured in a cell-free system using nuclear extract from an ESX- and HER2/neu-overexpressing human breast cancer cell line, SKBR-3.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	California Institute of Technology; California Institute of Technology; Roswell Park Cancer Institute; University of California System; University of California San Francisco	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.				NATIONAL CANCER INSTITUTE [R01CA026056, R37CA026056, R01CA036773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051747] Funding Source: NIH RePORTER; NCI NIH HHS [CA36773, CA26056] Funding Source: Medline; NIGMS NIH HHS [GM51747] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657; BKOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BROGGINI M, 1994, ANTI-CANCER DRUG DES, V9, P373; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; EPSTEIN FH, 1994, NEW ENGL J MED, V330, P328; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Graves BJ, 1996, NATURE, V384, P322, DOI 10.1038/384322a0; HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; Neely L, 1997, J MOL BIOL, V274, P439, DOI 10.1006/jmbi.1997.1411; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Parks ME, 1996, J AM CHEM SOC, V118, P6153, DOI 10.1021/ja9607289; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SUN DY, 1995, CHEM BIOL, V2, P457, DOI 10.1016/1074-5521(95)90263-5; Swalley SE, 1996, J AM CHEM SOC, V118, P8198, DOI 10.1021/ja9611598; SYNDER R C, 1991, Biochemistry, V30, P4290; Tripathy D., 1993, ONCOGENES TUMOR SUPP, P15; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; White S, 1996, BIOCHEMISTRY-US, V35, P12532, DOI 10.1021/bi960744i; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	31	57	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24246	24254		10.1074/jbc.M000820200	http://dx.doi.org/10.1074/jbc.M000820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818092	Green Accepted, hybrid			2022-12-25	WOS:000088683300004
J	Driller, L; Wellinger, RJ; Larrivee, M; Kremmer, E; Jaklin, S; Feldmann, HM				Driller, L; Wellinger, RJ; Larrivee, M; Kremmer, E; Jaklin, S; Feldmann, HM			A short C-terminal domain of Yku70p is essential for telomere maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; KU PROTEIN; YEAST KU; S-PHASE; REPAIR; HOMOLOG; IDENTIFICATION	The Yku heterodimer from Saccharomyces cerevisiae, comprising Yku70p and Yku80p, is involved in the maintenance of a normal telomeric DNA end structure and is an essential component of nonhomologous end joining (NHEJ). To investigate the role of the Yku70p subunit in these two different pathways, we generated C-terminal deletions of the Yku70 protein and examined their ability to complement the phenotypes of a yku70(-) strain. Deleting only the 30 C-terminal amino acids of Yku70p abolishes Yku DNA binding activity and causes a ykuphenotype; telomeres are shortened, and NHEJ is impaired. Using conditions in which at least as much mutant protein as full-length protein is normally detectable in cell extracts, deleting only 25 C-terminal amino acids of Yku70p results in no measurable effect on DNA binding of the Yku protein, and the cells are fully proficient for NHEJ. Nevertheless, these cells display considerably shortened telomeres, and significant amounts of single-stranded overhangs of the telomeric guanosine-rich strands are observed. Co-overexpression of this protein with Yku80p could rescue some but not all of the telomere-related phenotypes. Therefore, the C-terminal domain in Yku70p defines at least one domain that is especially involved in telomere maintenance but not in NHEJ.	Univ Munich, Inst Biochem, D-81377 Munich, Germany; Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany	University of Munich; University of Sherbrooke; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Feldmann, HM (corresponding author), Univ Munich, Inst Biochem, Feodor Lynen Str 25, D-81377 Munich, Germany.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759				BLIER PR, 1993, J BIOL CHEM, V268, P7594; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Jurk M, 1998, INT J CANCER, V75, P762, DOI 10.1002/(SICI)1097-0215(19980302)75:5<762::AID-IJC16>3.0.CO;2-8; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Wu XT, 1996, MOL CELL BIOL, V16, P5186	35	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24921	24927		10.1074/jbc.M002588200	http://dx.doi.org/10.1074/jbc.M002588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818099	hybrid			2022-12-25	WOS:000088683300092
J	Okada, Y; Ito, Y; Kikuchi, A; Nimura, Y; Yoshida, S; Suzuki, M				Okada, Y; Ito, Y; Kikuchi, A; Nimura, Y; Yoshida, S; Suzuki, M			Assignment of functional amino acids around the active site of human DNA topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; POLYMERASE-I; BETA-SHEET; YEAST; PROTEIN; EXPRESSION; MUTATION; RESISTANCE; MECHANISM; BREAKAGE	An expression library for active site mutants of human topoisomerase II alpha (TOP2 alpha) was constructed by replacing the sequence encoding residues 793-808 with a randomized oligonucleotide cassette. This plasmid library was transformed into a temperature-sensitive yeast strain (top2-1), and viable transformants were selected at the restrictive temperature. Among the active TOP2 alpha mutants, no substitution was allowed at Tyr(805), the 5' anchor of the cleaved DNA, and only conservative substitutions were allowed at Leu(794), Asp(797), Ala(801), and Arg(804). Thus, these 5 residues are critical for human TOP2 alpha activity, and the remaining mutagenized residues are less critical for function. Using the x-ray crystal structure of yeast TOP2 as a structural model, it can be deduced that these 5 functionally important residues lie in a plane. One of the possible functions of this plane may be that it interacts with the DNA substrate upon catalysis. The side chains of Ser(803) and Lys(798) which confer drug resistance, lie adjacent to this plane.	Nagoya Univ, Sch Med, Dis Mech & Control Res Inst, Cell Biol Lab, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dis Mech & Control Res Inst, Dept Surg 1, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dis Mech & Control Res Inst, Med Mycol Lab, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Suzuki, M (corresponding author), Nagoya Univ, Sch Med, Dis Mech & Control Res Inst, Cell Biol Lab, Nagoya, Aichi 4668550, Japan.	msuzuki@tsuru.med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron Paul R., 1994, V29B, P271; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DUBE DK, 1989, BIOCHEMISTRY-US, V28, P5703, DOI 10.1021/bi00440a001; Fass D, 1999, NAT STRUCT BIOL, V6, P322; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; HOOPER DC, 1991, EUR J CLIN MICROBIOL, V10, P223, DOI 10.1007/BF01966994; Hsiung Y, 1996, CANCER RES, V56, P91; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; PATEL S, 1993, BRIT J CANCER, V67, P456, DOI 10.1038/bjc.1993.87; PERUTZ MF, 1968, NATURE, V219, P902, DOI 10.1038/219902a0; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; Yokochi T, 1996, GENES CELLS, V1, P1069, DOI 10.1046/j.1365-2443.1996.d01-226.x	37	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24630	24638		10.1074/jbc.M003243200	http://dx.doi.org/10.1074/jbc.M003243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10807924	hybrid			2022-12-25	WOS:000088683300055
J	Schedlich, LJ; Le Page, SL; Firth, SM; Briggs, LJ; Jans, DA; Baxter, RC				Schedlich, LJ; Le Page, SL; Firth, SM; Briggs, LJ; Jans, DA; Baxter, RC			Nuclear import of insulin-like growth factor-binding protein-3 and-5 is mediated by the importin beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; CELL-SURFACE BINDING; BREAST-CANCER CELLS; LOCALIZATION SEQUENCE; IN-VITRO; IGF-I; TRANSPORT FACTOR; HIGH-AFFINITY; PORE COMPLEX; FACTOR P97	Although insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 are known to modulate cell growth by reversibly sequestering extracellular insulinlike growth factors, several reports have suggested that IGFBP-3, and possibly also IGFBP-5, have important insulin-like growth factor-independent effects on cell growth. These effects may be related to the putative nuclear actions of IGFBP-3 and IGFBP-5, which we have recently shown are transported to the nuclei of T47D breast cancer cells. We now describe the mechanism for nuclear import of IGFBP-3 and IGFBP-5, In digitonin-permeabilized cells, where the nuclear envelope remained intact, nuclear translocation of wild-type IGFBP-3 appears to occur by a nuclear localization sequence (NLS)-dependent pathway mediated principally by the importin beta nuclear transport factor and requiring both ATP and GTP hydrolysis, Under identical conditions, an NLS mutant form of IGFBP-3, IGFBP-3[(228)KGRKR --> MDGEA], was unable to translocate to the nucleus. In cells where both the plasma membrane and nuclear envelope were permeabilized, wild-type IGFBP-3, but not the mutant form, accumulated in the nucleus, implying that the NLS was also involved in mediating binding to nuclear components. By fusing wildtype and mutant forms of NLS sequences (IGFBP-3 [215-232] and IGFBP-5 [201-218]) to the green fluorescent protein, we identified the critical residues of the NLS necessary and sufficient for nuclear accumulation. Using a Western ligand binding assay, wild-type IGFBP-3 and IGFBP-5, but not an NLS mutant form of IGFBP-3, were shown to be recognized by importin beta and the alpha/beta heterodimer but only poorly by importin alpha. Together these results suggest that the NLSs within the C-terminal domain of IGFBP-3 and IGFBP-5 are required for importin-beta-dependent nuclear uptake and probably also accumulation through mediating binding to nuclear components.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Australian National University; John Curtin School of Medical Research	Schedlich, LJ (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	lyns@med.usyd.edu.au	Baxter, Robert C/F-3927-2012; Briggs, Lyndall J/A-7549-2011	Baxter, Robert C/0000-0001-5061-2142; 				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P423, DOI 10.1210/jcem-65-3-423; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cohen P., 1999, Growth Hormone and IGF Research, V9, P317; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Firth SM, 1999, PROTEIN EXPRES PURIF, V16, P202, DOI 10.1006/prep.1999.1075; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; OH YM, 1993, J BIOL CHEM, V268, P14964; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yoneda Y, 1997, J BIOCHEM, V121, P811	58	225	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23462	23470		10.1074/jbc.M002208200	http://dx.doi.org/10.1074/jbc.M002208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811646	hybrid			2022-12-25	WOS:000088564200010
J	Szafer, E; Pick, E; Rotman, M; Zuck, S; Huber, I; Cassel, D				Szafer, E; Pick, E; Rotman, M; Zuck, S; Huber, I; Cassel, D			Role of coatomer and phospholipids in GTPase-activating protein-dependent hydrolysis of GTP by ADP-ribosylation factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; NONCATALYTIC DOMAIN; GOLGI MEMBRANES; KDEL RECEPTOR; ARF PROTEIN; SEC7 DOMAIN; BINDING; TRANSPORT; COMPLEX; CYTOHESIN-1	The binding of the coat protein complex, coatomer, to the Golgi is mediated by the small GTPase ADP-ribosylation factor-1 (ARF1), whereas the dissociation of coatomer, requires GTP hydrolysis on ARF1, which depends on a GTPase-activating protein (GAP). Recent studies demonstrate that when GAP activity is assayed in a membrane-free environment by employing an amino-terminal truncation mutant of ARF1 (Delta 17-ARF1) and a catalytic fragment of the ARF GTPase-activating protein GAP1, GTP hydrolysis is strongly stimulated by coatomer (Goldberg, J., (1999) Cell 96, 893-902). In this study, we investigated the role of coatomer in GTP hydrolysis on ARF1 both in solution and in a phospholipid environment. When GTP hydrolysis was assayed in solution using Delta 17-ARF1, coatomer stimulated hydrolysis in the presence of the full-length GAP1 as well as with a Saccharomyces cerevisiae ARF GAP (Gcs1) but had no effect on hydrolysis in the presence of the phosphoinositide dependent GAP, ASAP1. Using wild-type myristoylated ARF1 loaded with GTP in the presence of phospholipid vesicles, GAP1 by itself stimulated GTP hydrolysis efficiently, and coatomer had no additional effect. Disruption of the phospholipid vesicles with detergent resulted in reduced GAP1 activity that was stimulated by coatomer, a pattern that resembled Delta 17-ARF1 activity. Our findings suggest that in the biological membrane, the proximity between ARF1 and its GAP, which results from mutual binding to membrane phospholipids, may be sufficient for stimulation of ARF1 GTPase activity.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		Pick, Elah/G-6137-2018	Pick, Elah/0000-0002-6591-2217				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; HUBER I, 2000, IN PRESS METHODS ENZ; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	45	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23615	23619		10.1074/jbc.M003171200	http://dx.doi.org/10.1074/jbc.M003171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811810	hybrid			2022-12-25	WOS:000088564200030
J	Castelli, ME; Vescovi, EG; Soncini, FC				Castelli, ME; Vescovi, EG; Soncini, FC			The phosphatase activity is the target for Mg2+ regulation of the sensor protein PhoQ in Salmonella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; BACTERIAL CHEMOTAXIS; BACILLUS-SUBTILIS; PHOSPHOTRANSFER; PHOSPHORYLATION; TYPHIMURIUM; ENVZ; TRANSMITTER; SPORULATION	The PhoP/PhoQ two component system controls the expression of essential virulence traits in the pathogenic bacterium Salmonella enterica serovar Typhimurium. Environmental deprivation of Mg2+ activates the PhoP/PhoQ signal transduction cascade, which re suits in an increased expression of genes necessary for survival inside the host. It was previously demonstrated that the interaction of Mg2+ with the periplasmic domain of PhoQ promotes a conformational change in the sensor protein that leads to the down-regulation of PhoP-activated genes. We have now examined the regulatory effect of Mg2+ On the putative activities of the membrane-bound PhoQ. We demonstrated that Mg2+ promotes a phospho-PhoP phosphatase activity in the sensor protein. This activity depends on the intactness of the conserved Ris-277, suggesting that the phosphatase active site overlaps the H box. The integrity of the N-terminal domain of PhoQ was essential for the induction of the phosphatase activity, because Mg2+ did not stimulate the release of inorganic phosphate from phospho-PhoP in a fusion protein that lacks this sensing domain. These findings reveal that the sensor PhoQ harbors a phospho-PhoP phosphatase activity, and that this phosphatase activity is the target of the extracellular Mg2+-triggered regulation of the PhoP/PhoQ system.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Santa Fe, Argentina	National University of Rosario	Soncini, FC (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Santa Fe, Argentina.	pat-bact@citynet.net.ar		Garcia Vescovi, Eleonora/0000-0002-4431-8606; Castelli, Maria Eugenia/0000-0002-9449-9177; Soncini, Fernando/0000-0002-8925-7763				AIBA H, 1989, J BIOL CHEM, V264, P14090; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; Blat Y, 1998, J MOL BIOL, V284, P1191, DOI 10.1006/jmbi.1998.2224; CAVICCHIOLI R, 1995, J BACTERIOL, V177, P2416, DOI 10.1128/jb.177.9.2416-2424.1995; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1991, METHOD ENZYMOL, V200, P188; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; NINFA AJ, 1996, ESCHERICHIA COLI SAL, V1, P1246; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shi L, 1999, BIOCHEMISTRY-US, V38, P10119, DOI 10.1021/bi990658t; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Vescovi EG, 1997, J BIOL CHEM, V272, P1440, DOI 10.1074/jbc.272.3.1440; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	32	93	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22948	22954		10.1074/jbc.M909335199	http://dx.doi.org/10.1074/jbc.M909335199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807931	hybrid			2022-12-25	WOS:000088419400048
J	Hofer-Warbinek, R; Schmid, JA; Stehlik, C; Binder, BR; Lipp, J; de Martin, R				Hofer-Warbinek, R; Schmid, JA; Stehlik, C; Binder, BR; Lipp, J; de Martin, R			Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ZINC-FINGER PROTEIN; KINASE COMPLEX; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MAP KINASE; BETA; A20; TRANSCRIPTION; PATHWAY	Exposure of endothelial and many other cell types to tumor necrosis factor alpha generates both apoptotic and anti-apoptotic signals. The anti-apoptotic pathway leads to activation of the transcription factor NF-kappa B that regulates the expression of genes such as A20 or members of the IAP gene family that protect cells from tumor necrosis factor cu-mediated apoptosis, In turn, some anti-apoptotic genes have been shown to modulate NF-KB activity. Here we demonstrate that XIAP, a NF-kappa B-dependent member of the IAP gene family, is a strong stimulator of NF-kappa B, Expression of XIAP leads to increased nuclear translocation of the p65 subunit of NF-kappa B via a novel signaling pathway that involves the mitogen-activated protein kinase kinase kinase TAK1. We show that TAK1 physically interacts with NIK and with IKK2, and both XIAP or active TAK1 can stimulate IKK2 kinase activity. Thus, XIAP may be part of a system of regulatory loops that balance a cell's response to environmental stimuli.	Univ Vienna, VIenna Int Res Cooperat Ctr, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria	University of Vienna	de Martin, R (corresponding author), Univ Vienna, VIenna Int Res Cooperat Ctr, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	rainer.de.martin@univie.ac.at	Schmid, Johannes A./C-7659-2009; Stehlik, Christian/AAG-2132-2021	Schmid, Johannes A./0000-0002-6586-3507; Stehlik, Christian/0000-0002-3782-2484				Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; CHENG Q, 1994, J BIOL CHEM, V269, P13551; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KARIN M, 1998, CANC J SCI AM S1, V4, P92; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JC, 1996, BLOOD, V88, P3880, DOI 10.1182/blood.V88.10.3880.bloodjournal88103880; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	47	195	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22064	22068		10.1074/jbc.M910346199	http://dx.doi.org/10.1074/jbc.M910346199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807933	hybrid			2022-12-25	WOS:000088363800045
J	Majumder, PK; Pandey, P; Sun, XG; Cheng, KD; Datta, R; Saxena, S; Kharbanda, S; Kufe, D				Majumder, PK; Pandey, P; Sun, XG; Cheng, KD; Datta, R; Saxena, S; Kharbanda, S; Kufe, D			Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome C release and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTIC DIFFERENTIATION; PROTEOLYTIC ACTIVATION; CELLS; CASPASE-8; COMPLEX; SIGNAL; DATP	Apoptosis is induced by the release of cytochrome c from mitochondria to the cytoplasm. The present studies demonstrate that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces translocation of protein kinase C (PKC) delta from the cytoplasm to mitochondria. The results also show that translocation of PKC delta results in release of cytochrome c, The functional significance of this event is further supported by the demonstration that PKC delta translocation is required for TPA-induced apoptosis, These findings demonstrate that translocation of PKC delta to mitochondria is responsible, at least in part, for inducing cytochrome c release and apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Lovelace Resp Res Inst, Albuquerque, NM 87115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Lovelace Respiratory Research Institute	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058200] Funding Source: NIH RePORTER; NCI NIH HHS [CA42082] Funding Source: Medline; NIGMS NIH HHS [GM58200] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; CHEN CY, 1995, ONCOGENE, V11, P1487; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERRO TJ, 1993, AM J PHYSIOL, V264, pL7, DOI 10.1152/ajplung.1993.264.1.L7; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STONE RM, 1988, BLOOD, V72, P208; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	24	261	269	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21793	21796		10.1074/jbc.C000048200	http://dx.doi.org/10.1074/jbc.C000048200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10818086	hybrid			2022-12-25	WOS:000088363800005
J	Jing, NJ; Marchand, C; Liu, J; Mitra, R; Hogan, ME; Pommier, Y				Jing, NJ; Marchand, C; Liu, J; Mitra, R; Hogan, ME; Pommier, Y			Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAINS; DNA-BINDING DOMAIN; CATALYTIC DOMAIN; ACTIVE-SITE; I INTEGRASE; PROTEIN; CORE; MULTIMERIZATION; IDENTIFICATION	The G-tetrad-forming oligonucleotides T30177 and T30695 have been identified as potent inhibitors of human immunodeficiency virus type 1 integrase (HIV-1 IN) activity (Rando, R. F., Ojwang, J., Elbaggari, A., Reyes, G. R., Tinder, R., McGrath, M. S., and Hogan, M. E. (1995) J. Biol. Chem. 270, 1754-1760; Mazumder, A., Neamati, N., Ojwang, J. O., Sunder, S., Rando, R. F., and Pommier, Y. (1996) Biochemistry 35, 13762-13771; Jing, N., and Hogan, M. E. (1998) J. Biol. Chem. 273, 34992-34999). To understand the inhibition of HIV-1 IN activity by the G-quartet inhibitors, we have designed the oligonucleotides T40215 and T40216, composed of three and four G-quartets with stem lengths of 19 and 24 Angstrom, respectively. The fact that increasing the G-quartet stem length from 15 to 24 Angstrom kept inhibition of HIV-1 IN activity unchanged suggests that the binding interaction occurs between a GTGT loop domain of the G-quartet inhibitors and a catalytic site of HIV-1 ZN, referred to as a face-to-face interaction. Docking the NMR structure of T30695 (Jing and Hogan (1998)) into the x-ray structure of the core domain of HIV-1 IN, HIV-1 IN-(51-209) (Maignan, S., Guilloteau, J.-P., Qing, Z.-L., Clement-Mella, C., and Mikol, V. (1998) J. Mel. Biol. 282, 359-368), was performed using the GRAMM program. The statistical distributions of hydrogen bonding between HIV-1 IN and T30695 were obtained from the analyses of 1000 random docking structures. The docking results show a high probability of interaction between the GTGT loop residues of the G-quartet inhibitors and the catalytic site of HIV-1 IN, in agreement with the experimental observation.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jing, NJ (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	njing@bcm.tmc.edu	Marchand, Christophe/D-8559-2016		NIGMS NIH HHS [GM60153] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BROWN PO, 1998, INTEGRATION RETROVIR; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Este JA, 1998, MOL PHARMACOL, V53, P340, DOI 10.1124/mol.53.2.340; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Haugan IR, 1995, BIOCHEM BIOPH RES CO, V217, P802, DOI 10.1006/bbrc.1995.2843; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421; Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992; Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967; Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; Vakser IA, 1996, PROTEIN ENG, V9, P37, DOI 10.1093/protein/9.1.37; Vakser IA, 1996, PROTEIN ENG, V9, P741, DOI 10.1093/protein/9.9.741; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	40	100	104	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21460	21467		10.1074/jbc.M001436200	http://dx.doi.org/10.1074/jbc.M001436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801812	hybrid			2022-12-25	WOS:000088230600068
J	Haycock, JW; Rowe, SJ; Cartledge, S; Wyatt, A; Ghanem, G; Morandini, R; Rennie, IG; MacNeil, S				Haycock, JW; Rowe, SJ; Cartledge, S; Wyatt, A; Ghanem, G; Morandini, R; Rennie, IG; MacNeil, S			alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; MELANOCORTIN RECEPTOR; ANTIINFLAMMATORY ACTIVITY; PERIPHERAL INFLAMMATION; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; RESPONSIVE FACTOR; MSH	We have previously shown that or-melanocyte-stimulating hormone (alpha-MSH) can oppose tumor necrosis factor (alpha activation of NF-KB (1-2 h) and intercellular adhesion molecule 1 up-regulation (mRNA by 3 h and protein by 24 h) in melanocytes and melanoma cells. The present study reports on the ability of four MSH peptides to control intracellular peroxide levels and glutathione peroxidase (GPx) activity in pigmentary and nonpigmentary cells. In human HBL melanoma and HaCaT keratinocytes tumor necrosis factor alpha and H2O2 both activated GPx in a time- and concentration-dependent manner (by 30-45 min). (alpha-MSH peptides were found to inhibit the stimulated GPx activity and had biphasic dose-response curves. MSH 1-13 and MSH [Nle(4)-D-Phe(7)] achieved maximum inhibition at 10(-10) and 10(-12) M, respectively. Higher concentrations (10-100 fold) of MSH 4-10 and MSH. 11-13 were required to produce equivalent levels of inhibition. alpha-MSH was also capable of reducing peroxide accumulation within 15 min, and again this inhibition was biphasic. The data support a role of (alpha-MSH in acute protection of cells to oxidative/cytokine action that precedes NF-kappa B and GPx activation. The rapidity and potency of the response to alpha-MSH in pigmentary and nonpigmentary cells suggest this to be a central role of this peptide in cutaneous cells.	Univ Sheffield, No Gen Hosp, Div Clin Sci, Med Sect, Sheffield S5 7AU, S Yorkshire, England; No Gen Hosp, Dept Clin Chem, Sheffield S5 7AU, S Yorkshire, England; Free Univ Brussels, Inst Bordet, Lab Oncol & Expt Surg, B-1000 Brussels, Belgium; Univ Sheffield, Royal Hallamshire Hosp, Dept Opthalmol & Orthopt, Sheffield S10 2JF, S Yorkshire, England	Northern General Hospital; University of Sheffield; Northern General Hospital; Institut Jules Bordet; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Sheffield	Haycock, JW (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci, Med Sect, Sheffield S5 7AU, S Yorkshire, England.	j.w.haycock@shef.ac.uk	Haycock, John/B-4259-2008	Richardson, Sarah/0000-0002-1160-6062; Haycock, John/0000-0002-3950-3583				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BASS DA, 1983, J IMMUNOL, V130, P1910; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BHARDWAJ RS, 1994, ARCH DERMATOL RES, V287, P85, DOI 10.1007/BF00370724; Bhardwaj RS, 1996, J IMMUNOL, V156, P2517; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; CERIANI G, 1994, NEUROENDOCRINOLOGY, V59, P138, DOI 10.1159/000126650; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONE RD, 1992, COLLOQ INSE, V222, P27; DROGE W, 1994, FASEB J, V8, P1131; EBERLE AN, 1988, MELANTROPHINS CHEM P; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GANTZ I, 1993, GENOMICS, V18, P166, DOI 10.1006/geno.1993.1448; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GHANEM GE, 1988, INT J CANCER, V41, P248, DOI 10.1002/ijc.2910410216; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAN D, 1995, BIOCHEM BIOPH RES CO, V207, P258, DOI 10.1006/bbrc.1995.1181; Hartmeyer M, 1997, J IMMUNOL, V159, P1930; Haycock JW, 1999, J INVEST DERMATOL, V113, P560, DOI 10.1046/j.1523-1747.1999.00739.x; Hedley SJ, 1998, BRIT J DERMATOL, V138, P536; HILTZ ME, 1991, PEPTIDES, V12, P767, DOI 10.1016/0196-9781(91)90131-8; HILTZ ME, 1989, FASEB J, V3, P2282, DOI 10.1096/fasebj.3.11.2550304; HOFFMAN M, 1987, J LEUKOCYTE BIOL, V42, P704, DOI 10.1002/jlb.42.6.704; IYENGAR B, 1995, PIGM CELL RES, V8, P142, DOI 10.1111/j.1600-0749.1995.tb00655.x; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; KIPPENBERGER S, 1995, EUR J DERMATOL, V5, P395; LIPTON JM, 1991, PEPTIDES, V12, P795, DOI 10.1016/0196-9781(91)90135-C; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Loir B, 1997, EUR J BIOCHEM, V244, P923, DOI 10.1111/j.1432-1033.1997.00923.x; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Luger TA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P87, DOI 10.1038/jidsymp.1997.17; MARTIN LW, 1991, PEPTIDES, V12, P297, DOI 10.1016/0196-9781(91)90015-H; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORANDINI R, 1994, INT J CANCER, V56, P129; Morandini R, 1998, J CELL PHYSIOL, V175, P276, DOI 10.1002/(SICI)1097-4652(199806)175:3<276::AID-JCP5>3.0.CO;2-L; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NATALI P, 1990, CANCER RES, V50, P1271; Rajora N, 1997, J NEUROSCI, V17, P2181; SAWER TK, 1988, MELANTROPIC PEPTIDE, P59; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; Slominski A, 1996, BBA-GEN SUBJECTS, V1289, P247, DOI 10.1016/0304-4165(95)00159-X; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WATANABE T, 1993, BRAIN RES BULL, V32, P311, DOI 10.1016/0361-9230(93)90192-E; WEISS JM, 1991, EUR J PHARMACOL, V192, P177, DOI 10.1016/0014-2999(91)90087-7; YOHN JJ, 1990, J INVEST DERMATOL, V95, P233, DOI 10.1111/1523-1747.ep12478093	54	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15629	15636		10.1074/jbc.275.21.15629	http://dx.doi.org/10.1074/jbc.275.21.15629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821844	hybrid			2022-12-25	WOS:000087291400006
J	Leys, D; Backers, K; Meyer, TE; Hagen, WR; Cusanovich, MA; Van Beeumen, JJ				Leys, D; Backers, K; Meyer, TE; Hagen, WR; Cusanovich, MA; Van Beeumen, JJ			Crystal structures of an oxygen-binding cytochrome c from Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING TRANSCRIPTION FACTOR; SOLUBLE GUANYLATE-CYCLASE; HEME PROTEIN; METHYLOPHILUS-METHYLOTROPHUS; ANGSTROM RESOLUTION; LIGAND-BINDING; NITRIC-OXIDE; RHODOSPIRILLUM-RUBRUM; SITE; COOA	The photosynthetic bacterium Rhodobacter sphaeroides produces a heme protein (SHP), which is an unusual c-type cytochrome capable of transiently binding oxygen during autooxidation, Similar proteins have not only been observed in other photosynthetic bacteria but also in the obligate methylotroph Methylophilus methylotrophus and the metal reducing bacterium Shewanella putrefaciens, A three-dimensional structure of SRP was derived using the multiple isomorphous replacement phasing method. Besides a model for the oxidized state (to 1.82 Angstrom resolution), models for the reduced state (2.1 Angstrom resolution), the oxidized molecule liganded with cyanide (1.90 Angstrom resolution), and the reduced molecule Liganded with nitric oxide (2.20 Angstrom resolution) could be derived. The SHP structure represents a new variation of the class I cytochrome c fold. The oxidized state reveals a novel sixth heme ligand, Asn(88), which moves away from the iron upon reduction or when small molecules bind, The distal side of the heme has a striking resemblance to other heme proteins that bind gaseous compounds. In SHP the liberated amide group of Asn(88) stabilizes solvent-shielded ligands through a hydrogen bond.	Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Delft Univ Technol, Kluyver Dept Biotechnol, NL-2600 AA Delft, Netherlands; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	Delft University of Technology; University of Arizona	Van Beeumen, JJ (corresponding author), Dept Biochem Physiol & Microbiol, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	jozef.vanbeeumen@rug.ac.be	Hagen, Wilfred R./H-8918-2017	Hagen, Wilfred R./0000-0002-1609-6671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JF, 1998, STRUCTURE, V6, P1315, DOI 10.1016/S0969-2126(98)00131-2; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISIG DA, 1995, J BIOL CHEM, V270, P20754, DOI 10.1074/jbc.270.35.20754; BRADEN BC, 1994, J MOL BIOL, V238, P42, DOI 10.1006/jmbi.1994.1266; BROWN WD, 1969, J BIOL CHEM, V244, P6696; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CARTER DC, 1985, J MOL BIOL, V184, P279, DOI 10.1016/0022-2836(85)90380-8; CHOUDHURY K, 1992, J BIOL CHEM, V267, P25656; COSTA HS, 1993, EUR J BIOCHEM, V215, P817, DOI 10.1111/j.1432-1033.1993.tb18097.x; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; GRAY GO, 1983, ARCH BIOCHEM BIOPHYS, V22, P83; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Kadziola A, 1997, STRUCTURE, V5, P203, DOI 10.1016/S0969-2126(97)00179-2; Klarskov K, 1998, BIOCHEMISTRY-US, V37, P5995, DOI 10.1021/bi972498w; KLARSKOV K, 1999, BIOCHIM BIOPHYS ACTA, V26, P47; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Matias PM, 1996, PROTEIN SCI, V5, P1342, DOI 10.1002/pro.5560050713; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V807, P308, DOI 10.1016/0005-2728(85)90263-4; MEYER TE, 1984, BIOCHEMISTRY-US, V23, P4761, DOI 10.1021/bi00315a035; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OTWINOSKI Z, 1991, ISOMORPHOUS REPLACEM, V80; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Price NJ, 1999, BBA-BIOENERGETICS, V1413, P55, DOI 10.1016/S0005-2728(99)00085-7; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; Roussel A, 1992, TURBO FRODO BIOGRAPH; SANTOS H, 1988, BIOCHIM BIOPHYS ACTA, V954, P277, DOI 10.1016/0167-4838(88)90083-0; Schelvis JPM, 1998, BIOCHEMISTRY-US, V37, P16289, DOI 10.1021/bi981547h; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; Vandenberghe I, 1998, BIOCHEMISTRY-US, V37, P13075, DOI 10.1021/bi981076z; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; VONWACHENFELDT C, 1994, FEBS LETT, V340, P109, DOI 10.1016/0014-5793(94)80182-7; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; ZOBRIST M, 1978, J AM CHEM SOC, V100, P1944, DOI 10.1021/ja00474a060	43	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16050	16056		10.1074/jbc.275.21.16050	http://dx.doi.org/10.1074/jbc.275.21.16050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821858	hybrid			2022-12-25	WOS:000087291400061
J	Tamarit, J; Gerez, C; Meier, C; Mulliez, E; Trautwein, A; Fontecave, M				Tamarit, J; Gerez, C; Meier, C; Mulliez, E; Trautwein, A; Fontecave, M			The activating component of the anaerobic ribonucleotide reductase from Escherichia coli - An iron-sulfur center with only three cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; S-ADENOSYLMETHIONINE; ELECTRON-TRANSFER; 4FE-4S CLUSTERS; PROTEIN; ENZYME; LIGAND; SERINE; RECONSTITUTION; QUANTITATION	Class III anaerobic ribonucleotide reductase small component, named protein beta, contains a (4Fe-4S) center. its function is to mediate electron transfer from reduced flavodoxin to S-adenosylmethionine, required for the introduction of a glycyl radical in the large component, named protein or, which then becomes active for the reduction of ribonucleotides. By site-directed mutagenesis we demonstrate that the three cysteines of the conserved CXXXCXXC sequence are involved in iron chelation. Such a sequence is also present in the activase of the pyruvate formate-lyase and in the biotin synthase, both carrying an iron-sulfur center involved in reductive activation of S-adenosylmethionine. Even though they are able to bind iron in the (4Fe-4S) form, as shown by Mossbauer spectroscopy, the corresponding Cys to Ala mutants are catalytically inactive. Mutation of the two other cysteines of the protein did not result in inactivation. We thus conclude that the (4Fe-4S) cluster has, in the wild type protein, only three cysteine ligands and a fourth still unidentified ligand.	Univ Grenoble 1, EP 1087 CNRS, Commissariat Energie Atom Dept Biol Mol & Struct, Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lubeck	Fontecave, M (corresponding author), Univ Grenoble 1, EP 1087 CNRS, Commissariat Energie Atom Dept Biol Mol & Struct, Lab Chim & Biochim,Ctr Redox Biol, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Tamarit, Jordi/C-6316-2008	Tamarit, Jordi/0000-0003-3227-6928				AUGIER V, 1993, BIOCHEMISTRY-US, V32, P2013, DOI 10.1021/bi00059a018; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BERTINI I, 1995, STRUCT BOND, V83, P1; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; MOSS ML, 1990, J BIOL CHEM, V265, P18112; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Mulliez E, 1999, J BIOL INORG CHEM, V4, P614, DOI 10.1007/s007750050385; MULLIEZ E, 1999, IRON METABOLISM, P161; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de Choudens S, 1999, FEBS LETT, V453, P25, DOI 10.1016/S0014-5793(99)00694-8; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Siedow A, 1999, J BACTERIOL, V181, P4919, DOI 10.1128/JB.181.16.4919-4928.1999; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; Xia B, 1996, BIOCHEMISTRY-US, V35, P9488, DOI 10.1021/bi960467f	29	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15669	15675		10.1074/jbc.275.21.15669	http://dx.doi.org/10.1074/jbc.275.21.15669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821845	Green Published, hybrid			2022-12-25	WOS:000087291400012
J	Wada, T; Yamazaki, T; Kyogoku, Y				Wada, T; Yamazaki, T; Kyogoku, Y			The structure and the characteristic DNA binding property of the C-terminal domain of the RNA polymerase alpha subunit from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR CONTACT DOMAIN; TRANSCRIPTION ACTIVATION; BACTERIAL PROMOTERS; FUNCTIONAL MAP; PROTEIN; ELEMENT; IDENTIFICATION; INVOLVEMENT; REPRESSORS; ASSIGNMENT	The C-terminal domain of the alpha subunit of the RNA polymerase (alpha CTD) from Escherichia coli (Ec) regulates transcription by interacting with many kinds of proteins and promoter upstream (UP) elements consisting of AT-rich sequences. However, it is unclear how this system is common in all eubacteria. We investigate the structure and properties of alpha CTD from an extremely thermophilic eubacterium, Thermus thermophilus (Tt). The solution structure of Tt alpha CTD (85 amino acids) was determined by NMR, and the interaction between Tt alpha CTD and DNA with different sequences was investigated by means of chemical shift perturbation experiments. The tertiary structure of Tt alpha CTD is almost identical with that of Ec alpha CTD despite 32% sequence homology. However, Tt alpha CTD interacts with the upstream region sequence of the promoter in the Tt 16 S ribosomal protein operon rather than the Ec UP element DNA. The upstream region sequence of Tt is composed of 25 base pairs with 40% AT, unlike the Ec UP element with 80% AT. The DNA binding site in Tt alpha CTD is located on the surface composed of helix 4 and the loop preceding helix 4. The electric charges on this surface are not remarkably localized like those of Ec alpha CTD.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Kyogoku, Y (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Aiyar SE, 1998, P NATL ACAD SCI USA, V95, P14652, DOI 10.1073/pnas.95.25.14652; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BROWN JL, 1973, J BIOL CHEM, V248, P409; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; GAAL T, 1994, NUCLEIC ACIDS RES, V22, P2344, DOI 10.1093/nar/22.12.2344; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HARTMANN RK, 1989, J BACTERIOL, V171, P2933, DOI 10.1128/jb.171.6.2933-2941.1989; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MASEDA H, 1995, FEMS MICROBIOL LETT, V128, P127, DOI 10.1111/j.1574-6968.1995.tb07511.x; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; WANG AC, 1995, J BIOMOL NMR, V5, P376; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Yura K, 1999, CELL MOL LIFE SCI, V55, P472, DOI 10.1007/s000180050304	33	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16057	16063		10.1074/jbc.275.21.16057	http://dx.doi.org/10.1074/jbc.275.21.16057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821859	hybrid			2022-12-25	WOS:000087291400062
J	Anders, DL; Blevins, T; Smothers, CT; Woodward, JJ				Anders, DL; Blevins, T; Smothers, CT; Woodward, JJ			Reduced ethanol inhibition of N-methyl-D-aspartate receptors by deletion of the NR1 C0 domain or overexpression of alpha-actinin-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INACTIVATION; NMDA RECEPTORS; HIPPOCAMPAL-NEURONS; CA2+-DEPENDENT INACTIVATION; HEK-293 CELLS; ALPHA-ACTININ; SUBUNIT; SENSITIVITY; CALMODULIN; CHANNELS	The depressant actions of ethanol on central nervous system activity appear to be mediated by its actions on a number of important membrane associated ion channels including the N-methyl-D-aspartate (MMDA) subtype of ionotropic glutamate receptor. Although no specific site of action for ethanol on the NMDA receptor has been found, previous studies suggest that the ethanol sensitivity of the receptor may be affected by intracellular C-terminal domains of the receptor that regulate the calcium-dependent inactivation of the receptor. In the present study, co-expression of the NR2A subunit and an NR1 subunit that lacks the alternatively spliced intracellular C1 cassette did not reduce the effects of ethanol on channel function as measured by patch-clamp electrophysiology, Full inhibition was also observed in cells expressing an NR1 subunit truncated at the end of the CO domain (NR1(863stop)). However, the inhibitory effects of ethanol were reduced by expression of an NR1 CO domain deletion mutant (NR1 Delta(839-863)), truncation mutant (NR1(858stop)), or a triple-point mutant (Arg to Ala, Lys to Ala, and Asn to Ala at 859-861) previously shown to significantly reduce calcium-dependent inactivation. A similar reduction in the effects of ethanol on wild-type NR1/2A but not NR1/2B or NR1/2C receptors was observed after co-expression of full-length or truncated human skeletal muscle alpha-actinin-2 proteins that produce a functional knockout of the C0 domain. The effects of ethanol on hippocampal and cortical NMDA-induced currents were similarly attenuated in low calcium recording conditions, suggesting that a C0domain-dependent process may confer additional ethanol sensitivity to NMDA receptors.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, MCV Stn, Richmond, VA 23298 USA	Virginia Commonwealth University	Woodward, JJ (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, MCV Stn, Med Coll Virginia Campus, Richmond, VA 23298 USA.	jwoodwar@hsc.vcu.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA009986, R01AA009986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007027] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA009986, AA09986, AA00238, R37 AA009986] Funding Source: Medline; NIDA NIH HHS [DA07027] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anders DL, 1999, ALCOHOL CLIN EXP RES, V23, P357, DOI 10.1111/j.1530-0277.1999.tb04122.x; Blevins T, 1997, J NEUROCHEM, V69, P2345; BULLER AL, 1995, MOL PHARMACOL, V48, P717; Cervino V, 1998, J BIOL CHEM, V273, P29811, DOI 10.1074/jbc.273.45.29811; CHU B, 1995, J NEUROCHEM, V65, P140; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Clayton R, 2000, NEUROCHEM INT, V36, P67, DOI 10.1016/S0197-0186(99)00097-2; Dopico AM, 1999, NEUROCHEM INT, V35, P103, DOI 10.1016/S0197-0186(99)00051-0; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Krupp JJ, 1996, MOL PHARMACOL, V50, P1680; KUNER T, 1993, NEUROREPORT, V5, P297, DOI 10.1097/00001756-199312000-00029; Kyrozis A, 1996, J PHYSIOL-LONDON, V495, P449, DOI 10.1113/jphysiol.1996.sp021606; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MASOOD K, 1994, MOL PHARMACOL, V45, P324; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Mirshahi T, 1998, J NEUROCHEM, V71, P1095; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SIMSON PE, 1993, BRAIN RES, V607, P9, DOI 10.1016/0006-8993(93)91483-9; Smothers CT, 1997, J PHARMACOL EXP THER, V283, P1214; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Walter HJ, 1999, NEUROCHEM INT, V35, P95, DOI 10.1016/S0197-0186(99)00050-9; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Yang XH, 1996, J PHARMACOL EXP THER, V278, P114; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	30	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15019	15024		10.1074/jbc.275.20.15019	http://dx.doi.org/10.1074/jbc.275.20.15019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809744	hybrid			2022-12-25	WOS:000087128300036
J	Chen, XJ; Bauer, BE; Kuchler, K; Clark-Walker, GD				Chen, XJ; Bauer, BE; Kuchler, K; Clark-Walker, GD			Positive and negative control of multidrug resistance by the Sit4 protein phosphatase in Kluyveromyces lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; YEAST SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL GENOME INTEGRITY; MULTIPLE-DRUG-RESISTANCE; DNA-SEQUENCE ANALYSIS; PLASMA-MEMBRANE; P-GLYCOPROTEIN; FUNCTIONAL EXPRESSION; ENCODING GENE; TRANSCRIPTIONAL CONTROL	The nuclear gene encoding the Sit4 protein phosphatase was identified in the budding yeast Kluyveromyces lactis, IL lactis cells carrying a disrupted sit4 allele are resistant to oligomycin, antimycin, ketoconazole, and econazole but hypersensitive to paromomycin, sorbic acid, and 4-nitroquinoline-N-oxide (4-NQO), Overexpression of SIT4 leads to an elevation in resistance to paromomycin and to lesser extent tolerance to sorbic acid, but it has no detectable effect on resistance to 4-NQO, These observations suggest that the Sit4 protein phosphatase has a broad role in modulating multidrug resistance in K. lactis. Expression or activity of a membrane transporter specific for paromomycin and the ABC pumps responsible for 4-NQO and sorbic acid would be positively regulated by Sit4p, In contrast, the function of a Pdr5-type transporter responsible for ketoconazole and econazole extrusion, and probably also for efflux of oligomycin and antimycin, is likely to be negatively regulated by the phosphatase, Drug resistance of sit4 mutants was shown to be mediated by ABC transporters as efflux of the anionic fluorescent dye rhodamine 6G, a substrate for the Pdr5-type pump, is markedly increased in sit4 mutants in an energy-dependent and FK506-sensitive manner.	Australian Natl Univ, Res Sch Biol Sci, Mol Genet & Evolut Grp, Canberra, ACT 2601, Australia; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	Australian National University; University of Vienna; Vienna Biocenter (VBC)	Chen, XJ (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Mol Genet & Evolut Grp, Biol Pl,RSBS Bldg,GPO Box 475, Canberra, ACT 2601, Australia.		kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; AVNER PR, 1973, EUR J BIOCHEM, V15, P312; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; Bastians H, 1996, J CELL SCI, V109, P2865; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRUNNER A, 1977, MOL GEN GENET, V152, P183, DOI 10.1007/BF00268816; CENTER MS, 1983, BIOCHEM BIOPH RES CO, V115, P159, DOI 10.1016/0006-291X(83)90983-X; CHEN XJ, 1988, GENE, V69, P181, DOI 10.1016/0378-1119(88)90429-5; CHEN XJ, 1995, EMBO J, V14, P3277, DOI 10.1002/j.1460-2075.1995.tb07331.x; CHEN XJ, 1994, MOL CELL BIOL, V14, P4501, DOI 10.1128/MCB.14.7.4501; CHEN XJ, 1992, MOL GEN GENET, V233, P97, DOI 10.1007/BF00587566; Chen XJ, 1996, GENETICS, V144, P1445; CHEN XJ, 1993, GENETICS, V133, P517; Chen XJ, 1996, GENE, V172, P131, DOI 10.1016/0378-1119(96)00125-4; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; COWMAN AF, 1990, INT J PARASITOL, V20, P503, DOI 10.1016/0020-7519(90)90198-V; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V206, P119, DOI 10.1006/bbrc.1995.1017; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GIEZT D, 1992, NUCLEIC ACIDS RES, V20, P1425; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; HAMADA H, 1987, CANCER RES, V47, P2860; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kolaczkowski M, 1998, MICROB DRUG RESIST, V4, P143, DOI 10.1089/mdr.1998.4.143; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; MA LD, 1995, BIOCHEMISTRY-US, V34, P3338, DOI 10.1021/bi00010a024; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; OOI BG, 1985, EUR J BIOCHEM, V152, P709, DOI 10.1111/j.1432-1033.1985.tb09251.x; Piper P, 1998, EMBO J, V17, P4257, DOI 10.1093/emboj/17.15.4257; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; RAY MK, 1988, BIOCHIM BIOPHYS ACTA, V951, P213, DOI 10.1016/0167-4781(88)90042-5; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; Rebbeor JF, 1998, J BIOL CHEM, V273, P33449, DOI 10.1074/jbc.273.50.33449; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Ruetz S, 1996, J BIOL CHEM, V271, P4154; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Sherman F., 1983, METHODS YEAST GENETI; SHIMANUKI M, 1993, MOL BIOL CELL, V4, P303, DOI 10.1091/mbc.4.3.303; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; STARK MJR, 1994, FEMS MICROBIOL LETT, V117, P121; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; UEDA K, 1993, FEBS LETT, V330, P179; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wendler F, 1997, J BIOL CHEM, V272, P27091, DOI 10.1074/jbc.272.43.27091; WESOLOWSKILOUVEL M, 1988, YEAST, V4, P71, DOI 10.1002/yea.320040108; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3	84	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14865	14872		10.1074/jbc.275.20.14865	http://dx.doi.org/10.1074/jbc.275.20.14865			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809730	hybrid			2022-12-25	WOS:000087128300015
J	Shi, J; Sugrue, SP				Shi, J; Sugrue, SP			Dissection of protein linkage between keratins and pinin, a protein with dual location at desmosome-intermediate filament complex and in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSENSUS SEQUENCE MOTIF; CULTURED-CELLS; EPITHELIAL-CELLS; COILED COILS; EXPRESSION; IDENTIFICATION; MELANOMA; DESMOPLAKIN; ENVOPLAKIN; VIMENTIN	Pinin is a cell adhesion-associated and nuclear protein that has been shown to localize in the vicinity of intermediate filament (IF) convergence upon the cytoplasmic face of the desmosomal plaque as well as in the nucleus. The localization of pinin to the desmosomes has been correlated with the reinforcement of intercellular adhesion and increased LF organization. In this study, keratins 18, 8, and 19 were identified to interact with the amino end domain of pinin in a two-hybrid screening. Further truncation analyses indicated that the 2B domain of keratin contains the sequence responsible for interacting with pinin, The amino end of pinin (residues 1-98) is sufficient to bind to keratin, Point mutation analyses revealed two essential residues within the pinin fragment 1-98, leucine 8 and leucine 19, for the interaction with keratin, Finally, in vitro protein overlay binding assays confirmed the direct interaction of the amino end domain of pinin with keratins, while pinin mutant L8P GST fusion protein failed to bind to keratins in the overlay assay. Coupled with our previous morphological observations and transfection studies, these data suggest that pinin may play a role in epithelial cell adhesion and the IF complex through a direct interaction with the keratin filaments.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	sugrue@anatomy.med.ufl.edu			NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aho S, 1999, J CELL BIOCHEM, V72, P356, DOI 10.1002/(SICI)1097-4644(19990301)72:3<356::AID-JCB5>3.0.CO;2-M; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; AYNARDI MW, 1984, J CELL BIOL, V98, P1407, DOI 10.1083/jcb.98.4.1407; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Brandner JM, 1998, EUR J CELL BIOL, V75, P295, DOI 10.1016/S0171-9335(98)80063-0; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; Fuchs E, 1997, SOC GEN PHY, V52, P141; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HATZFELD M, 1994, J CELL SCI, V107, P2259; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; James P, 1996, GENETICS, V144, P1425; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; KOUKLIS PD, 1992, J CELL SCI, V102, P31; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SCHUSSLER MH, 1992, AM J PATHOL, V140, P559; Shi YJ, 2000, ONCOGENE, V19, P289, DOI 10.1038/sj.onc.1203328; Shi YJ, 2000, INVEST OPHTH VIS SCI, V41, P1337; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Troyanovsky S M, 1998, Subcell Biochem, V31, P263; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; ZACKROFF RV, 1984, J CELL BIOL, V98, P1231, DOI 10.1083/jcb.98.4.1231; ZARBO RJ, 1990, MODERN PATHOL, V3, P494	40	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14910	14915		10.1074/jbc.275.20.14910	http://dx.doi.org/10.1074/jbc.275.20.14910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809736	hybrid			2022-12-25	WOS:000087128300021
J	Shnyreva, M; Schullery, DS; Suzuki, H; Higaki, F; Bomsztyk, K				Shnyreva, M; Schullery, DS; Suzuki, H; Higaki, F; Bomsztyk, K			Interaction of two multifunctional proteins - Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNRNP-K; TRANSCRIPTIONAL REGULATION; GENE; PROMOTER; ACTIVATION; REPRESSOR; DOMAIN; YB-1; IDENTIFICATION; TRANSLATION	The heterogeneous nuclear ribonucleoprotein (hnRNP) K, a component of the hnRNP particles, appears to be involved in several steps of regulation of gene expression, To gain insight into mechanisms of K protein action, we performed two-hybrid screens using full-length hnRNP K as a bait. Several novel protein partners were identified, including Y-box-binding protein (YB-1), splicing factors 9G8 and SRp20, DNA-methyltransferase, hnRNP L, and hnRNP U. In vitro binding studies and co-immunoprecipitation from cellular extracts provided evidence for direct interaction between hnRNP K and YB-1. Two distinct domains in YB-1 were responsible for binding to K protein. Each protein was able to transactivate transcription from a polypyrimidine-rich promoter; however, this effect was reduced when K and YB-1 proteins were coexpressed suggesting a functional ineeraction between these two proteins.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Box 356521, Seattle, WA 98195 USA.	karolb@u.washington.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45978] Funding Source: Medline; NIGMS NIH HHS [GM 45134] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Delling U, 1998, ANTIMICROB AGENTS CH, V42, P1034, DOI 10.1128/AAC.42.5.1034; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; Dhalla AK, 1998, BIOCHEM J, V336, P373, DOI 10.1042/bj3360373; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Safak R, 1999, MOL CELL BIOL, V19, P2712; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TAFURI SR, 1992, NEW BIOL, V4, P349; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	32	93	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15498	15503		10.1074/jbc.275.20.15498	http://dx.doi.org/10.1074/jbc.275.20.15498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809782	hybrid			2022-12-25	WOS:000087128300097
J	Kondo, Y; Koga, S; Komata, T; Kondo, S				Kondo, Y; Koga, S; Komata, T; Kondo, S			Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component	ONCOGENE			English	Article						2-5A; antisense; telomerase; prostate cancer; apoptosis	HUMAN TELOMERASE ACTIVITY; MALIGNANT GLIOMA; TARGETING RNA; IN-VITRO; CELLS; INHIBITION; APOPTOSIS; 2-5A; DIFFERENTIATION; CARCINOMA	Prostate cancer is the most common malignancy of elderly men in the United States. Since there is no curative treatment for advanced prostate cancer, exploration of novel modalities of treatment is essential. Telomerase, a ribsnucleoprotein, is detected in the vast majority of prostate cancer, but not in normal or benign prostatic hyperplasin tissues. Thus, telomerase is expected to be a very strong candidate for targeted therapy of prostate cancer. In this study, we synthesized a 19-mer antisense oligonucleotide against the RNA component of human telomerase (hTR) linked to a 2-5A molecule (2-5A-anti-hTR) and examined its cytotoxic effect on prostate cancer cells. The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence. We here show that treatment with 2-5A-anti-hTR in the presence of a cationic liposome reduced cell viability of turner cell lines tested to 9-18% within 6 days, In contrast, normal fibroblast cells mere resistant to the treatment. Its effect was mainly due to induction of apoptosis by activated caspase family members. Furthermore, treatment of subcutaneous tumors in nude mice with 2-SA-anti-hTR significantly suppressed the tumor growth through induction of apoptosis (P < 0.001), The treatment with 2-5A-anti-hTR may be a promising strategy for the treatment modality of prostate cancer with telomerase activity.	CUNY, Mt Sinai Med Ctr, Dept Neurosurg, New York, NY 10029 USA; Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Neurosurg, 1 Gustave L Levy Pl,Box 1136, New York, NY 10029 USA.				NCI NIH HHS [1R01CA80233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, CANCER SURV, V28, P197; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo S, 1996, ONCOGENE, V13, P1279; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Naitoh John, 1998, Cancer Research, V58, P2895; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Sikora K, 1997, BRIT J UROL, V79, P64, DOI 10.1111/j.1464-410X.1997.tb16923.x; Sommerfeld HJ, 1996, CANCER RES, V56, P218; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGO PA, 1995, CA CANC J CLIN, V45, P8030; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	29	80	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2205	2211		10.1038/sj.onc.1203538	http://dx.doi.org/10.1038/sj.onc.1203538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822370				2022-12-25	WOS:000086974100005
J	Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S				Pandey, P; Farber, R; Nakazawa, A; Kumar, S; Bharti, A; Nalin, C; Weichselbaum, R; Kufe, D; Kharbanda, S			Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3	ONCOGENE			English	Article						Hsp27; cytochrome c; caspase-3; apoptosis	HEAT-SHOCK PROTEIN; PROGRAMMED CELL-DEATH; EMBRYONIC STEM-CELLS; ALPHA-B-CRYSTALLIN; CAENORHABDITIS-ELEGANS; PROTEOLYTIC ACTIVATION; ICE/CED-3 PROTEASE; INDUCED APOPTOSIS; CARCINOMA-CELLS; DNA-DAMAGE	The release of mitochondrial cytochrome c by genotoxic stress induces the formation of a cytosolic complex with Apaf-1 (mammalian CED4 homolog) and thereby the activation of procaspase-3 (cas-3) and procaspase-9 (cas-9). Here we demonstrate that heat-shock protein 27 (Hsp27) inhibits cytochrome c (cyt c)-dependent activation of cas-3. Hsp27 had no effect on cyt c release, Apaf-1 and cas-9 activation. By contrast, our results show that Hsp27 associates with cas-3, but not Apaf-1 or cas-9, and inhibits activation of cas-3 by cas-9-mediated proteolysis, Furthermore, the present results demonstrate that immunodepletion of Hsp27 depletes cas-3, Importantly, treatment of cells with DNA damaging agents dissociates the Hsp27/cas-3 complex and relieves inhibition of cas-3 activation. These findings define a novel function for Hsp27 and provide the first evidence that a heat shock protein represses cas-3 activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; University of Chicago	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA075216, R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431, CA75216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MANSER PW, 1999, J BIOL CHEM, V274, P22635; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MING Z, 1993, J BIOL CHEM, V268, P35; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	46	241	253	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					1975	1981		10.1038/sj.onc.1203531	http://dx.doi.org/10.1038/sj.onc.1203531			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803458				2022-12-25	WOS:000086613200001
J	Gao, TY; Bunemann, M; Gerhardstein, BL; Ma, H; Hosey, MM				Gao, TY; Bunemann, M; Gerhardstein, BL; Ma, H; Hosey, MM			Role of the C terminus of the alpha(1C) (Ca(v)1.2) subunit in membrane targeting of cardiac L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; BETA-SUBUNITS; CARBOXYL-TERMINUS; CHARGE MOVEMENT; PROTEIN-KINASE; PHOSPHORYLATION; SITES; INACTIVATION; CALMODULIN; ALPHA(1)-SUBUNIT	We have previously demonstrated that formation of a complex between L-type calcium (Ca2+) channel alpha(1C) (Ca(V)1.2) and beta subunits was necessary to target the channels to the plasma membrane when expressed in tsA201 cells. In the present study, we identified a region in the C terminus of the alpha(1C) subunit that was required for membrane targeting. Using a series of C-terminal deletion mutants of the alpha(1C) subunit, a domain consisting of amino acid residues 1623-1666 ("targeting domain") in the C terminus of the alpha(1C) subunit has been identified to be important for correct targeting of L-type Ca2+ channel complexes to the plasma membrane. Although cells expressing the wild-type alpha(1C) and beta(2a) subunits exhibited punctate clusters of channel complexes along the plasma membrane with little intracellular staining, co-expression of deletion mutants of the alpha(1C) subunit that lack the targeting domain with the beta(2a) subunit resulted in an intracellular localization of the channels. In addition, three other regions in the C terminus of the alpha(1C) subunit that were downstream of residues 1623-1666 were found to contribute to membrane targeting of the L-type channels. Deletion of these domains in the alpha(1C) subunit resulted in a reduction of plasma membrane-localized channels, and a concomitant increase in channels localized intracellularly, Taken together, these results have demonstrated that a targeting domain in the C terminus of the alpha(1C) subunit was required for proper plasma membrane localization of the L-type Ca2+ channels.	Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Northwestern University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Chicago Ave,S215, Chicago, IL 60611 USA.				NHLBI NIH HHS [HL 23306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chien AJ, 1998, J BIOENERG BIOMEMBR, V30, P377, DOI 10.1023/A:1021941706726; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; De Waard M, 1996, Ion Channels, V4, P41; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Neuhuber B, 1998, P NATL ACAD SCI USA, V95, P5015, DOI 10.1073/pnas.95.9.5015; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WEI XY, 1994, J BIOL CHEM, V269, P1635; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	33	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25436	25444		10.1074/jbc.M003465200	http://dx.doi.org/10.1074/jbc.M003465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10816591	hybrid			2022-12-25	WOS:000088849400052
J	Davies, JP; Ioannou, YA				Davies, JP; Ioannou, YA			Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; DISEASE TYPE-C; CHOLESTEROL HOMEOSTASIS; CULTURED FIBROBLASTS; SONIC HEDGEHOG; GENE; DEGRADATION; TRANSPORT; NPC1; NIEMANN-PICK-C1-DISEASE	The Niemann-Pick C1 (NPC1) protein is predicted to be a polytopic glycoprotein, and it contains a region with extensive homology to the sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol regulatory element binding protein cleavage-activating protein (SCAP). To aid the functional characterization of NPC1, a model of NPC1 topology was evaluated by expression of epitope-tagged NPC1 proteins and investigation of epitope accessibility in selectively permeabilized cells. These results were further confirmed by expression of NPC1 and identification of glycosylated domains that are located in the lumen of the endoplasmic reticulum. Our data indicate that this glycoprotein contains 13 transmembrane domains, 3 large and 4 small luminal loops, 6 small cytoplasmic loops, and a cytoplasmic tail. Furthermore, our data show that the putative SSD of NPC1 is oriented in the same manner as those of HMG-R and SCAP, providing strong evidence that this domain is functionally important.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ioannou, YA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, 5th Ave & 100th St, New York, NY 10029 USA.							Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DAHL NK, 1994, J LIPID RES, V35, P1839; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Greer WL, 1998, AM J HUM GENET, V63, P52, DOI 10.1086/301931; Greer WL, 1999, AM J HUM GENET, V65, P1252, DOI 10.1086/302620; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ioannou YA, 1998, BIOCHEM J, V332, P789, DOI 10.1042/bj3320789; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Millat G, 1999, AM J HUM GENET, V65, P1321, DOI 10.1086/302626; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; OGATA S, 1994, J BIOL CHEM, V269, P5210; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Sambrook J., 2002, MOL CLONING LAB MANU; Steinberg SJ, 1996, J INHERIT METAB DIS, V19, P769, DOI 10.1007/BF01799171; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; VANIER MT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P328, DOI 10.1016/0925-4439(91)90069-L; Vanier MT, 1996, AM J HUM GENET, V58, P118; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Yamamoto T, 1999, HUM GENET, V105, P10, DOI 10.1007/s004390051057; [No title captured]	38	227	232	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24367	24374		10.1074/jbc.M002184200	http://dx.doi.org/10.1074/jbc.M002184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821832	hybrid			2022-12-25	WOS:000088683300018
J	Hoffenberg, S; Liu, X; Nikolova, L; Hall, HS; Dai, WP; Baughn, RE; Dickey, BF; Barbieri, MA; Aballay, A; Stahl, PD; Knoll, BJ				Hoffenberg, S; Liu, X; Nikolova, L; Hall, HS; Dai, WP; Baughn, RE; Dickey, BF; Barbieri, MA; Aballay, A; Stahl, PD; Knoll, BJ			A novel membrane-anchored rab5 interacting protein required for homotypic endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; GDP DISSOCIATION INHIBITOR; COILED COILS; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; 2-HYBRID SYSTEM; PLASMA-MEMBRANE; CELL-SURFACE; K562 CELLS; TRANSFERRIN	The ras-related GTPase rab5 is rate-limiting for homotypic early endosome fusion. We used a yeast two-hybrid screen to identify a rab5 interacting protein, rab5ip. The cDNA sequence encodes a ubiquitous 75-kDa protein with an N-terminal transmembrane domain (TM), a central coiled-coil structure, and a C-terminal region homologous to several centrosome-associated proteins. rab5ip lacking the transmembrane domain (rab5ipTM(-)) had a greater affinity in vitro for rab5-guanosine 5'-O-2-(thio)diphosphate than for rab5-guanosine 5'-3-O-(thio)triphosphate. In transfected HeLa cells, rab5ipTM(-) was partly cytosolic and localized (by immunofluorescence) with a rab5 mutant believed to be in a GDP conformation (GFp-rab5(G78A)) but not with GFP-rab5(Q79L), a GTPase-deficient mutant. rab5ip with the transmembrane domain (rab5ipTM(+)) was completely associated with the particulate fraction and localized extensively with GFP-rab5(wt) in punctate endosome-like structures. Overexpression of rab5ipTM(+) using Sindbis virus stimulated the accumulation of fluid-phase horseradish peroxidase by BHK-81 cells, and homotypic endosome fusion in vitro was inhibited by antibody against rab5ip. rab5ipTM(-) inhibited rab5(wt)-stimulated endosome fusion but did not inhibit fusion stimulated by rab5(Q79L). rab5ip represents a novel rab5 interacting protein that may function on endocytic vesicles as a receptor for rab5-GDP and participate in the activation of rab5.	Baylor Coll Med, Dept Med, Div Pulm, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Houston Vet Affairs Med Ctr, Houston, TX 77030 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Washington University (WUSTL)	Knoll, BJ (corresponding author), Univ Houston, Coll Pharm, Dept Pharmcol & Pharmaceut Sci, Bldg SR2,Rm 521D,4800 Calhoun, Houston, TX 77204 USA.	bknoll@uh.edu	Stahl, Philip/D-6315-2012					AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ARAKI S, 1990, J BIOL CHEM, V265, P13007; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Bai C, 1996, METHOD ENZYMOL, V273, P331; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Green EG, 1997, BIOCHEM BIOPH RES CO, V239, P612, DOI 10.1006/bbrc.1997.7520; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HARPER JW, 1993, CELL, V75, P805; HOFFENBERG S, 1995, J BIOL CHEM, V270, P5048, DOI 10.1074/jbc.270.10.5048; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; ISHIKAWA K, 1998, DNA RES, V5, P176; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JIN MJ, 1993, J BIOL CHEM, V268, P18390; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GP, 1993, J BIOL CHEM, V268, P24475; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malone CJ, 1999, DEVELOPMENT, V126, P3171; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SATO S, 1999, DNA RES, V4, P215; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Sung YJ, 1996, J BIOL CHEM, V271, P30537, DOI 10.1074/jbc.271.48.30537; THATTE HS, 1994, J CELL PHYSIOL, V160, P345, DOI 10.1002/jcp.1041600216; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	57	36	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24661	24669		10.1074/jbc.M909600199	http://dx.doi.org/10.1074/jbc.M909600199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818110	hybrid			2022-12-25	WOS:000088683300059
J	Martinez, J; Ren, YG; Thuresson, AC; Hellmann, U; Astrom, J; Virtanen, A				Martinez, J; Ren, YG; Thuresson, AC; Hellmann, U; Astrom, J; Virtanen, A			A 54-kDa fragment of the poly(A)-specific ribonuclease is an oligomeric, processive, and cap-interacting poly(A)-specific 3 ' exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLY(A) BINDING-PROTEIN; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; MAMMALIAN-CELLS; XENOPUS OOCYTES; SYSTEM; DEADENYLATION; DEGRADATION	We have previously identified a HeLa cell 3' exonuclease specific for degrading poly(A) tails of mRNAs, Here we report on the purification and identification of a calf thymus 54-kDa polypeptide associated with a similar 3' exonuclease activity. The 54-kDa polypeptide was shown to be a fragment of the poly(A)-specific ribonuclease 74-kDa polypeptide. The native molecular mass of the nuclease activity was estimated to be 180-220 kDa, Protein/protein cross-linking revealed an oligomeric structure, most likely consisting of three subunits. The purified nuclease activity released 5'-AMP as the reaction product and degraded poly(A) in a highly processive fashion. The activity required monovalent cations and was dependent on divalent metal ions. The RNA substrate requirement was investigated, and it was found that the nuclease was highly poly(A)-specific and that only 3' end-located poly(A) was degraded by the activity. RNA substrates capped with m(7)G(5')ppp(5')G were more efficiently degraded than noncapped RNA substrates. Addition of free m7G(5')ppp(5')G cap analogue inhibited poly(A) degradation in vitro, suggesting a functional link between the RNA 5' end cap structure and poly(A) degradation at the 3' end of the RNA.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Amersham Pharmacia Biotech, SE-75125 Uppsala, Sweden	Uppsala University; Ludwig Institute for Cancer Research	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se		Martinez, Javier/0000-0001-9152-7323				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BACHMANN M, 1984, FEBS LETT, V171, P25, DOI 10.1016/0014-5793(84)80453-6; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Hellman U, 1997, SPRING LAB MAN, P97; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Virtanen A, 1997, Prog Mol Subcell Biol, V18, P199; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x	40	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24222	24230		10.1074/jbc.M001705200	http://dx.doi.org/10.1074/jbc.M001705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801819	hybrid			2022-12-25	WOS:000088564200109
J	Nicole, P; Lins, L; Rouyer-Fessard, C; Drouot, C; Fulcrand, P; Thomas, A; Couvineau, A; Martinez, J; Brasseur, R; Laburthe, M				Nicole, P; Lins, L; Rouyer-Fessard, C; Drouot, C; Fulcrand, P; Thomas, A; Couvineau, A; Martinez, J; Brasseur, R; Laburthe, M			Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC(1) and VPAC(2) receptors and development of a highly selective VPAC(1) receptor agonist - Alanine scanning and molecular modeling of the peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-COUPLED RECEPTORS; HUMAN VIP1 RECEPTOR; GILA MONSTER VENOM; ADENYLATE-CYCLASE; CAMP PRODUCTION; LIGAND-BINDING; AMINO-ACIDS; SECRETIN; FAMILY	The widespread neuropeptide vasoactive intestinal peptide (VIP) has two receptors VPAC(1) and VPAC(2). Solid-phase syntheses of VIP analogs in which each amino acid has been changed to alanine (Ala scan) or glycine was achieved and each analog was tested for: (i) three-dimensional structure by ab initio molecular modeling; (ii) ability to inhibit I-125-VIP binding (K-i) and to stimulate adenylyl cyclase activity (EC50) in membranes from cell clones stably expressing human recombinant VPAC(1) or VPAC(2) receptor. The data show that substituting residues at 14 positions out of 28 in VIP resulted in a > 10-fold increase of K-i or EC50 at the VPAC(1) receptor. Modeling of the three-dimensional structure of native VIP (central alpha-helice from Val(5) to Asn(24) with random coiled N and C terminus) and analogs shows that substitutions of His(1), Val(5), Arg(14), Lys(15), Lys(21), Leu(23), and Ile(26) decreased biological activity without altering the predicted structure, supporting that those residues directly interact with VPAC(1) receptor. The interaction of the analogs with human VPAC(2) receptor is similar to that observed with VPAC(1) receptor, with three remarkable exceptions: substitution of Thr(11) and Asn(28) by alanine increased K-i for binding to VPAC(2) receptor; substitution of Tyr(22) by alanine increased EC50 for stimulating adenylyl cyclase activity through interaction with the VPAC(2) receptor. By combining 3 mutations at positions 11, 22, and 28, we developed the [Ala(11,22,28)]VIP analog which constitutes the first highly selective (>1,000-fold) human VPAC(1) receptor agonist derived from VIP ever described.	Univ Paris 07, INSERM, U410, Unite Neuroendocrinol & Biol Cellulaire Digest, F-75018 Paris, France; Univ Montpellier I, Fac Med, CNRS, UMR 5810, F-34060 Montpellier, France; Univ Montpellier 2, Fac Pharm, F-34060 Montpellier, France; Fac Sci Agron Etat Gembloux, Ctr Biophys Mol Numer, B-5030 Gembloux, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; University of Liege	Laburthe, M (corresponding author), Univ Paris 07, INSERM, U410, Unite Neuroendocrinol & Biol Cellulaire Digest, F-75018 Paris, France.	laburthe@bichat.peptide	couvineau, alain/T-3466-2019; LINS, LAURENCE/Y-1661-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013; Martinez, Jean/R-9421-2019	couvineau, alain/0000-0003-2912-5168; LINS, LAURENCE/0000-0001-7772-6748; couvineau, alain/0000-0003-2912-5168; Martinez, Jean/0000-0002-9267-4621				AMIRANOFF B, 1983, FEBS LETT, V164, P299, DOI 10.1016/0014-5793(83)80305-6; Ando E, 1996, Biomed Pept Proteins Nucleic Acids, V2, P41; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Barany G., 1992, PEPTIDES CHEM BIOL, P603; Benhabiles N, 1998, J COMPUT BIOL, V5, P351, DOI 10.1089/cmb.1998.5.351; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BOLIN DR, 1996, DRUG DES DISCOV, V3, P107; BRADFORD M, 1979, ANAL BIOCHEM, V78, P248; BRASSEUR R, 1995, J MOL GRAPH MODEL, V13, P312, DOI 10.1016/0263-7855(95)00052-6; CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201; COUVINEAU A, 1984, BIOCHEM BIOPH RES CO, V121, P493, DOI 10.1016/0006-291X(84)90209-2; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dickinson T, 1999, TRENDS PHARMACOL SCI, V20, P324, DOI 10.1016/S0165-6147(99)01340-1; DOURTOGLOU V, 1984, SYNTHESIS-STUTTGART, P572, DOI 10.1055/s-1984-30895; DU BH, 1985, BIOCHEM BIOPH RES CO, V128, P1093, DOI 10.1016/0006-291X(85)91052-6; Du K, 1997, BIOCHEM BIOPH RES CO, V230, P289, DOI 10.1006/bbrc.1996.5949; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gaudin P, 1996, EUR J PHARMACOL, V302, P207, DOI 10.1016/0014-2999(96)00096-9; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gozes I, 1999, CURR MED CHEM, V6, P1019; Gozes I, 1999, P NATL ACAD SCI USA, V96, P4143, DOI 10.1073/pnas.96.7.4143; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOSHINO M, 1984, FEBS LETT, V178, P233, DOI 10.1016/0014-5793(84)80607-9; Juarranz MG, 1999, EUR J BIOCHEM, V265, P449, DOI 10.1046/j.1432-1327.1999.00769.x; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Knudsen SM, 1998, ANN NY ACAD SCI, V865, P259, DOI 10.1111/j.1749-6632.1998.tb11186.x; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LABURTHE M, 1988, ANN NY ACAD SCI, V527, P296; Laburthe M, 1999, CONT ENDOCRINOL, V8, P125; LABURTHE M, 1986, MOL PHARMACOL, V29, P23; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; Lutz EM, 1999, BRIT J PHARMACOL, V128, P934, DOI 10.1038/sj.bjp.0702872; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; Moody TW, 1997, LIFE SCI, V61, P1657, DOI 10.1016/S0024-3205(97)00771-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUSSO GF, 1988, BIOCHEMISTRY-US, V27, P8174, DOI 10.1021/bi00421a028; MUTT V, 1988, ANN NY ACAD SCI, V527, P1; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; OTTAWAY CA, 1992, J NEUROIMMUNOL, V39, P49, DOI 10.1016/0165-5728(92)90173-I; RAHMAN M, 1994, J MOL GRAPHICS, V12, P212, DOI 10.1016/0263-7855(94)80090-1; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SAID SI, 1998, LUNG BIOL HEALTH DIS, V112, P345; SVOBODA M, 1994, BIOCHEM BIOPH RES CO, V205, P1617, DOI 10.1006/bbrc.1994.2852; THERIAULT Y, 1991, BIOPOLYMERS, V31, P459, DOI 10.1002/bip.360310411; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; UNSON CG, 1994, J BIOL CHEM, V269, P12548; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016	59	143	158	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24003	24012		10.1074/jbc.M002325200	http://dx.doi.org/10.1074/jbc.M002325200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801840	hybrid			2022-12-25	WOS:000088564200083
J	Wei, Y; Chen, J; Rosas, G; Tompkins, DA; Holt, PA; Rao, R				Wei, Y; Chen, J; Rosas, G; Tompkins, DA; Holt, PA; Rao, R			Phenotypic screening of mutations in Pmr1, the yeast secretory pathway Ca2+/Mn2+-ATPase, reveals residues critical for ion selectivity and transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CA2+ BINDING; DOMAIN; CA2+-ATPASE; GOLGI; NA,K-ATPASE; PUMP; SER(775)	Thirty-five mutations were generated in the yeast secretory pathway/Golgi ion pump, Pmr1, targeting oxygen-containing side chains within the predicted transmembrane segments M4, M5, M6, M7, and M8, likely to be involved in coordination of Ca2+ and Mn2+ ions. Mutants were expressed in low copy number in a yeast strain devoid of endogenous Ca2+ pumps and screened for loss of Ca2+ and Mn2+ transport on the basis of hypersensitivity to 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraaceetic acid (BAPTA) and Mn2+ toxicity, respectively. Three classes of mutants were found: mutants indistinguishable from wild type (Class 1), mutants indistinguishable from the pmr1 null strain (Class 2), and mutants with differential sensitivity to BAPTA and Mn2+ toxicity (Class 3), We show that Class 1 mutants retain normal/near normal properties, including Ca-45 transport, Golgi localization, and polypeptide conformation. In contrast, Class 2 mutants lacked any detectable Ca-45 transport; of these, a subset also showed defects in trafficking and protein folding, indicative of structural problems. Two residues identified as Class 2 mutants in this screen, Asn(774) and Asp(778) in MG, also play critical roles in related ion pumps and are therefore likely to be common architectural components of the cation-binding site. Class 3 mutants appear to have altered selectivity for Ca2+ and Mn2+ ions, as exemplified by mutant Q783A in MG. These results demonstrate the utility of phenotypic screening in the identification of residues critical for ion transport and selectivity in cation pumps.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu		Tompkins, David/0000-0002-2112-2299	NIGMS NIH HHS [GM52414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; Ambesi A, 1998, ACTA PHYSIOL SCAND, V163, P107; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HAMA H, 1994, J BIOL CHEM, V269, P1063; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLennan DH, 1997, ANN NY ACAD SCI, V834, P175, DOI 10.1111/j.1749-6632.1997.tb52249.x; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Sen Gupta S, 1998, J BIOL CHEM, V273, P34328; Sorin A, 1997, J BIOL CHEM, V272, P9895; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	26	56	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23927	23932		10.1074/jbc.M002618200	http://dx.doi.org/10.1074/jbc.M002618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801855	hybrid			2022-12-25	WOS:000088564200072
J	Zhao, JS; Shi, W; Chen, H; Warburton, D				Zhao, JS; Shi, W; Chen, H; Warburton, D			Smad7 and Smad6 differentially modulate transforming growth factor beta-induced inhibition of embryonic lung morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; N-MYC EXPRESSION; TGF-BETA; BRANCHING MORPHOGENESIS; ORGAN-CULTURES; RAT LUNG; RECEPTOR; ANTAGONIST; FIBROSIS; GROWTH-FACTOR-BETA-1	Transforming growth factors B (TGF-beta) are known negative regulators of lung development, and excessive TGF-beta production has been noted in pulmonary hypoplasia associated with lung fibrosis, Inhibitory Smad7 was recently identified to antagonize TGF-beta family signaling by interfering with the activation of TGF-beta signal-transducing Smad complexes. To investigate whether Smad7 can regulate TGF-beta-induced inhibition of lung morphogenesis, ectopic overexpression of Smad7 was introduced into embryonic mouse lungs in culture using a recombinant adenovirus containing Smad7 cDNA. Although exogenous TGF-beta efficiently reduced epithelial lung branching morphogenesis in control virus-infected lung culture, TGF-beta-induced branching inhibition was abolished after epithelial transfer of the Smad7 gene into lungs in culture. Smad7 also prevented TGF-beta-mediated down-regulation of surfactant protein C gene expression, a marker of bronchial epithelial differentiation, in cultured embryonic lungs. Moreover, we found that Smad7 transgene expression blocked Smad2 phosphorylation induced by exogenous TGF-beta ligand in lung culture, indicating that Smad7 exerts its inhibitory effect on both lung growth and epithelial cell differentiation through modulation of TGF-beta pathway-restricted Smad activity. However, the above anti-TGF-beta signal transduction effects were not observed in cultured embryonic lungs with Smad6 adenoviral gene transfer, suggesting that Smad7 and Smad6 differentially regulate TGF-beta signaling in developing lungs. Our data therefore provide direct evidence that Smad7, but not Smad6, prevents TGF-beta-mediated inhibition of both lung branching morphogenesis and cytodifferentiation, establishing the mechanistic basis for Smad7 as a novel target to ameliorate aberrant TGF-beta signaling during lung development, injury, and repair.	Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Childrens Hosp Los Angeles, Res Inst, Dept Surg, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Dev Biol Program, Los Angeles, CA 90027 USA	University of Southern California; Children's Hospital Los Angeles; Children's Hospital Los Angeles	Zhao, JS (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA 103, Los Angeles, CA 90033 USA.		Warburton, David/AAD-5709-2020		NHLBI NIH HHS [HL44977, HL44060, HL61286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061286, R01HL044977, R01HL044060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baldwin HS, 1997, GENE THER, V4, P1142, DOI 10.1038/sj.gt.3300525; Bitzer M, 2000, GENE DEV, V14, P187; BLANCO LN, 1993, PEDIATR RES, V34, P334, DOI 10.1203/00006450-199309000-00019; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771; Kotecha S, 1996, J PEDIATR-US, V128, P464, DOI 10.1016/S0022-3476(96)70355-4; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; SERRA R, 1995, DEVELOPMENT, V121, P3057; SERRA R, 1994, DEVELOPMENT, V120, P2153; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhao JS, 1998, MECH DEVELOP, V72, P89, DOI 10.1016/S0925-4773(98)00019-7; Zhao JS, 1998, DEV BIOL, V194, P182, DOI 10.1006/dbio.1997.8825; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298; Zhao JS, 2000, MECH DEVELOP, V93, P71, DOI 10.1016/S0925-4773(00)00281-1; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	37	68	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23992	23997		10.1074/jbc.M002433200	http://dx.doi.org/10.1074/jbc.M002433200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801843	hybrid			2022-12-25	WOS:000088564200081
J	Bingham, R; Ekunwe, SIN; Falk, S; Snyder, L; Kleanthous, C				Bingham, R; Ekunwe, SIN; Falk, S; Snyder, L; Kleanthous, C			The major head protein of bacteriophage T4 binds specifically to elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-TU; ESCHERICHIA-COLI; TRANSFER RNA; CELL-DEATH; TRANSLATION; KIRROMYCIN; EFFECTOR; COMPLEX; PEPTIDE; REGION	Lit protease in Escherichia coli K-12 strains induces cell death in response to bacteriophage T4 infection by cleaving translation elongation factor (EF) Tu and shutting down translation. Suicide of the cell is timed to the appearance late in the maturation of the phage of a short peptide sequence in the major head protein, the Gol peptide, which activates proteolysis. In the present work we demonstrate that the Gol peptide binds specifically to domains II and III of EF-Tu, creating the unique substrate for the Lit protease, which then cleaves domain I, the guanine nucleotide binding domain. The conformation of EF-Tu is important for binding and Lit cleavage, because both are sensitive to the identity of the bound nucleotide, with GDP being preferred over GTP. We propose that association of the T4 coat protein with EF-Tu plays a role in phage head assembly but that this association marks infected cells for suicide when Lit is present. Based on these data and recent observations on human immunodeficiency virus type 1 maturation, we speculate that associations between host translation factors and coat proteins may be integral to viral assembly in both prokaryotes and eukaryotes.	Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	Michigan State University; University of East Anglia	Snyder, L (corresponding author), Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; ARAI KI, 1976, J BIOCHEM, V79, P69, DOI 10.1093/oxfordjournals.jbchem.a131060; BASCHONG W, 1988, J ULTRA MOL STRUCT R, V99, P189, DOI 10.1016/0889-1605(88)90063-8; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERGSLAND KJ, 1990, J MOL BIOL, V213, P477, DOI 10.1016/S0022-2836(05)80209-8; Black Lindsay W., 1994, P218; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V228, P748; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; Cetin R, 1998, BIOCHEMISTRY-US, V37, P486, DOI 10.1021/bi970443o; CHAMPNESS WC, 1982, J MOL BIOL, V155, P395, DOI 10.1016/0022-2836(82)90478-8; Cimarelli A, 1999, J VIROL, V73, P5388, DOI 10.1128/JVI.73.7.5388-5401.1999; Das T, 1998, P NATL ACAD SCI USA, V95, P1449, DOI 10.1073/pnas.95.4.1449; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; Georgiou T, 1998, P NATL ACAD SCI USA, V95, P2891, DOI 10.1073/pnas.95.6.2891; Georgopoulos Costa P., 1994, P213; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; KAO C, 1987, J BACTERIOL, V69, P1232; Kawaguchi Y, 1997, J VIROL, V71, P1019, DOI 10.1128/JVI.71.2.1019-1024.1997; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; LIPPMANN C, 1993, J BIOL CHEM, V268, P601; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; Monod C, 1997, J MOL BIOL, V267, P237, DOI 10.1006/jmbi.1996.0867; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; PINGOUD A, 1982, EUR J BIOCHEM, V123, P261, DOI 10.1111/j.1432-1033.1982.tb19762.x; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SNYDER L, 1995, MOL MICROBIOL, V15, P415, DOI 10.1111/j.1365-2958.1995.tb02255.x; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; Swanstrom R., 1997, P263; VANNOORT JM, 1986, EUR J BIOCHEM, V160, P557; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WITTINGHOFER A, 1980, EUR J BIOCHEM, V108, P423, DOI 10.1111/j.1432-1033.1980.tb04738.x; WOLF H, 1974, P NATL ACAD SCI USA, V71, P4910, DOI 10.1073/pnas.71.12.4910; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; YU YTN, 1994, P NATL ACAD SCI USA, V91, P802, DOI 10.1073/pnas.91.2.802	40	31	33	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23219	23226		10.1074/jbc.M002546200	http://dx.doi.org/10.1074/jbc.M002546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801848	hybrid			2022-12-25	WOS:000088419400085
J	Chen, MG; Zhang, ZM; Tawiah-Boateng, MA; Hardwicke, PMD				Chen, MG; Zhang, ZM; Tawiah-Boateng, MA; Hardwicke, PMD			A Ca2+-dependent tryptic cleavage site and a protein kinase A phosphorylation site are present in the Ca2+ regulatory domain of scallop muscle Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; SARCOPLASMIC-RETICULUM; ADDUCTOR MUSCLE; SMOOTH-MUSCLE; CLONING; ATPASE; HEART; PURIFICATION; ACID; IDENTIFICATION	Digestion of scallop muscle membrane fractions with trypsin led to release of soluble polypeptides derived from the large cytoplasmic domain of a Na+-Ca2+ exchanger. In the presence of 1 mM Ca2+, the major product was a peptide of similar to 37 kDa, with an N terminus corresponding to residue 401 of the NCX1 exchanger. In the presence of 10 mM EGTA, similar to 16- and similar to 19-kDa peptides were the major products. Polyclonal rabbit IgG raised against the 37-kDa peptide also bound to the 16- and 19-kDa soluble tryptic peptides and to a 105-110-kDa polypeptide in the undigested membrane preparation. The 16 kDa fragment corresponded to the N-terminal part of the 37-kDa peptide. The conformation of the precursor polypeptide chain in the region of the C terminus of the 16-kDa tryptic peptide was thus altered by the binding of Ca2+. Phosphorylation of the parent membranes with the catalytic subunit of protein kinase A and [gamma-P-32]ATP led to incorporation of P-32 into the 16-and 37-kDa soluble fragments. A site may exist within the Ca2+ regulatory domain of a scallop muscle Na+- Ca2+ exchanger that mediates direct modulation of secondary Ca2+ regulation by cAMP.	So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Hardwicke, PMD (corresponding author), So Illinois Univ, Dept Biochem & Mol Biol, Mail Code 4413, Carbondale, IL 62901 USA.	phardwicke@siumed.edu						BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CASTELLANI L, 1983, J CELL BIOL, V97, P557, DOI 10.1083/jcb.97.2.557; CHEON J, 1988, J BIOL CHEM, V263, P2309; Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; COX DA, 1993, TRENDS PHARMACOL SCI, V14, P408, DOI 10.1016/0165-6147(93)90063-P; DIPOLO R, 1994, SCIENCE, V266, pC1382; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; DURKIN JT, 1991, ANN NY ACAD SCI, V639, P189, DOI 10.1111/j.1749-6632.1991.tb17306.x; Hardwicke PMD, 1999, BBA-BIOMEMBRANES, V1417, P1, DOI 10.1016/S0005-2736(98)00241-7; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P229, DOI 10.1007/BF01739813; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; He ZP, 1998, J GEN PHYSIOL, V111, P857, DOI 10.1085/jgp.111.6.857; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; KALABOKIS VN, 1993, BIOCHEMISTRY-US, V32, P4389, DOI 10.1021/bi00067a031; KALABOKIS VN, 1993, BIOCHIM BIOPHYS ACTA, V1147, P35, DOI 10.1016/0005-2736(93)90313-O; KALABOKIS VN, 1991, J BIOL CHEM, V266, P22044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; Lederer WJ, 1996, ANN NY ACAD SCI, V779, P7, DOI 10.1111/j.1749-6632.1996.tb44764.x; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI WH, 1992, J BIOL CHEM, V267, P17983; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOESSER KE, 1992, J MUSCLE RES CELL M, V13, P161, DOI 10.1007/BF01874153; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NUNZI MG, 1981, J ULTRA MOL STRUCT R, V76, P134, DOI 10.1016/S0022-5320(81)80012-3; Philipson K D, 1993, Int Rev Cytol, V137C, P199; Philipson KD, 1996, ANN NY ACAD SCI, V779, P20, DOI 10.1111/j.1749-6632.1996.tb44766.x; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REEVES JP, 1994, J EXP BIOL, V196, P375; Ruknudin A, 1997, AM J PHYSIOL-CELL PH, V273, pC257, DOI 10.1152/ajpcell.1997.273.1.C257; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shi X, 1998, COMP BIOCHEM PHYS B, V120, P359, DOI 10.1016/S0305-0491(98)10025-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22961	22968		10.1074/jbc.M001743200	http://dx.doi.org/10.1074/jbc.M001743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816565	hybrid			2022-12-25	WOS:000088419400050
J	Matthews, RT; Gary, SC; Zerillo, C; Pratta, M; Solomon, K; Arner, EC; Hockfield, S				Matthews, RT; Gary, SC; Zerillo, C; Pratta, M; Solomon, K; Arner, EC; Hockfield, S			Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; CHONDROITIN SULFATE PROTEOGLYCAN; AGGRECAN-DEGRADING ACTIVITY; C-TERMINAL DOMAIN; MONOCLONAL-ANTIBODIES; PROTEIN BEHAB; RAT-BRAIN; BREVICAN; CLONING; EXPRESSION	Brain-enriched hyaluronan binding (BERAB)/brevican is a brain-specific extracellular matrix protein containing a cleavage site between Glu(395)-Ser(396), which bears remarkable homology to the "aggrecanase" site in the cartilage proteoglycan aggrecan. Expression of BEHAB/brevican is dramatically increased in human gliomas, notoriously invasive tumors. Recently, we showed that the rat 9L gliosarcoma cell line, which does not express BEHAB/brevican and forms non-invasive tumors when grown as intracranial grafts, can form invasive tumors when transfected with a 5' cDNA fragment of BEHAB/brevican, but not when transfected with the full-length cDNA, In marked contrast, the highly invasive CNS-1 glioma cell line expresses and cleaves BEHAB/brevican protein when grown as an intracranial graft. These results suggest that both synthesis and cleavage of BEHAB/brevican protein may play a role in the invasiveness of gliomas. We report here, using an antibody developed to the neoepitope created by BEHAB/brevican cleavage at the Glu(395)-Ser(396) site, that the CNS-1 cells are able to cleave the protein in vitro. We characterized the CNS-1 derived cleavage activity by assaying its ability to cleave BEHAB/brevican proteoglycan, and determined that the enzyme is a constitutively expressed, secreted activity. Using a variety of protease inhibitors, reverse transcriptase-polymerase chain reaction, and specific antibodies, we determined that this activity is likely to be a member of the ADAMTS family of metalloproteinases, specifically ADAMTS4. These results suggest a novel function for ADAMTS family members in BEHAB/brevican cleavage and glioma and indicate that inhibition of ADAMTS in glioma may provide a novel therapeutic strategy.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06520 USA; Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA	Yale University; DuPont	Matthews, RT (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, SHM C-405,333 Cedar St, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035228] Funding Source: NIH RePORTER; NINDS NIH HHS [T32NS207224, R01NS35228] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; Billington CJ, 1998, BIOCHEM J, V336, P207, DOI 10.1042/bj3360207; CAMPION C, 1989, PCTGB8903199; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; Gary SC, 1998, CURR OPIN NEUROBIOL, V8, P576, DOI 10.1016/S0959-4388(98)80083-4; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; JAWORSKI DM, 1995, J NEUROSCI, V15, P1352; Jaworski DM, 1996, CANCER RES, V56, P2293; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; XUE CB, 1997, Patent No. 9718207; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 1996, PERSPECT DEV NEUROBI, V3, P307; Zhang H, 1998, J NEUROSCI, V18, P2370	25	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22695	22703		10.1074/jbc.M909764199	http://dx.doi.org/10.1074/jbc.M909764199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801887	hybrid			2022-12-25	WOS:000088419400016
J	Weaver, AJ; Sullivan, WP; Felts, SJ; Owen, BAL; Toft, DO				Weaver, AJ; Sullivan, WP; Felts, SJ; Owen, BAL; Toft, DO			Crystal structure and activity of human p23, a heat shock protein 90 co-chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR; HSP90; COMPLEXES; HETEROCOMPLEXES; COCHAPERONE; INTERACTS; BINDING; MODELS; ERRORS; MAPS	p23 is a co-chaperone for the heat shock protein, hsp90. This protein binds hsp90 and participates in the folding of a number of cell regulatory proteins, but its activities are still unclear. We have solved a crystal structure of human p23 lacking 35 residues at the COOH terminus. The structure reveals a disulfide-linked dimer with each subunit containing eight beta-strands in a compact antiparallel beta-sandwich fold, In solution, however, p23 is primarily monomeric and the dimer appears to be a minor component. Conserved residues are clustered on one face of the monomer and define a putative surface region and binding pocket for interaction(s) with hsp90 or protein substrates, p23 contains a COOH-terminal tail that is apparently less structured and is unresolved in the crystal structure, This tail is not needed for the binding of pas to hsp90 or to complexes with the progesterone receptor. However, the tail is necessary for optimum active chaperoning of the progesterone receptor, as well as the passive chaperoning activity of p23 in assays measuring inhibition of heat-induced protein aggregation.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; HKL Res Inc, Ithaca, NY 14853 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st SW, Rochester, MN 55905 USA.	toft.david@mayo.edu	Owen, Barbara/AAD-2322-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR VERSION 3 1; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASTILLA LH, 1995, THESIS U MICHIGAN; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNIGHT S, 1989, THESIS SWEDISH U AGR; Knoblauch R, 1999, MOL CELL BIOL, V19, P3748; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Munoz MJ, 1999, GENETICS, V153, P1561; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Zhang XY, 1996, FEBS LETT, V392, P179, DOI 10.1016/0014-5793(96)00810-1	41	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23045	23052		10.1074/jbc.M003410200	http://dx.doi.org/10.1074/jbc.M003410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811660	hybrid			2022-12-25	WOS:000088419400060
J	Ilan, N; Cheung, L; Pinter, E; Madri, JA				Ilan, N; Cheung, L; Pinter, E; Madri, JA			Platelet-endothelial cell adhesion molecule-1 (CD31), a scaffolding molecule for selected catenin family members whose binding is mediated by different tyrosine and serine/threonine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSENDOTHELIAL MIGRATION; TUBE FORMATION; PECAM-1 CD31; CYCLIN D1; IN-VITRO; DESMOPLAKIN; PROTEIN; PLAKOGLOBIN; JUNCTIONS	Platelet-endothelial cell adhesion molecule (PECAM)-1 is a 130-kDa glycoprotein commonly used as an endothelium-specific marker. Evidence to date suggests that PECAM-1 is more than just an endothelial cell. marker but is intimately involved in signal transduction pathways. This is mediated in part by phosphorylation of specific tyrosine residues within the ITAM domain of PECAM-1 and by recruitment of adapter and signaling molecules. Recently we demonstrated that PECAM-1/beta-catenin association functions to regulate beta-catenin localization and, moreover, to modulate beta-catenin tyrosine phosphorylation levels. Here we show that: 1) not only beta-catenin, but also gamma-catenin is associated with PECAM-1 in vitro and in vivo; 2) PKC enzyme directly phosphorylates purified PECAM-1; 3) PKC-derived PECAM-1 serine/threonine phosphorylation inversely correlates with gamma-catenin association; 4) PECAM-1 recruits gamma-catenin to cell-cell junctions in transfected SW480 cells; and 5) gamma-catenin may recruit PECAM-1 into an insoluble cytoskeletal fraction. These data further support the concept that PECAM-1 functions as a binder and modulator of catenins and provides a molecular mechanism for previously reported PECAM-1/cytoskeleton interactions.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St,POB 208023, New Haven, CT 06520 USA.	joseph.madri@yale.edu			NHLBI NIH HHS [R37-HL28373] Funding Source: Medline; NIDDK NIH HHS [P01-DK38979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Duncan GS, 1999, J IMMUNOL, V162, P3022; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 1999, J CELL SCI, V112, P3005; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kim CS, 1998, LAB INVEST, V78, P583; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LASTRES P, 1994, J IMMUNOL, V153, P4206; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MAHOOTI S, 2000, IN PRESS AM J PATHOL; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsumura T, 1997, J IMMUNOL, V158, P3408; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; OBESO J, 1990, LAB INVEST, V63, P259; Orsulic S, 1999, J CELL SCI, V112, P1237; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Pellegatta F, 1998, J BIOL CHEM, V273, P27768, DOI 10.1074/jbc.273.43.27768; Pinter E, 1999, AM J PATHOL, V154, P1367, DOI 10.1016/S0002-9440(10)65391-6; Pinter E, 1997, AM J PATHOL, V150, P1523; Pumphrey NJ, 1999, FEBS LETT, V450, P77, DOI 10.1016/S0014-5793(99)00446-9; Rattan V, 1996, AM J PHYSIOL-ENDOC M, V271, pE711, DOI 10.1152/ajpendo.1996.271.4.E711; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; Schnittler HJ, 1998, BASIC RES CARDIOL, V93, P30; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Sultana C, 1999, J CELL PHYSIOL, V179, P67, DOI 10.1002/(SICI)1097-4652(199904)179:1<67::AID-JCP9>3.0.CO;2-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Valiron O, 1996, J CELL SCI, V109, P2141; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808	53	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21435	21443		10.1074/jbc.M001857200	http://dx.doi.org/10.1074/jbc.M001857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801826	hybrid			2022-12-25	WOS:000088230600065
J	Liadaki, KN; Liu, T; Xu, SZ; Ishida, BY; Duchateaux, PN; Krieger, JP; Kane, J; Krieger, M; Zannis, VI				Liadaki, KN; Liu, T; Xu, SZ; Ishida, BY; Duchateaux, PN; Krieger, JP; Kane, J; Krieger, M; Zannis, VI			Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I - Effect of lipid association and APOA-I mutations on receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; ONE-STEP PURIFICATION; NI-NTA RESIN; SR-BI; HEPATIC LIPASE; TANGIER-DISEASE; CASSETTE TRANSPORTER-1; RECOMBINANT PROTEINS; MEDIATED ENDOCYTOSIS	The binding of apoA-I-containing ligands to the HDL receptor scavenger receptor class B type I (SR-BI) was characterized using two different assays. The first employed conventional binding or competition assays with I-125-labeled ligands. The second is a new nonradioactive ligand binding assay, in which the receptor-associated ligand is detected by quantitative immunoblotting ("immunoreceptor assay"). Using both methods, we observed that the K-d value for spherical HDL (density = 1.1-1.13 g/ml) was similar to 16 mu g of protein/ml, while the values for discoidal reconstituted HDL (rHDL) containing proapoA-I or plasma apoA-I were substantially lower (similar to 0.4-5 mu g of protein/ml). We also observed reduced affinity and/or competition for spherical I-125-HDL cell association by higher relative to lower density HDL and very poor competition by lipid-free apoA-I and pre-beta-1 HDL. Deletion of either 58 carboxyl-terminal or 59 amino-terminal residues from apoA-I, relative to full-length control apoA-I, resulted in little or no change in the affinity of corresponding rHDL particles. However, rHDL particles containing a double mutant lacking both terminal domains competed poorly with spherical I-125-HDL for binding to SR-BI. These findings suggest an important role for apoA-I and its conformation/organization within particles in mediating HDL binding to SR-BI and indicate that the NH2 and COOH termini of apoA-I directly or indirectly contribute independently to binding to SR-BI.	Boston Univ, Med Ctr, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; Univ Crete, Dept Biochem, Heraklion 71110, Crete, Greece; Univ Crete, Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Calif San Francisco, Sch Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Boston University; University of Crete; University of Crete; Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Zannis, VI (corresponding author), Boston Univ, Med Ctr, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, W-509, Boston, MA 02118 USA.		Krieger, Marco/AAE-8611-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048739, P01HL041484, R01HL052212] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL41484, HL48739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON S, 1993, J BIOL CHEM, V268, P3530; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson D., 1995, FOCUS, V17, P53; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; BARKIA A, 1991, ATHEROSCLEROSIS, V87, P135, DOI 10.1016/0021-9150(91)90016-V; BATSCH JR, 1986, METHOD ENZYMOL, V129, P3; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; Collet X, 1999, J LIPID RES, V40, P1185; Crowe J, 1995, MOL BIOTECHNOL, V4, P247, DOI 10.1007/BF02779018; Crowe J, 1996, Methods Mol Biol, V58, P491; DASHTI N, 1989, BIOCHEM BIOPH RES CO, V163, P574, DOI 10.1016/0006-291X(89)92176-1; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; Foger B, 1999, J BIOL CHEM, V274, P36912, DOI 10.1074/jbc.274.52.36912; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hammad SM, 1999, P NATL ACAD SCI USA, V96, P10158, DOI 10.1073/pnas.96.18.10158; ISHIDA BY, 1990, J LIPID RES, V31, P227; JAMES RW, 1989, BIOCHIM BIOPHYS ACTA, V1002, P292, DOI 10.1016/0005-2760(89)90343-3; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KARATHANASIS SK, 1985, BIOCH BIOL PLASMA PR, V11, P475; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; Lambert G, 1999, J LIPID RES, V40, P1294; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MATZ CE, 1982, J BIOL CHEM, V257, P4535; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; NOWICKA G, 1990, J LIPID RES, V31, P1947; OConnor PM, 1997, ANAL BIOCHEM, V251, P234, DOI 10.1006/abio.1997.2258; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SorciThomas MG, 1996, J LIPID RES, V37, P673; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Thuahnal ST, 1999, CIRCULATION, V100, P37; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; VANLOO B, 1995, J LIPID RES, V36, P1686; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Xu SZ, 1997, J LIPID RES, V38, P1289; ZANNIS VI, 1983, P NATL ACAD SCI-BIOL, V80, P2574, DOI 10.1073/pnas.80.9.2574; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	82	131	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21262	21271		10.1074/jbc.M002310200	http://dx.doi.org/10.1074/jbc.M002310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801839	hybrid			2022-12-25	WOS:000088230600042
J	Kubota, H; Sakaki, Y; Ito, T				Kubota, H; Sakaki, Y; Ito, T			GI domain-mediated association of the eukaryotic initiation factor 2 alpha kinase GCN2 with its activator GCN1 is required for general amino acid control in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; PHAGOCYTE NADPH OXIDASE; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; EIF-2-ALPHA KINASE; DROSOPHILA-MELANOGASTER; TRANSLATION INITIATION; EIF2-ALPHA KINASE; HOMOLOG; EXPRESSION	In response to the starvation of a single amino acid, the budding yeast Saccharomyces cerevisiae activates numerous genes involved in various amino acid biosynthetic pathways, all of which are under the control of transcription factor GCN4. This general amino acid control response is based on de-repressed translation of GCN4 mRNA, which is induced by the activation of the eIF2 alpha kinase, GCN2. Although it is known that in vivo activation of GCN2 requires GCN1, the mode of GCN1 action remains to be elucidated at the molecular level. Here, we show that GCN2 interacts with GCN1 via the GI domain, a novel protein-binding module that occurs at the N terminus; mutations to conserved residues of this domain abolish its binding to GCN1. Furthermore, the yeast cells with GCN2 defective in interaction with GCN1 fail to display general control response. A similar phenotype is observed in cells overexpressing the GI domain of GCN2 or its target region on GCN1, Thus, GI domain-mediated association of GCN2 to GCN1 is required for general amino acid control. This finding provides the first insight into the molecular mechanism for the activation of GCN2 by GCN1.	Kanazawa Univ, Inst Canc Res, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; University of Tokyo	Ito, T (corresponding author), Kanazawa Univ, Inst Canc Res, Div Genome Biol, 13-1 Takeramachi, Kanazawa, Ishikawa 9200934, Japan.			Ito, Takashi/0000-0001-6097-2803				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; DEALDANA CRV, 1995, EMBO J, V14, P3148; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Doerks T, 1998, TRENDS GENET, V14, P248, DOI 10.1016/S0168-9525(98)01486-3; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1997, J BIOL CHEM, V272, P2161; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; James P, 1996, GENETICS, V144, P1425; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Olsen DS, 1998, GENETICS, V149, P1495; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Sattlegger E, 1998, J BIOL CHEM, V273, P20404, DOI 10.1074/jbc.273.32.20404; Sood R, 2000, GENETICS, V154, P787; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yamada Y, 1999, BIOCHEM BIOPH RES CO, V256, P162, DOI 10.1006/bbrc.1999.0297; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	29	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20243	20246		10.1074/jbc.C000262200	http://dx.doi.org/10.1074/jbc.C000262200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801780	hybrid			2022-12-25	WOS:000088084500004
J	Thoden, JB; Blanchard, CZ; Holden, HM; Waldrop, GL				Thoden, JB; Blanchard, CZ; Holden, HM; Waldrop, GL			Movement of the biotin carboxylase B-domain as a result of ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; RESOLUTION; SUBUNIT; CARBOXYLTRANSFERASE; SUPERFAMILY; SUBSTRATE	Acetyl-CoA carboxylase catalyzes the first committed step in fatty acid synthesis. In Escherichia coli, the enzyme is composed of three distinct protein components: biotin carboxylase, biotin carboxyl carrier protein, and carboxyltransferase. The biotin carboxylase component has served for many years as a paradigm for mechanistic studies devoted toward understanding more complicated biotin-dependent carboxylases. The three-dimensional x-ray structure of an unliganded form of E. coli biotin carboxylase was originally solved in 1994 to 2.4-Angstrom resolution. This study revealed the architecture of the enzyme and demonstrated that the protein belongs to the ATP-grasp superfamily. Here we describe the three-dimensional structure of the E, coli biotin carboxylase complexed with ATP and determined to 2.5-Angstrom resolution. The major conformational change that occurs upon nucleotide binding is a rotation of approximately 45 degrees of one domain relative to the other domains thereby closing off the active site pocket. Key residues involved in binding the nucleotide to the protein include Lys-116, His-236, and Glu-201. The backbone amide groups of Gly-165 and Gly-166 participate in hydrogen bonding interactions with the phosphoryl oxygens of the nucleotide. A comparison of this closed form of biotin carboxylase with carbamoyl-phosphate synthetase is presented.	Louisiana State Univ, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Louisiana State University System; Louisiana State University; University of Wisconsin System; University of Wisconsin Madison	Waldrop, GL (corresponding author), Louisiana State Univ, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA.				NIDDK NIH HHS [DK47814] Funding Source: Medline; NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; CLIMENT I, 1986, ARCH BIOCHEM BIOPHYS, V251, P465, DOI 10.1016/0003-9861(86)90353-X; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gibson GE, 1998, BIOORG CHEM, V26, P255, DOI 10.1006/bioo.1998.1103; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6646; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KONDO H, 1991, P NATL ACAD SCI USA, V88, P9730, DOI 10.1073/pnas.88.21.9730; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LI SJ, 1992, J BIOL CHEM, V267, P16841; OGITA T, 1988, BIOCHEMISTRY-US, V27, P8028, DOI 10.1021/bi00421a009; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	24	95	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16183	16190		10.1074/jbc.275.21.16183	http://dx.doi.org/10.1074/jbc.275.21.16183			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821865	hybrid			2022-12-25	WOS:000087291400079
J	Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y				Kanno, S; Oda, N; Abe, M; Terai, Y; Ito, M; Shitara, K; Tabayashi, K; Shibuya, M; Sato, Y			Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial calls	ONCOGENE			English	Article						VEGF; Flt-1; KDR; migration; proliferation	PLACENTA GROWTH-FACTOR; FOCAL ADHESION KINASE; DOMAIN-CONTAINING RECEPTOR; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR DOMAIN; CELL-MIGRATION; PHOSPHORYLATION; EXPRESSION	Vascular endothelial growth factor (VEGF) is a principal regulator of vasculogenesis and angiogenesis, VEGF expresses its effects by binding to two VEGF receptors, Flt-1 and KDR, However, properties of FI-l and KDR in the signal transduction of VEGF-mediated effects in endothelial cells (ECs) were not entirely clarified, We investigated this issue by using two newly developed blocking monoclonal antibodies (mAbs) against Flt-1 and KDR, VEGF elicits DKA. synthesis and cell migration of human umbilical, vein endothelial cells (HUVECs). The pattern of inhibition of these effects by two mAbs indicates that DNA. synthesis is preferentially mediated by KDR, In contrast, the regulation of cell migration by VEGF appears to be more complicated. Flt-1 regulates cell, migration through modulating actin reorganization, which is essential for cell motility. a distinct signal is generated by KDR, which influences cell migration by regulating cell adhesion via the assembly of vinculin in focal adhesion plaque and tyrosine-phosphorylation of focal adhesion kinase (FAK) and paxillin.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Sendai, Miyagi 980, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida 194, Japan; Univ Tokyo, Dept Genet, Inst Med Sci, Tokyo, Japan	Tohoku University; Tohoku University; Kyowa Kirin Ltd; University of Tokyo	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Sendai, Miyagi 9808575, Japan.		Kanno, Shin-ichiro/AAE-4549-2019					Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANAI N, 1986, CANCER RES, V46, P4438; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; SHITARA K, 1987, CANCER RES, V47, P1267; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Zhu ZP, 1998, CANCER RES, V58, P3209; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	39	231	254	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2138	2146		10.1038/sj.onc.1203533	http://dx.doi.org/10.1038/sj.onc.1203533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815805				2022-12-25	WOS:000086728000007
J	Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J				Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J			IL-2 and long-term T cell activation induce physical and functional interaction between STAT5 and ETS transcription factors in human T cells	ONCOGENE			English	Article						T lymphocytes; IL-2/IL-2R; STAT5; ETS; transcription	RECEPTOR-ALPHA GENE; NF-KAPPA-B; DNA-BINDING ACTIVITY; COOPERATIVE INTERACTION; SYNERGISTIC ACTIVATION; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; CYCLE PROGRESSION; TYROSINE KINASES; INTERFERON-ALPHA	Activation of Stat5 by many cytokines implies that it cannot alone insure the specificity of the regulation of its target genes. Ne have evidenced a physical and functional interaction between members of two unrelated transcription factor families, Ets-l, Ets-2 and Stat5, which could contribute to the proliferative response to interleukin 2, Competition with GAS - and EBS-specific oligonucleotides and immunoassays with a set of anti-Stat and anti-Ets families revealed that the IL-2-induced Stat5-Ets complex recognizes several GAS motifs identified as target sites for activated Stat5 dimers, Coimmunoprecipitation experiments evidenced that a Stat5/Ets-1/2 complex is formed in vivo in absence of DNA. GST-pun down experiments demonstrated that the C-terminal domain of Ets-1 is sufficient for this interaction in vitro. Cotransfection experiments in Kit225 T cells resulted in cooperative transcriptional activity. between both transcription factors in response to a combination of IL-2, PMA and ionomycin. A Stat5-Ets protein complex mas the major inducible DNA-binding complex bound to the human IL-2rE GASd/EBSd motif in long-term proliferating normal human T cells activated by CD2 and CD28, These results suggest that the inducible Stat5-Ets protein interaction plays a role in the regulation of gene expression in response to IL-2 in human T T lmphocytes.	INSERM, U119, F-13009 Marseille, France; Inst Curie, CNRS, UMR146, F-91405 Orsay, France; Hop Cochin, ICGM, INSERM, U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Imbert, J (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Kahn-Perlès, Brigitte/M-3513-2016; Imbert, Jean/AAG-1165-2020; GHYSDAEL, Jacques/F-3377-2013; Imbert, Jean/G-3248-2013; Lecine, Patrick/H-9338-2016	Kahn-Perlès, Brigitte/0000-0001-5673-5901; Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Lecine, Patrick/0000-0002-8091-7286; Gouilleux, Fabrice/0000-0001-6047-1718				Anderson MK, 1999, DEVELOPMENT, V126, P3131; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Bucher P, 1997, IMMUNOBIOLOGY, V198, P136, DOI 10.1016/S0171-2985(97)80034-4; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; COFFER P, 1994, ONCOGENE, V9, P911; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Genuario RR, 1996, J BIOL CHEM, V271, P4388; Ghysdael J, 1997, ON COGENES TRANSCRIP, P29; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HORI T, 1987, BLOOD, V70, P1069; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; John S, 1999, MOL CELL BIOL, V19, P1910; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Miyazaki T, 1996, CANCER SURV, V27, P25; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	68	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2086	2097		10.1038/sj.onc.1203542	http://dx.doi.org/10.1038/sj.onc.1203542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815800	Green Published			2022-12-25	WOS:000086728000002
J	Cuervo, AM; Dice, JF				Cuervo, AM; Dice, JF			Age-related decline in chaperone-mediated autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; AGING HUMAN-FIBROBLASTS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRACELLULAR PROTEINS; ALTERED DEGRADATION; CYTOSOLIC PROTEINS; PEPTIDE SEQUENCES; SELECTIVE UPTAKE; RIBONUCLEASE-A; PROTEOLYSIS	Intracellular protein degradation rates decrease with age in many tissues and organs. In cultured cells, chaperone-mediated autophagy, which is responsible for the selective degradation of cytosolic proteins in lysosomes, decreases with age. In this work we use lysosomes isolated from rat liver to analyze age-related changes in the levels and activities of the main components of chaperone-mediated autophagy. Lysosomes from "old" (22-month-old) rats show lower rates of chaperone-mediated autophagy, and both substrate binding to the lysosomal membrane and transport into lysosomes decline with age. A progressive age-related decrease in the levels of the lysosome-associated membrane protein type 2a that acts as a receptor for chaperone-mediated autophagy was responsible for decreased substrate binding in lysosomes from old rats as well as from late passage human fibroblasts. The cytosolic levels and activity of the 73-kDa heat-shock cognate protein required for substrate targeting to lysosomes were unchanged with age. The levels of lysosome-associated hsc73 were increased only in the oldest rats. This increase may be an attempt to compensate for reduced activity of the pathway with age.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Dice, JF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE ON AGING [R01AG006116, R37AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [AG06116, AG00829] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; CUERVO AM, 1998, FRONT BIOSCI, V3, P25; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEPRIESTER W, 1984, MECH AGEING DEV, V26, P205, DOI 10.1016/0047-6374(84)90094-0; Dice J. F., 2000, LYSOSOMAL PATHWAYS P; DICE JF, 1982, J BIOL CHEM, V257, P4624; DICE JF, 1993, PHYSIOL REV, V73, P149, DOI 10.1152/physrev.1993.73.1.149; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FERLAND G, 1992, MECH AGEING DEV, V64, P49, DOI 10.1016/0047-6374(92)90095-U; Gafni A, 1997, J AM GERIATR SOC, V45, P871, DOI 10.1111/j.1532-5415.1997.tb01518.x; GLASER T, 1994, P NATL ACAD SCI USA, V91, P7879, DOI 10.1073/pnas.91.17.7879; Jadot M, 1996, BIOCHEM BIOPH RES CO, V223, P353, DOI 10.1006/bbrc.1996.0898; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makrides S., 1983, BIOL REV, V83, P393; OHSUMI Y, 1983, J BIOCHEM, V93, P547; OKADA AA, 1984, MECH AGEING DEV, V26, P341, DOI 10.1016/0047-6374(84)90105-2; PAN JX, 1993, EXP GERONTOL, V28, P39, DOI 10.1016/0531-5565(93)90018-9; SCHELLENS JPM, 1974, CELL TISSUE RES, V155, P455; Shibatani T, 1996, J GERONTOL A-BIOL, V51, pB316, DOI 10.1093/gerona/51A.5.B316; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; Terman A, 1998, MECH AGEING DEV, V104, P277, DOI 10.1016/S0047-6374(98)00073-6; Terman A, 1995, GERONTOLOGY, V41, P319; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WING SS, 1991, BIOCHEM J, V275, P165, DOI 10.1042/bj2750165	40	467	483	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31505	31513		10.1074/jbc.M002102200	http://dx.doi.org/10.1074/jbc.M002102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10806201	hybrid			2022-12-25	WOS:000089762700105
J	Zhang, H; Huang, QH; Ke, N; Matsuyama, S; Hammock, B; Godzik, A; Reed, JC				Zhang, H; Huang, QH; Ke, N; Matsuyama, S; Hammock, B; Godzik, A; Reed, JC			Drosophila pro-apoptotic Bcl-2/Bax homologue reveals evolutionary conservation of cell death mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; FAMILY PROTEINS; BH3 DOMAIN; MITOCHONDRIA; PROCASPASE-9; TRANSLATION; ACTIVATION; MEMBER; MCL-1; BAX	Genetic analysis of programmed cell death in Drosophila reveals many similarities with mammals. Heretofore, a missing link in the fly has been the absence of any Bcl-2/Bax family members, proteins that function in mammal as regulators of mitochondrial cytochrome c release. A Drosophila homologue of the human killer protein Bok (DBok) was identified. The predicted structure of DBok is similar to pore-forming Bcl-2/Bax family members. DBok induces apoptosis in insect and human cells, which is suppressible by anti-apoptotic human Bcl-2 family proteins. A caspase inhibitor suppressed DBok-induced apoptosis but did not prevent DBob-induced cell death. Moreover, DBok targets mitochondria and triggers cytochrome c release through a caspase-independent mechanism. These characteristics of DBok reveal evolutionary conservation of cell death mechanisms in flies and humans.	Burnham Inst, Program Apoptosis & Cell Death Regulat, La Jolla, CA 92037 USA; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Davis	Reed, JC (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Regulat, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X	NIGMS NIH HHS [GM 60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Krajewska M, 1996, AM J PATHOL, V148, P1567; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	84	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27303	27306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10811653				2022-12-25	WOS:000089144800084
J	Goldberg, M; Peshkovsky, C; Shifteh, A; Al-Awqati, Q				Goldberg, M; Peshkovsky, C; Shifteh, A; Al-Awqati, Q			mu-protocadherin, a novel developmentally regulated protocadherin with mucin-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-CELL ADHESION; CADHERIN; EXPRESSION; APOPTOSIS; EPISIALIN; MADCAM-1; COMPLEX; CLONING; HOMOLOG	Branching morphogenesis is a central event during the development of kidneys, lungs, and other organs. We previously generated a monoclonal antibody, 3D2-E9, that inhibited branching morphogenesis and caused widespread apoptosis, We now report the purification of its antigen and cloning of its full-length cDNA. Its cDNA. encodes an integral membrane protein that contains four cadherin-like ectodomains and a thrice tandemly repeated region enriched in threonine, serine, and proline, similar to those of mucins, We thus term this protein mu-protocadherin, reflecting the hybrid nature of its extracellular region, mu-Protocadherin is expressed in two forms that are developmentally regulated, with the shorter isoform lacking the mucin-like repeats. Expression of the long isoform in heterologous cells results in adhesion of the expressing cells, suggesting that it is a new cell adhesion molecule. mu-Protocadherin contains both N and O glycosylations. It is expressed at lateral and basal surfaces of epithelia during kidney and lung development and is located in coated pits. Colocalization of mu-protocadherin with beta-catenin was noted primarily at the junction of the lateral and basal membrane. The cytoplasmic domain contains four proline-rich regions, similar to SH3 binding regions, Thus, it is likely that adhesive interactions mediated by mu-protocadherin induce signaling events that regulate branching morphogenesis.	Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Goldberg, M (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pediat, 3959 Broadway BHS Rm 724, New York, NY 10032 USA.	mg81@columbia.edu	Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK 55388-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Cho EA, 1998, DEVELOPMENT, V125, P803; COLES HSR, 1993, DEVELOPMENT, V118, P777; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FERRARA P, 1993, TECHNIQUES PROTEIN C, V4, P379; Frohman Michael A., 1995, P381; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Goldberg MR, 1997, AM J PHYSIOL-RENAL, V272, pF79, DOI 10.1152/ajprenal.1997.272.1.F79; GOLDBERG MR, 1998, AM J RESP CRIT CARE, V157, P543; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HUAN LJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P79, DOI 10.1016/0167-4781(92)90056-6; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Leung E, 1996, IMMUNOL CELL BIOL, V74, P490, DOI 10.1038/icb.1996.81; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPICER AP, 1991, J BIOL CHEM, V266, P15099; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	33	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24622	24629		10.1074/jbc.M000234200	http://dx.doi.org/10.1074/jbc.M000234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801787	hybrid			2022-12-25	WOS:000088683300054
J	Jensen, PE; Gilpin, M; Knoetzel, J; Scheller, HV				Jensen, PE; Gilpin, M; Knoetzel, J; Scheller, HV			The PSI-K subunit of photosystem I is involved in the interaction between light-harvesting complex I and the photosystem I reaction center core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORDEUM-VULGARE L.; ARABIDOPSIS-THALIANA; PROTEIN-PHOSPHORYLATION; TARGETED INACTIVATION; ANTENNA PROTEINS; BARLEY; GENE; IDENTIFICATION; MUTANTS; ORGANIZATION	PSI-K is a subunit of photosystem I. The function of PSI-K was characterized in Arabidopsis plants transformed with a psaK cDNA in antisense orientation, and several lines without detectable PSI-K protein were identified. Plants without PSI-K have a 19% higher chlorophyll alb ratio and 19% more P700 than wild-type plants. Thus, plants without PSI-R compensate by making more photosystem I. The photosystem I electron transport in vitro is unaffected in the absence of PSI-K. Light response curves for oxygen evolution indicated that the photosynthetic machinery of PSI-K-deficient plants have less capacity to utilize light energy. Plants without PSI-K have less state 1-state 2 transition. Thus, the redistribution of absorbed excitation energy between the two photosystems is reduced. Low temperature fluorescence emission spectra revealed a 2-nm blue shift in the long wavelength emission in plants lacking PSI-K. Furthermore, thylakoids and isolated PSI without PSI-K had 20-30% less Lhca2 and 30-40% less Lhca3, whereas Lhca1 and Lhca4 were unaffected. During electrophoresis under mildly denaturing conditions, all four Lhca subunits were partially dissociated from photosystem I lacking PSI-K, The observed effects demonstrate that PSI-K has a role in organizing the peripheral light-harvesting complexes on the core antenna of photosystem I.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Copenhagen, Denmark	University of Copenhagen	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Copenhagen, Denmark.		Jensen, Poul Erik/A-4862-2014; Scheller, Henrik V/A-8106-2008; Scheller, Henrik/AAH-4770-2020	Jensen, Poul Erik/0000-0001-6524-7723; Scheller, Henrik V/0000-0002-6702-3560; Scheller, Henrik/0000-0002-6702-3560				ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P49, DOI 10.1016/0005-2728(90)90177-6; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; HOSHINA S, 1989, FEBS LETT, V258, P305, DOI 10.1016/0014-5793(89)81680-1; IKEUCHI M, 1990, FEBS LETT, V263, P274, DOI 10.1016/0014-5793(90)81391-Z; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; KNOETZEL J, 1991, PLANTA, V185, P111, DOI 10.1007/BF00194522; KNOETZEL J, 1992, EUR J BIOCHEM, V206, P209, DOI 10.1111/j.1432-1033.1992.tb16918.x; Knoetzel J, 1998, FEBS LETT, V436, P339, DOI 10.1016/S0014-5793(98)01158-2; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LAM E, 1984, FEBS LETT, V168, P10, DOI 10.1016/0014-5793(84)80197-0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MATIS P, 1981, ISRAEL J CHEM, V21, P316; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; Nakamoto H, 1999, PLANT CELL PHYSIOL, V40, P9, DOI 10.1093/oxfordjournals.pcp.a029479; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PRESS WH, 1989, NUMERICAL RECIPES PA, V185, P111; Scheller HV, 1997, PHYSIOL PLANTARUM, V100, P842, DOI 10.1034/j.1399-3054.1997.1000410.x; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; Soukoulis V, 1999, BIOPHYS J, V76, P2711, DOI 10.1016/S0006-3495(99)77423-0; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; WYNN RM, 1990, FEBS LETT, V262, P45, DOI 10.1016/0014-5793(90)80150-H; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	42	119	133	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24701	24708		10.1074/jbc.M000550200	http://dx.doi.org/10.1074/jbc.M000550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818090	hybrid			2022-12-25	WOS:000088683300064
J	Rizzo, MA; Shome, K; Watkins, SC; Romero, G				Rizzo, MA; Shome, K; Watkins, SC; Romero, G			The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; PHOSPHOLIPASE-D; BINDING; ENDOCYTOSIS; INSULIN; CELLS	The serine/threonine kinase Raf-1 is an essential component of the MAPK cascade. Activation of Raf-1 by extracellular signals is initiated by association with intracellular membranes. Recruitment of Raf-1 to membranes has been reported to be mediated by direct association with Res and by the phospholipase D product phosphatidic acid (PA). Here we report that insulin stimulation of HIRcB fibroblasts leads to accumulation of Res, Raf-1, phosphorylated MEK, phosphorylated MAPK, and PA on endosomal membranes, Mutations that disrupt Raf-PA interactions prevented recruitment of Raf-1 to membranes, whereas disruption of Ras-Raf interactions did not affect agonist-dependent translocation, Expression of a dominant-negative Pas mutant did not prevent insulin-dependent Raf-1 translocation, but inhibited phosphorylation of MAPK Finally, the PA-binding region of Raf-1 was sufficient to target green fluorescent protein to membranes, and its overexpression blocked recruitment of Raf-1 to membranes and disrupted insulin dependent MAPK phosphorylation, These results indicate that agonist-dependent Raf-1 translocation is primarily mediated by a direct interaction with PA and is independent of association with Ras.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Callaghan L, 1999, EUR J BIOCHEM, V265, P361; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chiariello M, 1999, FEBS LETT, V453, P20, DOI 10.1016/S0014-5793(99)00686-9; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DENT P, 1995, MOL CELL BIOL, V15, P4125; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lu KK, 1998, CELL GROWTH DIFFER, V9, P367; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mineo C, 1997, J BIOL CHEM, V272, P10345; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHEIN CH, 1989, BIOTECHNOLOGY, V7, P1141; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	269	282	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23911	23918		10.1074/jbc.M001553200	http://dx.doi.org/10.1074/jbc.M001553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801816	hybrid			2022-12-25	WOS:000088564200070
J	Woodbury, RL; Topping, TB; Diamond, DL; Suciu, D; Kumamoto, CA; Hardy, SJS; Randall, LL				Woodbury, RL; Topping, TB; Diamond, DL; Suciu, D; Kumamoto, CA; Hardy, SJS; Randall, LL			Complexes between protein export chaperone SecB and SecA - Evidence for separate sites on SecA providing binding energy and regulatory interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE; TRANSLOCATION; OVERPRODUCTION; PRECURSOR; SECRETION; MUTATION; REQUIRES; LIGANDS; ATP	During localization to the periplasmic space or to the outer membrane of Escherichia coli some proteins are dependent on binding to the cytosolic chaperone SecB, which in turn is targeted to the membrane by specific interaction with SecA, a peripheral component of the translocase. Five variant forms of SecB, previously demonstrated to be defective in mediating export in vivo (Grannon, P, M., and Kumamoto, C, A. (1993) J. Biol, Chem. 288, 1590-1595; Kimsey, H. K,, Dagarag, M, D,, and Kumamoto, C, A. (1995) J, Biol, Chem. 270, 22831-22835) were investigated with respect to their ability to bind SecA both in solution and at the membrane translocase. We present evidence that at least two regions of SecA are involved in the formation of active complexes with SecB, The variant forms of SecB were all capable of interacting with SecA in solution to form complexes with stability similar to that of complexes between SecA and wild-type SecB, However, the variant forms were defective in interaction with a separate region of SecA, which was shown to trigger a change that was correlated to activation of the complex. The region of SecA involved in activation of the complexes was defined as the extreme carboxyl-terminal 21 aminoacyl residues.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Washington State University; Tufts University	Randall, LL (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	topping@wsu.edu			NIGMS NIH HHS [GM29798, T32-GM08336, GM36415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008336, R37GM029798, R01GM036415, R01GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; Cook HA, 1999, J BACTERIOL, V181, P3010, DOI 10.1128/JB.181.10.3010-3017.1999; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; GANNON PM, 1993, J BIOL CHEM, V268, P1590; GELLER BL, 1990, J BACTERIOL, V172, P4870, DOI 10.1128/jb.172.9.4870-4876.1990; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; KIMSEY HH, 1995, J BIOL CHEM, V270, P22831, DOI 10.1074/jbc.270.39.22831; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; Muren EM, 1999, J BIOL CHEM, V274, P19397, DOI 10.1074/jbc.274.27.19397; Randall LL, 1998, METHOD ENZYMOL, V290, P444, DOI 10.1016/S0076-6879(98)90037-4; Randall LL, 1998, PROTEIN SCI, V7, P1195, DOI 10.1002/pro.5560070514; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; Topping TB, 1997, J BIOL CHEM, V272, P19314, DOI 10.1074/jbc.272.31.19314; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	26	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24191	24198		10.1074/jbc.M002885200	http://dx.doi.org/10.1074/jbc.M002885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807917	hybrid			2022-12-25	WOS:000088564200105
J	Feierberg, I; Luzhkov, V; Aqvist, J				Feierberg, I; Luzhkov, V; Aqvist, J			Computer simulation of primary kinetic isotope effects in the proposed rate-limiting step of the glyoxalase I catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME CATALYSIS; TRIOSEPHOSPHATE ISOMERASE; PROTON-TRANSFER; ACTIVE-SITE; MECHANISM; DYNAMICS	The proposed rate-limiting step of the glyoxalase I catalyzed reaction is the proton abstraction from the C1 carbon of the substrate by Glu(172). Here we examine primary kinetic isotope effects and the influence of quantum dynamics on this process by computer simulations. The calculations utilize the empirical valence bond method in combination with the molecular dynamics free energy perturbation technique and path integral simulations. For the enzyme-catalyzed reaction a H/D kinetic isotope effect of 5.0 +/- 1.3 is predicted in reasonable agreement with the experimental result of about 3. Furthermore, the magnitude of quantum mechanical effects is found to be very similar for the enzyme reaction and the corresponding uncatalyzed process in solution, in agreement with other studies. The problems associated with attaining the required accuracy in order for the present approach to be useful as a diagnostic tool for the study of enzyme reactions are also discussed.	Uppsala Univ, Ctr Biomed, Dept Mol & Cell Biol, S-75124 Uppsala, Sweden; Russian Acad Sci, Inst Chem Phys Problems, Chernogolovka 142432, Moscow Region, Russia	Uppsala University; Russian Academy of Sciences; Institute of Problems of Chemical Physics of the Russian Academy of Sciences	Aqvist, J (corresponding author), Uppsala Univ, Ctr Biomed, Dept Mol & Cell Biol, Box 596, S-75124 Uppsala, Sweden.	aqvist@xray.bmc.uu.se	Luzhkov, Victor/AAE-1857-2019	Luzhkov, Victor/0000-0003-2528-4567				ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5588, DOI 10.1021/bi00670a025; Alhambra C, 1999, J AM CHEM SOC, V121, P2253, DOI 10.1021/ja9831655; ANDERSON SR, 1994, BIOCHEMISTRY-US, V33, P10545, DOI 10.1021/bi00200a041; Aqvist J, 1996, J BIOL CHEM, V271, P10010, DOI 10.1074/jbc.271.17.10010; AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; AQVIST J, 1992, J MOL STRUC-THEOCHEM, V88, P135, DOI 10.1016/0166-1280(92)87163-T; AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; BERNE BJ, 1986, ANNU REV PHYS CHEM, V37, P401; Cameron AD, 1999, BIOCHEMISTRY-US, V38, P13480, DOI 10.1021/bi990696c; FEJERBERG I, 1999, FEBS LETT, V453, P90; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; Hwang JK, 1996, J AM CHEM SOC, V118, P11745, DOI 10.1021/ja962007f; HWANG JK, 1991, J PHYS CHEM-US, V95, P8445, DOI 10.1021/j100175a009; KALLARAKAL AT, 1995, BIOCHEMISTRY-US, V34, P2788, DOI 10.1021/bi00009a007; KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; LEADLAY PF, 1976, BIOCHEMISTRY-US, V15, P5617, DOI 10.1021/bi00670a029; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(99)00012-1; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; Ridderstrom M, 1998, J BIOL CHEM, V273, P21623, DOI 10.1074/jbc.273.34.21623; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SAUNDERS WH, 1985, J AM CHEM SOC, V107, P164, DOI 10.1021/ja00287a029; Schlegel HB., 2009, GAUSSIAN 09 REVISION; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597; VOTH GA, 1989, J CHEM PHYS, V91, P7749, DOI 10.1063/1.457242; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Warshel A, 1991, COMPUTER MODELING CH	31	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22657	22662		10.1074/jbc.M000726200	http://dx.doi.org/10.1074/jbc.M000726200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801792	hybrid			2022-12-25	WOS:000088419400011
J	Wassenberg, JJ; Reed, RC; Nicchitta, CV				Wassenberg, JJ; Reed, RC; Nicchitta, CV			Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94 II. Ligand-mediated activation of GRP94 molecular chaperone and peptide binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; IN-VIVO; ATP BINDING; IMMUNOGLOBULIN-CHAINS; FLUORESCENT-PROBE; CITRATE SYNTHASE; STRESS PROTEINS; OLIGOMERIZATION	The N-terminal domain of eukaryotic Hsp90 proteins contains a conserved adenosine nucleotide binding pocket that also serves as the binding site for the Hsp90 inhibitors geldanamycin and radicicol, Although this domain is essential for Hsp90 function, the molecular basis for adenosine nucleotide-dependent regulation of GRP94, the endoplasmic reticulum paralog of Hsp90, remains to be established. We report that bis-ANS (1,1'-is(4-anilino-5-napthalenesulfonic acid), an environment sensitive fluorophore known to interact with nucleotide-binding domains, binds to the adenosine nucleotide-binding domain of GRP94 and thereby activates its molecular chaperone and peptide binding activities. bis-ANS was observed to elicit a tertiary conformational change in GRP94 similar to that occurring upon heat shock, which also activates GRP94 function. bis-ANS activation of GRP94 function was efficiently blocked by radicicol, an established inhibitory ligand for the adenosine nucleotide binding pocket. Confirmation of the N-terminal nucleotide binding pocket as the bis-ANS-binding site was obtained following covalent incorporation of bis-ANS into GRP94, trypsinolysis, and sequencing of bis-ANS-labeled limit digestion products. These data identify a ligand dependent regulation of GRP94 function and suggest a model whereby GRP94 function is regulated through a ligand-dependent conversion of GRP94 from an inactive to an active conformation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	c.nicchitta@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [F32CA083355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NCI NIH HHS [IF32CA8335501] Funding Source: Medline; NIDDK NIH HHS [DK53058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CARERI G, 1975, Critical Reviews in Biochemistry, V3, P141, DOI 10.3109/10409237509102555; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Chavany C, 1996, J BIOL CHEM, V271, P4974; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Ferreira LR, 1996, CONNECT TISSUE RES, V33, P265, DOI 10.3109/03008209609028884; Gerloff DL, 1997, PROTEINS, V27, P450, DOI 10.1002/(SICI)1097-0134(199703)27:3<450::AID-PROT12>3.3.CO;2-9; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; JAENICKE R, 1990, FEBS LETT, V268, P344, DOI 10.1016/0014-5793(90)81283-T; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KIM KS, 1986, BIOCHEM BIOPH RES CO, V140, P881, DOI 10.1016/0006-291X(86)90717-5; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MYERS JS, 1975, J BIOL CHEM, V250, P3785; Nair S, 1999, J IMMUNOL, V162, P6426; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; Nemoto T, 1996, J BIOCHEM-TOKYO, V120, P249; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Sastry S, 1999, J BIOL CHEM, V274, P12023, DOI 10.1074/jbc.274.17.12023; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Seale JW, 1996, BIOCHEMISTRY-US, V35, P4079, DOI 10.1021/bi953087n; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAKASHI R, 1977, P NATL ACAD SCI USA, V74, P2334, DOI 10.1073/pnas.74.6.2334; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	61	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22806	22814		10.1074/jbc.M001476200	http://dx.doi.org/10.1074/jbc.M001476200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816560	hybrid			2022-12-25	WOS:000088419400030
J	Chaney, M; Pitt, M; Buck, M				Chaney, M; Pitt, M; Buck, M			Sequences within the DNA cross-linking patch of sigma(54) involved in promoter recognition, sigma isomerization, and open complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN NTRC; TRANSCRIPTION FACTOR SIGMA-54; CORE RNA-POLYMERASE; TURN-HELIX MOTIF; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; REGION-I; ENHANCER RESPONSIVENESS; NUCLEOTIDE-SEQUENCE; DOMAIN-STRUCTURE	The bacterial RNA polymerase holoenzyme containing the sigma(54) subunit functions in enhancer-dependent transcription. Mutagenesis has been used to probe the function of a sequence in the sigma(54) DNA binding domain that includes residues that cross-link to promoter DNA. Several activities of the sigma and holoenzyme are shown to depend on the cross linking patch. The patch contributes to promoter binding by sigma(54), and holoenzyme and is involved in activator-dependent sigma isomerization, As part of the sigma(54)-holoenzyme, some residues in the patch limit basal transcription. Other cross-linking patch sequences appear to limit activator-dependent open complex formation. Deletion of 19 residues adjacent to the cross-linking patch resulted in a holoenzyme unable to respond to activator but capable of activator-independent (bypass) transcription in vitro. Overall results are consistent with the cross-linking patch directing interactions to the -12 promoter region to set basal and activated levels of transcription.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England	Imperial College London	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.							AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCK M, 1989, NUCLEIC ACIDS RES, V17, P2597, DOI 10.1093/nar/17.7.2597; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; CANNON W, 1995, NUCLEIC ACIDS RES, V23, P351, DOI 10.1093/nar/23.3.351; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 1999, NUCLEIC ACIDS RES, V27, P2478, DOI 10.1093/nar/27.12.2478; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chan CL, 1996, STRUCTURE, V4, P1235, DOI 10.1016/S0969-2126(96)00131-1; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DIXON R, 1980, NATURE, V286, P128, DOI 10.1038/286128a0; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gallegos MT, 1999, J BIOL CHEM, V274, P25285, DOI 10.1074/jbc.274.36.25285; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Jovanovic G, 1996, J BACTERIOL, V178, P1936, DOI 10.1128/jb.178.7.1936-1945.1996; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; Leonetti JP, 1998, EMBO J, V17, P1467, DOI 10.1093/emboj/17.5.1467; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Oguiza JA, 1999, MOL MICROBIOL, V33, P873, DOI 10.1046/j.1365-2958.1999.01542.x; Parkinson G, 1996, NAT STRUCT BIOL, V3, P837, DOI 10.1038/nsb1096-837; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Taylor M, 1996, MOL MICROBIOL, V22, P1045, DOI 10.1046/j.1365-2958.1996.01547.x; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	44	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22104	22113		10.1074/jbc.M002253200	http://dx.doi.org/10.1074/jbc.M002253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807913	hybrid			2022-12-25	WOS:000088363800051
J	Garat, C; Van Putten, V; Refaat, ZA; Dessev, C; Han, SY; Nemenoff, RA				Garat, C; Van Putten, V; Refaat, ZA; Dessev, C; Han, SY; Nemenoff, RA			Induction of smooth muscle alpha-actin in vascular smooth muscle cells by arginine vasopressin is mediated by c-Jun amino-terminal kinases and p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; GROWTH-FACTOR; ANGIOTENSIN-II; INDUCED STIMULATION; MAMMALIAN-CELLS; GENE-EXPRESSION; LUNG-CANCER; TRANSCRIPTION; PROMOTER	Exposure of vascular smooth muscle cells to arginine vasopressin (AVP) increases smooth muscle alpha-actin (SM-alpha-actin) expression through activation of the SM- alpha-actin promoter. The goal of this study was to determine the role of the mitogen-activated protein kinase (MAP kinase) family in regulation of SM-alpha-actin expression. AVP activated all three MAP kinase family members: ERKs, JNKs, and p38 MAP kinase, Inhibition of JNKs or p38 decreased AVP-stimulated SM-alpha-actin promoter activity, whereas inhibition of ERKs had no effect. A 150-base pair region of the promoter containing two CArG boxes was sufficient to mediate regulation by vasoconstrictors, Mutations in either CArG box decreased AVP-stimulated promoter activity. Electrophoretic mobility shift assays using oligonucleotides corresponding to either CArG box resulted in a complex of similar mobility whose intensity was increased by AVP, Antibodies against serum response factor (SRF) completely supershifted this complex, indicating that SRF binds to both CArG boxes. Overexpression of SRF increased basal promoter activity, but activity was still stimulated by AVP, AVP stimulation rapidly increased SRF phosphorylation, These data indicate that both JNKs and p38 participate in regulation of SM- alpha-actin expression. SRF, which binds to two critical CArG boxes in the promoter, represents a potential target of these kinases.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Pharmacol, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039902, P01DK019928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62824] Funding Source: Medline; NIDDK NIH HHS [DK 19928, DK 39902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERK BC, 1989, BIOCHEM PHARMACOL, V38, P219, DOI 10.1016/0006-2952(89)90030-0; BOXER LM, 1989, J BIOL CHEM, V264, P1284; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Butterfield L, 1999, BIOCHEM J, V338, P681, DOI 10.1042/0264-6021:3380681; CAMPBELL JH, 1991, BASIC RES CARDIOL, V86, P3; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GILLE H, 1992, NATURE, V414, P358; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KOCHER O, 1989, IN VITRO CELL DEV B, V25, P424; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MEYERLEHNERT H, 1988, AM J PHYSIOL, V254, pF254; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Owens GK, 1997, AGENT ACTION SUPPL, V48, P3; OWENS GK, 1995, PHYSIOL REV, V75, P487; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSS R, 1984, AM J PATHOL, V114, P79; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Tournier C, 1999, MOL CELL BIOL, V19, P1569; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	48	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22537	22543		10.1074/jbc.M003000200	http://dx.doi.org/10.1074/jbc.M003000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807920	hybrid			2022-12-25	WOS:000088363800105
J	Paine, CT; Paine, ML; Luo, W; Okamoto, CT; Lyngstadaas, SP; Snead, ML				Paine, CT; Paine, ML; Luo, W; Okamoto, CT; Lyngstadaas, SP; Snead, ML			A tuftelin-interacting protein (TIP39) localizes to the apical secretory pole of mouse ameloblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMELOGENIN GENE-EXPRESSION; TOOTH DEVELOPMENT; EXTRACELLULAR-MATRIX; MOLECULAR MECHANISMS; ENAMELIN TUFTELIN; EPITHELIAL-CELLS; KINASE CK2; SEQUENCE; CLONING; ORGANOGENESIS	Enamel biomineralization is a complex process that involves interactions between extracellular matrix proteins. To identify proteins interacting with tuftelin, a potential nucleator of enamel crystallites, the yeast two-hybrid system was applied to a mouse tooth expression library and a tuftelin-interacting protein (TIP) was isolated for further characterization. Polyclonal antibodies were prepared against two recombinant variants of this protein, Both antibodies identified a major protein product in tooth organs at 39 kDa, and this protein has been called TIP39, Northern analysis showed TIP39 messenger RNA in multiple organs, a pattern similar to that of tuftelin messenger RNA. In situ hybridization of mandibles of 1-day-old mice detected TIP39 RNA in secretory ameloblasts and odontoblasts, Immunolocalization of TIP39 and tuftelin in cultured ameloblast-like cells showed that these two proteins colocalize, Within the developing tooth organ, TIP39 and tuftelin immunolocalized to the apical pole of secretory ameloblasts (Tomes' processes) and to the newly secreted extracellular enamel matrix. TIP39 amino acid sequence appears to be highly conserved with similarities to proteins in species as diverse as yeast and primates. Available sequence data and the findings reported here suggest a role for TIP39 in the secretory pathway of extracellular proteins.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pharmaceut Sci, Sch Pharm, Los Angeles, CA 90033 USA; Univ Oslo, Fac Dent, Inst Oral Pathol, N-0317 Oslo, Norway	University of Southern California; University of Southern California; University of Oslo	Paine, ML (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA Rm 142, Los Angeles, CA 90033 USA.	paine@hsc.usc.edu		Lyngstadaas, Staale Petter/0000-0002-6361-7644	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE006988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011704] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11704, DE06988, DE07211] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUSUBEL FM, 1990, CURRENT MOL BIOL; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bashir MM, 1997, ARCH ORAL BIOL, V42, P489, DOI 10.1016/S0003-9969(97)00039-3; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHEN LS, 1992, ARCH ORAL BIOL, V37, P771, DOI 10.1016/0003-9969(92)90110-T; DEUTSCH D, 1995, INT J DEV BIOL, V39, P135; DEUTSCH D, 1991, J BIOL CHEM, V266, P16021; Dhamija S, 1999, J BIOL CHEM, V274, P20738, DOI 10.1074/jbc.274.29.20738; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; Fincham AG, 1995, CONNECT TISSUE RES, V32, P119, DOI 10.3109/03008209509013713; Fong CD, 1998, EUR J ORAL SCI, V106, P324, DOI 10.1111/j.1600-0722.1998.tb02193.x; Goldberg M, 1996, Adv Dent Res, V10, P126; Goldberg M, 1999, CALCIFIED TISSUE INT, V65, P66, DOI 10.1007/s002239900659; Hu CC, 1998, CONNECT TISSUE RES, V39, P47, DOI 10.3109/03008209809023911; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lowenstam HA, 1989, BIOMINERALISATION, P175; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101; MacDougall M, 1998, J DENT RES, V77, P1970, DOI 10.1177/00220345980770120401; Paine CT, 1998, CONNECT TISSUE RES, V38, P257, DOI 10.3109/03008209809017046; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 1996, CONNECT TISSUE RES, V35, P157, DOI 10.3109/03008209609029187; Pinna LA, 1997, INT J BIOCHEM CELL B, V29, P551, DOI 10.1016/S1357-2725(96)00142-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; SIMMER JP, 1995, DENT ENAMEL FORMATIO, P59; Slavkin Harold C., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P315; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; SNEAD ML, 1988, DEVELOPMENT, V104, P77; STRYER L, 1988, BIOCHEMISTRY-US, P27; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Viegas-Pequignot E., 1992, PRACTICAL APPROACHES, P137; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; White SN, 2000, J AM CERAM SOC, V83, P238, DOI 10.1111/j.1151-2916.2000.tb01181.x; ZeichnerDavid M, 1997, INT J DEV BIOL, V41, P27	41	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22284	22292		10.1074/jbc.M000118200	http://dx.doi.org/10.1074/jbc.M000118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806191	hybrid			2022-12-25	WOS:000088363800073
J	Sukhodolets, MV; Jin, DJ				Sukhodolets, MV; Jin, DJ			Interaction between RNA polymerase and RapA, a bacterial homolog of the SWI/SNF protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPT CLEAVAGE FACTORS; ESCHERICHIA-COLI; GENE-EXPRESSION; MUTAGENESIS; GREA; RESISTANCE; HELICASES; LOCATION; BINDING; SUBUNIT	Recently, we identified a novel Escherichia coli RNA polymerase (RNAP)-associated protein, an ATPase, called RapA (Sukhodolets, M, V., and Jin, D. J. (1998) J. Biol. Chem. 273, 7018-7023), RapA is a bacterial homolog of SWI2/SNF2. We showed that RapA forms a stable complex with RNAP holoenzyme and that binding to RNAP holoenzyme stimulates the ATPase activity of RapA. We have further analyzed the interactions between purified RapA and the two forms of RNAP: core RNAP and RNAP holoenzyme, We found that RapA interacts with either form of RNAP, However, RapA exhibits higher affinity for core RNAP than for RNAP holoenzyme. Chemical cross-linking of the RNAP-RapA complex indicated that the RapA-binding sites are located at the interface between the alpha and beta' subunits of RNAP, Contrary to previously reported results (Muzzin, O,, Campbell, E., A, Xia, L., Severinova, E., Darst, S. A, and Severinov, K, (1998) J. Biol. Chem, 273, 15157-15161), our in vivo analysis of a rapA null mutant suggested that RapA is not likely to be directly involved in DNA repair.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jin, DJ (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2E14,9000 Rockville Pike, Bethesda, MD 20892 USA.	djjin@helix.nih.gov						ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess R.R., 1987, RNA POLYM REGULATION, P3; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FENG GH, 1994, J BIOL CHEM, V269, P22282; FRIEDMAN DI, 1983, LAMBDA 2, P21; FUQUA WC, 1992, BIOTECHNIQUES, V12, P223; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GUZMAN LM, 1995, J BACTERIOL, V177, P4221; HILLEL Z, 1977, BIOCHEMISTRY-US, V16, P3334, DOI 10.1021/bi00634a008; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Miller J.H., 1972, EXPT MOL GENETICS; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Muzzin O, 1998, J BIOL CHEM, V273, P15157, DOI 10.1074/jbc.273.24.15157; NEIGEBORN L, 1984, GENETICS, V108, P845; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; POLYAKOV A, 1988, J MOL BIOL, V281, P465; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SPARKOWSKI J, 1991, J BACTERIOL, V173, P5256, DOI 10.1128/jb.173.17.5256-5257.1991; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WITKIN EM, 1966, SCIENCE, V152, P1345, DOI 10.1126/science.152.3727.1345	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22090	22097		10.1074/jbc.M000056200	http://dx.doi.org/10.1074/jbc.M000056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801781	hybrid			2022-12-25	WOS:000088363800049
J	Tsuda, T; Ikeda, Y; Taniguchi, N				Tsuda, T; Ikeda, Y; Taniguchi, N			The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization - Possible role of a specific chain in controllable receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; TYROSINE KINASE-ACTIVITY; FACTOR EGF RECEPTOR; GLIOMA CELL-LINE; SIGNAL-TRANSDUCTION; BINDING-DOMAIN; EXTRACELLULAR DOMAIN; CDNA CLONING; FACTOR-ALPHA; U373 MG	To elucidate a role(s) of Asn-linked sugar chain(s) in the function of epidermal growth factor receptor (EGFR), a series of the EGFR mutants were prepared in which potential glycosylation sites in the domain III were eliminated by site-directed mutagenesis, Although the wild-type and mutants of Asn-328, Asn-337, and Asn-389 underwent autophosphorylation in response to epidermal growth factor (EGF), the Asn-420 --> Gln mutant was found to be constitutively tyrosine-phosphorylated. This abnormal ligand-independent phosphorylation of the mutant appears to be due to a ligand-independent spontaneous oligomer formation, as shown by a crosslinking experiment using the purified soluble extracellular domain (sEGFR), As revealed by the dissociation of the Asn-420 --> Gln sEGFR oligomer by simple dilution, it seems likely that the equilibrium is shifted toward oligomer formation to an unusual degree. Furthermore, it was also found that the mutation caused a loss of the ability to bind EGF, These findings suggest that the sugar chain linked to Asn-420 plays a crucial role in EGF binding and prevents spontaneous oligomerization of the EGFR, which may otherwise lead to uncontrollable receptor activation, and support the view of a specific role of an Asn-linked sugar chain in the function of a glycoprotein.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAZEN M, 1995, J CELL PHYSL, V162, P74; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, J BIOL CHEM, V266, P13828; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Moscatello DK, 1996, ONCOGENE, V13, P85; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rebbaa A, 1996, J NEUROCHEM, V67, P2265; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WU DG, 1989, J BIOL CHEM, V264, P17469; ZENG FY, 1995, MOL CELL BIOCHEM, V142, P117, DOI 10.1007/BF00928932; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	36	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21988	21994		10.1074/jbc.M003400200	http://dx.doi.org/10.1074/jbc.M003400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801876	hybrid			2022-12-25	WOS:000088363800034
J	Zhang, P; Wang, YZ; Kagan, E; Bonner, JC				Zhang, P; Wang, YZ; Kagan, E; Bonner, JC			Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; PROTEIN-KINASE; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; PULMONARY FIBROSIS; INDUCED APOPTOSIS; IN-VITRO; CELLS; EXPRESSION; H2O2	Activation of ERK-1 and -2 by H2O2 in a variety of cell types requires epidermal growth factor receptor (EGFR) phosphorylation, In this study, we investigated the activation of ERK by ONOO- in cultured rat lung myofibroblasts. Western blot analysis using anti-phos-pho-ERK antibodies along with an ERK kinase assay using the phosphorylated heat- and acid-stable protein (PHAS-1) substrate demonstrated that ERK activation peaked within 15 min after ONOO- treatment and was maximally activated with 100 mu M ONOO-. Activation of ERK by ONOO- and H2O2 was blocked by the antioxidant N-acetyl-L-cysteine. Catalase blocked ERK activation by H2O2, but not by ONOO-, demonstrating that the effect of ONOO- was not due to the generation of H2O2, Both H2O2 and ONOO- induced phosphorylation of EGFR in Western blot experiments using an anti-phos-pho-EGFR antibody. However, the EGFR tyrosine kinase inhibitor AG1478 abolished ERK activation by H2O2, but not by ONOO-. Both H2O2 and ONOO- activated Raf-1, However, the Raf inhibitor forskolin blocked ERK activation by H2O2, but not by ONOO-. The MEK inhibitor PD98059 inhibited ERK activation by both H2O2 and ONOO-. Moreover, ONOO- or H2O2 caused a cytotoxic response of myofibroblasts that was prevented by preincubation with PD98059, In a cell-free kinase assay, ONOO- (but not H2O2) induced autophosphorylation and nitration of a glutathione S-transferase-MEK-1 fusion protein. Collectively, these data indicate that ONOO- activates EGFR and Raf-1, but these signaling intermediates are not required for ONOO--induced ERK activation. However, MEK-1 activation is required for ONOO--induced ERK activation in myofibroblasts, In contrast, H2O2-induced ERK activation is dependent on EGFR activation, which then leads to downstream Raf-1 and MEK-1 activation.	NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Uniformed Services University of the Health Sciences - USA	Bonner, JC (corresponding author), NIEHS, Pulm Pathobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NHLBI NIH HHS [HL-54196] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054196] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; Coin PG, 1996, J IMMUNOL, V156, P4797; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jackson RM, 1998, FREE RADICAL BIO MED, V25, P463, DOI 10.1016/S0891-5849(98)00101-4; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; Kondo H, 1997, FEBS LETT, V413, P236, DOI 10.1016/S0014-5793(97)00922-8; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lindroos PM, 1998, J IMMUNOL, V161, P3464; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanaka S, 1998, J CLIN INVEST, V102, P445, DOI 10.1172/JCI3169; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; XIA Z, 1995, SCIENCE, V270, P326; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	37	112	117	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22479	22486		10.1074/jbc.M910425199	http://dx.doi.org/10.1074/jbc.M910425199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801894	hybrid			2022-12-25	WOS:000088363800097
J	Okada, K; Fujita, T; Minamoto, K; Liao, H; Naka, Y; Pinsky, DJ				Okada, K; Fujita, T; Minamoto, K; Liao, H; Naka, Y; Pinsky, DJ			Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; P-SELECTIN BLOCKADE; REPERFUSION INJURY; CEREBRAL INJURY; GENE-EXPRESSION; OXYGEN RADICALS; MESSENGER-RNA; TRANSPLANTATION; INDUCTION	Little is known about interactions between endogenous anti-inflammatory paradigms and microvascular thrombosis in lung ischemia/reperfusion (I/R) injury. Interleukin (IL)-10 suppresses macrophage activation and down-regulates proinflammatory cytokine production, but there are no available data to suggest a link between IL-10, thrombosis, and fibrinolysis in the setting of I/R, We hypothesized that hypoxia/ischemia triggers IL-10 production, to dampen proinflammatory cytokine and adhesion receptor cascades and to restore vascular patency by fibrinolytic potentiation. Studies were performed in a mouse lung I/R model. IL-10 mRNA levels in lung were increased 43-fold over base line by 1 h of ischemia/2 h of reperfusion, with a corresponding increase in plasma IL-10. Expression was prominently localized in bronchial epithelial cells and mononuclear phagocytes, To study the link between IL-10 and fibrinolysis in vivo, the induction of plasminogen activator inhibitor-1 (PAI-1) was evaluated. Northern analysis demonstrated exaggerated pulmonary PAI-1 expression in IL-10 (-/-) mice after I/R, with a corresponding increase in plasma PAI/tissue-type plasminogen activator activity. In vivo, IL-10 (-/-) mice showed poor postischemic lung function and survival after I/R compared with IL-10 (+/+) mice. Despite a decrease in infiltration of mononuclear phagocytes in I/R lungs of IL-10 (-/-) mice, an increased intravascular pulmonary fibrin deposition was observed by immunohistochemistry and Western blotting, along with increased IL-1 expression. Recombinant IL-10 given to IL-10 (-/-) mice normalized the PAI/tissue-type plasminogen activator ratio, reduced pulmonary vascular fibrin deposition, and rescued mice from lung injury, Since recombinant hirudin (direct thrombin inhibitor) also sufficed to rescue IL-10 (-/-) mice, these data suggest a preeminent role for microvascular thrombosis in I/R lung injury. Ischemia-driven IL-10 expression confers postischemic pulmonary protection by augmenting endogenous fibrinolytic mechanisms.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, PH 10 Stem,630 W 168th St, New York, NY 10032 USA.	djp5@columbia.edu	Tomoyuki, Fujita/AAC-7464-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL59488, R01 HL55397] Funding Source: Medline; PHS HHS [R01 60900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abrahamsson T, 1996, THROMB HAEMOSTASIS, V75, P118; Autschbach F, 1998, AM J PATHOL, V153, P121, DOI 10.1016/S0002-9440(10)65552-6; Becherel PA, 1997, J IMMUNOL, V159, P5761; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang DM, 1997, AM J RESP CRIT CARE, V156, P1230, DOI 10.1164/ajrccm.156.4.9702095; Choudhri TF, 1999, J EXP MED, V190, P91, DOI 10.1084/jem.190.1.91; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; Fay WP, 1996, ARTERIOSCL THROM VAS, V16, P1277, DOI 10.1161/01.ATV.16.10.1277; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FRANCIS CW, 1980, BLOOD, V56, P456; FUJII S, 1992, CIRCULATION, V86, P2000, DOI 10.1161/01.CIR.86.6.2000; GERTLER JP, 1993, J VASC SURG, V18, P939, DOI 10.1016/0741-5214(93)90548-Z; GILROY RJ, 1993, AM REV RESPIR DIS, V147, P276, DOI 10.1164/ajrccm/147.2.276; GREENBERGER MJ, 1995, J IMMUNOL, V155, P722; Handt S, 1996, BLOOD, V87, P4204, DOI 10.1182/blood.V87.10.4204.bloodjournal87104204; HORGAN MJ, 1990, AM J PHYSIOL, V259, pL315, DOI 10.1152/ajplung.1990.259.4.L315; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; HUI KY, 1983, SCIENCE, V222, P1129, DOI 10.1126/science.6648524; Jander S, 1998, AM J PATHOL, V152, P975; KAPELANSKI DP, 1993, J HEART LUNG TRANSPL, V12, P294; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lalani I, 1997, ANN ALLERG ASTHMA IM, V79, P469, DOI 10.1016/S1081-1206(10)63052-9; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; MALEFYT RD, 1991, J EXP MED, V174, P1209; Martinez JAB, 1997, AM J PHYSIOL-LUNG C, V273, pL676, DOI 10.1152/ajplung.1997.273.3.L676; MULLIGAN MS, 1993, AM J PATHOL, V142, P1739; MULLIGAN MS, 1993, J IMMUNOL, V151, P5666; Naka Y, 1997, P NATL ACAD SCI USA, V94, P757, DOI 10.1073/pnas.94.2.757; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; Pajkrt D, 1997, BLOOD, V89, P2701, DOI 10.1182/blood.V89.8.2701; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; RANBY M, 1982, THROMB RES, V27, P743, DOI 10.1016/0049-3848(82)90012-3; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SEITZ M, 1995, EUR J IMMUNOL, V25, P1129, DOI 10.1002/eji.1830250443; SHANLEY TP, 1995, J IMMUNOL, V154, P3454; SHATOS MA, 1992, J BIOL CHEM, V267, P597; SHATOS MA, 1990, J BIOL CHEM, V265, P20443; Snell GI, 1996, J HEART LUNG TRANSPL, V15, P160; Sobel BE, 1998, CIRCULATION, V97, P2213, DOI 10.1161/01.CIR.97.22.2213; Wang CY, 1998, CIRC RES, V82, P762, DOI 10.1161/01.RES.82.7.762; Ward PA, 1996, ANN NY ACAD SCI, V796, P104, DOI 10.1111/j.1749-6632.1996.tb32572.x; WELLER A, 1992, J BIOL CHEM, V267, P15176; WIMAN B, 1983, CLIN CHIM ACTA, V127, P279, DOI 10.1016/S0009-8981(83)80012-6; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71	53	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21468	21476		10.1074/jbc.M002682200	http://dx.doi.org/10.1074/jbc.M002682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10806208	hybrid			2022-12-25	WOS:000088230600069
J	Opuni, K; Reeves, JP				Opuni, K; Reeves, JP			Feedback inhibition of sodium/calcium exchange by mitochondrial calcium accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA2+ CONCENTRATION; HAMSTER OVARY CELLS; CARDIAC MYOCYTES; DEHYDROGENASE ACTIVATION; INTERMEDIATE FILAMENTS; DEPENDENT REGULATION; NA+/CA2+ EXCHANGER; MODULATION; ATP; PHOSPHORYLATION	Chinese hamster ovary cells expressing the bovine cardiac Na+/Ca2+ exchanger were subjected to two periods of 5 and 3 min, respectively, during which the extracellular Na+ concentration ([Na+](o)) was reduced to 20 mM; these intervals were separated by a 5-min recovery period at 140 mM Na-o(+). The cytosolic Ca2+ concentration ([Ca2+](i)) increased during both intervals due to Na+-dependent Ca2+ influx by the exchanger. However, the peak rise in [Ca2+](i) during the second interval was only 26% of the first. The reduced rise in [Ca2+](i) was due to an inhibition of Na+/Ca2+ exchange activity rather than increased Ca2+ sequestration since the influx of Ba2+, which is not sequestered by internal organelles, was also inhibited by a prior interval of Ca2+ influx. Mitochondria accumulated Ca2+ during the first interval of reduced [Na+](o). as determined by an increase in fluorescence of the Ca2+-indicating dye rhod-2, which preferentially labels mitochondria. Agents that blocked mitochondrial Ca2+ accumulation (uncouplers, nocodazole) eliminated the observed inhibition of exchange activity during the second period of low [Na+](o). Conversely, diltiazem, an inhibitor of the mitochondrial Na+/Ca2+ exchanger, increased mitochondrial Ca2+ accumulation and also increased the inhibition of exchange activity. We conclude that Na+/Ca2+ exchange activity is regulated by a feedback inhibition process linked to mitochondrial Ca2+ accumulation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reeves, JP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Grad Sch Biomed Sci, 185 S Orange Ave, Newark, NJ 07103 USA.	reeves@umdnj.edu			NHLBI NIH HHS [HL49932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049932] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Condrescu M, 1999, J BIOL CHEM, V274, P33279, DOI 10.1074/jbc.274.47.33279; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; Condrescu M, 1999, BIOPHYS J, V76, pA253; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; COX DA, 1993, J CARDIOVASC PHARM, V21, P595, DOI 10.1097/00005344-199304000-00013; COX DA, 1993, TRENDS PHARMACOL SCI, V14, P408, DOI 10.1016/0165-6147(93)90063-P; DILISA F, 1993, CARDIOVASC RES, V27, P1840; DiPolo R, 1999, BBA-REV BIOMEMBRANES, V1422, P57, DOI 10.1016/S0005-2736(99)00002-4; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; He SW, 1998, J NEUROSCI, V18, P4833; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Ohata H, 1998, J BIOENERG BIOMEMBR, V30, P207, DOI 10.1023/A:1020588618496; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; Reeves JP, 1998, J BIOENERG BIOMEMBR, V30, P151, DOI 10.1023/A:1020569224915; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REEVES JP, 1998, INTERNET ASS BIOMEDI; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Shigekawa M, 1996, ANN NY ACAD SCI, V779, P249, DOI 10.1111/j.1749-6632.1996.tb44791.x; SOLTYS BJ, 1992, BIOCHEM CELL BIOL, V70, P1174, DOI 10.1139/o92-163; SUMMERHAYES IC, 1983, J CELL SCI, V61, P87	33	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21549	21554		10.1074/jbc.M003158200	http://dx.doi.org/10.1074/jbc.M003158200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801871	hybrid			2022-12-25	WOS:000088230600079
J	Ishii, T; Itoh, K; Takahashi, S; Sato, H; Yanagawa, T; Katoh, Y; Bannai, S; Yamamoto, M				Ishii, T; Itoh, K; Takahashi, S; Sato, H; Yanagawa, T; Katoh, Y; Bannai, S; Yamamoto, M			Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ANTIOXIDANT-RESPONSIVE ELEMENTS; MOUSE PERITONEAL-MACROPHAGES; NF-KAPPA-B; HYDROGEN-PEROXIDE; TRANSPORT ACTIVITY; SODIUM ARSENITE; FAMILY PROTEINS; SUBUNIT GENE	Electrophiles and reactive oxygen species have been implicated in the pathogenesis of many diseases. Transcription factor Nrf2 was recently identified as a general regulator of one defense mechanism against such havoc. Nrf2 regulates the inducible expression of a group of detoxication enzymes, such as glutathione S-transferase and NAD(P)H:quinone oxidoreductase, via antioxidant response elements. Using peritoneal macrophages from Nrf2-deficient mice, we show here that Nrf2 also controls the expression of a group of electrophile and oxidative stress-inducible proteins and activities, which includes heme oxygenase-l, A170, peroxiredoxin MSP23, and cystine membrane transport (system x(c)(-)) activity. The response to electrophilic and reactive oxygen species-producing agents was profoundly impaired in Nrf2-deficient cells. The lack of induction of system x(c)(-) activity resulted in the minimum level of intracellular glutathione, and Nrf2-deficient cells were more sensitive to toxic electrophiles. Several stress agents induced the DNA binding activity of Nrf2 in the nucleus without increasing its mRNA level. Thus Nrf2 regulates a wide-ranging metabolic response to oxidative stress.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba; University of Tsukuba	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.		Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013; Longo, Kenneth A/A-5631-2010; Yanagawa, Toru/GYU-6448-2022	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Yanagawa, Toru/0000-0003-0868-2563				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; BANNAI S, 1984, J BIOL CHEM, V259, P2435; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chen Q, 1997, MOL PHARMACOL, V52, P648, DOI 10.1124/mol.52.4.648; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; EATON DL, 1994, TOXICOL APPL PHARM, V126, P145, DOI 10.1006/taap.1994.1100; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Galloway DC, 1997, BIOCHEM J, V328, P99; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; ISHII T, 1993, J BIOL CHEM, V268, P18633; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J., 2002, MOL CLONING LAB MANU; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sie H, 1991, AM J MED, V9, P31, DOI DOI 10.1016/0002-9343(91)90281-2; TAKETANI S, 1990, J BIOCHEM-TOKYO, V108, P28, DOI 10.1093/oxfordjournals.jbchem.a123156; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	43	1188	1220	2	81	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16023	16029		10.1074/jbc.275.21.16023	http://dx.doi.org/10.1074/jbc.275.21.16023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821856	hybrid			2022-12-25	WOS:000087291400057
J	Asahi, M; McKenna, E; Kurzydlowski, K; Tada, M; MacLennan, DH				Asahi, M; McKenna, E; Kurzydlowski, K; Tada, M; MacLennan, DH			Physical interactions between phospholamban and sarco(endo)plasmic reticulum Ca2+-ATPases are dissociated by elevated Ca2+, but not by phospholamban phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; MYOCARDIAL-CONTRACTILITY; FUNCTIONAL ASSOCIATION; CYTOPLASMIC DOMAIN; TRANSPORT ATPASE; PROTEIN-KINASE; MECHANISM; PUMP; CALCIUM; SITES	Previous co-immunoprecipitation studies (Asahi, M,, Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1999) J, Biol, Chem. 274, 32855-32862) revealed that physical interactions between phospholamban (PLN) and the fast-twitch skeletal muscle sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA1a) were retained, even with PLN monoclonal antibody 1D11 bound to an epitope lying between PLN residues 7 and 17, Because the 1D11 antibody relieves inhibitory interaction between the two proteins, it was of interest to determine whether PLN phosphorylation or elevation of Ca2+, which also relieves inhibitory interactions between PLN and SERCA, would disrupt physical interactions. Co-immunoprecipitation was measured in the presence of increasing concentrations of Ca2+ or after phosphorylation of PLN by protein kinase k Physical interactions were dissociated by elevated Ca2+ but not by PLN phosphorylation, The addition of ATP enhanced interactions between PLN and SERCA. The further addition of vanadate and thapsigargin, both of which stabilize the E-2 conformation, did not diminish binding of PLN to SERCA. These data suggest that physical interactions between PLN and SERCA are stable when SERCA is in the Ca2+-free E-2 conformation but not when it is in the E-1 conformation and that phosphorylation of PLN does not dissociate physical interactions between PLN and SERCA.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Merck Res Labs, Dept Pharmacol, West Point, PA 19486 USA; Osaka Univ, Sch Med, Dept Med & Pathophysiol, Suita, Osaka 5650891, Japan	University of Toronto; Merck & Company; Osaka University	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JONES LR, 1993, J BIOL CHEM, V268, P11486; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; Mayer EJ, 2000, BIOCHEM BIOPH RES CO, V267, P40, DOI 10.1006/bbrc.1999.1920; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; Negash S, 1996, BIOCHEMISTRY-US, V35, P11247, DOI 10.1021/bi960864q; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PICK U, 1982, J BIOL CHEM, V257, P6111; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SASAKI T, 1992, J BIOL CHEM, V267, P1674; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; TADA M, 1975, J BIOL CHEM, V250, P2640; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	36	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15034	15038		10.1074/jbc.275.20.15034	http://dx.doi.org/10.1074/jbc.275.20.15034			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809745	hybrid			2022-12-25	WOS:000087128300038
J	De Laurenzi, V; Raschella, G; Barcaroli, D; Annicchiarico-Petruzzelli, M; Ranalli, M; Catani, MV; Tanno, B; Costanzo, A; Levrero, M; Melino, G				De Laurenzi, V; Raschella, G; Barcaroli, D; Annicchiarico-Petruzzelli, M; Ranalli, M; Catani, MV; Tanno, B; Costanzo, A; Levrero, M; Melino, G			Induction of neuronal differentiation by p73 in a neuroblastoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; APOPTOTIC RESPONSE; DNA-DAMAGE; P53; GENE; EXPRESSION; IDENTIFICATION; PROMOTER; PROTEIN; CANCERS	The p53-related p73 and p63 genes encode proteins that share considerable structural and functional homology with p53, Despite similarities, their deletion in mice has different outcomes, implying that the three genes may play distinct roles in vivo. Here we show that endogenous p73 levels increase in neuroblastoma cells induced to differentiate by retinoic acid and that exogenously expressed p73, but not p53, is sufficient to induce both morphological (neurite outgrowth) and biochemical (expression of neurofilaments and neural cell adhesion molecule (N-CAM); down-regulation of N-MYC and up-regulation of pRB) markers of neuronal differentiation. This activity is shared, to different extents, by all p73 isoforms, whereas the transcriptionally inactive mutants of p73 isoforms are ineffective. Conversely, blockage of endogenous p73 isoforms with a dominant negative p73 results in the abrogation of retinoid-induced N-CAM promoter-driven transcription. Our results indicate that the p73 isoforms activate a pathway that is not shared by p53 and that is required for neuroblastoma cell differentiation in vitro.	Tor Vergata Univ, Dept Expt Med, Biochem Lab, IRCCS,IDI, I-00133 Rome, Italy; ENEA, Sect Toxicol & Biochem Sci, I-00060 Rome, Italy; Univ Rome La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Italian National Agency New Technical Energy & Sustainable Economics Development; Sapienza University Rome	Melino, G (corresponding author), Tor Vergata Univ, Dept Expt Med, Biochem Lab, IRCCS,IDI, Via Tor Vergata 135, I-00133 Rome, Italy.		Costanzo, Antonio/GZG-2433-2022; Catani, M. Valeria/ABA-6919-2021; Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Costanzo, Antonio/D-3896-2012; De Laurenzi, Vincenzo/K-7471-2016; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Catani, M. Valeria/0000-0002-7088-9242; Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; De Laurenzi, Vincenzo/0000-0002-7506-1743; Levrero, Massimo/0000-0002-4978-0875				Agami R, 1999, NATURE, V399, P809; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; BARTON CH, 1990, BIOCHEM J, V268, P161, DOI 10.1042/bj2680161; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Ferreira A, 1996, J CELL SCI, V109, P1509; Gong JG, 1999, NATURE, V399, P806; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Nomoto S, 1998, CANCER RES, V58, P1380; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; SOZZI G, 1988, CANCER GENET CYTOGEN, V30, P151, DOI 10.1016/0165-4608(88)90104-5; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tsao H, 1999, CANCER RES, V59, P172; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	31	146	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15226	15231		10.1074/jbc.275.20.15226	http://dx.doi.org/10.1074/jbc.275.20.15226			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809758	hybrid			2022-12-25	WOS:000087128300062
J	Lehman, AL; Dahmus, ME				Lehman, AL; Dahmus, ME			The sensitivity of RNA polymerase II in elongation complexes to C-terminal domain phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; MAJOR LATE PROMOTER; HIV-1 TAT PROTEIN; PRE-MESSENGER-RNA; IN-VITRO; P-TEFB; SACCHAROMYCES-CEREVISIAE; CALF THYMUS; INITIATION; INVITRO	The phosphorylation state of the carboxyl-terminal domain (CTD) of the largest RNA polymerase (RNAP) II subunit plays an important role in the regulation of transcript elongation. This report examines the sensitivity of RNAP II to dephosphorylation by CTD phosphatase (CTDP) and addresses factors that regulate its sensitivity. The CTDP sensitivity of RNAP IIO in paused elongation complexes on a dC-tailed template does not significantly differ from that of free RNAP IIO. RNAP IIO contained in elongation complexes that initiate transcription from the adenovirus-2 major late promoter in the presence of a nuclear extract is relatively resistant to dephosphorylation. Complexes treated with 1% Sarkosyl remain elongation-competent but demonstrate a 5-fold increase in CTDP sensitivity. Furthermore, the sensitivity of RNAP IIO in both control and Sarkosyl-treated elongation complexes is dependent on their position relative to the start site of transcription. Elongation complexes 11-24 nucleotides downstream are more sensitive to dephosphorylation than complexes 50-150 nucleotides downstream. The incubation of Sarkosyl-treated elongation complexes with nuclear extract restores the original resistance to dephosphorylation. These results suggest that a conformational change occurs in RNAP II as it clears the promoter, which results in an increased resistance to dephosphorylation. Furthermore, the sensitivity to dephosphorylation can be modulated by a factor(s) present in the nuclear extract.	Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Dahmus, ME (corresponding author), Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAI H, 1987, J BIOL CHEM, V262, P298; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; Coin F, 1998, COLD SPRING HARB SYM, V63, P105, DOI 10.1101/sqb.1998.63.105; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANG ME, 1993, J BIOL CHEM, V268, P25033; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P289; Luse DS, 1998, COLD SPRING HARB SYM, V63, P289, DOI 10.1101/sqb.1998.63.289; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moreland RJ, 1998, J BIOL CHEM, V273, P26610, DOI 10.1074/jbc.273.41.26610; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	51	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14923	14932		10.1074/jbc.275.20.14923	http://dx.doi.org/10.1074/jbc.275.20.14923			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809737	hybrid			2022-12-25	WOS:000087128300023
J	Moon, YA; Lee, JJ; Park, SW; Ahn, YH; Kim, KS				Moon, YA; Lee, JJ; Park, SW; Ahn, YH; Kim, KS			The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE PROMOTER; TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIATION FACTOR-1; CULTURED-CELLS; IN-VITRO; GENE; EXPRESSION; LIVER; CHOLESTEROL	ATP citrate-lyase (ACL) is a key enzyme supplying acetyl-CoA for fatty acid and cholesterol synthesis. Its expression is drastically up-regulated when an animal is fed a low fat, high carbohydrate diet after prolonged fasting. In this report, we describe the role of sterol regulatory element-binding proteins (SREBPs) in the transactivation of the rat ACL promoter. ACL promoter activity was markedly stimulated by the overexpression of SREBP-1a and, to a lesser extent, by SREBP-2 in Alexander human hepatoma cells. The promoter elements responsive to SREBPs were located within the 55-base pair sequences from -114 to -60. The gel mobility shift assay revealed four SREBP-1a binding sites in this region. Of these four elements, the -102/-94 region, immediately upstream of the inverted Y-box, and the -70/-61 region, just adjacent to Sp1 binding site, played critical roles in SREBPs-mediated stimulation. The mutation in the inverted Y-box and the coexpression of dominant negative nuclear factor-Y (NF-Y) significantly attenuated the transactivation by SREBP-1a, suggesting that NF-Y binding is a prerequisite for SREBPs to activate the ACL promoter. However, the multiple Sp1 binding sites did not affect the transactivation of the ACL promoter by SREBPs. The binding affinity of SREBP-1a to SREs of the ACL promoter also was much higher than that of SREBP-2. The transactivation potencies of the chimeric SREBPs, of which the activation domains (70 amino acids of the amino terminus) were derived from the different species of their carboxyl-terminal region, were similar to those of SREBPs corresponding to their carboxyl termini. Therefore, it is suggested that the carboxyl-terminal portions of SREBPs containing DNA binding domains are important in determining their transactivation potencies to a certain promoter.	Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Kwandong Univ, Coll Med, Dept Biochem, Kangnung 210701, Jangwon Do, South Korea	Yonsei University; Yonsei University Health System; Catholic Kwandong University	Kim, KS (corresponding author), Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, 134 Shinchon Dong, Seoul 120752, South Korea.		AHN, Yong Ho/H-6712-2017	AHN, Yong Ho/0000-0002-4133-0757; Kim, Kyung-sup/0000-0001-8483-8537; Park, Sahng Wook/0000-0002-9594-7074				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Gibson D M, 1972, Adv Enzyme Regul, V10, P187, DOI 10.1016/0065-2571(72)90014-3; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gribble AD, 1998, J MED CHEM, V41, P3582, DOI 10.1021/jm980091z; Guan GM, 1997, J BIOL CHEM, V272, P10295; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KIM KS, 1992, BIOCHEM BIOPH RES CO, V189, P264, DOI 10.1016/0006-291X(92)91553-3; KIM KS, 1994, BIOCHEM J, V302, P759, DOI 10.1042/bj3020759; KORNACKER MS, 1965, P NATL ACAD SCI USA, V54, P899, DOI 10.1073/pnas.54.3.899; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Park SW, 1997, BBA-GENE STRUCT EXPR, V1353, P236, DOI 10.1016/S0167-4781(97)00094-8; Pearce NJ, 1998, BIOCHEM J, V334, P113, DOI 10.1042/bj3340113; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG XD, 1993, J BIOL CHEM, V268, P14497	36	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30280	30286		10.1074/jbc.M001066200	http://dx.doi.org/10.1074/jbc.M001066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10801800	hybrid			2022-12-25	WOS:000089577900051
J	Chen, YH; Ramos, KS				Chen, YH; Ramos, KS			A CCAAT/enhancer-binding protein site within antioxidant/electrophile response element along with CREB-binding protein participate in the negative regulation of rat GST-Ya gene in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; RECEPTOR NUCLEAR TRANSLOCATOR; UPSTREAM STIMULATORY FACTOR-1; MEDIATED SIGNAL-TRANSDUCTION; MOUSE AH RECEPTOR; C-HA-RAS; TRANSCRIPTIONAL ACTIVATION; SUBUNIT GENE; DNA-BINDING; INDUCIBLE EXPRESSION	Studies were conducted to evaluate the negative regulatory function of rat (r)GST-Ya antioxidant/electrophile response element (ARE/EpRE) in vascular smooth muscle cells (vSMCs), We report that CCAAT/enhancerbinding protein (C/EBP)-beta interacts with ARE/EpRE in the rGST-Ya promoter and that aryl hydrocarbon receptor (AhR) is present within the protein complex binding to the C/EBP site. Overexpression of C/EBP-beta or C/EBP-alpha repressed, whereas AhR enhanced, 1.6CAT reporter activity in cells treated with benzo(a)pyrene (BaP). Overexpression of CREB-binding protein (CBP) nullified repression of rGST-Ya transcription. Human adenovirus E1A protein abrogated cotransactivation by CBP but an E1A mutant did not. Overexpression of C/EBPs abrogated stimulation of 1.6CAT by CBP or AhR alone, or in combination, regardless of BaP treatment. Similar profiles were observed using an AhRECAT construct. The C/EBP site within the ARE/EpRE inhibited chemical inducibility of the AhRE. The pattern of mouse GST-Ya regulation by BaP was similar to that of rGST Ya. We conclude that multiple mechanisms mediate negative regulation of GST-Ya gene in vSMCs, most significant of which are that C/EBP-beta inhibits AhRE or ARE/EpRE inducibility of GST-Ya, limiting CBP levels compromise gene induction, functional interference exists between AhRE and ARE/EpRE, and AhR alone, or in combination with C/EBP-beta, functions as a repressor of the ARE/EpRE.	Texas A&M Univ, Coll Vet Med, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Ramos, KS (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, R01ES004849] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04849, ES 09106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bral CM, 1997, MOL PHARMACOL, V52, P974, DOI 10.1124/mol.52.6.974; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARRIER F, 1994, BIOCHEM PHARMACOL, V48, P1767, DOI 10.1016/0006-2952(94)90463-4; Chen YH, 1999, BIOCHEM BIOPH RES CO, V265, P18, DOI 10.1006/bbrc.1999.1609; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; DANIEL V, 1987, DNA-J MOLEC CELL BIO, V6, P317, DOI 10.1089/dna.1987.6.317; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; He NG, 1998, TOXICOL APPL PHARM, V152, P83, DOI 10.1006/taap.1998.8511; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JAKOBY WB, 1977, TRENDS BIOCHEM SCI, V2, P229, DOI 10.1016/0968-0004(77)90116-5; Jakoby WB, 1984, PROGR DRUG METABOLIS, V8, P11; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang L, 1996, BIOCHEMISTRY-US, V35, P13136, DOI 10.1021/bi960844o; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASHFI K, 1994, BIOCHEM PHARMACOL, V47, P1903, DOI 10.1016/0006-2952(94)90321-2; Kobayashi A, 1997, J BIOCHEM, V122, P703; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI H, 1994, J BIOL CHEM, V269, P28098; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISRA P, 1995, TOXICOL APPL PHARM, V133, P27, DOI 10.1006/taap.1995.1123; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; OU XL, 1995, ARCH BIOCHEM BIOPHYS, V316, P116, DOI 10.1006/abbi.1995.1017; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PESSAHRASMUSSEN H, 1993, INT ANGIOL, V12, P348; PIMENTAL RA, 1993, MOL CELL BIOL, V13, P4365, DOI 10.1128/MCB.13.7.4365; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; Ramos KS, 1999, ANNU REV PHARMACOL, V39, P243, DOI 10.1146/annurev.pharmtox.39.1.243; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1993, STRUCTURE FUNCTION G, P119; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3862; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; SMITH GJ, 1980, CANCER RES, V40, P1787; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; Takahashi Y, 1997, BIOCHEM BIOPH RES CO, V240, P293, DOI 10.1006/bbrc.1997.7651; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796	66	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27366	27376						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10818089				2022-12-25	WOS:000089144800094
J	Huque, Y; Fieschi, F; Torrents, E; Gibert, I; Eliasson, R; Reichard, P; Sahlin, M; Sjoberg, BM				Huque, Y; Fieschi, F; Torrents, E; Gibert, I; Eliasson, R; Reichard, P; Sahlin, M; Sjoberg, BM			The active form of the R2F protein of class Ib ribonucleotide reductase from Corynebacterium ammoniagenes is a diferric protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; MAGNETIC-RESONANCE; MANGANESE IONS; IRON CENTER; CATALASE; ENZYME; SITE; SPECTROSCOPY; ACTIVATION	Corynebacterium ammoniagenes contains a ribonucleotide reductase (RNR) of the class Ib type. The small subunit (R2F) of the enzyme has been proposed to contain a manganese center instead of the dinuclear iron center, which in other class I RNRs is adjacent to the essential tyrosyl radical. The nrdF gene of C, ammoniagenes, coding for the R2F component, was cloned in an inducible Escherichia coli expression vector and overproduced under three different conditions: in manganese-supplemented medium, in iron-supplemented medium, and in medium without addition of metal ions. A prominent typical tyrosyl radical EPR signal was observed in cells grown in rich medium. Iron-supplemented medium enhanced the amount of tyrosyl radical, whereas cells grown in manganese-supplemented medium had no such radical. In highly purified R2F protein, enzyme activity was found to correlate with tyrosyl radical content, which in turn correlated with iron content, Similar results were obtained for the R2F protein of Salmonella typhimurium class Ib RNR, The UV-visible spectrum of the C, ammoniagenes R2F radical has a sharp 408-nm band. Its EPR signal at g = 2.005 is identical to the signal of S. typhimurium R2F and has a doublet with a splitting of 0.9 millitesla (mT), with additional hyperfine splittings of 0.7 mT, According to X-band EPR at 77-95 K, the inactive manganese form of the C, ammoniagenes R2F has a coupled dinuclear Mn(II) center. Different attempts to chemically oxidize Mn-R2F showed no relation between oxidized manganese and tyrosyl radical formation, Collectively, these results demonstrate that enzymatically active C. ammoniagenes RNR is a generic class Ib enzyme, with a tyrosyl radical and a diferric metal cofactor.	Stockholm Univ, Arrhenius Labs F3, Dept Mol Biol, S-10691 Stockholm, Sweden; Inst Biol Struct, Lab Cristallog Macromol, F-38027 Grenoble 1, France; Autonomous Univ Barcelona, Dept Genet & Microbiol, Bellaterra 08193, Spain; Autonomous Univ Barcelona, Inst Biol Fonamental, Bacterial Mol Genet Grp, Bellaterra 08193, Spain; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Stockholm University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Autonomous University of Barcelona; Autonomous University of Barcelona; Karolinska Institutet	Sjoberg, BM (corresponding author), Stockholm Univ, Arrhenius Labs F3, Dept Mol Biol, S-10691 Stockholm, Sweden.		Fieschi, Franck/W-2748-2019; Torrents, Eduard/C-7184-2008; Gibert, Isidre/L-9834-2014	Torrents, Eduard/0000-0002-3010-1609; Gibert, Isidre/0000-0003-1442-2258; FIESCHI, Franck/0000-0003-1194-8107; Sjoberg, Britt-Marie/0000-0001-5953-3360				Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; ATTA M, 1992, J BIOL CHEM, V267, P20682; AULING G, 1994, MET IONS BIOL SYST, V30, P131; Barynin VV, 1997, J INORG BIOCHEM, V67, P196, DOI [10.1128/AEM.70.7.3839-3844, DOI 10.1128/AEM.70.7.3839-3844]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunold TC, 1998, J AM CHEM SOC, V120, P8724, DOI 10.1021/ja981394l; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Fieschi F, 1998, J BIOL CHEM, V273, P4329, DOI 10.1074/jbc.273.8.4329; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; Griepenburg U, 1998, BIOCHEMISTRY-US, V37, P7992, DOI 10.1021/bi972801t; GRIEPENBURG U, 1996, FREE RADICAL RES, V26, P473; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; KHANGULOV S, 1993, BIOCHEMISTRY-US, V32, P4912, DOI 10.1021/bi00069a028; KHANGULOV SV, 1990, BIOCHIM BIOPHYS ACTA, V1020, P305, DOI 10.1016/0005-2728(90)90161-V; KHANGULOV SV, 1995, BIOCHEMISTRY-US, V34, P2015, DOI 10.1021/bi00006a023; KHANGULOV SV, 1990, BIOCHIM BIOPHYS ACTA, V1020, P25, DOI 10.1016/0005-2728(90)90089-M; Larsson A, 1996, EUR J BIOCHEM, V237, P58, DOI 10.1111/j.1432-1033.1996.0058n.x; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Oehlmann W, 1998, BIOTECHNOL LETT, V20, P483, DOI 10.1023/A:1005492213490; OKA T, 1968, J BACTERIOL, V96, P1760, DOI 10.1128/JB.96.5.1760-1767.1968; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIMPFFWEILAND G, 1981, BIOCHEM BIOPH RES CO, V102, P1276, DOI 10.1016/S0006-291X(81)80149-0; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	37	51	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25365	25371		10.1074/jbc.M002751200	http://dx.doi.org/10.1074/jbc.M002751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10801858	hybrid, Green Published			2022-12-25	WOS:000088849400044
J	Mongiat, M; Mungiguerra, G; Bot, S; Mucignat, MT; Giacomello, E; Doliana, R; Colombatti, A				Mongiat, M; Mungiguerra, G; Bot, S; Mucignat, MT; Giacomello, E; Doliana, R; Colombatti, A			Self-assembly and supramolecular organization of EMILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; HUMAN COLLAGEN-X; IN-VITRO; VIII COLLAGEN; GLOBULAR DOMAIN; NECROSIS-FACTOR; ALPHA-1(X) NC1; CDNA SEQUENCE; TRIPLE-HELIX; GLYCOPROTEIN	The primary structure of human Elastin microfibril interface-located protein (EMILIN), an elastic fiber-associated glycoprotein, consists of a globular Clq domain (gC1q) at the C terminus, a short collagenous stalk, a long region with a high potential for forming coiled-coil CY helices, and a cysteine-rich N-terminal sequence. It is not known whether the EMILIN gC1q domain is involved in the assembly process and in the supramolecular organization as shown for the similar domain of collagen X By employing the yeast two-hybrid system the EMILIN gC1q domains interacted with themselves, proving for the first time that this interaction occurs in vivo. The gC1q domain formed oligomers running as trimers in native gels that were less stable than the comparable trimers of the collagen X gC1q domain since they did not withstand heating. The collagenous domain was trypsin-resistant and migrated at a size corresponding to a triple helix under native conditions. In reducing agarose gels, EMILIN also migrated as a trimer, whereas under non-reducing conditions it formed polymers of many millions of daltons, A truncated fragment lacking gC1q and collagenous domains assembled to a much lesser extent, thus deducing that the C-terminal domain(s) are essential for the formation of trimers that finally assemble into large EMILIN multimers.	Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy.	acolombatti@ets.it	Doliana, Roberto/AAA-1479-2019; Mucignat, Maria Teresa/AAY-3908-2020; Mongiat, Maurizio/H-8297-2018; Giacomello, Emiliana/E-3080-2018	Doliana, Roberto/0000-0002-8324-7564; Mucignat, Maria Teresa/0000-0002-9601-054X; Mongiat, Maurizio/0000-0001-6509-0068; Giacomello, Emiliana/0000-0003-3329-6269; colombatti, alfonso/0000-0002-3676-2379	Telethon [E.0704] Funding Source: Medline	Telethon(Fondazione Telethon)		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; Doliana R, 1999, J BIOL CHEM, V274, P16773, DOI 10.1074/jbc.274.24.16773; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; Greenhill NS, 2000, MATRIX BIOL, V19, P19, DOI 10.1016/S0945-053X(99)00053-0; HAYWARD CPM, 1991, BLOOD, V77, P2556; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; KITTELBERGER R, 1989, BIOCHEM BIOPH RES CO, V159, P414, DOI 10.1016/0006-291X(89)90007-7; KOHNFELDT E, 1997, FEBS LETT, V414, P557; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; MENENDEZARIAS L, 1988, COMPUT APPL BIOSCI, V4, P479; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEROSA F, 1990, J IMMUNOL METHODS, V128, P9, DOI 10.1016/0022-1759(90)90458-8; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; Reid K B, 1989, Behring Inst Mitt, P8; Rosenblum ND, 1996, BIOCHEM BIOPH RES CO, V227, P205, DOI 10.1006/bbrc.1996.1490; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	53	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25471	25480		10.1074/jbc.M001426200	http://dx.doi.org/10.1074/jbc.M001426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10821830	hybrid			2022-12-25	WOS:000088849400057
J	Nechaev, S; Chlenov, M; Severinov, K				Nechaev, S; Chlenov, M; Severinov, K			Dissection of two hallmarks of the open promoter complex by mutation in an RNA polymerase core subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-SUBUNIT; TRANSCRIPTION INITIATION; ACTIVE-CENTER; DNA; MUTANTS; SIGMA(70); MECHANISM; PATHWAY; PROTEIN	Deletion of 10 evolutionarily conserved amino acids from the beta subunit of Escherichia coli RNA polymerase leads to a mutant enzyme that is unable to efficiently hold onto DNA, Open promoter complexes formed by the mutant enzyme are in rapid equilibrium with closed complexes and, unlike the wild-type complexes, are highly sensitive to the DNA competitor heparin (Martin, E,, Sagitov, V,, Burova, E., Nikiforov, V,, and Goldfarb, A (1992) J, Biol, Chem. 267, 20175-20180), Here we show that despite this instability, the mutant enzyme forms partially open complexes at temperatures as low as 0 degrees C when the wild-type complex is fully closed. Thus, the two hallmarks of the open promoter complex, the stability toward a challenge with DNA competitors and the sensitivity toward low temperature, can be uncoupled by mutation and may be independent in the wild-type complex. We use the high resolution structure of Thermus aquaticus RNA polymerase core to build a functional model of promoter complex formation that accounts for the observed defects of the E. coli RNA polymerase mutants.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Inst Mol Genet, Moscow 123182, Russia	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016; Nechaev, Sergei/AAQ-3450-2021		NIGMS NIH HHS [R01 GM30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KORZHEVA N, 2000, IN PRESS SCIENCE; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; Li XY, 1998, J BIOL CHEM, V273, P23549, DOI 10.1074/jbc.273.36.23549; MARTIN E, 1992, J BIOL CHEM, V267, P20175; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Ozoline ON, 1997, NUCLEIC ACIDS RES, V25, P4703, DOI 10.1093/nar/25.23.4703; POLYAKOV A, 1995, CELL, V83, P33; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; WALDBURGER C, 1990, J MOL BIOL, V215, P579; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	33	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25516	25522		10.1074/jbc.M002511200	http://dx.doi.org/10.1074/jbc.M002511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10811806	hybrid			2022-12-25	WOS:000088849400063
J	Hosoda, H; Kojima, M; Matsuo, H; Kangawa, K				Hosoda, H; Kojima, M; Matsuo, H; Kangawa, K			Purification and characterization of rat des-Gln(14)-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; PROTEIN-COUPLED RECEPTOR; NATRIURETIC PEPTIDE; BIOLOGICAL-ACTIVITIES; MOLECULAR-BIOLOGY; BRAIN; NEUROPEPTIDE; PITUITARY; SECRETION; AGONIST	Ghrelin, a peptide purified from the stomach, is an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) and potently stimulates growth hormone release from the pituitary, Ghrelin is modified with an n-octanoyl group at Ser(3). This modification is essential for the activity of ghrelin, Previously, it was not known whether other ligands for GHS-R existed. Here, we report the purification of the second endogenous ligand for GHS-B from rat stomach. This ligand, named des-Gln(14)-ghrelin, is a 27-amino acid peptide, whose sequence is identical to ghrelin except for one glutamine, Southern blotting analysis under low hybridization conditions indicates that no homologue for ghrelin exists in rat genomic DNA. Furthermore, genomic sequencing and cDNA analysis indicate that des-Gln(14)- ghrelin is not encoded by a gene distinct from ghrelin but is encoded by an mRNA created by alternative splicing of the ghrelin gene. This is the first example of a novel mechanism that produces peptide multiplicity, Des-Gln(14)-ghrelin has an n-octanoyl modification at Ser(3) like ghrelin, which is also essential for its activity. Des-Gln(14)-ghrelin-stimulated growth hormone releases when injected into rats. Thus, growth hormone release is regulated by two gastric peptides, ghrelin and des-Gln(14)-ghrelin.	Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Kojima, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Biochem, Fujishirodai 5-7-1, Suita, Osaka 5658565, Japan.	mkojima@ri.ncvc.go.jp						ABURAYA M, 1991, BIOCHEM BIOPH RES CO, V177, P40, DOI 10.1016/0006-291X(91)91945-9; Ames RS, 1999, NATURE, V401, P282, DOI 10.1038/45809; Bowers CY, 1998, CELL MOL LIFE SCI, V54, P1316, DOI 10.1007/s000180050257; BOWERS CY, 1980, ENDOCRINOLOGY, V106, P663, DOI 10.1210/endo-106-3-663; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; KOJIMA M, 1994, J BIOL CHEM, V269, P13136; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MINAMINO N, 1991, BIOCHEM BIOPH RES CO, V179, P535, DOI 10.1016/0006-291X(91)91404-Z; Muller EE, 1999, PHYSIOL REV, V79, P511, DOI 10.1152/physrev.1999.79.2.511; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/pnas.92.15.7001; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSENFELD MG, 1992, ANN NY ACAD SCI, V657, P1, DOI 10.1111/j.1749-6632.1992.tb22754.x; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; TATEMOTO K, 1985, BIOCHEM BIOPH RES CO, V128, P947, DOI 10.1016/0006-291X(85)90138-X; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	29	296	318	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21995	22000		10.1074/jbc.M002784200	http://dx.doi.org/10.1074/jbc.M002784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801861	hybrid, Green Submitted			2022-12-25	WOS:000088363800035
J	Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K				Kinashi, T; Katagiri, K; Watanabe, S; Vanhaesebroeck, B; Downward, J; Takatsu, K			Distinct mechanisms of alpha(5)beta(1) integrin activation by Ha-Ras and R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MATRIX ADHESION; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; AFFINITY MODULATION; PHOSPHOLIPASE-C; LIGAND-BINDING; FIBRONECTIN; KINASE; RECEPTOR; TRANSFORMATION	To investigate the possible roles of the Ras/Rho family members in the inside-out signals to activate integrins, we examined the ability of Ras/Rho small GTPases to stimulate avidity of alpha(5)beta(1) (VLA-5) to fibronectin in bone marrow-derived mast cells. We found that both Ha-Ras(Val-12) and R-Ras(Val-38) had strong stimulatory effects on adhesion and ligand binding activity of VLA-5 to fibronectin, However, only Ha-Ras(Val-12)-, but not R-Ras(Val-38)-induced adhesion was inhibited by wortmannin, which suggests that Ha-Ras(Val-12) is dependent on phosphatidylinositol (PI) 3-kinase on adhesion whereas R-Ras(Val-38) has another PI 3-kinase independent pathway to induce adhesion. The effector loop mutant Ha-Ras(Val-12)E37G, but not Y40C retained the ability to stimulate adhesion of mast cells to fibronectin. Consistently, PI 3-kinase p110 delta, predominantly expressed in mast cells, interacted with Ha-Ras(Val-12) E37G, but not Y40C, which was also correlated with the levels of Akt phosphorylation in mast cells. Furthermore, marked adhesion was induced by a membrane-targeted version of p110 delta, These results indicate that Ha-Ras(Val-12) activated VLA-B through PI 3-kinase p110 delta. The mutational effects of the R-Ras effector loop region on adhesion were not correlated with PI 3-kinase activities, consistent with our contention that R-Ras has a distinct pathway to modulate avidity of VLA-5.	Kyoto Univ, Grad Sch Med, Dept Mol Immunol & Allergy, Bayer Chair,Sakyo Ku, Kyoto 6068501, Japan; Univ Tokyo, Inst Med Sci, Dept Immunol, Tokyo 108, Japan; Ludwig Inst Canc Res, Cell Signalling Lab, London W1P 8BT, England; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Kyoto University; University of Tokyo; Ludwig Institute for Cancer Research; Cancer Research UK	Takatsu, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Immunol, Bayer Chair,Sakyo Ku, Kyoto 6068501, Japan.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FORSYTH J, 1992, METHOD ENZYMOL, V215, P311; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kinashi T, 1999, J IMMUNOL, V162, P2850; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KINASHI T, 1994, BLOOD CELLS, V20, P25; KINASHI T, 1994, BLOOD, V83, P1033; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Levesque JP, 1996, BLOOD, V88, P1168, DOI 10.1182/blood.V88.4.1168.bloodjournal8841168; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Osada M, 1999, MOL CELL BIOL, V19, P6333; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pulcinelli FM, 1998, BIOCHEM PHARMACOL, V56, P1481, DOI 10.1016/S0006-2952(98)00146-4; RODRIGUEZ VP, 1996, EMBO J, V15, P2442; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shibayama H, 1999, BLOOD, V93, P1540, DOI 10.1182/blood.V93.5.1540.405k10_1540_1548; SMYTH SS, 1993, BLOOD, V81, P2827; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SPRINGER TA, 1990, NATURE, V346, P426; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Walker EM, 1998, BIOCHEM PHARMACOL, V56, P1455, DOI 10.1016/S0006-2952(98)00256-1; Wei JY, 1997, J LEUKOCYTE BIOL, V61, P397, DOI 10.1002/jlb.61.4.397; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; ZANG Z, 1996, CELL, V85, P61	48	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22590	22596		10.1074/jbc.M000633200	http://dx.doi.org/10.1074/jbc.M000633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801791	hybrid			2022-12-25	WOS:000088363800113
J	Sambasivarao, D; Turner, RJ; Simala-Grantz, JL; Shaw, G; Hu, J; Weiner, JH				Sambasivarao, D; Turner, RJ; Simala-Grantz, JL; Shaw, G; Hu, J; Weiner, JH			Multiple roles for the twin arginine leader sequence of dimethyl sulfoxide reductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENGINEERED 3FE-4S CLUSTER; IRON-SULFUR CLUSTER; DIMETHYLSULFOXIDE REDUCTASE; TRANSLOCATION PATHWAY; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; THYLAKOID MEMBRANE; PLASMA-MEMBRANE; EXPORT PATHWAY	Dimethyl sulfoxide (Me2SO) reductase of Escherichia coli is a terminal electron transport chain enzyme that is expressed under anaerobic growth conditions and is required for anaerobic growth with Me2SO as the terminal electron acceptor. The trimeric enzyme is composed of a membrane extrinsic catalytic dimer (DmsAB) and a membrane intrinsic anchor (DmsC). The amino terminus of DmsA has a leader sequence with a twin arginine motif that targets DmsAB to the membrane via a novel Sec-independent mechanism termed MTT for membrane targeting and translocation. We demonstrate that the Met-1 present upstream of the twin arginine motif serves as the correct translational start site. The leader is essential for the expression of DmsA, stability of the DmsAB dimer, and membrane targeting of the reductase holoenzyme, Mutation of arginine 17 to aspartate abolished membrane targeting. The reductase was labile in the leader sequence mutants. These mutants failed to support growth on glycerol-Me2SO minimal medium. Replacing the DmsA leader with the TorA leader of trimethylamine N-oxide reductase produced a membrane-bound DmsABC with greatly reduced enzyme activity and inefficient anaerobic respiration indicating that the twin arginine leaders may play specific roles in the assembly of redox enzymes.	Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada	University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada.		Turner, Raymond J./M-3961-2015	Turner, Raymond J./0000-0002-9263-0776				Benoit S, 1998, J BACTERIOL, V180, P6625, DOI 10.1128/JB.180.24.6625-6634.1998; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Brink S, 1998, FEBS LETT, V434, P425, DOI 10.1016/S0014-5793(98)01028-X; DONGEN WV, 1988, FEMS MICROBIOL LETT, V50, P5; Dreusch A, 1997, BBA-BIOENERGETICS, V1319, P311, DOI 10.1016/S0005-2728(96)00174-0; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Halbig D, 1999, FEBS LETT, V447, P95, DOI 10.1016/S0014-5793(99)00269-0; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATOUR DJ, 1989, BIOCHEM CELL BIOL, V67, P251, DOI 10.1139/o89-038; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 1998, BIOCHEM J, V332, P35, DOI 10.1042/bj3320035; SAMBASIVARAO D, 1991, CURR MICROBIOL, V23, P105, DOI 10.1007/BF02092258; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Trieber CA, 1996, J BIOL CHEM, V271, P4620; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	33	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22526	22531		10.1074/jbc.M909289199	http://dx.doi.org/10.1074/jbc.M909289199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801884	hybrid			2022-12-25	WOS:000088363800103
J	Yang, ZY; Wara-Aswapati, N; Chen, CM; Tsukada, J; Auron, PE				Yang, ZY; Wara-Aswapati, N; Chen, CM; Tsukada, J; Auron, PE			NF-IL6 (C/EBP beta) vigorously activates il1b gene expression via a Spi-1 (PU.1) protein-protein tether	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROINTERLEUKIN-1-BETA GENE; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; REGULATORY DOMAIN; MOLECULAR-CLONING; IL-1-BETA GENE; FAMILY MEMBERS; NUCLEAR FACTOR; T-CELLS; C-JUN	Two classes of transcription factors, ETS and bZIP, stand out as key mediators of monocyte commitment and differentiation. The ETS domain factor Spi-1 (also called PU.1) and the bZIP factor NF-IL6 (also called C/EBP beta) have been shown to be involved in the transcriptional regulation of interleukin-1 beta gene (il1b) and other monocyte-specific genes. We now show that these two factors strongly cooperate on the il1b core promoter (-59/+12) in the absence of direct NF-IL6 binding to DNA. Transient transfection assays, using mutated il1b core promoters, showed that the Spi-1, but not the NF-IL6, binding site is absolutely required for functional cooperativity, Furthermore, the NF-IL6 transactivation domain (TAD) is functionally indispensable and more critical than that of Spi-1. Additionally, TAD-deficient NF-IL6 functions as a dominant negative for Spi-1-mediated activation, suggesting the involvement of the bZIP DNA binding domain. This is supported by the demonstration of in vitro interaction between the NF-IL6 bZIP and Spi-1 winged helix-turn-helix (wHTH) DNA binding domains, arguing that NF-IL6 vigorously activates the il1b core promoter via protein-tethered transactivation mediated by Spi-1.	Harvard Univ, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Hematol & Oncol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Auron, PE (corresponding author), Harvard Inst Med, Rm 245,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NCI NIH HHS [CA68544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; BURAS JA, 1994, J IMMUNOL, V152, P4444; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARK BD, 1988, MONOKINES OTHER NONL, P47; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAYNOR R, 1991, BLOOD, V77, P2618; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HEILAND S, 1995, MOL CELL BIOL, V15, P6623; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOLLINEDO F, 1991, EUR J BIOCHEM, V200, P483, DOI 10.1111/j.1432-1033.1991.tb16208.x; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; POLL V, 1990, CELL, V63, P643; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; SCOTT LM, 1992, BLOOD, V80, P1725; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Wara-Aswapati N, 1999, MOL CELL BIOL, V19, P6803; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	47	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21272	21277		10.1074/jbc.M000145200	http://dx.doi.org/10.1074/jbc.M000145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801783	hybrid			2022-12-25	WOS:000088230600043
J	Darbon, JM; Penary, M; Escalas, N; Casagrande, F; Goubin-Gramatica, F; Baudouin, C; Ducommun, B				Darbon, JM; Penary, M; Escalas, N; Casagrande, F; Goubin-Gramatica, F; Baudouin, C; Ducommun, B			Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR GENISTEIN; BREAST-CARCINOMA CELLS; TOPOISOMERASE-II; PROTEIN-KINASE; MAMMALIAN-CELLS; G(2) CHECKPOINT; RADIOSENSITIZING AGENT; CYCLE CHECKPOINT; LEUKEMIA-CELLS; G2 ARREST	Genistein, a natural isoflavone found in soybeans, exerts a number of biological actions suggesting that it may have a role in cancer prevention. We have previously shown that it potently inhibits OCM-1 melanoma cell proliferation by inducing a G(2) cell cycle arrest. Here we show that genistein exerts this effect by impairing the Cdc25C-dependent Tyr-15 dephosphorylation of Cdk1, as the overexpression of this phosphatase allows the cells to escape G(2) arrest and enter an abnormal chromatin condensation stage. Caffeine totally overrides the genistein-induced G(2) arrest, whereas the block caused by etoposide is not bypassed and that caused by adriamycin is only partially abolished. We also report that genistein activates the checkpoint kinase Chk2 as efficiently as the two genotoxic agents and that caffeine may counteract the activation of Chk2 by genistein but not by etoposide. In contrast, caffeine abolishes the accumulation of p53 caused by all the compounds. Wortmannin does not suppress the Chk2 activation in any situation, suggesting that the ataxia telangiectasia-mutated kinase is not involved in this regulation. Finally, unlike etoposide and adriamycin, genistein induces only a weak response in terms of DNA damage in OCM-1 cells. Taken together, these results suggest that the G(2) checkpoints activated by genistein and the two genotoxic agents involve different pathways.	Univ Toulouse 3, UMR 5088 CNRS, Lab Biol Cellulaire & Mol Controle Proliferat Cel, F-31062 Toulouse, France; Inst Rech Pierre Fabre, Fac Med Rangueil, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Darbon, JM (corresponding author), Univ Toulouse 3, UMR 5088 CNRS, Lab Biol Cellulaire & Mol Controle Proliferat Cel, 118 Route Narbonne, F-31062 Toulouse, France.	darbon@cict.fr	DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Araki R, 1999, CANCER RES, V59, P3543; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cans C, 1999, ANTICANCER RES, V19, P1241; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Choi YH, 1998, INT J ONCOL, V13, P391; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Ling YH, 1996, MOL PHARMACOL, V49, P832; LOCK RB, 1990, CANCER RES, V50, P3761; MARKOVITS J, 1989, CANCER RES, V49, P5111; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; Rauth S, 1997, BRIT J CANCER, V75, P1559, DOI 10.1038/bjc.1997.268; ROSS WE, 1985, BIOCHEM PHARMACOL, V34, P4191, DOI 10.1016/0006-2952(85)90273-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shao ZM, 1998, J CELL BIOCHEM, V69, P44, DOI 10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.3.CO;2-B; Shao ZM, 1998, CANCER RES, V58, P4851; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; YAMASHITA Y, 1990, BIOCHEM PHARMACOL, V39, P737; Zhou JR, 1998, CANCER RES, V58, P5231	46	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15363	15369		10.1074/jbc.275.20.15363	http://dx.doi.org/10.1074/jbc.275.20.15363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809772	hybrid			2022-12-25	WOS:000087128300080
J	Ellison, PA; Sellers, JR; Cremo, CR				Ellison, PA; Sellers, JR; Cremo, CR			Kinetics of smooth muscle heavy meromyosin with one thiophosphorylated head	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; LIGHT-CHAIN KINASE; 2 HEADS; ADENOSINE-TRIPHOSPHATASE; ATPASE ACTIVITY; SCALLOP MYOSIN; GIZZARD MYOSIN; ACTIN; COOPERATIVITY; CONFORMATION	Actin-activated MgATPase of smooth muscle heavy meromyosin is activated by thiophosphorylation of two regulatory light chains, one on each head domain. To understand cooperativity between heads, we examined the kinetics of heavy meromyosin (HMM) with one thiophosphorylated head, Proteolytic gizzard heavy meromyosin regulatory light chains were partially exchanged with recombinant thiophosphorylated His-tagged light chains, and HMM with one thiophosphorylated head was isolated by nickel-affinity chromatography, In vitro motility was observed By steady-state kinetic analysis, one-head thiophosphorylated heavy meromyosin had a similar K-m value for actin but a V-max value of similar to 50% of the fully thiophosphorylated molecule. However, single turnover analysis, which is not sensitive to small amounts of active heads, showed that one-head thiophosphorylated heavy meromyosin was 46-120 times more active than unphosphorylated HMM but only 7-19% as active as the fully thiophosphorylated molecule. Discrepancy between the single turnover and steady-state values could be explained by a small fraction of rigor heads. These rigor heads would have a large effect on the steady-state kinetics of one-head thiophosphorylated HMM. In summary, thiophosphorylation of one head leads to a molecule with unique intermediate kinetics suggesting that thiophosphorylation of one head cooperatively alters the kinetics of the partner head and vice versa.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cremo, CR (corresponding author), Univ Nevada, 1664 N Virginia St, Reno, NV 89503 USA.				NIAMS NIH HHS [AR40917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040917, R29AR040917] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; DASH PK, 1991, BIOCHEM INT, V25, P1013; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HACKNEY DD, 1984, P NATL ACAD SCI-BIOL, V81, P5345, DOI 10.1073/pnas.81.17.5345; HARRIS DE, 1995, AM J PHYSIOL-CELL PH, V269, pC1160, DOI 10.1152/ajpcell.1995.269.5.C1160; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; IKEBE M, 1982, J BIOCHEM-TOKYO, V91, P1809, DOI 10.1093/oxfordjournals.jbchem.a133874; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; MESSER NG, 1988, FEBS LETT, V234, P49, DOI 10.1016/0014-5793(88)81300-0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; Press W. H., 1992, NUMERICAL RECIPES C, V2nd, P656; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SCHLAGER G, 1999, STAT BIOCH, P72; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STULL JT, 1990, PROG CLIN BIOL RES, V327, P107; *SYN SOFTW, 1996, KAL HDB, P543; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WAGNER PD, 1985, J BIOL CHEM, V260, P8084; WAGNER PD, 1986, J BIOL CHEM, V261, P7778; WHITE HD, 1985, J BIOL CHEM, V260, P982; Wu XD, 1999, J BIOL CHEM, V274, P20328, DOI 10.1074/jbc.274.29.20328	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15142	15151		10.1074/jbc.275.20.15142	http://dx.doi.org/10.1074/jbc.275.20.15142			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809750	hybrid			2022-12-25	WOS:000087128300052
J	Yuan, ZQ; Sun, M; Feldman, RI; Wang, G; Ma, XL; Jiang, C; Coppola, D; Nicosia, SV; Cheng, JQ				Yuan, ZQ; Sun, M; Feldman, RI; Wang, G; Ma, XL; Jiang, C; Coppola, D; Nicosia, SV; Cheng, JQ			Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer	ONCOGENE			English	Article						Akt; PI 3-kinase; signal transduction; ovarian cancer	RAC PROTEIN-KINASE; V-HA-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; GROWTH-FACTORS; CELL-SURVIVAL; ONCOGENE; PHOSPHORYLATION; AMPLIFICATION	We previously demonstrated that AKT2, a member of protein kinase B family, is activated by a number of growth factors via Pas and PI 3-kinase signaling pathways. Here we report the frequent activation of AKT2 in human primary ovarian cancer and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase (P1 3-kinase)/Akt pathway. In vitro AKT2 kinase assay analyses in 91 ovarian cancer specimens revealed elevated levels of AKT2 activity (>3-fold) in 33 cases (36.3%). The majority of tumors displaying activated AKT2 were high grade and stages III and IV. Immunostaining and Western blot analyses using a phospho-ser-473 Akt antibody that detects the activated form of AKT2 (AKT2 phosphorylated at serine-474) confirmed the frequent activation of AKT2 in ovarian cancer specimens, Phosphorylated AKT2 in tumor specimens localized to the cell membrane and cytoplasm but not the nucleus. To address the mechanism of AKT2 activation, we measured in vitro PI 3-kinase activity in 43 ovarian cancer specimens, including the 33 cases displaying elevated AKT2 activation, High levels of PI 3-kinase activity were observed in 20 cases, 15 of which also exhibited AKT2 activation. The remaining five cases displayed elevated AKT1 activation. Among the cases with elevated AKT2, but not PI 3-kinase activity (18 cases), three showed down-regulation of PTEN protein expression. Inhibition of PI 3-kinase/AKT2 by wortmannin or LY294002 induces apoptosis in ovarian cancer cells exhibiting activation of the PI 3-kinase/AKT2 pathway. These findings demonstrate for the first time that activation of AKT2 is a common occurrence in human ovarian cancer and that PI 3-kinase/Akt pathway may be an important target for ovarian cancer intervention.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA077935, R29CA077935] Funding Source: NIH RePORTER; NCI NIH HHS [CA77935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liu AX, 1998, CANCER RES, V58, P2973; McMenamin ME, 1999, CANCER RES, V59, P4291; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Obata K, 1998, CANCER RES, V58, P2095; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	39	319	373	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2324	2330		10.1038/sj.onc.1203598	http://dx.doi.org/10.1038/sj.onc.1203598			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822383				2022-12-25	WOS:000086974300007
J	Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU				Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU			Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity	ONCOGENE			English	Article						PDGF; STATs; Src	PROTEIN-TYROSINE KINASE; STIMULATING FACTOR-RECEPTOR; FACTOR-ALPHA RECEPTOR; CELL-PROLIFERATION; PDGF RECEPTOR; C-SRC; PHOSPHORYLATION SITES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC REGION	Members of the STAT family of transcriptional regulators modulate the expression of a variety of gene products that promote cell proliferation, survival and transformation. Although initially identified as mediators of cytokine signaling, the STAT proteins are also activated by, and thus mag contribute to the actions of, polypeptide growth factors. To define the mechanism by which these factors activate STATs, me examined the process of Stat3 activation in Balb/c-3T3 fibroblasts treated with platelet-derived growth factor (PDGF), As STATs are activated by tyrosine phosphorylation, and as PDGF receptors are ligand-activated tyrosine kinases, we considered the possibility that Stat3 interacts with and is phosphorylated by PDGF receptors, We find that Stat3 associates with PDGF beta receptors in both the presence and, surprisingly, the absence of PDGF, Moreover, Stat3 was phosphorylated on tyrosine in PDGF beta receptor immunoprecipitates of PDGF-treated but not untreated cells. Although required, receptor activation was insufficient for Stat3 activation. When added to cells in combination with a pharmacologic agent (PD180970) that specifically inhibits the activity of Src family tyrosine kinases, PDGF did not activate Stat3 as monitored by electrophoretic mobility shift assay. PD180970 did not affect MAPK activation by PDGF or the JAK-dependent activation of Stat3 by interleukin-6, The necessity of Src activity for Stat3 activation by PDGF was further evidenced by data showing the presence of Src in complexes containing both Stat3 and PDGF beta receptors in PDGF-treated cells. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated. Additional data demonstrate that Src kinase activity is also required for PDGF stimulation of DNA synthesis in density-arrested cells.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Pledger, WU (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67360, CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; COATS SR, 1994, BIOCHEM J, V297, P379, DOI 10.1042/bj2970379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GarciaOlivares A, 1997, ENVIRONMETRICS, V8, P1, DOI 10.1002/(SICI)1099-095X(199701)8:1<1::AID-ENV230>3.3.CO;2-2; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HARRINGTON MA, 1985, J CELL BIOCHEM, V27, P67, DOI 10.1002/jcb.240270202; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Heldin CH, 1996, CANCER SURV, V27, P7; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Marais R, 1996, CANCER SURV, V27, P101; MARENGERE LEM, 1994, J CELL SCI, P97; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; OLASHAW NE, 1983, NATURE, V306, P272, DOI 10.1038/306272a0; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	100	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2075	2085		10.1038/sj.onc.1203548	http://dx.doi.org/10.1038/sj.onc.1203548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815799				2022-12-25	WOS:000086728000001
J	Alevizopoulos, K; Sanchez, B; Amati, B				Alevizopoulos, K; Sanchez, B; Amati, B			Conserved region 2 of adenovirus E1A has a function distinct from pRb binding required to prevent cell cycle arrest by p16(INK4a) or p27(Kip1)	ONCOGENE			English	Article						E1A; p27; p16; pRb; E2F	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; HISTONE DEACETYLASE; GROWTH SUPPRESSION; REPRESS TRANSCRIPTION; NEGATIVE MODULATION; FAMILY PROTEINS; DROSOPHILA CTBP	Ectopic expression of the CDK inhibitors (CKIs) p16(INK4a) and p27(Kip1) in Rat1 fibroblasts induces dephosphorylation and activation of Retinoblastoma-family proteins (pRb, p107 and p130), their association with E2F proteins, and cell cycle arrest in G1, The growth-inhibitory action of p16, in particular, is believed to be mediated essentially via pRb activation. The 12S E1A protein of human Adenovirus 5 associates with pRb-family proteins via residues in its Conserved Regions (CR) 1 and 2, in particular through the motif LXCXE in CR2. These interactions are required for E1A to prevent G1 arrest upon co-expression of CKIs, We show here that mutating either of two conserved motifs adjacent to LXCXE in CR2, GFP and SDDEDEE, also impairs the ability of E1A to overcome G1 arrest by p16 or p27, Strikingly, however, these mutations affect neither the association of E1A with pRb, p07 and p130, nor its ability to derepress E2F-1 transcriptional activity in transient transfection assays. One of the E1A mutants, however, is defective in derepressing several endogenous E2F target genes in the presence of p16 or p27, Thus, CR2 possesses an essential function besides pRb-binding, We speculate that this function might be required for the full derepression of E2F-regulated genes in their natural chromatin context.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Amati, B (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; EGAN C, 1989, ONCOGENE, V4, P383; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1992, SCIENCE, V258, P424; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Putzer BM, 1997, J VIROL, V71, P9538; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	76	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2067	2074		10.1038/sj.onc.1203534	http://dx.doi.org/10.1038/sj.onc.1203534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803468				2022-12-25	WOS:000086613200011
J	Miravalle, L; Tokuda, T; Chiarle, R; Giaccone, G; Bugiani, O; Tagliavini, F; Frangione, B; Ghiso, J				Miravalle, L; Tokuda, T; Chiarle, R; Giaccone, G; Bugiani, O; Tagliavini, F; Frangione, B; Ghiso, J			Substitutions at codon 22 of Alzheimer's A beta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN GENE; SMOOTH-MUSCLE CELLS; MIS-SENSE MUTATION; APP GENE; SECONDARY STRUCTURE; AMYLOID ANGIOPATHY; PRION PROTEIN; DISEASE; HEMORRHAGE; DEMENTIA	Cerebral amyloid angiopathy is commonly associated with normal aging and Alzheimer's disease and it is also the principal feature of hereditary cerebral hemorrhage with amyloidosis Dutch type, a familial condition associated to a point mutation G to C at codon 693 of the amyloid beta (AP) precursor protein gene resulting in a Glu to Gin substitution at position 22 of the A beta (E22Q). The patients carrying the A beta E22Q variant usually present with lobar cerebral hemorrhages before 50 years of age. A different mutation described in several members of three Italian kindred who presented with recurrent hemorrhagic strokes late in life, between 60 and 70 years of age, also associated with extensive cerebrovascular amyloid deposition has been found at the same position 22, this time resulting in a Glu to Lye substitution (E22K). We have compared the secondary structure, aggregation, and fibrillization properties of the two A beta 40 variants and the wild type peptide. Using flow cytometry analysis after staining with propidium iodide and annexin V, we also evaluated the cytotoxic effects of the peptides on human cerebral endothelial cells in culture. Under the conditions tested, the E22Q peptide exhibited the highest content of P-sheet conformation and the fastest aggregation/fibrillization properties. The Dutch variant also induced apoptosis of cerebral endothelial cells at a concentration of 25 mu M, whereas the wild type AP and the E22K mutant had no effect. The data suggest that different amino acids at position 22 confer distinct structural properties to the peptides that appear to influence the onset and aggressiveness of the disease rather than the phenotype.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy	New York University; IRCCS Istituto Neurologico Besta	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.		Tagliavini, Fabrizio/AAO-7891-2021; giaccone, giorgio/AAB-9978-2019; Giaccone, Giorgio/J-6212-2012	Tagliavini, Fabrizio/0000-0003-1039-7315; giaccone, giorgio/0000-0002-4803-0802; CHIARLE, Roberto/0000-0003-1564-8531	NIA NIH HHS [AG08721, AG05891] Funding Source: Medline; NINDS NIH HHS [NS38777] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, R01AG008721, R37AG005891] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADROER R, 1993, NEUROSCI LETT, V150, P33, DOI 10.1016/0304-3940(93)90101-P; Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; BALBIN M, 1992, HUM GENET, V89, P580; BROOKS WS, 1995, NEUROSCI LETT, V199, P183, DOI 10.1016/0304-3940(95)12046-7; Bugiani O., 1998, NEUROBIOL AGING, V19, pS238; CARTER DA, 1992, NAT GENET, V2, P255, DOI 10.1038/ng1292-255; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cummings BJ, 1996, NEUROBIOL AGING, V17, P259, DOI 10.1016/0197-4580(95)02060-8; Davis J, 1999, AMYLOID, V6, P157, DOI 10.3109/13506129909007321; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; FABIAN H, 1993, J MOL BIOL, V232, P967, DOI 10.1006/jmbi.1993.1442; FIDANI L, 1992, HUM MOL GENET, V1, P165, DOI 10.1093/hmg/1.3.165; FORSELL C, 1995, NEUROSCI LETT, V184, P90, DOI 10.1016/0304-3940(94)11176-J; Gallo G, 1996, AM J PATHOL, V148, P1397; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; Hendriks L, 1996, EUR J BIOCHEM, V237, P6, DOI 10.1111/j.1432-1033.1996.0006n.x; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Janek K, 1999, BIOCHEMISTRY-US, V38, P8246, DOI 10.1021/bi990510+; JONES CT, 1992, NAT GENET, V1, P306, DOI 10.1038/ng0792-306; KAMINO K, 1992, AM J HUM GENET, V51, P998; Kiuru S, 1999, ANN NEUROL, V45, P305, DOI 10.1002/1531-8249(199903)45:3<305::AID-ANA5>3.0.CO;2-E; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NILSBERTH C, 1999, SOC NEUROSCI, V25; PEACOCK ML, 1994, ANN NEUROL, V35, P432, DOI 10.1002/ana.410350410; PEACOCK ML, 1993, NEUROLOGY, V43, P1254, DOI 10.1212/WNL.43.6.1254; Petersen RB, 1997, ANN NEUROL, V41, P307, DOI 10.1002/ana.410410305; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; STRUBLE RG, 1985, BRAIN RES, V361, P267, DOI 10.1016/0006-8993(85)91298-3; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Tagliavini F., 1999, ALZHEIMERS REP, V2, P23; TIMMERS WF, 1990, NEUROSCI LETT, V118, P223, DOI 10.1016/0304-3940(90)90632-J; Van Nostrand WE, 1998, J NEUROCHEM, V70, P216; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 1996, AM J PATHOL, V148, P361; WATTENDORFF AR, 1982, J NEUROL SCI, V55, P121, DOI 10.1016/0022-510X(82)90094-6; Wisniewski T, 1998, AMYLOID, V5, P212; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; ZUBENKO GS, 1992, J NEUROPATH EXP NEUR, V51, P459, DOI 10.1097/00005072-199207000-00008	53	211	219	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27110	27116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10821838				2022-12-25	WOS:000089144800060
J	Michalet, S; Teixeira, F; Gilquin, B; Mourier, G; Servent, D; Drevet, P; Binder, P; Tzartos, S; Menez, A; Kessler, P				Michalet, S; Teixeira, F; Gilquin, B; Mourier, G; Servent, D; Drevet, P; Binder, P; Tzartos, S; Menez, A; Kessler, P			Relative spatial position of a snake neurotoxin and the reduced disulfide bond alpha(Cys(192)-Cys(193)) at the alpha gamma interface of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING SITES; 3-DIMENSIONAL SOLUTION STRUCTURE; DELTA-SUBUNIT; TORPEDO-CALIFORNICA; CURAREMIMETIC TOXINS; AFFINITY ALKYLATION; ELECTRIC TISSUE; AMINO-ACIDS; IDENTIFICATION	We determined the distances separating five functionally important residues (Gln(10), Lys(27), Trp(29), Arg(33), and Lys(47)) of a three-fingered snake neurotoxin from the reduced disulfide bond alpha(Cys(192)-Cys(193)) located at the alpha gamma interface of the Torpedo nicotinic acetylcholine receptor. Each toxin position was substituted individually for a cysteine, which was then linked to a maleimido moiety through three different spacers, varying in length from 10 to 22 Angstrom. We estimated the coupling efficiency between the 15 toxin derivatives and the reduced cystine alpha(192-193) by gel densitometry of Coomassie Blue-stained gels. A nearly quantitative coupling was observed between alpha Cys(192) and/or (alpha Cys(193) and all probes introduced at the tip of the first (position 10) and second (position 33) loops of Naja nigricollis cy-neurotoxin. These data sufficed to locate the reactive thiolate in a ''croissant-shaped" volume comprised between the first two loops of the toxin. The volume was further restrained by taking into account the absence or partial coupling of the other derivatives. Altogether, the data suggest that (alpha Cys(192) and/or alpha Cys(193) at the alpha gamma interface of a muscular-type acetylcholine receptor, is tare) located in a volume located between 11.5 and 15.5 Angstrom from the alpha-carbons at positions 10 and 33 of the toxin, under the tip of the toxin first loop and close to the second one.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; DGA, DSP, STTC, F-00460 Armees, France; Hellenic Pasteur Inst, Athens 11521, Greece	CEA; UDICE-French Research Universities; Universite Paris Saclay	Kessler, P (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.	pascal.kessler@cea.fr	Teixeira-Clerc, Fatima/C-9884-2009	Servent, Denis/0000-0002-0774-1691				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; BARRANTES FJ, 1980, BIOCHEMISTRY-US, V19, P2957, DOI 10.1021/bi00554a022; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; DAMLE VN, 1978, BIOCHEMISTRY-US, V17, P2039, DOI 10.1021/bi00604a002; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8616, DOI 10.1021/bi00084a032; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; KARLIN A, 1976, ANAL BIOCHEM, V76, P442, DOI 10.1016/0003-2697(76)90339-0; KARLIN A, 1973, P NATL ACAD SCI USA, V70, P3636, DOI 10.1073/pnas.70.12.3636; Karlin A, 1977, Methods Enzymol, V46, P582; KARLIN A, 1968, P NATL ACAD SCI USA, V60, P668, DOI 10.1073/pnas.60.2.668; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; MENEZ A, 1976, BIOCHIM BIOPHYS ACTA, V453, P121, DOI 10.1016/0005-2795(76)90256-7; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Mourier G, 2000, PROTEIN ENG, V13, P217, DOI 10.1093/protein/13.3.217; MOURIER G, 1996, PEPTIDES, P659; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PILLET L, 1993, J BIOL CHEM, V268, P909; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P4268, DOI 10.1021/bi00363a014; Ruoppolo M, 1998, BIOCHEMISTRY-US, V37, P16060, DOI 10.1021/bi981492j; SAITOH T, 1980, FEBS LETT, V116, P30, DOI 10.1016/0014-5793(80)80522-9; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1978, MOL PHARMACOL, V14, P710; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; TZARTOS SJ, 1992, EUR J BIOCHEM, V207, P915, DOI 10.1111/j.1432-1033.1992.tb17124.x; Utkin YN, 1998, EUR J BIOCHEM, V253, P229, DOI 10.1046/j.1432-1327.1998.2530229.x; WALKER JW, 1984, BIOCHEMISTRY-US, V23, P2329, DOI 10.1021/bi00306a002; WEBER M, 1974, MOL PHARMACOL, V10, P1; WOHLFEIL ER, 1991, BIOCHEMISTRY-US, V30, P7231, DOI 10.1021/bi00243a027; WOLOSIN JM, 1980, EUR J BIOCHEM, V109, P495, DOI 10.1111/j.1432-1033.1980.tb04821.x; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	51	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25608	25615		10.1074/jbc.M002362200	http://dx.doi.org/10.1074/jbc.M002362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10807914	hybrid			2022-12-25	WOS:000088849400075
J	Ritchie, H; Lawrie, LC; Crombie, PW; Mosesson, MW; Booth, NA				Ritchie, H; Lawrie, LC; Crombie, PW; Mosesson, MW; Booth, NA			Cross-linking of plasminogen activator inhibitor 2 and alpha(2)-antiplasmin to fibrin(ogen)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HUMAN-FIBRINOGEN; ALPHA-2-PLASMIN INHIBITOR; ALPHA-CHAIN; STABILIZING FACTOR; PLASMA-FIBRINOGEN; CRYSTAL-STRUCTURE; FACTOR-XIIIA; TRANSGLUTAMINASES; TYPE-2	In this study, we identified lysine residues in the fibrinogen A alpha chain that serve as substrates during transglutaminase (TG)-mediated cross-linking of plasminogen activator inhibitor 2 (PAI-2), Comparisons were made with alpha(2)-antiplasmin (alpha(2)-AP), which is known to cross-link to lysine 303 of the A alpha chain. A 30-residue peptide containing Lys-303 specifically competed with fibrinogen for cross-linking to alpha(2)-AP but not for crosslinking to PAI-2, Further evidence that PAI-2 did not cross-link via Lys-303 was the cross-linking of PAI-2 to I-9 and des-alpha C fibrinogens, which lack 100 and 390 amino acids from the C terminus of the A alpha chain, respectively. PAI-(2) or alpha(2)-AP was cross-linked to fibrinogen and digested with trypsin or endopeptidase Glu-C, and the resulting peptides analyzed by mass spectrometry, Peptides detected were consistent with tissue TG (tTG)-mediated cross-linking of PAI-2 to lysines 148, 176, 183, 457 and factor XIIIa-mediated cross-linking of PAI-2 to lysines 148, 230, and 413 in the A alpha chain. alpha(2)-AP was crosslinked only to lysine 303, Cross-linking of PAI-S to fibrinogen did not compete with alpha(2)-AP, and the two proteins utilized different lysines in the A alpha chain. Therefore, PAI-2 and alpha(2)-AP can cross-link simultaneously to the alpha polymers of a fibrin clot and promote resistance to lysis.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53201 USA	University of Aberdeen; Versiti Blood Center of Wisconsin	Booth, NA (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland.	n.a.booth@abdn.ac.uk						AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1703, DOI 10.1021/bi00627a028; Dougherty KM, 1999, P NATL ACAD SCI USA, V96, P686, DOI 10.1073/pnas.96.2.686; Falkenberg M, 1996, THROMB HAEMOSTASIS, V75, P933; FRANCIS CW, 1988, BLOOD, V71, P1361; FRETTO LJ, 1978, J BIOL CHEM, V253, P2184; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; Haroon ZA, 1998, CIRCULATION, V98, P48; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HENSCHEN A, 1983, FIBRINOGEN RECENT BI, P67; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KIMURA S, 1986, J BIOL CHEM, V261, P5591; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; Mosesson MW, 1997, BLOOD COAGUL FIBRIN, V8, P257, DOI 10.1097/00001721-199707000-00001; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; RAMPLING MW, 1978, THROMB RES, V12, P287, DOI 10.1016/0049-3848(78)90299-2; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Ritchie H, 1998, EXP CELL RES, V242, P439, DOI 10.1006/excr.1998.4118; Ritchie H, 1999, THROMB HAEMOSTASIS, V81, P96; Romanic AM, 1998, CIRC RES, V83, P264, DOI 10.1161/01.RES.83.3.264; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SIEBENLIST KR, 1994, J BIOL CHEM, V269, P28414; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P5817, DOI 10.1021/bi952264h; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; SMITH EB, 1995, EUR HEART J, V16, P11, DOI 10.1093/eurheartj/16.suppl_A.11; Sobel JH, 1996, J BIOL CHEM, V271, P19288, DOI 10.1074/jbc.271.32.19288; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577	47	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24915	24920		10.1074/jbc.M002901200	http://dx.doi.org/10.1074/jbc.M002901200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816585	hybrid			2022-12-25	WOS:000088683300091
J	Lemaire, C; Hamel, P; Velours, J; Dujardin, G				Lemaire, C; Hamel, P; Velours, J; Dujardin, G			Absence of the mitochondrial AAA protease Yme1p restores F-0-ATPase subunit accumulation in an oxa1 deletion mutant of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ATP-DEPENDENT DEGRADATION; INNER MEMBRANE; GENE-EXPRESSION; ENZYME COMPLEX; NUCLEAR GENE; N-TERMINI; YEAST; SYNTHASE; MUTATIONS	The nuclear gene OXA1 encodes a protein located within the mitochondrial inner membrane that is required for the biogenesis of both cytochrome c oxidase (Cox) and ATPase, In the absence of Oxa1p, the translocation of the mitochondrially encoded subunit Cox2p to the intermembrane space (also referred to as export) is prevented, and it has been proposed that Oxa1p could be a component of a general mitochondrial export machinery. We have examined the role of Oxa1p in light of its relationships with two mitochondrial proteases, the matrix protease Afg3p-Rca1p and the intermembrane space protease Yme1p, by analyzing the assembly and activity of the Cox and ATPase complexes in Delta oxa1, Delta oxa1 Delta afg3, and Delta oxa1 Delta yme1 mutants. We show that membrane subunits of both complexes are specifically degraded in the absence of Oxa1p, Neither Afg3p nor Yme1p is responsible for the degradation of Cox subunits, However, the F-0 subunits Atp4p, Atp6p, and Atp17p are stabilized in the Delta oxa1 Delta yme1 double mutant, and oligomycin-sensitive ATPase activity is restored, showing that the increased stability of the ATPase subunits allows significant translocation and assembly to occur even in the absence of Oxa1p, These results suggest that Oxa1p is not essential for the export of ATPase subunits, In addition, although respiratory function is dispensable in Saccharomyces cerevisiae, we show that the simultaneous inactivation of AFG3 and YME1 is lethal and that the essential function does not reside in their protease activity.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaire, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Lemaire, C (corresponding author), CNRS, Ctr Genet Mol, Ave Terrasse, F-91198 Gif Sur Yvette, France.	lemaire@cgm.cnrs-gif.fr						Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; ARTL H, 1996, CELL, V85, P875; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BEECHEY RB, 1975, BIOCHEM J, V148, P533, DOI 10.1042/bj1480533; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2000, MOL MICROBIOL, V35, P1135, DOI 10.1046/j.1365-2958.2000.01781.x; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; GORG A., 1985, SCI TOOLS, V32, P5; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Hamel P, 1998, GENETICS, V150, P601; HAMEL P, 1997, PLANT J, V12, P101; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; Lemaire C, 1998, CURR GENET, V34, P138, DOI 10.1007/s002940050378; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; Meyer W, 1997, CURR GENET, V31, P401, DOI 10.1007/s002940050222; Meyer W, 1997, BIOL CHEM, V378, P1373, DOI 10.1515/bchm.1997.378.11.1373; MUKHOPADHYAY A, 1992, J BIOL CHEM, V267, P25690; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; Straffon AFL, 1998, BBA-BIOMEMBRANES, V1371, P157, DOI 10.1016/S0005-2736(98)00034-0; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEBER ER, 1995, GENETICS, V140, P435; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	48	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23471	23475		10.1074/jbc.M002045200	http://dx.doi.org/10.1074/jbc.M002045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816574	Green Published, hybrid			2022-12-25	WOS:000088564200011
J	Marchal, C; Haguenauer-Tsapis, R; Urban-Grimal, D				Marchal, C; Haguenauer-Tsapis, R; Urban-Grimal, D			Casein kinase I-dependent phosphorylation within a PEST sequence and ubiquitination at nearby lysines signal endocytosis of yeast uracil permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; BUDDING YEAST; MALTOSE TRANSPORTER; DOWN-REGULATION; PROTEIN LIGASE; INTERNALIZATION; DEGRADATION; RECEPTOR; CLATHRIN	Uracil uptake by Saccharomyces cerevisiae is mediated by the FUR4-encoded uracil permease. The modification of uracil permease by phosphorylation at the plasma membrane is a key mechanism for regulating endocytosis of this protein. This modification in turn facilitates its ubiquitination and internalization. Following endocytosis, the permease is targeted to the lysosome/vacuole for proteolysis. We have previously shown that uracil permease is phosphorylated at several serine residues within a well characterized N-terminal PEST sequence. In this report, we provide evidence that lysine residues 38 and 41, adjacent to the PEST sequence, are the target sites for ubiquitination of the permease. Conservative substitutions at both Lys(38) and Lys(41) give variant permeases that are phosphorylated but fail to internalize. The PEST sequence contains potential phosphorylation sites conforming to the consensus sequences for casein kinase 1. Casein kinase 1 (CK1) protein kinases, encoded by the redundant YCKI and YCK2 genes, are located at the plasma membrane. Either alone supports growth, but loss of function of both is lethal. Here, we show that in CK1-deficient cells, the permease is poorly phosphorylated and poorly ubiquitinated. Moreover, CR1 overproduction rescued the defective endocytosis of a mutant permease in which the serine phosphoacceptors were replaced by threonine (a less effective phosphoacceptor), which suggests that Yck activity may play a direct role in phosphorylating the permease. Permease internalization was not greatly affected in CK1-deficient cells, despite the low level of ubiquitination of the protein. This may be due to CK1 having a second counteracting role in endocytosis as shown by the higher turnover of variant permeases with unphosphorylatable versions of the PEST sequence.	Univ Paris 06, Inst Jacques Monod, CNRS, UMRC9922, F-75251 Paris 05, France; Univ Paris 07, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Urban-Grimal, D (corresponding author), Univ Paris 06, Inst Jacques Monod, CNRS, UMRC9922, 2 Pl Jussieu, F-75251 Paris 05, France.	grimal@ijm.jussieu.fr	Haguenauer-Tsapis, Rosine/C-5446-2012					BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; Estrada E, 1996, J BIOL CHEM, V271, P32064, DOI 10.1074/jbc.271.50.32064; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Garnier C, 1996, MOL MICROBIOL, V21, P1061, DOI 10.1046/j.1365-2958.1996.621430.x; Geli MI, 1998, J CELL SCI, V111, P1031; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Medintz I, 1998, J BIOL CHEM, V273, P34454, DOI 10.1074/jbc.273.51.34454; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Opekarova M, 1998, YEAST, V14, P215, DOI 10.1002/(SICI)1097-0061(199802)14:3<215::AID-YEA214>3.0.CO;2-3; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Penalver E, 1999, J BACTERIOL, V181, P2555; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Seron K, 1999, J BACTERIOL, V181, P1793; Springael JY, 1999, J CELL SCI, V112, P1375; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; VANCURA A, 1994, J BIOL CHEM, V269, P19271; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Zeng GS, 1999, J CELL BIOL, V144, P71, DOI 10.1083/jcb.144.1.71	50	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23608	23614		10.1074/jbc.M001735200	http://dx.doi.org/10.1074/jbc.M001735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811641	hybrid			2022-12-25	WOS:000088564200029
J	Yu, R; Hinkle, PM				Yu, R; Hinkle, PM			Rapid turnover of calcium in the endoplasmic reticulum during signaling - Studies with cameleon calcium indicators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; FREE CA2+ CONCENTRATION; INTACT HELA-CELLS; FLUORESCENT INDICATORS; INTRACELLULAR CA2+; ENTRY; STORE; CHANNELS; LUMEN; DESENSITIZATION	HEK293 cells expressing the thyrotropin-releasing hormone (TRH) receptor were transfected with cameleon Ca2+ indicators designed to measure the free Ca2+ concentration in the cytoplasm, [Ca2+](cyt), and the endoplasmic reticulum (ER), [Ca2+](er). Basal [Ca2+](cyt) was about 50 nM; thyrotropin-releasing hormone (TRH) or other agonists increased [Ca2+](cyt) to 1 mu M or higher. Basal [Ca2+](er) averaged 500 mu M and fell to 50-100 mu M over 10 min in the presence of thapsigargin. TRH consistently decreased [Ca2+](er) to 100 mu M, independent of extracellular Ca2+, whereas agonists for endogenous receptors generally caused a smaller decline. When added with thapsigargin, all agonists rapidly decreased [Ca2+](er) to 5-10 mu M, indicating that there is substantial store refilling during signaling. TRH increased [Ca2+](cyt) and decreased [Ca2+](er) if applied after other agonists, whereas other agonists did not alter [Ca2+](cyt) or [Ca2+](er) if added after TRH. When Ca2+ was added back to cells that had been incubated with TRH in Ca2+-free medium, [Ca2+](cyt) and [Ca2+](er) increased rapidly. The increase in [Ca2+](er) was only partially blocked by thapsigargin but was completely blocked if cells were loaded with 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. acid. in conclusion, these new Ca2+ indicators showed that basal [Ca2+](er) is similar to 500 mu M, that [Ca2+](er) has to be > 100 mu M to support an increase in [Ca2+](cyt) by agonists, and that during signaling, intracellular Ca2+ stores are continuously refilled with cytoplasmic Ca2+ by the sarcoendoplasmic reticulum Ca2+-ATPase pump.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Sch Med & Dent, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.				NCI NIH HHS [CA 11098] Funding Source: Medline; NIDDK NIH HHS [DK19974, DK55280] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974, R21DK055280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; Bode HP, 1996, BIOCHEM PHARMACOL, V51, P993, DOI 10.1016/0006-2952(96)00048-2; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; HALLAM TJ, 1987, BIOCHEM J, V242, P411, DOI 10.1042/bj2420411; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nori A, 1996, CELL CALCIUM, V19, P375, DOI 10.1016/S0143-4160(96)90110-4; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; TAYLOR CW, 1995, BIOCHEM SOC T, V23, P637, DOI 10.1042/bst0230637; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yule DI, 1997, J BIOL CHEM, V272, P9093	34	66	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23648	23653		10.1074/jbc.M002684200	http://dx.doi.org/10.1074/jbc.M002684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811650	hybrid			2022-12-25	WOS:000088564200035
J	Li, Y; Pursell, ZF; Linn, S				Li, Y; Pursell, ZF; Linn, S			Identification and cloning of two histone fold motif-containing subunits of HeLa DNA polymerase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; REPLICATION; DELTA; REPAIR; CELLS; FORM; CDNA; PURIFICATION; PROTEINS; BINDING	HeLa DNA polymerase epsilon (pol epsilon), possibly involved in both DNA replication and DNA repair, was previously isolated as a complex of a 261-kDa catalytic subunit and a tightly bound 59-kDa accessory protein. Saccharomyces cerevisiae pol epsilon, however, consists of four subunits: a 256-kDa catalytic subunit with 39% identity to HeLa pol epsilon p261, a 80-kDa subunit (DPB2) with 26% identity to HeLa poi epsilon p59, a 23-kDa subunit (DPB3), and a 22-kDa subunit (DPB4). We report here the identification and the cloning of two additional subunits of HeLa poi epsilon, p17, and p12, Both proteins contain histone fold motifs which are present also in S. cerevisiae DPB4 and DPB3. The histone fold motifs of p17 and DPB4 are related to that of subunit A of the CCAAT binding factor, whereas the histone fold motifs found in p12 and DPB3 are homologous to that in subunit C of CCAAT binding factor. p17 together with p12, but not p17 or p12 alone, interact with both p261 and p59 subunits of HeLa pol epsilon. The genes for p17 and p12 can be assigned to chromosome locations 9q33 and 2p12, respectively.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	University of California System; University of California Berkeley; Roche Holding; Genentech	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.			Pursell, Zachary/0000-0001-5871-7192	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030415] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES08196] Funding Source: Medline; NIGMS NIH HHS [1R01GM30415] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoyagi N, 1997, BIOCHEM BIOPH RES CO, V230, P297, DOI 10.1006/bbrc.1996.5945; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; CHUI G, 1995, J BIOL CHEM, V270, P7799, DOI 10.1074/jbc.270.14.7799; CHUI G, 1995, THESIS U CALIFORNIA; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Harlow E., 1988, ANTIBODIES LAB MANUA; HWANG P, 1995, THESIS U CALIFORNIA; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; Jokela M, 1998, NUCLEIC ACIDS RES, V26, P730, DOI 10.1093/nar/26.3.730; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NIRANJANAKUMARI S, 1993, J BIOL CHEM, V268, P15557; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	34	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23247	23252		10.1074/jbc.M002548200	http://dx.doi.org/10.1074/jbc.M002548200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801849	hybrid			2022-12-25	WOS:000088419400089
J	Kim, T; Park, SG; Kim, JE; Seol, W; Ko, YG; Kim, S				Kim, T; Park, SG; Kim, JE; Seol, W; Ko, YG; Kim, S			Catalytic peptide of human glutaminyl-tRNA synthetase is essential for its assembly to the aminoacyl-tRNA synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE; TERMINAL EXTENSION; ENZYME; DETERGENTS; STABILITY; DOMAIN; LIVER; SALTS	Human glutaminyl-tRNA synthetase (QRS) is one of several mammalian aminoacyl-tRNA synthetases (ARSs) that form a macromolecular protein complex. To understand the mechanism of QRS targeting to the multi-ARS complex, we analyzed both exogenous and endogenous QRSs by immunoprecipitation after overexpression of various Myc-tagged QRS mutants in human embryonic kidney 293 cells. Whereas a deletion mutant containing only the catalytic domain (QRS-C) was targeted to the multi-ARS complex, a mutant QRS containing only the N-terminal appended domain (QRS-N) was not. Deletion mapping showed that the ATP-binding Rossman fold was necessary for targeting of QRS to the multi-ARS complex. Furthermore, exogenous Myc-tagged QRS-C was co-immunoprecipitated with endogenous QRS. Since glutaminylation of tRNA was dramatically increased in cells transfected with the full-length QRS, but not with either QRS-C or QRS-N, both the QRS catalytic domain and the N-terminal appended domain were required for full aminoacylation activity. When QRS-C was overexpressed, arginyl-tRNA synthetase and p43 were released from the multi-ARS complex along with endogenous QRS, suggesting that the N-terminal appendix of QRS is required to keep arginyl-tRNA synthetase and p43 within the complex. Thus, the eukaryote-specific N-terminal appendix of QRS appears to stabilize the association of other components in the multi-ARS complex, whereas the C-terminal catalytic domain is necessary for QRS association with the multi-ARS complex.	Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, Suwon 440746, Kyunggido, South Korea	Sungkyunkwan University (SKKU)	Kim, S (corresponding author), Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	ygkko@nature.skk.ac.kr; shkim@yurim.skku.ac.kr	Kim, Sunghoon/AAE-8314-2020					Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; DANG CV, 1986, BIOCHEM J, V239, P249, DOI 10.1042/bj2390249; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; ESCALANTE C, 1994, MOL CELL BIOCHEM, V140, P56; FREIST W, 1997, BIOL CHEM, V378, P103; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; LUDMERER SW, 1993, J BIOL CHEM, V268, P5519; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, FEBS LETT, V283, P1, DOI 10.1016/0014-5793(91)80539-F; NORCUM MT, 1991, J BIOL CHEM, V266, P15398; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; SIHAG RK, 1983, J BIOL CHEM, V258, P1846; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WALTER P, 1989, J BIOL CHEM, V264, P17126; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	23	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21768	21772		10.1074/jbc.M002404200	http://dx.doi.org/10.1074/jbc.M002404200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801842	hybrid			2022-12-25	WOS:000088230600106
J	Lopez-Fernandez, J; Palacios, D; Castillo, AI; Tolon, RM; Aranda, A; Karin, M				Lopez-Fernandez, J; Palacios, D; Castillo, AI; Tolon, RM; Aranda, A; Karin, M			Differentiation of lactotrope precursor GHFT cells in response to fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROLACTIN GENE; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; FUNCTIONAL COMPONENTS; PITUITARY DEVELOPMENT; TRANSGENIC MICE; MESSENGER-RNA; IN-VITRO; EXPRESSION; HORMONE	The mechanisms that control the emergence of different anterior pituitary cells from a common stem cell population are largely unknown. The immortalized GHFT cells derived from targeted expression of SV40 T antigen to mouse pituitary display characteristics of somatolactotropic progenitors in that they express the transcription factor GHF-1 (Pit-1) but not growth hormone (GH) or prolactin (PRL), We searched for factors capable of inducing lactotropic differentiation of GHFT cells. PRL gene expression was not observed in cells subjected to a variety of stimuli, which induce PRL gene expression in mature lactotropes, Only fibroblast growth factor-2 (FGF-2) was able to initiate the transcription, synthesis, and release of PRL in GHFT cells. However, induction of PRL expression was incomplete in FGF-2-treated cells, suggesting that additional factors are necessary to attain high levels of PRL transcription in fully differentiated lactotropes. We also show that the FGF-2 response element is located in the proximal PRL promoter. Stimulation of PRL expression by FGF-2 requires endogenous Ets factors and these factors as well as GHF-1 are expressed at low levels in the committed precursor, suggesting that these low levels are limiting for full PRL expression. Moreover, FGF-P effect on lactotrope differentiation is mediated, at least partially, by stimulation of the Has-signaling pathway. Our results suggest that, indeed, GHFT cells represent a valid model for studying lactotropic differentiation and that FGF-2 could play a key role both in initiating lactotrope differentiation and maintaining PRL expression.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Autonoma Madrid, E-28049 Madrid, Spain; Fdn Hosp Alcorcon, Unidad Endocrinol, Alcorcon, Spain; Fdn Hosp Alcorcon, Inst Invest, Alcorcon, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of California System; University of California San Diego; University of California System; University of California San Diego; Autonomous University of Madrid; Alcorcon Foundation University Hospital; Alcorcon Foundation University Hospital	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Aranda, Ana/ABG-8820-2020; Castillo, Ana/I-1269-2017; Tolón, Rosa/AAA-9401-2019; Tolón, Rosa M M/N-4364-2015; Palacios, Daniela/AAA-7608-2019; Palacios, Daniela/K-4698-2016	Aranda, Ana/0000-0002-8338-9589; Castillo, Ana/0000-0002-2873-1206; Tolón, Rosa M M/0000-0003-1087-4505; Palacios, Daniela/0000-0002-2207-2369; Palacios, Daniela/0000-0002-2207-2369	NIDDK NIH HHS [DK 38524] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATKIN SL, 1993, J CLIN ENDOCR METAB, V77, P831, DOI 10.1210/jcem.77.3.8370706; BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOHLEN P, 1984, P NATL ACAD SCI-BIOL, V81, P5364, DOI 10.1073/pnas.81.17.5364; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; Dasen JS, 1999, CURR OPIN GENET DEV, V9, P566, DOI 10.1016/S0959-437X(99)00015-5; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; Escalada J, 1996, ENDOCRINOLOGY, V137, P631, DOI 10.1210/en.137.2.631; FERRARA N, 1987, P NATL ACAD SCI USA, V84, P5773, DOI 10.1073/pnas.84.16.5773; GOURDJI D, 1994, MOL CELL ENDOCRINOL, V100, P133, DOI 10.1016/0303-7207(94)90292-5; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; HOEFFLER JP, 1985, ENDOCRINOLOGY, V117, P187, DOI 10.1210/endo-117-1-187; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACOB KK, 1994, J BIOL CHEM, V269, P25515; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; MALLO F, 1995, MOL CELL ENDOCRINOL, V114, P117, DOI 10.1016/0303-7207(95)03651-M; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MISSALE C, 1995, ENDOCRINOLOGY, V136, P1205, DOI 10.1210/en.136.3.1205; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; PORTER TE, 1994, ENDOCRINOLOGY, V134, P164, DOI 10.1210/en.134.1.164; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SANCHEZPACHECO A, 1995, ENDOCRINOLOGY, V136, P5391, DOI 10.1210/en.136.12.5391; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	47	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21653	21660		10.1074/jbc.M002129200	http://dx.doi.org/10.1074/jbc.M002129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801832	Green Published, hybrid			2022-12-25	WOS:000088230600092
J	Doege, H; Schurmann, A; Bahrenberg, G; Brauers, A; Joost, HG				Doege, H; Schurmann, A; Bahrenberg, G; Brauers, A; Joost, HG			GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOFACIAL LIGAND-BINDING; SUBCELLULAR-LOCALIZATION; MOLECULAR-BIOLOGY; PLASMA-MEMBRANE; SMALL-INTESTINE; ADIPOSE-TISSUE; CELLS; EXPRESSION; FORSKOLIN; LIVER	GLUTS is a novel glucose transporter-like protein that exhibits significant sequence similarity with the members of the sugar transport facilitator family (29.4% of amino acids identical with GLUT1), Human and mouse sequence (86.2% identical amino acids) comprise 12 putative membrane-spanning helices and several conserved motifs (sugar transporter signatures), which have previously been shown to be essential for transport activity, e.g. GRK in loop 2, PETPR in loop 6, QQLSGVN in helix 7, DRAGRR in loop 8, GWGPIPW in helix 10, and PETKG in the C-terminal tail. An expressed sequence tag (STS A005N15) corresponding with the 3'-untranslated region of GLUTS has previously been mapped to human chromosome 9, COS-7 cells transfected with GLUTS cDNA expressed a 42-kDa protein exhibiting specific, glucose-inhibitable cytochalasin B binding (K-D = 56.6 +/- 18 nM) and reconstitutable glucose transport activity (8.1 +/- 1.4 nmol/(mg protein x 10 s) versus 1.1 +/- 0.1 in control transfections), In human tissues, a 2.4-kilobase pair transcript was predominantly found in testis, but not in testicular carcinoma. Lower amounts of the mRNA were detected in most other tissues including skeletal muscle, heart, small intestine, and brain. GLUTS mRNA was found in testis from adult, but not from prepubertal rats; its expression in human testis was suppressed by estrogen treatment. It is concluded that GLUTS is a sugar transport facilitator with glucose transport activity and a hormonally regulated testicular function.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany	RWTH Aachen University	Joost, HG (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52057 Aachen, Germany.		Joost, Hans-Georg/J-4462-2013	Joost, Hans-Georg/0000-0002-5860-606X; Schurmann, Annette/0000-0002-4113-4377				BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Doege H, 1998, BIOCHEM J, V329, P289, DOI 10.1042/bj3290289; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOOREN L, 1986, J CLIN ENDOCR METAB, V63, P583, DOI 10.1210/jcem-63-3-583; GOULD GW, 1992, DIABETOLOGIA, V35, P304, DOI 10.1007/BF00401196; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HELLWIG B, 1991, MOL PHARMACOL, V40, P383; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOOST HG, 1987, MOL PHARMACOL, V31, P279; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KAYANO T, 1990, J BIOL CHEM, V265, P13276; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MORI H, 1994, J BIOL CHEM, V269, P11578; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ROBINSON FW, 1982, ANAL BIOCHEM, V122, P10, DOI 10.1016/0003-2697(82)90244-5; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SAUER N, 1993, BOT ACTA, V106, P277, DOI 10.1111/j.1438-8677.1993.tb00749.x; SCHURMANN A, 1989, FEBS LETT, V255, P259, DOI 10.1016/0014-5793(89)81102-0; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; SCHURMANN A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P245, DOI 10.1016/0167-4781(92)90022-R; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3; WEBER TM, 1988, RECEPTOR BIOCH MET B, V12, P171; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331	37	192	208	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16275	16280		10.1074/jbc.275.21.16275	http://dx.doi.org/10.1074/jbc.275.21.16275			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821868	hybrid			2022-12-25	WOS:000087291400090
J	Hashim, S; Mukherjee, K; Raje, M; Basu, SK; Mukhopadhyay, A				Hashim, S; Mukherjee, K; Raje, M; Basu, SK; Mukhopadhyay, A			Live Salmonella modulate expression of Rab proteins to persist in a specialized compartment and escape transport to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; MEMBRANE TRAFFICKING; CATHEPSIN-D; INTRACELLULAR TRAFFICKING; LISTERIA-MONOCYTOGENES; CONTAINING PHAGOSOMES; MACROPHAGE LYSOSOMES; TERMINAL LYSOSOMES; MURINE MACROPHAGES; VESICLE FUSION	We investigated the intracellular route of Salmonella in macrophages to determine a plausible mechanism for their survival in phagocytes, Western blot analysis of isolated phagosomes using specific antibodies revealed that by 5 min after internalization dead Salmonella-containing phagosomes acquire transferrin receptors (a marker for early endosomes), whereas by 30 min the dead bacteria are found in vesicles carrying the late endosomal markers cation-dependent mannose B-phosphate receptors, Rab7 and Rab9. In contrast, live Salmonella-containing phagosomes (LSP) retain a significant amount of Rab5 and transferrin receptor until 30 min, selectively deplete Rab7 and Rab9, and never acquire mannose 6-phosphate receptors even 90 min after internalization. Retention of Rab5 and Rab18 and selective depletion of Rab7 and Rab9 presumably enable the LSP to avoid transport to lysosomes through late endosomes. The presence of immature cathepsin D (48 kDa) and selective depletion of the vacuolar ATPase in LSP presumably contributes to the less acidic pH of LSP, In contrast, proteolytically processed cathepsin D (M-r 17,000) was detected by 30 min on the dead Salmonella-containing phagosomes, Morphological analysis also revealed that after uptake by macrophages, the dead Salmonella are transported to lysosomes, whereas the live bacteria persist in compartments that avoid fusion with lysosomes, indicating that live Salmonella bypass the normal endocytic route targeted to lysosomes and mature in a specialized compartment.	Natl Inst Immunol, Cell Biol Lab, New Delhi 110067, India; Inst Microbial Technol, Chandigarh 160036, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Cell Biol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.		Mukhopadhyay, Asok/C-4051-2009					ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; Barbieri MA, 1996, BIOCELL, V20, P331; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCHMEIER NA, 1991, INFECT IMMUN, V59, P2232, DOI 10.1128/IAI.59.7.2232-2238.1991; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DIEDRICH JF, 1990, NUCLEIC ACIDS RES, V18, P7184, DOI 10.1093/nar/18.23.7184; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fleischer S, 1974, Methods Enzymol, V31, P6; Funato K, 1997, J BIOL CHEM, V272, P16147, DOI 10.1074/jbc.272.26.16147; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GROVEL JP, 1991, CELL, V64, P915; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; JAHRAUS A, 1994, J CELL SCI, V107, P145; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; KEUSCH GT, 1994, HARRISONS PRINCIPLES, P671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LI GP, 1993, J BIOL CHEM, V268, P24475; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; LUTCKE A, 1994, J CELL SCI, V107, P3437; MAURIN M, 1992, INFECT IMMUN, V60, P5013, DOI 10.1128/IAI.60.12.5013-5016.1992; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; Mills SD, 1998, EUR J CELL BIOL, V77, P35, DOI 10.1016/S0171-9335(98)80100-3; Mordue DG, 1997, J IMMUNOL, V159, P4452; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Oh YK, 1996, INFECT IMMUN, V64, P3877, DOI 10.1128/IAI.64.9.3877-3883.1996; Oh YK, 1996, J CELL BIOL, V132, P585, DOI 10.1083/jcb.132.4.585; OMARY MB, 1981, J BIOL CHEM, V256, P2888; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; PORTILLO FG, 1995, J CELL BIOL, V129, P81; PORTILLO FG, 1995, TRENDS MICROBIOL, V3, P373; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Ward DM, 1997, J CELL BIOL, V139, P665, DOI 10.1083/jcb.139.3.665; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZURZOLO C, 1994, CELL BIOL LAB HDB, V3, P185	70	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16281	16288		10.1074/jbc.275.21.16281	http://dx.doi.org/10.1074/jbc.275.21.16281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821869	hybrid			2022-12-25	WOS:000087291400091
J	Liou, JY; Shyue, SK; Tsai, MJ; Chung, CL; Chu, KY; Wu, KK				Liou, JY; Shyue, SK; Tsai, MJ; Chung, CL; Chu, KY; Wu, KK			Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; MEDIATED TRANSFER; E-2 RECEPTORS; LOCALIZATION; MEMBRANE; CYTOCHROME-P450; IDENTIFICATION; TRANSLOCATION	The subcellular colocalization of prostacyclin synthase (PGIS) with prostaglandin H synthase (PGHS) has not been delineated. To test the hypothesis that its colocalization with PGHS is crucial for prostacyclin synthesis, we determined subcellular locations of PGIS, PGHS-1, and PGNS-2 in bovine aortic endothelial cells by immunofluorescent confocal microscopy. PGIS and PGHS-1 were colocalized to nuclear envelope (NE) and endoplasmic reticulum (ER) in resting and adenovirus-infected bovine aortic endothelial cells. PGIS and PGHS-2 were also colocalized to ER in serum-treated or adenovirus-cyclooxygenase-2-infected cells. By contrast, PGIS was not colocalized with PGHS-2 in cells induced with phorbol la-myristate 13-acetate where PGHS-2 was visualized primarily in vesicle-like structures. The lack of colocalization was accompanied by failed prostacyclin production. Resting ECV304 cells did not produce prostacyclin and had no detectable PGHS-1 and PGIS proteins. Confocal analysis showed abnormal colocalization of PGIS and PGHS-1 to a filamentous structure. Interestingly, the abundant PGIS and PGHS-1 expressed in adenovirus-infected ECV304 cells were colocalized to NE and ER, which synthesized a large quantity of prostacyclin, These findings underscore the importance of colocalization of PGHS and PGIS to ER and NE in prostacyclin synthesis.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	University of Texas System; Academia Sinica - Taiwan	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.	kkwu@heart.med.uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010; Liou, Jun-Yang/B-1065-2010; Shyue, Song-Kun/Q-2583-2018	Shyue, Song-Kun/0000-0002-1057-8696; CHUNG, CHIA-LIN/0000-0002-1612-0109	NHLBI NIH HHS [R01 HL50675] Funding Source: Medline; NINDS NIH HHS [P50 NS23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; HARA S, 1994, J BIOL CHEM, V269, P19897; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Lin YZ, 1998, ARCH BIOCHEM BIOPHYS, V352, P78, DOI 10.1006/abbi.1998.0599; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; MONCADA S, 1978, PHARMACOL REV, V30, P293; PEREIRA B, 1994, BIOCHEM BIOPH RES CO, V203, P59, DOI 10.1006/bbrc.1994.2148; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SANDUJA SK, 1991, BLOOD, V78, P3178; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shyue SK, 1997, J BIOL CHEM, V272, P3657, DOI 10.1074/jbc.272.6.3657; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1983, J BIOL CHEM, V258, P5922; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SPISNI E, 1995, EXP CELL RES, V219, P507, DOI 10.1006/excr.1995.1259; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; XU XM, 1993, J CLIN INVEST, V91, P1843, DOI 10.1172/JCI116398; Zoldhelyi P, 1996, CIRCULATION, V93, P10, DOI 10.1161/01.CIR.93.1.10	22	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15314	15320		10.1074/jbc.275.20.15314	http://dx.doi.org/10.1074/jbc.275.20.15314			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809766	hybrid			2022-12-25	WOS:000087128300073
J	Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y				Zochodne, B; Truong, AHL; Stetler, K; Higgins, RR; Howard, J; Dumont, D; Berger, SA; Ben-David, Y			Epo regulates erythroid proliferation and differentiation through distinct signaling pathways: implication for erythropoiesis and Friend virus-induced erythroleukemia	ONCOGENE			English	Article						erythropoiesis; epo; Fli-1; signal transduction; Friend erythroleukemia	COLONY-STIMULATING FACTOR; MURINE LEUKEMIA-VIRUS; STEM-CELL-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; STAT5 ACTIVATION; DNA-BINDING; F-MULV	We have recently isolated the erythroleukemic cell line, HB60-5 that proliferates in the presence of erythropoietin (Epo) and stem cell factor (SCF), but undergoes terminal differentiation in the presence of Epo alone. Ectopic expression of the ets related transcription factor Fli-1 in these cells resulted in the establishment of the Epo-dependent cell line HB60-ED that proliferates in the presence of Epo, In this study, me utilized these two cell lines to examine the signal transduction pathways that are activated in response to Epo and SCF stimulation, We demonstrate that Epo, but not SCF, phosphorylates STAT-5 in both HB60-5 and HB60-ED cells. Interestingly, SCF activates the Shc/ras pathway in HB60-5 cells while Epo does not. However, both Epo and SCF are capable of activating the Shc/ras pathway in HB60-ED cells, Furthermore, enforced expression of gp55 in HB60-5 cells by means of infection with the Spleen Focus Forming virus-P (SFFV-P), confers Epo independent growth, which is associated with the up-regulation of Fli-1, Activation of the Shc/ras pathway is readily detected in gp55 expressing cells in response to both Epo and SCF, and is associated with a block in STAT-SE tyrosine phosphorylation, These results suggest that STAT-5 activation, in the absence of Shc/ras activation, plays a role in erythroid differentiation. Moreover, Fli-1 is capable of switching Epo-induced differentiation to Epo-induced proliferation, suggesting that this ets factor regulated genes whose products modulate the Epo-Epo-R signal transduction pathway.	Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Immunol, Hlth Network, Arthrit & Immune Disorder Network, Toronto, ON M5G 2M9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Dept Med Biophys, Hlth Sci Ctr, 2075 Bayview Ave,S Wing, Toronto, ON M4N 3M5, Canada.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVID YB, 1988, ONCOGENE, V3, P179; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; JacobsHelber SM, 1997, J BIOL CHEM, V272, P6850, DOI 10.1074/jbc.272.11.6850; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Sattler M, 1997, J BIOL CHEM, V272, P10248; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	52	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2296	2304		10.1038/sj.onc.1203590	http://dx.doi.org/10.1038/sj.onc.1203590			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822380				2022-12-25	WOS:000086974300004
J	Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J				Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J			c-Myc antagonizes the effect of p53 on apoptosis and p21(WAF1) transactivation in K562 leukemia cells	ONCOGENE			English	Article						myc; p53; leukemia; K562; apoptosis; transactivation	WILD-TYPE P53; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; TEMPERATURE-SENSITIVE MUTANT; CHRONIC MYELOGENOUS LEUKEMIA; GROWTH ARREST; MEDIATED APOPTOSIS; BLASTIC CRISIS; TARGET GENES; CYCLE ARREST	c-myc protooncogene positively regulates cell proliferation and overexpression of c-myc is found in many solid tumors and leukemias, In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional interaction between c-Myc and p53. Using two different methods, we generated K562 transfectant cell lines with conditional expression of either c-Myc or p53. The cells expressed the p53(Vall35) mutant, which adopts a mild-type conformation at 32 degrees C, while c-Myc induction was achieved with a zinc-inducible expression vector. We found that p53 in mild-type conformation induces growth arrest and apoptosis of K562. Expression of c-Myc significantly attenuated apoptosis and impaired the transcriptional activity of D53 on p21(WAF1), fax and cytomegalovirus promoters. The impairment of p21(WAF1) transactivation by c-Myc was confirmed by transfection of a c-Myc-estrogen receptor fusion protein and by induction of c-myc by zinc in transfected cells. Also, p53-mediated up-regulation of p21(WAF1) mRNA protein mere significantly reduced by Myc, while Bas levels were unaffected. Consistently, c- Myc increased cyclin-dependent kinase 2 activity in K562 cells expressing p53 in wild-type conformation These results suggest that c-Myc overexpression may antagonize the pro-apoptotic function of p53, thus providing a molecular mechanism for frequently observed deregulation of c-myc in human cancer.	Hosp Marques de Valdecilla, Serv Hematol, Santander, Spain; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Lund Univ, Dept Hematol, Lund, Sweden	Hospital Universitario Marques de Valdecilla (HUMV); Philipps University Marburg; Lund University	Leon, J (corresponding author), Fac Med, Dept Biol Mol, Santander 39011, Spain.		Ehinger, Mats/H-8457-2016; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Ehinger, Mats/0000-0003-2342-1679; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Alarcon RM, 1996, CANCER RES, V56, P4315; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; AMATI B, 1998, FRONT BIOSCI, V3, pD520; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BI S, 1993, LEUKEMIA, V7, P1840; BLYTH K, 1995, ONCOGENE, V10, P1717; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JACKSON P, 1993, ONCOGENE, V8, P589; Jennings BA, 1998, LEUKEMIA RES, V22, P899, DOI 10.1016/S0145-2126(98)00097-6; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Melo JV, 1996, LEUKEMIA, V10, P751; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PREISLER HD, 1990, EUR J CANCER, V26, P960, DOI 10.1016/0277-5379(90)90620-9; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAYLOR WR, 1992, ONCOGENE, V7, P1383; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trepel M, 1997, LEUKEMIA, V11, P1842, DOI 10.1038/sj.leu.2400824; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WU R, 1988, J EXP MED, V187, P1671; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zeng YX, 1996, ONCOGENE, V12, P1557; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	89	58	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2194	2204		10.1038/sj.onc.1203541	http://dx.doi.org/10.1038/sj.onc.1203541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822369				2022-12-25	WOS:000086974100004
J	Yang, XH; He, ZM; Xin, BZ; Cao, L				Yang, XH; He, ZM; Xin, BZ; Cao, L			LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16(INK4a) expression	ONCOGENE			English	Article						EBV/LMP1; senescense; p16(INK4a); p21(WAF1)	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE PROTEIN-1; NF-KAPPA-B; HUMAN-DIPLOID FIBROBLASTS; REPLICATIVE SENESCENCE; NASOPHARYNGEAL CARCINOMAS; TUMOR-SUPPRESSOR; POINT MUTATION; P53 GENE; CELLS	Epstein-Barr virus is associated with a number of human proliferative and malignant diseases. It is capable of immortalizing human primary B-lymphocytes in vitro. Studies indicate that latent membrane protein LMP1 is one of the viral proteins essential for this process. In this report, LMP1 was shown to prevent primary mouse embryonic fibroblasts from entering into replicative senescence in vitro. It further suppresses the senescence-associated induction of p16(INK4a), commonly believed to be a key regulator of replicative senescence. In addition, LMP1 was shown to prevent premature senescence provoked by oncogenic ras in mouse embryonic fibroblasts, and to inhibit the oncogene ras-mediated induction of p16(INK4a) and p21(WAF1). In parallel, LMP1 also prevents ras-induced premature senescence in rat embryonic fibroblasts REF52 and human diploid fibroblasts IMR90. Moreover, LMP1 is capable of suppressing the p16(INK4a) promoter in REF52 and Saos-2 cells in a promoter reporter assay. Our findings suggest that with the expression of p16(INK4a) and replicative senescence being suppressed, LMP1 may play a key role in Epstein-Barr virus-associated proliferative diseases, and it may further contribute to cancer development by preventing premature senescence induced by mitogenic oncogenes.	Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Cao, L (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bond J, 1996, ONCOGENE, V13, P2097; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Gulley ML, 1998, AM J PATHOL, V152, P865; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUSEN HZ, 1970, NATURE, V227, P245, DOI 10.1038/227245a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENLE G, 1969, J NATL CANCER I, V43, P1147; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1975, LANCET, V1, P936; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	70	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2002	2013		10.1038/sj.onc.1203515	http://dx.doi.org/10.1038/sj.onc.1203515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803461				2022-12-25	WOS:000086613200004
J	Atkins, J; Glynn, P				Atkins, J; Glynn, P			Membrane association of and critical residues in the catalytic domain of human neuropathy target esterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; DELAYED NEUROTOXICITY; BRAIN; PHOSPHOROFLUORIDATE; ORGANOPHOSPHATES; PHOSPHOLIPASE; INHIBITION; DROSOPHILA; ASSAY; SITE	Neuropathy target esterase (NTE) is an integral membrane protein in vertebrate neurons and a member of a novel family of putative serine hydrolases. Here we show that NEST, a recombinant polypeptide expressed in Escherichia coli, reacts with an ester substrate and covalent inhibitors in a manner very similar to NTE, NEST comprises residues 727-1216 of human NTE, and site-directed mutagenesis revealed that serine 966 and two aspartate residues, Asp(1086) and Asp(960), are critical for catalysis. The results of mutating the 11 histidines in NEST suggest that NTE does not use a conventional catalytic triad, By reacting NEST with [H-3]diisopropyl fluorophosphate, Ser(966) was confirmed as the active-site serine, and evidence was obtained that an isopropyl group is transferred from the Ser(966) adduct to an aspartate residue. Detergent was required both for solubilization of NEST from lysates of E, coli and during purification procedures. Catalytic activity was lost in detergent extracts, but was restored when purified NEST was incorporated into dioleoylphosphatidylcholine liposomes, Hydropathy analysis did not indicate the presence of membrane-spanning segments within the NEST sequence. However, biochemical evidence including detergent-phase separation experiments and the resistance of liposome-incorporated NEST to proteolysis indicated that, unlike most eukaryotic serine hydrolases, the catalytic domain of NTE has integral membrane protein properties.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Glynn, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.							BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHANTRY A, 1989, J BIOL CHEM, V264, P21603; CLOTHIER B, 1979, BIOCHEM J, V177, P549, DOI 10.1042/bj1770549; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GLYNN P, 1994, BIOCHEM J, V301, P551, DOI 10.1042/bj3010551; Glynn P, 1999, BIOCHEM J, V344, P625, DOI 10.1042/0264-6021:3440625; JOHNSON MK, 1990, TOXICOL APPL PHARM, V102, P385, DOI 10.1016/0041-008X(90)90036-T; JOHNSON MK, 1977, ARCH TOXICOL, V37, P113, DOI 10.1007/BF00293860; JOHNSON MK, 1982, REV BIOCHEM TOXICOL, V4, P141; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Lush MJ, 1998, BIOCHEM J, V332, P1; MEREDITH C, 1989, J NEUROCHEM, V52, P1248, DOI 10.1111/j.1471-4159.1989.tb01872.x; MEREDITH C, 1988, J NEUROCHEM, V51, P1097, DOI 10.1111/j.1471-4159.1988.tb03073.x; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; RUEFFERTURNER ME, 1992, J NEUROCHEM, V58, P135; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; YOSHIDA M, 1995, J NEUROCHEM, V64, P1680; [No title captured]	22	59	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24477	24483		10.1074/jbc.M002921200	http://dx.doi.org/10.1074/jbc.M002921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816586	hybrid			2022-12-25	WOS:000088683300033
J	Chen, M; O'Toole, EA; Muellenhoff, M; Medina, E; Kasahara, N; Woodley, DT				Chen, M; O'Toole, EA; Muellenhoff, M; Medina, E; Kasahara, N; Woodley, DT			Development and characterization of a recombinant truncated type VII collagen "minigene" - Implication for gene therapy of dystrophic epidermolysis bullosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; EPIDERMAL GROWTH-FACTOR; COL7A1 UNDERLIE SEVERE; HUMAN KERATINOCYTES; ANCHORING FIBRILS; ACQUISITA ANTIGEN; BURN WOUNDS; IN-VIVO; PROCOLLAGEN; EXPRESSION	Dystrophic epidermolysis bullosa (DEB) is an inherited mechano-bullous disorder of skin caused by mutations in the type VII collagen gene. The lack of therapy for DEB provides an impetus to develop gene therapy strategies. However, the full-length 9-kilobase type VII collagen cDNA exceeds the cloning capacity of current viral delivery vectors. In this study, we produced a recombinant type VII minicollagen containing the intact noncollagenous domains, NC1 and NC2, and part of the central collagenous domain using stably transfected human 293 cell clones and purified large quantities of the recombinant minicollagen VII from culture media. Minicollagen VII was secreted as correctly-folded, disulfide-bonded, helical trimers resistant to protease degradation. Purified minicollagen VII bound to fibronectin, laminin-5, type I collagen, and type TV collagen. Furthermore, retroviral-mediated transduction of the minigene construct into DEB keratinocytes tin which type VII collagen was absent) resulted in persistent synthesis and secretion of a 230-kDa recombinant minicollagen VII. In comparison with parent DEB keratinocytes, the gene-corrected DEB keratinocytes demonstrated enhanced cell-substratum adhesion, increased proliferative potential, and reduced cell motility, features that reversed the DEB phenotype toward normal. We conclude that the use of the minicollagen VII may provide a strategy to correct the cellular manifestations of gene defects in DEB.	Univ So Calif, Dept Med, Div Dermatol, Inst Med Genet, Los Angeles, CA 90033 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90033 USA	University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Woodley, DT (corresponding author), Univ So Calif, Dept Med, Div Dermatol, Inst Med Genet, CRL 108,1303 Mission Rd, Los Angeles, CA 90033 USA.			O'Toole, Edel/0000-0002-4084-4836; Kasahara, Noriyuki/0000-0002-6069-9082	NIAMS NIH HHS [R01 AR33625] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033625] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Anderson WF, 1998, NATURE, V392, P25; BOYCE ST, 1983, J INVEST DERMATOL S1, V81, P335; BRIGGAMAN RA, 1975, J INVEST DERMATOL, V65, P71, DOI 10.1111/1523-1747.ep12598050; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chen M, 1997, J INVEST DERMATOL, V108, P125, DOI 10.1111/1523-1747.ep12332300; Choate KA, 1997, HUM GENE THER, V8, P895, DOI 10.1089/hum.1997.8.8-895; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; DEN H, 1997, NAT BIOTECHNOL, V15, P1388; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; FREIBERG RA, 1997, HUM MOL GENET, V6, P933; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Krueger GG, 1999, J INVEST DERMATOL, V112, P233, DOI 10.1046/j.1523-1747.1999.00499.x; LAPIERE JC, 1994, J INVEST DERMATOL, V94, P637; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; OKEEFE EJ, 1984, J INVEST DERMATOL, V82, P150, DOI 10.1111/1523-1747.ep12259708; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P2, DOI 10.1111/1523-1747.ep12462409; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PAULA R, 1994, EUR NEUROL, V34, P181; PITTMAN DD, 1993, BLOOD, V81, P2925; RYYANEN J, 1992, J CLIN INVEST, V89, P163; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; STANLEY JR, 1985, J INVEST DERMATOL, V85, P542, DOI 10.1111/1523-1747.ep12277377; UITTO J, 1995, P ASSOC AM PHYSICIAN, V107, P245; UITTO J, 1994, ARCH DERMATOL RES, V287, P16, DOI 10.1007/BF00370713; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VARANI J, 1989, J INVEST DERMATOL, V93, P449, DOI 10.1111/1523-1747.ep12284020; WOODLEY DT, 1988, JAMA-J AM MED ASSOC, V259, P2566, DOI 10.1001/jama.259.17.2566; WOODLEY DT, 1983, BIOCHIM BIOPHYS ACTA, V761, P278, DOI 10.1016/0304-4165(83)90077-6; WOODLEY DT, 1988, J CELL PHYSIOL, V136, P140, DOI 10.1002/jcp.1041360118; WOODLEY DT, 1985, BIOCHEM BIOPH RES CO, V130, P1267, DOI 10.1016/0006-291X(85)91751-6	45	50	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24429	24435		10.1074/jbc.M003440200	http://dx.doi.org/10.1074/jbc.M003440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821839	hybrid			2022-12-25	WOS:000088683300026
J	Lundin, L; Larsson, H; Kreuger, J; Kanda, S; Lindahl, U; Salmivirta, M; Claesson-Welsh, L				Lundin, L; Larsson, H; Kreuger, J; Kanda, S; Lindahl, U; Salmivirta, M; Claesson-Welsh, L			Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR DIMERIZATION; SULFATE OLIGOSACCHARIDES; SIGNAL-TRANSDUCTION; BINDING; REQUIREMENT; ACTIVATION; MECHANISM; DIFFERENTIATION; IDENTIFICATION; PATHWAYS	Fibroblast growth factors (FGFs) are known to induce formation of new blood vessels, angiogenesis. We show that FGF-induced angiogenesis can be modulated using selectively desulfated heparin, Chinese hamster ovary cells (CHO677) deficient in heparan sulfate biosynthesis were employed to assess the function of heparin/heparan sulfate in FGF receptor-1 (FGFR-1) signal transduction and biological responses. In the presence of FGF-2, FGFR-1 kinase and subsequent mitogen-activated protein kinase Erk2 activities were augmented in a dose-dependent manner, whereas high concentrations of heparin resulted in decreased activity. The length of the heparin oligomer, minimally an 8/10-mer, was critical for the ability to enhance FGFR-1 kinase activity, The N- and 2-O-sulfate groups of heparin were essential for binding to FGF-2, whereas stimulation of FGFR-1 and Erk2 kinases by FGF-2 also required the presence of 6-O-sulfate groups. Sulfation at 2-O- and 6-O-positions was moreover a prerequisite for binding of heparin to a lysine-rich peptide corresponding to amino acids 160-177 in the extracellular domain of FGFR-1, Selectively 6-O-desulfated heparin, which binds to FGF-2 but fails to bind the receptor, decreased FGF-2-induced proliferation of CHO677 cells, presumably by displacing intact heparin, Furthermore, FGF-2-induced angiogenesis in chick embryos was inhibited by 6-O-desulfated heparin, Thus, formation of a ternary complex of FGF-2, heparin, and FGFR-1 appears critical for the activation of FGFR-1 kinase and downstream signal transduction. Preventing complex formation by modified heparin preparations may allow regulation of FGF-2 functions, such as induction of angiogenesis.	Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Nagasaki Univ, Sch Med, Nagasaki 8528501, Japan	Nagasaki University	Claesson-Welsh, L (corresponding author), Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden.	Lena.Welsh@genpat.uu.se	Kreuger, Johan/HDM-1503-2022	Claesson-Welsh, Lena/0000-0003-4275-2000				Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Klagsbrun M, 1992, Semin Cancer Biol, V3, P81; Klein S, 1997, EXS, V79, P159; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1999, FRONT BIOSCI, V4, P165; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; ROSENBERG RD, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)80523-6; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	40	156	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24653	24660		10.1074/jbc.M908930199	http://dx.doi.org/10.1074/jbc.M908930199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816596	hybrid			2022-12-25	WOS:000088683300058
J	Parker, GE; Sandoval, RM; Feister, HA; Bidwell, JP; Rhodes, SJ				Parker, GE; Sandoval, RM; Feister, HA; Bidwell, JP; Rhodes, SJ			The homeodomain coordinates nuclear entry of the Lhx3 neuroendocrine transcription factor and association with the nuclear matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC APPARATUS PROTEIN; DOMAIN INTERACTOR NLI; CLASS HOMEOBOX GENE; LOCALIZATION SIGNAL; DIFFERENTIAL ACTIVATION; LIM; EXPRESSION; PITUITARY; IDENTIFICATION; ISOFORMS	LIM homeodomain transcription factors regulate development in complex organisms. To characterize the molecular signals required for the nuclear localization of these proteins, we examined the Lhx3 factor. Lhx3 is essential for pituitary organogenesis and motor neuron specification. By using functional fluorescent derivatives, we demonstrate that Lhx3 is found in both the nucleoplasm and nuclear matrix. Three nuclear localization signals were mapped within the homeodomain, and one was located in the carboxyl terminus. The homeodomain also serves as the nuclear matrix targeting sequence. No individual signal is alone required for nuclear localization of Lhx3; the signals work in combinatorial fashion. Specific combinations of these signals transferred nuclear localization to cytoplasmic proteins. Mutation of nuclear localization signals within the homeodomain inhibited Lhx3 transcriptional function. By contrast, mutation of the carboxyl-terminal signal activated Lhx3, indicating that this region is critical to transcriptional activity and may be a target of regulatory pathways. The pattern of conservation of the nuclear localization and nuclear matrix targeting signals suggests that the LIM homeodomain factors use similar mechanisms for subcellular localization. Furthermore, upon nuclear entry, association of Lhx3 with the nuclear matrix may contribute to LIM homeodomain factor interaction with other classes of transcription factors.	Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med,Div Nephrol, Renal Epithelial Biol Expt Lab Imaging Facil, Indianapolis, IN 46202 USA; Indiana Univ, Sch Dent, Dept Periodont, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Rhodes, SJ (corresponding author), Indiana Univ Purdue Univ, Dept Biol, 723 W Michigan St, Indianapolis, IN 46202 USA.				NIDCR NIH HHS [DE0126 53-01] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Christophe-Hobertus C, 1999, EUR J BIOCHEM, V265, P491, DOI 10.1046/j.1432-1327.1999.00796.x; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CORSETTI MT, 1995, J CELL SCI, V108, P187; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DAWID IB, 1998, TRENDS GENET, V14, P295; Day RN, 1999, MOL ENDOCRINOL, V13, P517, DOI 10.1210/me.13.4.517; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Feister HA, 1997, J CELL BIOCHEM, V67, P451, DOI 10.1002/(SICI)1097-4644(19971215)67:4<451::AID-JCB4>3.0.CO;2-R; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Glasgow E, 1997, DEV BIOL, V192, P405, DOI 10.1006/dbio.1997.8761; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; Meier BC, 1999, MOL CELL ENDOCRINOL, V147, P65, DOI 10.1016/S0303-7207(98)00213-5; Meisel L, 1996, PLANT MOL BIOL, V30, P1, DOI 10.1007/BF00017799; Merdes A, 1998, J CELL SCI, V111, P71; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Rhodes S. J., 1996, J ANIM SCI, V74, P94; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Sloop KW, 1999, MOL ENDOCRINOL, V13, P2212, DOI 10.1210/me.13.12.2212; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Torrungruang K, 1998, BONE, V22, P317, DOI 10.1016/S8756-3282(97)00300-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; ZENG CQ, 1994, P NATL ACAD SCI USA, V91, P1505, DOI 10.1073/pnas.91.4.1505; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	59	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23891	23898		10.1074/jbc.M000377200	http://dx.doi.org/10.1074/jbc.M000377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818088	hybrid			2022-12-25	WOS:000088564200067
J	Garzon-Rodriguez, W; Vega, A; Sepulveda-Becerra, M; Milton, S; Johnson, DA; Yatsimirsky, AK; Glabe, CG				Garzon-Rodriguez, W; Vega, A; Sepulveda-Becerra, M; Milton, S; Johnson, DA; Yatsimirsky, AK; Glabe, CG			A conformation change in the carboxyl terminus of Alzheimer's A beta(1-40) accompanies the transition from dimer to fibril as revealed by fluorescence quenching analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PROTEIN; INTRINSIC FLUORESCENCE; ACETYLCHOLINE-RECEPTOR; TRYPTOPHAN RESIDUES; PEPTIDE; DISEASE; AGGREGATION; BINDING; DEPOSITION; INVITRO	Alzheimer's disease is characterized by the presence of insoluble, fibrous deposits composed principally of amyloid beta (A beta) peptide. A number of studies have provided information on the fibril structure and on the factors affecting fiber formation, but the details of the fibril structure are not known. We used fluorescence quenching to investigate the solvent accessibility and surface charge of the soluble A beta(1-40) dimer and amyloid fibrils, Analogs of A beta(1-40) containing a single tryptophan were synthesized by substituting residues at positions 4, 10, 34, and 40 with tryptophan, Quenching measurements in the dimeric state indicate that the amino-terminal analogs (A beta F4W and A beta Y10W) are accessible to polar quenchers, and the more carboxyl-terminal analog A beta V34W is less accessible. A beta V40W, on the other hand, exhibits a low degree of quenching, indicating that this residue is highly shielded from the solvent in the dimeric state. Correcting for the effect of reduced translational and rotational diffusion, fibril formation was associated with a selective increase in solvent exposure of residues 34 and 40, suggesting that a conformation change may take place in the carboxyl-terminal region coincident with the dimer to fibril transition.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92512 USA; Natl Autonomous Univ Mexico, Fac Quim, Mexico City 04510, DF, Mexico	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Riverside; Universidad Nacional Autonoma de Mexico	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.			Yatsimirsky, Anatoly/0000-0002-4616-4831	NIGMS NIH HHS [GM 55246] Funding Source: Medline; NINDS NIH HHS [NS31230] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055246] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Barry JK, 1997, BIOCHEMISTRY-US, V36, P15632, DOI 10.1021/bi971685r; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; BURDICK D, 1992, J BIOL CHEM, V267, P546; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; EFTNIK MR, 1981, ANAL BIOCHEM, V114, P119; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Gibbons DL, 1996, J BIOL CHEM, V271, P31989, DOI 10.1074/jbc.271.50.31989; GUILIAN D, 1996, J NEUROSCI, V16, P6021; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; IVERSEN LL, 1995, BIOCHEM J, V311, P1; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSON DA, 1985, BIOPHYS J, V48, P949, DOI 10.1016/S0006-3495(85)83858-3; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P258; LeVine H, 1997, ARCH BIOCHEM BIOPHYS, V342, P306, DOI 10.1006/abbi.1997.0137; LEVINE H, 1993, PROTEIN SCI, V2, P4; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MERRILL AR, 1993, BIOCHEMISTRY-US, V32, P6974, DOI 10.1021/bi00078a023; POLKALSKY C, 1995, J BIOL CHEM, V270, P3809; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Shen F, 1996, J BIOL CHEM, V271, P4819; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; VALENZUELA CF, 1994, BIOCHEMISTRY-US, V33, P6586, DOI 10.1021/bi00187a028; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364	31	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22645	22649		10.1074/jbc.M000756200	http://dx.doi.org/10.1074/jbc.M000756200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10806193	hybrid			2022-12-25	WOS:000088419400009
J	Peilot, H; Rosengren, B; Bondjers, G; Hurt-Camejo, E				Peilot, H; Rosengren, B; Bondjers, G; Hurt-Camejo, E			Interferon-gamma induces secretory group IIA phospholipase A(2) in human arterial smooth muscle cells - Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; LOW-DENSITY-LIPOPROTEIN; ARACHIDONIC-ACID; SULFATE PROTEOGLYCAN; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ATHEROSCLEROSIS; BINDING; LYSOPHOSPHATIDYLCHOLINE; INTERLEUKIN-6	Increased expression of secretory non-pancreatic phospholipase A(2) (sPLA(2)-IIA) could be part of the inflammatory reaction in atherosclerosis. However, the factors controlling sPLA(2)-IIA production in human vascular cells are unknown. We investigated regulation of sPLA(2)-IIA expression and secretion by human arterial smooth muscle cells in culture (HASMC), SPLA(2)-IIA was induced after 3-14 days of culture in non-proliferating conditions. SPLA(2)-IIA was co-expressed with heavy caldesmon, a cytoskeleton protein, and p27, a G(1) cyclin inhibitor, proteins characteristically expressed by differentiated cells, Further incubation with 50-500 units/mi of interferon (IFN)-gamma significantly increased sPLA(2)-IIA mRNA and secretion. IFN-gamma-induced sPLA(2)-IIA was found to be active in cell media and associated with cell membrane proteoglycans. IFN-gamma induced sPLA(2)-IIA expression was antagonized by tumor necrosis factor (TNF)-alpha and interleukin (n)-10, TNF-alpha added individually induced a significant but transient (4 h) increase in sPLA(2)-IIA secretion. IL-10 by itself did not affect sPLA(2)-IIA expression and secretion. IFN-gamma-stimulated sPLA(2)-IIA transcription involved STAT-3 protein. Interestingly, IL-6 but not IFN-gamma up-regulated the sPLA(2)-IIA expression in HepG2 cells, thus sPLA(2)-IIA induction by IFN-gamma response appears to be cell specific. In summary, conditions leading to cell differentiation induced sPLA(2)-IIA expression in HASMC and further exposure to IFN-gamma can up-regulate sPLA(2)-IIA transcription and secretion. This IFN-gamma stimulatory effect can be modulated by other cytokines.	Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Dis, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Hurt-Camejo, E (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Dis, S-41345 Gothenburg, Sweden.	Eva.Hurt@wlab.wall.gu.se						Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Boe A, 1999, CYTOKINE, V11, P1057, DOI 10.1006/cyto.1999.0502; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; CROWL RM, 1991, J BIOL CHEM, V266, P2647; CROWTHER JR, 1995, METHOD MOL BIOL, V42, P161; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Duplaa C, 1997, CIRC RES, V80, P159; Durante W, 1997, J BIOL CHEM, V272, P30154, DOI 10.1074/jbc.272.48.30154; Eckey R, 1997, ATHEROSCLEROSIS, V132, P165, DOI 10.1016/S0021-9150(97)00088-9; Elinder LS, 1997, ARTERIOSCL THROM VAS, V17, P2257, DOI 10.1161/01.ATV.17.10.2257; GLUKHOVA MA, 1990, J BIOL CHEM, V265, P13042; Hansson GK, 1997, CURR OPIN LIPIDOL, V8, P301, DOI 10.1097/00041433-199710000-00009; Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364, DOI 10.1161/01.ATV.19.10.2364; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; Hurt-Camejo E, 1999, J BIOL CHEM, V274, P18957, DOI 10.1074/jbc.274.27.18957; HurtCamejo E, 1997, ATHEROSCLEROSIS, V132, P1, DOI 10.1016/S0021-9150(97)00085-3; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; HURTCAMEJO E, 1995, ARTERIOSCLER THROMB, V15, P1456; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kugiyama K, 1999, CIRCULATION, V100, P1280, DOI 10.1161/01.CIR.100.12.1280; LIBBY P, 1995, ANN NY ACAD SCI, V748, P158; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Menschikowski M, 2000, ARTERIOSCL THROM VAS, V20, P751, DOI 10.1161/01.ATV.20.3.751; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; Nevalainen TJ, 1997, PROG SURG, V24, P104, DOI 10.1159/000075470; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; Pfeilschifter J, 1997, PROG SURG, V24, P31, DOI 10.1159/000075465; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Schiering A, 1999, ATHEROSCLEROSIS, V144, P73, DOI 10.1016/S0021-9150(99)00045-3; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Shanahan CM, 1999, CURR OPIN LIPIDOL, V10, P507, DOI 10.1097/00041433-199912000-00005; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Subbanagounder G, 1999, CIRC RES, V85, P311, DOI 10.1161/01.RES.85.4.311; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; THOOESEN L, 1998, J IMMUNOL, V161, P3421; VADAS P, 1989, AM J PATHOL, V134, P807; WallbergJonsson S, 1997, J RHEUMATOL, V24, P445; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, V1, P421; Wong JT, 1998, J BIOL CHEM, V273, P6830, DOI 10.1074/jbc.273.12.6830; Wu RH, 1998, ARTERIOSCL THROM VAS, V18, P626, DOI 10.1161/01.ATV.18.4.626; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	60	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22895	22904		10.1074/jbc.M002783200	http://dx.doi.org/10.1074/jbc.M002783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811652	hybrid			2022-12-25	WOS:000088419400042
J	Small, KM; Forbes, SL; Rahman, FF; Bridges, KM; Liggett, SB				Small, KM; Forbes, SL; Rahman, FF; Bridges, KM; Liggett, SB			A four amino acid deletion polymorphism in the third intracellular loop of the human alpha(2C)-adrenergic receptor confers impaired coupling to multiple effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACOUSTIC STARTLE REFLEX; HUMAN BETA(2)-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTORS; ALPHA(2)-ADRENERGIC RECEPTOR; GENETIC ALTERATION; PHOSPHOLIPASE-C; DOWN-REGULATION; SUBTYPE; AGONIST; EXPRESSION	The alpha(2)-adrenergic receptors (alpha(2)ARs) play a critical role in modulating neurotransmitter release in the central and peripheral sympathetic nervous systems. A polymorphism of the alpha(2C)AR subtype localized to human chromosome 4 (the pharmacologic alpha(2C)AR subtype) within an intracellular domain has been identified in normal individuals. The polymorphism (denoted De1322-325) is because of an in-frame 12-nucleic acid deletion encoding a receptor lacking Gly-Ala-Gly-Pro in the third intracellular loop. To delineate the functional consequences of this structural alteration, Chinese hamster ovary cells were permanently transfected with constructs encoding wild-type human alpha(2C)AR and the polymorphic receptor, The De1322-325 variant had decreased high affinity,agonist binding (K-H = 7.3 +/- 0.95 vel sus 3.7 +/- 0.43 nM; %R-H = 31 +/- 4 versus 49 +/- 4) compared with wild-type indicating impaired formation of the agonist-receptor-C: protein complex, The polymorphic receptor displayed markedly depressed epinephrine-promoted coupling to G(i), inhibiting adenylyl cyclase by 10 +/- 4.3% compared with 73 +/- 2.4% for wild-type alpha(2C)AR, This also was so for the endogenous ligand norepinephrine and full and partial synthetic agonists, Depressed agonist-promoted coupling to the stimulation of MAP kinase (similar to 71% impaired) and inositol phosphate production (similar to 60% impaired) was also found with the polymorphic receptor. The Del322-325 receptor was similar to 10 times more frequent in African-Americans compared with Caucasians (allele frequencies 0.381 versus 0.040). Given this significant loss of function phenotype in several signal transduction cascades and the skewed ethnic prevalence, Del322-325 represents a pharmacoethnogenetic locus and may also be the basis for interindividual variation in cardiovascular or central nervous system pathophysiology.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave,Rm 7507, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL53436] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adolfsson PI, 1998, GYNECOL OBSTET INVES, V45, P145, DOI 10.1159/000009944; Bjorklund M, 1998, MOL PHARMACOL, V54, P569; Comings DE, 1999, CLIN GENET, V55, P160, DOI 10.1034/j.1399-0004.1999.550304.x; Dorn GW, 1997, BIOCHEMISTRY-US, V36, P6415, DOI 10.1021/bi970080s; EASON MG, 1993, MOL PHARMACOL, V44, P70; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EASON MG, 1992, J BIOL CHEM, V267, P25473; FRASER CM, 1989, J BIOL CHEM, V264, P11754; Gavin KT, 1997, N-S ARCH PHARMACOL, V355, P406, DOI 10.1007/PL00004961; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; Jewell-Motz EA, 1998, BIOCHEMISTRY-US, V37, P15720, DOI 10.1021/bi980999r; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; Kumari V, 1996, PSYCHOPHARMACOLOGY, V123, P353, DOI 10.1007/BF02246646; Large V, 1997, J CLIN INVEST, V100, P3005, DOI 10.1172/JCI119854; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; MORGAN CA, 1993, PSYCHOPHARMACOLOGY, V110, P342, DOI 10.1007/BF02251291; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; Rosin DL, 1996, J COMP NEUROL, V372, P135; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; Sallinen J, 1999, MOL PSYCHIATR, V4, P443, DOI 10.1038/sj.mp.4000543; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; Sallinen J, 1998, J NEUROSCI, V18, P3035; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; Shi TJS, 1999, NEUROREPORT, V10, P2835, DOI 10.1097/00001756-199909090-00025; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Tanila H, 1999, EUR J NEUROSCI, V11, P599, DOI 10.1046/j.1460-9568.1999.00464.x	38	152	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23059	23064		10.1074/jbc.M000796200	http://dx.doi.org/10.1074/jbc.M000796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801795	hybrid			2022-12-25	WOS:000088419400062
J	Weinstein, EA; Li, HW; Lawson, JA; Rokach, J; FitzGerald, GA; Axelsen, PH				Weinstein, EA; Li, HW; Lawson, JA; Rokach, J; FitzGerald, GA; Axelsen, PH			Prothrombinase acceleration by oxidatively damaged phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; IN-VIVO; THROMBIN; ISOPROSTANES; ACTIVATION; MEMBRANES; ATHEROGENESIS; GENERATION; PRODUCTS	The optimally efficient production of thrombin by the prothrombinase complex relies on suitable positioning of its component factors and substrate on phosphatidylserine-containing lipid membranes. The presence of oxidatively damaged phospholipids in a membrane disrupts the normal architecture of a lipid bilayer and might therefore be expected to interfere with prothrombinase activity. To investigate this possibility we prepared phosphatidylserine-containing lipid vesicles containing oxidized arachidonoyl lipids, and we examined their ability to accelerate thrombin production by prothrombinase. Oxidized arachidonoyl chains caused dose-dependent increases in prothrombinase activity up to 6-fold greater than control values. These increases were completely attenuated by the presence of alpha-tocopherol, gamma-tocopherol, or ascorbate. Over the course of a 300-min oxidation, the ability of arachidonoyl lipids to accelerate prothrombinase peaked at 60 min and then declined to base-line levels. These results suggest that instead of being impeded by oxidative membrane damage, prothrombinase activity is enhanced by one or more products of nonenzymatic lipid oxidation.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Johnson Fdn Mol Biophys, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	Axelsen, PH (corresponding author), Univ Penn, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; FAGER G, 1995, CIRC RES, V77, P645, DOI 10.1161/01.RES.77.4.645; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GOROG P, 1995, ATHEROSCLEROSIS, V115, P121, DOI 10.1016/0021-9150(94)05506-E; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; KUNG C, 1994, J BIOL CHEM, V269, P25838; LAMBA OP, 1991, BIOCHIM BIOPHYS ACTA, V1081, P181, DOI 10.1016/0005-2760(91)90024-C; LAMBA OP, 1994, FREE RADICAL BIO MED, V16, P591, DOI 10.1016/0891-5849(94)90059-0; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Li HW, 1999, P NATL ACAD SCI USA, V96, P13381, DOI 10.1073/pnas.96.23.13381; MANN KG, 1990, BLOOD, V76, P1; MARCUS AJ, 1969, J LIPID RES, V10, P108; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Narayanan S, 1999, ANN CLIN LAB SCI, V29, P275; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; Rota S, 1998, BLOOD, V91, P508, DOI 10.1182/blood.V91.2.508.508_508_515; Smith EB, 1996, ATHEROSCLEROSIS, V124, P137, DOI 10.1016/0021-9150(96)05837-6; VOSSEN RCRM, 1993, LIPIDS, V28, P857, DOI 10.1007/BF02536243; White D.A., 1973, PHOSPHOLIPID COMPOSI; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22925	22930		10.1074/jbc.M002438200	http://dx.doi.org/10.1074/jbc.M002438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801844	hybrid			2022-12-25	WOS:000088419400045
J	Amdjadi, K; Sefton, BM				Amdjadi, K; Sefton, BM			Ultraviolet light-induced stimulation of the JNK mitogen-activated protein kinase in the absence of Src family tyrosine kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; T-CELL ACTIVATION; ANTIGEN RECEPTOR; GENE-EXPRESSION; GROWTH-FACTOR; JUN KINASE; HA-RAS; LCK; UV	In T cells, the JNK mitogen-activated protein kinase is activated by simultaneous stimulation of the T-cell receptor and CD28 or by a number of stress stimuli including ultraviolet light, hydrogen peroxide, and anisomycin, Lck, a Src family kinase, is essential for T-cell receptor-mediated activation of JNK, We asked whether Lck was also involved in stress-mediated activation of JNK, JNK was activated by ultraviolet light irradiation in all of the four T-cell lines we examined, but Lck was not. Additionally, JNK activation by ultraviolet light, hydrogen peroxide, and anisomycin was completely normal in T cells lacking Lck, These data suggest that Lck is not activated by ultraviolet light irradiation, nor is it required for JNK activation in T cells by any of the stress stimuli we tested. We also examined JNK activation by ultraviolet light in mouse fibroblasts expressing no known Src kinases, The activation of JNK by ultraviolet light was completely normal in these cells. Finally, treatment of lymphoid and epithelial cells with a Src kinase family inhibitor PPB-reduced tyrosine phosphorylation of cellular proteins markedly without affecting ultraviolet light-induced activation of JNK, These results suggest that Src kinases are not essential for ultraviolet light-induced activation of JNK in a diverse variety of cell types.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Mol Pathol, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Amdjadi, K (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA017289, P30CA014195, R01CA042350] Funding Source: NIH RePORTER; NCI NIH HHS [CA42350, CA14195, CA17289] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUSCHER M, 1988, ONCOGENE, V3, P301; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HURLEY TR, 1989, ONCOGENE, V4, P265; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMPS MP, 1988, ONCOGENE, V2, P305; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; OEHM A, 1992, J BIOL CHEM, V267, P10709; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Renzing J, 1996, J CELL SCI, V109, P1105; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEFTON BM, 1991, ONCOGENE, V6, P683; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tyrrell RM, 1996, PHOTOCHEM PHOTOBIOL, V63, P380, DOI 10.1111/j.1751-1097.1996.tb03049.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WALKER GC, 1985, ENVIRON HEALTH PERSP, V62, P115, DOI 10.2307/3430102; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549; Zhuang LH, 1999, J IMMUNOL, V162, P1440	59	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22520	22525		10.1074/jbc.M002573200	http://dx.doi.org/10.1074/jbc.M002573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801851	hybrid			2022-12-25	WOS:000088363800102
J	Lannoy, VJ; Rodolosse, A; Pierreux, CE; Rousseau, GG; Lemaigre, FP				Lannoy, VJ; Rodolosse, A; Pierreux, CE; Rousseau, GG; Lemaigre, FP			Transcriptional stimulation by hepatocyte nuclear factor-6 - Target-specific recruitment of either CREB-binding protein (CBP) or p300/CBP-associated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HOMEODOMAIN PROTEINS; GENE-EXPRESSION; ONECUT CLASS; LIVER; RECEPTOR; COACTIVATOR; DOMAIN; ACTIVATION; MEMBER	Transcription factors of the ONECUT class, whose prototype is HNF-6, contain a single cut domain and a divergent homeodomain characterized by a phenylalanine at position 48 and a methionine at position 50, The cut domain is required for DNA binding. The homeodomain is required either for DNA binding or for transcriptional stimulation, depending on the target gene. Transcriptional stimulation by the homeodomain involves the F48M50 dyad, We investigate here how HNF-6 stimulates transcription. We identify transcriptionally active domains of HNF-6 that are conserved among members of the ONECUT class and show that the cut domain of HNF-6 participates to DNA binding and, via a LXXLL motif, to transcriptional stimulation, We also demonstrate that, on a target gene to which HNF-6 binds without requirement for the homeodomain, transcriptional stimulation involves an interaction of HNF-6 with the coactivator CREB-binding protein (CBP). This interaction depends both on the LXXLL motif of the cut domain and on the F48M50 dyad of the homeodomain, On a target gene for which the homeodomain is required for DNA binding, but not for transcriptional stimulation, HNF-6 interacts with the coactivator p300/CBP-associated factor but not with CBP. These data show that a transcription factor can act via different, sequence-specific, mechanisms that combine distinct modes of DNA binding with the use of different coactivators.	Univ Catholique Louvain, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Lemaigre, FP (corresponding author), Univ Catholique Louvain, Hormone & Metab Res Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.			Lemaigre, Frederic/0000-0002-3609-434X				ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lamprecht C, 1999, J BIOL CHEM, V274, P17643, DOI 10.1074/jbc.274.25.17643; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MENDEL DB, 1991, J BIOL CHEM, V266, P677; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Pierreux CE, 1999, P NATL ACAD SCI USA, V96, P8961, DOI 10.1073/pnas.96.16.8961; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Samadani U, 1996, MOL CELL BIOL, V16, P6273; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Spek CA, 1998, J BIOL CHEM, V273, P10168, DOI 10.1074/jbc.273.17.10168; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	40	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22098	22103		10.1074/jbc.M000855200	http://dx.doi.org/10.1074/jbc.M000855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811635	hybrid			2022-12-25	WOS:000088363800050
J	Fan, YX; McPhie, P; Miles, EW				Fan, YX; McPhie, P; Miles, EW			Thermal repair of tryptophan synthase mutations in a regulatory intersubunit salt bridge - Evidence from arrhenius plots, absorption spectra, and primary kinetic isotope effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ALPHA(2)BETA(2) COMPLEX REVEALS; INDUCED CONFORMATIONAL-CHANGES; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; BETA-SUBUNIT; ALPHA-SUBUNIT; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITE	This work is aimed at understanding how protein structure and conformation regulate activity and allosteric communication in the tryptophan synthase alpha(2)beta(2) complex from Salmonella typhimurium. Previous erystallographic and kinetic results suggest that both monovalent cations and a salt bridge between alpha subunit Asp(56) and beta subunit Lys(167) play allosteric roles. Here we show that mutation of either of these salt bridging residues produced deleterious effects that could be repaired by increased temperature in combination with CsCl or with NaCl plus an alpha subunit ligand, alpha-glycerol 3-phosphate. Arrhenius plots of the activity data under these conditions were nonlinear, The same conditions yielded temperature-dependent changes in the equilibrium distribution of enzyme-substrate intermediates and in primary kinetic isotope effects. We correlate the results with a model in which the mutant enzymes are converted by increased temperature from a low activity, "open" conformation to a high activity, "closed" conformation under certain conditions. The allosteric ligand and different monovalent cations affected the equilibrium between the open and closed forms. The results suggest that alpha subunit Asp(56) and beta subunit Lys(167) are not essential for catalysis and for allosteric communication between the alpha and beta subunits but that their mutual interaction is important in stabilization of the active, closed form of the alpha(2)beta(2) complex.	NIDDK, Sect Enzyme Struct & Funct, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Miles, EW (corresponding author), NIDDK, Sect Enzyme Struct & Funct, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr MSC 0830, Bethesda, MD 20892 USA.	EdithM@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIHDK034002, Z01DK034002, Z01DK024942, Z01DK024140, ZIADK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED SA, 1991, J BIOL CHEM, V266, P21548; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P11; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 2000, IN PRESS BIOCH VITAM; Fan YX, 2000, BIOCHEMISTRY-US, V39, P4692, DOI 10.1021/bi9921586; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Rhee S, 1998, J BIOL CHEM, V273, P8553, DOI 10.1074/jbc.273.15.8553; Rhee S, 1998, BIOCHEMISTRY-US, V37, P10653, DOI 10.1021/bi980779d; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rowlett R, 1998, BIOCHEMISTRY-US, V37, P2961, DOI 10.1021/bi972286z; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1997, J BIOL CHEM, V272, P7859, DOI 10.1074/jbc.272.12.7859; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANG XJ, 1993, J BIOL CHEM, V268, P22269	31	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20302	20307		10.1074/jbc.M001135200	http://dx.doi.org/10.1074/jbc.M001135200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801803	hybrid			2022-12-25	WOS:000088084500014
J	Krull, RE; Chen, P; Novak, J; Kirk, M; Barnes, S; Baker, J; Krishna, NR; Caufield, PW				Krull, RE; Chen, P; Novak, J; Kirk, M; Barnes, S; Baker, J; Krishna, NR; Caufield, PW			Biochemical structural analysis of the lantibiotic mutacin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; STREPTOCOCCUS-MUTANS; LACTOCOCCUS-LACTIS; POSTTRANSLATIONAL MODIFICATIONS; BIOLOGICAL-ACTIVITIES; NUCLEOTIDE-SEQUENCE; BIOSYNTHESIS; GENE; EXPRESSION; PEPTIDES	Mutacin II is a post-translationally modified lantibiotic peptide secreted by Streptococcus mutans T8, which inhibits the energy metabolism of sensitive cells. The deduced amino acid sequence of promutacin II is NRWWQGVVPTVSYECRMNSWQHVFTCC, which is capable of forming three thioether bridges. It was not obvious, however, how the three thioether bridges are organized. To examine the bridging, the cyanogen bromide cleavage products of mutacin II and its variants generated by protein engineering, C15A, C26A, and C15A/C26A, were analyzed by mass spectrometry, Analysis of the wild type molecule and the C15A variant excluded several possibilities and also indicated a high fidelity of formation of the thioether bridges. This allowed us to further resolve the structure by analysis (mass spectrometry and tandem mass spectrometry) of the cyanogen bromide cleavage fragments of the C26A and C15A/C26A mutants. Nuclear magnetic resonance analysis established the presence of one and two dehydrobutyrine residues in mutacin II and the C15A variant, respectively, thus yielding the final structure, The results of this investigation showed that the C-terminal part contains three thioether bridges connecting Cys residues 15, 26, and 27 to Ser/Thr residues 10, 12 and 19, respectively, with Thr(25) being modified to dehydrobutyrine.	Univ Alabama, Dept Oral Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Krull, RE (corresponding author), Univ Alabama, Dept Oral Biol, Birmingham, AL 35294 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009082] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR06487] Funding Source: Medline; NIDCR NIH HHS [DE09082] Funding Source: Medline; PHS HHS [S10] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAUFIELD PW, 1985, INFECT IMMUN, V48, P51, DOI 10.1128/IAI.48.1.51-56.1985; CAUFIELD PW, 1998, 5 C STREPT GEN VICH; Chen P, 1998, APPL ENVIRON MICROB, V64, P2335; Chen P, 1997, PROTEIN ENG, V10, P82; Chen P, 1999, APPL ENVIRON MICROB, V65, P1356; CHIKINDAS ML, 1995, ANTIMICROB AGENTS CH, V39, P2656, DOI 10.1128/AAC.39.12.2656; DEVOS WM, 1995, MOL MICROBIOL, V17, P427, DOI 10.1111/j.1365-2958.1995.mmi_17030427.x; HYNES WL, 1993, APPL ENVIRON MICROB, V59, P1969, DOI 10.1128/AEM.59.6.1969-1971.1993; Kupke T, 1996, ANTON LEEUW INT J G, V69, P139, DOI 10.1007/BF00399419; Maniatis T., 1982, MOL CLONING LAB MANU; MILLER EJ, 1991, ANAL BIOCHEM, V196, P54, DOI 10.1016/0003-2697(91)90116-B; Novak J, 1996, ANAL BIOCHEM, V236, P358, DOI 10.1006/abio.1996.0181; NOVAK J, 1994, J BACTERIOL, V176, P4316, DOI 10.1128/jb.176.14.4316-4320.1994; Novak J, 1997, PROTEIN ENG, V10, P87; PIARD JC, 1993, J BIOL CHEM, V268, P16361; Pridmore D, 1996, APPL ENVIRON MICROB, V62, P1799, DOI 10.1128/AEM.62.5.1799-1802.1996; RINCE A, 1994, APPL ENVIRON MICROB, V60, P1652, DOI 10.1128/AEM.60.5.1652-1657.1994; ROSS KF, 1993, APPL ENVIRON MICROB, V59, P2014, DOI 10.1128/AEM.59.7.2014-2021.1993; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SHAH GR, 1993, ANAL BIOCHEM, V214, P343, DOI 10.1006/abio.1993.1503; vandenHooven HW, 1996, FEBS LETT, V391, P317, DOI 10.1016/0014-5793(96)00771-5; Woodruff WA, 1998, GENE, V206, P37, DOI 10.1016/S0378-1119(97)00578-7	23	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15845	15850		10.1074/jbc.275.21.15845	http://dx.doi.org/10.1074/jbc.275.21.15845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821848	hybrid			2022-12-25	WOS:000087291400034
J	Baranano, DE; Wolosker, H; Bae, BI; Barrow, RK; Snyder, SH; Ferris, CD				Baranano, DE; Wolosker, H; Bae, BI; Barrow, RK; Snyder, SH; Ferris, CD			A mammalian iron ATPase induced by iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; OXIDATIVE STRESS; HEME OXYGENASE; RESPONSIVE ELEMENT; CELLULAR IRON; MENKES GENE; RAT-LIVER; TRANSPORT; METABOLISM; IDENTIFICATION	While molecular mechanisms for iron entry and storage within cells have been elucidated, no system to mediate iron efflux has been heretofore identified. We now describe an ATP requiring iron transporter in mammalian cells. Fe-55 is transported into microsomal vesicles in a Mg-ATP-dependent fashion. The transporter is specific for ferrous iron, is temperature- and time-dependent, and detected only with hydrolyzable nucleotides. It differs from all known ATPases and appears to be a P-ty-pe ATPase. The Fe-ATPase is localized together with heme ogygenase-1 to microsomal membranes with both proteins greatly enriched in the spleen. Iron treatment markedly induces ATP-dependent iron transport in RAW 264.7 macrophage cells with an initial phase that is resistant to cycloheximide and actinomycin D and a later phase that is inhibited by these agents. Iron release, elicited in intact rats by glycerol-induced rhabdomyolysis, induces ATP-dependent iron transport in the kidney. Mice with genomic deletion of heme oxygenase-l have selective tissue iron accumulation and display augmented ATP-dependent iron transport in those tissues that accumulate iron.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ferris, CD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	cferris@jhmi.edu		Wolosker, Herman/0000-0001-5508-9194; BAE, BYOUNG-IL/0000-0002-9958-678X	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA005900] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-05900, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER E, 1980, BRIT J HAEMATOL, V45, P607, DOI 10.1111/j.1365-2141.1980.tb07184.x; Brunner-Dopper L, 1998, ANAL BIOCHEM, V261, P128, DOI 10.1006/abio.1998.2712; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Conrad ME, 1998, SEMIN HEMATOL, V35, P1; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; GEMSA D, 1973, J CLIN INVEST, V52, P812, DOI 10.1172/JCI107245; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gurgueira SA, 1996, J BIOL CHEM, V271, P13616, DOI 10.1074/jbc.271.23.13616; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McCord JM, 1998, SEMIN HEMATOL, V35, P5; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUALLEM S, 1985, P NATL ACAD SCI USA, V82, P4433, DOI 10.1073/pnas.82.13.4433; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; PIMSTONE NR, 1971, J EXP MED, V133, P1264, DOI 10.1084/jem.133.6.1264; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Rouault T A, 1996, EXS, V77, P183; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG311, DOI 10.1152/ajpgi.1999.276.2.G311; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Umbreit JN, 1998, SEMIN HEMATOL, V35, P13; Zager RA, 1996, KIDNEY INT, V49, P314, DOI 10.1038/ki.1996.48	37	106	115	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15166	15173		10.1074/jbc.275.20.15166	http://dx.doi.org/10.1074/jbc.275.20.15166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809751	hybrid			2022-12-25	WOS:000087128300055
J	Matsubayashi, Y; Sakagami, Y				Matsubayashi, Y; Sakagami, Y			120-and 160-kDa receptors for endogenous mitogenic peptide, phytosulfokine-alpha, in rice plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING-SITES; GENE ENCODES; SULFATED PENTAPEPTIDE; PROTEOLYTIC CLEAVAGE; ARABIDOPSIS-THALIANA; INSULIN-RECEPTOR; MESOPHYLL-CELLS; GLYCOSYLATION; PROTEIN	Plant cells in culture secrete a sulfated peptide named phytosulfokine-alpha (PSK-alpha), and this peptide induces the cell division and/or cell, differentiation by means of specific high and low affinity receptors, Putative receptor proteins for this autocrine type growth factor were identified by photoaffinity labeling of plasma membrane fractions derived from rice suspension cells. Incubation of membranes with a photoactivable I-125-labeled PSK-alpha analog, [N-epsilon-(4-azidosalicyl)Lys(5)]PSR-alpha (ASPSK-alpha), followed by UV irradiation resulted in specific labeling of 120- and 160-kDa bands in SDS-polyacrylamide gel electrophoresis, The labeling of both bands was completely inhibited by unlabeled PSK-ru and partially decreased by PSK-alpha analogs possessing moderate binding activities. In contrast, PSR-cu analogs that have no biological activity showed no competition for I-125-AS-PSK-alpha binding, confirming the specificity of binding proteins. Analysis of the affinity of I-125 incorporation into the protein by ligand saturation experiments gave apparent K-d values of 5.0 nM for the 120-kDa band and 5.4 nM for the 160-kDa band, suggesting that both proteins correspond to the high affinity binding site. Treatment of I-125-AS-PSK-or cross-linked proteins with peptide N-glycosidase F demonstrated that both proteins contained approximately 10 kDa of N-linked oligosaccharides, Specific cross-linking of I-125-AS-PSK-alpha was also observed by using plasma membranes derived from carrot and tobacco cells, indicating the widespread occurrence of the binding proteins. Together, these data suggest that the 120- and 160-kDa proteins are PSK-cu receptors that mediate the biological activities of PSK-alpha.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Bioact Nat Prod Chem, Nagoya, Aichi 4648601, Japan	Nagoya University	Matsubayashi, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Bioact Nat Prod Chem, Nagoya, Aichi 4648601, Japan.		MATSUBAYASHI, Yoshikatsu/AAA-9705-2019	Matsubayashi, Yoshikatsu/0000-0002-2669-2119				Alba FJ, 1996, BIOTECHNIQUES, V21, P625; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSEL D, 1982, J BIOL CHEM, V257, P9845; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; Hanai H, 2000, PLANT CELL PHYSIOL, V41, P27, DOI 10.1093/pcp/41.1.27; HAZUM E, 1983, ENDOCR REV, V4, P352, DOI 10.1210/edrv-4-4-352; Herve C, 1996, J MOL BIOL, V258, P778, DOI 10.1006/jmbi.1996.0286; Kobayashi T, 1999, J EXP BOT, V50, P1123, DOI 10.1093/jexbot/50.336.1123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Marx J, 1996, SCIENCE, V273, P1338, DOI 10.1126/science.273.5280.1338; MASSAGUE J, 1981, J BIOL CHEM, V256, P3182; Matsubayashi Y, 1999, BIOSCI BIOTECH BIOCH, V63, P1847, DOI 10.1271/bbb.63.1847; Matsubayashi Y, 1999, EUR J BIOCHEM, V262, P666, DOI 10.1046/j.1432-1327.1999.00409.x; Matsubayashi Y, 1997, P NATL ACAD SCI USA, V94, P13357, DOI 10.1073/pnas.94.24.13357; Matsubayashi Y, 1999, PLANTA, V207, P559, DOI 10.1007/s004250050518; Matsubayashi Y, 1999, PLANT PHYSIOL, V120, P1043, DOI 10.1104/pp.120.4.1043; Matsubayashi Y, 1996, P NATL ACAD SCI USA, V93, P7623, DOI 10.1073/pnas.93.15.7623; Matsubayashi Y, 1996, BIOCHEM BIOPH RES CO, V225, P209, DOI 10.1006/bbrc.1996.1155; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; REED BC, 1981, P NATL ACAD SCI-BIOL, V78, P2908, DOI 10.1073/pnas.78.5.2908; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SCHALLER GE, 1993, FEBS LETT, V333, P306, DOI 10.1016/0014-5793(93)80676-L; Scheer JM, 1999, PLANT CELL, V11, P1525, DOI 10.1105/tpc.11.8.1525; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SUTTER A, 1979, J BIOL CHEM, V254, P5972; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; VANDERWALT B, 1982, P NATL ACAD SCI-BIOL, V79, P1492; Yang HP, 1999, P NATL ACAD SCI USA, V96, P13560, DOI 10.1073/pnas.96.23.13560	33	52	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15520	15525		10.1074/jbc.275.20.15520	http://dx.doi.org/10.1074/jbc.275.20.15520			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809784	hybrid			2022-12-25	WOS:000087128300100
J	Sallmann, FR; Vodenicharov, MD; Wang, ZQ; Poirier, GG				Sallmann, FR; Vodenicharov, MD; Wang, ZQ; Poirier, GG			Characterization of sPARP-1 - An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; DEPENDENT TRANSCRIPTION; ESCHERICHIA-COLI; DAMAGE; EXPRESSION; BINDING; BLOT; DIFFERENTIATION; PURIFICATION; APOPTOSIS	Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme that catalyzes the synthesis of poly(ADP-ribose) (pADPr) from its substrate NAD(+) upon binding to DNA strand breaks. Poly(ADP-ribosyl)ation has been implicated in many cellular processes including replication, transcription, and the maintenance of genomic stability. However, studies with mice and cells lacking PARP-1 reveal a critical role for the enzyme in the maintenance of genomic integrity only. Recently, a significant level of poly(ADP-ribose) polymerase activity has been detected in fibroblasts derived from mice lacking PARP-1 following treatment with genotoxic agents (Shieh, W. M., AmB, J-C., Wilson, M. V., Wang, Z-Q,, Koh, D. W., Jacobson, M. K., and Jacobson, E. L. (1998) J. Biol. Chem. 273, 30069-30072), We have isolated a cDNA that originates from PARP-1 (-/-) fibroblasts and encodes a polypeptide of 493 amino acid residues bearing poly(ADP-ribose) polymerase activity. This protein, that we named sPARP-1 for short poly(ADP-ribose) polymerase-1, has a calculated mass of 55.3 kDa and is identical in deduced amino acid sequence to the catalytic domain of PARP-1. Radiation hybrid analysis assigned the sPARP-1 gene to the chromosome 1H5-H6 in an immediate proximity to the known location of PARP-1 gene, indicating that sPARP-1 and PARP-1 are most probably products of the same gene. Active sPARP-1 is present in both PARP-1 (+/+) and PARP-1 (-/-) cells as demonstrated by activity-Western blotting and immunostaining using a specific antibody developed against sPARP-1, Like PARP-1, sPARP-1 is localized in the cell nucleus, uses NAD(+) as a substrate and is inhibited by nicotinamide analogues. sPARP-1 produces pADPr of similar length and structure to that of PARP-1. However, contrary to PARP-1, sPARP-1 does not require DNA strand breaks for its activation, although it is stimulated following genotoxic treatments.	Univ Laval, CHUQ, CHUL Res Ctr, Med Res Ctr,Hlth & Environm Unit,PolyADP Ribose M, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Ste Foy, PQ G1V 4G2, Canada; Int Agcy Res Canc, F-69372 Lyon 08, France	Laval University; Laval University; World Health Organization; International Agency for Research on Cancer (IARC)	Poirier, GG (corresponding author), Univ Laval, CHUQ, CHUL Res Ctr, Med Res Ctr,Hlth & Environm Unit,PolyADP Ribose M, 2705 Boul Laurier, Ste Foy, PQ G1V 4G2, Canada.	Guy.Poirier@crchul.ulaval.ca		Poirier, Guy/0000-0002-4869-1424; Vodenicharov, Momchil/0000-0002-5509-9891				Affar EB, 1998, ANAL BIOCHEM, V259, P280, DOI 10.1006/abio.1998.2664; AFFAR EB, 1987, BIOCHIM BIOPHYS ACTA, V1428, P137; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Aoufouchi S, 1997, BIOCHEM J, V325, P543, DOI 10.1042/bj3250543; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRIAND JP, 1992, J IMMUNOL METHODS, V156, P255, DOI 10.1016/0022-1759(92)90033-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; D'Amours D, 1997, ANAL BIOCHEM, V249, P106, DOI 10.1006/abio.1997.2153; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; Harlow E., 1988, ANTIBODIES LAB MANUA; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Legault J, 1997, MOL CELL BIOL, V17, P5437, DOI 10.1128/MCB.17.9.5437; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; MALANGA M, 1994, J BIOL CHEM, V269, P17691; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Pacini A, 1999, J BIOL CHEM, V274, P35107, DOI 10.1074/jbc.274.49.35107; PAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; Shah GM, 1995, ANAL BIOCHEM, V232, P251, DOI 10.1006/abio.1995.0016; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; SIMONIN F, 1991, ANAL BIOCHEM, V195, P226, DOI 10.1016/0003-2697(91)90321-J; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	59	75	77	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15504	15511		10.1074/jbc.275.20.15504	http://dx.doi.org/10.1074/jbc.275.20.15504			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809783	hybrid			2022-12-25	WOS:000087128300098
J	Capell, A; Steiner, H; Willem, M; Kaiser, H; Meyer, C; Walter, J; Lammich, S; Multhaup, G; Haass, C				Capell, A; Steiner, H; Willem, M; Kaiser, H; Meyer, C; Walter, J; Lammich, S; Multhaup, G; Haass, C			Maturation and pro-peptide cleavage of beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; ECTODOMAIN PHOSPHORYLATION; ASPARTYL PROTEASE; GAMMA-SECRETASE; CELLS; MUTATION; LOCALIZATION; ENDOCYTOSIS; GENERATION	Amyloid beta-peptide is generated by two sequential proteolytic cleavages mediated by beta-secretase (BACE) and gamma-secretase. PACE was recently identified as a membrane-associated aspartyl protease. We have now analyzed the maturation and pro-peptide cleavage of BACE. Pulse-chase experiments revealed that BACE is posttranslationally modified during transport to the cell surface, which can be monitored by a significant increase in the molecular mass. The increase in molecular mass is caused by complex N-glycosylation. Treatment with tunicamycin and N-glycosidase F led to a PACE derivative with a molecular weight corresponding to an unmodified version. In contrast, the mature form of BACE was resistant to endoglycosidase Il treatment. The cytoplasmic tail of PACE was required for efficient maturation and trafficking through the Golgi; a BACE variant lacking the cytoplasmic tail undergoes inefficient maturation. In contrast a soluble BACE variant that does not contain a membrane anchor matured more rapidly than full-length BACE. Pro-BACE was predominantly located within the endoplasmic reticulum, Propeptide cleavage occurred immediately before full maturation and trafficking through the Golgi.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; Univ Heidelberg, Ctr Mol Biol ZMBH, D-69120 Heidelberg, Germany	University of Munich; Ruprecht Karls University Heidelberg	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, Schillerstr 44, D-80336 Munich, Germany.		Wang, Caihong/T-5837-2019; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912				Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FAN W, 1999, SCIENCE, V286, pA1255; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Saunders AJ, 1999, SCIENCE, V286; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamazaki T, 1997, J NEUROSCI, V17, P1004; Yamazaki T, 1996, J CELL SCI, V109, P999; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	31	229	241	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30849	30854		10.1074/jbc.M003202200	http://dx.doi.org/10.1074/jbc.M003202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10801872	hybrid			2022-12-25	WOS:000089762700019
J	Curran, AC; Hwang, I; Corbin, J; Martinez, S; Rayle, D; Sze, H; Harper, JF				Curran, AC; Hwang, I; Corbin, J; Martinez, S; Rayle, D; Sze, H; Harper, JF			Autoinhibition of a calmodulin-dependent calcium pump involves a structure in the stalk that connects the transmembrane domain to the ATPase catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; P-TYPE ATPASES; SINGLE-POINT MUTATIONS; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; REGULATED CA2+-ATPASE; ENDOPLASMIC-RETICULUM; N-TERMINUS; CA2+ PUMP; BINDING	The regulation of Ca2+-pumps is important for controlling [Ca2+] in the cytosol and organelles of all eukaryotes. Here, we report a genetic strategy to identify residues that function in autoinhibition of a novel calmodulin-activated Ca2+-pump with an N-terminal regulatory domain (isoform ACA2 from Arabidopsis). Mutant pumps with constitutive activity were identified by complementation of a yeast (K616) deficient in two Ca2+-pumps. Fifteen mutations were found that disrupted a segment of the N-terminal autoinhibitor located between Lys(23) and Arg(54). Three mutations (E167K, D219N, and E341R) were found associated with the stalk that connects the ATPase catalytic domain (head) and with the transmembrane domain. Enzyme assays indicated that the stalk mutations resulted in calmodulin-independent activity, with V-max K-mATP, and K(mCa)2+ similar to that of a pump in which the N-terminal autoinhibitor had been deleted. A highly conservative substitution at Asp(219) (D219E) still produced a deregulated pump, indicating that the autoinhibitory structure in the stalk is highly sensitive to perturbation. In plasma membrane H+-ATPases from yeast and plants, similarly positioned mutations resulted in hyperactive pumps. Together, these results suggest that a structural feature of the stalk is of general importance in regulating diverse P-type ATPases.	Scripps Res Inst, Dept Cell Biol BCC283, La Jolla, CA 92037 USA; Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA; Univ Maryland, Maryland Agr Expt Stn, College Pk, MD 20742 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	Scripps Research Institute; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; California State University System; San Diego State University	Harper, JF (corresponding author), Scripps Res Inst, Dept Cell Biol BCC283, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Adamo HP, 1998, BIOCHEM J, V331, P763, DOI 10.1042/bj3310763; Askerlund P, 1997, PLANT PHYSIOL, V114, P999, DOI 10.1104/pp.114.3.999; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt PC, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P397; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Chung WS, 2000, PLANT CELL, V12, P1393, DOI 10.1105/tpc.12.8.1393; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ERASO P, 1994, J BIOL CHEM, V269, P10393; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Harper JF, 1998, J BIOL CHEM, V273, P1099, DOI 10.1074/jbc.273.2.1099; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Hwang I, 2000, PLANT PHYSIOL, V122, P157, DOI 10.1104/pp.122.1.157; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Malmstrom S, 2000, PLANT PHYSIOL, V122, P517, DOI 10.1104/pp.122.2.517; Malmstrom S, 1997, FEBS LETT, V400, P324, DOI 10.1016/S0014-5793(96)01448-2; Monteith GR, 1998, J PHARMACOL TOXICOL, V40, P183, DOI 10.1016/S1056-8719(99)00004-0; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Palmgren MG, 1999, J EXP BOT, V50, P883, DOI 10.1093/jexbot/50.suppl_1.883; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Scarborough GA, 1999, CURR OPIN CELL BIOL, V11, P517, DOI 10.1016/S0955-0674(99)80075-1; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Stokes DL, 1999, CURR BIOL, V9, P672, DOI 10.1016/S0960-9822(99)80307-8; STRATHREN JN, 1991, METHODS ENZYMOLOGY G, V94, P406; Talla E, 1998, J BIOL CHEM, V273, P27831, DOI 10.1074/jbc.273.43.27831; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	36	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30301	30308		10.1074/jbc.M002047200	http://dx.doi.org/10.1074/jbc.M002047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10818096	hybrid			2022-12-25	WOS:000089577900054
J	Liu, WH; Schachtman, DP; Zhang, W				Liu, WH; Schachtman, DP; Zhang, W			Partial deletion of a loop region in the high affinity K+ transporter HKT1 changes ionic permeability leading to increased salt tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; VIBRIO-ALGINOLYTICUS; EXTRACELLULAR LOOP; UPTAKE SYSTEM; POTASSIUM-TRANSPORT; INTRACELLULAR LOOP; GENE-CLUSTER; DOMAIN-IV; NA+	HKT1 is a high affinity K+ transporter protein that is a member of a large superfamily of transporters found in plants, bacteria, and fungi. These transporters are primarily involved in K+ uptake and are energized by Na+ or H+. HKT1 is energized by Na+ but also mediates low affinity Naf uptake and may therefore be a pathway for Na+ uptake, which is toxic to plants. The aim of this study was to identify regions of HKT1 that are involved in K+/Na+ selectivity and alter the amino acid composition in those regions to increase the ionic selectivity of the transporter. A highly charged loop was identified, and two deletions were created that resulted in the removal of charged and uncharged amino acids. The functional changes caused by the deletions were studied in yeast and Xenopus oocytes. The deletions improved the K+/Na+ selectivity of the transporter and increased the salt tolerance of the yeast cells in which they were expressed. In light of recent structural models of members of this symporter superfamily, it was necessary to determine the orientation of this highly charged loop. Introduction of an epitope tag allowed us to demonstrate that this loop faces the outside of the membrane where it is likely to facilitate the interaction with cations such as K+ and Na+. This study has identified an important structural feature in HKT1 that in part determines its K+/Na+ selectivity Understanding the structural basis of the functional characteristics in transporters such as HKT1 may have important implications for increasing the salt tolerance of higher plants.	CSIRO, Hort Unit, Glen Osmond, SA 5064, Australia; Flinders Med Ctr, Bedford Pk, SA 5042, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Flinders Medical Centre	Schachtman, DP (corresponding author), CSIRO, Hort Unit, POB 350, Glen Osmond, SA 5064, Australia.	daniel.schachtman@pi.csiro.au	Zhang, Wei/E-9051-2013	Zhang, Wei/0000-0002-5111-4097; Schachtman, Daniel/0000-0003-1807-4369				Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bailey J.E., 1986, BIOCH ENG FUNDAMENTA; Bihler H, 1999, FEBS LETT, V447, P115, DOI 10.1016/S0014-5793(99)00281-1; Chao TH, 1999, J BIOL CHEM, V274, P9721, DOI 10.1074/jbc.274.14.9721; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 1992, IONIC CHANNELS EXCIT; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; LichtenbergFrate H, 1996, J MEMBRANE BIOL, V152, P169, DOI 10.1007/s002329900095; Maathuis FJM, 1997, PLANTA, V203, P229, DOI 10.1007/s004250050186; MAATHUIS FJM, 1996, PLANT PHYSIOL, V112, P1; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; MUNNS R, 1993, PLANT CELL ENVIRON, V16, P15, DOI 10.1111/j.1365-3040.1993.tb00840.x; Nair SK, 2000, NATURE, V404, P715, DOI 10.1038/35008182; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; Nakamura T, 1998, MICROBIOL-SGM, V144, P2281, DOI 10.1099/00221287-144-8-2281; Rios G, 1997, YEAST, V13, P515, DOI 10.1002/(SICI)1097-0061(199705)13:6<515::AID-YEA102>3.0.CO;2-X; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; Rubio F, 1999, J BIOL CHEM, V274, P6839, DOI 10.1074/jbc.274.11.6839; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schachtman D, 1999, TRENDS PLANT SCI, V4, P281, DOI 10.1016/S1360-1385(99)01428-4; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHLOSSER A, 1995, J BACTERIOL, V177, P1908, DOI 10.1128/jb.177.7.1908-1910.1995; Schneider H, 1997, J BIOL CHEM, V272, P16158, DOI 10.1074/jbc.272.26.16158; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; STUMPE A, 1996, TRANSPORT PROCESSES, P473; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617	48	33	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27924	27932						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10821831				2022-12-25	WOS:000089197100055
J	Gaullier, JM; Ronning, E; Gillooly, DJ; Stenmark, H				Gaullier, JM; Ronning, E; Gillooly, DJ; Stenmark, H			Interaction of the EEA1 FYVE finger with phosphatidylinositol 3-phosphate and early endosomes - Role of conserved residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MEMBRANE-FUSION; PROTEIN; BINDING; MOTIF; LOCALIZATION; PTDINS(3)P; PRODUCTS; RAB	FYVE zinc finger domains, which are conserved in multiple proteins from yeast to man, interact specifically with the membrane lipid phosphatidylinositol 3-phosphate (PtdIns(3)P). Here we have investigated the structural requirements for the interaction of the FYVE finger of the early endosome antigen EEA1 with PtdIns(3)P and early endosomes. The binding of the FYVE finger to PtdIns(3)P is Zn2+-dependent, and Zn2+ could not be replaced by any other bivalent cations tested. By surface plasmon resonance, the wild-type FYVE finger was found to bind to PtdIns(3)P with an apparent K-D of about 50 nM and a 1:1 stoichiometry. Mutagenesis of cysteines involved in Zn2+ coordination, basic residues thought to be directly involved in ligand binding and other conserved residues, resulted in a 6- to > 100-fold decreased affinity for PtdIns(3)P, A mutation in the putative PtdIns(3)P-binding pocket, R1375A, may prove particularly informative, because it led to a strongly decreased affinity for PtdIns(3)P without affecting the FYVE three-dimensional structure, as measured by fluorescence spectroscopy. Whereas the C terminus of EEA1 localizes to early endosomes when expressed in mammalian cells, all the FYVE mutants with reduced affinity for PtdIns(3)P were found to be largely cytosolic. Furthermore, whereas expression of the wild-type EEA1 C terminus interferes with early endosome morphology, the point mutants were without detectable effect. These results support recently proposed models for the ligand binding of the FYVE domain and indicate that PtdIns(3)P binding is crucial for the localization and function of EEA1.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.		Stenmark, Harald/B-8868-2008					Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; PASTERIS NG, 1994, CELL, V79, P669; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8	31	115	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24595	24600		10.1074/jbc.M906554199	http://dx.doi.org/10.1074/jbc.M906554199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10807926	hybrid			2022-12-25	WOS:000088683300050
J	Shliom, O; Huang, M; Sachais, B; Kuo, A; Weisel, JW; Nagaswami, C; Nassar, T; Bdeir, K; Hiss, E; Gawlak, S; Harris, S; Mazar, A; Higazi, AA				Shliom, O; Huang, M; Sachais, B; Kuo, A; Weisel, JW; Nagaswami, C; Nassar, T; Bdeir, K; Hiss, E; Gawlak, S; Harris, S; Mazar, A; Higazi, AA			Novel interactions between urokinase and its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CELL-MIGRATION; ENZYMATIC-ACTIVITY; ENDOTHELIAL-CELLS; FIBRIN DEPOSITION; BOUND UROKINASE; HUMAN MONOCYTES; BINDING; EXPRESSION	Urokinase-type plasminogen activator (uPA) binds to its receptor (uPAR) with a K-d of about 1 nM. The catalytic activity of the complex is apparent at uPA concentrations close to K-d. Other functions of the complex, such as signal transduction, are apparent at much higher concentrations (35-60 nM). In the present study, we show that uPA and recombinant soluble uPAR (suPAR), at concentrations that exceed the K-d and the theoretical saturation levels (10-80 nM), establish novel interactions that lead to a further increase in the activity of the single-chain uPA (scuPA)/suPAR and two-chain uPA (tcuPA)/suPAR complexes. Experiments performed using dynamic light scattering, gel filtration, and electron microscopy techniques indicate that suPAR forms dimers and oligomers, The three techniques provide evidence that the addition of an equimolar concentration of scuPA leads to the dissociation of these dimers and oligomers, Biacore data show that suPAR dimers and oligomers bind scuPA with decreased affinity when compared with monomers, We postulate that uPAR. is present in equilibrium between oligomer/dimer/monomer forms. The binding of uPA to suPAR dimers and oligomers occurs with lower affinity than the binding to monomer. These novel interactions regulate the activity of the resultant complexes and may be involved in uPA/uPAR mediated signal transduction.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Beth Israel Deaconess Med Ctr, Ctr Thrombosis & Hemostasis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Angstrom Pharmaceut Inc, Dept Biol, San Diego, CA 92121 USA	University of Pennsylvania; University of Pennsylvania; Hebrew University of Jerusalem; Hadassah University Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Higazi, AA (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.		Sachais, Bruce/D-1236-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169, R01HL030954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58107, HL30954, HL60169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anichini E, 1997, BIOCHEMISTRY-US, V36, P3076, DOI 10.1021/bi9619379; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Bianchi E, 1996, J CLIN INVEST, V98, P1133, DOI 10.1172/JCI118896; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CAO DR, 1995, J IMMUNOL, V154, P1817; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1994, J INTERN MED, V236, P455, DOI 10.1111/j.1365-2796.1994.tb00824.x; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FOWLER WE, 1979, J MOL BIOL, V134, P214; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; Higazi AAR, 1996, THROMB RES, V84, P243, DOI 10.1016/S0049-3848(96)00184-3; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KIRSCHHEIMER JC, 1987, FED AM SOC EXP BIOL, V1, P125; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANGEL WF, 1991, J BIOL CHEM, V266, P9408; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Shapiro RL, 1997, AM J PATHOL, V150, P359; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Wang JY, 1997, EUR J BIOCHEM, V247, P256, DOI 10.1111/j.1432-1033.1997.00256.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; Yamamoto K, 1996, J CLIN INVEST, V97, P2440, DOI 10.1172/JCI118691; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	44	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24304	24312		10.1074/jbc.M002024200	http://dx.doi.org/10.1074/jbc.M002024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801829	hybrid			2022-12-25	WOS:000088683300011
J	Iniguez, MA; Martinez-Martinez, S; Punzon, C; Redondo, JM; Fresno, M				Iniguez, MA; Martinez-Martinez, S; Punzon, C; Redondo, JM; Fresno, M			An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; TRANSCRIPTION FACTOR NFAT1; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; SWISS 3T3 CELLS; FACTOR KAPPA-B; PHORBOL ESTER; RHEUMATOID-ARTHRITIS; RESPONSE ELEMENT; CYCLOSPORINE-A	We have previously reported that transcriptional induction of cyclooxygenase-2 (COX-2) isoenzyme occurs early after T cell receptor triggering, suggesting functional implications of cyclooxygenase activity in this process. Here, we identify the cis-acting elements responsible for the transcriptional activation of this gene in human T lymphocytes. COX-2 promoter activity was induced upon T cell activation both in primary resting T lymphocytes and in Jurkat cells. This induction was abrogated by inhibition of calcineurin phosphatase with the immunosuppressive drug cyclosporin A, whereas expression of an active calcineurin catalytic subunit enhanced COX-2 transcriptional activation. Moreover, co-transfection of nuclear factor of activated T cells (NFAT) wild type protein transactivated COX-2 promoter activity. Conversely, dominant negative mutants of NFATc or c-Jun proteins inhibited COX-2 induction. Electro phoretic mobility shift assays and site-directed mutagenesis allowed the identification of two regions of DNA located in the positions -117 and -58 relative to the transcriptional start site that serves as NEAT recognition sequences. These results emphasize the central role that the Ca2+/calcineurin pathway plays in COX-2 transcriptional regulation in T lymphocytes pointing to NFAT/activator protein-1 transcription factors as essential for COX-2 promoter regulation in these cells.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain.		Redondo, Juan Miguel/H-6351-2015; Peña, Miguel Angel Iñiguez/J-8518-2012	Redondo, Juan Miguel/0000-0001-5779-9122; Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Fresno Escudero, Manuel/0000-0002-9223-5477				Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; delArco PG, 1996, J BIOL CHEM, V271, P26335; Della Bella S, 1997, PROSTAG LEUKOTR ESS, V56, P177; DOUGADOS M, 1994, CLIN EXP RHEUMATOL, V12, pS75; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GOODWIN JS, 1989, CURR OPIN IMMUNOL, V3, P295; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; Hall VC, 1997, J RHEUMATOL, V24, P1467; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Iniguez MA, 1999, J IMMUNOL, V163, P111; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUMAR GS, 1994, PROSTAG LEUKOTR ESS, V50, P331; KVANTA A, 1992, CELL SIGNAL, V4, P275, DOI 10.1016/0898-6568(92)90067-I; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MAKOVER D, 1991, ONCOGENE, V6, P455; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Moulton PJ, 1996, BRIT J BIOMED SCI, V53, P317; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Pablos JL, 1999, CLIN EXP IMMUNOL, V115, P86; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PETRAK D, 1994, J IMMUNOL, V153, P2046; PHILIPPS RP, 1991, IMMUNOL TODAY, V12, P349; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; ZHOU LB, 1994, J IMMUNOL, V153, P5026	63	192	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23627	23635		10.1074/jbc.M001381200	http://dx.doi.org/10.1074/jbc.M001381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816557	hybrid			2022-12-25	WOS:000088564200032
J	Liang, Y; Medhekar, R; Brockman, HL; Quinn, DM; Hui, DY				Liang, Y; Medhekar, R; Brockman, HL; Quinn, DM; Hui, DY			Importance of arginines 63 and 423 in modulating the bile salt-dependent and bile salt-independent hydrolytic activities of rat carboxyl ester lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; SITE-SPECIFIC MUTAGENESIS; STIMULATED LIPASE; ACTIVATED LIPASE; HUMAN-MILK; MOLECULAR-CLONING; BINDING-SITE; HYDROLASE; CDNA; LYSOPHOSPHOLIPASE	Previous studies using chemical modification approach have shown the importance of arginine residues in bile salt activation of carboxyl ester lipase (CEL) activity. However, the x-ray crystal structure of CEL failed to show the involvement of arginine residues in CEL-bile salt interaction. The current study used a site-specific mutagenesis approach to determine the role of arginine residues 63 and 423 in bile salt-dependent and bile salt-independent hydrolytic activities of rat GEL. Mutations of Arg(63) to Ala(63) (R63A) and Arg(425) to Gly(423) (R423G) resulted in enzymes with increased bile salt-independent hydrolytic activity against lysophosphatidylcholine, having 6.5- and 2-fold higher k(cat) values, respectively, in comparison to wild type GEL. In contrast, the R63A and R423A mutant enzymes displayed 5- and 11-fold decreases in k(cat), in comparison with wild type GEL, for bile salt-dependent cholesteryl ester hydrolysis. Although taurocholate induced similar changes in circular dichroism spectra for wild type, R63A, and R423G proteins, this bile salt was less efficient in protecting the mutant enzymes against thermal inactivation in comparison with control GEL. Lipid binding studies revealed less R63A and R423G mutant CEL were bound to 1,2-diolein monolayer at saturation compared with wild type GEL. These results, along with computer modeling of the CEL protein, indicated that Arg(63) and Arg(423) are not involved directly with monomeric bile salt binding. However, these residues participate in micellar bile salt modulation of CEL enzymatic activity through intramolecular hydrogen bonding with the C-terminal domain. These residues are also important, probably through similar intramolecular hydrogen bond formation, in stabilizing the enzyme in solution and at the lipid-water interface.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Cincinnati; University of Iowa; University of Minnesota System	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17371] Funding Source: Medline; NIDDK NIH HHS [DK54504] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BLACKBERG L, 1993, FEBS LETT, V323, P207, DOI 10.1016/0014-5793(93)81340-6; CAMPESE D, 1984, BIOCHIM BIOPHYS ACTA, V784, P147, DOI 10.1016/0167-4838(84)90121-3; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; Chen JCH, 1998, BIOCHEMISTRY-US, V37, P5107, DOI 10.1021/bi972989g; COLWELL NS, 1993, BIOCHIM BIOPHYS ACTA, V1172, P175, DOI 10.1016/0167-4781(93)90288-O; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DIPERSIO LP, 1992, PROTEIN EXPRES PURIF, V3, P114, DOI 10.1016/S1046-5928(05)80027-0; DIPERSIO LP, 1994, BIOCHEMISTRY-US, V33, P3442, DOI 10.1021/bi00177a038; DIPERSIO LP, 1993, J BIOL CHEM, V268, P300; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; HUI DY, 1993, BIOCHEM J, V291, P65, DOI 10.1042/bj2910065; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; JACOBSON PW, 1990, J BIOL CHEM, V265, P515; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; Li F, 1998, BIOCHEM J, V329, P675, DOI 10.1042/bj3290675; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; LOMBARDO D, 1983, EUR J BIOCHEM, V133, P327, DOI 10.1111/j.1432-1033.1983.tb07466.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKAY K, 1995, GENE, V165, P255, DOI 10.1016/0378-1119(95)00564-M; MOMSEN WE, 1990, J COLLOID INTERF SCI, V135, P547, DOI 10.1016/0021-9797(90)90025-J; Momsen WE, 1997, METHOD ENZYMOL, V286, P292; Nyberg L, 1998, J PEDIATR GASTR NUTR, V27, P560, DOI 10.1097/00005176-199811000-00013; REUE K, 1991, J LIPID RES, V32, P267; RUDD EA, 1987, BIOCHIM BIOPHYS ACTA, V918, P106, DOI 10.1016/0005-2760(87)90184-6; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8430, DOI 10.1021/bi00399a060; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Wang XQ, 1997, STRUCTURE, V5, P1209, DOI 10.1016/S0969-2126(97)00271-2; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	37	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24040	24046		10.1074/jbc.M003187200	http://dx.doi.org/10.1074/jbc.M003187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811659	hybrid			2022-12-25	WOS:000088564200087
J	Crews, C; Wilkinson, KD; Wells, L; Perkins, C; Fridovich-Keil, JL				Crews, C; Wilkinson, KD; Wells, L; Perkins, C; Fridovich-Keil, JL			Functional consequence of substitutions at residue 171 in human galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST EXPRESSION SYSTEM; URIDYLYL-ENZYME; GALACTOSEMIA; PURIFICATION; MUTATIONS; INSIGHT; SITE	Impairment of the human enzyme galactose-l-phosphate uridylyltransferase (hGALT) results in the potentially lethal disorder classic galactosemia. Although a variety of naturally occurring mutations have been identified in patient alleles, few have been well characterized. We have explored the functional significance of a common patient mutation, F171S, using a strategy of conservative substitution at the defined residue followed by expression of the wild-type and, alternatively, substituted proteins in a null-background strain of yeast, As expected from patient studies, the F171S-hGALT protein demonstrated <0.1% wild-type levels of activity, although two of three conservatively substituted moieties, F171L- and F171Y-hGALT, demonstrated similar to 10% and similar to 4% activity, respectively. The third protein, F171W, demonstrated severely reduced abundance, precluding further study. Detailed kinetic analyses of purified wild-type, P171L- and F171Y-hGALT enzymes, coupled with homology modeling of these proteins, enabled us to suggest that the effects of these substitutions resulted largely from altering the position of a catalytically important residue, Gln-188, and secondarily, by altering the subunit interface and perturbing hexose binding to the uridylylated enzyme. These results not only provide insight into the functional impact of a single common patient allele and offer a paradigm for similar studies of other clinically or biochemically important residues, but they further help to elucidate activity of the wild-type human GALT enzyme.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Genet, Rm 431C,Dent Bldg,1462 Clifton Rd NE, Atlanta, GA 30322 USA.	jfridov@emory.edu	Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046403, R01DK046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308, T32GM008490] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403] Funding Source: Medline; NIGMS NIH HHS [GM30308, T32 GM008490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FREY PA, 1982, METHOD ENZYMOL, V87, P20; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; FridovichKeil JL, 1995, BIOCHEM MOL MED, V56, P121, DOI 10.1006/bmme.1995.1067; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; HELMER GR, 1981, ARCH BIOCHEM BIOPHYS, V210, P573, DOI 10.1016/0003-9861(81)90223-X; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; REICHARDT JKV, 1992, BIOCHEMISTRY-US, V31, P5430, DOI 10.1021/bi00139a002; Segal S, 1995, METABOLIC MOL BASES, P967; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; Tyfield L, 1999, HUM MUTAT, V13, P417, DOI 10.1002/(SICI)1098-1004(1999)13:6<417::AID-HUMU1>3.0.CO;2-0; Venclovas C, 1999, PROTEINS, P73; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; Wang BBT, 1998, MOL GENET METAB, V63, P263, DOI 10.1006/mgme.1998.2678; WANG BT, 1996, AM J HUM GENET S, V59, P292; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22847	22853		10.1074/jbc.M001053200	http://dx.doi.org/10.1074/jbc.M001053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811638	hybrid			2022-12-25	WOS:000088419400035
J	Poltilove, RMK; Jacobs, AR; Haft, CR; Xu, P; Taylor, SI				Poltilove, RMK; Jacobs, AR; Haft, CR; Xu, P; Taylor, SI			Characterization of Drosophila insulin receptor substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL EXTENSION; TYROSINE KINASE; SIGNAL-TRANSDUCTION; GENE-PRODUCT; S6 KINASE; PROTEIN; GROWTH; CELL; MELANOGASTER; HOMOLOG	Insulin receptor substrate (IRS) proteins are phosphorylated by multiple tyrosine kinases, including the insulin receptor. Phosphorylated IRS proteins bind to SH2 domain-containing proteins, thereby triggering downstream signaling pathways. The Drosophila insulin receptor (dIR) C-terminal extension contains potential binding sites for signaling molecules, suggesting that dIR might not require an IRS protein to accomplish its signaling functions. However, we obtained a cDNA encoding Drosophila IRS (dIRS), and we demonstrated expression of dIRS in a Drosophila cell line. Like mammalian IRS proteins, the N-terminal portion of dIRS contains a pleckstrin homology domain and a phosphotyrosine binding domain that binds to phosphotyrosine residues in both human and Drosophila insulin receptors. When coexpressed with dIRS in COS-7 cells, a chimeric receptor (the extracellular domain of human IR fused to the cytoplasmic domain of dIR) mediated insulin-stimulated tyrosine phosphorylation of dIRS. Mutating the juxtamembrane NPXY motif markedly reduced the ability of the receptor to phosphorylate dIRS. In contrast, the NPXY motifs in the C-terminal extension of dIR were required for stable association with dIRS. Coimmunoprecipitationexperimentsdemonstratedinsulin-dependent binding of dIRS to phosphatidylinositol 3-kinase and SHP2. However, we did not detect interactions with Grb2, SHC, or phospholipase C-gamma. Taken together with published genetic studies, these biochemical data support the hypothesis that dIRS functions directly downstream from the insulin receptor in Drosophila.	NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Grad Program Genet, Washington, DC 20052 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); George Washington University	Taylor, SI (corresponding author), NIDDKD, Diabet Branch, NIH, Bldg 10,Rm 9S213, Bethesda, MD 20892 USA.	sitaylormd@aol.com						Albert S, 1997, GENE, V198, P181, DOI 10.1016/S0378-1119(97)00313-2; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Auclair M, 1999, J CLIN ENDOCR METAB, V84, P3197, DOI 10.1210/jc.84.9.3197; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Bridges CB, 1919, GENETICS, V4, P283; CASE RD, 1994, J BIOL CHEM, V269, P10467; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FERNANDEZALMONACID R, 1987, MOL CELL BIOL, V7, P2718, DOI 10.1128/MCB.7.8.2718; FRANKE TF, 1994, ONCOGENE, V9, P141; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Huang H, 1999, DEVELOPMENT, V126, P5365; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER H, 1987, BIOL CHEM H-S, V368, P471, DOI 10.1515/bchm3.1987.368.1.471; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LEROITH D, 1981, DIABETES, V30, P70, DOI 10.2337/diabetes.30.1.70; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Marin-Hincapie M, 1999, J BIOL CHEM, V274, P24987, DOI 10.1074/jbc.274.35.24987; MARINHINCAPIE M, 1995, ENDOCRINOLOGY, V136, P2357, DOI 10.1210/en.136.6.2357; MENESES P, 1975, COMP BIOCHEM PHYS A, V51, P483, DOI 10.1016/0300-9629(75)90398-9; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; SEECOF RL, 1974, CELL DIFFER DEV, V3, P63, DOI 10.1016/0045-6039(74)90041-4; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Smith A, 1999, BBA-GENE STRUCT EXPR, V1447, P313, DOI 10.1016/S0167-4781(99)00172-4; Solow BT, 1999, MOL ENDOCRINOL, V13, P1784, DOI 10.1210/me.13.10.1784; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1985, METHOD ENZYMOL, V109, P656; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Watson KL, 1996, P NATL ACAD SCI USA, V93, P13694, DOI 10.1073/pnas.93.24.13694; White MF, 1998, CURR TOP MICROBIOL, V228, P179; YAMAGUCHI T, 1995, BIOCHEMISTRY-US, V34, P4962, DOI 10.1021/bi00015a007; Yenush L, 1996, MOL CELL BIOL, V16, P2509; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23346	23354		10.1074/jbc.M003579200	http://dx.doi.org/10.1074/jbc.M003579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801879	hybrid			2022-12-25	WOS:000088419400103
J	Proenza, C; Wilkens, C; Lorenzon, NM; Beam, KG				Proenza, C; Wilkens, C; Lorenzon, NM; Beam, KG			A carboxyl-terminal region important for the expression and targeting of the skeletal muscle dihydropyridine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; CALCIUM-CHANNEL; ALPHA-1 SUBUNIT; CA2+ CHANNEL; MEMBRANE; PROTEINS; FAMILY; BRAIN	We have used the yeast two-hybrid technique and expression of truncated/mutated dihydropyridine receptors (DHPRs) to investigate whether the carboxyl tail of the DHPR is involved in targeting to junctions between the sarcolemma and sarcoplasmic reticulum in skeletal muscle. The carboxyl tail was extremely reactive in yeast two-hybrid library screens, with the reactivity residing in amino acids 1621-1647 and abolished by a point mutation (V1642D), Dysgenic myotubes were injected with cDNA encoding green fluorescent protein fused to the amino terminus of DHPRs truncated after either residue 1620 (Delta 1621-1873) or residue 1542 (Delta 1543-1873) or of full-length DHPRs with the V1642D mutation (V1642D), For either Delta 1621-1873 or V1642D, the restoration of excitation-contraction coupling was reduced similar to 40%, and the number of functional DHPRs in the sarcolemma was reduced similar to 30%, compared with the wildtype DHPR. The restoration of excitation-contraction coupling and surface expression was more drastically reduced (by similar to 90 and similar to 55%, respectively) for h1543-1873. Fluorescence microscopy revealed that Delta 1621-1873 and V1642D were concentrated in a longitudinally restricted region near the injected nucleus, whereas wild-type DHPRs were present relatively uniformly along the length of a myotube, The intensity of fluorescence was greatly reduced for Delta 1543-1873, indicating a low level of protein expression, Thus, residues 1543-1647 appear to play a role in the biosynthetic processing, transport, and/or anchoring of DHPRs, with residues 1543-1620 being particularly important for expression.	Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Physiol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Beam, KG (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.			Proenza, Catherine/0000-0003-4324-6206	NINDS NIH HHS [NS24444] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Gee SH, 1998, J NEUROSCI, V18, P128; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; POWELL J, 1998, J CELL BIOL, V134, P375; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; Takekura H, 1999, DEV DYNAM, V214, P372, DOI 10.1002/(SICI)1097-0177(199904)214:4<372::AID-AJA9>3.0.CO;2-Q; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WEI XY, 1994, J BIOL CHEM, V269, P1635	22	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23169	23174		10.1074/jbc.M003389200	http://dx.doi.org/10.1074/jbc.M003389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801875	hybrid			2022-12-25	WOS:000088419400077
J	Schulbach, MC; Brennan, PJ; Crick, DC				Schulbach, MC; Brennan, PJ; Crick, DC			Identification of a short (C-15) chain Z-isoprenyl diphosphate synthase and a homologous long (C-50) chain isoprenyl diphosphate synthase in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; CIS-PRENYLTRANSFERASE; DOLICHOL SYNTHESIS; WALL SYNTHESIS; YEAST RER2; KEY ENZYME; CELL-WALL; BIOSYNTHESIS; PEPTIDOGLYCAN; LOCALIZATION	We report the cloning, overexpression, and partial characterization of two unique Z-isoprenyl diphosphate synthase homologs from Mycobacterium tuberculosis, The first enzyme, Rv1086, adds one isoprene unit to omega,E-geranyl diphosphate, The product, omega,E,Z-farnesyl diphosphate, is the putative substrate of the second enzyme, Rv2361c, This enzyme adds seven more isoprene units to omega,E,Z-farnesyl diphosphate and releases decaprenyl diphosphate. Both open reading frames were cloned from the BI. tuberculosis H37Rv genome and overexpressed in M. smegmatis, Membrane and cytosol fractions from wild type and the two recombinant strains were assayed for [C-14]isopentenyl diphosphate incorporation into isoprenyl diphosphates in the presence of various allylic isoprenyl diphosphate accepters. Membrane fractions of recombinant cells overexpressing Rv2361c incubated with farnesyl diphosphate showed a 10-fold increase of [C-14]isopentenyl diphosphate incorporation into decaprenyl diphosphate, Membrane fractions of recombinant cells overexpressing Rv1086 incubated with geranyl diphosphate showed a 5-fold increase of [C-14]isopentenyl diphosphate incorporation into farnesyl diphosphate. Analysis of the stereochemistry revealed that all of the overexpressed farnesyl diphosphate was in the omega,E,Z-configuration. This is the first description of a short chain isoprenyl diphosphate synthase that generates products with Z-stereo-chemistry. Previously, all known short chain isoprenyl diphosphate synthases catalyze the synthesis of products with E-stereochemistry.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Colorado State University	Crick, DC (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.		Crick, Dean/H-8251-2017	Crick, Dean/0000-0001-9281-7058	NIAID NIH HHS [AI46393, AI18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Baddiley J, 1972, Essays Biochem, V8, P35; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CORNISHBOWDEN A, 1987, EUR J BIOCHEM, V167, P181; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; Fujihashi M, 1999, ACTA CRYSTALLOGR D, V55, P1606, DOI 10.1107/S0907444999008768; HIGASHI Y, 1970, J BIOL CHEM, V245, P3683; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; Kellogg BA, 1997, CURR OPIN CHEM BIOL, V1, P570, DOI 10.1016/S1367-5931(97)80054-3; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sato M, 1999, MOL CELL BIOL, V19, P471; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; VANHEIJENOORT J, 1996, ESCHERICHIA COLI SAL; Wolucka BA, 1998, GLYCOBIOLOGY, V8, P955, DOI 10.1093/glycob/8.10.955; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	27	70	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22876	22881		10.1074/jbc.M003194200	http://dx.doi.org/10.1074/jbc.M003194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816587	hybrid			2022-12-25	WOS:000088419400039
J	Xu, KM; Robida, AM; Murphy, TJ				Xu, KM; Robida, AM; Murphy, TJ			Immediate-early MEK-1-dependent stabilization of rat smooth muscle cell cyclooxygenase-2 mRNA by G alpha(q)-coupled receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; N-TERMINAL KINASE; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL REGULATION; DOWN-REGULATION; 3'-UNTRANSLATED REGION; MAMMALIAN-CELLS	Activation of G alpha(q)-coupled P2Y nucleotide receptors strongly (>100-fold) induces the rat vascular smooth muscle cell cyclooxygenase-2 (COX-2) mRNA, yet transcription is induced only similar to 3-fold over 1 h. Intact cell decay analysis of tetracycline-suppressible luciferase chimera mRNAs shows that regulated stabilization of the intrinsically unstable mRNA contributes to this response. Deletion mapping of the 2468-base COX-2 mRNA 3'-untranslated region (UTR) shows that a distal, 130 base AU-rich region functions as a cis-acting regulated stabilization response element, which under basal conditions serves as the dominant instability determinant for the 3'-UTR. Regulation of this response is through the p42/44 MAP kinases, whereas the p38 MAP kinases are not involved. The stabilization response element binds avidly and specifically to a prominent nuclear-enriched similar to 90-kDa factor and several less abundantly labeled mRNA binding proteins that are unaffected by P2Y receptor signaling. Although other instability determinants are located throughout the rat COX-2 mRNA 3'-UTR, mitogen signaling only interferes with rapid decay mediated by its most distal 130 bases. A complex of nuclear factors that bind this mRNA region specifically may include candidate targets for regulatory modulation, These observations support the general notion that the rapid induction of immediate-early gene expression through mitogenic receptors involves simultaneous activation of transcriptional and post-transcriptional mechanisms.	Emory Univ, Dept Pharmacol, Sch Med, Atlanta, GA 30322 USA; Emory Univ, Grad Program Mol & Syst Pharmacol, Sch Med, Grad Div Biomed & Biol Sci, Atlanta, GA 30322 USA	Emory University; Emory University	Murphy, TJ (corresponding author), Emory Univ, Dept Pharmacol, Sch Med, 5031 OW Rollins Res Bldg, Atlanta, GA 30322 USA.				NHLBI NIH HHS [HL52810, HL56107] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052810, R01HL056107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 2000, J MOL CELL CARDIOL, V32, P391, DOI 10.1006/jmcc.1999.1085; Adams B, 1999, MOL PHARMACOL, V55, P1028, DOI 10.1124/mol.55.6.1028; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Beard SE, 1996, MUTAT RES-GENET TOX, V371, P1, DOI 10.1016/S0165-1218(96)90089-0; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; BRAISER AR, 1989, BIOTECHNIQUES, V7, P1116; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brown CY, 1996, P NATL ACAD SCI USA, V93, P13721, DOI 10.1073/pnas.93.24.13721; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHERRY LM, 1982, ENVIRON MUTAGEN, V4, P259, DOI 10.1002/em.2860040308; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DUBOIS RN, 1994, AM J PHYSIOL, V266, P822; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Goppelt-Struebe M, 1999, BIOCHEM J, V339, P329, DOI 10.1042/0264-6021:3390329; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Grignani F, 1998, CANCER RES, V58, P14; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Han YL, 1999, J IMMUNOL, V163, P1435; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MORRIS JK, 1995, ENDOCRINOLOGY, V136, P1549, DOI 10.1210/en.136.4.1549; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; NICKENIG G, 1994, MOL PHARMACOL, V46, P653; Nickenig G, 1996, MOL PHARMACOL, V50, P743; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XF, 1998, MOL PHARMACOL, V54, P514, DOI 10.1124/mol.54.3.514; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu KM, 2000, J BIOL CHEM, V275, P7604, DOI 10.1074/jbc.275.11.7604; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	63	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23012	23019		10.1074/jbc.M001611200	http://dx.doi.org/10.1074/jbc.M001611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816563	hybrid			2022-12-25	WOS:000088419400056
J	McDonald, JA				McDonald, JA			Prologue: Integrins minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Mayo Clin Scottsdale, Samuel C Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	McDonald, JA (corresponding author), Mayo Clin Scottsdale, Samuel C Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							BORNSTEIN P, 1982, PATHOBIOLOGY ENDOTHE, V6, P215; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9	2	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21783	21783		10.1074/jbc.R000007200	http://dx.doi.org/10.1074/jbc.R000007200			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807935	hybrid			2022-12-25	WOS:000088363800002
J	Tanner, KG; Langer, MR; Kim, YJ; Denu, JM				Tanner, KG; Langer, MR; Kim, YJ; Denu, JM			Kinetic mechanism of the histone acetyltransferase GCN5 from yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; CATALYTIC MECHANISM; COENZYME-A; ADA-COMPLEX; ACETYLATION; BINDING; PROTEIN; TRANSCRIPTION; FLUORESCENCE; COACTIVATOR	The transcriptional coactivator GCN5 from yeast (yGCN5) is a histone acetyltransferase that is essential for activation of target genes. GCN5 is a member of a large family of histone acetyltransferases that are conserved between yeast and humans, To understand the molecular mechanisms of histone/protein acetylation, a detailed kinetic analysis was performed. Pi-substrate kinetic analysis using acetyl-coenzyme A (AcCoA) and an H3 histone synthetic peptide indicated that both substrates must bind to form a ternary complex before catalysis, Product inhibition studies revealed that the product CoA was a competitive inhibitor versus AcCoA Desulfo-CoA, a dead-end inhibitor, also demonstrated simple competitive inhibition versus AcCoA Acetylated (Lys14Ac) H3 peptide displayed noncompetitive inhibition against both H3 peptide and AcCoA These results support a sequential ternary complex (ordered Bi-Bi) kinetic mechanism, where AcCoA binds first, followed by H3 histone, Acetylated (Lys14Ac) H3 product is released first, and CoA is the last product to leave. Also, two methods were developed to measure the binding affinities of AcCoA/CoA for GCN5, Employing the fluorescent CoA analog etheno-CoA (epsilon CoA, 1-N-6-etheno-CoA), a K-d, for epsilon COA of 5.1 +/- 1.1 mu M was determined by fluorescence anisotropy. This value was similar to the K-d value of 8.5 +/- 2.6 mu M for AcCoA obtained using equilibrium dialysis and to the K-i (inhibition constant) of 6.7 mu M for CoA obtained from steady-state kinetic assays. Together, these data suggest that the acetyl moiety of AcCoA contributes little to the binding energy.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NIDDK NIH HHS [T32 DK07680] Funding Source: Medline; NIGMS NIH HHS [GM 59785-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1993, PROTEIN SCI, V2, P800, DOI 10.1002/pro.5560020510; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Basso LA, 1997, BBA-PROTEIN STRUCT M, V1340, P63, DOI 10.1016/S0167-4838(97)00032-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; FAVILLA R, 1988, BIOCHIM BIOPHYS ACTA, V955, P321, DOI 10.1016/0167-4838(88)90211-7; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P8050, DOI 10.1021/bi00421a012; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Klebl BM, 1996, ANAL BIOCHEM, V239, P145, DOI 10.1006/abio.1996.0309; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Segel IH, 1993, ENZYME KINETICS, P506; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	33	120	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22048	22055		10.1074/jbc.M002893200	http://dx.doi.org/10.1074/jbc.M002893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811654	hybrid			2022-12-25	WOS:000088363800043
J	Wu, J; Liu, SL; Zhu, JL; Norton, PA; Nojiri, S; Hoek, JB; Zern, MA				Wu, J; Liu, SL; Zhu, JL; Norton, PA; Nojiri, S; Hoek, JB; Zern, MA			Roles of tissue transglutaminase in ethanol-induced inhibition of hepatocyte proliferation and alpha 1-adrenergic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ORNITHINE DECARBOXYLASE ACTIVITY; LIVER-REGENERATION; PHOSPHOLIPASE-C; RAT HEPATOCYTES; DNA-SYNTHESIS; IN-VITRO; ACTIVATION; INTOXICATION; FIBROGENESIS	The mechanisms by which ethanol inhibits hepatocyte proliferation have been a source of some considerable investigation. Our studies have suggested a possible role for tissue transglutaminase (tTG) in this process. Others have shown that tTG has two distinctly different functions: it catalyzes protein cross-linking, which can lead to apoptosis and enhancement of extracellular matrix stability, and it can function as a G protein (G alpha(h)) Under that circumstance, we speculated that the cross-linking activity would be decreased and that it would function to enhance hepatocyte proliferation in response to adrenergic stimulation. Ethanol treatment inhibited hepatocyte proliferation and led to enhanced tTG crosslinking activity, whereas treatment of hepatocytes with an alpha 1 adrenergic agonist, phenylephrine, enhanced hepatocyte proliferation while decreasing tTG cross-linking, However, phenylephrine treatment of several hepatoma cell lines had no effect on cellular proliferation or tTG cross-linking activity, and of note, Northern blot analysis demonstrated that whereas primary hepatocytes had high levels of the alpha 1 beta adrenergic receptor (alpha 1BAR) mRNA, the hepatoma cell lines did not have this mRNA. When the Hep G(2) cell line was stably transduced with an expression vector containing the alpha 1BR cDNA, the cell line responded to phenylephrine treatment with enhanced proliferation and with decreased tTG cross-linking activity. Ethanol treatment of the alpha 1BAR-transfected cells suppressed the phospholipase C-mediated signaling pathways, as detected in the phenylephrine-induced Ca2+ response. These results suggest that phenylephrine stimulation of hepatocyte proliferation appears to be occurring through the alpha 1BAR, which is known to be coupled with the tTG G protein moiety, G alpha(h), and that tTG appears to play a significant role in either enhancing or inhibiting hepatocyte proliferation, depending on its cellular location and on whether it functions as a cross-linking enzyme or a G protein.	Univ Calif Davis, Med Ctr, Transplant Res Program, Sacramento, CA 95817 USA; Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of California System; University of California Davis; University of California System; University of California Davis; Jefferson University; Jefferson University	Zern, MA (corresponding author), Univ Calif Davis, Med Ctr, Transplant Res Program, 4635 2nd Ave,Suite 1001, Sacramento, CA 95817 USA.			Hoek, Jan/0000-0001-7127-4218; Norton, Pamela/0000-0003-1327-9250	NIAAA NIH HHS [AA-06386] Funding Source: Medline; NIDDK NIH HHS [DK09762, DK-41875] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041875, F32DK009762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006386] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; CARTER EA, 1985, BIOCHEM BIOPH RES CO, V128, P767, DOI 10.1016/0006-291X(85)90113-5; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIEHL AM, 1990, HEPATOLOGY, V12, P633, DOI 10.1002/hep.1840120402; DIEHL AM, 1988, HEPATOLOGY, V8, P237, DOI 10.1002/hep.1840080208; DOLYNCHUK KN, 1994, PLAST RECONSTR SURG, V93, P567, DOI 10.1097/00006534-199493030-00020; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FRIZELL E, 1995, HEPATOLOGY, V21, P847, DOI 10.1002/hep.1840210335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; Hoek JB, 1998, ALCOHOL CLIN EXP RES, V22, p224S, DOI 10.1111/j.1530-0277.1998.tb04007.x; HOUCK KA, 1989, J CELL PHYSIOL, V141, P503, DOI 10.1002/jcp.1041410308; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Katoh S, 1996, EXP CELL RES, V222, P255, DOI 10.1006/excr.1996.0032; KATOH S, 1993, ARCH BIOCHEM BIOPHYS, V303, P421, DOI 10.1006/abbi.1993.1304; Knopp J, 1997, ANN NY ACAD SCI, V827, P489, DOI 10.1111/j.1749-6632.1997.tb51859.x; KNUDSEN TB, 1996, MOL CELLULAR METHODS, P183; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; Kurose I, 1997, HEPATOLOGY, V25, P368; LAMB RG, 1994, HEPATOLOGY, V19, P174, DOI 10.1016/0270-9139(94)90069-8; LEE CH, 1992, J BIOL CHEM, V267, P16044; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Saso K, 1996, ALCOHOL CLIN EXP RES, V20, pA330; SHIBLEY IA, 1995, ALCOHOL CLIN EXP RES, V19, P209, DOI 10.1111/j.1530-0277.1995.tb01494.x; TANAKA T, 1993, ALCOHOL ALCOHOLISM, V28, P41, DOI 10.1093/alcalc/28.Supplement_1B.41; WANDS JR, 1979, GASTROENTEROLOGY, V77, P528; WU DQ, 1992, J BIOL CHEM, V267, P25798; Wu J, 1998, LIVER GROWTH REPAIR, P558; YANG LJ, 1991, J BIOL CHEM, V266, P22451; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	36	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22213	22219		10.1074/jbc.M000091200	http://dx.doi.org/10.1074/jbc.M000091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801782	hybrid			2022-12-25	WOS:000088363800064
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SARCOPLASMIC-RETICULUM; MULTIDRUG-RESISTANCE; CYSTEINE; PROTEINS; MUTANTS; DOMAIN; PURIFICATION; INHIBITION; MUTATIONS	P-glycoprotein (P-gp) is an ATP-dependent drug pump that contains two nucleotide-binding domains (NBDs), Disulfide cross-linking analysis was done to determine if the two NBDs are close to each other. Residues within or close to the Walker A (GNSGCGKS in NDB1 and GSSGCGKS in NBD2) sequences for nucleotide binding were replaced with cysteine, and the mutant P-gps were subjected to oxidative cross-linking. Cross-linking was detected in two mutants, G427C(NBD1)/Cys-1074(NBD2) and L439C(NBD1)/Cys-1074(NBD2), because the crosslinked proteins migrated slower in SDS gels. Mutants G427C(NBD1)/Cys-1074(NBD2) and L439C(NBD1)/Cys-1074(NBD2) retained 10% and 82%, respectively, of the drug-stimulated ATPase activity relative to that of Cysless P-gp. The cross-linking properties of the more active mutant L439C(NBD1)/Cys-1074(NBD2) were then studied. Cross-linking was reversed by addition of dithiothreitol and could be prevented by pretreatment of the mutant with N-ethylmaleimide. Cross-linking was also inhibited by MgATP, but not by the verapamil. Oxidative cross-linking of mutant L439C(NBD1)/Cys-1074(NBD2) resulted in almost complete inhibition of drug-stimulated ATPase activity. More than 60% of the drug-stimulated ATPase activity, however, was recovered after treatment with dithiothreitol, The results indicate that the two predicted nucleotide-binding sites are close to each other and that cross-linking inhibits ATP hydrolysis.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [R01 CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Huang GM, 1998, NATURE, V396, P307, DOI 10.1038/24477; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Nuti SL, 2000, BIOCHEMISTRY-US, V39, P3424, DOI 10.1021/bi992392w; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	30	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19435	19438		10.1074/jbc.C000222200	http://dx.doi.org/10.1074/jbc.C000222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10806188	hybrid			2022-12-25	WOS:000087941300001
J	Pedrajas, JR; Miranda-Vizuete, A; Javanmardy, N; Gustafsson, JA; Spyrou, G				Pedrajas, JR; Miranda-Vizuete, A; Javanmardy, N; Gustafsson, JA; Spyrou, G			Mitochondria of Saccharomyces cerevisiae contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; MAMMALIAN PEROXIREDOXIN; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; CELL-DEATH; CLONING; EXPRESSION; GENE	Peroxiredoxins are ubiquitously expressed proteins that reduce hydroperoxides using disulfur-reducing compounds as electron donors. Peroxiredoxins (Prxs) have been classified in two groups dependent on the presence of either one (l-Cys Prx) or two (a-Cys Prx) conserved cysteine residues. Moreover, 8-Cys Prxs, also named thioredoxin peroxidases, have peroxide reductase activity with the use of thioredoxin as biological electron donor. However, the biological reducing agent for the l-Cys Prx has not yet been identified. We report here the characterization of a l-Cys Prx from yeast Saccharomyces cerevisiae that we have named Prx1p. Prx1p is located in mitochondria, and it is overexpressed when cells use the respiratory pathway, as well as in response to oxidative stress conditions. We show also that Prx1p has peroxide reductase activity in vitro using the yeast mitochondrial thioredoxin system as electron donor. In addition, a mutated form of Prx1p containing the absolutely conserved cysteine as the only cysteine residue also shows thioredoxin-dependent peroxide reductase activity. This is the first example of 1-Cys Prx that has thioredoxin peroxidase activity. Finally, exposure of null Prxlp mutant cells to oxidant conditions reveals an important role of the mitochondrial 1-Cys Prx in protection against oxidative stress.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.		IBIS, REDOX/J-7473-2017; Pedrajas, José Rafael/M-9758-2015; Miranda-Vizuete, Antonio/D-6927-2012	Pedrajas, José Rafael/0000-0003-1998-0638; Miranda-Vizuete, Antonio/0000-0002-6856-5396				Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Cha MK, 1995, BIOCHEM BIOPH RES CO, V217, P900, DOI 10.1006/bbrc.1995.2856; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LAWRENCE AR, 1976, BIOCHEM BIOPH RES CO, V71, P350; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; MIRANDAVIZUETE A, 1997, J BIOL CHEM, V272, P11761; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; PON L, 1991, MOL CELLULAR BIOL YE; SAITO H, 1995, EXP CELL RES, V217, P272, DOI 10.1006/excr.1995.1087; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Sherman F., 1986, METHODS YEAST GENETI; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8917, DOI 10.1073/pnas.84.24.8917; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P21	37	148	155	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16296	16301		10.1074/jbc.275.21.16296	http://dx.doi.org/10.1074/jbc.275.21.16296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821871	hybrid			2022-12-25	WOS:000087291400093
J	Rafiq, I; Xavier, GD; Hooper, S; Rutter, GA				Rafiq, I; Xavier, GD; Hooper, S; Rutter, GA			Glucose-stimulated preproinsulin gene expression and nuclear trans-location of pancreatic duodenum homeobox-1 require activation of phosphatidylinositol 3-kinase but not p38 MAP/SAPK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; INSULIN MESSENGER-RNA; MAP KINASE HOMOLOG; ISLET BETA-CELLS; PROTEIN-KINASE; DEPENDENT TRANSLOCATION; CELLULAR STRESSES; PROMOTER ACTIVITY; BINDING-ACTIVITY; MAMMALIAN-CELLS	Exposure of islet beta-cells to elevated glucose concentrations (30 versus 3 mM) prompts enhanced preproinsulin (PPI) gene transcription and the trans-location to the nucleoplasm of pancreatic duodenum homeobox-1 (PDX-1; Rafiq, I., Kennedy, H., and Rutter, G. A. (1998) J. Biol. Chem 273, 23241-23247). Here, we show that in MIN6 beta-cells, over-expression of p110.CAAX, a constitutively active form of phosphatidylinositol 3-kinase (PI3K) mimicked the activatory effects of glucose on PPI promoter activity, whereas Delta p85, a dominant negative form of the p85 subunit lacking the p110-binding domain, and the P13K inhibitor LY 294002, blocked these effects. Similarly, glucose-stimulated nuclear trans-location of endogenous PDX-1 was blocked by Delta p85 expression, and wortmannin or LY 294002 blocked the trans-location from the nuclear membrane to the nucleoplasm of epitope-tagged PDX-1.c-myc. By contrast, SE 203580, an inhibitor of stress-activated protein kinase-a (SAPK2)/p38 MAP kinase, had no effect on any of the above parameters, and PPI promoter activity and PDX-1,c-myc localization were unaffected by over-expression of the upstream kinase MKK6 (MAP kinase kinase-6) or wild-type p38/SAPK2, respectively. Furthermore, no change in the activity of extracted pS8/SAPK2 could be detected after incubation of cells at either 3 or 30 mM glucose. These data suggest that stimulation of PI3K is necessary and sufficient for the effects of glucose on PPI gene transcription, acting via a downstream signaling pathway that does not involve p58/SAPK2.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	University of Bristol; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Rutter, Guy/0000-0001-6360-0343; da Silva Xavier, Gabriela/0000-0002-0678-012X	Diabetes UK [13/0004672] Funding Source: Medline	Diabetes UK(Diabetes UK)		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1978, BIOCHEM J, V174, P517, DOI 10.1042/bj1740517; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, BIOCHEM SOC T, V25, pS569, DOI 10.1042/bst025s569; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EFRAT S, 1991, J BIOL CHEM, V266, P11141; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Miley HE, 1997, J PHYSIOL-LONDON, V504, P191, DOI 10.1111/j.1469-7793.1997.00191.x; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rutter GA, 1998, CHEM BIOL, V5, pR285, DOI 10.1016/S1074-5521(98)90287-3; Rutter GA, 1999, CURR BIOL, V9, pR443, DOI 10.1016/S0960-9822(99)80277-2; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WELSH M, 1985, J BIOL CHEM, V260, P3590; WELSH M, 1986, DIABETES, V35, P228, DOI 10.2337/diabetes.35.2.228; Xavier GD, 1999, DIABETOLOGIA, V42, pA124; XAVIER GD, IN PRESS P NATL ACAD; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243	52	94	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15977	15984		10.1074/jbc.275.21.15977	http://dx.doi.org/10.1074/jbc.275.21.15977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821851	hybrid			2022-12-25	WOS:000087291400051
J	Feiken, E; van Etten, I; Gebbink, MFBG; Moolenaar, WH; Zondag, GCM				Feiken, E; van Etten, I; Gebbink, MFBG; Moolenaar, WH; Zondag, GCM			Intramolecular interactions between the juxtamembrane domain and phosphatase domains of receptor protein-tyrosine phosphatase RPTP mu - Regulation of catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMOPHILIC BINDING; DIMERIZATION; ALPHA; KAPPA; INHIBITION; LAR	RPTP mu is a receptor-like protein-tyrosine phosphatase (RPTP) whose ectodomain mediates homotypic cell-cell interactions. The intracellular part of RPTP mu contains a relatively long juxtamembrane domain (158 amino acids; aa) and two conserved phosphatase domains (C1 and C2), The membrane-proximal C1 domain is responsible for the catalytic activity of RPTP mu, whereas the membrane-distal C2 domain serves an unknown function. The regulation of RPTP activity remains poorly understood, although dimerization has been proposed as a general mechanism of inactivation. Using the yeast two-hybrid system, we find that the C1 domain binds to an N-terminal noncatalytic region in RPTP mu, termed JM (aa 803-955), consisting of a large part of the juxtamembrane domain (120 as) and a small part of the C1 domain (33 as). When co-expressed in COS cells, the JM polypeptide binds to both the C1 and the C2 domain. Strikingly, the isolated JM polypeptide fails to interact with either full-length RPTP mu or with truncated versions of RPTP mu that contain the JM region, consistent with the dM-C1 and JM-C2 interactions being intramolecular rather than intermolecular, Furthermore, we find that large part of the juxtamembrane domain (aa 814-922) is essential for C1 to be catalytically active. Our findings suggest a model in which RPTP mu activity is regulated by the juxtamembrane domain undergoing intramolecular interactions with both the C1 and C2 domain.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; SAP J, 1994, MOL CELL BIOL, V14, P1; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zondag GCM, 1996, J CELL BIOL, V134, P1513, DOI 10.1083/jcb.134.6.1513; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	28	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15350	15356		10.1074/jbc.275.20.15350	http://dx.doi.org/10.1074/jbc.275.20.15350			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809770	hybrid			2022-12-25	WOS:000087128300078
J	Padilla, PI; Wada, A; Yahiro, K; Kimura, M; Niidome, T; Aoyagi, H; Kumatori, A; Anami, M; Hayashi, T; Fujisawa, J; Saito, H; Moss, J; Hirayama, T				Padilla, PI; Wada, A; Yahiro, K; Kimura, M; Niidome, T; Aoyagi, H; Kumatori, A; Anami, M; Hayashi, T; Fujisawa, J; Saito, H; Moss, J; Hirayama, T			Morphologic differentiation of HL-60 cells is associated with appearance of RPTP beta and induction of Helicobacter pylori VacA sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; PROTEIN-TYROSINE-PHOSPHATASE; VACUOLATING CYTOTOXIN; TERMINAL DIFFERENTIATION; RETINOIC ACID; HL60 CELLS; LINE; EXPRESSION; TOXIN; PROLIFERATION	Phorbol la-myristate Is-acetate (PMA) induces differentiation of human leukemic HL-60 cells into cells with macrophage-like characteristics and enhances the susceptibility of HL-60 cells to the Helicobacter pylori VacA toxin (de Bernard, M., Moschioni., M., Papini, E., Telford, J. L., Rappuoli, Il., and Montecucco, C. (1998) FEES Lett. 436, 218-222). We examined the mechanism by which HL-60 cells acquire sensitivity to VacA, in particular, looking for expression of RPTP beta, a VacA-binding protein postulated to be the VacA receptor (Yahiro, K., Niidome, T., Kimura, M., Hatakeyama, T., Aoyagi, H., Kurazono, H., Imagawa, K., Wads, A, Moss, J., and Hirayama, T. (1999) J. BioL Chem, 274, 36693-36699). PMA induced expression of RPTP beta mRNA and protein as determined by RNase protection assay and indirect immunofluorescence studies, respectively. Vitamin D-3 and interferon-gamma, which stimulate differentiation of HL-60 cells into monocyte-like cells, also induced VacA sensitivity and expression of RPTP beta mRNA, whereas 1.2% Me,SO and retinoic acid, which stimulated the maturation of HL-60 into granulocyte-like cells, did not. RPTP beta antisense oligonucleotide inhibited induction of VacA sensitivity and expression of RPTP beta. Double immunostaining studies also indicated that newly expressed RPTP beta colocalized with VacA in PMA-treated HL-60 cells. In agreement with these data, BHK-21 cells, which are insensitive to VacA, when transfected with the RPTP beta cDNA, acquired VacA sensitivity. All data are consistent with the conclusion that acquisition of VacA sensitivity by PMA-treated HL-60 cells results from induction of RPTP beta, a protein that functions as the VacA receptor.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 852, Japan; Nagasaki Univ, Inst Trop Med, Dept Biochem, Nagasaki 8528523, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528523, Japan; Nagasaki Univ Hosp, Dept Pathol, Nagasaki 8528501, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708506, Japan; Dana Farber Canc Inst, Dept Tumor Immunol, Boston, MA 02115 USA; NHKBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Kansai Medical University; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 852, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; Cover TL, 1998, TRENDS MICROBIOL, V6, P127, DOI 10.1016/S0966-842X(98)01231-1; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1992, J BIOL CHEM, V267, P10570; de Bernard M, 1998, FEBS LETT, V436, P218, DOI 10.1016/S0014-5793(98)01132-6; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; Juan G, 1998, EXP CELL RES, V244, P83, DOI 10.1006/excr.1998.4165; Kasugai I, 1997, CANCER LETT, V120, P223, DOI 10.1016/S0304-3835(97)00313-3; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; KOEFFLER HP, 1980, BLOOD, V56, P344; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MAURIZIO M, 1998, BIOCHEM BIOPH RES CO, V248, P334; MeighanMantha RL, 1997, EXP CELL RES, V234, P321, DOI 10.1006/excr.1997.3631; Nagata H, 1999, MICROB PATHOGENESIS, V26, P103, DOI 10.1006/mpat.1998.0256; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; TANAKA H, 1983, BIOCHEM BIOPH RES CO, V117, P86, DOI 10.1016/0006-291X(83)91544-9; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345	37	61	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15200	15206		10.1074/jbc.275.20.15200	http://dx.doi.org/10.1074/jbc.275.20.15200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809755	hybrid			2022-12-25	WOS:000087128300059
J	Manna, SK; Aggarwal, BB				Manna, SK; Aggarwal, BB			All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappa B, activated protein-1 and apoptosis in human lung cancer cells	ONCOGENE			English	Article						ATRA; TNF; NF-kappa B; AP-1; apoptosis	TUMOR-NECROSIS-FACTOR; LYMPHOMA U-937 CELLS; FACTOR-ALPHA; SURFACE EXPRESSION; CELLULAR-RESPONSE; GROWTH-INHIBITION; INTERFERON-GAMMA; HL-60 CELLS; LINE HL-60; DIFFERENTIATION	Retinoids modulate the growth and differentiation effects of TNF but the mechanism is not understood. In this study, we investigated the effect of all-tr all-trans-retinoic acid (ATRA) on the cell surface expression of TNF receptors and receptor-mediated signaling in various human lung cancer cell lines. ATRA treatment of cells that express wild-type p53 (A549 and H460), or null p53 (H1299), or mutant p53 (H596) increased the number of TNF receptors, as determined by the specific binding of I-125-labeled TNF to these cells, in a dose- and time-dependent manner. Treatment with 2 mu M ATRA for 24 h at 37 degrees C produced the maximal increase. Scatchard analysis indicated that the increase inducted by ATRA was due to an increase in receptor number and not to an increase in affinity. The upmodulation of TNF receptors nas also confirmed by covalent receptor-ligand cross-linking studies. The increase in TNF receptors sensitized H596 cells to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, A549 cells, however, were completely resistant to TNF-induced activation of NF-kappa B, AP-1 and apoptosis, Treatment of these cells with as little as 0.5 mu M ATRA was effective in converting TNF-resistant cells to TNF-sensitive. Overall our results indicate that ATRA induces the TNF receptors in human lung cancer cells, which sensitizes them to TNF-induced signaling leading to activation of NF-kappa B, AP-1 and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; AGGARWAL BB, 1987, J BIOL CHEM, V262, P10000; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P624; AMOS B, 1989, PHARM RETINOIDS SKIN, P26; BEAUPAIN R, 1990, ANTICANCER RES, V10, P1061; Benner S E, 1995, Oncology (Williston Park), V9, P205; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHAMBAUTGUERIN AM, 1995, J NEUROCHEM, V65, P537; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAN H, 1994, J BIOL CHEM, V269, P31424; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; DE LUCA LM, 1991, FASEB J, V5, P2924; DRACH J, 1993, CANCER RES, V53, P2100; FALK LA, 1991, BLOOD, V77, P1248; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gridley DS, 1996, ONCOL RES, V8, P485; HAN SK, 1994, AM J RESP CELL MOL, V11, P270, DOI 10.1165/ajrcmb.11.3.8086165; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Haridas V, 1998, J IMMUNOL, V160, P3152; HASS PE, 1985, J BIOL CHEM, V260, P2214; HEMMI H, 1987, BLOOD, V69, P501; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JETTEN AM, 1980, NATURE, V284, P626, DOI 10.1038/284626a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KILIAN PL, 1988, MONOKINES OTHER NONL, P203; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOTAN R, 1992, CANCER RES, V52, P4878; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MEHTA K, 1994, J LEUKOCYTE BIOL, V55, P336, DOI 10.1002/jlb.55.3.336; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Oridate N, 1995, J CELL BIOCHEM, P80; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PECK R, 1991, EUR J CANCER, V27, P53, DOI 10.1016/0277-5379(91)90061-H; Pestana ES, 1996, ACTA ONCOL, V35, P473, DOI 10.3109/02841869609109925; POGREBNIAK HW, 1991, J THORAC CARDIOV SUR, V102, P904, DOI 10.1016/S0022-5223(19)33941-8; PREWITT TW, 1994, J THORAC CARDIOV SUR, V107, P43; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; Sheski FD, 1999, J LAB CLIN MED, V133, P265, DOI 10.1016/S0022-2143(99)90083-5; SIDELL N, 1991, J IMMUNOL, V146, P3809; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2829; TOBLER A, 1987, BLOOD, V70, P1940; TOTPAL K, 1995, BLOOD, V85, P3547, DOI 10.1182/blood.V85.12.3547.bloodjournal85123547; TRINCHIERI G, 1987, BLOOD, V69, P1218; WINZEN R, 1992, J IMMUNOL, V148, P3454; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHENG ZS, 1990, CANCER RES, V50, P1201; Zou CP, 1998, CLIN CANCER RES, V4, P1345	57	50	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2110	2119		10.1038/sj.onc.1203547	http://dx.doi.org/10.1038/sj.onc.1203547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815802				2022-12-25	WOS:000086728000004
J	Ji, HL; Chalfant, ML; Jovov, B; Lockhart, JP; Parker, SB; Fuller, CM; Stanton, BA; Benos, DJ				Ji, HL; Chalfant, ML; Jovov, B; Lockhart, JP; Parker, SB; Fuller, CM; Stanton, BA; Benos, DJ			The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CFTR CHLORIDE CHANNELS; NA+ CHANNEL; XENOPUS OOCYTES; AIRWAY EPITHELIA; LIDDLES-SYNDROME; ION PERMEATION; CELL-SURFACE; SYNTAXIN 1A; DOMAIN	Epithelial sodium channel (ENaC) and cystic fibrosis transmembrane conductance regulator (CFTR) are colocalized in the apical membrane of many epithelia, These channels are essential for electrolyte and water secretion and/or reabsorption, In cystic fibrosis airway epithelia, a hyperactivated epithelial Na+ conductance operates in parallel with defective Cl- secretion. Several groups have shown that CFTR down-regulates ENaC activity, but the mechanisms and the regulation of CFTR by ENaC are unknown. To test the hypothesis that ENaC and CFTR regulate each other, and to identify the region(s) of ENaC involved in the interaction between CFTR and ENaC, rENaC and its mutants were co-expressed with CFTR in Xenopus oocytes, Whole cell macroscopic sodium currents revealed that wild type (wt) alpha beta gamma-rENaC-induced Na+ current was inhibited by coexpression of CFTR, and further inhibited when CFTR was activated with a cAMP-raising mixture (CKT), Conversely, alpha beta gamma-rENaC stimulated CFTR-mediated Cl- currents up to similar to 6-fold, Deletion mutations in the intracellular tails of the three rENaC subunits suggested that the carboxyl terminus of the beta subunit was required both for the down-regulation of ENaC by activated CFTR and the up-regulation of CFTR by ENaC, However, both the carboxyl terminus of the beta subunit and the amino terminus of the gamma subunit were essential for the down-regulation of rENaC by unstimulated CFTR, Interestingly, down-regulation of rENaC by activated CFTR was Cl--dependent, while stimulation of CFTR by rENaC was not dependent on either cytoplasmic Na+ or a depolarized membrane potential. In summary, there appear to be at least two different sites in ENaC involved in the intermolecular interaction between CFTR and ENaC.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Dartmouth Coll, Sch Med, Dept Physiol, Hanover, NH 03755 USA	University of Alabama System; University of Alabama Birmingham; Dartmouth College	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.		JI, HONGLONG/N-7822-2014; Fuller, Cathy/B-4046-2011	JI, HONGLONG/0000-0002-3228-7144; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, P50DK053090, R01DK051067] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51067, DK45881, DK53090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Berdiev BK, 2000, BIOPHYS J, V78, P1881, DOI 10.1016/S0006-3495(00)76737-3; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; DUSZYK M, 1989, CAN J PHYSIOL PHARM, V67, P1362, DOI 10.1139/y89-217; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; Grubb BR, 1997, AM J PHYSIOL-GASTR L, V272, pG393, DOI 10.1152/ajpgi.1997.272.2.G393; He ZP, 1998, AM J PHYSIOL-CELL PH, V275, pC958, DOI 10.1152/ajpcell.1998.275.4.C958; Hopf A, 1999, J BIOL CHEM, V274, P13894, DOI 10.1074/jbc.274.20.13894; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; Ito S, 1997, J NEUROSCI METH, V75, P21, DOI 10.1016/S0165-0270(97)02258-9; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; JIANG Q, 1999, PEDIATR PULM, V19, P195; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Jovov B, 1998, AM J PHYSIOL-CELL PH, V275, pC449, DOI 10.1152/ajpcell.1998.275.2.C449; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Letz B, 1997, AM J PHYSIOL-CELL PH, V272, pC657, DOI 10.1152/ajpcell.1997.272.2.C657; Ling BN, 1997, J BIOL CHEM, V272, P594; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Seibert FS, 1999, BBA-BIOMEMBRANES, V1461, P275, DOI 10.1016/S0005-2736(99)00163-7; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Tousson A, 1996, J CELL SCI, V109, P1325; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5	57	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27947	27956						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10821834				2022-12-25	WOS:000089197100058
J	Chen, NY; Chen, CC; Lau, LF				Chen, NY; Chen, CC; Lau, LF			Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; LAMININ RECEPTOR; CCN FAMILY; EXPRESSION; IDENTIFICATION; PRODUCT; PROTEIN	The angiogenic inducer Cyr61 is an extracellular matrix-associated heparin-binding protein that can mediate cell, adhesion, stimulate cell migration, and enhance growth factor-stimulated DNA synthesis in both fibroblasts and endothelial cells in culture. In vivo, Cyr61 induces neovascularization and promotes tumor growth. Cyr61 is a prototypic member of a highly conserved family of secreted proteins that includes connective tissue growth factor, nephroblastoma overexpressed, Elm-1/WISP-1, Cop-1/WISP-2, and WISP-3. Encoded by an immediate early gene, Cyr61 synthesis is induced by serum growth factors in cultured fibroblasts and in dermal fibroblasts during cutaneous wound healing. We previously demonstrated that Cyr61 mediates adhesion of vascular endothelial cells and activation-dependent adhesion of blood platelets through direct interaction with integrins alpha(V)beta(3) and alpha(IIb)beta(3), respectively. In this study, we show that the adhesion of primary human skin fibroblasts to Cyr61 is mediated through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans (HSPGs), which most likely serve as co-receptors. Either destruction of cell surface HSPGs or prior occupancy of the Cyr61 heparin-binding site completely blocked cell adhesion to Cyr61. A heparin-binding defective mutant of Cyr61 was unable to mediate fibroblast adhesion through integrin alpha(6)beta(1) but still mediated endothelial cell adhesion through integrin alpha(V)beta(3) indicating that endothelial cell adhesion through integrin alpha(V)beta(3) is independent of the heparin-binding activity of Cyr61. These results identify Cyr61 as a novel adhesive substrate for integrin alpha(6)beta(1) and provide the first demonstration of the requirement for HSPGs in integrin-mediated cell attachment. In addition, these findings suggest that Cyr61 might elicit disparate biological effects in different cell types through interaction with distinct integrin receptors.	Univ Illinois, Coll Med, Dept Mol Genet MC669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet MC669, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carloni V, 1998, GASTROENTEROLOGY, V115, P433, DOI 10.1016/S0016-5085(98)70210-0; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Couchman JR, 1999, J CELL SCI, V112, P3415; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, THESIS U ILLINOIS CH; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OLIVER MH, 1989, J CELL SCI, V92, P513; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PIGOTT R, 1993, ADHESION MOL, P158; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Stappert Jorg, 1994, P59; THORSTEINSDOTTIR S, 1995, DEV DYNAM, V204, P240, DOI 10.1002/aja.1002040304; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; Yamamoto H, 1996, INT J CANCER, V65, P519, DOI 10.1002/(SICI)1097-0215(19960208)65:4<519::AID-IJC21>3.0.CO;2-3; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	55	154	168	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24953	24961		10.1074/jbc.M003040200	http://dx.doi.org/10.1074/jbc.M003040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821835	hybrid			2022-12-25	WOS:000088683300096
J	Sun, WY; Vincent, S; Settleman, J; Johnson, GL				Sun, WY; Vincent, S; Settleman, J; Johnson, GL			MEK kinase 2 binds and activates protein kinase C-related kinase 2 - Bifurcation of kinase regulatory pathways at the level of an MAPK kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-TRANSFORMATION; SIGNAL-TRANSDUCTION; POTENTIAL EFFECTOR; PUTATIVE TARGET; 2-HYBRID SYSTEM; ADAPTER PROTEIN; SMALL GTPASE; RAT-LIVER; PKN; RHO	MEK kinase 2 (MEKK2) is a 70-kDa protein serine/threonine kinase that has been shown to function as a mitogen-activated protein kinase (MAPK) kinase kinase, MEKK2 has its kinase domain in the COOH-terminal moiety of the protein. The NH,-terminal moiety of MEKK2 has no signature motif that would suggest a defined regulatory function. Yeast two-hybrid screening was performed to identify proteins that bind MEKK2. Protein kinase C-related kinase 2 (PRK2) was found to bind MEKK2; PRK2 has been previously shown to bind RhoA and the Src homology 3 domain of Nck, PRK2 did not bind MEKK3, which is closely related to MEKK2. The MEKK2 binding site maps to amino acids 637-660 in PRK2, which is distinct from the binding sites for RhoA and Nck. This sequence is divergent in the closely related kinase PRK1, which did not bind MEKK2. In cells, MEKK2 and PRK2 are co-immunoprecipitated and PRK2 is activated by MEKK2, Similarly, purified recombinant MEKK2 activated PRK2 in vitro. MEKK2 activation of PRK2 is independent of MEKK2 regulation of the c-Jun NH,-terminal kinase pathway. MEKK2 activation of PRK2 results in a bifurcation of signaling for the dual control of MAPK pathways and PRK2 regulated responses.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02139 USA; Harvard Univ, Sch Med, Charlestown, MA 02139 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Massachusetts General Hospital; Harvard University	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave,C-236, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074-7613(00)80116-8; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Singer WD, 1996, J BIOL CHEM, V271, P4504; Stapleton G, 1998, DEV BIOL, V193, P36, DOI 10.1006/dbio.1997.8791; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Yu WP, 1997, J BIOL CHEM, V272, P10030; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	55	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24421	24428		10.1074/jbc.M003148200	http://dx.doi.org/10.1074/jbc.M003148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818102	hybrid			2022-12-25	WOS:000088683300025
J	Wagner, L; Oliyarnyk, O; Gartner, W; Nowotny, P; Groeger, M; Kaserer, K; Waldhausl, W; Pasternack, MS				Wagner, L; Oliyarnyk, O; Gartner, W; Nowotny, P; Groeger, M; Kaserer, K; Waldhausl, W; Pasternack, MS			Cloning and expression of secretagogin, a novel neuroendocrine-and pancreatic islet of Langerhans-specific Ca2+-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; INSULIN-SECRETION; KINASE-II; CALBINDIN D28K; RINM5F CELLS; BETA-CELLS; CALRETININ; CA2+; OSCILLATIONS; CALMODULIN	We have cloned a novel pancreatic beta cell and neuroendocrine cell-specific calcium-binding protein termed secretagogin. The cDNA obtained by immunoscreening a human pancreatic cDNA library using the recently described murine monoclonal antibody D24 contains an open reading frame of 828 base pairs. This codes for a cytoplasmic protein with six putative EF finger hand calcium-binding motifs, The gene could be localized to chromosome 6 by alignment with GenBanb genomic sequence data, Northern blot analysis demonstrated abundant expression of this protein in the pancreas and to a lesser extent in the thyroid, adrenal medulla, and cortex. In addition it was expressed in scant quantity in the gastrointestinal tract (stomach, small intestine, and colon). Thyroid tissue expression of secretagogin was restricted to C-cells, Using a sandwich capture enzyme-linked immunosorbent assay with a detection limit of 6.5 pg/ml, considerable amounts of constitutively secreted protein could be measured in tissue culture supernatants of stably transfected RIN-BF and dog insulinoma (INS-H1) cell clones; however, in stably transfected Jurkat cells, the protein was only secreted upon CD3 stimulation. Functional analysis of transfected cell lines expressing secretagogin revealed an influence on calcium flux and cell proliferation. In RIN-5F cells, the antiproliferative effect is possibly due to secretagogin-triggered down-regulation of substance P transcription.	Univ Vienna, Div Clin Endocrinol & Metab, Dept Med 3, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria; Massachusetts Gen Hosp, Infect Dis Unit, Serv Pediat, Boston, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	University of Vienna; University of Vienna; University of Vienna; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wagner, L (corresponding author), Univ Vienna, Div Clin Endocrinol & Metab, Dept Med 3, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Oliyarnyk, Olena/Q-6380-2019	Oliyarnyk, Olena/0000-0002-4912-6187				ANDRESSEN C, 1993, CELL TISSUE RES, V271, P181, DOI 10.1007/BF00318606; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BIDEN TJ, 1987, J BIOL CHEM, V262, P9437; Cao DR, 1997, J CELL SCI, V110, P497; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Celio RC, 1996, GUIDEBOOK CALCIUM BI; CELIO RC, 1996, GUIDEBOOK CALCIUM BI, P23; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GILON P, 1993, J BIOL CHEM, V268, P22265; GROSS MD, 1993, J BIOL CHEM, V268, P20917; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HELLMAN B, 1994, DIABETES METAB, V20, P123; HELLMAN B, 1994, DIABETOLOGIA, V37, pS11, DOI 10.1007/BF00400821; HUNZIKER W, 1986, P NATL ACAD SCI USA, V83, P7578, DOI 10.1073/pnas.83.20.7578; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MCGREGOR GP, 1995, ENDOCRINOLOGY, V136, P2538, DOI 10.1210/en.136.6.2538; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; Meier TJ, 1998, J NEUROCHEM, V71, P1013; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MINGHETTI PP, 1988, MOL ENDOCRINOL, V2, P355, DOI 10.1210/mend-2-4-355; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; Ozawa H, 1995, CELL STRUCT FUNCT, V20, P415, DOI 10.1247/csf.20.415; PARMENTIER M, 1991, EUR J BIOCHEM, V196, P79, DOI 10.1111/j.1432-1033.1991.tb15788.x; PARMENTIER M, 1991, CYTOGENET CELL GENET, V57, P41, DOI 10.1159/000133111; Reddy D, 1997, P NATL ACAD SCI USA, V94, P1961, DOI 10.1073/pnas.94.5.1961; RESIBOIS A, 1992, NEUROSCIENCE, V46, P101, DOI 10.1016/0306-4522(92)90012-Q; RIBAR TJ, 1995, J BIOL CHEM, V270, P28688, DOI 10.1074/jbc.270.48.28688; ROTH J, 1982, ENDOCRINOLOGY, V110, P2216, DOI 10.1210/endo-110-6-2216; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; VALDEOLMILLOS M, 1993, DIABETES, V42, P1210, DOI 10.2337/diabetes.42.8.1210; Wagner L, 1998, J ENDOCRINOL, V156, P469, DOI 10.1677/joe.0.1560469; WAGNER L, 1999, DIABETES STOFFWE S1, V8, P97; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; WILSON PW, 1988, J MOL BIOL, V200, P615, DOI 10.1016/0022-2836(88)90475-5; WINSKY L, 1995, J NEUROCHEM, V65, P381; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yamaguchi K, 1999, J BIOL CHEM, V274, P3610, DOI 10.1074/jbc.274.6.3610	49	136	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24740	24751		10.1074/jbc.M001974200	http://dx.doi.org/10.1074/jbc.M001974200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10811645	hybrid			2022-12-25	WOS:000088683300070
J	Mariotti, M; De Benedictis, L; Avon, E; Maier, JAM				Mariotti, M; De Benedictis, L; Avon, E; Maier, JAM			Interaction between endothelial differentiation-related factor-1 and calmodulin in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FIBROBLAST GROWTH-FACTOR; TRANSCRIPTIONAL COACTIVATOR; BINDING-PROTEIN; NITRIC-OXIDE; ANGIOGENESIS; MBF1; CA2+/CALMODULIN; MECHANISMS; GENE	Calmodulin (CaM) is the principal Ca2+ receptor protein inside the cell. When activated by Ca2+, CaM binds and activates target proteins, thus altering the metabolism and physiology of the cell, Under basal conditions, calcium-free CaM binds to other proteins termed CaM-binding proteins, Recently, we described endothelial differentiation-related factor (EDF)-1 as a protein involved in the repression of endothelial cell differentiation (Dragoni, I., Mariotti, M., Consalez, G, G., Soria, M., and Maier, J. A. M. (1998) J, Biol, Chem. 273, 31119-31124). Here we report that (i) EDF-1 binds CaM in vitro and in vice; (ii) EDF-1 is phosphorylated in vitro and in vivo by protein kinase C; and (iii) EDF-1-CaM interaction is modulated by the concentrations of Ca2+ and by the phosphorylation of EDF-1 by protein kinase C both in vitro and in vivo,In addition, 12-O-tetradecanoylphorbol-13-acetate treatment of human umbilical vein endothelial cell stimulates the nuclear translocation of EDF-1. On the basis of the high homology of EDF-1 with multiprotein bridging factor-1, a transcriptional coactivator that binds TATA-binding protein (TBP), we also demonstrate that EDF-1 interacts with TBP in vitro and in human endothelial cells, We hypothesize that EDF-1 serves two main functions in endothelial cells as follows: (i) to bind CaM in the cytosol at physiologic concentrations of Ca2+ and (ii) to act in the nucleus as a transcriptional coactivator through its binding to TBP.	Univ Milan, Dept Biomed Sci & Technol, Milan, Italy; DIBIT H San Raffaele, Mol Oncol Unit, Milan, Italy	University of Milan	Maier, JAM (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Olgettina 58-60, Milan, Italy.	maier.jeanette@hsr.it	Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BUELT MK, 1994, J BIOL CHEM, V269, P29367; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; Cohen P, 1988, CALMODULIN; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Dragoni I, 1998, J BIOL CHEM, V273, P31119, DOI 10.1074/jbc.273.47.31119; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fukumura D, 1998, CANCER METAST REV, V17, P77, DOI 10.1023/A:1005908805527; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Kabe Y, 1999, J BIOL CHEM, V274, P34196, DOI 10.1074/jbc.274.48.34196; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MACIAG T, 1990, ADV ONCOLOGY, P83; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MEANS AR, 1998, RECENT PROG HORM RES, V44, P223; MEIRI KF, 1988, J NEUROSCI, V8, P2571; Moroianu J, 1999, J CELL BIOCHEM, P76; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Smith ML, 1998, MOL BRAIN RES, V62, P12, DOI 10.1016/S0169-328X(98)00207-1; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; Takemaru K, 1998, MOL CELL BIOL, V18, P4971, DOI 10.1128/MCB.18.9.4971; Truant R, 1998, EUR J CELL BIOL, V77, P269, DOI 10.1016/S0171-9335(98)80085-X; Ziemianin B, 1999, J PHYSIOL PHARMACOL, V50, P597	31	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24047	24051		10.1074/jbc.M001928200	http://dx.doi.org/10.1074/jbc.M001928200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816571	hybrid			2022-12-25	WOS:000088564200088
J	Chen, SX; Halkier, BA				Chen, SX; Halkier, BA			Characterization of glucosinolate uptake by leaf protoplasts of Brassica napus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; AMINO-ACID-TRANSPORT; OILSEED RAPE; SUGAR UPTAKE; BETA-VULGARIS; L LEAVES; COTYLEDONS; SEEDS; BIOSYNTHESIS; MUSTARD	The uptake of radiolabeled p-hydroxybenzylglucosinolate (p-OHBG) by protoplasts isolated from leaves of Brassica napus was detected using silicone oil filtration technique. The uptake was pH-dependent with higher uptake rates at acidic pH. Imposition of a pH gradient (internal alkaline) across the plasma membrane resulted in a rapid uptake of p-OHBG, which was inhibited in the presence of carbonyl cyanide m-chlorophenylhydrazone, indicating that the uptake is dependent on a proton motive force. Dissipation of the internal positive membrane potential generated a small influx as compared with that seen for pH gradient (Delta pH). Kinetic studies demonstrated the presence of two uptake systems, a saturable and a linear component. The saturable kinetics indicated carrier-mediated translocation with a K-m of 1.0 11mM and a V-max of 28.7 nmol/mu l/h, The linear component had very low substrate affinity. The carrier-mediated transport had a temperature coefficient (Q(10)) of 1.8 +/- 0.2 in the temperature range from 4-30 degrees C, The uptake was against a concentration gradient and was sensitive to protonophores, uncouplers, H+-ATPase inhibitors, and the sulfhydryl group modifier p-chloro-mercuriphenylsulfonic acid. The carrier-mediated up take system had high specificity for glucosinolates because glucosinolate degradation products, amino acids, sugars, or glutathione conjugates did not compete for p-OHBG uptake. Glucosinolates with different side chains were equally good competitors of p-OHBG; uptake, which indicates that the uptake system has low specificity for the glucosinolate side chains. Our data provide the first evidence of an active transport of glucosinolates by a proton coupled symporter in the plasma membrane of rape leaves.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, DK-1871 Frederiksberg, Denmark	University of Copenhagen; University of Copenhagen	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Halkier, Barbara A/H-3196-2014	Halkier, Barbara A/0000-0002-3742-702X				BERGMANN F, 1970, Z PFLANZENPHYSIOL, V62, P362; BLACKMAN MS, 1980, PLANT PHYSIOL, V66, P261, DOI 10.1104/pp.66.2.261; BODNARYK RP, 1992, PHYTOCHEMISTRY, V31, P2671, DOI 10.1016/0031-9422(92)83609-3; BORSTLAP AC, 1987, PLANT SCI, V48, P55, DOI 10.1016/0168-9452(87)90070-7; Brown MM, 1997, PHYSIOL PLANTARUM, V101, P533, DOI 10.1034/j.1399-3054.1997.1010312.x; Brudenell AJP, 1999, J EXP BOT, V50, P745, DOI 10.1093/jexbot/50.335.745; BUCKHOUT TJ, 1989, PLANTA, V178, P393, DOI 10.1007/BF00391867; BUSH DR, 1988, PLANT PHYSIOL, V88, P487, DOI 10.1104/pp.88.2.487; Chen SX, 2000, PHYTOCHEM ANALYSIS, V11, P174, DOI 10.1002/(SICI)1099-1565(200005/06)11:3<174::AID-PCA513>3.0.CO;2-Q; DONALDSO.TW, 1973, PLANT PHYSIOL, V52, P638, DOI 10.1104/pp.52.6.638; DOUGHTY KJ, 1991, ANN APPL BIOL, V118, P469, DOI 10.1111/j.1744-7348.1991.tb05648.x; Du LC, 1998, PHYTOCHEMISTRY, V48, P1145, DOI 10.1016/S0031-9422(97)00877-7; FIELDSEND J, 1994, ANN APPL BIOL, V124, P531, DOI 10.1111/j.1744-7348.1994.tb04157.x; FIEUW S, 1991, PLANT SCI, V76, P9, DOI 10.1016/0168-9452(91)90212-Q; GIJZEN M, 1994, J PLANT PHYSIOL, V144, P17, DOI 10.1016/S0176-1617(11)80985-5; GIJZEN M, 1989, PLANT PHYSIOL, V89, P260, DOI 10.1104/pp.89.1.260; GLIMELIUS K, 1984, PHYSIOL PLANTARUM, V61, P38, DOI 10.1111/j.1399-3054.1984.tb06097.x; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; Hauser M, 2000, J BIOL CHEM, V275, P3037, DOI 10.1074/jbc.275.5.3037; KORITSAS VM, 1991, ANN APPL BIOL, V118, P209, DOI 10.1111/j.1744-7348.1991.tb06099.x; Larsen PO, 1981, BIOCH PLANT PRODUCTS, V7, P501; LEIN KA, 1972, Z PFLANZENPHYSIOL, V67, P333, DOI 10.1016/S0044-328X(72)80094-1; LYKKESFELDT J, 1993, PLANT PHYSIOL, V102, P609, DOI 10.1104/pp.102.2.609; MAGRATH R, 1993, PLANT BREEDING, V111, P249, DOI 10.1111/j.1439-0523.1993.tb00637.x; MARSHALL J, 1994, PLANT J, V5, P683, DOI 10.1111/j.1365-313X.1994.00683.x; MAYNARD JW, 1982, PLANT PHYSIOL, V69, P734, DOI 10.1104/pp.69.3.734; McDonald R, 1996, PLANTA, V198, P54, DOI 10.1007/BF00197586; Merritt SZ, 1996, J CHEM ECOL, V22, P1133, DOI 10.1007/BF02027950; MITHEN R, 1992, EUPHYTICA, V63, P71, DOI 10.1007/BF00023913; Murashige T, 1962, PHYSIOL PLANTARUM, V15, P475; ODRISCOLL D, 1991, J CELL SCI, V100, P237; PICK U, 1987, PLANT MEMBRANE STRUC, P241; PORTER AJR, 1991, ANN APPL BIOL, V118, P461, DOI 10.1111/j.1744-7348.1991.tb05647.x; Ritte G, 1999, PLANT PHYSIOL, V121, P647, DOI 10.1104/pp.121.2.647; THEODOROPOULOS PA, 1989, J EXP BOT, V40, P1223, DOI 10.1093/jxb/40.11.1223; TOROSER D, 1995, J EXP BOT, V46, P1753, DOI 10.1093/jxb/46.11.1753; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P540, DOI 10.1007/BF02341029; ZHAO FJ, 1994, J SCI FOOD AGR, V64, P295, DOI 10.1002/jsfa.2740640309; ZHAO FJ, 1993, J SCI FOOD AGR, V63, P29, DOI 10.1002/jsfa.2740630106	40	34	36	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22955	22960		10.1074/jbc.M002768200	http://dx.doi.org/10.1074/jbc.M002768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816580	hybrid			2022-12-25	WOS:000088419400049
J	Duewel, HS; Woodard, RW				Duewel, HS; Woodard, RW			A metal bridge between two enzyme families - 3-deoxy-D-manno-octulosonate-8-phosphate synthase from Aquifex aeolicus requires a divalent metal for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID 8-PHOSPHATE SYNTHASE; 3-DEOXY-D-ARABINO-HEPTULOSONATE 7-PHOSPHATE SYNTHASE; PUTATIVE REACTION INTERMEDIATE; SITE-DIRECTED MUTAGENESIS; ACETYLGLUCOSAMINE ENOLPYRUVOYL TRANSFERASE; ELECTRONIC ABSORPTION-SPECTROSCOPY; ESCHERICHIA-COLI; CATALYTIC MECHANISM; EPSP SYNTHASE; 3-DEOXY-D-MANNO-2-OCTULOSONATE-8-PHOSPHATE SYNTHASE	The enzymes 3-deoxy-D-manno-octulosonic acid-8-phosphate synthase (KDO8PS) and 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthase (DAHPS) catalyze analogous condensation reactions between phosphoenolpyruvate and D-arabinose 5-phosphate or D-erythrose 4-phosphate, respectively. While several similarities exist between the two enzymatic reactions, classic studies on the Escherichia coli enzymes have established that DAMPS is a metalloenzyme, whereas KDO8PS has no metal requirement. Here, we demonstrate that KDO8PS from Aquifex aeolicus, representing only the second member of the KDO8PS family to be characterized in detail, is a metalloenzyme, The recombinant KDO8PS, as isolated, displays an absorption band at 505 nm and contains approximately 0.4 and 0.2-0.3 eq of zinc and iron, respectively, per enzyme subunit. EDTA inactivates the enzyme in a time- and concentration-dependent manner and eliminates the absorption at 505 nm, The addition of Cu2+ to RDO8PS produces an intense absorption at 375 nm, while neither Co2+ nor Ni2+ produce such an effect, The EDTA-treated enzyme is reactivated by a wide range of divalent metal ions including Ca2+, Cd2+, Co2+, Cu2+, Fe2+, Mg2+, Mn2+ Ni2+ and Zn2+ and is reversibly inhibited by higher concentrations (>1 mM) of certain metals. Analysis of several metal forms of the enzyme by plasma mass spectrometry suggests that the enzyme preferentially binds one, two, or four metal ions per tetramer, These observations strongly suggest that A. aeolicus KDO8PS is a metalloenzyme in vivo and point to a previously unrecognized relationship between the KDO8PS and DAMPS families.	Univ Michigan, Interdepartmental Program Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akowski JP, 1997, BIOCHEMISTRY-US, V36, P15817, DOI 10.1021/bi971135t; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANDERSON KS, 1988, J AM CHEM SOC, V110, P6577, DOI 10.1021/ja00227a056; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; ANDERSON KS, 1990, CHEM REV, V90, P1131, DOI 10.1021/cr00105a004; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P1604, DOI 10.1021/bi00405a032; ANTON DL, 1983, BIOCHEMISTRY-US, V22, P5903, DOI 10.1021/bi00294a033; AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; AVERILL BA, 1993, METHOD ENZYMOL, V226, P33, DOI 10.1016/0076-6879(93)26004-S; BAASOV T, 1993, EUR J BIOCHEM, V217, P991, DOI 10.1111/j.1432-1033.1993.tb18330.x; BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; Brabetz W, 1997, EUR J BIOCHEM, V244, P66, DOI 10.1111/j.1432-1033.1997.00066.x; BROWN ED, 1994, BIOCHEMISTRY-US, V33, P10638, DOI 10.1021/bi00201a010; Burrows LL, 1996, J ENDOTOXIN RES, V3, P353, DOI 10.1177/096805199600300410; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOONG RL, 1992, NEW PHYTOL, V121, P165, DOI 10.1111/j.1469-8137.1992.tb01101.x; DOONG RL, 1991, PLANT CELL ENVIRON, V14, P113, DOI 10.1111/j.1365-3040.1991.tb01377.x; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DOY CH, 1965, BIOCHIM BIOPHYS ACTA, V104, P377, DOI 10.1016/0304-4165(65)90343-0; DSouza FW, 1997, BIOORG MED CHEM LETT, V7, P2457, DOI 10.1016/S0960-894X(97)10019-1; Duewel HS, 1999, BIOCHEM BIOPH RES CO, V263, P346, DOI 10.1006/bbrc.1999.1361; FLOSS HG, 1972, J BIOL CHEM, V247, P736; Haslam E., 1993, SHIKIMIC ACID METABO; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; Hunt JA, 1999, BIOCHEMISTRY-US, V38, P9054, DOI 10.1021/bi9900166; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; KUHN R, 1963, BIOCHEM Z, V338, P554; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Lewis J, 1999, BIOCHEMISTRY-US, V38, P7372, DOI 10.1021/bi9830258; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; MARET W, 1993, METHOD ENZYMOL, V226, P52; MARQUARDT JL, 1993, J AM CHEM SOC, V115, P10398, DOI 10.1021/ja00075a081; Radaev S, 2000, ACTA CRYSTALLOGR D, V56, P516, DOI 10.1107/S0907444900002389; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAY PH, 1982, METHOD ENZYMOL, V83, P525; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; REEVES P, 1994, BACTERIAL CELL WALL, P281; RICK PD, 1984, REV INFECT DIS, V6, P455; RICK PD, 1977, J BIOL CHEM, V252, P4895; Rieger CE, 1997, ANAL BIOCHEM, V246, P86, DOI 10.1006/abio.1996.9962; Salleh HM, 1996, BIOORG MED CHEM LETT, V6, P133, DOI 10.1016/0960-894X(95)00570-J; Salleh HM, 1996, BIOCHEMISTRY-US, V35, P8942, DOI 10.1021/bi952373w; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONER R, 1976, J BIOL CHEM, V251, P5440; SHEFLYAN G, 2000, IN PRESS J BACTERIOL; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; SOLOMON EI, 1993, METHOD ENZYMOL, V226, P1, DOI 10.1016/0076-6879(93)26003-R; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walsh AG, 1999, FEMS MICROBIOL LETT, V173, P27, DOI 10.1111/j.1574-6968.1999.tb13480.x; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3; WARREN L, 1959, J BIOL CHEM, V234, P1971; ZEMELL RI, 1975, J BIOL CHEM, V250, P4959	68	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22824	22831		10.1074/jbc.M000133200	http://dx.doi.org/10.1074/jbc.M000133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811802	hybrid			2022-12-25	WOS:000088419400032
J	Regelsberger, G; Jakopitsch, C; Ruker, F; Krois, D; Peschek, GA; Obinger, C				Regelsberger, G; Jakopitsch, C; Ruker, F; Krois, D; Peschek, GA; Obinger, C			Effect of distal cavity mutations on the formation of compound I in catalase-peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; CYTOSOLIC ASCORBATE PEROXIDASE; SITE-DIRECTED MUTAGENESIS; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; ELECTRON-TRANSFER; RADICAL SITE; PURIFICATION	Catalase-peroxidases have a predominant catalase activity but differ from monofunctional catalases in exhibiting a substantial peroxidase activity and in having different residues in the heme cavity. We present a kinetic study of the formation of the key intermediate compound I by probing the role of the conserved distal amino acid triad Arg-Trp-Ris of a recombinant catalase-peroxidase in its reaction with hydrogen peroxide, peroxoacetic acid, and m-chloroperbenzoic acid. Both the wild-type enzyme and six mutants (R119A, R119N, TY122F, W122A, H123Q, H123E) have been investigated by steady-state and stopped-flow spectroscopy. The turnover number of catalase activity of R119A is 14.6%, R119N 0.5%, H123E 0.03%, and H123Q 0.02% of wild-type activity. Interestingly, W122F and W122A completely lost their catalase activity but retained their peroxidase activity. Bimolecular rate constants of compound I formation of the wild-type enzyme and the mutants have been determined. The Trp-122 mutants for the first time made it possible to follow the transition of the ferric enzyme to compound I by hydrogen peroxide spectroscopically underlining the important role of Trp-122 in catalase activity. The results demonstrate that the role of the distal His-Arg pair in catalase-peroxidases is important in the heterolytic cleavage of hydrogen peroxide (i.e. compound I formation), whereas the distal tryptophan is essential for compound I reduction by hydrogen peroxide.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria; Univ Vienna, Inst Organ Chem, A-1090 Vienna, Austria; Univ Vienna, Inst Phys Chem Mol Bioenerget, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Vienna; University of Vienna	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.	cobinger@edv2.boku.ac.at	Obinger, Christian/AAV-3173-2021	Regelsberger, Gunther/0000-0002-3233-1491; Rueker, Florian/0000-0001-7639-2686; Obinger, Christian/0000-0002-7133-3430; Jakopitsch, Christa/0000-0002-5855-2057				BALNY C, 1987, FEBS LETT, V221, P349, DOI 10.1016/0014-5793(87)80954-7; BEERS RF, 1952, J BIOL CHEM, V195, P133; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GOODIN DB, 1987, J BIOL CHEM, V262, P7719; HAGER LP, 1972, J AM CHEM SOC, V94, P4364, DOI 10.1021/ja00767a068; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Kohli RM, 1998, BIOTECHNIQUES, V25, P184, DOI 10.2144/98252bm01; LEVY E, 1992, ARCH BIOCHEM BIOPHYS, V296, P321, DOI 10.1016/0003-9861(92)90579-L; LOEWEN PC, 1997, OXIDATIVE STRESS MOL, P273; LOO S, 1975, BIOCHEMISTRY-US, V14, P3467, DOI 10.1021/bi00686a027; Mandelman D, 1998, BIOCHEMISTRY-US, V37, P17610, DOI 10.1021/bi981958y; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Marquez LA, 1996, FEBS LETT, V389, P153, DOI 10.1016/0014-5793(96)00562-5; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; Obinger C, 1999, FREE RADICAL RES, V31, pS243; Obinger C, 1997, BIOCHEM BIOPH RES CO, V235, P545, DOI 10.1006/bbrc.1997.6847; OHLSSON PI, 1986, BIOCHIM BIOPHYS ACTA, V874, P160, DOI 10.1016/0167-4838(86)90113-5; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Regelsberger G, 1999, FEMS MICROBIOL LETT, V170, P1, DOI 10.1111/j.1574-6968.1999.tb13348.x; Regelsberger G, 1999, BIOCHEMISTRY-US, V38, P10480, DOI 10.1021/bi990886n; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; ROE JA, 1993, J BIOL CHEM, V268, P20037; SCHOLES CP, 1989, ISRAEL J CHEM, V29, P85; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMULEVICH G, 1990, BIOCHEMISTRY-US, V29, P7174, DOI 10.1021/bi00483a004; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	42	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22854	22861		10.1074/jbc.M002371200	http://dx.doi.org/10.1074/jbc.M002371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811647	hybrid			2022-12-25	WOS:000088419400036
J	Wang, L; Ungermann, C; Wickner, W				Wang, L; Ungermann, C; Wickner, W			The docking of primed vacuoles can be reversibly arrested by excess Sec17p (alpha-SNAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; INTRACELLULAR MEMBRANE-FUSION; NSF ATTACHMENT PROTEINS; IN-VITRO; T-SNARE; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; HOMOTYPIC FUSION; ATPASE ACTIVITY; YEAST VACUOLES	Homotypic vacuole fusion occurs in ordered stages of priming, docking, and fusion. Priming, which prepares vacuoles for productive association, requires Sec17p (the yeast homolog of alpha-SNAP), Sec18p (the yeast NSF, an ATP-driven chaperone), and ATP. Sec17p is initially an integral part of the cis-SNARE complex together with vacuolar SNARE proteins and Sec18p (NSF). Previous studies have shown that Sec17p is rapidly released from the vacuole membrane during priming as the cis-SNARE complex is disassembled, but the order and causal relationship of these subreactions has not been known. We now report that the addition of excess recombinant his(6)-Sec17p to primed vacuoles can block subsequent docking. This inhibition is reversible by Sec18p, but the reaction cannot proceed to the tethering and trans-SNARE pairing steps of docking while the Sec17p block is in place. Once docking has occurred, excess Sec17p does not inhibit membrane fusion per se. Incubation of cells with thermosensitive Sec17-1p at nonpermissive temperature causes SNARE complex disassembly. These data suggest that Sec17p can stabilize vacuolar cis-SNARE complexes and that the release of Sec17p by Sec18p and ATP allows disassembly of this complex and activates its components for docking.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.							Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MORGAN A, 1994, J BIOL CHEM, V269, P29347; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9	34	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22862	22867		10.1074/jbc.M001447200	http://dx.doi.org/10.1074/jbc.M001447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816559	hybrid			2022-12-25	WOS:000088419400037
J	Xu, T; Forgac, M				Xu, T; Forgac, M			Subunit D (Vma8p) of the yeast vacuolar H+-ATPase plays a pole in coupling of proton transport and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; NEUROSPORA-CRASSA; DELTA-SUBUNIT; V-ATPASE; ADENOSINE-TRIPHOSPHATASE; INTERSUBUNIT ROTATION; STRUCTURAL-CHANGES; CDNA SEQUENCE	To investigate the function of subunit D in the vacuolar H+-ATPase (V-ATPase) complex, random and site-directed mutagenesis was performed on the VMA8 gene encoding subunit D in yeast. Mutants were selected for the inability to grow at pH 7.5 but the ability to grow at pH 5.5. Mutations leading to reduced levels of subunit D in whole cell lysates were excluded from the analysis. Seven mutants were isolated that resulted in pH-dependent growth but that contained nearly wild-type levels of subunit D and nearly normal assembly of the V-ATPase as assayed by subunit A levels associated with isolated vacuoles. Each of these mutants contained 2-3 amino acid substitutions and resulted in loss of 60-100% of proton transport and 68-93% of concanamycin-sensitive ATPase activity. To identify the mutations responsible for the observed effects on activity, 14 single amino acid substitutions and 3 double amino acid substitutions were constructed by site-directed mutagenesis and analyzed as described above, Six of the single mutations and all three of the double mutations led to significant (>30%) loss of activity, with the mutations having the greatest effects on activity clustering in the regions Val(71)-Gly(80) and Lys(209)-Met(221). In addition, both M221V and the double mutant V71D/E220V led to significant uncoupling of proton transport and ATPase activity, whereas the double mutant G80D/K209E actually showed increased coupling efficiency. Both a mutant showing reduced coupling and a mutant with only 6% of wild-type proton transport activity showed normal dissociation of the V-ATPase complex in vivo in response to glucose deprivation. These results suggest that subunit D plays an important role in coupling of proton transport and ATP hydrolysis and that only low rates of turnover of the enzyme are required to support in vivo dissociation.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGLER R, 1995, J BIOL CHEM, V270, P9185; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Capaldi RA, 2000, J EXP BIOL, V203, P29; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; HAZARD AL, 1994, J BIOL CHEM, V269, P427; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SHIN K, 1992, J BIOL CHEM, V267, P20835; STAPLES RR, 1993, GENETICS, V135, P981; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	65	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22075	22081		10.1074/jbc.M002983200	http://dx.doi.org/10.1074/jbc.M002983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801866	hybrid			2022-12-25	WOS:000088363800047
J	McCarthy, TL; Ji, CH; Chen, Y; Kim, KK; Imagawa, M; Ito, Y; Centrella, M				McCarthy, TL; Ji, CH; Chen, Y; Kim, KK; Imagawa, M; Ito, Y; Centrella, M			Runt domain factor (Runx)-dependent effects on CCAAT/enhancer-binding protein delta expression and activity in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; FACTOR-I GENE; GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR CBFA1; NUCLEOTIDE-SEQUENCE; RECEPTOR PROMOTER; RESPONSE ELEMENT; CELL-CULTURES; C/EBP FAMILY; DNA-BINDING	Transcription factor CCAAT/enhancer-binding protein delta (C/EBP delta) is normally associated with acute-phase gene expression. However, it is expressed constitutively in primary osteoblast cultures where it increases insulin-like growth factor I synthesis in a cAMP-dependent way. Here we show that the 3' proximal region of the C/EBP delta gene promoter contains a binding sequence for Hunt domain factor Runx2, which is essential for osteogenesis. This region of the C/EBP delta promoter directed high reporter gene expression in osteoblasts, and specifically bound Runx2 in osteoblast-derived nuclear extract. C/EBP delta gene promoter activity was reduced by mutating the Runx binding sequence or by co-transfecting with Runx2 antisense expression plasmid, and was enhanced by overexpression of Runx-2. Exposure to prostaglandin E-2 increased Runx-dependent gene transactivation independently of Runx2 binding to DNA. Runx2 bound directly to the carboxyl-terminal region of C/EBP delta itself, and its ability to drive C/EBP delta expression was suppressed when C/EBP delta or its carboxyl-terminal fragment was increased by overexpression. Consistent effects also occurred on C/EBP delta-dependent increases in gene expression driven by synthetic or insulin-like growth factor I gene promoter fragments. These interactions between Runx2 and C/EBP delta, and their activation by prostaglandin E-2, provide new evidence for their importance during skeletal remodeling, inflammatory bone disease, or fracture repair.	Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, New Haven, CT 06520 USA; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Osaka, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 60601, Japan	Yale University; Osaka University; Kyoto University	Centrella, M (corresponding author), Yale Univ, Sch Med, Dept Surg, Plast Surg Sect, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056310] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK56310] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1993, ANN PLAS SURG, V31, P434, DOI 10.1097/00000637-199311000-00008; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Centrella Michael, 1998, Frontiers in Bioscience, V3, pD113; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Fukuoka T, 1997, BIOCHEM BIOPH RES CO, V231, P30, DOI 10.1006/bbrc.1996.6031; Gilpin DA, 1996, SURGERY, V119, P674, DOI 10.1016/S0039-6060(96)80192-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Yoshiaki, 1997, Leukemia (Basingstoke), V11, P279; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756-3282(99)00111-8; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LU J, 1995, MOL CELL BIOL, V15, P1651; McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 2000, IN PRESS CRIT REV OR; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Meyers S, 1996, ONCOGENE, V13, P303; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; Yamanaka R, 1998, INT J MOL MED, V1, P213; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	63	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21746	21753		10.1074/jbc.M002291200	http://dx.doi.org/10.1074/jbc.M002291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801838	hybrid			2022-12-25	WOS:000088230600103
J	Ghiselli, G; Iozzo, RV				Ghiselli, G; Iozzo, RV			Overexpression of bamacan/SMC3 causes transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; STRUCTURAL MAINTENANCE; CHROMOSOMES SMC; CDNA CLONING; PROTEIN; COMPLEX; GENE; RECOMBINATION; COMPONENTS	Bamacan can occur in certain cell types as either a secreted proteoglycan assembled into basement membranes or as an intracellular protein known as structural maintenance of chromosome 3 (SMC3). To assess the role of this protein in tumorigenesis, we investigated whether induced overexpression of bamacan/SMC3 could transform normal fibroblasts. We generated a full-length cDNA encoding the entire mouse bamacan/SMC3 and demonstrated appropriate transcription and translation into a 146-kDa protein. AU the NIH and Balb/c 3T3 murine fibroblasts overexpressing this bamacan/SMC3 transgene generated foci of transformation and acquired anchorage-independent growth. The increased levels of bamacan/SMC3 expression achieved in the transfected fibroblasts were the same as those detected in a series of spontaneously transformed murine and human colon carcinoma cells. Moreover, a 3-4-fold overexpression of bamacan/SMC3 was detected in similar to 70% of human colon carcinoma specimens from matched pairs (n = 19, p < 0.0002) and in a cohort of intestinal tumors from Apc-deficient Min/+ mice. These results support the concept that deregulated expression of bamacan/SMC3 is involved in cell transformation.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cell Biol Program, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhmedov AT, 1999, J BIOL CHEM, V274, P38216, DOI 10.1074/jbc.274.53.38216; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Farr KA, 1999, EUR J BIOCHEM, V263, P14, DOI 10.1046/j.1432-1327.1999.00510.x; Ghiselli G, 1999, J BIOL CHEM, V274, P17384, DOI 10.1074/jbc.274.24.17384; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; IOZZO RV, 1987, HISTOCHEMISTRY, V88, P23, DOI 10.1007/BF00490162; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KINZLER K, 1991, CELL, V87, P159; MCCARTHY KJ, 1989, J CELL BIOL, V109, P3187, DOI 10.1083/jcb.109.6.3187; MCCARTHY KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P401, DOI 10.1177/41.3.8429203; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433	22	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20235	20238		10.1074/jbc.C000213200	http://dx.doi.org/10.1074/jbc.C000213200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801778	hybrid			2022-12-25	WOS:000088084500002
J	Lu, B; Morrow, JA; Weisgraber, KH				Lu, B; Morrow, JA; Weisgraber, KH			Reorganization of the four-helix bundle of human apolipoprotein E in binding to phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAINS; APOLIPOPHORIN-III; LIPID-BINDING; EXCHANGEABLE APOLIPOPROTEIN; LIPOPROTEIN PARTICLES; CONFORMATIONAL-CHANGES; DENSITY LIPOPROTEINS; ALZHEIMERS-DISEASE; AQUEOUS-SOLUTION; DISULFIDE BONDS	Conformational reorganization of the amino-terminal four-helix bundle (22-kDa fragment) of apolipoprotein E (apoE) in binding to the phospholipid dimyristoylphosphatidylcholine (DMPC) to form discoidal particles was investigated by introducing single, double, and triple interhelical disulfide bonds to restrict the opening of the bundle. Interaction of apoE with DMPC was assessed by vesicle disruption, turbidimetric clearing, and gel filtration assays. The results indicate that the formation of apoE(.)DMPC discoidal particles occurs in a series of steps. A triple disulfide mutant, in which all four helices were tethered, did not form complexes but could release encapsulated 5-(6)-carboxylfluorescein from DMPC vesicles, indicating that the initial interaction does not involve major reorganization of the helical bundle. Initial interaction is followed by the opening of the four-helix bundle to expose the hydrophobic faces of the amphipathic helices, In this step, helices 1 and 2 and helices 3 and 4 preferentially remain paired, since these disulfide-linked mutants bound to DMPC in a manner similar to that of the 22-kDa fragment of apoE4, In contrast, mutants in which helices 2 and 3 and/or helices 1 and 4 paired bound poorly to DMPC, However, all single and double helical pairings resulted in the formation of larger discs than were formed by the 22-kDa fragment, indicating that further reorganization of the helices occurs following the initial opening of the four helix bundle in which the protein assumes its final lipid-bound conformation, In support of this rearrangement, reducing the disulfide bonds converted the large disulfide mutant discs to normal size.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Weisgraber, KH (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, POB 419100, San Francisco, CA 94141 USA.	kweisgraber@gladstone.ucaf.edu			NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J MOL BIOL, V202, P179, DOI 10.1016/0022-2836(88)90531-1; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1998, J LIPID RES, V39, P1173; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fisher CA, 1999, J LIPID RES, V40, P93; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; MIMS MP, 1990, BIOCHEMISTRY-US, V29, P6639, DOI 10.1021/bi00480a013; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WEINSTEIN DB, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90186-1; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	39	92	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20775	20781		10.1074/jbc.M003508200	http://dx.doi.org/10.1074/jbc.M003508200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801877	hybrid			2022-12-25	WOS:000088084500078
J	Sonoda, Y; Matsumoto, Y; Funakoshi, M; Yamamoto, D; Hanks, SK; Kasahara, T				Sonoda, Y; Matsumoto, Y; Funakoshi, M; Yamamoto, D; Hanks, SK; Kasahara, T			Anti-apoptotic role of focal adhesion kinase (FAK) - Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PEROXIDE-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; DNA FRAGMENTATION; OXIDATIVE STRESS; CYTOCHROME-C; ACTIVATION; DEATH; BCL-2	Focal adhesion kinase (FAK) has an anti-apoptotic role in anchorage-dependent cells via an unknown mechanism. To elucidate the role of FAK in anti-apoptosis, we have established several FAK cDNA-transfected HL-60 cell lines and examined whether FAK-transfected cells have resistance to apoptotic stimuli. FAK-transfected HL-60 (HL-60/FAK) cells were highly resistant to apoptosis induced with hydrogen peroxide (1 mM) and etoposide (50 mu g/ml) compared with the parental HL-60 cells or the vector-transfected cells, when determined using viability assay, DNA fragmentation, and flow cytometry analysis. Because no proteolytic cleavage of pro-caspase 3 to mature caspase 3 fragment was observed in HL-60/FAK cells, FAK was presumed to inhibit an upstream signal pathway leading to the activation of caspase 3, HL-60/FAK activated the phosphatidylinositide 3'-OH-kinase-Akt survival pathway and exhibited significant activation of NF-KB with marked induction of inhibitor-of-apoptosis proteins (IAPs: cIAP-1, cIAP-2, XIAP), regardless of the hydrogen peroxide-treated or untreated conditions, whereas no significant IAPs were detected in the parental or vector-transfected HL-60 cells. Apoptotic agents induced higher NF-kappa B activation in HL-60/FAK cells than in HL-60/Vect cells, and it appeared that sustained NF-kappa B activation is critical to the anti-apoptotic states in HL-60/FAK cells. Mutagenesis of FAK cDNA revealed that Y397 and Y925, which are involved in the tyrosine-phosphorylation sites, were prerequisite for the anti-apoptotic activity as well as induction of IAPs, and that K454, which is involved in the kinase activity, was also required for the full anti-apoptotic activity of FAK. Taken together, we have demonstrated definitively that FAK-transfected HL-60 cells, otherwise sensitive to apoptosis, become resistant to the apoptotic stimuli. We conclude that FAK activates the phosphatidylinositide 3'-OH-kinase-Akt survival pathway with the concomitant activation of NF-kappa B and induction of IAPs, which ultimately inhibit apoptosis by inhibiting caspase-3 cascade.	Kyoritsu Coll Pharm, Dept Biochem, Minato Ku, Tokyo 1058512, Japan; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Keio University; Vanderbilt University	Kasahara, T (corresponding author), Kyoritsu Coll Pharm, Dept Biochem, Minato Ku, Shibakoen 1-5-30, Tokyo 1058512, Japan.							ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Atabay C, 1996, J NEUROSCI RES, V43, P465; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ibrado AM, 1996, CANCER RES, V56, P4743; Ilic D, 1998, J CELL BIOL, V143, P547; Iwata S, 1997, J IMMUNOL, V158, P3108; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NAGATA S, 1997, CELL, V88, P335; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ozes ON, 1999, NATURE, V401, P82; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schaller MD, 1997, SOC GEN PHY, V52, P241; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; SU MSS, 1991, TRANSPLANT P, V23, P2912; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	45	279	295	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16309	16315		10.1074/jbc.275.21.16309	http://dx.doi.org/10.1074/jbc.275.21.16309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821872	hybrid			2022-12-25	WOS:000087291400095
J	Zvaritch, E; Backx, PH; Jirik, F; Kimura, Y; de Leon, S; Schmidt, AG; Hoit, BD; Lester, JW; Kranias, EG; MacLennan, DH				Zvaritch, E; Backx, PH; Jirik, F; Kimura, Y; de Leon, S; Schmidt, AG; Hoit, BD; Lester, JW; Kranias, EG; MacLennan, DH			The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MYOCARDIAL-CONTRACTILITY; MICE; DOMAIN; GENE; PHOSPHORYLATION; OVEREXPRESSION; CARDIOMYOPATHY; HYPERTROPHY; CA2+-ATPASE	Transgenic mice were generated with cardiac-specific overexpression of the monomeric, dominant-acting, superinhibitory L37A and I40A mutant forms of phospholamban (PLN), and their phenotypes were compared with wild-type (wt) mice or a-fold overexpressors of wt PLN (wtOE). The level of PLN monomer in cardiac microsomes was increased 11-13-fold, and the apparent affinity of the sarco(endo)plasmic reticulum Ca2+ ATPase for Ca2+ was decreased from pCa 6.22 in wt or 6.12 in wtOE to 5.81 in L37A and 5.72 in I40A. Basal physiological parameters, measured in isolated myocytes, indicated a significant reduction in the rates of shortening (+dL/dt) and relengthening (-dL/dt), Hemodynamic measurements indicated that peak systolic pressure was unaffected but that pressure changes (+dP/dt and -dP/dt) were lowered significantly in both mutant lines, and relaxation time (tau) was also lengthened significantly. Echocardiography for both mutants showed depressed systolic function and an increase in left ventricular mass of over 1.4-fold. Significant decreases in left ventricular shortening fraction and velocity of circumferential shortening and increases in ejection time were corrected by isoproterenol. The use of antibodies specific against Ser(16)- and Thr(17)-PLN peptides showed. that phosphorylation of both pentameric and monomeric PLN were increased between 1.2- and 2.4-fold in both the L37A and I40A lines but not in the wtOE line. These observations show that overexpression of superinhibitory mutant forms of PW causes depression of contractile parameters with induction of cardiac hypertrophy, as assessed with echocardiography.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Physiol & Med, Toronto, ON M5S 1A1, Canada; Univ British Columbia, Dept Med, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University of Toronto; University of Toronto; University of British Columbia; University System of Ohio; University of Cincinnati	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026057, P50HL052318, R01HL026057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26057, HL52318] Funding Source: Medline; PHS HHS [P4012358] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANVERSA P, 1991, AM J CARDIOL, V68, pD7; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; BASSAND JP, 1995, EUR HEART J, V16, P58, DOI 10.1093/eurheartj/16.suppl_I.58; BERS DM, 1991, EXCITATION CONTRACTI; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJII J, 1989, J BIOL CHEM, V264, P12950; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HAUGE BM, 1992, METHODS ARABIDOPSIS; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; JONES LR, 1985, J BIOL CHEM, V260, P7721; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MANNING WJ, 1994, AM J PHYSIOL, V266, pH1672, DOI 10.1152/ajpheart.1994.266.4.H1672; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SLACK JP, 1997, CIRCULATION S, V96, P179; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TADA M, 1975, J BIOL CHEM, V250, P2640; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250	33	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14985	14991		10.1074/jbc.275.20.14985	http://dx.doi.org/10.1074/jbc.275.20.14985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809743	hybrid			2022-12-25	WOS:000087128300031
J	Yasuda, M; Chinnadurai, G				Yasuda, M; Chinnadurai, G			Functional identification of the apoptosis effector BH3 domain in cellular protein BNIP1	ONCOGENE			English	Article						BNIP1; BH3 domain; apoptosis; heterodimerization	INTERACTING PROTEIN; E1B 19K; BCL-2; DEATH; DISTINCT; SEQUENCE; NIP3; BAK	BCL-2 family proteins play a central role in apoptosis regulation in mammals and in C. elegans. Mammalian cellular and viral anti-apoptosis proteins such as BCL-2 and E1B-19K interact with several cellular proteins. Some of these interacting proteins promote apoptosis and belong to the BCL-2 family. Certain BCL-2 family pro-apoptotic proteins such as BAX and BAK share extensive sequence homology with BCL-2. In contrast, certain pro-apoptotic proteins such as BIK and BID share a single death effector domain, BH3, with other BCL-2 family proteins. By mutational analysis, we show that one of the cellular proteins, BNIP1 (previously Nip-1), that interacts with BCL-2 family anti-apoptosis proteins is a 'BH3 alone' pro-apoptotic protein. Transient transfection of BNIP1 induces a moderate level of apoptosis, Deletions of the N-terminal 32 amino acid region and the C-terminal tl aas-membrane domain did not significantly affect pro-apoptotic activity. In contrast, deletions encompassing a region containing a motif similar to the BH3-domain abrogated the apoptotic activity. Substitution of BNIP1 BH3 domain for the corresponding sequence in BAX efficiently restored the apoptotic activity of BAX, establishing the functional identity of the BH3 domain of BNIP1. The N-terminal deletions of BNIP1 (that retain the BH3 domain) enhanced the level of interaction with BCL-X-L. Mutants containing the BH3 deletions were still able to heterodimerize with BCL-X-L while mutants lacking both the N-terminal region and the BH3 domain were unable to heterodimerize, suggesting that BNIP1 may bind to BCL-XL via two different binding motifs.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-73803, CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Han J, 1996, MOL CELL BIOL, V16, P5857; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X	18	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2363	2367		10.1038/sj.onc.1203565	http://dx.doi.org/10.1038/sj.onc.1203565			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822388				2022-12-25	WOS:000086974300012
J	Veal, E; Groisman, R; Eisenstein, M; Gill, G				Veal, E; Groisman, R; Eisenstein, M; Gill, G			The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells	ONCOGENE			English	Article						differentiation; mouse embryonic stem cell; NTERA-2 embryonal carcinoma cells; secreted glycoprotein	HEXAMETHYLENE BISACETAMIDE HMBA; RETINOIC ACID; MONOCLONAL-ANTIBODY; TGF-ALPHA; LINE; EXPRESSION; GROWTH; TERATOCARCINOMAS; ACTIVATION; INDUCTION	Differentiation of the human embryonal carcinoma cell Line NTERA-2 is characterized by changes in morphology, altered patterns of gene expression, reduced proliferative potential, and a loss of tumorigenicity. The cellular repressor of E1A-stimulated genes, CREG, was previously shown to antagonize transcriptional activation and cellular transformation by the Adenovirus EIA oncoprotein. These properties suggested that CREG may function to inhibit cell growth and/or promote differentiation, Here we show that CREG is a secreted glycoprotein which enhances differentiation of NTERA-2 cells. Northern blot analysis reveals that, although CREG mRNA is widely expressed in adult tissues, CREG mRNA is not significantly expressed in pluripotent mouse embryonic stem cells or NTERA-2 embryonal carcinoma cells. CREG mRNA is rapidly induced upon in vitro differentiation of both mouse embryonic stem cells and human NTERA-2 cells, We show that constitutive expression of CREG in NTERA-2 cells enhances neuronal differentiation upon treatment with retinoic acid. Media enriched in CREG was also found to promote NTERA-2 differentiation in the absence of an inducer such as retinoic acid. These studies suggest that secreted CREG protein participates in a signaling cascade important for differentiation of pluripotent stem cells such as those found in teratocarcinomas.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Veal, Elizabeth/0000-0002-1152-5473; Groisman, Sonia/0000-0003-1153-3841; Groisman, Regina/0000-0003-3990-7622				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1994, LAB INVEST, V71, P243; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942	25	76	96	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2120	2128		10.1038/sj.onc.1203529	http://dx.doi.org/10.1038/sj.onc.1203529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815803				2022-12-25	WOS:000086728000005
J	Li, CY; Lee, JS; Ko, YG; Kim, JI; Seo, JS				Li, CY; Lee, JS; Ko, YG; Kim, JI; Seo, JS			Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; STRESS-INDUCED APOPTOSIS; N-TERMINAL KINASE; ULTRAVIOLET-LIGHT; TNF-ALPHA; HSP70; SUPPRESSION; MITOCHONDRIA; EXPRESSION; INDUCTION	Heat shock protein 70 (HSP70) has been shown to act as an inhibitor of apoptosis. We have also observed an inhibitory effect of HSP70 on apoptotic cell death both in preheated U937 and stably transfected HSP70-over-expressing U937 (U937/HSP70) cells. However, the molecular mechanism whereby HSP70 prevents apoptosis still remains to be solved. To address this issue, we investigated the effect of HSP70 on apoptotic processes in an in vitro system. Caspase-3 cleavage and DNA fragmentation were detected in cytosolic fractions from normal cells upon addition of dATP, but not from preheated U937 or U937/hsp70 cells. Moreover, the addition of purified recombinant HSP70 to normal cytosolic fractions prevented caspase-3 cleavage and DNA fragmentation, suggesting that HSP70 prevents apoptosis upstream of caspase-3 processing. Because cytochrome c was still released from mitochondria into the cytosol by Lethal heat shock despite prevention of caspase-3 activation and cell death in both preheated U937 and U937/hsp70 cells, it was evident that HSP70 acts downstream of cytochrome c release. Results obtained in vitro with purified deletion mutants of HSP70 showed that the carboxyl one-third region (from amino acids 438 to 641) including the peptide-binding domain and the carboxyl-terminal EEVD sequence was essential to prevent caspase-3 processing. From these results, we conclude that HSP70 acts as a strong suppressor of apoptosis acting downstream of cytochrome c release and upstream of caspase-3 activation.	Seoul Natl Univ, Coll Med, Ilchun Inst Mol Med, Jongno Gu, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem, Med Res Ctr,Jongno Gu, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Seo, JS (corresponding author), Seoul Natl Univ, Coll Med, Ilchun Inst Mol Med, Jongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.	jeongsun@snu.ac.kr	KIM, JONG-IL/D-1019-2011; Seo, Jeong-Sun/J-2763-2012	KIM, JONG-IL/0000-0002-7240-3744; 				Ahn JH, 1999, MOL CELLS, V9, P200; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kwak HJ, 1998, CELL IMMUNOL, V187, P1, DOI 10.1006/cimm.1998.1309; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBEL T, 1997, SCIENCE, V276, P1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trost SU, 1998, J CLIN INVEST, V101, P855, DOI 10.1172/JCI265; WEI YQ, 1994, CANCER RES, V54, P4952; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	56	384	412	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25665	25671		10.1074/jbc.M906383199	http://dx.doi.org/10.1074/jbc.M906383199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10806214	hybrid			2022-12-25	WOS:000088849400081
J	Hill, MM; Connolly, LM; Simpson, RJ; James, DE				Hill, MM; Connolly, LM; Simpson, RJ; James, DE			Differential protein phosphorylation in 3T3-L1 adipocytes in response to insulin versus platelet-derived growth factor - No evidence for a phosphatidylinositide 3-kinase-independent pathway in insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; ATP-CITRATE LYASE; RAT ADIPOSE-CELLS; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; SER/THR KINASE; ACTIVATION	Insulin regulates glucose metabolism in adipocytes via a phosphatidylinositide 3-kinase (PI3K)-dependent pathway that appears to involve protein phosphorylation, However, the generation of phosphoinositides is not sufficient for insulin action, and it has been suggested that insulin regulation of glucose metabolism may involve both PI3K-dependent and -independent pathways, the latter being insulin specific. To test this hypothesis, we have designed a phosphoprotein screen to study insulin-specific phosphoproteins that may be either downstream or in parallel to PI3K, Nineteen insulin-regulated phosphospots were detected in the cytosol and high speed pellet fractions, only six of which were significantly regulated by platelet-derived growth factor. importantly, almost all (92%) of the insulin-specific phosphoproteins identified using this approach were sensitive to the PI3K inhibitor wortmannin, Thus, we obtained no evidence for an insulin-specific, PI3K-independent signaling pathway. A large proportion (62%) of the insulin-specific phosphoproteins mere enriched in the same high speed pellet fraction to which PI3K was recruited in response to insulin. Thus, our data suggest that insulin specifically stimulates the phosphorylation of a novel subset of downstream targets and this may in part be because of the unique localization of PI3K in response to insulin in adipocytes.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	University of Queensland; University of Queensland; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute	James, DE (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.	D.James@cmcb.uq.edu.au	Hill, Michelle Mei Chih/G-4417-2010	Hill, Michelle Mei Chih/0000-0003-1134-0951; Simpson, Richard/0000-0002-9834-0796; James, David/0000-0001-5946-5257				ALEXANDER MC, 1979, J BIOL CHEM, V254, P8052; ARAND M, 1994, CELL BIOL LAB HDB, V3, P276; AVRUCH J, 1976, J BIOL CHEM, V251, P1505; AVRUCH J, 1976, J BIOL CHEM, V251, P1511; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Carlsen J, 1999, CELL SIGNAL, V11, P713, DOI 10.1016/S0898-6568(99)00040-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Diggle TA, 1998, BIOCHEM J, V336, P525, DOI 10.1042/bj3360525; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; GUY GR, 1994, ELECTROPHORESIS, V15, P417, DOI 10.1002/elps.1150150160; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Moritz Robert L., 1994, Methods (Orlando), V6, P213, DOI 10.1006/meth.1994.1024; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; OVCHINNIKOV LP, 1990, FEBS LETT, V275, P209, DOI 10.1016/0014-5793(90)81473-2; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Proud CG, 1997, BIOCHEM J, V328, P329; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; RAMAKRISHNA S, 1979, J BIOL CHEM, V254, P9232; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	43	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24313	24320		10.1074/jbc.M001823200	http://dx.doi.org/10.1074/jbc.M001823200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801824	hybrid			2022-12-25	WOS:000088683300012
J	Holmes, EH; Yen, TY; Thomas, S; Joshi, R; Nguyen, A; Long, T; Gallet, F; Maftah, A; Julien, R; Macher, BA				Holmes, EH; Yen, TY; Thomas, S; Joshi, R; Nguyen, A; Long, T; Gallet, F; Maftah, A; Julien, R; Macher, BA			Human alpha 1,3/4 fucosyltransferases - Characterization of highly conserved cysteine residues and N-linked glycosylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; SINGLE AMINO-ACID; MOLECULAR-CLONING; FUCOSYL-TRANSFERASE; HUMAN ALPHA-1,3/4-FUCOSYL-TRANSFERASES; DIRECTED MUTAGENESIS; SUBSTRATE-BINDING; FUCT-III; EXPRESSION; ALPHA-1,3-FUCOSYL-TRANSFERASE	Human alpha 1,3 fucosyltransferases (FucTs) contain four highly conserved cysteine (Cys) residues, in addition to a free Cys residue that lies near the binding site for GDP-fucose (Holmes, E, H,, Xu, Z., Sherwood, A.L., and Macher, B, A (1995) J. Biol. Chem. 270, 8145-8151), The participation of the highly conserved Cys residues in disulfide bonds and their functional significance were characterized by mass spectrometry (MS) analyses and site-directed mutagenesis, respectively. Among the human FucTs is a subset of enzymes (FucT III, V, and VI) having highly homologous sequences, especially in the catalytic domain, and Cys residues in FucT III and V were characterized. The amino acid sequence of FucT III was characterized. Peptides containing the four conserved Cys residues were detected after reduction and alkylation, and found to be involved in disulfide bonds. The disulfide bond pattern was characterized by multiple stage MS analysis and the use of Glu-C protease and MS/MS analysis. Disulfide bonds in FucT III occur between Cys residues (Cys(81) to Cys(338) and Cys(91) to Cys(341)) at the N and C termini of the catalytic domain, bringing these ends close together in space. Mutagenesis of highly conserved Cys residues to Ser in FucT V resulted in proteins lacking enzymatic activity. Three of the four mutants have molecular weights similar to wild type enzyme and maintained an ability to bind GDP, whereas the other (Cys(104)) produced a series of lower molecular weight bands when characterized by Western blot analysis, and did not bind GDP. FucTs have highly conserved, potential N-linked sites, and our mass spectrometry analyses demonstrated that both N-linked sites are modified with oligosaccharides.	San Francisco State Univ, Off Res & Sponsored Programs, Dept Chem & Biochem, San Francisco, CA 94132 USA; NW Hosp, Dept Cell Surface Biochem, Seattle, WA 98134 USA; INRA, UMR 1061, F-87060 Limoges, France; Univ Limoges, Fac Sci, UPRES 1074, F-87060 Limoges, France	California State University System; San Francisco State University; INRAE; Universite de Limoges	Macher, BA (corresponding author), San Francisco State Univ, Off Res & Sponsored Programs, Dept Chem & Biochem, 1600 Holloway Ave, San Francisco, CA 94132 USA.	macher@sfsu.edu	Thomas, Scott/AAF-2683-2020		NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [RR11805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Gallet PF, 1998, GLYCOBIOLOGY, V8, P919, DOI 10.1093/glycob/8.9.919; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; Kageyama N, 1999, J BIOCHEM-TOKYO, V125, P838, DOI 10.1093/oxfordjournals.jbchem.a022357; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	24	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24237	24245		10.1074/jbc.M000888200	http://dx.doi.org/10.1074/jbc.M000888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816554	hybrid			2022-12-25	WOS:000088683300003
J	Webel, R; Menon, I; O'Tousa, JE; Colley, NJ				Webel, R; Menon, I; O'Tousa, JE; Colley, NJ			Role of asparagine-linked oligosaccharides in rhodopsin maturation and association with its molecular chaperone, NinaA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; CYCLOPHILIN HOMOLOG NINAA; SECRETORY PATHWAY; DROSOPHILA-MELANOGASTER; RETINAL DEGENERATION; TRANSGENIC MICE; PERIPHERAL PHOTORECEPTORS; CYSTEINE RESIDUE-110; ELECTRON-MICROSCOPY; GLYCOSYLATION SITE	Many proteins require N-linked glycosylation for conformational maturation and interaction with their molecular chaperones. In Drosophila, rhodopsin (Rh1), the most abundant rhodopsin, is glycosylated in the endoplasmic reticulum (ER) and requires its molecular chaperone, NinaA, for exit from the ER and transport through the secretory pathway, Studies of vertebrate rhodopsins have generated several conflicting proposals regarding the role of glycosylation in rhodopsin maturation. We investigated the role of Rh1 glycosylation and Rh1/NinaA interactions under in vivo conditions by analyzing transgenic flies expressing Rh1 with isoleucine substitutions at each of the two consensus sites for N-linked glycosylation (N20I and N196I). We show that Asn(20) is the sole site for glycosylation. The Rh1(N20I) protein is retained within the secretory pathway, causing an accumulation of ER cisternae and dilation of the Golgi complex. NinaA associates with nonglycosylated Rh1(N20I); therefore, retention of nonglycosylated rhodopsin within the ER is not due to the lack of Rh1(N20I)/NinaA interaction. We further show that Rh1(N20I) interferes with wild type Rh1 maturation and triggers a dominant form of retinal degeneration. We conclude that during maturation Rh1 is present in protein complexes containing NinaA and that Rh1 glycosylation is required for transport of the complexes through the secretory pathway. Failure of this transport process leads to retinal degeneration.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Notre Dame	Colley, NJ (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.	njcolley@facstaff.wisc.edu		O'Tousa, Joseph/0000-0001-9754-6816	NATIONAL EYE INSTITUTE [R01EY008768, R29EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [EY06808, R01 EY008768, EY08768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BRITT SG, 1993, NEURON, V11, P29, DOI 10.1016/0896-6273(93)90268-V; BROWN G, 1994, VISUAL NEUROSCI, V11, P619, DOI 10.1017/S0952523800002509; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; COLLEY NJ, 1990, J CELL SCI, V95, P11; DAIGER SP, 1995, BEHAV BRAIN SCI, V18, P452, DOI 10.1017/S0140525X00039212; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FLIESLER SJ, 1985, P NATL ACAD SCI USA, V82, P1116, DOI 10.1073/pnas.82.4.1116; FLIESLER SJ, 1985, J CELL BIOL, V100, P574, DOI 10.1083/jcb.100.2.574; FLIESLER SJ, 1988, P KAG INT S GLYC MED, P316; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HELLER J, 1970, BIOCHEMISTRY-US, V9, P864, DOI 10.1021/bi00806a021; HUBER A, 1990, J BIOL CHEM, V265, P17906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; Katanosaka K, 1998, FEBS LETT, V424, P149, DOI 10.1016/S0014-5793(98)00160-4; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KEAN EL, 1976, EXP EYE RES, V23, P89, DOI 10.1016/0014-4835(76)90193-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; LI ZY, 1994, EXP EYE RES, V58, P397, DOI 10.1006/exer.1994.1032; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; MORI Y, 1989, MOL ENDOCRINOL, V3, P575, DOI 10.1210/mend-3-3-575; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; OTOUSA JE, 1992, VISUAL NEUROSCI, V8, P385, DOI 10.1017/S0952523800004910; Papermaster D.S., 1982, CELL BIOL EYE, P475; PAPERMASTER DS, 1995, NAT MED, V1, P874, DOI 10.1038/nm0995-874; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEPHENSON RS, 1983, SYM SOC EXP BIOL, P477; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Wolff Tanya, 1993, P1277; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473; WRIGHT R, 1990, New Biologist, V2, P915; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	67	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24752	24759		10.1074/jbc.M002668200	http://dx.doi.org/10.1074/jbc.M002668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10811808	hybrid			2022-12-25	WOS:000088683300071
J	Law, RM; Stafford, A; Quick, MW				Law, RM; Stafford, A; Quick, MW			Functional regulation of gamma-aminobutyric acid transporters by direct tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-SURFACE EXPRESSION; BRAIN GABA TRANSPORTER; RAT HIPPOCAMPAL SLICE; SEROTONIN TRANSPORTERS; GLUTAMATE TRANSPORTERS; DOPAMINE TRANSPORTER; XENOPUS-OOCYTES; MICE LACKING; CHANNELS	Tyrosine phosphorylation regulates multiple cell signaling pathways and functionally modulates a number of ion channels and receptors, Neurotransmitter transporters, which act to clear transmitter from the synaptic cleft, are regulated by multiple second messenger pathways that exert their effects, at least in part, by causing a redistribution of the transporter protein to or from the cell surface. To test the hypothesis that tyrosine phosphorylation affects transporter function and to determine its mechanism of action, we examined the regulation of the rat brain gamma-aminobutyric acid (GABA) transporter GAT1 expressed endogenously in hippocampal neurons and expressed heterologously in Chinese hamster ovary cells. Inhibitors of tyrosine kinases decreased GABA uptake; inhibitors of tyrosine phosphatases increased GABA uptake. The decrease in uptake seen with tyrosine kinase inhibitors was correlated with a decrease in tyrosine phosphorylation of GAT1 and resulted in a redistribution of the transporter from the cell surface to intracellular locations. A mutant GAT1 construct that was refractory to tyrosine phosphorylation could not be regulated by tyrosine kinase inhibitors. Activators of protein kinase C, which are known to cause a redistribution of GAT1 from the cell surface, were additive to the effects of tyrosine kinase inhibitors suggesting that multiple signaling pathways control transporter redistribution. Application of brain-derived neurotrophic factor, which activates receptor tyrosine kinases, up-regulated GAT1 function suggesting one potential trigger for the cellular regulation of GAT1 signaling by tyrosine phosphorylation, These data support the hypothesis that transporter expression and function is controlled by the interplay of multiple cell signaling cascades.	Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Quick, MW (corresponding author), Univ Alabama Birmingham, Dept Neurobiol, CIRC 446,1719 6th Ave S, Birmingham, AL 35294 USA.	quick@nrc.uab.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010509, R29DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Arnoult C, 1997, EMBO J, V16, P1593, DOI 10.1093/emboj/16.7.1593; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; BECKMAN ML, 1999, J NEUROSCI RC, V9, P1; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; CASADO M, 1993, J BIOL CHEM, V268, P27313; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; COREY JL, 1994, MOL MEMBR BIOL, V11, P23, DOI 10.3109/09687689409161026; COREY JL, 1994, J BIOL CHEM, V269, P14759; Davis KE, 1998, J NEUROSCI, V18, P2475; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HELMESTE DM, 1995, EUR J PHARMACOL, V280, pR5, DOI 10.1016/0014-2999(95)00323-D; Huff PA, 1999, CHURCH HIST, V68, P225, DOI 10.2307/3170179; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; Martin D.L., 1976, GABA NERVOUS SYSTEM, P347; Molokanova E, 1997, J NEUROSCI, V17, P9068; OSAWA I, 1994, NEUROSCI RES, V19, P287, DOI 10.1016/0168-0102(94)90041-8; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; Prasad PD, 1997, EUR J PHARMACOL, V325, P85, DOI 10.1016/S0014-2999(97)00100-3; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 1997, J NEUROSCI, V17, P2967; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ribak CE, 1996, J COMP NEUROL, V367, P595, DOI 10.1002/(SICI)1096-9861(19960415)367:4<595::AID-CNE9>3.0.CO;2-#; SATO K, 1995, FEBS LETT, V375, P99, DOI 10.1016/0014-5793(95)01191-G; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; Simon JR, 1997, NEUROSCI LETT, V224, P201, DOI 10.1016/S0304-3940(97)13479-6; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; SOLIS JM, 1992, J NEUROSCI, V12, P3466; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TAPLEY P, 1992, ONCOGENE, V7, P371; THOMSEN C, 1995, EPILEPSY RES, V21, P79, DOI 10.1016/0920-1211(95)00010-8; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Zhu MY, 1998, J NEUROCHEM, V70, P1547	41	73	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23986	23991		10.1074/jbc.M910283199	http://dx.doi.org/10.1074/jbc.M910283199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816599	hybrid			2022-12-25	WOS:000088564200080
J	Takahashi, H; Isobe, T; Horibe, S; Takagi, J; Yokosaki, Y; Sheppard, D; Saito, Y				Takahashi, H; Isobe, T; Horibe, S; Takagi, J; Yokosaki, Y; Sheppard, D; Saito, Y			Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha(9)beta(1) and alpha(4)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; VONWILLEBRAND-FACTOR; SURFACE RECEPTORS; ENDOTHELIAL-CELLS; BINDING-SITE; III REPEAT; FIBRONECTIN; PROPOLYPEPTIDE; SEQUENCE; SUBUNIT	We previously reported that MOLT-3 human lymphocyte-like leukemia cells adhere to tissue-type transglutaminase (tTG) through the integrin alpha(4)beta(1). We now report that G-361 human melanoma cells also adhere to tTG, although they do not express alpha(4)beta(1) G-361 cells utilize two additional integrins, alpha(9)beta(1) and alpha(5)beta(1) to adhere to tTG, Furthermore, blood coagulation factor XIII (FXIII), another member of the transglutaminase family that is highly homologous to tTG;, and propolypeptide of von Willebrand factor (pp-vWF) also promoted cell adhesion through alpha(9)beta(1) or alpha(4)beta(1) in G-361 or MOLT-3 cells, respectively. In the case of pp-vWF, alpha(9)beta(1) and alpha(4)beta(1) both bind to the same site, comprised of 15 amino acid residues and designated T2-15, Moreover, SW480 human colon cancer cells stably transfected to express alpha(9)beta(1), but not mock transfectants, adhered to tTG, FXIII, pp-vWF, and T2-15/bovine serum albumin conjugate. These data identify tTG, FXIII, and pp-vWF as shared ligands for the integrins alpha(9)beta(1) and alpha(4)beta(1) This report is the first to unambiguously show that these two integrins share the same cell adhesion site within one protein and provides strong support for classifying alpha(9)beta(1-) and alpha(4)-integrins as functionally related members of an integrin subfamily.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Natl Hiroshima Hosp, Dept Internal Med, Higashihiroshima 7390041, Japan; Natl Hiroshima Hosp, Dept Lab Med, Higashihiroshima 7390041, Japan; Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA	Tokyo Institute of Technology; University of California System; University of California San Francisco	Saito, Y (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AI33259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Bayless KJ, 1998, J CELL SCI, V111, P1165; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CHULUYAN HE, 1995, J IMMUNOL, V155, P3135; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKURA K, 1985, AGR BIOL CHEM TOKYO, V49, P3527, DOI 10.1080/00021369.1985.10867289; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; Isobe T, 1997, J BIOL CHEM, V272, P8447, DOI 10.1074/jbc.272.13.8447; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MCDONAGH J, 1976, BIOCHIM BIOPHYS ACTA, V446, P345, DOI 10.1016/0005-2795(76)90002-7; MOULD AP, 1990, J BIOL CHEM, V265, P4020; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; TAKAGI J, 1994, EUR J BIOCHEM, V222, P861, DOI 10.1111/j.1432-1033.1994.tb18933.x; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Ueki S, 1996, J CELL SCI, V109, P2727; USUI T, 1992, EUR J BIOCHEM, V205, P363, DOI 10.1111/j.1432-1033.1992.tb16788.x; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328	36	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23589	23595		10.1074/jbc.M003526200	http://dx.doi.org/10.1074/jbc.M003526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816592	hybrid			2022-12-25	WOS:000088564200026
J	De Deken, X; Wang, DT; Many, MC; Costagliola, S; Libert, F; Vassart, G; Dumont, JE; Miot, F				De Deken, X; Wang, DT; Many, MC; Costagliola, S; Libert, F; Vassart, G; Dumont, JE; Miot, F			Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYCLIC-AMP; H2O2-GENERATING SYSTEM; HYDROGEN-PEROXIDE; H2O2 GENERATION; NA+/I SYMPORTER; CELLS INVITRO; PROTEIN; THYROTROPIN; IODIDE	Two cDNAs encoding NADPH oxidases and constituting the thyroid H2O2 generating system have been cloned. The strategy of cloning was based on the functional similarities between H2O2 generation in leukocytes and the thyroid, according to the hypothesis that one of the components of the thyroid system would belong to the gp(91Phox)/Mox1 gene family and display sequence similarities with gp91(Phox). Screening at low stringency with a gp91(Phox) probe of cDNA libraries from thyroid cells in primary culture yielded two distinct human cDNA clones harboring open reading frames of 1551 (ThOX1) and 1548 amino acids (ThOX2), respectively. The encoded polypeptides display 83% sequence similarity and are clearly related to gp91(Phox) (53 and 47% similarity). The theoretical molecular mass of 177 kDa is close to the apparent molecular mass of 180 kDa of the native corresponding porcine flavoprotein and the protein(s) detected by Western blot in dog and human thyroid. ThOX1 and ThOX2 display sequence similarities of 53% and 61%, respectively, with a predicted protein of Caenorhabditis elegans over their entire length. They show along their first 500 amino acids a similarity of 43% with thyroperoxidase. The corresponding genes of ThOX1 and ThOX2 are closely linked on chromosome 15q15.8, The dog mRNA expression is thyroid-specific and up-regulated by agents activating the cAMP pathway as is the synthesis of the polypeptides they are coding for. In human thyroid the positive regulation by cAMP is less pronounced. The proteins ThOX1 and ThOX2 accumulate at the apical membrane of thyrocytes and are co-localized with thyroperoxidase.	Free Univ Brussels, Hop Erasme, Inst Rech Interdisciplinaire, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Serv Genet Med, B-1070 Brussels, Belgium; Univ Catholique Louvain, Histol Lab, B-1200 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain	Miot, F (corresponding author), Free Univ Brussels, IRIBHN, Campus Erasme,Bat C,808 Route Lennik, B-1070 Brussels, Belgium.		costagliola, sabine/D-4864-2012	Wang, Dantong/0000-0003-2379-8222				ALEXANDER NM, 1977, ENDOCRINOLOGY, V100, P1610, DOI 10.1210/endo-100-6-1610; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BJORKMAN U, 1984, ENDOCRINOLOGY, V115, P392; BJORKMAN U, 1995, MOL CELL ENDOCRINOL, V111, P99, DOI 10.1016/0303-7207(95)03552-I; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V19, P5294; CORVILAIN B, 1994, J CLIN ENDOCR METAB, V79, P152, DOI 10.1210/jc.79.1.152; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; Corvilain B, 2000, AM J PHYSIOL-ENDOC M, V278, pE692, DOI 10.1152/ajpendo.2000.278.4.E692; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DEME D, 1985, FEBS LETT, V186, P107, DOI 10.1016/0014-5793(85)81349-1; DEMEESTERMIRKINE N, 1984, CLIN ENDOCRINOL, V20, P473, DOI 10.1111/j.1365-2265.1984.tb03444.x; DEVIJLDER JJM, 1996, WERNER INGBARS THYRO, P479; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; DUPUY C, 1989, EUR J BIOCHEM, V185, P597, DOI 10.1111/j.1432-1033.1989.tb15155.x; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Gorin Y, 1996, EUR J BIOCHEM, V240, P807, DOI 10.1111/j.1432-1033.1996.0807h.x; LEFORT A, 1989, EMBO J, V8, P111, DOI 10.1002/j.1460-2075.1989.tb03354.x; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NIEPOMNISZCZE H, 1987, J CLIN ENDOCR METAB, V65, P344, DOI 10.1210/jcem-65-2-344; NUNEZ J, 1982, VITAM HORM, V39, P175, DOI 10.1016/S0083-6729(08)61137-1; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; RASPE E, 1995, ENDOCRINOLOGY, V136, P965, DOI 10.1210/en.136.3.965; Riou C, 1999, ENDOCRINOLOGY, V140, P1990, DOI 10.1210/en.140.5.1990; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; Savonet V, 1997, ANAL BIOCHEM, V247, P165, DOI 10.1006/abio.1997.2055; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Sheffield VC, 1996, NAT GENET, V12, P424, DOI 10.1038/ng0496-424; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Taurog Alvin, 1996, P47; Uyttersprot N, 1997, MOL CELL ENDOCRINOL, V131, P195, DOI 10.1016/S0303-7207(97)00108-1; VANSANDE J, 1982, MOL CELL ENDOCRINOL, V26, P31, DOI 10.1016/0303-7207(82)90004-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wilkin F, 1996, J BIOL CHEM, V271, P28451, DOI 10.1074/jbc.271.45.28451; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; [No title captured]	45	473	495	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23227	23233		10.1074/jbc.M000916200	http://dx.doi.org/10.1074/jbc.M000916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10806195	hybrid			2022-12-25	WOS:000088419400086
J	Hammarstrom, P; Persson, M; Owenius, R; Lindgren, M; Carlsson, U				Hammarstrom, P; Persson, M; Owenius, R; Lindgren, M; Carlsson, U			Protein substrate binding induces conformational changes in the chaperonin GroEL - A suggested mechanism for unfoldase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARBONIC-ANHYDRASE; PROBING SUBSTRUCTURE; CRYSTAL-STRUCTURE; SPIN; FLEXIBILITY; POLYPEPTIDE; DYNAMICS; HIDDEN; CPN60; SECB	Chaperonins are molecules that assist proteins during folding and protect them from irreversible aggregation. We studied the chaperonin GroEL and its interaction with the enzyme human carbonic anhydrase LI (HCA II), which induces unfolding of the enzyme. We focused on conformational changes that occur in GroEL during formation of the GroEL-HCA II complex. We measured the rate of GroEL cysteine reactivity toward iodo[2-C-14]acetic acid and found that the cysteines become more accessible during binding of a cysteine free mutant of HCA II. Spin labeling of GroEL with N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)iodoacetamide revealed that this additional binding occurred because buried cysteine residues become accessible during HCA LI binding. In addition, a GroEL variant labeled with 6-iodoacetamidofluorescein exhibited decreased fluorescence anisotropy upon HCA II:binding, which resembles the effect of GroES/ATP binding. Furthermore, by producing cysteine-modified GroEL with the spin label N-(1-oxyl-2,2,5,5 -tetramethyl-3-pyrrolidinyl)iodoacetamide and the fluorescent label 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid, we detected increases in spin-label mobility and fluorescence intensity in GroEL upon HCA II binding. Together, these results show that conformational changes occur in the chaperonin as a consequence of protein substrate binding. Together with previous results on the unfoldase activity of GroEL, we suggest that the chaperonin opens up as the substrate protein binds. This opening mechanism may induce stretching of the protein, which would account for reported unfoldase activity of GroEL and might explain how GroEL can actively chaperone proteins larger than HCA II.	Linkoping Univ, Dept Chem, IFM, S-58183 Linkoping, Sweden	Linkoping University	Carlsson, U (corresponding author), Linkoping Univ, Dept Chem, IFM, S-58183 Linkoping, Sweden.			Lindgren, Mikael/0000-0001-6649-7871				ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bochkareva E, 1999, J BIOL CHEM, V274, P20756, DOI 10.1074/jbc.274.30.20756; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Churchich JE, 1997, J BIOL CHEM, V272, P19645, DOI 10.1074/jbc.272.32.19645; Csermely P, 1999, BIOESSAYS, V21, P959, DOI 10.1002/(SICI)1521-1878(199911)21:11<959::AID-BIES8>3.0.CO;2-1; Falke S, 1999, BIOPHYS J, V76, pA23; FRESKGARD PO, 1991, FEBS LETT, V289, P117, DOI 10.1016/0014-5793(91)80922-P; GOROVITS BM, 1995, J BIOL CHEM, V270, P13057, DOI 10.1074/jbc.270.22.13057; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16672, DOI 10.1021/bi9615001; HAMMARSTROM P, 2000, BIOPHYS J, V78, pA203; HAMMARSTROM P, 2000, THESIS LINKOPING U L; Haugland R., 1996, HDB FLUORESCENT PROB; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; Jai EA, 1999, J PROTEIN CHEM, V18, P387, DOI 10.1023/A:1021055932648; MARTENSSON LG, 1993, BIOCHEMISTRY-US, V32, P224, DOI 10.1021/bi00052a029; Mendoza JA, 1996, J BIOL CHEM, V271, P16344, DOI 10.1074/jbc.271.27.16344; NYMAN PO, 1964, BIOCHIM BIOPHYS ACTA, V85, P141, DOI 10.1016/0926-6569(64)90174-9; Owenius R, 1999, BIOPHYS J, V77, P2237, DOI 10.1016/S0006-3495(99)77064-5; Persson M, 1999, BIOCHEMISTRY-US, V38, P432, DOI 10.1021/bi981442e; PERSSON M, 1995, BBA-PROTEIN STRUCT M, V1247, P195, DOI 10.1016/0167-4838(94)00227-8; Persson M, 1996, BBA-PROTEIN STRUCT M, V1298, P191, DOI 10.1016/S0167-4838(96)00125-2; Persson M, 1997, FEBS LETT, V411, P43, DOI 10.1016/S0014-5793(97)00663-7; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; SVENSSON M, 1995, BIOCHEMISTRY-US, V34, P8606, DOI 10.1021/bi00027a010; THEVENIN BJM, 1994, P NATL ACAD SCI USA, V91, P1741, DOI 10.1073/pnas.91.5.1741; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEBER G, 1970, P NATL ACAD SCI USA, V65, P823, DOI 10.1073/pnas.65.4.823; WEBER G, 1960, BIOCHEM J, V75, P335, DOI 10.1042/bj0750335; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	39	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22832	22838		10.1074/jbc.M000649200	http://dx.doi.org/10.1074/jbc.M000649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811634	hybrid			2022-12-25	WOS:000088419400033
J	McLean, GW; Fincham, VJ; Frame, MC				McLean, GW; Fincham, VJ; Frame, MC			v-Src induces tyrosine phosphorylation of focal adhesion kinase independently of tyrosine 347 and formation of a complex with Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED CELL-MIGRATION; TUMOR-SUPPRESSOR PTEN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SUBCELLULAR-LOCALIZATION; EXTRACELLULAR-MATRIX; PROTEIN; PP125(FAK); BINDING; FAMILY	The non-receptor tyrosine kinase FAK plays a key role at sites of cellular adhesion. It is subject to regulatory tyrosine phosphorylation in response to a variety of stimuli, including integrin engagement after attachment to extracellular matrix, oncogene activation, and growth factor stimulation. Here we use an antibody that specifically recognizes the phosphorylated form of the putative FAK autophosphorylation site, Tyr(397). W, demonstrate that FAK phosphorylation induced by integrins during focal adhesion assembly differs from that induced by activation of a temperature-sensitive v-Src, which is associated with focal adhesion turnover and transformation. Specifically, although v-Src induces tyrosine phosphorylation of FAK, there is no detectable phosphorylation of Tyr(397). Moreover, activation of v-Src results in a net decrease in fibronectin-stimulated phosphorylation of Tyr(397), suggesting possible antagonism between v-Src and integrin-induced phosphorylation. Our mutational analysis further indicates that the binding of v-Src to Tyr(397) of FAK in its phosphorylated form, which is normally mediated, at least in part, by the SH2 domain of Src, is not essential for v-Src-induced cell transformation. We conclude that different stimuli can induce phosphorylation of FAK on distinct tyrosine residues, linking specific phosphorylation events to ensuing biological responses.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	McLean, GW (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Aplin AE, 1998, PHARMACOL REV, V50, P197; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Danker K, 1998, EXP CELL RES, V239, P326, DOI 10.1006/excr.1997.3916; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1999, J CELL SCI, V112, P947; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; ILIE D, 1995, NATURE, V377, P539; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARSDEN HS, 1978, J VIROL, V28, P624, DOI 10.1128/JVI.28.2.624-642.1978; MCLEAN GW, 1991, J IMMUNOL METHODS, V137, P149, DOI 10.1016/0022-1759(91)90019-C; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	45	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23333	23339		10.1074/jbc.M909322199	http://dx.doi.org/10.1074/jbc.M909322199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816598	hybrid			2022-12-25	WOS:000088419400101
J	Mounsey, JP; John, JE; Helmke, SM; Bush, EW; Gilbert, J; Roses, AD; Perryman, MB; Jones, LR; Moorman, JR				Mounsey, JP; John, JE; Helmke, SM; Bush, EW; Gilbert, J; Roses, AD; Perryman, MB; Jones, LR; Moorman, JR			Phospholemman is a substrate for myotonic dystrophy protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CHLORIDE CHANNEL; XENOPUS-OOCYTES; CELL-CYCLE; INTERCOSTAL MUSCLE; SODIUM-CHANNELS; CL CONDUCTANCE; GAMMA-SUBUNIT; CTG REPEAT; GENE DBF2; INACTIVATION	The genetic abnormality in myotonic muscular dystrophy, multiple CTG repeats lie upstream of a gene that encodes a novel protein kinase, myotonic dystrophy protein kinase (DMPK). Phospholemman (PLM), a major membrane substrate for phosphorylation by protein kinases A and C, induces Cl currents (I-Cl(PLM)) when expressed in Xenopus oocytes. To test the idea that PLM is a substrate for DMPK, we measured in vitro phosphorylation of purified PLM by DMPK. To assess the functional effects of PLM phosphorylation we compared I-Cl(PLM) in Xenopus oocytes expressing PLM alone to currents in oocytes co-expressing DMPK; and examined the effect of DMPK on oocyte membrane PLM expression. We found that PLM is indeed a good substrate for DMPK in vitro. Co-expression of DMPK with PLM in oocytes resulted in a reduction in ICl(PLM) .This was most likely a specific effect of phosphorylation of PLM by DMPK, as the effect was not present in oocytes expressing a phos(-) PLM mutant in which all potential phosphorylation had been disabled by Ser --> Ala substitution. The biophysical characteristics of I-Cl(PLM) were not changed by DMPK or by the phos(-) mutation. Co-expression of DMPK reduced the expression of PLM in oocyte membranes, suggesting a possible mechanism for the observed reduction in I-Cl(PLM) amplitude. These data show that PLM is a substrate for phosphorylation by DMPK and provide functional evidence for modulation of PLM function by phosphorylation.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biol Phys, Charlottesville, VA 22908 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiol, Dept Med, Denver, CO 80262 USA; Duke Univ, Med Ctr, Dept Internal Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Dept Internal Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Dept Pharmacol, Indianapolis, IN 46202 USA	University of Virginia; University of Virginia; University of Virginia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Mounsey, JP (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Box 6012,MR4 Bldg, Charlottesville, VA 22908 USA.		Moorman, J Randall/ABG-9946-2020		NCRR NIH HHS [M01-RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; Bush EW, 1996, J BIOL CHEM, V271, P548, DOI 10.1074/jbc.271.1.548; CANNON SC, 1993, BIOPHYS J, V65, P270, DOI 10.1016/S0006-3495(93)81045-2; Chen LSK, 1997, GENOMICS, V41, P435, DOI 10.1006/geno.1997.4665; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; DURIEUX ME, 1992, AM J PHYSIOL, V263, P896; FAHLKE C, 1993, NEURON, V10, P225, DOI 10.1016/0896-6273(93)90313-G; FRANKE C, 1990, J PHYSIOL-LONDON, V425, P391, DOI 10.1113/jphysiol.1990.sp018110; FRANKE C, 1991, MUSCLE NERVE, V14, P762, DOI 10.1002/mus.880140811; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FURMAN RE, 1978, ANN NEUROL, V4, P357, DOI 10.1002/ana.410040411; GRUENER R, 1979, MUSCLE NERVE, V2, P165, DOI 10.1002/mus.880020303; HOUSE C, 1987, J BIOL CHEM, V262, P772; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; Jones DH, 1997, J CELL BIOL, V139, P1545, DOI 10.1083/jcb.139.6.1545; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; LIPICKY RJ, 1966, J GEN PHYSIOL, V50, P89, DOI 10.1085/jgp.50.1.89; LIPICKY RJ, 1977, PATHOGENESIS HUMAN M, P729; LOO DDF, 1981, CAN J PHYSIOL PHARM, V59, P7, DOI 10.1139/y81-002; LU KP, 1994, J BIOL CHEM, V269, P6603; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1994, ONCOGENE, V9, P3417; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; Mounsey JP, 1999, BBA-MOL CELL RES, V1451, P305, DOI 10.1016/S0167-4889(99)00102-0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; TIMCHENKO L, 1995, P NATL ACAD SCI USA, V92, P5366, DOI 10.1073/pnas.92.12.5366; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WALAAS SI, 1994, BIOCHEM J, V304, P635, DOI 10.1042/bj3040635; Wald H, 1996, AM J PHYSIOL-RENAL, V271, pF322, DOI 10.1152/ajprenal.1996.271.2.F322; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Zhao YM, 1997, J BIOL CHEM, V272, P10013	52	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23362	23367		10.1074/jbc.M000899200	http://dx.doi.org/10.1074/jbc.M000899200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811636	hybrid			2022-12-25	WOS:000088419400105
J	Pirone, DM; Fukuhara, S; Gutkind, JS; Burbelo, PD				Pirone, DM; Fukuhara, S; Gutkind, JS; Burbelo, PD			SPECs, small binding proteins for Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; ACTIN POLYMERIZATION; PLASMA-MEMBRANE; KINASE PATHWAY; ARP2/3 COMPLEX; N-WASP; GTPASES; ACTIVATION; EFFECTOR; DOMAIN	The Rho GTPase, Cdc42, regulates a wide variety of cellular activities including actin polymerization, focal complex assembly, and kinase signaling. We have identified a new family of very small Cdc42-binding proteins, designated SPECs (for Small Protein Effector of Cdc42), that modulates these regulatory activities. The two human members, SPEC1 and SPECS, encode proteins of 79 and 84 amino acids, respectively. Both contain a conserved N-terminal region and a centrally located CRIB (Cdc42/Rac Interactive Binding) domain. Using a yeast two-hybrid system, we found that both SPECs interact strongly with Cdc42, weakly with Rad, and not at all with RhoA. Transfection analysis revealed that SPEC1 inhibited Cdc42-induced c-Jun N-terminal kinase (JNK) activation in COS1 cells in a manner that required an intact CRIB domain. Immunofluorescence experiments in MH-3T3 fibroblasts demonstrated that both SPEC1 and SPECS showed a cortical localization and induced the formation of cell surface membrane blebs, which was not dependent on Cdc42 activity. Cotransfection experiments demonstrated that SPEC1 altered Cdc42-induced cell shape changes both in COS1 cells and in NIH-3T3 fibroblasts and that this alteration required an intact CRIB domain. These results suggest that SPECs act as novel scaffold molecules to coordinate and/or mediate Cdc42 signaling activities.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Burbelo, PD (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Rm EG16,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.		Burbelo, Peter D./B-1027-2009; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burbelo PD, 1999, P NATL ACAD SCI USA, V96, P9083, DOI 10.1073/pnas.96.16.9083; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; ERICKSON CA, 1976, EXP CELL RES, V99, P375, DOI 10.1016/0014-4827(76)90595-4; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.3.CO;2-M; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nur-E-Kamal MSA, 1999, ONCOGENE, V18, P7787; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trinkaus J P, 1980, Prog Clin Biol Res, V41, P887; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	46	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22650	22656		10.1074/jbc.M002832200	http://dx.doi.org/10.1074/jbc.M002832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816584	hybrid			2022-12-25	WOS:000088419400010
J	Toman, PD; Chisholm, G; McMullin, H; Gieren, LM; Olsen, DR; Kovach, RJ; Leigh, SD; Fong, BE; Chang, R; Daniels, GA; Berg, RA; Hitzeman, RA				Toman, PD; Chisholm, G; McMullin, H; Gieren, LM; Olsen, DR; Kovach, RJ; Leigh, SD; Fong, BE; Chang, R; Daniels, GA; Berg, RA; Hitzeman, RA			Production of recombinant human type I procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROLYL 4-HYDROXYLASE; PROTEIN DISULFIDE-ISOMERASE; MOLECULAR-CLONING; III COLLAGEN; REQUIRES COEXPRESSION; ALPHA-SUBUNIT; TRIPLE-HELIX; BETA-SUBUNIT; CHAINS; CELLS	The expression of stable recombinant human collagen requires an expression system capable of post-translational modifications and assembly of the procollagen polypeptides. Two genes were expressed in the yeast Saccharomyces cerevisiae to produce both propeptide chains that constitute human type I procollagen. Two additional genes were expressed coding for the subunits of prolyl hydroxylase, an enzyme that post-translationally modifies procollagen and that confers heat (thermal) stability to the triple helical conformation of the collagen molecule. Type I procollagen was produced as a stable heterotrimeric helix similar to type I procollagen produced in tissue culture. A key requirement for glutamate was identified as a medium supplement to obtain high expression levels of type I procollagen as heat-stable heterotrimers in Saccharomyces, Expression of these four genes was sufficient for correct assembly and processing of type I procollagen in a eucaryotic system that does not produce collagen.	Cohes Technol, Palo Alto, CA 94303 USA; Genotypes Inc, San Francisco, CA 94080 USA		Toman, PD (corresponding author), Cohes Technol, 2500 Faber Pl, Palo Alto, CA 94303 USA.	dtoman@cson.com						BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BECKER DM, 1996, CURRENT PROTOCOLS MO, V2; BERG RA, 1980, BIOCHEM J, V189, P491, DOI 10.1042/bj1890491; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; CLARK CC, 1979, J BIOL CHEM, V254, P798; De Baetselier-Van Broekhoven A, 1994, Bioprocess Technol, V19, P431; FASIOLO F, 1981, J BIOL CHEM, V256, P2324; Ferreira LR, 1996, CONNECT TISSUE RES, V33, P265, DOI 10.3109/03008209609028884; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FISHER LW, 1989, CONNECT TISSUE RES, V21, P373; FLEISCHMAJER R, 1983, P NATL ACAD SCI-BIOL, V80, P3354, DOI 10.1073/pnas.80.11.3354; GEDDIS AE, 1993, MATRIX, V13, P399, DOI 10.1016/S0934-8832(11)80045-4; Haralson MA, 1995, EXTRACELLULAR MATRIX, P1; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HITZEMAN RA, 1990, METHOD ENZYMOL, V185, P421; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; John DCA, 1999, NAT BIOTECHNOL, V17, P385, DOI 10.1038/7945; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LEE ST, 1988, J BIOL CHEM, V263, P13414; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; STACEY A, 1987, J VIROL, V61, P2549, DOI 10.1128/JVI.61.8.2549-2554.1987; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; Toman PD, 1999, TRANSGENIC RES, V8, P415, DOI 10.1023/A:1008959924856; Tomita M, 1997, J BIOCHEM, V121, P1061; Vaughan PR, 1998, DNA CELL BIOL, V17, P511, DOI 10.1089/dna.1998.17.511; Vuorela A, 1997, EMBO J, V16, P6702, DOI 10.1093/emboj/16.22.6702; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	44	81	90	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23303	23309		10.1074/jbc.M002284200	http://dx.doi.org/10.1074/jbc.M002284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801837	hybrid			2022-12-25	WOS:000088419400097
J	Yamada, T; Morisseau, C; Maxwell, JE; Argiriadi, MA; Christianson, DW; Hammock, BD				Yamada, T; Morisseau, C; Maxwell, JE; Argiriadi, MA; Christianson, DW; Hammock, BD			Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-RADIOBACTER AD1; ALKYLATION HALF-REACTION; EPOXYEICOSATRIENOIC ACIDS; JUVENILE-HORMONE; HUMAN LIVER; MECHANISM; PROTEIN; EXPRESSION; ACETYLCHOLINESTERASE; INTERMEDIATE	Epoxide hydrolases (EH) catalyze the hydrolysis of epoxides and arene oxides to their corresponding diols. The crystal structure of murine soluble EH suggests that Tyr(465) and Tyr(381) act as acid catalysts, activating the epoxide ring and facilitating the formation of a covalent intermediate between the epoxide and the enzyme. To explore the role of these two residues, mutant enzymes were produced and the mechanism of action was analyzed. Enzyme assays on a series of substrates confirm that both Tyr(465) and Tyr(381) are required for full catalytic activity. The kinetics of chalcone oxide hydrolysis show that mutation of Tyr(465) and Tyr(381) decreases the rate of binding and the formation of an intermediate, suggesting that both tyrosines polarize the epoxide moiety to facilitate ring opening. These two tyrosines are, however, not implicated in the hydrolysis of the covalent intermediate. Sequence comparisons showed that Tyr(465) is conserved in microsomal EHs. The substitution of analogous Tyr(374) with phenylalanine in the human microsomal EH dramatically decreases the rate of hydrolysis of cis-stilbene oxide. These results suggest that these tyrosines perform a significant mechanistic role in the substrate activation by EHs.	Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA	University of California System; University of California Davis; University of Pennsylvania	Hammock, BD (corresponding author), Univ Calif Davis, Dept Entomol, 1 Shields Ave, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002710, P30ES005707, P42ES004699] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04699, 1P30-ES05707, R01-ES02710] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Arand M, 1999, BIOCHEM J, V337, P37, DOI 10.1042/0264-6021:3370037; Arand M, 1999, BIOCHEM J, V344, P273, DOI 10.1042/0264-6021:3440273; Arand M, 1996, J BIOL CHEM, V271, P4223; Argiriadi MA, 2000, J BIOL CHEM, V275, P15265, DOI 10.1074/jbc.M000278200; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BELL PA, 1993, J BIOL CHEM, V268, P14011; BLUMENSTEIN JJ, 1993, J ORG CHEM, V58, P924, DOI 10.1021/jo00056a027; BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; BORHAN B, 1995, ANAL BIOCHEM, V231, P188, DOI 10.1006/abio.1995.1520; Debernard S, 1998, INSECT BIOCHEM MOLEC, V28, P409, DOI 10.1016/S0965-1748(98)00014-9; DIETZE EC, 1994, ANAL BIOCHEM, V216, P176, DOI 10.1006/abio.1994.1023; Gandolfi A.J., 1997, COMPREHENSIVE TOXICO, P283; GILLOT C, 1983, ACT 8 C UN INT PHLEB, V1, P273; Grant DF, 1996, BIOCHEM PHARMACOL, V51, P503, DOI 10.1016/0006-2952(95)02227-9; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUEX N, 1996, EXPERIENTIA, V52, P26; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laughlin LT, 1998, BIOCHEMISTRY-US, V37, P2897, DOI 10.1021/bi972737f; Moghaddam MF, 1997, NAT MED, V3, P562, DOI 10.1038/nm0597-562; Morisseau C, 1998, ARCH BIOCHEM BIOPHYS, V356, P214, DOI 10.1006/abbi.1998.0756; Morisseau C, 1999, P NATL ACAD SCI USA, V96, P8849, DOI 10.1073/pnas.96.16.8849; MUMBY SM, 1979, ANAL BIOCHEM, V92, P16, DOI 10.1016/0003-2697(79)90619-5; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Oltman CL, 1998, CIRC RES, V83, P932; Ordentlich A, 1998, J BIOL CHEM, V273, P19509, DOI 10.1074/jbc.273.31.19509; PHILLIPS DH, 1994, DRUG METAB REV, V26, P443, DOI 10.3109/03602539409029808; PINOT F, 1995, J BIOL CHEM, V270, P7968, DOI 10.1074/jbc.270.14.7968; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Rink R, 1999, J AM CHEM SOC, V121, P7417, DOI 10.1021/ja990501o; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TINGLE MD, 1993, BIOCHEM PHARMACOL, V46, P1529, DOI 10.1016/0006-2952(93)90319-R; Tzeng HF, 1998, BIOCHEMISTRY-US, V37, P2905, DOI 10.1021/bi9727388; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059; Zou JY, 2000, STRUCTURE, V8, P111, DOI 10.1016/S0969-2126(00)00087-3	44	90	98	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23082	23088		10.1074/jbc.M001464200	http://dx.doi.org/10.1074/jbc.M001464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10806198	hybrid			2022-12-25	WOS:000088419400065
J	Yao, DD; Mackenzie, B; Ming, H; Varoqui, H; Zhu, HM; Hediger, MA; Erickson, JD				Yao, DD; Mackenzie, B; Ming, H; Varoqui, H; Zhu, HM; Hediger, MA; Erickson, JD			A novel system A isoform mediating Na+/neutral amino acid cotransport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; PYRUVATE-CARBOXYLASE; PRIMARY CULTURES; RAT-BRAIN; GLUTAMATE TRANSPORTERS; GLUTAMINASE ACTIVITY; ALPHA-KETOGLUTARATE; CNS TRANSMITTER; VESICULAR GABA; IN-VIVO	A cDNA clone encoding a plasma membrane alanine-preferring transporter (SAT2) has been isolated from glutamatergic neurons in culture and represents the second member of the system A family of neutral amino acid transporters. SAT2 displays a widespread distribution and is expressed in most tissues, including heart, adrenal gland, skeletal muscle, stomach, fat, brain, spinal cord, colon, and lung, with lower levels detected in spleen. No signal is detected in liver or testis. In the central nervous system, SAT2 is expressed in neurons. SAT2 is significantly up-regulated during differentiation of cerebellar granule cells and is absent from astrocytes in primary culture. The functional properties of SATE, examined using transfected fibroblasts and in cRNA-injected voltage-clamped Xenopus oocytes, show that small aliphatic neutral amino acids are preferred substrates and that transport is voltage- and Na+-dependent (1:1 stoichiometry), pH-sensitive, and inhibited by alpha-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of system A. Kinetic analyses of alanine and MeAIB uptake by SAT2 are saturable, with Michaelis constants (K-m) of 200-500 mu M. In addition to its ubiquitous role as a substrate for oxidative metabolism and a major vehicle of nitrogen transport, SAT2 may provide alanine to function as the amino group donor to alpha-keto-glutarate to provide an alternative source for neurotransmitter synthesis in glutamatergic neurons.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Erickson, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.			Hediger, Matthias/0000-0003-1946-027X; Mackenzie, Bryan/0000-0002-9661-8838	NINDS NIH HHS [NS36936] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDAWI MSM, 1986, BIOCHEM J, V238, P131, DOI 10.1042/bj2380131; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BRADFORD HF, 1976, BRAIN RES, V110, P115, DOI 10.1016/0006-8993(76)90212-2; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; BRADFORD NM, 1982, BIOCHIM BIOPHYS ACTA, V689, P55, DOI 10.1016/0005-2736(82)90188-2; CESAR M, 1995, J NEUROCHEM, V64, P2312; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1995, NUTR REV, V53, P74, DOI 10.1111/j.1753-4887.1995.tb01506.x; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; DUDECK KL, 1987, J BIOL CHEM, V262, P12565; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; FELIG P, 1975, ANNU REV BIOCHEM, V44, P933, DOI 10.1146/annurev.bi.44.070175.004441; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HAMBERGER A, 1979, BRAIN RES, V168, P531, DOI 10.1016/0006-8993(79)90307-X; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; Hassel B, 1997, J CEREBR BLOOD F MET, V17, P1230, DOI 10.1097/00004647-199711000-00012; HAUSSINGER D, 1992, MAMMALIAN AMINO ACID TRANSPORT, P113; Hediger MA, 1999, AM J PHYSIOL-RENAL, V277, pF487, DOI 10.1152/ajprenal.1999.277.4.F487; HERTZ L, 1979, PROG NEUROBIOL, V13, P277, DOI 10.1016/0301-0082(79)90018-2; HERTZ L, 1988, GLUTAMATE GLUTAMINE; KAUFMAN EE, 1992, J NEUROCHEM, V58, P258, DOI 10.1111/j.1471-4159.1992.tb09304.x; KIHARA M, 1989, J NEUROCHEM, V52, P1127, DOI 10.1111/j.1471-4159.1989.tb01857.x; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KVAMME E, 1986, EXCITATORY AMMINO AC, P41; Laake JH, 1999, NEUROSCIENCE, V88, P1137, DOI 10.1016/S0306-4522(98)00298-X; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LIN GR, 1994, ARCH BIOCHEM BIOPHYS, V312, P308, DOI 10.1006/abbi.1994.1314; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; Mackenzie B., 1999, BIOMEMBRANE TRANSPOR, P327; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; NAJLERAHIM A, 1990, MOL BRAIN RES, V7, P317, DOI 10.1016/0169-328X(90)90082-O; NICKLAS WJ, 1983, GLUTAMINE GLUTAMATE, P219; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PALACIN M, 1990, BIOCHEM J, V270, P189, DOI 10.1042/bj2700189; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PENG L, 1991, NEUROCHEM RES, V16, P29, DOI 10.1007/BF00965824; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; RAMAHAROBANDRO N, 1982, BRAIN RES, V244, P113, DOI 10.1016/0006-8993(82)90909-X; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHANK RP, 1989, NEUROCHEM RES, V14, P371, DOI 10.1007/BF01000041; SHANK RP, 1984, J NEUROCHEM, V42, P1153, DOI 10.1111/j.1471-4159.1984.tb12724.x; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Sonnewald U, 1997, GLIA, V21, P56, DOI 10.1002/(SICI)1098-1136(199709)21:1<56::AID-GLIA6>3.0.CO;2-#; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; WEILER CT, 1982, J NEUROCHEM, V32, P559; WESTERGAARD N, 1993, J NEUROSCI RES, V35, P540, DOI 10.1002/jnr.490350510; WESTERGAARD N, 1995, DEV NEUROSCI-BASEL, V17, P203, DOI 10.1159/000111288; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x; YUDKOFF M, 1986, BIOCHEM J, V234, P185, DOI 10.1042/bj2340185	62	189	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22790	22797		10.1074/jbc.M002965200	http://dx.doi.org/10.1074/jbc.M002965200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811809	hybrid			2022-12-25	WOS:000088419400028
J	Baumann, H; Wang, YP; Richards, CD; Jones, CA; Black, TA; Gross, KW				Baumann, H; Wang, YP; Richards, CD; Jones, CA; Black, TA; Gross, KW			Endotoxin-induced renal inflammatory response - Oncostatin M as a major mediator of suppressed renin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; GENE-TRANSCRIPTION; NITRIC-OXIDE; IN-VIVO; C-FOS; PROMOTER; MICE; RAT; ANGIOTENSINOGEN; INDUCTION	The systemic response to endotoxin is characterized by hypotension and severe reductions in blood pressure, leading to cardiovascular collapse that can accompany septicemia. The renin/ansotensin system would normally be expected to respond to hypotensive challenge; however, inflammation appears to modify this response. This study identifies a strong acute phase response of the kidney that is characterized by enhanced expression of serum amyloid A, haptoglobin and tissue inhibitor for metalloproteinase-1 and a reduced expression of renin, Equivalent regulatory effects were observed for the immortalized As4.1 kidney cell line that models certain features of juxtaglomerular cells. Oncostatin M, a known endotoxin-responsive proinflammatory cytokine, proved to be an effective inhibitor of renin gene expression. Suppression by oncostatin M involves activated STAT5 and requires an inhibitory element in the renin promoter that functions separately from cell type-specific enhancer elements. The renal acute phase reaction, unlike the liver acute phase reaction, is more strongly dependent on locally produced inflammatory factors.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	Roswell Park Cancer Institute; McMaster University	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.			Richards, Carl/0000-0002-0081-2231	NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL48459] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Duymelinck C, 1998, KIDNEY INT, V54, P804, DOI 10.1046/j.1523-1755.1998.00050.x; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAGEYAMA R, 1985, BIOCHEM BIOPH RES CO, V129, P826, DOI 10.1016/0006-291X(85)91966-7; Kaibara A, 1998, CYTOKINE, V10, P452, DOI 10.1006/cyto.1997.0313; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lopez-Novoa JM, 1999, KIDNEY INT, V55, P1672, DOI 10.1046/j.1523-1755.1999.00450.x; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Mashimo H, 1999, AM J PHYSIOL-GASTR L, V277, pG745, DOI 10.1152/ajpgi.1999.277.4.G745; Matsukawa A, 1998, INFLAMM RES, V47, pS137; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; NAEMURA JR, 1993, LYMPHOKINE CYTOK RES, V12, P187; OHTANI R, 1989, LIFE SCI, V44, P237, DOI 10.1016/0024-3205(89)90601-2; OKAMOTO H, 1987, BIOCHEM PHARMACOL, V36, P3069, DOI 10.1016/0006-2952(87)90225-5; OKAMOTO H, 1987, BIOCHEM BIOPH RES CO, V145, P1225, DOI 10.1016/0006-291X(87)91568-3; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P13704; SCHREIBER G, 1993, ACUTE PHASE PROTEINS, P39; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; THOMPSON HA, 1995, ENDOCRINOLOGY, V136, P3037, DOI 10.1210/en.136.7.3037; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; WERNZE H, 1979, HORM METAB RES, V11, P371, DOI 10.1055/s-0028-1092741; Wiese A, 1999, BIOL CHEM, V380, P767, DOI 10.1515/BC.1999.097; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	36	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22014	22019		10.1074/jbc.M002830200	http://dx.doi.org/10.1074/jbc.M002830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806209	hybrid			2022-12-25	WOS:000088363800038
J	Mora-Garcia, P; Sakamoto, KM				Mora-Garcia, P; Sakamoto, KM			Granulocyte colony-stimulating factor induces egr-1 up-regulation through interaction of serum response element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; TERNARY COMPLEX-FORMATION; FIBROBLAST GROWTH-FACTOR; MYELOID-LEUKEMIA CELLS; IMMEDIATE-EARLY GENES; C-FOS PROMOTER; SIGNALING PATHWAYS; ACTIVATION DOMAIN; IN-VIVO; KINASE	Granulocyte colony-stimulating factor (G-CSF) stimulates the proliferation and maturation of myeloid progenitor cells both in vitro and in vivo, We showed that G-CSF rapidly and transiently induces expression of egr-1 in the NFS60 myeloid cell line. Transient transfections of NFS60 cells with recombinant constructs containing various deletions of the human egr-1 promoter identified the serum response element (SRE) between nucleotides (nt) -418 and -391 as a critical G-CSF-responsive sequence. The SRE (SRE-1) contains a CArG box, the binding site for the serum response factor (SRF), which is flanked at either side by an ETS protein binding site, We demonstrated that a single copy of the wild-type SRE-1 in the minimal promoter plasmid, pTE2, is sufficient to induce transcriptional activation in response to G-CSF and that both the ETS protein binding site and the CArG box are required for maximal transcriptional activation of the pTE2-SRE-1 construct. In electromobility shift assays using NFS60 nuclear extracts, we identified SRF and the ETS protein Fli-1 as proteins that bind the SRE-1. We also demonstrated through electrophoretic mobility shift assays, using an SRE-1 probe containing a CArG mutation, that Fli-1 binds the SRE-1 independently of SRF, Our data suggest that SRE-binding proteins potentially play a role in G-CSF-induced egr-1 expression in myeloid cells.	Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA; Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center	Sakamoto, KM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Hematol Oncol, A2-412 MDCC, Los Angeles, CA 90095 USA.			Sakamoto, Kathleen/0000-0003-0494-8838	NCI NIH HHS [CA68221-03, CA68221-02S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA068221, R29CA068221] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Cowley DO, 2000, GENE DEV, V14, P366; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEMETRI GD, 1991, BLOOD, V78, P2791; Dinkel A, 1998, J EXP MED, V188, P2215, DOI 10.1084/jem.188.12.2215; Ernst P, 1996, MOL CELL BIOL, V16, P6121; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GASCAN H, 1989, LYMPHOKINE RES, V8, P79; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND R, 1994, GENE DEV, P1803; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; Janknecht R, 1999, SCIENCE, V284, P443, DOI 10.1126/science.284.5413.443; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; KARABANDA S, 1991, J CLIN INVEST, V88, P571; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; KREIDER BL, 1992, ONCOGENE, V7, P135; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KUMAR A, 1972, P NATL ACAD SCI USA, V69, P681, DOI 10.1073/pnas.69.3.681; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; METCALF D, 1989, LEUKEMIA, V3, P349; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nicola N A, 1987, J Cell Physiol Suppl, VSuppl 5, P9; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8454; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V7, P2789; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	69	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22418	22426		10.1074/jbc.M001731200	http://dx.doi.org/10.1074/jbc.M001731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806199	hybrid			2022-12-25	WOS:000088363800090
J	Malyankar, UM; Scatena, M; Suchland, KL; Yun, TJ; Clark, EA; Giachelli, CM				Malyankar, UM; Scatena, M; Suchland, KL; Yun, TJ; Clark, EA; Giachelli, CM			Osteoprotegerin is an alpha(v)beta(3)-induced, NF-kappa B-dependent survival factor for endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; FAMILY MEMBER; ACTIVATION; APOPTOSIS; EXPRESSION; RECEPTOR; LIGAND; ALPHA; DEATH; DIFFERENTIATION	Osteopontin protects endothelial cells from apoptosis induced by growth factor withdrawal. This interaction is mediated by the alpha(v)beta(3) integrin and is NF-kappa B-dependent (Scatena, M., Almeida, M., Chaisson, M. L,, Fausto, N., Nicosia, R. F., and Giachelli, C. M. (1998) J. Cell Biol. 141, 1083-1093). In the present study we used differential cloning to identify osteopontin-induced, NF-kappa B-dependent genes in endothelial cells. One of the genes identified in this screen was osteoprotegerin, a member of the tumor necrosis factor receptor superfamily, By Northern and Western blot analysis, osteoprotegerin mRNA and protein levels were very low in endothelial cells plated on the non-integrin cell attachment factor, poly-D-lysine. In contrast, osteoprotegerin mRNA and protein levels were induced 5-7-fold following alpha(v)beta(3) ligation by osteopontin. Osteoprotegerin induction by osteopontin was time-dependent and observed as early as 3 h following treatment. NF-kappa B inactivation achieved by over expression of an I kappa B super repressor in endothelial cells completely inhibited osteoprotegerin induction by osteopontin. Finally, purified osteoprotegerin protected endothelial cells with inactive NF-kappa B from apoptosis induced by growth factor deprivation. These data suggest that alpha(v)beta(3)-mediated endothelial survival depends on osteoprotegerin induction by NF-kappa B and indicate a new function for osteoprotegerin in endothelial cells.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Giachelli, CM (corresponding author), Univ Washington, Dept Bioengn, Box 351720, Seattle, WA 98195 USA.		Clark, Edward/K-3462-2012	Clark, Edward A/0000-0001-8061-5475	NHLBI NIH HHS [HL18645] Funding Source: Medline; NIDDK NIH HHS [DK47659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yun TJ, 1998, J IMMUNOL, V161, P6113; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	23	314	335	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					20959	20962		10.1074/jbc.C000290200	http://dx.doi.org/10.1074/jbc.C000290200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10811631	hybrid			2022-12-25	WOS:000088230600001
J	Szekeres, PG; Muir, AI; Spinage, LD; Miller, JE; Butler, SI; Smith, A; Rennie, GI; Murdock, PR; Fitzgerald, LR; Wu, HL; McMillan, LJ; Guerrera, S; Vawter, L; Elshourbagy, NA; Mooney, JL; Bergsma, DJ; Wilson, S; Chambers, JK				Szekeres, PG; Muir, AI; Spinage, LD; Miller, JE; Butler, SI; Smith, A; Rennie, GI; Murdock, PR; Fitzgerald, LR; Wu, HL; McMillan, LJ; Guerrera, S; Vawter, L; Elshourbagy, NA; Mooney, JL; Bergsma, DJ; Wilson, S; Chambers, JK			Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; GASTROINTESTINAL-TRACT; CONSCIOUS RATS; GUINEA-PIG; IMMUNOREACTIVITY; EXPRESSION; CLONING; HORMONE; PEPTIDE; U-8	Neuromedins are a family of peptides best known for their contractile activity on smooth muscle preparations. The biological mechanism of action of neuromedin U remains unknown, despite the fact that the peptide was first isolated in 1985, Here we show that neuromedin U potently activates the orphan G protein-coupled receptor FM3, with subnanomolar potency, when FM3 is transiently expressed in human HEK-293 cells. Neuromedins B, C, K, and N are all inactive at this receptor, Quantitative reverse transcriptase-polymerase chain reaction analysis of neuromedin U expression in a range of human tissues showed that the peptide is highly expressed in the intestine, pituitary, and bone marrow, with lower levels of expression seen in stomach, adipose tissue, lymphocytes, spleen, and the cortex. Similar analysis of FM3 expression showed that the receptor is widely expressed in human tissue with highest levels seen in adipose tissue, intestine, spleen, and lymphocytes, suggesting that neuromedin U may have a wide range of presently undetermined physiological effects. The discovery that neuromedin U is an endogenous agonist for FM3 will significantly aid the study of the full physiological role of this peptide.	SmithKline Beecham Pharmaceut, Dept Basc Biol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Renal Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bioinformat, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Szekeres, PG (corresponding author), SmithKline Beecham Pharmaceut, Dept Basc Biol, New Frontiers Sci Pk, Harlow CM19 5AW, Essex, England.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; AUGOOD SJ, 1988, REGUL PEPTIDES, V20, P281, DOI 10.1016/0167-0115(88)90063-8; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; AUSTIN C, 1994, J MOL ENDOCRINOL, V12, P257, DOI 10.1677/jme.0.0120257; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1990, CELL TISSUE RES, V260, P131, DOI 10.1007/BF00297498; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; GARDINER SM, 1990, REGUL PEPTIDES, V29, P215, DOI 10.1016/0167-0115(90)90084-A; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HONZAWA M, 1987, NEUROSCIENCE, V23, P1103, DOI 10.1016/0306-4522(87)90185-0; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MALENDOWICZ LK, 1994, RES EXP MED, V194, P69, DOI 10.1007/BF02576368; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OKIMURA K, 1992, CHEM PHARM BULL, V40, P1500; Salmon AL, 2000, J BIOL CHEM, V275, P4549, DOI 10.1074/jbc.275.7.4549; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441; YUE TL, 1991, NEUROSCIENCE, V44, P215, DOI 10.1016/0306-4522(91)90262-M	29	146	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20247	20250		10.1074/jbc.C000244200	http://dx.doi.org/10.1074/jbc.C000244200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10811630	hybrid			2022-12-25	WOS:000088084500005
J	Verdile, G; Martins, RN; Duthie, M; Holmes, E; St George-Hyslop, PH; Fraser, PE				Verdile, G; Martins, RN; Duthie, M; Holmes, E; St George-Hyslop, PH; Fraser, PE			Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; ALZHEIMERS-DISEASE; BETA-PROTEIN; GAMMA-SECRETASE; MUTANT PRESENILINS; CULTURED-CELLS; DISTINCT SITES; GENERATION; COMPLEX; PEPTIDE	Presenilin 1 (PS1) plays a pivotal role in the production of the amyloid-beta protein, which is central to the pathogenesis of Alzheimer's disease. It has been demonstrated that PS1 regulates the gamma-secretase proteolysis of the amyloid precursor protein (APP) C-terminal fragment (APP-C100), which is the final step in amyloid-beta protein production. The mechanism and detailed pathway of this PS1 activity has yet to be fully resolved, but it may be due to a presenilin-controlled trafficking of the APP fragment or possibly an inherent PS1 proteolytic activity. We have investigated the possibility of a direct interaction of PS1 and the APP-C100 within the high molecular mass presenilin complex. However, the APP-C100 is rapidly degraded, and if it forms, then any PS1-APP complex is likely to be very transitory. To circumvent this problem, we have utilized the protease inhibitor N-acetyl-leucyl-norleucinal (LLnL) and the lysosomotropic agent NH4Cl, which inhibits the turnover of the APP-C100, Under these conditions, levels of the fragment increased appreciably, and as shown by glycerol gradient analysis, the APP-C100 shifted to a higher molecular mass complex that overlapped with PS1. Immunoprecipitation studies demonstrated that a significant population of the APP-C100 co-precipitated with PS1. These findings suggest that PSI may mediate the shuttling of APP fragments and/or facilitate their presentation for gamma-secretase cleavage through a direct interaction.	Univ Western Australia, Hollywood Private Hosp, Dept Surg, Perth, WA 6009, Australia; Univ Western Australia, Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA 6009, Australia; Univ Toronto, Ctr Res Neurodegenerat Dis, W Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, W Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Neurol, W Toronto, ON M5S 3H2, Canada	University of Western Australia; University of Western Australia; University of Toronto; University of Toronto; University of Toronto	Martins, RN (corresponding author), Univ Western Australia, Hollywood Private Hosp, Dept Surg, Perth, WA 6009, Australia.	rmartins@cyllene.uwa.edu.au		Martins, Ralph/0000-0002-4828-9363; Verdile, Giuseppe/0000-0003-2475-0124				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Greenfield JP, 1999, J BIOL CHEM, V274, P33843, DOI 10.1074/jbc.274.48.33843; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Kim SS, 1997, J MOL NEUROSCI, V9, P49, DOI 10.1007/BF02789394; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Kouchi Z, 1999, BIOCHEM BIOPH RES CO, V254, P804, DOI 10.1006/bbrc.1998.9977; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nishimura M, 1999, CLIN GENET, V55, P219, DOI 10.1034/j.1399-0004.1999.550401.x; Peraus GC, 1997, J NEUROSCI, V17, P7714; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Sudoh S, 1998, J NEUROCHEM, V71, P1535; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Trischler M, 1999, J CELL SCI, V112, P4773; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Waragai M, 1997, BIOCHEM BIOPH RES CO, V239, P480, DOI 10.1006/bbrc.1997.7488; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20794	20798		10.1074/jbc.C000208200	http://dx.doi.org/10.1074/jbc.C000208200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801777	hybrid			2022-12-25	WOS:000088084500081
J	Reddy, VB; Kounga, K; Mariano, F; Lerner, EA				Reddy, VB; Kounga, K; Mariano, F; Lerner, EA			Chrysoptin is a potent glycoprotein IIb/IIIa fibrinogen receptor antagonist present in salivary gland extracts of the deerfly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-AGGREGATION; PROTEIN; PEPTIDE; INHIBITOR; BINDING; APYRASE; FLY	Salivary gland lysates of the deerfly (genus Chrysops) contain chrysoptin, an inhibitor of ADP-induced platelet aggregation, which presumably assists the fly in obtaining a blood meal. Chrysoptin has now been isolated, and its cDNA has been cloned and expressed. Chrysoptin was purified to homogeneity using anion exchange and hydrophobic interaction chromatography and found to be a protein with a molecular mass of 65 kDa as determined by gel electrophoresis, N-terminal amino acid sequencing allowed for the synthesis of degenerate oligonucleotides that led to cloning, from salivary gland specific mRNA, of the cDNA encoding this platelet inhibitor. No RGD sites are present in the predicted sequence. A search of GenBank(TM) did not reveal significant sequence homology between chrysoptin and other proteins. The molecular mass predicted from the cDNA was 59 kDa. Predicted glycosylation and phosphorylation sites may account for this difference in molecular mass, as recombinant chrysoptin expressed in Sf21 cells had a molecular mass of 65 kDa, matching that of the natural protein. Chrysoptin functions by inhibiting the binding of fibrinogen to the fibrinogen/glycoprotein IIb/IIIa receptor on platelets with an IC50 of 95 pmol. These results reveal that insect salivary glands are a source of fibrinogen receptor antagonists.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Lerner, EA (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, E Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044510, R01AR042005] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR42005, R01 AR44510] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BATTASTINI AMO, 1991, NEUROCHEM RES, V16, P1303, DOI 10.1007/BF00966661; Bednar MM, 1999, STROKE, V30, P887, DOI 10.1161/01.STR.30.4.887; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; Cupp MS, 1998, J EXP BIOL, V201, P1553; DICKINSON RG, 1976, AUST J EXP BIOL MED, V54, P475, DOI 10.1038/icb.1976.48; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GREVELINK SA, 1993, P NATL ACAD SCI USA, V90, P9155, DOI 10.1073/pnas.90.19.9155; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HUANG TF, 1987, J BIOL CHEM, V262, P16157; JACOBS JW, 1990, THROMB RES, V15, P869; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LERNER EA, 1991, J BIOL CHEM, V266, P11234; LOSCALZO J, 1986, J CLIN INVEST, V78, P1112, DOI 10.1172/JCI112668; MANT MJ, 1981, BRIT J HAEMATOL, V48, P601, DOI 10.1111/j.1365-2141.1981.00601.x; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; RIBEIRO JMC, 1980, J INSECT PHYSIOL, V26, P303, DOI 10.1016/0022-1910(80)90138-9; RIBEIRO JMC, 1988, J PARASITOL, V74, P1068, DOI 10.2307/3282240; RIBIERO JMC, 1991, COMP BIOCH PHYSL, V100, P109; Scarborough RM, 1999, CIRCULATION, V100, P437, DOI 10.1161/01.CIR.100.4.437; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WEINTRAUB BD, 1983, ENDOCRINOLOGY, V112, P1331, DOI 10.1210/endo-112-4-1331	25	25	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15861	15867		10.1074/jbc.275.21.15861	http://dx.doi.org/10.1074/jbc.275.21.15861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821849	hybrid			2022-12-25	WOS:000087291400036
J	Kortesmaa, J; Yurchenco, P; Tryggvason, K				Kortesmaa, J; Yurchenco, P; Tryggvason, K			Recombinant laminin-8 (alpha(4)beta(1)gamma(1)) - Production, purification, and interactions with integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; CONGENITAL MUSCULAR-DYSTROPHY; HOMOZYGOUS NONSENSE MUTATION; ADULT-MOUSE TISSUES; ENDOTHELIAL-CELLS; CHAIN GENE; MOLECULAR-CLONING; SKELETAL-MUSCLE; GAMMA-3 CHAIN; ALPHA-4 CHAIN	Laminins are a large family of heterotrimeric extracellular matrix glycoproteins that, in addition to having structural roles, take part in the regulation of processes such as cell migration, differentiation, and proliferation. The laminin cu, chain is widely distributed both in adults and during development in tissues such as cardiac, skeletal and smooth muscle fibers, vascular endothelia, lungs, and in peripheral nerves. It can associate with laminin beta(1)/gamma(1) chains to form laminin-8 and with the beta(2)/gamma(1) chains to form laminin-9. Functional studies on these laminins have been hampered by poor availability of the protein in pure and soluble forms. To facilitate studies on laminin-8, recombinant laminin-8 was produced in a mammalian expression system, purified and shown to form native Y-shaped molecules in rotary shadowing electron microscopy. Integrins mediating cell adhesion to laminin-8 were identified using function-blocking mAbs. The integrin specificities were found to differ somewhat from that of laminin-l. Integrin alpha(6)beta(1) was found to be a major mediator of adhesion of HT-1080 and cultured capillary endothelial cells to laminin-8, Considering the expression patterns of laminin-8 and integrin alpha(6)beta(1) it is likely that the former is a ligand for the latter in vivo as well.	Karolinska Inst, Dept Med Biochem & Biopys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA	Karolinska Institutet; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biopys, Div Matrix Biol, S-17177 Stockholm, Sweden.			Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1996, LAMININS, P127; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CONFORTI G, 1994, CELL ADHES COMMUN, V1, P279, DOI 10.3109/15419069409097260; CONFORTI G, 1992, BLOOD, V80, P437; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; ILL CR, 1984, J CELL BIOL, V99, P2140, DOI 10.1083/jcb.99.6.2140; Kanda S, 1999, EXP CELL RES, V248, P203, DOI 10.1006/excr.1999.4400; KIVIRIKKO S, 1995, HUM MOL GENET, V4, P959, DOI 10.1093/hmg/4.5.959; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; McDearmon EL, 1998, J BIOL CHEM, V273, P24139, DOI 10.1074/jbc.273.37.24139; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; Ringelmann B, 1999, EXP CELL RES, V246, P165, DOI 10.1006/excr.1998.4244; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SONNENBERG A, 1990, J CELL SCI, V96, P207; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	45	112	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14853	14859		10.1074/jbc.275.20.14853	http://dx.doi.org/10.1074/jbc.275.20.14853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809728	hybrid			2022-12-25	WOS:000087128300013
J	van den Heuvel, RHH; Fraaije, MW; Mattevi, A; van Berkel, WJH				van den Heuvel, RHH; Fraaije, MW; Mattevi, A; van Berkel, WJH			Asp-170 is crucial for the redox properties of vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-CRESOL METHYLHYDROXYLASE; PENICILLIUM-SIMPLICISSIMUM; AMINO-ACID; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-PUTIDA; BINDING; ENZYME; FAD; 4-ALKYLPHENOLS; FLAVINYLATION	Vanillyl-alcohol oxidase is a flavoprotein containing a covalent flavin that catalyzes the oxidation of 4-(methogymethyl)phenol to 4-hydroxybenzaldehyde. The reaction proceeds through the formation of a p-quinone methide intermediate, after which, water addition takes place. Asp-170, located near the N5-atom of the flavin, has been proposed to act as an active site base. To test this hypothesis, we have addressed the properties of D170E, D170S, D170A, and D170N variants. Spectral and fluorescence analysis, together with the crystal structure of D170S, suggests that the Asp-170 replacements do not induce major structural changes. However, in D170A and D170N, 50 and 100%, respectively, of the flavin is non-covalently bound. Kinetic characterization of the vanillyl-alcohol oxidase variants revealed that Asp170 is required for catalysis, D170E is 50-fold less active, and the other Asp-170 variants are about 10(3)-fold less active than wild type enzyme. Impaired catalysis of the Asp-170 variants is caused by slow flavin reduction. Furthermore, the mutant proteins have lost the capability of forming a stable complex between reduced enzyme and the p-quinone methide intermediate. The redox midpoint potentials in D170E (+6 mV) and D170S (-91 mV) are considerably decreased compared with wild type vanillyl-alcohol oxidase (+55 mV), This supports the idea that Asp-170 interacts with the protonated N5-atom of the reduced cofactor, thus increasing the FAD redox potential. Taken together, we conclude that Asp170 is involved in the process of autocatalytic flavinylation and is crucial for efficient redox catalysis.	Wageningen Univ, Dept Biomol Sci, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, I-27100 Pavia, Italy	Wageningen University & Research; University of Pavia	van Berkel, WJH (corresponding author), Wageningen Univ, Dept Biomol Sci, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.		mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019; Fraaije, Marco/E-8421-2014; van Berkel, Willem J.H./O-2431-2014	mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Fraaije, Marco/0000-0001-6346-5014				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benen JAE, 1998, J BIOL CHEM, V273, P7865, DOI 10.1074/jbc.273.14.7865; Bodell WJ, 1998, CARCINOGENESIS, V19, P437, DOI 10.1093/carcin/19.3.437; Bolton JL, 1997, CHEM-BIOL INTERACT, V107, P185, DOI 10.1016/S0009-2797(97)00079-3; Chang FC, 1999, BIOCHEMISTRY-US, V38, P7168, DOI 10.1021/bi982203u; Clark W.M., 1960, OXIDATION REDUCTION, P184; Cunane LM, 2000, J MOL BIOL, V295, P357, DOI 10.1006/jmbi.1999.3290; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fraaije MW, 1998, EUR J BIOCHEM, V253, P712, DOI 10.1046/j.1432-1327.1998.2530712.x; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; FROST JW, 1980, J AM CHEM SOC, V102, P7157, DOI 10.1021/ja00543a069; GHISLA S, 1979, J BIOL CHEM, V254, P662; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GIBSON T, 1984, THESIS U CAMBRIDGE U; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Mancini-Samuelson GJ, 1998, BIOCHEMISTRY-US, V37, P14605, DOI 10.1021/bi981414w; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; MCINTIRE W, 1984, BIOCHEM J, V224, P617, DOI 10.1042/bj2240617; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Miller JR, 1999, J BIOL CHEM, V274, P23515, DOI 10.1074/jbc.274.33.23515; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V3, P557; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PALFEY BA, 1994, BIOCHEMISTRY-US, V33, P1545, DOI 10.1021/bi00172a035; Pollegioni L, 1997, J BIOL CHEM, V272, P4924, DOI 10.1074/jbc.272.8.4924; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; van den Heuvel RHH, 1998, J BACTERIOL, V180, P5646, DOI 10.1128/JB.180.21.5646-5651.1998; VISSER AJWG, 1995, BBA-BIOENERGETICS, V1229, P381, DOI 10.1016/0005-2728(95)00026-F; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	46	37	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14799	14808		10.1074/jbc.275.20.14799	http://dx.doi.org/10.1074/jbc.275.20.14799			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809721	hybrid, Green Published			2022-12-25	WOS:000087128300006
J	Vasavada, RC; Garcia-Ocana, A; Zawalich, WS; Sorenson, RL; Dann, P; Syed, M; Ogren, L; Talamantes, F; Stewart, AF				Vasavada, RC; Garcia-Ocana, A; Zawalich, WS; Sorenson, RL; Dann, P; Syed, M; Ogren, L; Talamantes, F; Stewart, AF			Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; PANCREATIC-ISLETS; INSULIN-SECRETION; RAT PANCREAS; GROWTH; MOUSE; REPLICATION; OVEREXPRESSION; HYPERPLASIA; PREGNANCY	The factors that regulate pancreatic beta cell proliferation are not well defined. In order to explore the role of murine placental lactogen (PL)-I (mPL-I) in islet mass regulation in vivo, we developed transgenic mice in which mPL-I is targeted to the beta cell using the rat insulin II promoter. Rat insulin II-mPL-I mice displayed both fasting and postprandial hypoglycemia (71 and 105 mg/dl, respectively) as compared with normal mice (92 and 129 mg/dl; p < 0.00005 for both). Plasma insulin concentrations were inappropriately elevated, and insulin content in the pancreas was increased 2-fold. Glucose-stimulated insulin secretion by perifused islets was indistinguishable from controls at 7.5, 15, and 20 mM glucose. Beta cell proliferation rates were twice normal (p = 0.0005). This hyperplasia, together with a 20% increase in beta cell size, resulted in a a-fold increase in islet mass (p = 0.0005) and a 1.45-fold increase in islet number (p = 0.0012). In mice, murine PL-I is a potent islet mitogen, is capable of increasing islet mass, and is associated with hypoglycemia over the long term. It can be targeted to the beta cell using standard gene targeting techniques. Potential exists for beta cell engineering using this strategy.	Univ Pittsburgh, Med Ctr, Sch Med, Div Endocrinol, Pittsburgh, PA 15213 USA; Yale Univ, Sch Nursing, New Haven, CT 06520 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Yale University; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Santa Cruz	Vasavada, RC (corresponding author), Univ Pittsburgh, Med Ctr, Sch Med, Div Endocrinol, BST E-1140,3550 Terrace St, Pittsburgh, PA 15213 USA.				NIDDK NIH HHS [DK 55023, DK 47168, DK 41230] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055023, R01DK041230, R01DK047168] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; COLOSI P, 1988, ENDOCRINOLOGY, V123, P2662, DOI 10.1210/endo-123-6-2662; DAVALLI AM, 1995, DIABETES, V44, P104, DOI 10.2337/diabetes.44.1.104; Efrat S, 1996, DIABETES REV, V4, P224; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; KORC M, 1993, J CLIN INVEST, V92, P1113, DOI 10.1172/JCI116677; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; MONTANA E, 1994, J CLIN INVEST, V93, P1577, DOI 10.1172/JCI117137; OGREN L, 1989, ENDOCRINOLOGY, V125, P2253, DOI 10.1210/endo-125-5-2253; Otonkoski T, 1996, ENDOCRINOLOGY, V137, P3131, DOI 10.1210/en.137.7.3131; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; Porter SE, 1998, ENDOCRINOLOGY, V139, P3743, DOI 10.1210/en.139.9.3743; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Sorenson RL, 1997, HORM METAB RES, V29, P301, DOI 10.1055/s-2007-979040; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; SWENNE I, 1985, DIABETES, V34, P803, DOI 10.2337/diabetes.34.8.803; Vasavada RC, 1996, J BIOL CHEM, V271, P1200, DOI 10.1074/jbc.271.2.1200; Vasavada RC, 1998, RECENT PROG HORM RES, V53, P305; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; ZAWALICH WS, 1991, BIOCHEM J, V278, P49, DOI 10.1042/bj2780049	32	164	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15399	15406		10.1074/jbc.275.20.15399	http://dx.doi.org/10.1074/jbc.275.20.15399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809775	hybrid			2022-12-25	WOS:000087128300085
J	Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP				Midgley, CA; Desterro, JMP; Saville, MK; Howard, S; Sparks, A; Hay, RT; Lane, DP			An N-terminal p14(ARF) peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo	ONCOGENE			English	Article						p53 tumour suppressor; Mdm2; p14(ARF); ubiquitination; protein stability; transcriptional activation	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; NUCLEAR EXPORT; DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; MAMMALIAN-CELLS; STABILIZES P53; HUMAN SARCOMAS	The p53 tumour suppressor protein is down-regulated by the action of Mdm2, which targets p53 for rapid degradation by the ubiquitin-proteasome pathway. The p14(ARF) protein is also a potent tumour suppressor that acts by binding to Mdm2 and blocking Mdm2-dependent p53 degradation and transcriptional silencing, We have screened a series of overlapping synthetic peptides derived from the p14(ARF) protein sequence and found that a peptide corresponding to the first 20 amino acids of ARF (Peptide 3) could bind human Mdm2, The binding site for Peptide 3 on Mdm2 was determined by deletion mapping and lies adjacent to the binding site of the anti-Mdm2 antibody 2A10, which on microinjection into cells can activate p53-dependent transactivation of a reporter plasmid, To determine whether Peptide 3 could similarly activate p53, we expressed a fusion of green fluorescent protein and Peptide 3 in MCF7 and U-2 OS cells and were able to demonstrate induction of p53 protein and p53-dependent transcription. Peptide 3 was able to block in vitro ubiquitination of p53 mediated by Mdm2, Small peptides which are sufficient to block degradation of p53 could provide therapeutic agents able to restore p53-dependent cell death pathways in tumours that retain wild-type p53 expression.	Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9TS, Fife, Scotland	University of Dundee; University of St Andrews	Lane, DP (corresponding author), Univ Dundee, Dept Biochem, Canc Res Campaign Cell Transformat Grp, WTB-MSI Bldg,Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Hay, Ronald T/F-9338-2011	Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MAKI CG, 1996, CANCER RES, V56, P2694; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; VOJTESEK B, 1993, J CELL SCI, V105, P607; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	65	227	238	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2312	2323		10.1038/sj.onc.1203593	http://dx.doi.org/10.1038/sj.onc.1203593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822382				2022-12-25	WOS:000086974300006
J	Boutillier, AL; Trinh, E; Loeffler, JP				Boutillier, AL; Trinh, E; Loeffler, JP			Caspase-dependent cleavage of the retinoblastoma protein is an early step in neuronal apoptosis	ONCOGENE			English	Article						apoptosis; cerebellar neuron; retinoblastoma protein; caspase; CPP32	CEREBELLAR GRANULE NEURONS; ICE-LIKE PROTEASE; TUMOR-SUPPRESSOR PROTEIN; CELL-DEATH; ICE/CED-3 PROTEASE; SIGNALING PATHWAY; MDM2 ONCOPROTEIN; FAMILY PROTEINS; GENE-PRODUCT; DEGRADATION	Rb-deficient embryos (Rb-/-) show abnormal degeneration of neurons and die at mid-gestation, suggesting that RE may protect against apoptosis. Having previously shown that cyclin D1 accumulates during K+-induced apoptosis of granule neurons, we chose to investigate the role of RB under these conditions. We show that RB is cleaved in its C-terminus during the onset of neuronal apoptosis. Caspase 3-like activity increases following K+ deprivation and the time course correlates with RB cleavage and apoptosis, Although the use of a specific caspase 3-like inhibitor (z-DEBD.fmk) delays RB cleavage and reduces DNA fragmentation, data implicate other caspases in these processes. However K+ deprivation induces a gradual production of the active p20 subunit of caspase 3 (CPP32) that coincides with RB disappearance at the cellular level. Nuclear detection of a transfected HA-tagged caspase cleavage-resistant RB mutant (DEAG/D to DEAA/D) revealed a significant decrease in apoptosis of neurons expressing the RB mutant (less than 5%) relative to the wild type form of RB (40%) during K+ deprivation. Taken together, these data show that caspase-dependent cleavage of RB is an early permissive step of the apoptosis-inducing signaling pathway in neurons, They indicate a major role of RB in neuronal protection.	CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), CNRS, UMR 7519, 21 Rue Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Armstrong RC, 1997, J NEUROSCI, V17, P553; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DOU QP, 1998, FRONT BIOSCI, V3, P419; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GALLO V, 1987, J NEUROSCI, V7, P2203; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KONDO S, 1995, ONCOGENE, V10, P2001; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Lynch T, 1997, MOL PSYCHIATR, V2, P227, DOI 10.1038/sj.mp.4000242; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulz JB, 1996, J NEUROSCI, V16, P4696; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; Sohm F, 1999, ONCOGENE, V18, P2762, DOI 10.1038/sj.onc.1202634; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	56	51	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2171	2178		10.1038/sj.onc.1203532	http://dx.doi.org/10.1038/sj.onc.1203532			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822366				2022-12-25	WOS:000086974100001
J	Fuki, IV; Iozzo, RV; Williams, KJ				Fuki, IV; Iozzo, RV; Williams, KJ			Perlecan heparan sulfate proteoglycan - A novel receptor that mediates a distinct pathway for ligand catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	69th Annual Scientific Session of the American-Heart-Association	NOV 09-16, 1996	NEW ORLEANS, LOUISIANA	Amer Heart Assoc, Hoechst Marion Roussel Inc, Kansas City			LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-BETA; COLON-CARCINOMA-CELLS; INTRACELLULAR DEGRADATIVE PATHWAYS; MOUSE PERITONEAL-MACROPHAGES; APOLIPOPROTEIN-E; FIBROBLAST GROWTH; REMNANT LIPOPROTEINS; CHYLOMICRON REMNANTS; IN-VITRO	Cell surface heparan sulfate proteoglycans (HSPGs) participate in the catabolism of many physiologically important ligands. We previously reported that syndecan HSPGs directly mediate endocytosis, independent of coated pits. We now studied perlecan, a major cell surface HSPG genetically distinct from syndecans. Cells expressing perlecan but no other proteoglycans bound, internalized, and degraded atherogenic lipoproteins enriched in lipoprotein lipase. Binding was blocked by heparitinase, and degradation by chloroquine. Antibodies against beta(1) integrins reduced initial ligand binding, consistent with their roles as cell surface attachment sites for perlecan. By several criteria, catabolism via perlecan was distinct from either coated pits or the syndecan pathway. The kinetics of internalization (t(1/2) = 6 h) and degradation (t(1/2) similar to 18 h) were remarkably slow, unlike the other pathways. Blockade of the low density lipoprotein receptor-related protein did not slow perlecan-dependent internalization. Internalization via perlecan was inhibited by genistein but unaffected by cytochalasin D, a pattern distinct from coated pits or syndecan-mediated endocytosis. Finally, we examined cooperation between perlecan and low density lipoprotein receptors and found limited synergy. Our results demonstrate that perlecan mediates internalization and lysosomal delivery that is kinetically and biochemically distinct from other known uptake pathways and is consistent with a very slow component of HSPG-dependent ligand processing found in vitro and in vivo.	Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Williams, KJ (corresponding author), Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Dept Med, Jefferson Alumni Hall,Rm 349,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NHLBI NIH HHS [HL38956, HL58884, HL56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038956, R01HL058884, P50HL056984, R29HL038956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BEISIEGEL U, 1994, ANN NY ACAD SCI, V737, P53, DOI 10.1111/j.1749-6632.1994.tb44301.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brown CT, 1999, J BIOL CHEM, V274, P7111, DOI 10.1074/jbc.274.11.7111; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; de Yebenes EG, 1999, J NEUROCHEM, V73, P812, DOI 10.1046/j.1471-4159.1999.0730812.x; DODGE GR, 1990, J BIOL CHEM, V265, P18023; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Evanko SP, 1998, AM J PATHOL, V152, P533; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; FUKI IV, 1996, CIRCULATION S1, V94, P698; FUKI IV, 2000, IN PRESS BIOCH J; GLEIZES PE, 1995, EUR J CELL BIOL, V66, P47; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; JI ZS, 1995, J LIPID RES, V36, P583; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUTON F, 1994, J IMMUNOL, V153, P63; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1999, J LIPID RES, V40, P1; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIRANDA AF, 1974, J CELL BIOL, V62, P406, DOI 10.1083/jcb.62.2.406; MORTIMER BC, 1995, J BIOL CHEM, V270, P28767, DOI 10.1074/jbc.270.48.28767; MULDER M, 1993, J BIOL CHEM, V268, P9369; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Panzenboeck U, 1997, J LIPID RES, V38, P239; QUARTO N, 1994, J CELL SCI, V107, P3201; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; RESCAN PY, 1993, AM J PATHOL, V142, P199; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Seo T, 1997, J LIPID RES, V38, P765; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; SPADY DK, 1992, SEMIN LIVER DIS, V12, P373, DOI 10.1055/s-2008-1040407; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; Tumova S, 1997, J BIOL CHEM, V272, P9078; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; WILLIAMS KJ, 1997, CURR OPIN LIPIDOL, V8, P252; Williams KJ, 1991, CIRCULATION S2, V84, P566; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Windler E, 1996, HEPATOLOGY, V24, P344; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	82	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25742	25750		10.1074/jbc.M909173199	http://dx.doi.org/10.1074/jbc.M909173199			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10818109	hybrid			2022-12-25	WOS:000088849400090
J	Gerber, D; Shai, Y				Gerber, D; Shai, Y			Insertion and organization within membranes of the delta-endotoxin pore-forming domain, helix 4-loop-helix 5, and inhibition of its activity by a mutant helix 4 peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THURINGIENSIS INSECTICIDAL PROTEINS; BRUSH-BORDER MEMBRANE; BACILLUS-THURINGIENSIS; PHOSPHOLIPID-MEMBRANES; CHANNEL FORMATION; LIPID BILAYERS; MANDUCA-SEXTA; ION-CHANNEL; CRYSTAL-STRUCTURE; ALPHA-5 SEGMENT	The pore-forming domain of Bacillus thuringiensis Cry1Ac insecticidal protein comprises of a seven alpha-helix bundle (alpha 1-alpha 7). According to the "umbrella model," alpha 4 and alpha 5 helices form a hairpin structure thought to be inserted into the membrane upon binding. Here, we have synthesized and characterized the hairpin domain, alpha 4-loop-alpha 5, its alpha 4 and alpha 5 helices, as well as mutant alpha 4 peptides based on mutations that increased or decreased toxin toxicity. Membrane permeation studies revealed that the alpha 4-loop-alpha 5 hairpin is extremely active compared with the isolated helices or their mixtures, indicating the complementary role of the two helices and the need for the loop for efficient insertion into membranes. Together with spectrofluorometric studies, we provide direct evidence for the role of alpha 4-loop-alpha 5 as the membrane-inserted pore-forming hairpin in which alpha 4 and alpha 5 line the lumen of the channel and alpha 5 also participates in the oligomerization of the toxin. Strikingly, the addition of the active alpha 4 mutant peptide completely inhibits alpha 4-loop-alpha 5 pore formation, thus providing, to our knowledge, the first example that a mutated helix within a pore can function as an "immunity protein" by directly interacting with the segments that form the pore. This presents a potential means of interfering with the assembly and function of other membrane proteins as well.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; Aronson AI, 1999, APPL ENVIRON MICROB, V65, P2503; ARONSON AI, 1995, J BACTERIOL, V177, P4059, DOI 10.1128/jb.177.14.4059-4065.1995; BAYLEY H, 1997, CURR BIOL, V7, P763; BenEfraim I, 1997, BIOPHYS J, V72, P85, DOI 10.1016/S0006-3495(97)78649-1; BenEfraim I, 1996, PROTEIN SCI, V5, P2287, DOI 10.1002/pro.5560051115; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; Cabiaux V, 1997, INT J BIOL MACROMOL, V21, P285, DOI 10.1016/S0141-8130(97)00078-0; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; Dean DH, 1996, GENE, V179, P111, DOI 10.1016/S0378-1119(96)00442-8; Engelman DM, 1996, SCIENCE, V274, P1850, DOI 10.1126/science.274.5294.1850; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GAZIT E, 1994, BIOCHEM J, V304, P895, DOI 10.1042/bj3040895; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; Kumar ASM, 1999, J BACTERIOL, V181, P6103; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Rajamohan F, 1998, PROG NUCLEIC ACID RE, V60, P1, DOI 10.1016/S0079-6603(08)60887-9; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SCHESSER JH, 1977, APPL ENVIRON MICROB, V33, P878, DOI 10.1128/AEM.33.4.878-880.1977; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; Uawithya P, 1998, BIOCHEM MOL BIOL INT, V44, P825; VACHON V, 1995, J MEMBRANE BIOL, V148, P57, DOI 10.1007/BF00234156; WU D, 1992, J BIOL CHEM, V267, P2311; ZHANG YL, 1993, J BIOL CHEM, V268, P10176; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	51	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23602	23607		10.1074/jbc.M002596200	http://dx.doi.org/10.1074/jbc.M002596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811807	hybrid			2022-12-25	WOS:000088564200028
J	Kingsbury, DJ; Griffin, TA; Colbert, RA				Kingsbury, DJ; Griffin, TA; Colbert, RA			Novel propeptide function in 20 S proteasome assembly influences beta subunit composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE FORMATION; INTERFERON-GAMMA; PROTEIN ACTIVATOR; CELL-PROTEINS; COMPLEX; MATURATION; IDENTIFICATION; GENERATION; PEPTIDES; GENES	The assembly of eukaryotic 20 S proteasomes involves the formation of half-proteasomes where precursor beta-type subunits gather in position on an alpha-subunit ring, followed by the association of two half-proteasomes and beta-subunit processing. In vertebrates three additional beta-subunits (beta 1i/LMP2, beta 2iIMECL1, and beta 5i/LMP7) can be synthesized and substituted for constitutive homologues (beta 1/delta, beta 2/Z, and beta 5/X) to yield immunoproteasomes, which are important for generating certain antigenic peptides. We have shown previously that when all six beta-subunits are present, cooperative assembly mechanisms limit the diversity of proteasome populations. Specifically, LMP7 is incorporated preferentially over X into preproteasomes containing LMP2 and MECL1. We show here that the LMP7 propeptide is responsible for this preferential incorporation, and it also enables LMP7 to incorporate into proteasomes containing delta and Z. In contrast, the X propeptide restricts incorporation to proteasomes with delta and Z, Furthermore, we demonstrate that the LMP7 propeptide can function in trans when expressed on LMP2, and that its NH2-terminal and mid-regions are particularly critical for function, In addition to identifying a novel propeptide function, our results raise the possibility that one consequence of LMP7 incorporation into both immunoproteasomes and delta/Z proteasomes may be to increase the diversity of antigenic peptides that can be generated.	Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Colbert, RA (corresponding author), Childrens Hosp, Med Ctr, William S Rowe Div Rheumatol, Cincinnati, OH 45229 USA.				NIAMS NIH HHS [AR02013] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002013] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BROWN MG, 1993, J IMMUNOL, V151, P1193; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GRIFFIN TA, 2000, IN RPESS MOL CELL BI, V3; Groettrup M, 1997, P NATL ACAD SCI USA, V94, P8970, DOI 10.1073/pnas.94.17.8970; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; Macagno A, 1999, EUR J IMMUNOL, V29, P4037, DOI 10.1002/(SICI)1521-4141(199912)29:12<4037::AID-IMMU4037>3.0.CO;2-T; Monaco JJ, 1995, ANNU REV GENET, V29, P729, DOI 10.1146/annurev.ge.29.120195.003501; Nandi D, 1996, J IMMUNOL, V156, P2361; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; Schmidt M, 1999, J MOL BIOL, V288, P117, DOI 10.1006/jmbi.1999.2660; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; VAN KL, 1994, IMMUNITY, V1, P533; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; Zuhl F, 1997, FEBS LETT, V418, P189, DOI 10.1016/S0014-5793(97)01370-7	43	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24156	24162		10.1074/jbc.M001742200	http://dx.doi.org/10.1074/jbc.M001742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816564	hybrid			2022-12-25	WOS:000088564200101
J	Vostrov, AR; Quitschke, WW				Vostrov, AR; Quitschke, WW			Plasma hyaluronan-binding protein is a serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; PRECURSOR PROMOTER; TRANSCRIPTIONAL ACTIVITY; TRANSGENIC MICE; CTCF; PURIFICATION; EXPRESSION; SEQUENCES; DOMAIN; REPRESSOR	CTCF is an essential factor for optimal transcription from the amyloid beta-protein precursor promoter. A proteolytic activity detected in bovine, rabbit, horse, and human serum cleaves CTCF at three major sites, resulting in a modified mobility shift pattern of the fragments that retain DNA binding ability. The protease was purified to electrophoretic homogeneity, partially sequenced, and identified as the plasma hyaluronan-binding protein. The proteolytic activity was selectively abolished by various serine protease inhibitors, including the Kunitz-type protease inhibitor domain of amyloid beta-protein precursor. Reduction with beta-mercaptoethanol showed that the 70-kDa protein consists of two polypeptides with apparent molecular masses of 44 and 30 kDa. The serine protease domain was localized to the 30-kDa polypeptide as determined by [H-3]diisopropyl-fluorophosphate binding.	SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quitschke, WW (corresponding author), SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30994] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fox NW, 1997, BIOCHEM BIOPH RES CO, V240, P759, DOI 10.1006/bbrc.1997.7728; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHNE AC, 1993, J MOL BIOL, V232, P747, DOI 10.1006/jmbi.1993.1428; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Maniatis T., 1989, MOL CLONING LAB MANU; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; Quitschke WW, 1996, J BIOL CHEM, V271, P22231, DOI 10.1074/jbc.271.36.22231; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WANG J, 1987, NUCLEIC ACIDS RES, V15, P10105, DOI 10.1093/nar/15.24.10105; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x	19	7	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22978	22985		10.1074/jbc.M904640199	http://dx.doi.org/10.1074/jbc.M904640199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816595	hybrid			2022-12-25	WOS:000088419400052
J	Wang, W; Nagashima, M; Schneider, M; Morser, J; Nesheim, M				Wang, W; Nagashima, M; Schneider, M; Morser, J; Nesheim, M			Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; PROTEIN-C; COFACTOR ACTIVITY; PROCARBOXYPEPTIDASE-B; HUMAN PLASMA; TAFI; COAGULATION; SPECIFICITY; MECHANISM; RESIDUES	Deletion and point mutants of soluble thrombomodulin were used to compare and contrast elements of primary structure required for the activation of thrombin-activable fibrinolysis inhibitor (TAFI) and protein C. The smallest mutant capable of efficiently promoting TAFI activation contained residues including the c-loop of epidermal growth factor-3 (EGF3) through EGF6. This mutant is 13 residues longer than the smallest mutant that functioned well with protein C; the latter consisted of residues from the interdomain loop connecting EGF3 and EGF4 through EGF6. Alanine point mutants showed no loss of function in protein C activation for mutations within the c-loop of EGF3. In TAFI activation, however, alanine mutations cause a 50% reduction at Tyr-337, 67% reductions at Asp-338 and Leu-339, and 90% or greater reductions at Val-340, Asp-341, and Glu-343. A mutation at Asp-349 in the peptide connecting EGF3 to EGF4 eliminated activity against both TAFI and protein C. Oxidation of Met-388 in the peptide connecting EGF5 to EGF6 reduced the rate of protein C activation by 80% but marginally, if at all, affected the rate of TAFI activation. Mutation at Phe-376 severely reduced protein C activation but only marginally influenced that of TAFI. A Q387P mutation, however, severely reduced both activities. TAFI activation was shown to be Ca2+-dependent. The response, unlike that of protein C, was monotonic and was half-maximal at 0.25 mM Ca2+. Like protein C activation, TAFI activation was eliminated by a monoclonal antibody directed at the thrombin-binding domain (EGF5) but was not affected by one directed at EGF2. Thus, elements of structure in the thrombin-binding domain are needed for the activation of both protein C and TAFI, but more of the primary structure is needed for TAFI activation. In addition, some residues are needed for one of the reactions but not the other.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Berlex BioSci, Richmond, CA 94804 USA	Queens University - Canada; Queens University - Canada	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NHLBI NIH HHS [HL46703-6] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; Delorme MA, 1996, THROMB HAEMOSTASIS, V75, P747; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30, DOI 10.1111/j.1749-6632.1991.tb43689.x; ESMON NL, 1982, J BIOL CHEM, V257, P859; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HAYASHI T, 1990, J BIOCHEM-TOKYO, V108, P874, DOI 10.1093/oxfordjournals.jbchem.a123295; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Kokame K, 1998, J BIOL CHEM, V273, P12135, DOI 10.1074/jbc.273.20.12135; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LIGHT DR, 1999, EUR J BIOCHEM, V262, P1; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; Nesheim ME, 1999, FIBRINOLYSIS PROTEOL, V13, P72, DOI 10.1016/S0268-9499(99)90082-6; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; SADLER JE, 1993, HAEMOSTASIS, V23, P183; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TSIANG M, 1992, J BIOL CHEM, V267, P6164; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; Wang W., 1998, Fibrinolysis and Proteolysis, V12, P11; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; YE J, 1992, J BIOL CHEM, V267, P11023	29	82	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22942	22947		10.1074/jbc.M001760200	http://dx.doi.org/10.1074/jbc.M001760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801821	hybrid			2022-12-25	WOS:000088419400047
J	Duconge, F; Di Primo, C; Toulme, JJ				Duconge, F; Di Primo, C; Toulme, JJ			Is a closing "GA pair" a rule for stable loop-loop RNA complexes?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; IN-VITRO SELECTION; DIMERIZATION INITIATION SITE; KISSING HAIRPIN COMPLEX; COLE1 ROM PROTEIN; HIV-1 GENOMIC RNA; CRYSTAL-STRUCTURE; PRIMER FORMATION; MELTING CURVES; VIRUS GENOME	RNA hairpin aptamers specific for the trans-activation-responsive (TAR) RNA element of human immunodeficiency virus type 1 were identified by in vitro selection (Duconge, F., and Toulme, J. J. (1999) RNA 5, 1605-1614), The high affinity sequences selected at physiological magnesium concentration (3 mM) were shown to form a loop-loop complex with the targeted TAR RNA. The stability of this complex depends on the aptamer loop closing "GA pair" as characterized by preliminary electrophoretic mobility shift assays. Thermal denaturation monitored by UV-absorption spectroscopy and binding kinetics determined by surface plasmon resonance show that the GA pair is crucial for the formation of the TAR-RNA aptamer complex. Both thermal denaturation and surface plasmon resonance experiments show that any other "pairs" leads to complexes whose stability decreases in the order AG > GG > GU > AA > GC > UA >> CA, CU. The binding kinetics indicate that stability is controlled by the off-rate rather than by the on-rate. Comparison with the complex formed with the TAR* hairpin, a rationally designed TAR RNA ligand (Chang, K. Y,, and Tinoco, I. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8705-8709), demonstrates that the GA pair is a key determinant which accounts for the 50-fold increased stability of the TAR-aptamer complex (K-d = 2.0 nM) over the TAR-TAR* one (K-d = 92.5 nM) at physiological concentration of magnesium. Replacement of the wild-type GC pair next to the loop of RNA I' by a GA pair stabilizes the RNA I'-RNA II' loop-loop complex derived from the one involved in the control of the ColE1 plasmid replication. Thus, the GA pair might be the preferred one for stable loop-loop interactions.	Univ Victor Segalen, Inst Federat Rech Pathol Infect, INSERM, U386, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Toulme, JJ (corresponding author), Univ Victor Segalen, Inst Federat Rech Pathol Infect, INSERM, U386, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean-jacques.toulme@bordeaux.inserm.fr	Di primo, Carmelo/M-6984-2018; Duconge, Frederic/C-6729-2012	Di primo, Carmelo/0000-0002-0509-8399; Duconge, Frederic/0000-0002-8595-0050; Toulme, Jean-jacques/0000-0002-8432-5034				Auffinger P, 1999, J MOL BIOL, V292, P467, DOI 10.1006/jmbi.1999.3080; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Biswas R, 1997, J MOL BIOL, V270, P511, DOI 10.1006/jmbi.1997.1118; Blight KJ, 1997, J VIROL, V71, P7345, DOI 10.1128/JVI.71.10.7345-7352.1997; Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730; Boiziau C, 1997, ANTISENSE NUCLEIC A, V7, P369, DOI 10.1089/oli.1.1997.7.369; Breslauer K J, 1994, Methods Mol Biol, V26, P347; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021; Crouch RJ, 1999, METH MOL B, V118, P143; Dirheimer G.K.G., 1995, TRNA STRUCTURE BIOSY; Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318; DUCONGE F, 1999, THESIS U V SEGALEN B; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; Ellington A D, 1995, Biotechnol Annu Rev, V1, P185, DOI 10.1016/S1387-2656(08)70052-8; Ennifar E, 1999, STRUCTURE, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; Heus HA, 1997, J MOL BIOL, V271, P147, DOI 10.1006/jmbi.1997.1158; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; Jestin JL, 1997, EMBO J, V16, P2945, DOI 10.1093/emboj/16.10.2945; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Lee AJ, 1998, STRUCTURE, V6, P993, DOI 10.1016/S0969-2126(98)00101-4; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; LEONTIS NB, 2000, IN PRESS Q REV BIOPH; MASUKATA H, 1986, CELL, V44, P125, DOI 10.1016/0092-8674(86)90491-5; Mishra RK, 1996, P NATL ACAD SCI USA, V93, P10679, DOI 10.1073/pnas.93.20.10679; MISHRA RK, 1994, CR ACAD SCI III-VIE, V317, P977; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; Scarabino D, 1999, EMBO J, V18, P4571, DOI 10.1093/emboj/18.16.4571; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; SERRA MJ, 1993, NUCLEIC ACIDS RES, V21, P3845, DOI 10.1093/nar/21.16.3845; TINOCO I, 1993, RNA WORLD; TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; Westhof E, 2000, STRUCTURE, V8, pR55, DOI 10.1016/S0969-2126(00)00112-X	46	69	77	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21287	21294		10.1074/jbc.M002694200	http://dx.doi.org/10.1074/jbc.M002694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801857	hybrid			2022-12-25	WOS:000088230600045
J	Wilson, CM; Farmery, MR; Bulleid, NJ				Wilson, CM; Farmery, MR; Bulleid, NJ			Pivotal role of calnexin and mannose trimming in regulating the endoplasmic reticulum-associated degradation of major histocompatibility complex class I heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; MONOCLONAL-ANTIBODIES; SECRETORY PATHWAY; QUALITY-CONTROL; PROTEASOME; ER; MEMBRANE; CYTOSOL; GLYCOPROTEIN; TRANSPORT	We have established a mammalian semipermeabilized cell system that faithfully reconstitutes the proteasome-mediated degradation of major histocompatibility complex Class I heavy chain. We show that degradation required unfolding of the protein and was cytosol- and ATP-dependent and that dislocation and degradation required proteasome activity. When the interaction of heavy chain with calnexin was prevented, the rate of degradation was accelerated, suggesting that an interaction with calnexin stabilized heavy chain. Stabilization of heavy chain to degradation was also achieved either by preventing mannose trimming or by removal of the N-linked glycosylation site. This demonstrates that glycosylation and mannose trimming are required to ensure degradation of heavy chain. When degradation or mannose trimming was inhibited, heavy chain formed a prolonged interaction with immunoglobulin heavy chain binding protein, ERp57, and protein disulfide isomerase. Taken together, these results indicate that calnexin association and mannose trimming provide a mechanism to regulate the folding, assembly, and degradation of glycoproteins entering the secretory pathway.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Wilson, Cornelia/0000-0001-6584-6179; Bulleid, Neil/0000-0002-9839-5279				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; STAM NJ, 1986, J IMMUNOL, V137, P2299; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	40	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21224	21232		10.1074/jbc.M000567200	http://dx.doi.org/10.1074/jbc.M000567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801790	hybrid			2022-12-25	WOS:000088230600037
J	Farmery, MR; Allen, S; Allen, AJ; Bulleid, NJ				Farmery, MR; Allen, S; Allen, AJ; Bulleid, NJ			The role of ERp57 in disulfide bond formation during the assembly of major histocompatibility complex class I in a synchronized semipermeabilized cell translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REDUCTASE ERP57; PEPTIDE BINDING; MONOCLONAL-ANTIBODIES; LOADING COMPLEX; ALPHA-2 DOMAIN; MOLECULES; CALNEXIN; TAP; CALRETICULIN; PROTEINS	We have established a semipermeabilized cell system that reproduces the folding and assembly of a major histocompatibility complex (MHC) class I complex as it would occur in the intact cell. The translation of the MHC class I heavy chain (HLA-B27) in this system was synchronized allowing the folding and assembly of polypeptide chains synthesized within a short time frame to be analyzed. This has enabled us to dissect the time course of interaction of both disulfide and nondisulfide-bonded heavy chain with various molecular chaperones during its assembly in a functionally intact endoplasmic reticulum, The results demonstrate that unassembled, nondisulfide-bonded forms of heavy chain interact initially with calnexin, A later and more prolonged interaction of calreticulin, specifically with assembled, disulfide-bonded heavy chain, highlights distinct differences in the roles of these two proteins in the assembly of MHC class I molecules. We also demonstrate that the thiol-dependent reductase ERp57 initially interacts with nondisulfide-bonded heavy chain, but this rapidly becomes disulfide-bonded and indicates that heavy chain folding occurs during its interaction with ERp57, In addition, we also confirm a direct interaction between MHC class I heavy chain and tapasin, emphasizing the role that this protein plays in the later stages of MHC class I assembly.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.			Bulleid, Neil/0000-0002-9839-5279				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HILL A, 1993, IMMUNOGENETICS, V37, P95; HOWELL DN, 1985, J IMMUNOL, V134, P971; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; RUPP K, 1994, J BIOL CHEM, V269, P2501; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; STAM NJ, 1986, J IMMUNOL, V137, P2299; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Tan L, 1997, J IMMUNOL METHODS, V209, P25, DOI 10.1016/S0022-1759(97)00142-7; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; WANG H, 1994, J BIOL CHEM, V269, P22276; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679	30	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14933	14938		10.1074/jbc.275.20.14933	http://dx.doi.org/10.1074/jbc.275.20.14933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809738	hybrid			2022-12-25	WOS:000087128300024
J	Iwabuchi, K; Zhang, YM; Handa, K; Withers, DA; Sinay, P; Hakomori, S				Iwabuchi, K; Zhang, YM; Handa, K; Withers, DA; Sinay, P; Hakomori, S			Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to lyso-GM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA B16 CELLS; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; ADHESION; SRC; GANGLIOSIDE; SURFACE; PROTEIN; GM3; GLYCOSPHINGOLIPIDS	GM3 ganglioside at the surface of mouse melanoma B16 cells is clustered and organized with signal transducer molecules c-Src, Rho A, and focal adhesion kinase (FAR) to form a membrane unit separable from caveolae, which are enriched in cholesterol and caveolin but do not contain GM3 or the above three signal transducers, The GMS-enriched membrane units are involved in GM3-dependent cell adhesion coupled with activation of c-Src, Rho A, and FAK and are termed the "glycosphingolipid signaling domain" or the "glycosignaling domain" (GSD), In order to assess the essential components that display GSD function, membranes with properties similar to those of GSD were reconstituted using GM3, sphingomyelin, and c-Src, with or without other lipid components. The reconstituted membrane thus prepared displayed GM3-dependent adhesion to plates coated with Gg3 or anti-GM3 antibody, resulting in enhanced c-Src phosphorylation (c-Src phosphorylation response). This response in reconstituted membrane depends on GM3 concentration and was not observed when GM3 was absent or replaced with other gangliosides GM1 or GD1a, or with LacCer, The GM3-dependent c-Src phosphorylation response was enhanced when cholesterol and phosphatidylcholine were added. Although GM3, sphingomyelin, and c-Src are essential for GSD function, a small quantity of cholesterol and phosphatidylcholine may act as an auxiliary factor to stabilize membrane. GSD function in terms of GM3-dependent adhesion and signaling was blocked in the presence of lyso-GM3 or its analogue but not psychosine, lactosyl-sphingosine, or lyso-phosphatidylcholine. Such susceptibility of reconstituted GSD to lyso-GM3 and other lyse compounds is the same as GSD of original B16 cells. Thus, functional organization of the reconstituted membrane closely simulates that of GSD in B16 cells, which is based on clustered GM3 organized with c-Src as the essential components.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Ecole Normale Super, CNRS, UMR 8642, Dept Chim, F-75231 Paris 05, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			NCI NIH HHS [CA80054, OIG CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080054, R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; DOHI T, 1988, CANCER RES, V48, P5680; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KLENK E, 1960, Z VERDAUUNGS STOFFWE, V20, P180; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; RACKER E, 1985, RECONSTITUTIONS TRAN; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SEYAMA Y, 1974, J BIOCHEM-TOKYO, V75, P837, DOI 10.1093/oxfordjournals.jbchem.a130455; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; TAKETOMI T, 1963, J BIOCHEM-TOKYO, V54, P444, DOI 10.1093/oxfordjournals.jbchem.a127811; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YU S, 1997, GLYCOCONJ J S, V14, pS53; Zhang YM, 2000, BIOCHEMISTRY-US, V39, P2459, DOI 10.1021/bi991882l; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	33	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15174	15181		10.1074/jbc.275.20.15174	http://dx.doi.org/10.1074/jbc.275.20.15174			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809752	hybrid			2022-12-25	WOS:000087128300056
J	Souza, RL; Green-Willms, NS; Fox, TD; Tzagoloff, A; Nobrega, FG				Souza, RL; Green-Willms, NS; Fox, TD; Tzagoloff, A; Nobrega, FG			Cloning and characterization of COX18, a Saccharomyces cerevisiae PET gene required for the assembly of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; NUCLEAR GENE; ESCHERICHIA-COLI; MESSENGER-RNA; YEAST; MITOCHONDRIAL; PROTEIN; TRANSLATION; EXPRESSION; SUBUNIT	Nuclear mutants of Saccharomyces cerevisiae assigned to complementation group G34 are respiratory-deficient and lack cytochrome oxidase activity and the characteristic spectral peaks of cytochromes a and a,. The corresponding gene was cloned by complementation, sequenced, and identified as reading frame YGR062C on chromosome VII. This gene was named COX18, The COX18 gene product is a polypeptide of 316 amino acids with a putative amino-terminal mitochondrial targeting sequence and predicted transmembrane domains. Respiratory chain carriers other than cytochromes a and a, and the ATPase complex are present at near wild-type levels in cox18 mutants, indicating that the mutations specifically affect cytochrome oxidase. The synthesis of Cox1p and Cox3p in mutant mitochondria is normal whereas Cox2p is barely detected among labeled mitochondrial polypeptides. Transcription of COX2 does not require COX18 function, and a chimeric COX3-COX2 mRNA did not suppress the respiratory defect in the null mutant, indicating that the mutation does not impair transcription or translation of the mRNA. Western analysis of cytochrome oxidase subunits shows that inactivation of the COX18 gene greatly reduces the steady state amounts of subunit 2 and results in variable decreases in other subunits of cytochrome oxidase. A gene fusion expressing a biotinylated form of Cox18p complements cox18 mutants. Biotinylated Cox18p is a mitochondrial integral membrane protein. These results indicate Cox18p to be a new member of a group of mitochondrial proteins that function at a late stage of the cytochrome oxidase assembly pathway.	Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, BR-12244000 Sao Jose Dos Campos, SP, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508900 Sao Paulo, SP, Brazil; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Universidade do Vale do Paraiba; Universidade de Sao Paulo; Cornell University; Columbia University	Nobrega, FG (corresponding author), Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, Av Shishima Hifumi 2911, BR-12244000 Sao Jose Dos Campos, SP, Brazil.			Fox, Thomas/0000-0001-7629-3661	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187, R01GM029362] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07617, GM50187, GM29362, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; Andreichuk YV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P742; ARIT H, 1996, CELL, V85, P875; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURKHARD R, 1995, PROTEIN SCI, V4, P5121; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hikkel I, 1997, CURR GENET, V32, P267, DOI 10.1007/s002940050276; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MULERO JJ, 1993, GENETICS, V133, P509; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; POUTRE CG, 1987, GENETICS, V115, P637; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Rose M. D., 1990, METHODS YEAST GENETI, P140; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHEN ZH, 1989, NUCLEIC ACIDS RES, V17, P4535, DOI 10.1093/nar/17.12.4535; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975	47	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14898	14902		10.1074/jbc.275.20.14898	http://dx.doi.org/10.1074/jbc.275.20.14898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809734	hybrid			2022-12-25	WOS:000087128300019
J	da Costa, CA; Ancolio, K; Checler, F				da Costa, CA; Ancolio, K; Checler, F			Wild-type but not Parkinson's disease-related Ala-53 -> Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-APP MATURATION; ALZHEIMERS-DISEASE; NEUROBLASTOMA-CELLS; LEWY BODIES; EARLY EVENT; DEATH; PRESENILINS; MUTATION; PHOSPHORYLATION; EXPRESSION	Recent works suggest that alpha-synuclein could play a central role in Parkinson's disease (PD), Thus, two mutations were reported to be associated with rare autosomal dominant forms of the disease. We examined whether alpha-synuclein could modulate the caspase-mediated response and vulnerability of murine neurons in response to various apoptotic stimuli. We established TSM1 neuronal cell lines overexpressing wild-type (wt) alpha-synuclein or the PD-related Ala-SS --> Thr mutant alpha-synuclein, Under basal conditions, acetyl-Asp-Glu-Val-Asp-aldehyde-sensitive caspase activity appears significantly lower in wt alpha-synuclein-expressing cells than in neurons expressing the mutant. Interestingly, wt alpha-synuclein drastically reduces the caspase activation of TSM1 neurons upon three distinct apoptotic stimuli including staurosporine, etoposide, and ceramide C-2 when compared with mock-transfected cells. This inhibitory control of the caspase response triggered by apoptotic agents was abolished by the PD-related pathogenic mutation. Comparison of wildtype and mutated alpha-synuclein-expressing cells also indicates that the former exhibits much less vulnerability in response to staurosporine and etoposide as measured by the sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]- bis(4-methoxy-B-nitro)benzenesulfonic acid assay. Altogether, our study indicates that wild-type alpha-synuclein exerts an antiapoptotic effect in neurons that appears to be abolished by the Parkinson's disease related mutation, thereby suggesting a possible mechanism underlying both sporadic and familial forms of this neurodegenerative disease.	Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Checler, F (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X				Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Checler F, 1999, IUBMB LIFE, V48, P33, DOI 10.1080/152165499307396; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Duan WZ, 1999, ANN NEUROL, V46, P587, DOI 10.1002/1531-8249(199910)46:4<587::AID-ANA6>3.0.CO;2-M; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Fall CP, 1999, J NEUROSCI RES, V55, P620, DOI 10.1002/(SICI)1097-4547(19990301)55:5<620::AID-JNR9>3.0.CO;2-S; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; JENNER P, 1996, NEUROLOGY S3, V47, P161; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Marambaud P, 1999, BRIT J PHARMACOL, V126, P1186, DOI 10.1038/sj.bjp.0702406; Marambaud P, 1998, MOL MED, V4, P715, DOI 10.1007/BF03401766; Marshall KA, 1997, BIOCHEM BIOPH RES CO, V240, P84, DOI 10.1006/bbrc.1997.7604; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/S0304-3940(96)12961-X; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ruberg M, 1997, REV NEUROL, V153, P499; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; Tompkins MM, 1997, AM J PATHOL, V150, P119; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Ziv I, 1997, J NEURAL TRANSM-SUPP, P69	38	173	173	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24065	24069		10.1074/jbc.M002413200	http://dx.doi.org/10.1074/jbc.M002413200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818098	hybrid			2022-12-25	WOS:000088564200090
J	DeAngelis, PL; Padgett-McCue, AJ				DeAngelis, PL; Padgett-McCue, AJ			Identification and molecular cloning of a chondroitin synthase from Pasteurella multocida type F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; HYALURONAN SYNTHASE; SEROGROUP-F; CAPSULE; POLYSACCHARIDE; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; GLYCOSAMINOGLYCANS; PHAGOCYTOSIS; PURIFICATION	Pasteurella multocida Type F, the minor fowl cholera pathogen, produces an extracellular polysaccharide capsule that is a putative virulence factor. It was reported that the capsule was removed by treating microbes with chondroitin AC lyase, We found by acid hydrolysis that the polysaccharide contained galactosamine and glucuronic acid. We molecularly cloned a Type F polysaccharide synthase and characterized its enzymatic activity. The 965-residue enzyme, called P, multocida chondroitin synthase (pmCS), is 87% identical at the nucleotide and the amino acid level to the hyaluronan synthase, pmHAS, from P, multocida Type A. A recombinant Escherichia coli-derived truncated, soluble version of pmCS (residues 1-704) was shown to catalyze the repetitive addition of sugars from UDP-GalNAc and UDP-GlcUA to chondroitin oligosaccharide accepters in vitro. Other structurally related sugar nucleotide precursors did not substitute in the elongation reaction. Polymer molecules composed of similar to 10(3) sugar residues were produced, as measured by gel filtration chromatography, The polysaccharide synthesized in vitro was sensitive to the action of chondroitin AC lyase but resistant to the action of hyaluronan lyase. This is the first report identifying a glycosyltransferase that forms a polysaccharide composed of chondroitin disaccharide repeats, [beta(1,4)GlcUA-beta(1,3)GalNAc](n). In analogy to known hyaluronan syntheses, a single polypeptide species, pmCS, possesses both transferase activities.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CARTER GR, 1953, AM J VET RES, V14, P475; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DELUCA S, 1968, J BIOL CHEM, V243, P2725; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARMON BG, 1991, AM J VET RES, V52, P1507; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; JING W, 2000, IN PRESS GLYCOBIOLOG; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lidholt K, 1997, BIOCHEM SOC T, V25, P866, DOI 10.1042/bst0250866; Lidholt K, 1997, J BIOL CHEM, V272, P2682, DOI 10.1074/jbc.272.5.2682; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; RAHEMTULLA F, 1975, COMP BIOCHEM PHYS B, V50, P631, DOI 10.1016/0305-0491(75)90102-9; RIMLER RB, 1994, VET REC, V134, P191, DOI 10.1136/vr.134.8.191; Rimler RB, 1995, VET MICROBIOL, V47, P287, DOI 10.1016/0378-1135(95)00127-1; RIMLER RB, 1987, J CLIN MICROBIOL, V25, P615, DOI 10.1128/JCM.25.4.615-618.1987; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; ROSNER H, 1992, CARBOHYD RES, V223, P329, DOI 10.1016/0008-6215(92)80032-V; SILBERT JE, 1968, BIOCHEM BIOPH RES CO, V31, P990, DOI 10.1016/0006-291X(68)90551-2; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; TELSER A, 1965, P NATL ACAD SCI USA, V54, P912, DOI 10.1073/pnas.54.3.912; Tsuchida K, 1999, EUR J BIOCHEM, V264, P461, DOI 10.1046/j.1432-1327.1999.00635.x; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	32	65	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24124	24129		10.1074/jbc.M003385200	http://dx.doi.org/10.1074/jbc.M003385200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818104	hybrid			2022-12-25	WOS:000088564200097
J	Scott, DA; Docampo, R				Scott, DA; Docampo, R			Characterization of isolated acidocalcisomes of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-PYROPHOSPHATASE; PSEUDOALTEROMONAS DENITRIFICANS; CYCLOPRODIGIOSIN HYDROCHLORIDE; CHAGAS-DISEASE; V-ATPASES; LOCALIZATION; MEMBRANES; PLANT; COUNTERTRANSPORT; ACIDIFICATION	The acidocalcisome is an acidic calcium store in trypanosomatids with a vacuolar-type proton-pumping pyrophosphatase (V-H+-PPase) located in its membrane, In this paper, we describe a new method using iodixanol density gradients for purification of the acidocalcisome from Trypanosoma cruzi epimastigotes. Pyrophosphatase assays indicated that the isolated organelle was at least 60-fold purified compared with the large organelle (10,000 x g) fraction. Assays for other organelles generally indicated no enrichment in the acidocalcisome fraction; glycosomes were concentrated 5-fold. Vanadate-sensitive ATP-driven Ca2+ uptake (Ca(2+)ATPase) activity was detectable in the isolated acidocalcisome, but ionophore experiments indicated that it was not acidic. However, when pyrophosphate was added, the organelle acidified, and the rate of Ca2+ uptake increased. Use of the indicator Oxonol VI showed that V-H+-PPase activity generated a membrane potential. Use of sulfate or nitrate in place of chloride in the assay buffer did not affect V-H+-PPase activity, but there was less activity with gluconate, Organelle acidification was countered by the chloride/proton symport cycloprogidiosin. No vacuolar H+-ATPase activity was detectable in isolated acidocalcisomes. However, immunoblots showed the presence of at least a membrane-bound V-H(+)ATPase subunit, while experiments employing permeabilized epimastigotes suggested that vacuolar H+-ATPase and V-H+-PPase activities are present in the same Ca2+-containing compartment.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Scott, DA (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	d-scott1@uiuc.edu		Scott, David/0000-0002-8668-2449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; Benchimol M, 1998, BIOCHEM J, V332, P695, DOI 10.1042/bj3320695; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1104, P188, DOI 10.1016/0005-2736(92)90149-G; Docampo R, 1997, PARASITOL TODAY, V13, P129, DOI 10.1016/S0169-4758(97)01021-1; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Drose S, 1997, J EXP BIOL, V200, P1; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; DUSCHAK VG, 1991, FEMS MICROBIOL LETT, V83, P131, DOI 10.1111/j.1574-6968.1991.tb04430.x; FOK AK, 1993, J CELL SCI, V106, P1103; Kawauchi K, 1997, BIOCHEM BIOPH RES CO, V237, P543, DOI 10.1006/bbrc.1997.7186; Kim HS, 1999, BIOL PHARM BULL, V22, P532, DOI 10.1248/bpb.22.532; Klemm AR, 1998, BBA-BIOMEMBRANES, V1373, P17, DOI 10.1016/S0005-2736(98)00082-0; LEFURGEY A, 1990, MOL BIOCHEM PARASIT, V40, P77, DOI 10.1016/0166-6851(90)90081-V; LEVY D, 1990, J BIOL CHEM, V265, P19524; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Maeshima M, 1999, PLANT CELL PHYSIOL, V40, P439, DOI 10.1093/oxfordjournals.pcp.a029560; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Merzendorfer H, 1997, J EXP BIOL, V200, P225; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; Ratajczak R, 1999, PLANTA, V208, P205, DOI 10.1007/s004250050551; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Salvador JM, 1998, J BIOL CHEM, V273, P18230, DOI 10.1074/jbc.273.29.18230; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; SEGEL HL, 1970, METHODS ENZYMOL A, V17, P153; Urbina JA, 1999, J MOL MED-JMM, V77, P332, DOI 10.1007/s001090050359; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VICKERMAN K, 1977, ANN SOC BELG MED TR, V57, P441; WAGGONER AS, 1988, CELL PHYSL BLOOD, P211; *WHO, 1997, 13 WHO UNDPWBTDR, P112; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	39	64	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24215	24221		10.1074/jbc.M002454200	http://dx.doi.org/10.1074/jbc.M002454200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816577	hybrid			2022-12-25	WOS:000088564200108
J	Wang, YZ; Zhang, P; Rice, AB; Bonner, JC				Wang, YZ; Zhang, P; Rice, AB; Bonner, JC			Regulation of interleukin-1 beta-induced platelet-derived growth factor receptor-alpha expression in rat pulmonary myofibroblasts by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; FACTOR-KAPPA-B; MAP KINASE; SIGNAL-TRANSDUCTION; PDGF RECEPTOR; 3'-UNTRANSLATED REGION; CELLULAR STRESSES; GENE-EXPRESSION	The potential role of p38 mitogen-activated protein (MAP) kinase in platelet-derived growth factor receptor-alpha (PDGF-R alpha) gene expression was investigated using cultured rat pulmonary myofibroblasts. p38 MAP kinase was constitutively expressed in myofibroblasts and activated by interleukin (IL)-1 beta. A pyridinylimidazole compound, SB203580, completely inhibited the ability of p38 MAP kinase activity to phosphorylate PHAS-1 substrate. SB203580 inhibited IL-1 beta-induced up-regulation of PDGF-R alpha mRNA and protein in a concentration-dependent manner. Other kinase inhibitors, including the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor PD98059, did not block upregulation of PDGF-R alpha. The IL-1 beta-induced increase in the number of I-125 PDGF-AA-binding sites at the cell surface was reduced >70% by pretreatment with SB203580. Accordingly, an enhancement of PDGF-AA-stimulated DNA synthesis following IL-1 beta pretreatment was blocked > 70% by SB203580. SB203580 did not affect IL-1 beta-induced ERK activation, yet enhanced IL-1 beta-induced JNK activation approximately 2-fold. Treatment of cells with SB203580 after inhibition of transcription by actinomycin D decreased the half-life of IL-1 beta-induced PDGF-R alpha mRNA from >4 to similar to 1.5 h. Moreover, pretreatment of cells with cycloheximide blocked induction of PDGF-R alpha mRNA by IL-1 beta, suggesting that de novo protein synthesis was required for PDGF-R alpha mRNA stabilization. These data indicate that p38 MAP kinase regulates PDGF-R alpha expression at the translational level by signaling the synthesis of an mRNA-stabilizing protein.	NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Bonner, JC (corresponding author), NIEHS, Pulm Pathobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							Badger AM, 1998, J IMMUNOL, V161, P467; BAYAERT R, 1996, EMBO J, V15, P1914; BONNER JC, 1995, J BIOL CHEM, V270, P6389, DOI 10.1074/jbc.270.11.6389; BONNER JC, 1995, J BIOL CHEM, V270, P16236, DOI 10.1074/jbc.270.27.16236; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; BONNER JC, 1995, AM J RESP CELL MOL, V13, P496, DOI 10.1165/ajrcmb.13.4.7546780; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Boyle JE, 1999, AM J RESP CELL MOL, V20, P433, DOI 10.1165/ajrcmb.20.3.3284; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Coin PG, 1996, J IMMUNOL, V156, P4797; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Foey AD, 1998, J IMMUNOL, V160, P920; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAISA M, 1994, J INVEST DERMATOL, V103, P560, DOI 10.1111/1523-1747.ep12396856; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HELDIN CH, 1990, J CELL SCI, V96, P193; Kitami Y, 1999, CIRC RES, V84, P64; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasky JA, 1998, AM J RESP CRIT CARE, V157, P1652, DOI 10.1164/ajrccm.157.5.9704116; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lindroos PM, 1998, J IMMUNOL, V161, P3464; LINDROOS PM, 1995, AM J RESP CELL MOL, V13, P455, DOI 10.1165/ajrcmb.13.4.7546776; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; OsornioVargas AR, 1996, AM J PHYSIOL-LUNG C, V271, pL93, DOI 10.1152/ajplung.1996.271.1.L93; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAGAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Ridley SH, 1997, J IMMUNOL, V158, P3165; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	50	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22550	22557		10.1074/jbc.M909785199	http://dx.doi.org/10.1074/jbc.M909785199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807932	hybrid			2022-12-25	WOS:000088363800107
J	Jain, D; Kaur, K; Sundaravadivel, B; Salunke, DM				Jain, D; Kaur, K; Sundaravadivel, B; Salunke, DM			Structural and functional consequences of peptide-carbohydrate mimicry - Crystal structure of a carbohydrate-mimicking peptide bound to concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOPYRANOSIDE; MOLECULAR MIMICRY; BINDING; COMPLEX; RECOGNITION; RECEPTOR; IDENTIFICATION; RESOLUTION; LIGANDS; LECTINS	The functional consequences of peptide-carbohydrate mimicry were analyzed on the basis of the crystal structure of concanavalin A (ConA) in complex with a carbohydrate-mimicking peptide, DVFYPYPYASGS, The peptide binds to the non-crystallographically related monomers of two independent dimers of ConA in two different modes, in slightly different conformations, demonstrating structural adaptability in ConA-peptide recognition. In one mode, the peptide has maximum interactions with ConA, and in the other, it shows relatively fewer contacts within this site but significant contacts with the symmetry-related subunit, Neither of the peptide binding sites overlaps with the structurally characterized mannose and trimannose binding sites on Conk Despite this, the functional mimicry between the peptide and carbohydrate ligands was evident. The peptide-inhibited ConA induced T cell proliferation in a dose-dependent manner. The effect of the designed analogs of the peptide on ConA-induced T cell proliferation and their recognition by the antibody response against alpha-D-mannopyranoside indicate a role for aromatic residues in functional mimicry. Although the functional mimicry was observed between the peptide and carbohydrate moieties, the crystal structure of the ConA-peptide complex revealed that the two peptide binding sites are independent of the methyl alpha-D-mannopyranoside binding site.	Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Salunke, DM (corresponding author), Natl Inst Immunol, Struct Biol Unit, Aruna Asaf Ali Marg, New Delhi 110067, India.		Jain, Deepti/G-6921-2011	Jain, Deepti/0000-0002-8631-7230				Appelmelk BJ, 1997, TRENDS MICROBIOL, V5, P70, DOI 10.1016/S0966-842X(96)10084-6; BEELEY N, 1994, TRENDS BIOTECHNOL, V12, P213, DOI 10.1016/0167-7799(94)90117-1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; BRUNGER AT, 1990, XPLOR VERSION 3 1 SY; Chavali GB, 1997, J MOL BIOL, V272, P731, DOI 10.1006/jmbi.1997.1274; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; EDELMAN GM, 1978, J BIOL CHEM, V253, P3016; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Grewal N, 1997, BIOPHYS J, V73, P1190, DOI 10.1016/S0006-3495(97)78151-7; HARDMAN KD, 1976, BIOCHEMISTRY-US, V15, P1120, DOI 10.1021/bi00650a026; HARDMAN KD, 1973, BIOCHEMISTRY-US, V12, P4442, DOI 10.1021/bi00746a022; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; INBAR M, 1969, P NATL ACAD SCI USA, V63, P1418, DOI 10.1073/pnas.63.4.1418; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Loris R, 1996, J BIOL CHEM, V271, P30614, DOI 10.1074/jbc.271.48.30614; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ni Y, 1996, VET IMMUNOL IMMUNOP, V55, P205, DOI 10.1016/S0165-2427(96)05718-2; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; REEKE GN, 1975, J BIOL CHEM, V250, P1525; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; *SERC DAR LAB, 1979, CCP4 SUIT PROGR PROT; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; ZANETTA JP, 1994, HISTOL HISTOPATHOL, V9, P385	34	52	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16098	16102		10.1074/jbc.275.21.16098	http://dx.doi.org/10.1074/jbc.275.21.16098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821862	hybrid			2022-12-25	WOS:000087291400067
J	Kluck, RM; Ellerby, LM; Ellerby, HM; Naiem, S; Yaffe, MP; Margoliash, E; Bredesen, D; Mauk, AG; Sherman, F; Newmeyer, DD				Kluck, RM; Ellerby, LM; Ellerby, HM; Naiem, S; Yaffe, MP; Margoliash, E; Bredesen, D; Mauk, AG; Sherman, F; Newmeyer, DD			Determinants of cytochrome c pro-apoptotic activity - The role of lysine 72 trimethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-40 REPEAT REGION; CELL-FREE APOPTOSIS; SACCHAROMYCES-CEREVISIAE; YEAST ISO-1-CYTOCHROME-C; CHEMICAL MODIFICATION; SCHIZOSACCHAROMYCES-POMBE; PROCASPASE-9 ACTIVATION; MITOCHONDRIAL IMPORT; BINDING DOMAINS; MAMMALIAN-CELLS	Cytochrome c released from vertebrate mitochondria engages apoptosis by triggering caspase activation. We previously reported that, whereas cytochromes c from higher eukaryotes can activate caspases in Xenopus egg and mammalian cytosols, iso-l and iso-2 cytochromes c from the yeast Saccharomyces cerevisiae cannot. Here we examine whether the inactivity of the yeast isoforms is related to a post-translational modification of lysine 72, N-epsilon-trimethylation. This modification was found to abrogate pro-apoptotic activity of metazoan cytochrome c expressed in yeast. However, iso-l cytochrome c lacking the trimethylation modification also was devoid of pro-apoptotic activity. Thus, both lysine 72 trimethylation and other features of the iso-l sequence preclude pro-apoptotic activity. Competition studies suggest that the lack of pro-apoptotic activity was associated with a low affinity for Apaf-1. As cytochromes c that lack apoptotic function still support respiration, different mechanisms appear to be involved in the two activities.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Buck Ctr Res Aging, Novato, CA 94945 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	La Jolla Institute for Immunology; Buck Institute for Research on Aging; University of California System; University of California San Diego; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of British Columbia; University of Rochester	Newmeyer, DD (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	don_newmeyer@liai.org	Kluck, Ruth M/C-8413-2013	Kluck, Ruth M/0000-0002-7101-1925	NIA NIH HHS [AG12282] Funding Source: Medline; NIGMS NIH HHS [GM50284] Funding Source: Medline; NINDS NIH HHS [NS40251] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; CUTLER RL, 1987, PROTEIN ENG, V1, P95, DOI 10.1093/protein/1.2.95; DAUM G, 1982, J BIOL CHEM, V257, P3028; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; DETHMERS JK, 1979, J BIOL CHEM, V254, P1973; DIMARIA P, 1979, J BIOL CHEM, V254, P4645; DUMONT ME, 1996, ADV MOL CEL, V17, P103; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Greenhalf W, 1999, YEAST, V15, P1307, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.3.CO;2-V; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; HOLZSCHU D, 1987, J BIOL CHEM, V262, P7125; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; KOSHY TI, 1992, PROTEIN EXPRES PURIF, V3, P441, DOI 10.1016/1046-5928(92)90061-Z; Krause E, 1999, ANAL CHEM, V71, P4160, DOI 10.1021/ac990298f; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NEWMEYER DD, 1998, WEIRS HDB EXPT IMMUN, V3; PAIK WK, 1989, BIOCHEM CELL BIOL, V67, P602; PARK KS, 1987, J BIOL CHEM, V262, P14702; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; POLASTRO E, 1976, ARCH INT PHYSIOL BIO, V84, P1099; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Purring C, 1999, J AM CHEM SOC, V121, P7435, DOI 10.1021/ja991235h; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; RIEDER R, 1978, J BIOL CHEM, V253, P6045; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1968, J BIOL CHEM, V243, P5446; SHERMAN F, 1993, TRANSLATIONAL REGULA, V2, P117; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takakura H, 1997, BIOCHEMISTRY-US, V36, P2642, DOI 10.1021/bi962245n; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZOU H, 1999, J BIOL CHEM, V274, P11459; [No title captured]	59	102	105	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16127	16133		10.1074/jbc.275.21.16127	http://dx.doi.org/10.1074/jbc.275.21.16127			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821864	hybrid			2022-12-25	WOS:000087291400071
J	Kisselev, AF; Songyang, Z; Goldberg, AL				Kisselev, AF; Songyang, Z; Goldberg, AL			Why does threonine, and not serine, function as the active site nucleophile in proteasomes?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTACYSTIN BETA-LACTONE; HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; N-TERMINAL NUCLEOPHILE; 20S PROTEASOME; THERMOPLASMA-ACIDOPHILUM; PROTEIN-DEGRADATION; MULTICATALYTIC PROTEINASE; 3-DIMENSIONAL STRUCTURE; ANTIGEN PRESENTATION; CATALYTIC MECHANISM	Proteasomes belong to the N-terminal nucleophile group of amidases and function through a novel proteolytic mechanism, in which the hydroxyl group of the N-terminal threonines is the catalytic nucleophile. However, it is unclear why threonine has been conserved in all proteasomal active sites, because its replacement by a serine in proteasomes from the archaeon Thermoplasma acidophilum (T1S mutant) does not alter the rates of hydrolysis of Suc-LLVY-amc (Seemuller, E., Lupas, A., Stock, D., Lowe, J., Huber, R., and Baumeister, W. (1995) Science 268, 579-582) and other standard peptide amide substrates, However, we found that true peptide bonds in decapeptide libraries were cleaved by the T1S mutant 10-fold slower than by wild type (wt) proteasomes, In degrading proteins, the T1S proteasome was 3.5- to 6-fold slower than the wt, and this difference increased when proteolysis was stimulated using the proteasome-activating nucleotidase (PAN) ATPase complex. With mutant proteasomes, peptide bond cleavage appeared to be rate-limiting in protein breakdown, unlike with wt. Surprisingly, a peptide ester was hydrolyzed by both particles much faster than the corresponding amide, and the T1S mutant cleaved it faster than the wt. Moreover, the T1S mutant was inactivated by the ester inhibitor clasto-lactacystin-beta-lactone severalfold faster than the wt, but reacted with nonester irreversible inhibitors at similar rates. T1A and T1C mutants were completely inactive in all these assays. Thus, proteasomes lack additional active sites, and the N-terminal threonine evolved because it allows more efficient protein breakdown than serine.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Harvards Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu						Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 2000, J AM CHEM SOC, V122, P1237, DOI 10.1021/ja993588m; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HENDERSON PJF, 1991, ENZYME ASSAYS PRACTI, P277; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1995, COLD SPRING HARB SYM, V60, P515, DOI 10.1101/SQB.1995.060.01.055; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Orlowski M, 1997, BIOCHEMISTRY-US, V36, P13946, DOI 10.1021/bi970666e; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; ROA A, 1995, BIOCHEM BIOPH RES CO, V206, P629, DOI 10.1006/bbrc.1995.1089; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Schmidt M, 1997, FASEB J, V11, P1235, DOI 10.1096/fasebj.11.14.9409542; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHERMAN NY, 1996, STRESS INDUCIBLE CEL, P57; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Zhou SY, 1998, METH MOL B, V87, P87; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; ZWICKL P, 1999, PROTEASOMES PROKARYO, P8	66	96	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14831	14837		10.1074/jbc.275.20.14831	http://dx.doi.org/10.1074/jbc.275.20.14831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809725	hybrid			2022-12-25	WOS:000087128300010
J	Wilkinson, CRM; Ferrell, K; Penney, M; Wallace, M; Dubiel, W; Gordon, C				Wilkinson, CRM; Ferrell, K; Penney, M; Wallace, M; Dubiel, W; Gordon, C			Analysis of a gene encoding Rpn10 of the fission yeast proteasome reveals that the polyubiquitin-binding site of this subunit is essential when Rpn12/Mts3 activity is compromised	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ATPASE SUBUNIT; 26S PROTEASOME; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN-CHAIN; 20S PROTEASOME; REGULATORY PARTICLE; PROTEOLYTIC PATHWAY; PROTEIN-DEGRADATION; MOLECULAR-CLONING; 26-S PROTEASES	Substrates are targeted for proteolysis by the ubiquitin pathway by the addition of a polyubiquitin chain before being degraded by the 26 S proteasome, Previously, a subunit of the proteasome, S5a, was identified that was able to bind to polyubiquitin in vitro and thus proposed to act as a substrate recognition component. Deletion of the corresponding Saccharomyces cerevisiae gene, MCB1/RPN10, rendered cells viable indicating that other proteasomal polyubiquitin receptors must exist. In this study, we describe pus1(+), the fission yeast homologue of RPN10, This gene is also not required for cell viability; however, the Delta pus1 mutant is synthetically lethal with mutations in other proteasomal component-encoding genes, namely mts3, pad1, and mts4 (RPN12, RPN11, and RPN1), Overexpression of pus1(+) is able to rescue mts3-1 at 32 degrees C but overexpression of a cDNA encoding a version of Pus1 that does not bind to polyubiquitin cannot and leads to greatly reduced viability when used to rescue the mts3-1 Delta pus1 double mutant. The Mts3 protein was unable to bind to polyubiquitin in vitro, but the Pus1 and Mts3 proteins were found to bind to one another in vitro, which taken together with the genetic data suggests that they are also closely associated in vivo.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Humboldt Univ, Fac Med, Inst Biochem, D-10117 Berlin, Germany	University of Edinburgh; Humboldt University of Berlin	Gordon, C (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	colin.gordon@hgu.mrc.ac.uk		Dubiel, Wolfgang/0000-0002-3393-0701				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Girod PA, 1999, PLANT CELL, V11, P1457; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOUGH R, 1986, J BIOL CHEM, V261, P2391; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lambertson D, 1999, GENETICS, V153, P69; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Penney M, 1998, J BIOL CHEM, V273, P23938, DOI 10.1074/jbc.273.37.23938; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Pusch W, 1998, GENE, V207, P19, DOI 10.1016/S0378-1119(97)00599-4; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	53	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15182	15192		10.1074/jbc.275.20.15182	http://dx.doi.org/10.1074/jbc.275.20.15182			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809753	hybrid			2022-12-25	WOS:000087128300057
J	Ying, CW; Lin, DH				Ying, CW; Lin, DH			Estrogen-modulated estrogen receptor pit-1 protein complex formation and prolactin gene activation require novel protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; C-FOS EXPRESSION; RAT PROLACTIN; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC INTERACTIONS; ANTERIOR-PITUITARY; RIBONUCLEIC-ACID; NUCLEAR RECEPTOR; PROMOTER; GROWTH	Both estrogen receptor (ER) and Pit-1 proteins are essential for the estrogen-activated expression of the rat prolactin gene. Our results show that ER Pit-1 protein complex formation is reduced by estrogen in GH3 and PR1 rat pituitary tumor cells. In the latter, this decrease was blocked by cycloheximide, a protein synthesis inhibitor. On the other hand, the direct addition of estrogen to PR1 cell lysates had no effect on the formation of ER Pit-1 complexes. Estrogen-activated prolactin gene expression was also inhibited by cycloheximide, suggesting that some form of protein synthesis is involved in ER Pit-1 complex formation and subsequent prolactin gene activation. In support of this notion, we showed that estrogen-induced regulation of ER Pit-1 complex formation could be transferred from cell lysates prepared from estrogen-treated PR1 cells to control cell lysates. This is not true for GH3 cells; instead, direct administration of estrogen to GH3 cell lysates readily abolished ER Pit-1 protein complex formation in a dose-dependent manner, and such estrogen-induced regulation was blocked by the antiestrogen ICI 182,780, These findings thus indicate that 1) interaction between ER and Pit-1 proteins is estrogen-regulated in ways specific to different cell types, and 2) auxiliary protein factor synthesis may be involved in this process.	Soochow Univ, Dept Microbiol, Taipei 111, Taiwan	Soochow University	Ying, CW (corresponding author), Soochow Univ, Dept Microbiol, Taipei 111, Taiwan.							Allen DL, 1997, ENDOCRINOLOGY, V138, P2128, DOI 10.1210/en.138.5.2128; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141, DOI 10.1210/endo-112-3-1141; Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; CACAILLES V, 1995, EMBO, V14, P3741; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; ECKERT RL, 1982, J BIOL CHEM, V257, P8840; Farrow KN, 1996, J BIOL CHEM, V271, P17139, DOI 10.1074/jbc.271.29.17139; FURLOW J, 1993, J BIOL CHEM, V258, P12519; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GonzalezParra S, 1996, NEUROENDOCRINOLOGY, V63, P3, DOI 10.1159/000126930; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; INERSON RA, 1990, MOL ENDOCRINOL, V4, P1564; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KANEKO KJ, 1993, BIOCHEMISTRY-US, V32, P8348, DOI 10.1021/bi00083a039; KIINO DR, 1981, ENDOCRINOLOGY, V109, P1264, DOI 10.1210/endo-109-4-1264; KIM MK, 1993, J BIOL CHEM, V268, P23366; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; NEPHEW KP, 1995, ENDOCRINOLOGY, V136, P3007, DOI 10.1210/en.136.7.3007; NOWAKOWSKI BE, 1994, MOL ENDOCRINOL, V8, P1742, DOI 10.1210/me.8.12.1742; PASTORCIC M, 1995, CANCER RES, V55, P4892; PHODE PR, 1991, MOL CELL ENDOCRINOL, V82, P1; REINER GCA, 1986, CANCER RES, V46, P1124; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; SHULL JD, 1984, ENDOCRINOLOGY, V114, P1550, DOI 10.1210/endo-114-5-1550; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Ying CW, 1999, J STEROID BIOCHEM, V68, P145, DOI 10.1016/S0960-0760(99)00020-5	46	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15407	15412		10.1074/jbc.275.20.15407	http://dx.doi.org/10.1074/jbc.275.20.15407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809776	hybrid			2022-12-25	WOS:000087128300086
J	Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM				Cross, T; Griffiths, G; Deacon, E; Sallis, R; Gough, M; Watters, D; Lord, JM			PKC-delta is an apoptotic lamin kinase	ONCOGENE			English	Article						apoptosis; nuclear lamina; PKC-delta	PROTEIN-KINASE; C-DELTA; PROTEOLYTIC ACTIVATION; NUCLEAR TRANSLOCATION; HL-60 CELLS; PHOSPHORYLATION; ALPHA; DYNAMICS; SITES; DEATH	Protein kinase C-delta is activated during apoptosis, following proteolytic cleavage by caspase 3. Furthermore, overexpression of the catalytic kinase fragment of PKC-delta induces the nuclear phenotype associated with apoptosis, though the molecular basis of this effect has not been determined. In these studies we have examined the role of PKC-delta in the disassembly of the nuclear Lamina at apoptosis. The nuclear lamina is disassembled during mitosis and apoptosis and mitotic disassembly involves hyperphosphorylation of lamin proteins by mitotic lamin kinases. During apoptosis, lamin proteins are degraded by caspase 6 and the contribution made by phosphorylation has not been proven. We show here that protein kinase C-delta co-localized with lamin B during apoptosis and activation of PKC-delta by caspase 3 was concomitant with lamin B phosphorylation and proteolysis. Inhibition of PKC-delta delayed lamin proteolysis, even in the presence of active caspase 6, whilst inhibitors of mitotic lamin kinases were without effect. In addition recombinant human PKC-delta was able to phosphorylate lamin B in vitro suggesting that its actions are direct and not via an intermediary kinase. We propose that PKC-delta is an apoptotic lamin kinase and that efficient lamina disassembly at apoptosis requires both lamin hyperphosphorylation and caspase mediated proteolysis.	Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England; Queensland Inst Med Res, Brisbane, Qld 4006, Australia	University of Birmingham; QIMR Berghofer Medical Research Institute	Lord, JM (corresponding author), Univ Birmingham, Ctr Immune Regulat, MRC, Birmingham B15 2TT, W Midlands, England.		Watters, Dianne J/E-6007-2010; Gough, Michael/AAY-3419-2020; Sallis, Rosemary/H-4241-2014	Watters, Dianne J/0000-0002-2555-5825; Gough, Michael/0000-0002-5575-0074; Lord, Janet/0000-0003-1030-6786				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVANS CA, 1995, J CELL SCI, V108, P2591; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOZAK P, 1995, J CELL SCI, V108, P635; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Mikulits W, 1997, DNA CELL BIOL, V16, P849, DOI 10.1089/dna.1997.16.849; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; WHELAN RDH, 1998, EMBO J, V14, P6148; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yazaki T, 1996, MOL PHARMACOL, V50, P236; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	31	190	193	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2331	2337		10.1038/sj.onc.1203555	http://dx.doi.org/10.1038/sj.onc.1203555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822384				2022-12-25	WOS:000086974300008
J	Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD				Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD			Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability	ONCOGENE			English	Article						mismatch repair; hPMS2; colon cancer; MNNG; HPRT	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; CARCINOMA CELL-LINES; TUMOR-CELLS; NUCLEAR EXTRACTS; DEFICIENCY; DEFECTS; HYPERMUTABILITY; HETERODIMER; PHENOTYPES	Inactivation of DIVA-mismatch repair underlies the genesis of microsatellite unstable (MSI) colon cancers. hPMS2 is one of several genes encoding components of the DNA-mismatch repair complex, and germline hPMS2 mutations have been found in a fem kindreds with hereditary nonpolyposis colorectal carcinoma (HNPCC), in whom hereditary MSI colon cancers develop. Ho tr ever, mice bearing null hPMS2 genes do not develop colon cancers and hPMS2 mutations in sporadic human colon cancers have not been described, Here we report that in Vaco481 colon cancer the hPMS2 gene is inactivated by somatic mutations of both hPMS2 alleles, The cell line derived from this tumor is functionally deficient in DNA mismatch repair. This deficiency can be biochemically complemented by addition of a purified hMLH1-hPMS2 (hMutL alpha) complex, The hPMS2 deficient Vaco481 cancer cell line demonstrates microsatellite instability, an elevated HPRT gene mutation rate, and resistance to the cytotoxicity of the alkylator MNNG. We conclude that somatic inactivation of hPMS2 can play a role in development of sporadic MSI colon cancer expressing the full range of cancer phenotypes associated with inactivation of the mismatch repair system.	Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; Duke University; Howard Hughes Medical Institute; Duke University	Markowitz, SD (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA.			Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [R01 CA67409, R01 CA 70788] Funding Source: Medline; NIGMS NIH HHS [R01 GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, R01CA070788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinz JM, 1999, CARCINOGENESIS, V20, P215, DOI 10.1093/carcin/20.2.215; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; Umar A, 1997, CANCER RES, V57, P3949	35	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2249	2256		10.1038/sj.onc.1203568	http://dx.doi.org/10.1038/sj.onc.1203568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822375				2022-12-25	WOS:000086974100010
J	Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M				Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M			A new feature of Mpl receptor: ligand-induced transforming activity in FRE rat fibroblasts	ONCOGENE			English	Article						Mpl; transformation; fibroblasts; MAPK; Shc	PROTEIN-TYROSINE PHOSPHORYLATION; HUMAN BLOOD-PLATELETS; C-MPL; MEGAKARYOCYTIC DIFFERENTIATION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTOR; SHC PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PRIMARY REGULATOR	Mpl is the receptor for thrombopoietin, the primary regulator of platelet production by megakaryocytes. Upon stimulation by its ligand, Mpl receptor induces proliferation and differentiation of hematopoietic cell lines of various origins. In this paper, we show that Mpl is also able to transform FRE rat fibroblasts in the presence of MGDF (pegylated Megakaryocyte Growth and Development Factor), a modified form of its ligand. We also demonstrate that upon MGDF stimulation Mpl receptor activates the classical transduction pathways described for hematopoietic cell lines in FRE cells. Introduction of Mpl deletion mutants in FRE cells allowed us to demonstrate that the C-terminal region of the Mpl intracytoplasmic domain, which is involved in hematopoietic differentiation, is necessary for the transformation process. Within that region, site-directed mutagenesis showed that the Y112 residue, which is required for She phosphorylation, is essential for rat fibroblast transformation by Mpl/MGDF, suggesting the involvement of She in Mpl-mediated transformation. Interestingly, we showed that transformation correlated with strong and sustained MAPK activation. Neither Jak2 Stat3 nor Stat5 phosphorylation was sufficient to induce the transformation process. Taken altogether, our results suggest the oncogenicity of Mpl in fibroblastic cells in the presence of its ligand.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Hop Cochin, Inst Cochin Genet Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Souyri, M (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Souyri, Michele/L-5845-2017; PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163; PETIT, Laurence/0000-0002-2475-9367				Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Cocault L, 1996, BLOOD, V88, P1656; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eaton DL, 1997, EXP HEMATOL, V25, P1; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAWLEY RG, 1994, GENE THER, V1, P136; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; Takatoku M, 1997, J BIOL CHEM, V272, P7259, DOI 10.1074/jbc.272.11.7259; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	44	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2033	2042		10.1038/sj.onc.1203472	http://dx.doi.org/10.1038/sj.onc.1203472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803464				2022-12-25	WOS:000086613200007
J	Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C				Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C			Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours	ONCOGENE			English	Article						mitochondria; thyroid tumours; sequence variants; mutations	TUMORS; APOPTOSIS; CANCER	Somatic mutations in mtDNA have recently been identified in colorectal tumours, Studies of oncocytic tumours have led to hypotheses which propose that defects in oxidative phosphorylation may result in a compensatory increase in mitochondrial replication and/or gene expression. Mutational analysis of mtDNA in thyroid neoplasia, which is characterised by increased numbers of mitochondria and is also one of the most common sites of oncocytic tumours, has been limited to date. Using the recently developed technique of two-dimensional gene scanning, me have successfully examined 21 cases of thyroid tumours, six cases of nonneoplastic thyroid pathology, 30 population controls, nine foetal thyroid tissues and nine foetal tissues of nonthyroid origin, either kidney or liver. We have identified three different somatic mutations (23%) in papillary thyroid carcinomas. In addition, we have found significant differential distributions of mtDNA sequence variants between thyroid carcinomas and controls. Interestingly, these variants appear to be more frequent in the genes which encode complex I of the mitochondrial electron transport chain compared to normal population controls, These findings suggest first, that somatic mtDNA mutations may be involved in thyroid tumorigenesis and second, that the accumulation of certain non-somatic variants may be related to tumour progression in the thyroid.	Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, Columbus, OH 43210 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; San Antonio Canc Inst, Inst Drug Dev, San Antonio, TX USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Surg, Boston, MA 02114 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, 420 W 12th Ave, Columbus, OH 43210 USA.		Mutter, George L/C-5819-2009	Lunetta, Kathryn/0000-0002-9268-810X; Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; Dhanda RK, 1998, BIOTECHNIQUES, V25, P664, DOI 10.2144/98254dt06; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; JOHNSON D, 1996, AM J PATHOL, V149, P1786; Muller-Hocker J, 1998, ULTRASTRUCT PATHOL, V22, P91; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; SIGEL S, 1998, NONPARAMETRIC STAT B; Simon DK, 1999, ANNU REV MED, V50, P111; Stefaneanu L, 1979, Endocrinologie, V17, P233; TALLINI G, 1994, CYTOGENET CELL GENET, V66, P253, DOI 10.1159/000133706; van Orsouw NJ, 1998, GENOMICS, V52, P27, DOI 10.1006/geno.1998.5410; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112	22	145	162	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2060	2066		10.1038/sj.onc.1203537	http://dx.doi.org/10.1038/sj.onc.1203537			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803467				2022-12-25	WOS:000086613200010
J	Nakatsu, F; Sakuma, M; Matsuo, Y; Arase, H; Yamasaki, S; Nakamura, N; Saito, T; Ohno, H				Nakatsu, F; Sakuma, M; Matsuo, Y; Arase, H; Yamasaki, S; Nakamura, N; Saito, T; Ohno, H			A di-leucine signal in the ubiquitin moiety - Possible involvement in ubiquitination-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; EPITHELIAL NA+ CHANNEL; LIGAND-INDUCED INTERNALIZATION; CD4 DOWN-REGULATION; LIDDLES-SYNDROME; SORTING SIGNALS; HIV-1 NEF; DILEUCINE MOTIF; CLATHRIN; ADAPTER	Some plasma membrane receptors in yeast are known to be internalized and degraded in lysosomes up on ligand-dependent ubiquitination. However, the role of ubiquitination in endocytosis and lysosomal degradation in higher eukaryotes has been controversial. In order to directly assess this question, we investigated the fate of chimeric molecules in which ubiquitin moiety was fused in-frame to the cytoplasmic region of membrane proteins, The chimeric proteins with the wild-type ubiquitin were endocytosed and delivered to lysosomes efficiently. Mutant ubiquitin with lysine-to-arginine substitution could still mediate endocytosis, suggesting that polyubiquitination is not required for the endocytosis. We next searched for the existence of an endocytosis signal(s) in the ubiquitin moiety, and identified a di-leucine signal, Leu(43)-Ile(44). The Leu(43)-Ile(44) sequence mediated endocytosis and lysosomal sorting in a Leu(43)-dependent manner. These results suggest that the di-leucine signal in ubiquitin can be involved in ubiquitination-mediated endocytosis and lysosomal targeting of membrane proteins.	Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan; Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba 2608670, Japan; Inst Phys & Chem Res, RIKEN, Genomic Sci Ctr, Bioinformat Grp, Wako, Saitama 3510198, Japan	Kanazawa University; Chiba University; RIKEN	Ohno, H (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan.		Nakamura, Nobuhiro/F-7811-2011; Saito, Takashi/C-9684-2009; Arase, Hisashi/C-8442-2009; Ohno, Hiroshi/L-7899-2014	Nakamura, Nobuhiro/0000-0002-8836-6714; Saito, Takashi/0000-0001-9495-3547; Arase, Hisashi/0000-0002-1153-3166; Ohno, Hiroshi/0000-0001-8776-9661				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	36	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26213	26219		10.1074/jbc.M907720199	http://dx.doi.org/10.1074/jbc.M907720199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10818107	hybrid			2022-12-25	WOS:000088999700046
J	Arimura, N; Inagaki, N; Chihara, K; Menager, C; Nakamura, N; Amano, M; Iwamatsu, A; Goshima, Y; Kaibuchi, K				Arimura, N; Inagaki, N; Chihara, K; Menager, C; Nakamura, N; Amano, M; Iwamatsu, A; Goshima, Y; Kaibuchi, K			Phosphorylation of collapsin response mediator protein-2 by Rho-kinase - Evidence for two separate signaling pathways for growth cone collapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; INDUCED NEURITE RETRACTION; MYOTONIC-DYSTROPHY KINASE; FAMILY GTPASES; AXON GUIDANCE; CYTOSKELETAL REORGANIZATION; SERINE/THREONINE KINASE; LYSOPHOSPHATIDIC ACID; FOCAL ADHESIONS; PUTATIVE TARGET	We previously identified Rho-associated protein kinase (Rho-kinase) as a specific effector of Rho, In this study, we identified collapsin response mediator protein-2 (CRMP-2), as a novel Rho-kinase substrate in the brain. CRMP-2 is a neuronal protein whose expression is up-regulated during development. Rho-kinase phosphorylated CRMP-2 at Thr-555 in vitro. We produced an antibody that specifically recognizes CRMP-2 phosphorylated at Thr-555, Using this antibody, we found that Rho-kinase phosphorylated CRMP-2 downstream of Rho in COS7 cells. Phosphorylation of CRMP-2 was observed in chick dorsal root ganglion neurons during lysophosphatidic acid (LPA)-induced growth cone collapse, whereas the phosphorylation was not detected during semaphorin-3A-induced growth cone collapse. Both LPA-induced CRMP-2 phosphorylation and LPA-induced growth cone collapse were inhibited by Rho-kinase inhibitor UA1077 or Y-32885. LPA-induced growth cone collapse was also blocked by a dominant negative form of Rho-kinase. On the other hand, semaphorin-3A-induced growth cone collapse was not inhibited by a dominant negative form of Rho-kinase, Furthermore, overexpression of a mutant CRMP-2 in which Thr-555 was replaced by Ala significantly inhibited LPA-induced growth cone collapse. These results demonstrate the existence of Rho-kinase-dependent and -independent pathways for growth cone collapse and suggest that CRMP-2 phosphorylation by Rho-kinase is involved in the former pathway.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Nagoya Univ, Sch Med, Dept Cell Pharmacol, Showa Ku, Nagoya, Aichi 4668550, Japan; Yokohama City Univ, Sch Med, Dept Pharmacol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Nara Institute of Science & Technology; Nagoya University; Yokohama City University; Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 6300101, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524; Inagaki, Naoyuki/0000-0002-2664-9196				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Craig A. M, 1998, CULTURING NERVE CELL, P79; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jin Z, 1997, J NEUROSCI, V17, P6256; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LI W, 1992, GENETICS, V132, P675; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tigyi G, 1996, J NEUROCHEM, V66, P537; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VAN AL, 1997, GENE DEV, V11, P2295; Wang LH, 1996, J NEUROSCI, V16, P6197; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	53	269	280	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23973	23980		10.1074/jbc.M001032200	http://dx.doi.org/10.1074/jbc.M001032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818093	hybrid			2022-12-25	WOS:000088564200078
J	Backstrom, JR; Price, RD; Reasoner, DT; Sanders-Bush, E				Backstrom, JR; Price, RD; Reasoner, DT; Sanders-Bush, E			Deletion of the serotonin 5-HT2C receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B)-ADRENERGIC RECEPTOR; INDUCED DESENSITIZATION; CYTOPLASMIC TAIL; CHOROID-PLEXUS; CELLS; IDENTIFICATION; TRUNCATION; VARIANT; DOMAIN; SITES	Phosphorylation-deficient serotonin 5-HT2C receptors were generated to determine whether phosphorylation promotes desensitization of receptor responses. Phosphorylation of mutant 5-HT2C receptors that lack the carboxyl-terminal PDZ recognition motif (Ser(458)-Ser-Val-COOH; Delta PDZ) was not detectable based on a band-shift phosphorylation assay and incorporation of P-32. Treatment of cells stably expressing Delta PDZ or wild-type 5-HT2C receptors with serotonin produced identical maximal responses and EC50 values for eliciting [H-3]-inositol phosphate formation. In calcium imaging studies, treatment of cells expressing Delta PDZ or wild-type 5-HT2C receptors with 100 nM serotonin elicited initial maximal responses and decay rates that were indistinguishable. However, a second application of serotonin 2.5 min after washout caused maximal responses that were similar to 5-fold lower with Delta PDZ receptors relative to wild-type 5-HT2C receptors. After 10 min, responses of Delta PDZ receptors recovered to wild-type 5-HT2C receptor levels. Receptors with single mutations at Ser(458) (S458A) or Ser(459) (S459A) decreased serotonin-mediated phosphorylation to 50% of wild-type receptor levels. Furthermore, subsequent calcium responses of S459A receptors were diminished relative to S458A and wild-type receptors. These results establish that desensitization occurs in the absence of 5-HT2C receptor phosphorylation and suggest that receptor phosphorylation at Ser459 enhances resensitization of 5-HT2C receptor responses.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Backstrom, JR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 432 Med Res Bldg 1, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034007, R01MH034007, R03MH058839] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIMH NIH HHS [MH58839, MH34007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIYOSHI J, 1995, J NEUROCHEM, V64, P2473; ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; BACKSTROM JR, 1995, MOL BRAIN RES, V33, P311, DOI 10.1016/0169-328X(95)00156-M; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Briddon SJ, 1998, BRIT J PHARMACOL, V125, P727, DOI 10.1038/sj.bjp.0702145; BUCK F, 1991, BIOCHEM BIOPH RES CO, V178, P1421, DOI 10.1016/0006-291X(91)91052-E; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Canton H, 1996, MOL PHARMACOL, V50, P799; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Herrick-Davis K, 1999, J NEUROCHEM, V73, P1711, DOI 10.1046/j.1471-4159.1999.731711.x; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WATSON JA, 1995, CELL CALCIUM, V17, P120, DOI 10.1016/0143-4160(95)90081-0; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397	25	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23620	23626		10.1074/jbc.M000922200	http://dx.doi.org/10.1074/jbc.M000922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816555	hybrid			2022-12-25	WOS:000088564200031
J	Schreiber, S; Fleischer, J; Breer, H; Boekhoff, I				Schreiber, S; Fleischer, J; Breer, H; Boekhoff, I			A possible role for caveolin as a signaling organizer in olfactory sensory membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN SUBTYPES; PLASMA-MEMBRANE; SCAFFOLDING DOMAIN; ADENYLYL-CYCLASE; CELL-MEMBRANES; GENE FAMILY; MDCK CELLS; IN-VIVO; CHOLESTEROL; IDENTIFICATION	Fast kinetics acid sensitivity of olfactory signaling raise the question of whether the participating proteins may be associated in supramolecular transduction complexes. We found evidence that caveolin proteins could play an important role in organizing signaling elements in olfactory sensory neurons. Western blot analysis indicated that caveolins are highly enriched in olfactory sensory membranes, where they co-localize in detergent-insoluble complexes with key components of the signaling pathways. Furthermore, the results of immunoprecipitation experiments suggest that G; proteins and effector enzyme form preassembled subcellular complexes with caveolins, Since anti caveolin antibodies and synthetic peptides derived from the scaffolding domains of caveolin-1 and caveolin-2 effectively attenuated second messenger responses in sensory cilia preparations in a characteristic manner, the data led to the suggestion that caveolins could mediate the assembly of signaling complexes within specialized membrane microdomains of olfactory sensory neurons.	Univ Hohenheim, Inst Physiol 230, D-70593 Stuttgart, Germany	University Hohenheim	Boekhoff, I (corresponding author), Univ Hohenheim, Inst Physiol 230, Garbenstr 30, D-70593 Stuttgart, Germany.	boekhof@uni-hohenheim.de						Ache Barry W., 1994, Seminars in Cell Biology, V5, P55, DOI 10.1006/scel.1994.1008; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANHOLT RRH, 1986, J NEUROSCI, V6, P1962; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Breer Heinz, 1994, Seminars in Cell Biology, V5, P25, DOI 10.1006/scel.1994.1004; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Firestein S, 1996, CURR BIOL, V6, P666, DOI 10.1016/S0960-9822(09)00444-8; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; Krieger J, 1999, J BIOL CHEM, V274, P4655, DOI 10.1074/jbc.274.8.4655; Kroner C, 1996, NEUROREPORT, V7, P2989, DOI 10.1097/00001756-199611250-00038; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Morales Bernardo, 1996, Biological Research, V29, P333; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Noe J, 1998, J NEUROCHEM, V71, P2286; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Reed Randall R., 1994, Seminars in Cell Biology, V5, P33, DOI 10.1006/scel.1994.1005; REED RR, 1992, COLD SPRING HARB SYM, V57, P501, DOI 10.1101/SQB.1992.057.01.055; RIETVELD A, 1998, BIOCHIM BIOPHYS ACTA, V3, P467; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schandar M, 1998, J BIOL CHEM, V273, P16669, DOI 10.1074/jbc.273.27.16669; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; STEINER AL, 1972, J BIOL CHEM, V247, P1114; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	64	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24115	24123		10.1074/jbc.M001876200	http://dx.doi.org/10.1074/jbc.M001876200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816570	hybrid			2022-12-25	WOS:000088564200096
J	Tuske, S; Singh, K; Kaushik, N; Modak, MJ				Tuske, S; Singh, K; Kaushik, N; Modak, MJ			The J-helix of Escherichia coli DNA polymerase I (Klenow fragment) regulates polymerase and 3 '-5 '-exonuclease functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC FRAGMENT; TERNARY COMPLEXES; EDITING COMPLEX; TEMPLATE-PRIMER; BINDING; EXONUCLEASE; SITES; FIDELITY; RESIDUES; CRYSTAL	To assess the functional importance of the J-helix region of Escherichia coli DNA polymerase I, we performed site-directed mutagenesis of the following five residues: Asn-675, Gln 677, Asn-678, Ile-679, and Pro-680. Of these, the Q677A mutant is polymerase-defective with no change in its exonuclease activity. In contrast, the N678A mutant has unchanged polymerase activity but shows increased mismatch-directed exonuclease activity. Interestingly, mutation of Pro-680 has a Q677A-like effect on polymerase activity and an N678A-like effect on the exonuclease activity. Mutation of Pro-680 to Gly or Gin results in a 10-30-fold reduction in k(cat) on homo- and heteropolymeric template-primers, with no significant change in relative DNA binding affinity or K-m(dNTP). The mutants P680G and P680Q also showed a nearly complete loss in the processive mode of DNA synthesis. Since the side chain of proline is generally non-reactive, mutation of Pro-680 may be expected to alter the physical form of the J-helix itself. The biochemical properties of P680G/P680Q together with the structural observation that J-helix assumes helical or coiled secondary structure in the polymerase or exonuclease mode-bound DNA complexes suggest that the structural alteration in the J-helix region may be responsible for the controlled shuttling of DNA between the polymerase and the exonuclease sites.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, MJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.				NIGMS NIH HHS [GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CARROLL SS, 1990, CHEM REV, V90, P1291, DOI 10.1021/cr00105a011; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Rechkoblit O, 1999, BIOCHEMISTRY-US, V38, P11834, DOI 10.1021/bi990614k; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETLOW P, 1972, J BIOL CHEM, V247, P224; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Singh K, 1998, TRENDS BIOCHEM SCI, V23, P277, DOI 10.1016/S0968-0004(98)01250-X	27	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23759	23768		10.1074/jbc.M001804200	http://dx.doi.org/10.1074/jbc.M001804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818095	hybrid			2022-12-25	WOS:000088564200050
J	Aharoni, A; Weiner, L; Ottolenghi, M; Sheves, M				Aharoni, A; Weiner, L; Ottolenghi, M; Sheves, M			Bacteriorhodpsin experiences light-induced conformational alterations in nonisomerizable C-13=C-14 pigments - A study with EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON CRYSTALLOGRAPHY; PROTEIN-STRUCTURE; SPIN; DYNAMICS; CHROMOPHORE; PHOTOCYCLE; MUTANTS; EVENTS; PHOTOISOMERIZATION	The mechanism by which bacteriorhodopsin is activated following light absorption is not completely clear. We have detected protein conformational alterations following light absorption by retinal-based chromophores in the bacteriorhodopsin binding site by monitoring the rate of reduction-oxidation reactions of covalently attached spin labels, using EPR spectroscopy. It was found that the reduction reaction with hydroxylamine is light-catalyzed in the A103C-labeled pigment but not in E74C or M163C. The reaction is light-catalyzed even when isomerization of the C-13=C-14 bond of the retinal chromophore is prevented. The reverse oxidation reaction with molecular oxygen is effective only in apomembrane derived from the mutant A103C. This reaction is light-accelerated following light absorption of the retinal oxime, which occupies the binding site. The light-induced acceleration is evident also in "locked" bacteriorhodopsin in which isomerization around the C-13=C-14 bond is prevented. It is evident that the chromophore-protein covalent bond is not a prerequisite for protein response. In contrast to the case of the retinal oxime, a reduced C=N bond A103C-labeled pigment did not exhibit acceleration of the oxidation reaction following light absorption. Acceleration was observed, however, following substitution of the polyene by groups that modify the excited state charge delocalization. It is suggested that protein conformational alterations are induced by charge redistribution along the retinal polyene following light absorption.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Serv, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem	Ottolenghi, M (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.		Lev, Weiner/GZK-4484-2022	Aharoni, Amir/0000-0003-2701-6996				AKHTAR M, 1968, BIOCHEM J, V110, P693, DOI 10.1042/bj1100693; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BECHER B, 1977, BIOPHYS J, V19, P285, DOI 10.1016/S0006-3495(77)85588-4; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FAN J, 1983, J AM CHEM SOC, V105, P5162; FEIX YV, 1998, SPIN LABELING, P251; FREEDMAN KA, 1986, J AM CHEM SOC, V108, P1245, DOI 10.1021/ja00266a020; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 1999, INT REV CYTOL, V187, P161, DOI 10.1016/S0074-7696(08)62418-3; LEWIS A, 1978, P NATL ACAD SCI USA, V75, P549, DOI 10.1073/pnas.75.2.549; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Mitsuoka K, 1999, J MOL BIOL, V286, P861, DOI 10.1006/jmbi.1998.2529; NETTLETON DO, 1989, ARCH BIOCHEM BIOPHYS, V271, P414, DOI 10.1016/0003-9861(89)90291-9; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTOLENGHI M, 1995, ISR J CHEM, V35, P193; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Pfeiffer M, 1999, J MOL BIOL, V287, P163, DOI 10.1006/jmbi.1998.2593; Rink T, 1997, BIOPHYS J, V73, P983, DOI 10.1016/S0006-3495(97)78131-1; ROOZEN MJGW, 1990, J PHYS CHEM-US, V94, P7326, DOI 10.1021/j100381a068; Rousso I, 1997, P NATL ACAD SCI USA, V94, P7937, DOI 10.1073/pnas.94.15.7937; Rousso I, 1998, BIOPHYS J, V75, P413, DOI 10.1016/S0006-3495(98)77526-5; Rousso I, 1996, J AM CHEM SOC, V118, P11299, DOI 10.1021/ja960404k; SALEM L, 1975, NATURE, V258, P526, DOI 10.1038/258526a0; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SHEVES M, 1985, BIOCHEMISTRY-US, V24, P1260, DOI 10.1021/bi00326a031; STEINHOFF HJ, 1995, BIOPHYS CHEM, V56, P89, DOI 10.1016/0301-4622(95)00019-T; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; Xu D, 1996, BIOPHYS J, V70, P453, DOI 10.1016/S0006-3495(96)79588-7	40	24	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21010	21016		10.1074/jbc.M001208200	http://dx.doi.org/10.1074/jbc.M001208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801804	hybrid			2022-12-25	WOS:000088230600008
J	Fukuyama, K; Yoshida, M; Yamashita, A; Deyama, T; Baba, M; Suzuki, A; Mohri, H; Ikezawa, Z; Nakajima, H; Hirai, S; Ohno, S				Fukuyama, K; Yoshida, M; Yamashita, A; Deyama, T; Baba, M; Suzuki, A; Mohri, H; Ikezawa, Z; Nakajima, H; Hirai, S; Ohno, S			MAPK upstream kinase (MUK)-binding inhibitory protein, a negative regulator of MUK/dual leucine zipper-bearing kinase/leucine zipper protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED LINEAGE KINASE-2; SIGNAL-TRANSDUCTION; DIFFERENTIAL ACTIVATION; MOLECULAR-CLONING; BINDING-PROTEINS; CELL-DEATH; ZPK GENE; JNK; APOPTOSIS; PATHWAYS	Mitogen-activated protein kinase upstream kinase/dual leucine zipper-bearing kinase/leucine-zipper protein kinase (MUK/DLK/ZPK) is a MAPKKK class protein kinase that induces JNK/SAPK activation. We report here a protein named MBIP that binds to MUK/DLK/ZPK. MUK-binding inhibitory protein (MBIP) contains two tandemly orientated leucine-zipper-like motifs with a cluster of basic amino acids located between the two motifs. MBIP interacts with one of the two leucine-zipper-like motifs of MUK/DLK/ZPK and inhibits the activity of MUK/DLK/ZPK to induce JNK/SAPK activation. Notably, no similar effect was observed with another JNK/SAPK-inducing MAPKKK, COT/Tp1-2, showing the specificity of MBIP action. Furthermore, the overexpression of MBIP partially inhibits the activation of JNK by 0.3 M sorbitol in 293T cells. Taken together, these observations indicate that MBIP can function as a regulator of MUK/DLK/ZPK, a finding that may provide a clue to understanding the molecular mechanism of JNK/SAPK activation by hyperosmotic stress.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Yokohama City University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	sh3312@med.yokohama-cu.ac.jp	Ohno, Shigeo/B-1768-2010; Baba, Masaya/L-7490-2013; Baba, Masaya/ABE-4893-2020	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; 				Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Douziech M, 1999, J HISTOCHEM CYTOCHEM, V47, P1287, DOI 10.1177/002215549904701008; Douziech M, 1998, BIOCHEM BIOPH RES CO, V249, P927, DOI 10.1006/bbrc.1998.9249; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee TH, 1999, MOL BIOL CELL, V10, P1445, DOI 10.1091/mbc.10.5.1445; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Rasmussen RK, 1998, ELECTROPHORESIS, V19, P809, DOI 10.1002/elps.1150190535; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	45	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21247	21254		10.1074/jbc.M001488200	http://dx.doi.org/10.1074/jbc.M001488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801814	hybrid			2022-12-25	WOS:000088230600040
J	Svensson, EC; Huggins, GS; Dardik, FB; Polk, CE; Leiden, JM				Svensson, EC; Huggins, GS; Dardik, FB; Polk, CE; Leiden, JM			A functionally conserved N-terminal domain of the friend of GATA-2 (FOG-2) protein represses GATA4-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; HEART TUBE FORMATION; GENE-EXPRESSION; VENTRAL MORPHOGENESIS; ENDOTHELIAL-CELLS; BINDING PROTEIN; ENCODING GENE; CO-REPRESSOR; FAMILY; COFACTOR	GATA4 is a transcriptional activator of cardiac-restricted promoters and is required for normal cardiac morphogenesis. Friend of GATA-2 (FOG-2) is a multizine finger protein that associates with GATA4 and represses GATA4-dependent transcription. To better understand the transcriptional repressor activity of FOG-2 we performed a functional analysis of the FOG-2 protein. The results demonstrated that 1) zinc fingers 1 and 6 of FOG-2 are each capable of interacting with evolutionarily conserved motifs within the N-terminal zinc finger of mammalian GATA proteins, 2) a nuclear localization signal (RKRRK) (amino acids 736-740) is required to program nuclear targeting of FOG-2, and 3) FOG-2 can interact with the transcriptional co-repressor, C-terminal-binding protein-2 via a conserved sequence motif in FOG-2 (PIDLS). Surprisingly, however, this interaction with C-terminal-binding protein-2 is not required for FOG-2-mediated repression of GATA4-dependent transcription. instead, we have identified a novel N-terminal domain of FOG-2 (amino acids 1-247) that is both necessary and sufficient to repress GATA4-dependent transcription. This N-terminal repressor domain is functionally conserved in the related protein, Friend of GATA1, Taken together, these results define a set of evolutionarily conserved mechanisms by which FOG proteins repress GATA-dependent transcription and thereby form the foundation for genetic studies designed to elucidate the role of FOG-2 in cardiac development.	Harvard Univ, Sch Publ Hlth, Lab Cardiovasc Biol, Boston, MA 02115 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Chicago; Harvard University; Harvard Medical School	Leiden, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Lab Cardiovasc Biol, Bldg 2,Rm 117,677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL54592, R01 HL054592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854	38	99	102	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20762	20769		10.1074/jbc.M001522200	http://dx.doi.org/10.1074/jbc.M001522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801815	hybrid			2022-12-25	WOS:000088084500076
J	D'Haeze, W; Mergaert, P; Prome, JC; Holsters, M				D'Haeze, W; Mergaert, P; Prome, JC; Holsters, M			Nod factor requirements for efficient stem and root nodulation of the tropical legume Sesbania rostrata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITRO SULFOTRANSFERASE ACTIVITY; LIPO-OLIGOSACCHARIDE SIGNALS; AZORHIZOBIUM-CAULINODANS; RHIZOBIUM-MELILOTI; HOST-RANGE; ESCHERICHIA-COLI; IN-VITRO; STRUCTURAL MODIFICATIONS; SUBSTRATE-SPECIFICITY; SINORHIZOBIUM-SAHELI	Azorhizobium caulinodans ORS571 synthesizes mainly pentameric Nod factors with a household fatty acid, an N-methyl, and a 6-O-carbamoyl group at the nonreducing-terminal residue and with a D-arabinosyl, an L-fucosyl group, or both at the reducing-terminal residue. Nodulation on Sesbania rostrata was carried out with a set of bacterial mutants that produce well characterized Nod factor populations. Purified Nod factors were tested for their capacity to induce root hair formation and for their stability in an in vitro degradation assay with extracts of uninfected adventitious rootlets. The glycosylations increased synergistically the nodulation efficiency and the capacity to induce root hairs, and they protected the Nod factor against degradation. The D-arabinosyl group was more important than the L-fucosyl group for nodulation efficiency. Replacement of the 6-O-L-fucosyl group by a 6-O-sulfate ester did not affect Nod factor stability, but reduced nodulation efficiency, indicating that the L-fucosyl group may play a role in recognition. The 6-O-carbamoyl group contributes to nodulation efficiency, biological activity, and protection, but could be replaced by a 6-O-acetyl group for root nodulation. The results demonstrate that none of the studied substitutions is strictly required for triggering normal nodule formation. However, the nodulation efficiency was greatly determined by the synergistic presence of substitutions. Within the range tested, fluctuations of Nod factor amounts had little impact on the symbiotic phenotype.	Univ Ghent, Vakgrp Mol Genet, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Plantengenet, B-9000 Ghent, Belgium; Univ Toulouse 3, UMR 5623 CNRS, Interact Mol & Reactiv Chim & Photochim, Lab Spectrometrie Masse & Signaux Biol, F-31062 Toulouse, France	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	D'Haeze, W (corresponding author), Univ Ghent, Vakgrp Mol Genet, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	mahol@gengenp.rug.ac.be	Mergaert, Peter/M-1265-2019	Mergaert, Peter/0000-0002-5919-7317				ARDOUREL M, 1994, PLANT CELL, V6, P1357, DOI 10.1105/tpc.6.10.1357; ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BERG DE, 1980, J BACTERIOL, V142, P439, DOI 10.1128/JB.142.2.439-446.1980; Bladergroen MR, 1998, CURR OPIN PLANT BIOL, V1, P353, DOI 10.1016/1369-5266(88)80059-1; BLOEMBERG GV, 1995, BIOCHEMISTRY-US, V34, P12712, DOI 10.1021/bi00039a030; BLOEMBERG GV, 1994, MOL MICROBIOL, V11, P793, DOI 10.1111/j.1365-2958.1994.tb00357.x; CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; D'Haeze W, 1999, MOL PLANT MICROBE IN, V12, P68, DOI 10.1094/MPMI.1999.12.1.68; de Lajudie P, 1998, INT J SYST BACTERIOL, V48, P1277, DOI 10.1099/00207713-48-4-1277; DELAJUDIE P, 1994, INT J SYST BACTERIOL, V44, P715, DOI 10.1099/00207713-44-4-715; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DREYFUS B, 1988, INT J SYST BACTERIOL, V38, P89, DOI 10.1099/00207713-38-1-89; EHRHARDT DW, 1995, J BACTERIOL, V177, P6237, DOI 10.1128/jb.177.21.6237-6245.1995; FAUCHER C, 1989, MOL PLANT MICROBE IN, V2, P291, DOI 10.1094/MPMI-2-291; FELLE H, 1988, PHYSIOL PLANTARUM, V74, P583, DOI 10.1111/j.1399-3054.1988.tb02022.x; FELLE HH, 1995, PLANT J, V7, P939, DOI 10.1046/j.1365-313X.1995.07060939.x; Felle HH, 1996, PLANT J, V10, P295, DOI 10.1046/j.1365-313X.1996.10020295.x; Fernandez-Lopez M, 1998, P NATL ACAD SCI USA, V95, P12724, DOI 10.1073/pnas.95.21.12724; FernandezLopez M, 1996, MOL MICROBIOL, V20, P993, DOI 10.1111/j.1365-2958.1996.tb02540.x; GEELEN D, 1995, MOL MICROBIOL, V17, P387, DOI 10.1111/j.1365-2958.1995.mmi_17020387.x; GEELEN D, 1993, MOL MICROBIOL, V9, P145, DOI 10.1111/j.1365-2958.1993.tb01676.x; Gehring CA, 1997, MOL PLANT MICROBE IN, V10, P791, DOI 10.1094/MPMI.1997.10.7.791; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GOETHALS K, 1992, MOL PLANT MICROBE IN, V5, P405, DOI 10.1094/MPMI-5-405; Goormachtig S, 1998, PLANT CELL, V10, P905, DOI 10.1105/tpc.10.6.905; Goormachtig S, 1995, MOL PLANT MICROBE IN, V8, P816, DOI 10.1094/MPMI-8-0816; Heidstra R, 1996, NEW PHYTOL, V133, P25, DOI 10.1111/j.1469-8137.1996.tb04339.x; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; Kamst E, 1998, Subcell Biochem, V29, P29; KONDOROSI E, 1994, CURR PLANT SCI BIOT, V21, P115; Laeremans T, 1999, MOL PLANT MICROBE IN, V12, P820, DOI 10.1094/MPMI.1999.12.9.820; LopezLara IM, 1996, MOL MICROBIOL, V21, P397, DOI 10.1046/j.1365-2958.1996.00644.x; Lorquin J, 1997, MOL PLANT MICROBE IN, V10, P879, DOI 10.1094/MPMI.1997.10.7.879; MERGAERT P, 1995, J BIOL CHEM, V270, P29217, DOI 10.1074/jbc.270.49.29217; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; Mergaert P, 1996, MOL MICROBIOL, V21, P409, DOI 10.1046/j.1365-2958.1996.6451366.x; Mergaert P, 1997, MOL MICROBIOL, V25, P811, DOI 10.1111/j.1365-2958.1997.mmi526.x; Mergaert P, 1997, FEBS LETT, V409, P312, DOI 10.1016/S0014-5793(97)00461-4; Mergaert P, 1997, MOL PLANT MICROBE IN, V10, P683, DOI 10.1094/MPMI.1997.10.5.683; Miller DD, 1999, PLANT J, V17, P141, DOI 10.1046/j.1365-313X.1999.00358.x; Ovtsyna AO, 1998, MOL PLANT MICROBE IN, V11, P418, DOI 10.1094/MPMI.1998.11.5.418; Pingret JL, 1998, PLANT CELL, V10, P659; QuesadaVincens D, 1997, J BACTERIOL, V179, P5087, DOI 10.1128/jb.179.16.5087-5093.1997; Reli B., 1994, P 1 EUR NITR FIX C S, P69; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULTZE M, 1995, P NATL ACAD SCI USA, V92, P2706, DOI 10.1073/pnas.92.7.2706; Schultze M, 1996, WORLD J MICROB BIOT, V12, P137, DOI 10.1007/BF00364678; Schultze M, 1998, PLANT J, V16, P571, DOI 10.1046/j.1365-313x.1998.00326.x; Schultze M, 1998, ANNU REV GENET, V32, P33, DOI 10.1146/annurev.genet.32.1.33; SPAINK HP, 1992, MOL PLANT MICROBE IN, V5, P72, DOI 10.1094/MPMI-5-072; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1995, J BACTERIOL, V177, P6276, DOI 10.1128/jb.177.21.6276-6281.1995; STAEHELIN C, 1994, P NATL ACAD SCI USA, V91, P2196, DOI 10.1073/pnas.91.6.2196; STAEHELIN C, 1994, PLANT J, V5, P319, DOI 10.1111/j.1365-313X.1994.00319.x; STAEHELIN C, 1995, PLANT PHYSIOL, V108, P1607, DOI 10.1104/pp.108.4.1607; STOKKERMANS TJW, 1995, PLANT PHYSIOL, V108, P1587, DOI 10.1104/pp.108.4.1587	60	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15676	15684		10.1074/jbc.275.21.15676	http://dx.doi.org/10.1074/jbc.275.21.15676			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821846	hybrid			2022-12-25	WOS:000087291400013
J	Marchenko, ND; Zaika, A; Moll, UM				Marchenko, ND; Zaika, A; Moll, UM			Death signal-induced localization of p53 protein to mitochondria - A potential role in apoptotic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; NUCLEAR EXPORT; LEADER PEPTIDE; OUTER-MEMBRANE; BCL-2 PROTEIN; HELA-CELLS; ACTIVATION	The mechanism of p53-mediated apoptosis after cellular stress remains poorly understood. Evidence suggests that p53 induces cell death by a multitude of molecular pathways involving activation of target genes and transcriptionally independent direct signaling. Mitochondria play a key role in apoptosis, We show here that a fraction of p53 protein localizes to mitochondria at the onset of p53-dependent apoptosis but not during p53-independent apoptosis or p53-mediated cell cycle arrest. The accumulation of p53 to mitochondria is rapid (within 1 h after p53 activation) and precedes changes in mitochondrial membrane potential, cytochrome c release, and procaspase-3 activation. Immunoelectron microscopy and immuno-fluorescence-activated cell sorter analysis of isolated mitochondria show that the majority of mitochondrial p53 localizes to the membranous compartment, whereas a fraction is found in a complex with the mitochondrial import motor mt hsp70, After induction of ectopic p53 without additional DNA damage in p53-deficient cells, p53 again partially localizes to mitochondria, preceding the onset of apoptosis, Overexpression of anti-apoptotic Bcl-2 or Bcl-xL abrogates stress signal-mediated mitochondrial p53 accumulation and apoptosis but not cell cycle arrest, suggesting a feedback signaling loop between p53 and mitochondrial apoptotic regulators. Importantly, bypassing the nucleus by targeting p53 to mitochondria using import leader fusions is sufficient to induce apoptosis in p53-deficient cells. We propose a model where p53 can contribute to apoptosis by direct signaling at the mitochondria, thereby amplifying the transcription-dependent apoptosis of p53.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@path.som.sunysb.edu						AGGARWAL BB, 1985, METHOD ENZYMOL, V116, P448; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	55	761	783	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16202	16212		10.1074/jbc.275.21.16202	http://dx.doi.org/10.1074/jbc.275.21.16202			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821866	hybrid			2022-12-25	WOS:000087291400081
J	Renard, P; Percherancier, Y; Kroll, M; Thomas, D; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F				Renard, P; Percherancier, Y; Kroll, M; Thomas, D; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F			Inducible NF-kappa B activation is permitted by simultaneous degradation of nuclear I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED UBIQUITINATION; DEPENDENT DEGRADATION; TRANSCRIPTION FACTOR; PROTEASOME PATHWAY; IMMUNE-RESPONSES; EXPORT SIGNAL; LEPTOMYCIN-B; DNA-BINDING; BETA-TRCP; IKK-ALPHA	Signal-induced phosphorylation and ubiquitination of I kappa B alpha targets this inhibitor of NF-kappa B for proteasome-mediated degradation, thus permitting the release of active NF-kappa B. Upon cell stimulation, NF-kappa B activation results in neo-transcription and neosynthesis of its own inhibitor, I kappa B alpha, As reported earlier, the neosynthesized inhibitor is then accumulated in the nucleus, where it rapidly binds to and terminates the function of nuclear NF-kappa B upon withdrawal of the stimulus. The present work was aimed at understanding how NF-kappa B activity is preserved while stimuli persist, despite intense, simultaneous I kappa B alpha neosynthesis, which would be expected to end NF-kappa B activity. We here show that incoming I kappa B alpha in the nucleus represents a target for resident nuclear proteasome complexes. Signal-induced, proteasome-dependent degradation of phosphorylated and ubiquitinated I kappa B alpha! occurs in the nucleus, thus permitting the onset and persistence of NF-kappa B activity as long as stimulation is maintained. Our results suggest that intranuclear proteolysis of I kappa B alpha is necessarily required to avoid self-termination of NF-kappa B activity during cell activation.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bachelerie, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.		Arenzana-Seisdedos, Fernando/E-5835-2016; BACHELERIE, FRANCOISE/F-8823-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277; percherancier, yann/0000-0002-2410-5806				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	52	51	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15193	15199		10.1074/jbc.275.20.15193	http://dx.doi.org/10.1074/jbc.275.20.15193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809754	hybrid			2022-12-25	WOS:000087128300058
J	Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H				Yanagisawa, K; Uchida, K; Nagatake, M; Masuda, A; Sugiyama, M; Saito, T; Yamaki, K; Takahashi, T; Osada, H			Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers	ONCOGENE			English	Article						Smad; transforming growth factor-beta; lung cancer; growth inhibition; oligomerization	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR SMAD4; IN-VIVO ALTERATIONS; TGF-BETA; SIGNAL-TRANSDUCTION; DNA-BINDING; DPC4 GENE; RECEPTOR	Smad family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities. The loss of sensitivity to TGF-beta is frequent in human lung cancers and inactivation of Smad family members are thought to play important roles in disruption of TGF-beta signaling. In the study presented here, we characterized the biological and biochemical functions of six Smad2 and Smad4 mutants, which we previously identified in human lung cancers. All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription. Transcriptional activation of plasminogen activator inhibitor type 1 (PAI-1) was impaired in four of the six mutants due to the defects in homo- and/or hetero-oligomerization with wild-type Smads, In contrast, the remaining two Smad mutants showed a modest reduction in the PAI-1 transcriptional activation and apparently retained the ability to oligomerize with wild-type Smads, Significant loss of growth inhibition and Smad/hFAST-1-mediated transcriptional activation by all of the six mutants suggested that Smad mutants are indeed functionally impaired Smad mutations and may play a role in lung tumorigenesis, Moreover, the present findings suggest that in addition to the impairment in the homo- and/or hetero-oligomerization, there may be an alternative mechanism producing disruption of TGF-beta signaling, involving hFAST-1-or possibly other transcriptional cofactor(s)-mediated transcriptional activation.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagatake M, 1996, CANCER RES, V56, P2718; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	35	44	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2305	2311		10.1038/sj.onc.1203591	http://dx.doi.org/10.1038/sj.onc.1203591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822381				2022-12-25	WOS:000086974300005
J	Kimmelman, AC; Osada, M; Chan, AML				Kimmelman, AC; Osada, M; Chan, AML			R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells	ONCOGENE			English	Article						R-Ras3; M-Ras; PI3-K; Akt; survival	NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; NEURONAL SURVIVAL; NEURITE OUTGROWTH; ONCOGENIC RAS; R-RAS; TRANSFORMATION; KINASE; TARGET	The GTP-binding protein, R-Ras3/M-Ras, is a novel member of the Ras subfamily of GTPases which shows highest sequence similarity to the TC21 gene. R-Ras3 is highly expressed in both human and mouse brain and ectopic expression of a constitutively active mutant of R-Ras3 induces cellular transformation in NIH3T3 cells. To gain further insight into the normal cellular function of R-Ras3, we examined the ability of R-Ras3 in activating several known intracellular signaling cascades. We observed that R-Ras3 is a relatively weak activator of the mitogen-activated protein kinase/extracellular-signal-regulated kinases (MAPK/ERKs) when compared to the EI-Ras oncogene. On the contrary, both R-Ras3 and H-Ras activated the Jun N-terminal kinase (JNK) to a similar extent, Under similar experimental conditions, R-Ras3 significantly stimulated one of the phosphatidylinositol 3-kinase (PI3-K) downstream substrates, Akt/PKB/RAC (Akt), which has been extensively implicated in mediating cell survival signaling. The activation of Akt by R-Ras3 was most likely to be PI3-K-dependent since this biochemical event was blocked by the pharmacological inhibitors, Wortmannin and LY294002, as well as by a dominant negative mutant of PI3-K. More importantly, R-Ras3 affinity-precipitated PI3-K from cell extracts in a GTP-dependent manner, and associated lipid kinase activity,vas readily detectable in R-Ras3 immune complexes. The biological significance of R-Ras3 in inducing Akt kinase activity is evidenced by the ability of an activated R-Ras3 to confer cell survival in the rat pheochromocytoma cell line, PC12, As expected, this biological activity of R-Ras3 was also abrogated by the addition of LY294002. Thus, R-Ras3 represents a novel G-protein which may play a role in cell survival of neural-derived cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AML (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R01CA066654, R29CA078509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059771] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA66654] Funding Source: Medline; NIMH NIH HHS [MH59771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COLLINS F, 1991, J NEUROSCI, V11, P2582; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAEZ R, 1994, ONCOGENE, V9, P2977; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	48	41	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2014	2022		10.1038/sj.onc.1203530	http://dx.doi.org/10.1038/sj.onc.1203530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803462				2022-12-25	WOS:000086613200005
J	Diaz, JF; Strobe, R; Engelborghs, Y; Souto, AA; Andreu, JM				Diaz, JF; Strobe, R; Engelborghs, Y; Souto, AA; Andreu, JM			Molecular recognition of Taxol by microtubules - Kinetics and thermodynamics of binding of fluorescent Taxol derivatives to an exposed site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; TUBULIN DOUBLE RINGS; BETA-TUBULIN; GDP-TUBULIN; GUANOSINE 5'-TRIPHOSPHATE; NUCLEATED MICROTUBULES; PACLITAXEL RESISTANCE; PROTOFILAMENT NUMBER; COMPUTER-SIMULATION; PURIFIED TUBULIN	We have determined the kinetic scheme and the reaction rates of binding to microtubules of two fluorescent taxoids, 7-O-[N-(4'-fluoresceincarbonyl)-L-alanyl]Taxol (Flutax-1) and 7-O-[N-(2,7-difluoro-4'-fluoresceincarbonyl)-L-alanyl]Taxol (Flutax-2). Flutax-1 and Flutax-2 bind to microtubules with high affinity (K-a approximate to 10(7) M-1, 37 degrees C), The binding mechanism consists of a fast bimolecular reaction followed by at least two monomolecular rearrangements, which were characterized with stopped-flow techniques. The kinetic constants of the bimolecular reaction were 6.10 +/- 0.22 x 10(5) M-1 s(-1) and 13.8 +/- 1.8 x 10(5) M-1 s(-1) at 37 degrees C, respectively. A second slow binding step has been measured employing the change of fluorescence anisotropy of the probe. The reversal of this reaction is the rate-limiting step of dissociation, A third step has been detected using small angle x-ray scattering and involves a 2-nm increase in the diameter of microtubules. It is suggested that the first step entails the binding of the Taxol moiety and the second a relative immobilization of the fluorescent probe. The equilibrium and some kinetic measurements required the use of stabilized cross-linked microtubules, which preserved taxoid binding. The results indicate that the Taxol binding site is directly accessible, in contrast with its location at lumen in the current model of microtubules. An alternative structural model is considered in which the binding site is located between protofilaments, accessible from the microtubule surface.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; CSIC, Inst Quim Organ, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); KU Leuven; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)	Diaz, JF (corresponding author), CSIC, Ctr Invest Biol, C Velazquez 144, E-28006 Madrid, Spain.		Díaz, J. Fernando/U-3532-2017; Souto, Andre A/E-6737-2011; Díaz, J. Fernando/M-6853-2019	Díaz, J. Fernando/0000-0003-2743-3319; Souto, Andre A/0000-0002-2437-8767; Díaz, J. Fernando/0000-0003-2743-3319; Andreu, Jose M/0000-0001-8064-6933				ANDREU JM, 1994, J BIOL CHEM, V269, P31785; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BERG HC, 1983, RANDOM WALKS BIOL, P17; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; CAPLOW M, 1994, J BIOL CHEM, V269, P23399; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; CHOUDHURY GG, 1987, BIOCHEM CELL BIOL, V65, P558, DOI 10.1139/o87-072; CROSS AR, 1991, CELL MOTIL CYTOSKEL, V20, P272, DOI 10.1002/cm.970200403; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14184, DOI 10.1021/bi961356j; Diaz JF, 1998, REV SCI INSTRUM, V69, P286, DOI 10.1063/1.1148510; Diaz JF, 1996, BIOPHYS J, V70, P2408, DOI 10.1016/S0006-3495(96)79809-0; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DYE RB, 1993, J BIOL CHEM, V268, P6847; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; Gelmon K, 1999, J CLIN ONCOL, V17, P3038, DOI 10.1200/JCO.1999.17.10.3038; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; Han Y, 1996, BIOCHEMISTRY-US, V35, P14173, DOI 10.1021/bi960774l; HIMES RH, 1982, CELL BIOL INT REP, V6, P667; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; Jimenez-Barbaro J, 1998, BIOORGAN MED CHEM, V6, P1857, DOI 10.1016/S0968-0896(98)00149-7; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; KRUGER P, 1991, COMPUT PHYS COMMUN, V62, P371, DOI 10.1016/0010-4655(91)90108-W; KUMAR N, 1981, J BIOL CHEM, V256, P435; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Li YK, 2000, BIOCHEMISTRY-US, V39, P616, DOI 10.1021/bi992044u; McGuire WP, 1999, ANN ONCOL, V10, P29, DOI 10.1023/A:1008303300675; Menendez M, 1998, J BIOL CHEM, V273, P167, DOI 10.1074/jbc.273.1.167; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Oosawa F., 1975, THERMODYNAMICS POLYM, P204; PARNESS J, 1983, CELL MOTIL CYTOSKEL, V3, P123, DOI 10.1002/cm.970030203; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; PRAKASH V, 1982, J MOL BIOL, V160, P499, DOI 10.1016/0022-2836(82)90310-2; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1997, SEMIN ONCOL S19, V24, P1; SCHEELE RB, 1982, J MOL BIOL, V154, P485, DOI 10.1016/S0022-2836(82)80008-9; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Shi Q, 1998, CURR PHARM DESIGN, V4, P219; Souto AA, 1995, ANGEW CHEM INT EDIT, V34, P2710; SOUTO AA, 1997, THESIS U COMPLUTENSE; Symmons MF, 1996, J CELL SCI, V109, P2755; Turner D, 1996, ANAL BIOCHEM, V242, P20, DOI 10.1006/abio.1996.0422; Vulevic B, 1997, BIOPHYS J, V72, P1357, DOI 10.1016/S0006-3495(97)78782-4; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	58	110	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26265	26276		10.1074/jbc.M003120200	http://dx.doi.org/10.1074/jbc.M003120200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10818101	hybrid, Green Published			2022-12-25	WOS:000088999700054
J	Patil, AR; Thomas, CJ; Surolia, A				Patil, AR; Thomas, CJ; Surolia, A			Kinetics and the mechanism of interaction of the endoplasmic reticulum chaperone, calreticulin, with monoglucosylated (Glc(1)Man(9)GlcNAc(2)) substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; ASPARAGINE-LINKED OLIGOSACCHARIDES; CARBOHYDRATE-BINDING SPECIFICITY; MOLECULAR CHAPERONE; POLYMYXIN-B; CLASS-I; CALNEXIN; PROTEIN; LECTIN; GLYCOPROTEIN	Calreticulin is a lectin-like molecular chaperone of the endoplasmic reticulum in eukaryotes. Its interaction with N-glycosylated polypeptides is mediated by the glycan, Glc(1)Man(9)GlcNAc(2), present on the target glycoproteins. In this work, binding of monoglucosyl IgG (chicken) substrate to calreticulin has been studied using real time association kinetics of the interaction with the biosensor based on surface plasmon resonance (SPR). By SPR, accurate association and dissociation rate constants were determined, and these yielded a micromolar association constant. The nature of reaction was unaffected by immobilization of either of the reactants. The Scatchard analysis values for K-a agreed web crith the one obtained by the ratio k(1)/k(-1). The interaction was completely inhibited by free oligosaccharide, Glc(1)Man(9)GlcNAc(2), whereas Man(9)GlcNAc(2) did not bind to the calreticulin-substrate complex, attesting to the exquisite specificity of this interaction. The binding of calreticulin to IgG was used for the development of immunoassay and the relative affinity of the lectin-substrate association was indirectly measured. The values are in agreement with those obtained with SPR. Although the reactions are several orders of magnitude slower than the diffusion controlled processes, the data are qualitatively and quantitatively consistent with single-step bimolecular association and dissociation reaction. Analyses of the activation parameters indicate that reaction is enthalpically driven and does not involve a highly ordered transition state. Based on these data, the mechanism of its chaperone activity is briefly discussed.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Blikstad I, 1996, ANAL BIOCHEM, V233, P42, DOI 10.1006/abio.1996.0005; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARINA RD, 1980, BIOCHIM BIOPHYS ACTA, V631, P428, DOI 10.1016/0304-4165(80)90019-7; FASMAN GD, 1985, CRC HDB BIOCH MOL BI; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P7495, DOI 10.1021/bi00190a001; GUPTA D, 1994, GLYCOCONJUGATE J, V11, P558, DOI 10.1007/BF00731307; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Harris MR, 1998, J IMMUNOL, V160, P5404; Herbert Daniel N., 1995, Cell, V81, P425; Herbert Daniel N., 1997, Journal of Cell Biology, V139, P613; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JORDAN ET, 1995, EUR J BIOCHEM, V230, P958, DOI 10.1111/j.1432-1033.1995.tb20642.x; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laidler K. J., 1979, THEORIES CHEM REACTI, P41; LEE RT, 1989, BIOCHEMISTRY-US, V28, P8351, DOI 10.1021/bi00447a013; Lin ZL, 1996, P NATL ACAD SCI USA, V93, P1977, DOI 10.1073/pnas.93.5.1977; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; NATSUME T, 1994, J BIOL CHEM, V269, P31224; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OHTA M, 1991, GLYCOCONJUGATE J, V8, P400, DOI 10.1007/BF00731292; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302; PODDER SK, 1978, FEBS LETT, V85, P313, DOI 10.1016/0014-5793(78)80481-5; PURI KD, 1993, J BIOL CHEM, V268, P16378; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rao JH, 1999, J AM CHEM SOC, V121, P2629, DOI 10.1021/ja9838763; Reddy GB, 1999, J BIOL CHEM, V274, P4500, DOI 10.1074/jbc.274.8.4500; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; SHINOHARA Y, 1994, EUR J BIOCHEM, V223, P189, DOI 10.1111/j.1432-1033.1994.tb18982.x; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TARUN K, 1998, J BIOL CHEM, V273, P5528; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Thomas CJ, 1999, FEBS LETT, V445, P420, DOI 10.1016/S0014-5793(99)00150-7; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1997, GUIDE BOOK MOL CHAPE, P293; YAMAMOTO K, 1994, BIOCHEMISTRY-US, V33, P8159, DOI 10.1021/bi00192a021; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	67	71	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24348	24356		10.1074/jbc.M003102200	http://dx.doi.org/10.1074/jbc.M003102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821837	hybrid			2022-12-25	WOS:000088683300016
J	Patzer, SI; Hantke, K				Patzer, SI; Hantke, K			The zinc-responsive regulator Zur and its control of the znu gene cluster encoding the ZnuABC zinc uptake system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; UPTAKE REGULATION PROTEIN; BACILLUS-SUBTILIS; CLONING VECTORS; FUR REPRESSOR; BINDING; DNA; IDENTIFICATION; EXPRESSION; SEQUENCES	The synthesis of the Escherichia coli zinc transporter, encoded by the znuACB gene cluster, is regulated in response to the intracellular zinc concentration by the zur gene product. Inactivation of the zur gene demonstrated that Zur acts as a repressor when binding Zn2+ Eight chromosomal mutant zur alleles were sequenced to correlate the loss of Zur function with individual mutations. Wild-type Zur and Zur Delta 46-91 formed homoand heterodimers. Dimerization was independent of metal ions since it also occurred in the presence of metal chelators. Using an in vivo titration assay, the znu operator was narrowed down to a 31-base pair region overlapping the translational start site of znuA. This location was confirmed by footprinting assays. Zur directly binds to a single region comprising a nearly perfect palindrome. Zinc chelators completely inhibited and Zn2+ in low concentrations enhanced DNA binding of Zur, No evidence for autoregulation of Zur was found. Zur binds at least 2 zinc ions/dimer specifically. Although most of the mutant Zur proteins bound to the znu operator in vitro, no protection was observed in in vivo footprinting experiments. Analysis of the mutant Zur proteins suggested an amino-terminal DNA contact domain around residue 65 and a dimerization and Zn2+-binding domain toward the carboxyl-terminal end.	Univ Tubingen, Lehrstuhl Mikrobiol Membranphysiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Patzer, SI (corresponding author), Univ Tubingen, Lehrstuhl Mikrobiol Membranphysiol, Morgenstelle 28, D-72076 Tubingen, Germany.	silke.patzer@mikrobio.uni-tuebingen.de						Ausubel F., 1999, CURRENT PROTOCOLS MO; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS JM, 1984, J BACTERIOL, V157, P881, DOI 10.1128/JB.157.3.881-890.1984; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Dalet K, 1999, FEMS MICROBIOL LETT, V174, P111, DOI 10.1016/S0378-1097(99)00128-7; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Hantke K, 1997, CH MICROBIOL SER, P11; Heidrich C, 1996, FEMS MICROBIOL LETT, V140, P253, DOI 10.1016/0378-1097(96)00189-9; HENNECKE H, 1990, MOL MICROBIOL, V4, P1621, DOI 10.1111/j.1365-2958.1990.tb00538.x; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLM L, 1994, PROTEIN ENG, V7, P1449, DOI 10.1093/protein/7.12.1449; HUNT MD, 1994, J BACTERIOL, V176, P3944, DOI 10.1128/JB.176.13.3944-3955.1994; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Kaneko T, 1996, DNA Res, V3, P109; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LECAM E, 1994, P NATL ACAD SCI USA, V91, P11816, DOI 10.1073/pnas.91.25.11816; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; SAITO T, 1991, EUR J BIOCHEM, V197, P29, DOI 10.1111/j.1432-1033.1991.tb15878.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SCHMITT MP, 1995, INFECT IMMUN, V63, P4284, DOI 10.1128/IAI.63.11.4284-4289.1995; SHI JG, 1992, FEBS LETT, V303, P159, DOI 10.1016/0014-5793(92)80509-F; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1996, CURRENT PROTOCOLS MO; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	49	162	166	9	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24321	24332		10.1074/jbc.M001775200	http://dx.doi.org/10.1074/jbc.M001775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816566	hybrid			2022-12-25	WOS:000088683300013
J	Bryan, TM; Goodrich, KJ; Cech, TR				Bryan, TM; Goodrich, KJ; Cech, TR			A mutant of Tetrahymena telomerase reverse transcriptase with increased processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; DOUBLE-STRANDED DNA; CATALYTIC SUBUNIT GENE; ANGSTROM RESOLUTION; SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; EUPLOTES AEDICULATUS; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; HUMAN CANCER	The protein catalytic subunit of telomerase (TERT) is a reverse transcriptase (RT) that utilizes an internal RNA molecule as a template for the extension of chromosomal DNA ends. In all retroviral RTs there is a conserved tyrosine two amino acids preceding the catalytic aspartic acids in motif C, a motif that is critical for catalysis, In TERTs, however, this position is a leucine, valine, or phenylalanine, We developed and characterized a robust in vitro reconstitution system for Tetrahymena telomerase and tested the effects of amino acid substitutions on activity. Substitution of the retroviral-like tyrosine in motif C did not change overall enzymatic activity but increased processivity, This increase in processivity correlated with an increased affinity for telomeric DNA primer. Substitution of an alanine did not increase processivity, while substitution of a phenylalanine had an intermediate effect. The data suggest that this amino acid is involved in interactions with the primer in telomerase as in other RTs, and show that mutating an amino acid to that conserved in retroviral RTs makes telomerase more closely resemble these other RTs.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.	thomas.cech@colorado.edu	Bryan, Tracy M/B-8468-2014	Bryan, Tracy/0000-0002-7990-5501				Ahmed S, 1998, GENETICS, V150, P643; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hammond PW, 1997, NUCLEIC ACIDS RES, V25, P3698, DOI 10.1093/nar/25.18.3698; Hammond PW, 1998, BIOCHEMISTRY-US, V37, P5162, DOI 10.1021/bi972988o; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harris D, 1998, BIOCHEMISTRY-US, V37, P9630, DOI 10.1021/bi980549z; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kaushik N, 1999, BIOCHEMISTRY-US, V38, P2617, DOI 10.1021/bi9824285; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; Lendvay TS, 1996, GENETICS, V144, P1399; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Maine IP, 1999, BIOCHEMISTRY-US, V38, P15325, DOI 10.1021/bi991596+; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Petrov AV, 1998, FEBS LETT, V436, P35, DOI 10.1016/S0014-5793(98)01091-6; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YUE X, 1988, MOL BIOL EVOL, V5, P675; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAUG AJ, 1995, RNA, V1, P363; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	62	81	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24199	24207		10.1074/jbc.M003246200	http://dx.doi.org/10.1074/jbc.M003246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807925	hybrid			2022-12-25	WOS:000088564200106
J	Tomas-Zuber, M; Mary, JL; Lesslauer, W				Tomas-Zuber, M; Mary, JL; Lesslauer, W			Control sites of ribosomal S6 kinase B and persistent activation through tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; SIGNAL-REGULATED KINASE; COFFIN-LOWRY-SYNDROME; BARDET-BIEDL-SYNDROME; EARLY GENE INDUCTION; P38 MAP KINASE; C-JUN; INDUCED APOPTOSIS; NUCLEAR TRANSLOCATION	RSKB, a 90-kDa ribosomal S6 protein kinase family (RSK) member with two complete catalytic domains connected by a linker, is activated through p38- and ERK-mitogen-activated protein kinases, The N-terminal kinases of RSKs phosphorylate substrates; activation requires phosphorylation of linker and C-terminal kinase sites. Unlike other RSKs, the activation loop phosphorylation sites of both catalytic domains of RSKB, Ser(196) and Thr(568), were required for activity. RSKB activation depended on phosphorylation of linker Ser(343) and Ser(360) and associated with phosphorylation of nonconserved Ser(347), but Ser(347)-deficient RSKB retained partial activity. The known protein kinase A and protein kinase C inhibitors, H89 and Ro31-8220, blocked RSKB activity. Treatment of HeLa cells with tumor necrosis factor, epidermal growth factor, phorbol 12-myristate 13-acetate, and ionomycin but not: with insulin resulted in strong activation of endogenous RSKB, High RSKB activity and Ser(347)/Ser(360) phosphorylation persisted for 3 h in tumor necrosis factor-treated cells, in contrast to the short bursts of p38, ERK, and RSK1-3 activities. In conclusion, a variety of stimuli induced phosphorylation and activation of RSKB through both p38 and ERK pathways; the persistence of activation indicated that RSKB selectively escaped cell mechanisms causing rapid deactivation of upstream p38 and ERK and other RSKs.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; F Hoffmann La Roche & Co Ltd, Dept PRPN, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Dept PRPV, CH-4070 Basel, Switzerland	Yale University; Yale University; Roche Holding; Roche Holding	Lesslauer, W (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.	werner.lesslauer@yale.edu						Abidi F, 1999, EUR J HUM GENET, V7, P20, DOI 10.1038/sj.ejhg.5200231; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Berman DE, 1998, J NEUROSCI, V18, P10037; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blum S, 1999, J NEUROSCI, V19, P3535; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gass P, 1998, LEARN MEMORY, V5, P274; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; Maroney AC, 1998, J NEUROSCI, V18, P104; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Ni H, 1998, BIOCHEM BIOPH RES CO, V243, P492, DOI 10.1006/bbrc.1998.8135; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Pende M, 1997, J NEUROSCI, V17, P1291; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sgambato V, 1998, J NEUROSCI, V18, P8814; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watson A, 1998, J NEUROSCI, V18, P751; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Zhu SG, 1998, HUM GENET, V103, P674, DOI 10.1007/s004390050890	91	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23549	23558		10.1074/jbc.M002586200	http://dx.doi.org/10.1074/jbc.M002586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10806207	hybrid			2022-12-25	WOS:000088564200021
J	Yu, EY; Kim, SE; Kim, JH; Ko, JH; Cho, MH; Chung, IK				Yu, EY; Kim, SE; Kim, JH; Ko, JH; Cho, MH; Chung, IK			Sequence-specific DNA recognition by the Myb-like domain of plant telomeric protein RTBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; ARABIDOPSIS-THALIANA; LENGTH REGULATION; FISSION YEAST; TRF1; RAP1; END; OXYTRICHA; MECHANISM; COMPLEX	We have identified a rice gene encoding a DNA-binding protein that specifically recognizes the telomeric repeat sequence TTTAGGG found in plants. This gene, which we refer to as RTBP1 (rice telomere-binding protein 1), encodes a polypeptide with a predicted molecular mass of 70 kDa, RTBP1 is ubiquitously expressed in various organs and binds DNA with two or more duplex TTTAGGG repeats. The predicted protein sequence includes a single domain at the C terminus with extensive homology to Myb-like DNA binding motif, The Myb-like domain of RTBP1 is very closely related to that of other telomere-binding proteins, including TRF1, TRF2, Taz1p, and Tbf1p, indicating that DNA-binding domains of telomere-binding proteins are well conserved among evolutionarily distant species. To obtain precise information on the sequence of the DNA binding site recognized by RTBP1, we analyzed the sequence-specific binding properties of the isolated Myb-like domain of RTBP1. The isolated Myb-like domain was capable of sequence-specific DNA binding as a homodimer, Gel retardation analysis with a series of mutated telomere probes revealed that the internal GGGTTT sequence in the two-telomere repeats is critical for binding of Myb-like domain of RTBP1, which is consistent with the model of the TRF1 DNA complex showing that base-specific contacts are made within the sequence GGGTTA. To the best of our knowledge, RTBP1 is the first cloned gene in which the product is able to bind double-stranded telomeric DNA in plants. Because the Myb-like domain appears to be a significant motif for a large class of proteins that bind the duplex telomeric DNA, RTBP1 may play important roles in plant telomere function in vivo.	Yonsei Univ, Coll Sci, Dept Biochem, Bioprod Res Ctr, Seoul 120749, South Korea	Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Bioprod Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr	Ko, Jae-Heung/A-3370-2013	Ko, Jae-Heung/0000-0002-4035-874X				Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRIGATI C, 1993, MOL CELL BIOL, V13, P1306, DOI 10.1128/MCB.13.2.1306; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Fulneckova J, 2000, FEBS LETT, V467, P305, DOI 10.1016/S0014-5793(00)01178-9; GANAL MW, 1991, PLANT CELL, V3, P87, DOI 10.1105/tpc.3.1.87; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; KILIAN A, 1992, MOL GEN GENET, V235, P153, DOI 10.1007/BF00286193; Kim JH, 1998, PLANT MOL BIOL, V36, P661, DOI 10.1023/A:1005994719175; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Lee JH, 2000, PLANT MOL BIOL, V42, P547, DOI 10.1023/A:1006373917321; LUGERT T, 1994, PLANT MOL BIOL, V25, P493, DOI 10.1007/BF00043877; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nishikawa T, 1998, STRUCT FOLD DES, V6, P1057, DOI 10.1016/S0969-2126(98)00106-3; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; REGAD F, 1994, J MOL BIOL, V239, P163, DOI 10.1006/jmbi.1994.1360; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; SHENG H, 1995, MOL CELL BIOL, V15, P1144; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; Spink KG, 2000, NUCLEIC ACIDS RES, V28, P527, DOI 10.1093/nar/28.2.527; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vassetzky NS, 1999, NUCLEIC ACIDS RES, V27, P4687, DOI 10.1093/nar/27.24.4687; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; WU KS, 1993, PLANT MOL BIOL, V22, P861, DOI 10.1007/BF00027371; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314	46	90	107	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24208	24214		10.1074/jbc.M003250200	http://dx.doi.org/10.1074/jbc.M003250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811811	hybrid			2022-12-25	WOS:000088564200107
J	Fujimoto, H; Tadano-Aritomi, K; Tokumasu, A; Ito, K; Hikita, T; Suzuki, K; Ishizuka, I				Fujimoto, H; Tadano-Aritomi, K; Tokumasu, A; Ito, K; Hikita, T; Suzuki, K; Ishizuka, I			Requirement of seminolipid in spermatogenesis revealed by UDP-galactose : ceramide galactosyltransferase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION MASS-SPECTROMETRY; GERM-CELL; MOLECULAR-CLONING; MOUSE; GENE; GALACTOCEREBROSIDE; MEMBRANE; MEIOSIS; PROTEIN; SULFOGLYCOLIPIDS	Although seminolipid has long been suspected to play an essential role in spermatogenesis because of its uniquely abundant and temporally regulated expression in the spermatocytes, direct experimental evidence has been lacking. We have tested the hypothesis by examining the testis of the UDP-galactose:ceramide galactosyltransferase-deficient mouse, which is incapable of synthesizing seminolipid. Spermatogenesis in homozygous affected males is arrested at the late pachytene stage and the spermatogenic cells degenerate through the apoptotic process. This stage closely follows the phase of rapid seminolipid synthesis in the wild-type mouse. These observations not only provide the first experimental evidence that seminolipid is indeed essential for normal spermatogenesis but also support the broader concept that cell surface glycolipids are important in cellular differentiation and cell-to-cell interaction.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan; Univ N Carolina, Sch Med, Dept Neurol, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Ctr Neurosci, Chapel Hill, NC 27599 USA	Teikyo University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Fujimoto, H (corresponding author), Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [R01-NS24289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Bosio A, 1998, J NEUROCHEM, V70, P308; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; de Rooij DG, 1999, BIOL REPROD, V61, P842, DOI 10.1095/biolreprod61.3.842; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Drabent B, 1996, HISTOCHEM CELL BIOL, V106, P247; Ezoe T, 2000, J NEUROSCI RES, V59, P170, DOI 10.1002/(SICI)1097-4547(20000115)59:2<170::AID-JNR3>3.0.CO;2-G; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HAKOMORI S, 2000, ENCYC LIFE SCI; HANDA S, 1974, J BIOCHEM-TOKYO, V75, P77, DOI 10.1093/oxfordjournals.jbchem.a130385; Hirahara Y, 2000, EUR J BIOCHEM, V267, P1909, DOI 10.1046/j.1432-1327.2000.01139.x; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; IIDA N, 1989, J BIOL CHEM, V264, P5974; ISHIZUKA I, 1973, J BIOCHEM-TOKYO, V73, P77; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; ISHIZUKA I, 1985, NEW COMPREHENSIVE BI, V10, P101; JEGOU B, 1993, INT REV CYTOL, V147, P25, DOI 10.1016/S0074-7696(08)60766-4; Klink A, 1997, MAMM GENOME, V8, P376, DOI 10.1007/s003359900638; KORNBLATT MJ, 1974, CAN J BIOCHEM CELL B, V52, P689, DOI 10.1139/o74-098; KURODA H, 1989, J CELL PHYSIOL, V139, P329, DOI 10.1002/jcp.1041390215; KUSHI Y, 1985, J BIOCHEM-TOKYO, V97, P419, DOI 10.1093/oxfordjournals.jbchem.a135076; LINGWOOD C, 1981, J CELL BIOL, V89, P621, DOI 10.1083/jcb.89.3.621; LINGWOOD CA, 1986, BIOCHEM CELL BIOL, V64, P984, DOI 10.1139/o86-131; LINGWOOD CA, 1985, J CELL SCI, V75, P329; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; SassoneCorsi P, 1997, CELL, V88, P163, DOI 10.1016/S0092-8674(00)81834-6; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Sweeney C, 1996, DEVELOPMENT, V122, P53; TADANOARITOMI K, 1995, CARBOHYD RES, V273, P41, DOI 10.1016/0008-6215(95)00106-4; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; Tsunekawa N, 1999, MOL REPROD DEV, V52, P383, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;383::AID-MRD7&gt;3.0.CO;2-Z; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; WATANABE D, 1994, J BIOL CHEM, V269, P7744	37	91	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22623	22626		10.1074/jbc.C000200200	http://dx.doi.org/10.1074/jbc.C000200200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801776	hybrid			2022-12-25	WOS:000088419400005
J	O'Shea, SM; Harrison, NL				O'Shea, SM; Harrison, NL			Arg-274 and Leu-277 of the gamma-aminobutyric acid type A receptor alpha(2) subunit define agonist efficacy and potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; CHANNEL-LINING RESIDUES; GLYCINE RECEPTORS; BENZODIAZEPINE PHARMACOLOGY; ACETYLCHOLINE-RECEPTORS; XENOPUS OOCYTES; BINDING-SITE; AMINO-ACIDS; IDENTIFICATION; HYPEREKPLEXIA	Alanine-scanning mutagenesis and the whole cell voltage clamp technique were used to investigate the function of the extracellular loop between the second and third transmembrane domains (TM2-TM3) of the gamma-aminobutyric acid type A receptor (GABA(A)-R). A conserved arginine residue in the TM2-TM3 loop of the GABA(A)-R alpha(2) subunit was mutated to alanine, and the mutant alpha(2)(R274A) was co-expressed with wild-type beta(1) and gamma(2S) subunits in human embryonic kidney (HEIK) 293 cells. The GABA EC50 was increased by about 27-fold in the mutant receptor relative to receptors containing a wildtype alpha(2) subunit. Similarly, the GABA EC50 at alpha(2) (L277A)-beta(1 gamma)Y(2S) and alpha(2) (K279A)beta(1)gamma(2S) GABA(A)-R combinations was increased by 51- and 4-fold, respectively. The alpha(2)(R274A) or a,(L277A) mutations also reduced the maximal response of piperidine-4-sulfonic acid relative to GABA by converting piperidine 4-sulfonic acid into a weak partial agonist at the GABA(A)-R. Based on these results, we propose that alpha(2)(Arg-274) and alpha(2)(Leu-277) are crucial to the efficient transduction of agonist binding into channel gating at the GABA(A)-R.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, New York, NY 10021 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Dept Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA	Cornell University; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Harrison, NL (corresponding author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, CV Starr Lab Mol Neuropharmacol, 525 E 68th St, New York, NY 10021 USA.				NIDA NIH HHS [DA07255] Funding Source: Medline; NIGMS NIH HHS [GM45129, GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007255] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; DOWNIE DL, 1995, BRIT J PHARMACOL, V114, P1641, DOI 10.1111/j.1476-5381.1995.tb14952.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EBERT B, 1994, MOL PHARMACOL, V46, P957; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; Johnston GAR, 1996, PHARMACOL THERAPEUT, V69, P173, DOI 10.1016/0163-7258(95)02043-8; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; Krasowski MD, 1997, NEUROPHARMACOLOGY, V36, P941, DOI 10.1016/S0028-3908(97)00074-9; KROGSGAARDLARSEN P, 1981, J NEUROCHEM, V37, P401, DOI 10.1111/j.1471-4159.1981.tb00469.x; KROGSGAARDLARSEN P, 1980, J NEUROCHEM, V34, P756, DOI 10.1111/j.1471-4159.1980.tb11211.x; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LAUBE B, 1995, NEUROREPORT, V6, P897, DOI 10.1097/00001756-199504190-00018; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; O'Shea SM, 2000, BRAIN RES, V852, P344, DOI 10.1016/S0006-8993(99)02151-4; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Tretter V, 1997, J NEUROSCI, V17, P2728; Vafa B, 1998, INT REV NEUROBIOL, V42, P285, DOI 10.1016/S0074-7742(08)60613-3; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhou M, 1999, P NATL ACAD SCI USA, V96, P10466, DOI 10.1073/pnas.96.18.10466	41	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22764	22768		10.1074/jbc.M001299200	http://dx.doi.org/10.1074/jbc.M001299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801806	hybrid			2022-12-25	WOS:000088419400025
J	Roudabush, FL; Pierce, KL; Maudsley, S; Khan, KD; Luttrell, LM				Roudabush, FL; Pierce, KL; Maudsley, S; Khan, KD; Luttrell, LM			Transactivation of the EGF receptor mediates IGF-1-stimulated Shc phosphorylation and ERK1/2 activation in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; MITOGENIC SIGNAL-TRANSDUCTION; FACTOR-I RECEPTOR; KINASE ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; RAS ACTIVATION; INSULIN; SUBSTRATE-1	The receptor for insulin-like growth factor 1 (IGF-1) mediates multiple cellular responses, including stimulation of both proliferative and anti-apoptotic pathways. We have examined the role of cross talk between the IGF-1 receptor (IGF-1R) and the epidermal growth factor receptor (EGFR) in mediating responses to IGF-1, In COS-7 cells, IGF-1 stimulation causes tyrosine phosphorylation of the IGF-1R beta subunit, the EGFR, insulin receptor substrate-1 (IRS-1), and the Shc adapter protein, Shc immunoprecipitates performed after IGF-1 stimulation contain coprecipitated EGFR, suggesting that IGF-1R activation induces the assembly of EGFR-Shc complexes. Tyrphostin AG1478, an inhibitor of the EGFR kinase, markedly attenuates IGF-1-stimulated phosphorylation of EGFR, Shc, and ERK1/2 but has no effect on phosphorylation of IGF-1R, IRS-1, and protein kinase B (Akt), Cross talk between IGF-1 and EGF receptors is mediated through an autocrine mechanism involving matrix metalloprotease-dependent release of heparin-binding EGF (HB-EGF), because IGF-1-mediated ERK activation is inhibited both by [Glu(52)]Diphtheria toxin, a specific inhibitor of HB-EGF, and the metalloprotease inhibitor 1,10-phenanthroline. These data demonstrate that IGF-1 stimulation of the IRS-1/PI3K/Akt pathway and the EGFR/Shc/ERK1/2 pathway occurs by distinct mechanisms and suggest that IGF-1-mediated "transactivation" of EGFR accounts for the majority of IGF-1-stimulated Shc phosphorylation and subsequent activation of the ERK cascade.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Luttrell, LM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3821, Durham, NC 27710 USA.		Maudsley, Stuart/AAV-9929-2021; Maudsley, Stuart/Q-4782-2019	Maudsley, Stuart/0000-0002-1868-184X; Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, K08DK002352, R56DK055524] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02352, DK55524] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 2000, SCI STKE, V15, pPE1; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; delPeso L, 1997, SCIENCE, V278, P687; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; RIEF K, 1997, J BIOL CHEM, V272, P14426; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Schlondorff J, 1999, J CELL SCI, V112, P3603; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	53	220	225	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22583	22589		10.1074/jbc.M002915200	http://dx.doi.org/10.1074/jbc.M002915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10807918	hybrid			2022-12-25	WOS:000088363800112
J	Wagner, BA; Buettner, GR; Oberley, LW; Darby, CJ; Burns, CP				Wagner, BA; Buettner, GR; Oberley, LW; Darby, CJ; Burns, CP			Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOPEROXIDASE-CATALYZED OXIDATION; ACUTE PROMYELOCYTIC LEUKEMIA; HYDROGEN-PEROXIDE; RADICAL GENERATION; IONIZING-RADIATION; PROTEIN-KINASE; INTACT-CELLS; NITRITE NO2; DNA DAMAGE; ACTIVATION	We examined the mechanism of H2O2-induced cytotoxicity and its relationship to oxidation in human leukemia cells. The HL-60 promyelocytic leukemia cell line was sensitive to H2O2, and at concentrations up to about 20-25 mu M, the killing was mediated by apoptosis, There was limited evidence of lipid peroxidation, suggesting that the effects of H2O2 do not involve hydroxyl radical. When HL-60 cells were exposed to H2O2 in the presence of the spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN), we detected a 12-line electron paramagnetic resonance spectrum assigned to the POBN/POBN. N-centered spin adduct previously described in peroxidase-containing cell-free systems. Generation of this radical by HL-60 cells had the same H2O2 concentration dependence as initiation of apoptosis, In contrast, studies with the K562 human erythroleukemia cell line, which is often used for comparison with the HL-60, and with high passaged HL-60 cells (spent HL-60) studied under the same conditions failed to generate POBN., Cellular levels of antioxidant enzymes superoxide dismutase, glutathione peroxidase, and catalase did not explain the differences between these cell lines. Interestingly, the K562 and spent HL-60 cells, which did not generate the radical, also failed to undergo H2O2-induced apoptosis, Based on this we reasoned that the difference in H2O2-induced apoptosis might be due to the enzyme myeloperoxidase. Only the apoptosis-manifesting HL-60 cells contained appreciable immunoreactive protein or enzymatic activity of this cellular enzyme. When HL-60 cells were incubated with methimazole or 4-aminobenzoic acid hydrazide, which are inhibitors of myeloperoxidase, they no longer underwent H2O2-induced apoptosis, Hypochlorous acid stimulated apoptosis in both HL-60 and spent HL-60 cells, indicating that another oxidant generated by myeloperoxidase induces apoptosis and that it may be the direct mediator of H2O2-induced apoptosis, Taken together these observations indicate that H2O2-induced apoptosis in the HL-60 human leukemia cell is mediated by myeloperoxidase and is linked to a non-Fenton oxidative event marked by POBN..	Univ Iowa, Coll Med, Free Radical & Radiat Biol Grad Program, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Free Radical & Radiat Biol Grad Program, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Ctr Canc, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Burns, CP (corresponding author), Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA.	c-burns@uiowa.edu		Buettner, Garry/0000-0002-5594-1903	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARRICK BA, 1985, J CLIN INVEST, V76, P567, DOI 10.1172/JCI112008; BANDYOPADHYAY U, 1993, BIOCHEM J, V296, P79, DOI 10.1042/bj2960079; Bertling CJ, 1996, PHOTOCHEM PHOTOBIOL, V64, P137, DOI 10.1111/j.1751-1097.1996.tb02433.x; BOREK C, 1986, P NATL ACAD SCI USA, V83, P1490, DOI 10.1073/pnas.83.5.1490; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BUETTNER GR, 1990, FREE RADICAL RES COM, V10, P5, DOI 10.3109/10715769009145927; BUETTNER GR, 1985, CANCER LETT, V25, P297, DOI 10.1016/S0304-3835(15)30009-4; CACERESDITTMAR G, 1995, PHOTOCHEM PHOTOBIOL, V62, P176, DOI 10.1111/j.1751-1097.1995.tb05255.x; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; CHRIST M, 1993, IMMUNOLOGY, V78, P455; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROUTE F, 1982, INT J RADIAT BIOL, V41, P209, DOI 10.1080/09553008214550221; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DiPietrantonio AM, 1999, BIOCHEM BIOPH RES CO, V255, P477, DOI 10.1006/bbrc.1999.0208; DOERGE DR, 1995, XENOBIOTICA, V25, P761, DOI 10.3109/00498259509061891; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Fabisiak JP, 1998, BIOCHEMISTRY-US, V37, P13781, DOI 10.1021/bi9808262; FARBER JL, 1990, LAB INVEST, V62, P670; GALLAGHER R, 1979, BLOOD, V54, P713; GALLIN EK, 1987, BLOOD, V70, P694; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Halliwell B., 1989, FREE RADICAL BIO MED, P86; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson M, 1996, J IMMUNOL, V156, P42; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kakeya H, 1998, CANCER RES, V58, P4888; Kasai T, 1998, J IMMUNOL, V161, P6469; KOMIYAMA T, 1986, J PHARMACOBIO-DYNAM, V9, P651, DOI 10.1248/bpb1978.9.651; KOSTKA P, 1989, LIPIDS, V24, P545, DOI 10.1007/BF02535136; Kravtsov VD, 1998, BLOOD, V92, P968; KRINSKY NI, 1981, THROMB HAEMOSTASIS, V45, P116; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb NJ, 1999, CRIT CARE MED, V27, P1738, DOI 10.1097/00003246-199909000-00007; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; Lundqvist-Gustafsson H, 1999, J LEUKOCYTE BIOL, V65, P196, DOI 10.1002/jlb.65.2.196; Mansat V, 1997, CANCER RES, V57, P5300; MCCORMICK ML, 1995, J BIOL CHEM, V270, P29265, DOI 10.1074/jbc.270.49.29265; MELLO AC, 1984, BIOCHEM J, V218, P273, DOI 10.1042/bj2180273; MENEGHINI R, 1980, BIOCHIM BIOPHYS ACTA, V608, P167, DOI 10.1016/0005-2787(80)90144-6; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORIKAWA K, 1985, CANCER RES, V45, P3482; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; NORTH JA, 1992, J BIOL CHEM, V267, P5743; Otero G, 1997, CARCINOGENESIS, V18, P1569, DOI 10.1093/carcin/18.8.1569; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; PINCEMAIL J, 1988, EXPERIENTIA, V44, P450, DOI 10.1007/BF01940544; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; RESZKA K, 1988, PHOTOCHEM PHOTOBIOL, V47, P625, DOI 10.1111/j.1751-1097.1988.tb02758.x; Reszka KJ, 1997, CHEM RES TOXICOL, V10, P1325, DOI 10.1021/tx970039q; Reszka KJ, 1998, FREE RADICAL BIO MED, V25, P208, DOI 10.1016/S0891-5849(98)00058-6; Reszka KJ, 1999, FREE RADICAL BIO MED, V26, P669, DOI 10.1016/S0891-5849(98)00244-5; Robinson S, 1998, FEBS LETT, V430, P297, DOI 10.1016/S0014-5793(98)00679-6; SANGEETHA P, 1990, FREE RADICAL BIO MED, V8, P15, DOI 10.1016/0891-5849(90)90139-A; Saran M, 1997, INT J RADIAT BIOL, V72, P745, DOI 10.1080/095530097142906; Saran M, 1997, RADIAT RES, V147, P70, DOI 10.2307/3579445; SATO K, 1995, J INVEST DERMATOL, V105, P608, DOI 10.1111/1523-1747.ep12323724; SMITH ST, 1988, INT J RADIAT BIOL, V53, P829, DOI 10.1080/09553008814551161; SOHAL RS, 1993, BIOCHEM BIOPH RES CO, V196, P7, DOI 10.1006/bbrc.1993.2208; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; TAUROG A, 1989, ENDOCRINOLOGY, V124, P30, DOI 10.1210/endo-124-1-30; TUTTLE SW, 1994, INT J RADIAT ONCOL, V29, P357, DOI 10.1016/0360-3016(94)90289-5; WAGNER BA, 1993, CANCER RES, V53, P711; Wagner BA, 1998, CANCER RES, V58, P2809; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Witenberg B, 1999, BIOCHEM PHARMACOL, V57, P823, DOI 10.1016/S0006-2952(98)00351-7; Yamada K, 1997, ANTICANCER RES, V17, P2041; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	87	83	89	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22461	22469		10.1074/jbc.M001434200	http://dx.doi.org/10.1074/jbc.M001434200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801811	Green Submitted, hybrid			2022-12-25	WOS:000088363800095
J	Park, JB; Kim, JH; Kim, Y; Ha, SH; Kim, JH; Yoo, JS; Du, GW; Frohman, MA; Suh, PG; Ryu, SH				Park, JB; Kim, JH; Kim, Y; Ha, SH; Kim, JH; Yoo, JS; Du, GW; Frohman, MA; Suh, PG; Ryu, SH			Cardiac phospholipase D-2 localizes to sarcolemmal membranes and is inhibited by alpha-actinin in an ADP-ribosylation factor-reversible manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; STRESS FIBER FORMATION; PHOSPHATIDIC-ACID; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYACRYLAMIDE GELS; PLASMA-MEMBRANE; D ISOENZYMES; ACTIVATION; BINDING; CELL	Myocardial phospholipase D (PLD) has been implicated in the regulation of Ca2+ mobilization and contractile performance in the heart. However, the molecular identity of this myocardial PLD and the mechanisms that regulate it are not well understood. Using subcellular fractionation and Western blot analysis, we found that PLD2 is the major myocardial PLD and that it localizes primarily to sarcolemmal membranes. A 100-kDa PLD2-interacting cardiac protein was detected using a protein overlay assay employing purified PLD2 and then identified as alpha-actinin using peptide-mass fingerprinting with matrix-assisted laser desorption/ionization mass spectroscopy. The direct association between PLD2 and alpha-actinin was confirmed using an in vitro binding assay and localized to PLD2's N-terminal 185 amino acids. Purified alpha-actinin potently inhibits PLD2 activity (Ic(50) = 80 nM) in an interaction-dependent and ADP-ribosylation factor-reversible manner. Finally, alpha-actinin co-localizes with actin and with PLD2 in the detergent-insoluble fraction from sarcolemmal membranes. These results suggest that PLD2 is reciprocally regulated in sarcolemmal membranes by alpha-actinin and ARF1 and accordingly that a major role for PLD2 in cardiac function may involve reorganization of the actin cytoskeleton.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Korea Basic Sci Inst, Mass Spectrometry Anal Grp, Taejon 305333, South Korea; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Korea Basic Science Institute (KBSI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Jung Hwan/0000-0001-8548-4435; Kim, Yong/0000-0002-1387-2962	NIGMS NIH HHS [GM54813] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Dhalla NS, 1997, J MOL CELL CARDIOL, V29, P2865, DOI 10.1006/jmcc.1997.0522; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HENRY RA, 1995, AM J PHYSIOL, V269, P349; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen ON, 1996, ELECTROPHORESIS, V17, P938, DOI 10.1002/elps.1150170516; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Liu SY, 1998, J MOL CELL CARDIOL, V30, P1203, DOI 10.1006/jmcc.1998.0685; Lukowski S, 1998, BIOCHEM BIOPH RES CO, V248, P278, DOI 10.1006/bbrc.1998.8942; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; MORTZ E, 1994, BIOL MASS SPECTROM, V23, P249, DOI 10.1002/bms.1200230503; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; NOVAKOVA O, 1994, PHYSIOL RES, V43, P151; PANAGIA V, 1991, BIOCHIM BIOPHYS ACTA, V1064, P242, DOI 10.1016/0005-2736(91)90308-U; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Song J, 1998, J CELL SCI, V111, P2257; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Waite M, 1999, BBA-MOL CELL BIOL L, V1439, P187, DOI 10.1016/S1388-1981(99)00094-3; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; Xu YJ, 1996, CAN J CARDIOL, V12, P1092; XU YJ, 1996, AM J PHYSIOL, V271, P651; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; YE HP, 1994, CARDIOVASC RES, V28, P1828, DOI 10.1093/cvr/28.12.1828	55	108	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21295	21301		10.1074/jbc.M002463200	http://dx.doi.org/10.1074/jbc.M002463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801846	hybrid, Green Published			2022-12-25	WOS:000088230600046
J	Ryan, KJ; Charlet-B, N; Cooper, TA				Ryan, KJ; Charlet-B, N; Cooper, TA			Binding of PurH to a muscle-specific splicing enhancer functionally correlates with exon inclusion in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DROSOPHILA DOUBLESEX GENE; T ALTERNATIVE EXON; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SKELETAL-MUSCLE; IMP CYCLOHYDROLASE; NONMUSCLE CELLS; 3'-SPLICE SITE; PROTEIN; ELEMENTS	Regulated alternative splicing of avian cardiac troponin T (cTNT) pre-mRNA requires multiple intronic elements called muscle-specific splicing enhancers (MSEs) that flank the alternative exon 5 and promote muscle-specific exon inclusion. To understand the function of the MSEs in muscle-specific splicing, we sought to identify trans-acting factors that bind to these elements. MSE3, which is located 66-81 nucleotides downstream of exon 5, assembles a complex that is both sequence- and muscle-specific, Purification and characterization of the MSE3 complex identified one component as 5-aminoimidazole-4-carboxamide ribonucleotideformyltransferase/IMP cyclohydrolase (PurH), an enzyme involved in de novo purine synthesis, Recombinant human PurH protein directly binds MSE3 RNA and PurH is the primary determinant of sequence-specific binding in the native complex. Furthermore, we show a direct correlation between the in vitro binding affinity of both the MSE3 complex and recombinant PurH with functional activation of exon inclusion in vivo. Together, these results strongly suggest that PurH performs a second function as a component of a complex that regulates MSE3-dependent exon inclusion.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.		Charlet-Berguerand, Nicolas/GZM-6636-2022; Charlet-Berguerand, Nicolas/I-6727-2016	Charlet-Berguerand, Nicolas/0000-0002-4423-4920; Charlet-Berguerand, Nicolas/0000-0002-4423-4920	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045565, R29HL045565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashiya M, 1997, RNA, V3, P996; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BLACK DL, 1995, RNA, V1, P763; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 1999, MOL CELL BIOL, V19, P69; Chu E, 1999, MOL CELL BIOL, V19, P1582; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; COOPER TA, 1985, J BIOL CHEM, V260, P1140; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; GUO W, 1993, NUCLEIC ACIDS RES, V21, P4762, DOI 10.1093/nar/21.20.4762; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HAUER CR, 1993, J BIOL CHEM, V268, P4828; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN CH, 1995, RNA, V1, P234; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NI LY, 1991, GENE, V106, P197, DOI 10.1016/0378-1119(91)90199-L; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Rhee KH, 1997, J MOL BIOL, V265, P20, DOI 10.1006/jmbi.1996.0708; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEEK RM, 1982, METHOD ENZYMOL, V89, P305; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sioud M, 1996, J MOL BIOL, V257, P775, DOI 10.1006/jmbi.1996.0201; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WANG YC, 1997, EUKARYOTIC MRNA PROC, P242; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530; Zhang L, 1996, RNA, V2, P682	52	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20618	20626		10.1074/jbc.M909977199	http://dx.doi.org/10.1074/jbc.M909977199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801888	hybrid			2022-12-25	WOS:000088084500057
J	Cuajungco, MP; Goldstein, LE; Nunomura, A; Smith, MA; Lim, JT; Atwood, CS; Huang, XD; Farrag, YW; Perry, G; Bush, AI				Cuajungco, MP; Goldstein, LE; Nunomura, A; Smith, MA; Lim, JT; Atwood, CS; Huang, XD; Farrag, YW; Perry, G; Bush, AI			Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of A beta by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENILE PLAQUES; PROTEIN; AGGREGATION; DEPOSITION; ISOFORMS; PEPTIDE; NEURONS; DAMAGE; CORTEX; MICE	A beta binds Zn2+, Cu2+ and Fe3+ in vitro, and these metals are markedly elevated in the neocortex and especially enriched in amyloid plaque deposits of individuals with Alzheimer's disease (AD). Zn2+ precipitates A beta in vitro, and Cu2+ interaction with A beta promotes its neurotoxicity, correlating with metal reduction and the cell-free generation of H2O2 (A beta 1-42 > A beta 1-40 > ratA beta 1-40). Because Zn2+ is redox-inert, we studied the possibility that it may play an inhibitory role in H2O2-mediated A beta toxicity. In competition to the cytotoxic potentiation caused by coincubation with Cu2+, Zn2+ rescued primary cortical and human embryonic kidney 293 cells that were exposed to A beta 1-42, correlating with the effect of Zn2+ in suppressing Cu2+-dependent H2O2 formation from A beta 1-42. Since plaques contain exceptionally high concentrations of Zn2+, we examined the relationship between oxidation (8-OH guanosine) levels in AD-affected tissue and histological amyloid burden and found a significant negative correlation. These data suggest a protective role for Zn2+ in AD, where plaques form as the result of a more robust Zn2+ antioxidant response to the underlying oxidative attack.	Massachusetts Gen Hosp, Lab Oxidat Biol, Genet Aging Unit, Charlestown, MA 02129 USA; Univ Auckland, Sch Med, Dept Psychiat & Behav Sci, Auckland, New Zealand; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Asahikawa Med Coll, Dept Psychiat & Neurol, Asahikawa, Hokkaido 0788510, Japan	Harvard University; Massachusetts General Hospital; University of Auckland; Case Western Reserve University; Asahikawa Medical College	Bush, AI (corresponding author), Massachusetts Gen Hosp, Lab Oxidat Biol, Genet Aging Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.	bush@helix.mgh.harvard.edu	, Craig/AAB-3963-2022; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Cuajungco, Math/B-2647-2008; Perry, George/A-8611-2009; Smith, Mark A/A-9053-2009	Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Cuajungco, Math/0000-0003-0749-9564; Perry, George/0000-0002-6547-0172; Goldstein, Lee/0000-0001-8419-9800	NIA NIH HHS [R01-AG09287, R29 AG-12686] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012686, R01AG009287] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; ATWOOD CS, 2000, IN PRESS J NEUROCHEM; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CAMPBELL EB, 1991, ANAL BIOCHEM, V194, P268, DOI 10.1016/0003-2697(91)90229-M; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Du YS, 1997, J NEUROCHEM, V69, P299; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; Nunomura A, 1999, J NEUROSCI, V19, P1959; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Smith MA, 1997, J NEUROSCI, V17, P2653; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009	30	350	369	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2000	275	26					19439	19442		10.1074/jbc.C000165200	http://dx.doi.org/10.1074/jbc.C000165200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	330AU	10801774	hybrid			2022-12-25	WOS:000087941300002
J	Karhumaa, P; Parkkila, S; Waheed, A; Parkkila, AK; Kaunisto, K; Tucker, PW; Huang, CJ; Sly, WS; Rajaniemi, H				Karhumaa, P; Parkkila, S; Waheed, A; Parkkila, AK; Kaunisto, K; Tucker, PW; Huang, CJ; Sly, WS; Rajaniemi, H			Nuclear nonO/p54(nrb) protein is a nonclassical carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 CELL-DIFFERENTIATION; BINDING PROTEIN; CDNA CLONING; ISOENZYME-II; RNA-BINDING; EXPRESSION; LOCALIZATION; MN; TRANSCRIPTION; PURIFICATION	The growing carbonic anhydrase (CA) gene family includes 11 enzymatically active isozymes in mammals. Each of them has a characteristic cellular and subcellular distribution pattern. In this report, we demonstrate for the first time a nuclear protein with CA activity. A polypeptide recognized by CA II antibodies was purified from several rat tissues using CA inhibitor affinity chromatography. This polypeptide of apparent 66 kDa mass was characterized using amino acid sequencing and CA activity measurements. It appeared to be identical to nonO/p54(nrb), a previously cloned and characterized RNA and DNA binding nuclear factor. Recombinant nonO generated in baculovirus bound to the CA inhibitor affinity chromatography matrix and revealed detectable CA activity (25 units/mg). Hansson's histochemical staining of rat lymph nodes followed by light and electron microscopy showed nuclear CA activity in lymphocytes, suggesting that the nuclear nonO protein is catalytically active in vivo. These results demonstrate that a previously known transcription factor is a novel, nonclassical Ck Through its CA activity, the nonO may function in the maintenance of pH homeostasis in the nucleus.	Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Anat & Cell Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Clin Chem, FIN-90014 Oulu, Finland; Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Texas, Inst Cell & Mol Biol, Dept Mol Genet & Microbiol, Austin, TX 78712 USA	University of Oulu; University of Oulu; University of Oulu; University of Oulu; Saint Louis University; University of Texas System; University of Texas Austin	Karhumaa, P (corresponding author), Univ Oulu, Dept Anat & Cell Biol, Box 5000, FIN-90014 Oulu, Finland.			Parkkila, Seppo/0000-0001-7323-8536	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40163] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Basu A, 1997, MOL CELL BIOL, V17, P677, DOI 10.1128/MCB.17.2.677; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Earnhardt JN, 1998, BIOCHEMISTRY-US, V37, P10837, DOI 10.1021/bi980046t; Fujikawa-Adachi K, 1999, J BIOL CHEM, V274, P21228, DOI 10.1074/jbc.274.30.21228; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HANSSON HPJ, 1967, HISTOCHEMISTRY, V11, P112, DOI 10.1007/BF00571716; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; JEFFERY S, 1980, COMP BIOCHEM PHYS B, V66, P439, DOI 10.1016/0305-0491(80)90231-X; KAMAT JP, 1995, MOL REPROD DEV, V41, P8, DOI 10.1002/mrd.1080410103; KAUNISTO K, 1995, BIOL REPROD, V52, P1350, DOI 10.1095/biolreprod52.6.1350; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB BT, 1992, MOL CELL BIOL, V12, P4824, DOI 10.1128/MCB.12.11.4824; Lesburg CA, 1997, BIOCHEMISTRY-US, V36, P15780, DOI 10.1021/bi971296x; LIAO SY, 1994, AM J PATHOL, V145, P598; MAREN TH, 1960, J PHARMACOL EXP THER, V130, P26; McKiernan JM, 1997, CANCER RES, V57, P2362; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; MURAKAMI H, 1987, J BIOL CHEM, V262, P1382; PARKKILA AK, 1993, HISTOCHEMISTRY, V99, P37, DOI 10.1007/BF00268018; PARKKILA S, 1990, J HISTOCHEM CYTOCHEM, V38, P941, DOI 10.1177/38.7.2113069; PASTOREK J, 1994, ONCOGENE, V9, P2877; RIDDERSTRALE Y, 1985, ACTA PHYSIOL SCAND, V124, P408; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang YS, 1997, NUCLEIC ACIDS RES, V25, P2284, DOI 10.1093/nar/25.12.2284; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218; ZHU XL, 1990, J BIOL CHEM, V265, P8795	33	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16044	16049		10.1074/jbc.275.21.16044	http://dx.doi.org/10.1074/jbc.275.21.16044			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821857	hybrid			2022-12-25	WOS:000087291400060
J	Bean, AJ; Davanger, S; Chou, MF; Gerhardt, B; Tsujimoto, S; Chang, YC				Bean, AJ; Davanger, S; Chou, MF; Gerhardt, B; Tsujimoto, S; Chang, YC			Hrs-2 regulates receptor-mediated endocytosis via interactions with Eps15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; ADRENAL CHROMAFFIN CELLS; GROWTH-FACTOR RECEPTOR; SYNAPTIC VESICLE ENDOCYTOSIS; PROTEIN-PROTEIN INTERACTIONS; EH-DOMAIN; MULTIVESICULAR ENDOSOMES; HIPPOCAMPAL SYNAPSES; ACTIVE ZONE; CLATHRIN	Hrs-a, via interactions with SNAP-25, plays a regulatory role on the exocytic machinery. We now show that Hrs-a physically interacts with Eps15, a protein required for receptor-mediated endocytosis. The Hrs-2/Eps15 interaction is calcium dependent, inhibited by SNAP-25 and alpha-adaptin, and results in the inhibition of receptor-mediated endocytosis. Immunoelectron microscopy reveals Hrs-2 localization on the limiting membrane of multivesicular bodies, organelles in the endosomal pathway. These data show that Hrs-8 regulates endocytosis, delineate a biochemical pathway (Hrs-2-Eps15-AP2) in which Hrs-a functions, and suggest that Hrs-a acts to provide communication between endo- and exocytic processes.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77030 USA; Univ Bergen, Dept Cell Biol & Anat, N-5009 Bergen, Norway	University of Texas System; University of Texas System; University of Bergen	Bean, AJ (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, 6431 Fannin St,Rm 7-208, Houston, TX 77030 USA.		Davanger, Svend/AAN-8754-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058920] Funding Source: NIH RePORTER; NIMH NIH HHS [MH058920] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Betz WJ, 1998, ANNU REV PHYSIOL, V60, P347, DOI 10.1146/annurev.physiol.60.1.347; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; Carbone R, 1997, CANCER RES, V57, P5498; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; Kavalali ET, 1999, PHILOS T ROY SOC B, V354, P337, DOI 10.1098/rstb.1999.0385; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Koenig JH, 1999, J NEUROPHYSIOL, V81, P1495, DOI 10.1152/jn.1999.81.4.1495; Koenig JH, 1998, P NATL ACAD SCI USA, V95, P12677, DOI 10.1073/pnas.95.21.12677; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; SCHELLER RH, 1995, NEURON, V14, P893; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Tsujimoto S, 2000, J BIOL CHEM, V275, P2938, DOI 10.1074/jbc.275.4.2938; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	50	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15271	15278		10.1074/jbc.275.20.15271	http://dx.doi.org/10.1074/jbc.275.20.15271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809762	hybrid			2022-12-25	WOS:000087128300068
J	Bhattacharyya, AM; Horowitz, P				Bhattacharyya, AM; Horowitz, P			Alteration around the active site of rhodanese during urea-induced denaturation and its implications for folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; GUANIDINIUM CHLORIDE; ENZYME RHODANESE; LAURYL MALTOSIDE; PROTEIN; SUSCEPTIBILITY; REACTIVATION; EQUILIBRIUM; RESOLUTION; DETERGENT	The enzyme rhodanese contains two globular domains connected by a tether region and associated by strong hydrophobic interactions. The protein has proven to be very difficult to refold without assistance to prevent oxidation and aggregation. For this study, the active site cysteine 247, near the interdomain region, was modified with the environmentally sensitive fluorescent probe, 2-(4'-(iodoacetamido)anilino)naphthalene-6-sulfonic acid (IAANS), to yield a derivative that reversibly unfolds. Structural transitions during urea unfolding/ refolding were complex and multiphasic, Increasing urea concentrations increased the IAANS fluorescence intensity and polarization. Both values reached maxima at approximate to 4 M urea, where there is a concomitant large exposure of hydrophobic sites as reported by both IAANS and the noncovalent fluorescent probe, bis-ANS, The exposure of the hydrophobic sites arises from the decrease in strong interaction between the domain interfaces, which lead to their partial separation. This correlates with the loss of activity of the unlabeled enzyme, Above 4.5 M urea, there is progressive loss of rigid, hydrophobic surfaces, and both fluorescence and polarization of IAANS decrease, with accompanying loss of secondary structure. These results are consistent with a folding model in which there is an initial, rapid hydrophobic collapse of the denatured form to an intermediate with native like secondary structure, with exposed interdomain, hydrophobic surfaces. This step is followed by adjustment of the domain-domain interactions and the proper positioning of reduced cysteine 247 at the active site.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				PHS HHS [25177] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNI R, 1986, BIOCHEM INT, V12, P733; BETTON JM, 1984, BIOCHEMISTRY-US, V23, P6654, DOI 10.1021/bi00321a057; DESMADRIL M, 1984, BIOCHEMISTRY-US, V23, P11, DOI 10.1021/bi00296a003; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1986, J BIOL CHEM, V261, P6953; HOROWITZ PM, 1986, J BIOL CHEM, V261, P13887; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1992, ACS SYM SER, V516, P167; KOJ A, 1975, FEBS LETT, V57, P42, DOI 10.1016/0014-5793(75)80148-7; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P12414; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Shibatani T, 1999, J BIOL CHEM, V274, P33795, DOI 10.1074/jbc.274.47.33795; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1123; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; Trumpower B L, 1974, Biochem Biophys Res Commun, V57, P523; WENG L, 1978, J BIOL CHEM, V253, P8109; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811	25	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14860	14864		10.1074/jbc.275.20.14860	http://dx.doi.org/10.1074/jbc.275.20.14860			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809729	hybrid			2022-12-25	WOS:000087128300014
J	Broillet, MC				Broillet, MC			A single intracellular cysteine residue is responsible for the activation of the olfactory cyclic nucleotide-gated channel by NO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS NITRIC-OXIDE; BINDING-SITE; FUNCTIONAL EXPRESSION; S-NITROSYLATION; EXHALED AIR; ION-CHANNEL; SUBUNIT; RECEPTOR; NEURONS; PORE	The activation of cyclic nucleotide-gated (CNG) channels is the final step in olfactory and visual transduction, Previously we have shown that, in addition to their activation by cyclic nucleotides, nitric oxide (NO)-generating compounds can directly open olfactory CNG channels through a redox reaction that results in the S-nitrosylation of a free SH group on a cysteine residue. To identify the target site(s) of NO, we have now mutated the four candidate intracellular cysteine residues Cys-460, Cys-484, Cys-520, and Cys-552 of the rat olfactory rCNG2 (alpha) channel into serine residues. All mutant channels continue to be activated by cyclic nucleotides, but only one of them, the C460S mutant channel, exhibited a total loss of NO sensitivity. This result was further supported by a similar lack of NO sensitivity that we found for a natural mutant of this precise cysteine residue, the Drosophila melanogaster CNG channel. Cys460 is located in the C-linker region of the channel known to be important in channel gating, Kinetic analyses suggested that at least two of these Cys-460 residues on different channel subunits were involved in the activation by NO. Our results show that one single cysteine residue is responsible for NO sensitivity but that several channel subunits need to be activated for channel opening by NO.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Broillet, MC (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland.			Broillet, Marie-Christine/0000-0002-0487-6638				ALVING K, 1993, EUR RESPIR J, V6, P1368; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; Biel M, 1996, TRENDS CARDIOVAS MED, V6, P274, DOI 10.1016/S1050-1738(96)00105-3; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Bonigk W, 1999, J NEUROSCI, V19, P5332; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Brown RL, 1998, BIOPHYS J, V75, P825, DOI 10.1016/S0006-3495(98)77571-X; BUTLER AR, 1995, TRENDS PHARMACOL SCI, V16, P18, DOI 10.1016/S0165-6147(00)88968-3; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DUDEL J, 1990, BIOPHYS J, V57, P533, DOI 10.1016/S0006-3495(90)82569-8; FRANKE C, 1991, BIOPHYS J, V60, P1008, DOI 10.1016/S0006-3495(91)82138-5; GERLACH H, 1994, LANCET, V343, P518, DOI 10.1016/S0140-6736(94)91465-6; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GORDON SE, 1995, NEURON, V14, P177; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Li Z, 1998, NEURON, V20, P1039, DOI 10.1016/S0896-6273(00)80484-5; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MILLER C, 1990, BIOCHEMISTRY-US, V29, P5320, DOI 10.1021/bi00474a016; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PARK CS, 1995, BIOCHEMISTRY-US, V34, P13328, DOI 10.1021/bi00041a008; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; ROSKAMS AJ, 1994, NEURON, V13, P289; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Schedin U, 1996, PEDIATR RES, V40, P148, DOI 10.1203/00006450-199607000-00025; SCHEDIN U, 1995, ACTA ANAESTH SCAND, V39, P327, DOI 10.1111/j.1399-6576.1995.tb04071.x; Schedin U, 1997, ACTA ANAESTH SCAND, V41, P1133; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Wang XY, 1996, MOL PHARMACOL, V50, P687; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZHAO HQ, 1994, NEUROREPORT, V6, P149, DOI 10.1097/00001756-199412300-00038; Zong XG, 1998, EMBO J, V17, P353, DOI 10.1093/emboj/17.2.353	56	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15135	15141		10.1074/jbc.275.20.15135	http://dx.doi.org/10.1074/jbc.275.20.15135			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809749	hybrid			2022-12-25	WOS:000087128300051
J	Han, Y; Kodadek, T				Han, Y; Kodadek, T			Peptides selected to bind the Ga180 repressor are potent transcriptional activation domains in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROTEIN; HOLOENZYME; GAL4; DISPLAY; BACTERIOPHAGE; MEDIATOR; LIBRARY; TARGET; PHAGE	The activation domain of the yeast Gal4 protein binds specifically to the Gal80 repressor and is also thought to associate with one or more coactivators in the RNA polymerase II holoenzyme and chromatin remodeling machines. This is a specific example of a common situation in biochemistry where a single protein domain can interact with multiple partners, Are these different interactions related chemically? To probe this point, phage display was employed to isolate peptides from a library based solely on their ability to bind Gal80 protein in vitro, Peptide-Gal80 protein association is shown to be highly specific and of moderate affinity. The Gal80 protein-binding peptides compete with the native activation domain for the repressor, suggesting that they bind to the same site. It was then asked if these peptides could function as activation domains in yeast when tethered to a DNA binding domain. Indeed, this is the case. Furthermore, one of the Gal80-binding peptides binds directly to a domain of the Gal11 protein, a known coactivator. The fact that Gal80-binding peptides are functional activation domains argues that repressor binding and activation/coactivator binding are intimately related properties. This peptide library-based approach should be generally useful for probing the chemical relationship of different binding interactions or functions of a given native domain.	Univ Texas, SW Med Ctr, Dept Internal Med & Biochem, Ctr Biomed Invent,Ryburn Ctr Mol Cardiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med & Biochem, Ctr Biomed Invent,Ryburn Ctr Mol Cardiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	kodadek@ryburn.swmed.edu		Kodadek, Thomas/0000-0003-1930-4795	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055988] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL55988] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURTON DR, 1995, IMMUNOTECHNOLOGY, V1, P87, DOI 10.1016/1380-2933(95)00013-5; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Fancy DA, 1997, TETRAHEDRON, V53, P11953, DOI 10.1016/S0040-4020(97)00708-4; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Felici F, 1995, Biotechnol Annu Rev, V1, P149, DOI 10.1016/S1387-2656(08)70051-6; Gaudreau L, 1999, P NATL ACAD SCI USA, V96, P2668, DOI 10.1073/pnas.96.6.2668; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee YC, 1999, MOL CELL BIOL, V19, P2967; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x	33	42	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14979	14984		10.1074/jbc.275.20.14979	http://dx.doi.org/10.1074/jbc.275.20.14979			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809742	hybrid			2022-12-25	WOS:000087128300030
J	Huntington, JA; McCoy, A; Belzar, KJ; Pei, XY; Gettins, PGW; Carrell, RW				Huntington, JA; McCoy, A; Belzar, KJ; Pei, XY; Gettins, PGW; Carrell, RW			The conformational activation of antithrombin - A 2.85-angstrom structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INHIBITOR; MECHANISM; THROMBOSIS; RESOLUTION; ALGORITHM; SUBSTRATE; SEQUENCE; PROGRAM; MODEL	Antithrombin is unique among the serpins in that it circulates in a native conformation that is kinetically inactive toward its target proteinase, factor Xa, Activation occurs upon binding of a specific pentasaccharide sequence found in heparin that results in a rearrangement of the reactive center loop removing constraints on the active center P1 residue. We determined the crystal structure of an activated antithrombin variant, N135Q S380C-fluorescein (P14-fluorescein), in order to see how full activation is achieved in the absence of heparin and how the structural effects of the substitution in the hinge region are translated to the heparin binding region. The crystal structure resembles native antithrombin except in. the hinge and heparin binding regions. The absence of global conformational change allows for identification of specific interactions, centered on Glu(381) (P13), that are responsible for maintenance of the solution equilibrium between the native and activated forms and establishes the existence of an electrostatic link between the hinge region and the heparin binding region. A revised model for the mechanism of the allosteric activation of antithrombin is proposed.	Univ Cambridge, Wellcome Trust Ctr Study Mol Mech Dis, Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Cambridge; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Huntington, JA (corresponding author), Univ Cambridge, Wellcome Trust Ctr Study Mol Mech Dis, Inst Med Res, Dept Haematol, Wellcome Trust MRC Bldg,Hill Rd, Cambridge CB2 2XY, England.							Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P197; Leslie AGW, 1992, JOINT CCP4 ESFEACMB, V26; Li JP, 1999, STRUCTURE, V7, P103, DOI 10.1016/S0969-2126(99)80013-6; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Petitou M, 1997, GLYCOBIOLOGY, V7, P323, DOI 10.1093/glycob/7.3.323-e; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	35	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15377	15383		10.1074/jbc.275.20.15377	http://dx.doi.org/10.1074/jbc.275.20.15377			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809774	hybrid			2022-12-25	WOS:000087128300082
J	Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M				Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M			Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts	ONCOGENE			English	Article						human papillomaviruses; E7 protein; apoptosis; S phase; pRb destabilization	CELL-CYCLE REGULATION; ABL TYROSINE KINASE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; ONCOPROTEIN MDM2; LENS DEVELOPMENT; ADENOVIRUS E1A; STABILIZES P53; GROWTH ARREST	The HPV16 E7 oncoprotein neutralizes several cell cycle checkpoints, favouring the entry of quiescent cells into S phase, This activity is mediated in part by association of E7 with the pocket proteins and consequent activation of E2F transcription factors. In addition, HPV16 E7 protein is able to promote apoptosis, In this study we demonstrate that the ability to induce apoptosis is a common property of E7s belonging to both benign and malignant HPV types. The E7-induced apoptosis is mediated by inactivation of pRb, whilst neutralization of the other two pRB-related proteins, p107 and 130, is not sufficient to trigger apoptosis, Moreover, we show that certain point mutations in the conserved region 1 (CRI) of HPV16 E7 abolish the induction of apoptosis without altering the ability to stimulate S phase. Thus, these two E7-mediated cellular events, apoptosis and S phase entry, can be separated in immortalized rodent fibroblasts. Our findings demonstrate that the E7-mediated pRb destabilization is not required for its ability to drive quiescent cells into S phase and to induce apoptosis, Finally, expression of E7 proteins in NIH3T3, which lack a functional p19(ARF), does not lead to p53 accumulation, indicating that the E7 impacts upon additional cellular pathways to promote apoptosis.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Imperial Canc Res Fund, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boyer SN, 1996, CANCER RES, V56, P4620; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HU TH, 1995, INT J ONCOL, V6, P167; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	58	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2277	2285		10.1038/sj.onc.1203570	http://dx.doi.org/10.1038/sj.onc.1203570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822378				2022-12-25	WOS:000086974300002
J	Hoover, HE; Thuerauf, DJ; Martindale, JJ; Glembotski, CC				Hoover, HE; Thuerauf, DJ; Martindale, JJ; Glembotski, CC			alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38 - A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; HEAT-SHOCK PROTEINS; DESMIN-RELATED MYOPATHY; ACTIN REORGANIZATION; MAP KINASE; CARDIOMYOCYTE HYPERTROPHY; VENTRICULAR MYOCYTES; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; SAP KINASES	The MAPK kinase MKK6 selectively stimulates p38 MAPK and confers protection against stress-induced apoptosis in cardiac myocytes, However, the events lying downstream of p38 that mediate this protection are unknown, The small heat shock protein, alpha B-crystallin, which is expressed in only a few cell types, including cardiac myocytes, may participate in MKK6-mediated cytoprotection. In the present study, we showed that, in cultured cardiac myocytes, expression of MKK6(Glu), an active form of MKK6, led to p38-dependent increases in alpha B-crystallin mRNA, protein, and transcription. MKK6(Glu) also induced p3-dependent activation of the downstream MAPK-activated protein kinase, MAP-KAP-K2, and the phosphorylation of alpha B-crystallin on serine-59, Initially, exposure of cells to the hyperosmotic stressor, sorbitol, stimulated MKK6, p38, and MAP-KAP-K2 and increased phosphorylation of alpha B-crystallin on serine 59, However, after longer times of exposure to sorbitol, the cells began to undergo apoptosis. This sorbitol-induced apoptosis was increased when p38 was inhibited in a manner that would block alpha B-crystallin induction and phosphorylation, Thus, under these conditions, the activation of MKK6, p38, and MAPKAP-K2 by sorbitol can provide a degree of protection against stress-induced apoptosis, Supporting this view was the finding that sorbitol-induced apoptosis was nearly completely blocked in cells expressing MKK6(Glu). Therefore, the cytoprotective effects of MKK6 in cardiac myocytes are due, in part, to phosphorylation of alpha B-crystallin on serine 59 and to the induction of alpha B-crystallin gene expression,The MAPK kinase MKK6 selectively stimulates p38 MAPK and confers protection against stress-induced apoptosis in cardiac myocytes, However, the events lying downstream of p38 that mediate this protection are unknown, The small heat shock protein, alpha B-crystallin, which is expressed in only a few cell types, including cardiac myocytes, may participate in MKK6-mediated cytoprotection. In the present study, we showed that, in cultured cardiac myocytes, expression of MKK6(Glu), an active form of MKK6, led to p38-dependent increases in alpha B-crystallin mRNA, protein, and transcription. MKK6(Glu) also induced p38-dependent activation of the downstream MAPK-activated protein kinase, MAP-KAP-K2, and the phosphorylation of alpha B-crystallin on serine-59, Initially, exposure of cells to the hyperosmotic stressor, sorbitol, stimulated MKK6, p38, and MAP-KAP-K2 and increased phosphorylation of alpha B-crystallin on serine 59, However, after longer times of exposure to sorbitol, the cells began to undergo apoptosis. This sorbitol-induced apoptosis was increased when p38 was inhibited in a manner that would block alpha B-crystallin induction and phosphorylation, Thus, under these conditions, the activation of MKK6, p38, and MAP-KAP-K2 by sorbitol can provide a degree of protection against stress-induced apoptosis, Supporting this view was the finding that sorbitol-induced apoptosis was nearly completely blocked in cells expressing MKK6(Glu). Therefore, the cytoprotective effects of MKK6 in cardiac myocytes are due, in part, to phosphorylation of alpha B-crystallin on serine 59 and to the induction of alpha B-crystallin gene expression.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Inst Heart, San Diego, CA 92182 USA.				NHLBI NIH HHS [HL-46345, HL-56861] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benjamin IJ, 1997, DEV DYNAM, V208, P75; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Edwards YS, 1998, AM J PHYSIOL-LUNG C, V275, pL670, DOI 10.1152/ajplung.1998.275.4.L670; Force T, 1999, GENE EXPRESSION, V7, P337; GANOTE CE, 1987, AM J PATHOL, V129, P327; Geisler JG, 1999, J MUSCLE RES CELL M, V20, P661, DOI 10.1023/A:1005533013926; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Golenhofen N, 1998, AM J PHYSIOL-HEART C, V274, pH1457, DOI 10.1152/ajpheart.1998.274.5.H1457; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Haunstetter A, 2000, CARDIOVASC RES, V45, P795, DOI 10.1016/S0008-6363(99)00264-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; Lin Z, 1998, DEV BIOL, V199, P291, DOI 10.1006/dbio.1998.8920; LOKTIONOVA SA, 1998, AM J PHYSIOL, V275, pH2174; LONGONI S, 1990, MOL CELL BIOCHEM, V99, P113; Lutsch G, 1997, CIRCULATION, V96, P3466; Ma DC, 1998, EUR J HAEMATOL, V61, P27; Mann Douglas L., 1996, Cytokine and Growth Factor Reviews, V7, P341, DOI 10.1016/S1359-6101(96)00043-3; Martin JL, 1997, CIRCULATION, V96, P4343; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Parolari A, 1997, ANN THORAC SURG, V64, P1770, DOI 10.1016/S0003-4975(97)00998-3; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Van Noort JM, 1998, PROG BRAIN RES, V117, P435; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang PL, 1998, AM J PHYSIOL-GASTR L, V275, pG1454, DOI 10.1152/ajpgi.1998.275.6.G1454; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zu YL, 1997, J MOL CELL CARDIOL, V29, P2159, DOI 10.1006/jmcc.1997.0449	59	130	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23825	23833		10.1074/jbc.M003864200	http://dx.doi.org/10.1074/jbc.M003864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816593	hybrid			2022-12-25	WOS:000088564200058
J	Amano, S; Scott, IC; Takahara, K; Koch, M; Champliaud, MF; Gerecke, DR; Keene, DR; Hudson, DL; Nishiyama, T; Lee, S; Greenspan, DS; Burgeson, RE				Amano, S; Scott, IC; Takahara, K; Koch, M; Champliaud, MF; Gerecke, DR; Keene, DR; Hudson, DL; Nishiyama, T; Lee, S; Greenspan, DS; Burgeson, RE			Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 gamma 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; JUNCTIONAL EPIDERMOLYSIS-BULLOSA; DROSOPHILA EMBRYO; GENE; EXPRESSION; IDENTIFICATION; CLEAVAGE; CHORDIN; FAMILY; BMP-1	Epithelial cells maintained in culture medium containing low calcium proteolytically process laminin 5 (alpha 3 beta 3 gamma 2) within the alpha 3 and gamma 2 chains (1). Experiments were designed to identify the enzyme(s) responsible for the laminin 5 processing and the sites of proteolytic cleavage. To characterize the nature of laminin 5 processing, we determined the N-terminal amino acid sequences of the proteolytic fragments produced by the processing events. The results indicate that the first alpha 3 chain cleavage (200-165 kDa alpha 3) occurs within subdomain G4 of the G domain. The second cleavage (165-145 kDa alpha 3) occurs within the Ina domain, 11 residues N-terminal to the start of domain II. The gamma chain is cleaved within the second epidermal growth factor-like repeat of domain III. The sequence cleaved within the gamma 2 chain matches the consensus sequence for the cleavage of type I, II, and III procollagens by bone morphogenetic protein-1 (BMP-1), also known as type I procollagen C-proteinase (2). Recombinant BMP-1 cleaves gamma 2 in vitro, both within intact laminin 5 and at the predicted site of a recombinant gamma 2 short arm. alpha 3 is also cleaved by BMP-1 in vitro, but the cleavage site is yet to be determined. These results show the laminin alpha 3 and gamma 2 chains to be substrates for BMP-1 in vitro. We speculate that gamma 2 cleavage is required for formation of the laminin 5-6 complex. and that this complex is directly involved in assembly of the interhemidesmosomal basement membrane. This further suggests that BMP-1 activity facilitates basement membrane assembly, but not hemidesmosome assembly, in the laminin 5-rich dermal-epidermal-junction basement membrane in vivo.	Massachusetts Gen Hosp, MGH Harvard Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Shiseido Res Ctr, Life Sci Res Labs, Yokohama, Kanagawa 2368643, Japan; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Shriners Hosp Crippled Childrens, Portland, OR 97201 USA	Harvard University; Massachusetts General Hospital; Shiseido Company, Limited; University of Wisconsin System; University of Wisconsin Madison	Burgeson, RE (corresponding author), Massachusetts Gen Hosp, MGH Harvard Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.	bob.burgeson@cbrc2.mgh.harvard.edu	Lee, Seungbok/AAS-1529-2021; Koch, Manuel/AAG-9914-2021; Nishiyama, Toshio/C-5434-2013	Lee, Seungbok/0000-0002-6620-6269; Koch, Manuel/0000-0002-2962-7814; Nishiyama, Toshio/0000-0002-3459-2636; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR 35689, AR 38923, AR 43621] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621, R37AR035689, P01AR038923, R01AR035689] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; ALDINGER G, 1991, INT ORTHOP, V15, P169; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; Covey D C, 1989, Orthop Rev, V18, P857; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI L, 1995, GENETICS, V141, P271; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GAILLANO MF, 1820, J BIOL CHEM, V270, P21820; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holmes DF, 1996, J MOL BIOL, V261, P93, DOI 10.1006/jmbi.1996.0443; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; REDDI AH, 1993, J BONE MINER RES, V8, pS499; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH LT, 1988, J INVEST DERMATOL, V90, P480, DOI 10.1111/1523-1747.ep12460951; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Suzuki N, 1996, DEVELOPMENT, V122, P3587; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VAILLY J, 1995, J INVEST DERMATOL, V104, P434, DOI 10.1111/1523-1747.ep12666027; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	45	183	196	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22728	22735		10.1074/jbc.M002345200	http://dx.doi.org/10.1074/jbc.M002345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10806203	hybrid			2022-12-25	WOS:000088419400020
J	Steggerda, SM; Paschal, BM				Steggerda, SM; Paschal, BM			The mammalian Mog1 protein is a guanine nucleotide release factor for Ran	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; IMPORT; GTP; RAN/TC4; RCC1; NTF2; IDENTIFICATION; COMPLEX	Ran is a Ras-related GTPase that is essential for the transport of protein and RNA between the nucleus and the cytoplasm. Proteins that regulate the GTPase cycle and subcellular distribution of Ran include the cytoplasmic GTPase-activating protein (RanGAP) and its cofactors (RanBP1, RanBP2), the nuclear guanine nucleotide exchange factor (RanGEF), and the Ran import receptor (NTF2). The recent identification of the Saccharomyces cerevisiae protein Mog1p as a suppressor of temperature-sensitive Ran mutations suggests that additional regulatory proteins remain to be characterized. Here, we describe the identification and biochemical characterization of murine Mog1, which, like its yeast orthologue, is a nuclear protein that binds specifically to RanGTP, We show that Mog1 stimulates the release of GTP from Ran, indicating that Mog1 functions as a guanine nucleotide release factor in vitro. Following GTP release, Mog1 remains bound to nucleotide-free Ran in a conformation that prevents rebinding of the guanine nucleotide. These properties distinguish Mog1 from the well characterized RanGEF and suggest an unanticipated mechanism for modulating nuclear levels of RanGTP.	Univ Virginia, Ctr Hlth Sci, Ctr Cell Signaling, Dept Biochem & Mol Genet, Charlottesville, VA 22906 USA; Univ Virginia, Ctr Hlth Sci, Cell & Mol Biol Program, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Paschal, BM (corresponding author), Univ Virginia, Ctr Hlth Sci, Ctr Cell Signaling, Dept Biochem & Mol Genet, Box 800577,7161 Hosp W, Charlottesville, VA 22906 USA.	paschal@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Black BE, 1999, MOL CELL BIOL, V19, P8616; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Desai A, 1999, CURR BIOL, V9, pR704, DOI 10.1016/S0960-9822(99)80445-X; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Macara LG, 1999, CURR BIOL, V9, pR436, DOI 10.1016/S0960-9822(99)80275-9; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Sazer S, 2000, J CELL SCI, V113, P1111; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	34	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23175	23180		10.1074/jbc.C000252200	http://dx.doi.org/10.1074/jbc.C000252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811801	hybrid			2022-12-25	WOS:000088419400078
J	Stoner, M; Wang, F; Wormke, M; Nguyen, T; Samudio, I; Vyhlidal, C; Marme, D; Finkenzeller, G; Safe, S				Stoner, M; Wang, F; Wormke, M; Nguyen, T; Samudio, I; Vyhlidal, C; Marme, D; Finkenzeller, G; Safe, S			Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE BREAST-CARCINOMA; INDUCED TRANSCRIPTIONAL ACTIVATION; PERMEABILITY FACTOR EXPRESSION; ELEMENT-BINDING PROTEIN; RETINOIC ACID RECEPTOR; FACTOR GENE-EXPRESSION; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; FACTOR MESSENGER-RNA; C-FOS PROTOONCOGENE	Treatment of HEC1A endometrial cancer cells with 10 nM 17 beta-estradiol (E2) resulted in decreased vascular endothelial growth factor (VEGF) mRNA expression, and a similar response was observed using a construct, pVEGF1, containing a VEGF gene promoter insert from -2018 to +50, In HEC1A cells transiently transfected with pVEGF1 and a series of deletion plasmids, it was shown that E2-dependent down-regulation was dependent on wild-type estrogen receptor alpha (ER alpha) and reversed by the anti-estrogen ICI 182,780, and this response was not affected by progestins, Deletion analysis of the VEGF gene promoter identified an overlapping G/GC-rich site between -66 to -47 that was required for decreased transactivation by E2. Protein-DNA binding studies using electrophoretic mobility shift and DNA footprinting assays showed that both Sp1 and Sp3 proteins bound this region of the VEGF promoter. Coimmunoprecipitation and pull-down assays demonstrated that Sp3 and ER alpha proteins physically interact, and the interacting domains of both proteins are different from those previously observed for interactions between Sp1 and ER alpha proteins, Using a dominant negative form of Sp3 and transcriptional activation assays in Schneider SL-2 insect cells, it was confirmed that ER alpha-Sp3 interactions define a pathway for E2-mediated inhibition of gene expression, and this represents a new mechanism for decreased gene expression by E2.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Tumor Biol Ctr, Inst Mol Med, D-79106 Freiburg, Germany	Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.		Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Barroso I, 1999, J BIOL CHEM, V274, P17997, DOI 10.1074/jbc.274.25.17997; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BROWN LF, 1993, AM J PATHOL, V143, P1255; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Castro-Rivera E, 1998, J STEROID BIOCHEM, V64, P287, DOI 10.1016/S0960-0760(97)00202-1; CICATIELLO L, 1993, RECEPTOR, V3, P17; Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Duan RQ, 1999, MOL ENDOCRINOL, V13, P1511, DOI 10.1210/me.13.9.1511; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gasparini G, 1996, ANN ONCOL, V7, P441; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUANG RP, 1995, CANCER RES, V55, P5054; Hyder SM, 1997, CANCER LETT, V120, P165, DOI 10.1016/S0304-3835(97)00306-6; Hyder SM, 1998, CANCER RES, V58, P392; Hyder SM, 1996, CANCER RES, V56, P3954; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Joseph IBJK, 1997, CLIN CANCER RES, V3, P2507; Kladde MP, 1996, METHOD ENZYMOL, V274, P214; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Laitinen M, 1997, ENDOCRINOLOGY, V138, P4748, DOI 10.1210/en.138.11.4748; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Linderholm B, 1998, J CLIN ONCOL, V16, P3121, DOI 10.1200/JCO.1998.16.9.3121; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; MACCHIARINI P, 1992, LANCET, V340, P145, DOI 10.1016/0140-6736(92)93217-B; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Nakamura J, 1996, ENDOCRINOLOGY, V137, P5589, DOI 10.1210/en.137.12.5589; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Pratt MAC, 1998, MOL CELL BIOCHEM, V189, P119, DOI 10.1023/A:1006827015320; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; TOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.x; Toi M, 1996, CANCER, V77, P1101, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5; TOI M, 1995, BREAST CANCER RES TR, V36, P193, DOI 10.1007/BF00666040; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WAGNER SA, 1993, SCIENCE, V266, P395; WAKUI S, 1992, J PATHOL, V168, P257, DOI 10.1002/path.1711680303; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; YAMAOKA M, 1993, CANCER RES, V53, P5233; Yoshiji H, 1997, CANCER RES, V57, P3924; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	99	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22769	22779		10.1074/jbc.M002188200	http://dx.doi.org/10.1074/jbc.M002188200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816575	hybrid			2022-12-25	WOS:000088419400026
J	Keene, DR; San Antonio, JD; Mayne, R; McQuillan, DJ; Sarris, G; Santoro, S; Iozzo, RV				Keene, DR; San Antonio, JD; Mayne, R; McQuillan, DJ; Sarris, G; Santoro, S; Iozzo, RV			Acceleracted publication - Decorin binds near the C terminus of type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CORE PROTEIN; SMALL PROTEOGLYCAN; STAINING PATTERN; TENDON COLLAGEN; FIBRILS; FIBRILLOGENESIS; SULFATE; PROTEODERMATAN; MORPHOLOGY	Decorin belongs to a family of small leucine-rich proteoglycans that are directly involved in the control of matrix organization and cell growth, Genetic evidence indicates that decorin is required for the proper assembly of collagenous matrices. Here, we sought to establish the precise binding site of decorin on type I collagen. Using rotary shadowing electron microscopy and photoaffinity labeling, we mapped the binding site of decorin protein core to a narrow region near the C terminus of type I collagen. This region is located within the cyanogen bromide peptide fragment alpha 1(I) CB6 and is similar to 25 nm from the C terminus, in a zone that coincides with the c(1) band of the collagen fibril D-period. This location is very close to one of the major intermolecular cross-linking sites of collagen heterotrimers. Thus, decorin protein core possesses a unique binding specificity that could potentially regulate collagen fibril stability.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Shriners Hosp, Res Facil, Portland, OR 97201 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; LifeCell Corp, Branchburg, NJ 08876 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481] Funding Source: Medline; NHLBI NIH HHS [R01 HL63446] Funding Source: Medline; NIAMS NIH HHS [R01 AR10481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063446] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIRK DE, 1990, J CELL SCI, V95, P649; CHAPMAN JA, 1974, CONNECT TISSUE RES, V2, P137, DOI 10.3109/03008207409152099; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kadler KE, 1996, BIOCHEM J, V316, P1; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; MEEK KM, 1979, J BIOL CHEM, V254, P710; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; SWANSON S, 1992, MATRIX, V12, P56; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; YU L, 1993, DERMATAN SULPHATE PR, P183	31	160	167	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21801	21804		10.1074/jbc.C000278200	http://dx.doi.org/10.1074/jbc.C000278200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10823816	hybrid			2022-12-25	WOS:000088363800007
J	Park, HI; Ni, J; Gerkema, FE; Liu, D; Belozerov, VE; Sang, QXA				Park, HI; Ni, J; Gerkema, FE; Liu, D; Belozerov, VE; Sang, QXA			Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING-ENZYME; SEQUENCE-ANALYSIS; COLLAGENASE; CLONING; EXPRESSION; MT5-MMP	We report the discovery, cloning, and characterization of a novel human matrix metalloproteinase 26 (MMP-26) (matrixin) gene, endometase, an endometrial tumor-derived metalloproteinase. Among more than three million expressed sequence tags sequenced, the endometase gene was only obtained from human endometrial tumor cDNA library. Endometase mRNA was expressed specifically in human uterus, not in other tissues/cells tested, e.g. testis, heart, brain, lungs, liver, thymus, and melanoma G361. Endometase protein has a signal peptide, a propeptide domain, and a catalytic domain with a unique "cysteine switch" propeptide sequence, PHCGVPDGSD, and a zinc-binding motif, VAT-HEIGHSLGLQH. Endometase is 43, 41, 41, and 39% identical to human metalloelastase, stromelysin, collagenase-3, and matrilysin, respectively. The zymogen was expressed and isolated from Escherichia coli as inclusion bodies with a molecular mass of 28 kDa. The identity and homogeneity of the recombinant protein was confirmed by protein N-terminal sequencing, silver stain, and immunoblot analyses. The pro-enzyme was partially activated during the folding process. Endometase selectively cleaved type I gelatin and alpha(1)-proteinase inhibitor; however, it did not digest collagens, laminin, elastin, beta-casein, plasminogen, soybean trypsin inhibitor, or Bowman-Birk inhibitor. It hydrolyzed peptide substrates of matrixins and tumor necrosis factor-alpha concerting enzyme. Endometase may selectively cleave extracellular matrix proteins, inactivate serpins, and process cytokines.	Florida State Univ, Dept Chem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; GlaxoSmithKline; Human Genome Sciences Inc	Sang, QXA (corresponding author), Florida State Univ, Dept Chem, Chem Res Bldg DCL,Rm 203, Tallahassee, FL 32306 USA.				NATIONAL CANCER INSTITUTE [R29CA078646] Funding Source: NIH RePORTER; NCI NIH HHS [CA78646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOLLEN A, 1983, DNA-J MOLEC CELL BIO, V2, P255, DOI 10.1089/dna.1983.2.255; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Li H, 1998, MOL CARCINOGEN, V22, P84; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Llano E, 1999, CANCER RES, V59, P2570; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; PARKS WC, 1998, MATRIX METALLOPROTEI; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; VanDyk DE, 1997, BIOORG MED CHEM LETT, V7, P1219, DOI 10.1016/S0960-894X(97)00148-0; Velasco G, 2000, CANCER RES, V60, P877; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913	27	160	182	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20540	20544		10.1074/jbc.M002349200	http://dx.doi.org/10.1074/jbc.M002349200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801841	hybrid			2022-12-25	WOS:000088084500046
J	Abraham, DJ; Xu, SW; Black, CM; Sa, S; Xu, YL; Leask, A				Abraham, DJ; Xu, SW; Black, CM; Sa, S; Xu, YL; Leask, A			Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANCHORAGE-INDEPENDENT GROWTH; VASCULAR ENDOTHELIAL-CELLS; SYSTEMIC-SCLEROSIS; TNF-ALPHA; TGF-BETA; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; GENE-EXPRESSION; FIBROSIS	Connective tissue growth factor (CTGF) is over-expressed in a variety of fibrotic disorders, presumably secondary to the activation and production of transforming growth factor-p (TGF-P), a key inducer of fibroblast proliferation and matrix synthesis. The CTGF gene promoter has a TGF-P response element that regulates its expression in fibroblasts but not epithelial cells or lymphocytes. Recent studies have shown that the macrophage-produced cytokine tumor necrosis factor alpha (TNF alpha) is necessary to promote inflammation and to induce genes, such as matrix metalloproteinases, involved with the early stages of wound healing, In this study, we examined the ability of TNF alpha to modulate CTGF gene expression. TNF alpha was found to suppress the TGF-beta-induced expression of CTGF protein in cultured normal fibroblasts. The activity of TNF alpha was blocked by NF-kappa B inhibitors. We showed that sequences between -244 and -166 of the CTGF promoter were necessary for both TGF-beta and TNF alpha to modulate CTGF expression. There was a constitutive expression of CTGF by scleroderma fibroblasts that was increased by TGF-beta treatment, Although TNF alpha was able to repress TGF-beta-induced CTGF and collagen synthesis both in normal and scleroderma skin fibroblasts, fibroblasts cultured from scleroderma patients were more resistant to TNF alpha as TNF alpha was unable to suppress the basal level of CTGF expression in scleroderma fibroblasts, Thus, we suspect that the high level of constitutive CTGF expression in scleroderma fibroblasts and its inability to respond to negative regulatory cytokines may contribute to the excessive scarring of skin and internal organs in patients with scleroderma.	FibroGen Inc, San Francisco, CA 94080 USA; UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London W3 PF, England	FibroGen; University of London; University College London; UCL Medical School	Leask, A (corresponding author), FibroGen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.	aleask@fibrogen.com	Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020					Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BODENSON J, 1999, P NATL ACAD SCI USA, V96, P5668; BOKER K, 1991, J HEPATOL, V13, pS35, DOI 10.1016/0168-8278(91)90006-W; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; CAMBREY AD, 1994, AM J RESP CELL MOL, V11, P439, DOI 10.1165/ajrcmb.11.4.7917311; CHRIST M, 1994, J IMMUNOL, V153, P1936; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; Hasegawa M, 1997, J RHEUMATOL, V24, P663; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Lin J, 1998, CARDIOVASC RES, V38, P802, DOI 10.1016/S0008-6363(98)00055-8; Liu JY, 1998, AM J PATHOL, V153, P1839, DOI 10.1016/S0002-9440(10)65698-2; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McDade TP, 1999, J SURG RES, V83, P56, DOI 10.1006/jsre.1998.5560; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; PELTONEN J, 1990, ARTHRITIS RHEUM-US, V33, P1829, DOI 10.1002/art.1780331211; RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0; Serra R, 1996, NAT MED, V2, P390, DOI 10.1038/nm0496-390; SHAH M, 1994, J CELL SCI, V107, P1137; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; Xu SW, 1997, ARTHRITIS RHEUM-US, V40, P1237; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yamamoto T, 1999, CLIN IMMUNOL, V92, P6, DOI 10.1006/clim.1999.4720; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	40	217	233	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15220	15225		10.1074/jbc.275.20.15220	http://dx.doi.org/10.1074/jbc.275.20.15220			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809757	hybrid			2022-12-25	WOS:000087128300061
J	Wang, X; Weng, LP; Yu, Q				Wang, X; Weng, LP; Yu, Q			Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR	ONCOGENE			English	Article						PTPase; tyrosine phosphorylation; growth factor	EPIDERMAL GROWTH-FACTOR; MOTOR AXON GUIDANCE; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; KINASES; CELLS; SIGMA; OVEREXPRESSION; ASSOCIATION	LAR is a widely expressed receptor-like protein tyrosine phosphatase that is implicated in regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors, Genetic studies revealed that LAR regulates neuron axon path finding in Drosophila and mammary gland epithelial cell differentiation in mice. The molecular mechanism underlying the tissue specific function of LAR has not been clearly understood. We investigated the role and mechanism of LAR in peptide growth factors EGF and FGF signaling in human tissue culture cells in which the expression of LAR is under the control of an inducible promoter. We found that although both EGF and FGF induce activation of mitogen-activated protein kinase (MAPK), LAR only inhibits FGF-induced MAPK activation. LAR does not interact directly with the peptide growth factor receptors, since the ligand-induced autophosphorylation of growth factor receptors was not affected by induction of LAR, The specific effect of LAR on FGF-induced MAPK activation appeared to be mediated by specific inhibition of the phosphorylation of two signal transducers that act downstream of the FGF receptor, FRS2 and a 180 kDa protein, and by prevention of their interaction with the adaptor protein GRB2, In contrast, LAR selectively inhibited the epidermal growth factor (EGF)-induced phosphorylation of p130(CAS) and the formation of the complex between p130(CAS) and GRB2 but this effect did not influence the activation of MAPK by EGF, These data suggest that LAR and similar receptor-like protein tyrosine phosphatases may contribute to the regulation of transmembrane signaling by selectively inhibiting the tyrosine phosphorylation of specific signal transducers that act downstream of the plasma membrane-associated tyrosine kinases, The consequent inhibition of the Formation of signaling complexes by these proteins may contribute to the specificity of the signals generated by specific peptide growth factors as well as extracellular matrix proteins.	Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Ctr Pulm, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Yu, Q (corresponding author), Boston Univ, Med Ctr, Ctr Pulm, Dept Med, Boston, MA 02118 USA.				NHLBI NIH HHS [R01 HL 54044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 1997, J BIOL CHEM, V272, P448; AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Elchebly M, 1999, NAT GENET, V21, P330, DOI 10.1038/6859; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; KATSURA H, 1995, DEV DYNAM, V204, P89, DOI 10.1002/aja.1002040111; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YU Q, 1992, ONCOGENE, V7, P1051; Zinn K, 1998, CURR BIOL, V8, pR725, DOI 10.1016/S0960-9822(98)70459-2	38	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2346	2353		10.1038/sj.onc.1203558	http://dx.doi.org/10.1038/sj.onc.1203558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822386				2022-12-25	WOS:000086974300010
J	Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM				Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM			The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3 ' kinase	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); HGF/SF; c-Met; breast cancer; adriamycin (doxorubicin)	C-MET RECEPTOR; SCATTER FACTOR; CELL-DEATH; TUMOR-SUPPRESSOR; EXPRESSION; SURVIVAL; BRCA1; AKT; PHOSPHORYLATION; ACTIVATION	Scatter factor (SF) [aka, hepatocyte growth factor (HGF)] (designated HGF/SF) is a multifunctional cytokine that stimulates tumor cell invasion and angiogenesis. We recently reported that HGF/SF protects epithelial and carcinoma cells against cytotoxicity from DNA-damaging agents and that HGF/SF-mediated cytoprotection was associated with up-regulation of the anti-apoptotic protein Bcl-X-L in cells exposed to adriamycin, We now; report that in addition to blocking apoptosis, HGF/SF markedly enhances the repair of DNA strand breaks caused by adriamycin or gamma radiation. Constitutive expression of Bcl-X-L in MDA-MB-453 breast cancer cells not only simulated the HGF/SF-mediated chemoradioresistance, but also enhanced the repair of DNA strand breaks, The ability of HGF/SF to induce both chemoresistance and DNA repair was inhibited by wortmannin, suggesting that these activities of HGF/SF are due, in part, to a phosphatidylinositol-3'-kinase (PI3K) dependent signaling pathway. Consistent with this finding, HGF/SF induced the phosphorylation of c-Akt (protein kinase-B), a PI3K substrate implicated in apoptosis inhibition; and an expression vector encoding a dominant negative kinase inactive Akt partially but significantly inhibited HGF/SF-mediated cell protection and DNA repair. These findings suggest that HGF/SF activates a cell survival and DNA repair pathway;ay that involves signaling through PI3K and c-Akt and stabilization of the expression of Bcl-X-L and they implicate Bcl-X-L in the DNA repair process.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Rockville Ctr, Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Mercy Med Ctr, New York, NY 11570 USA; Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Neurosci, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Oncol, Baltimore, MD 21205 USA	Northwell Health; Yeshiva University; Memorial Sloan Kettering Cancer Center; Kennedy Krieger Institute; Johns Hopkins University; Kennedy Krieger Institute; Kennedy Krieger Institute	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS CA32148] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032148] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Husain A, 1998, CANCER RES, V58, P1120; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KOLIK G, 1997, MOL CELL BIOL, V17, P1595; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Packham G, 1996, ONCOGENE, V13, P461; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rodriguez C, 1996, J CELL PHYSIOL, V166, P387, DOI 10.1002/(SICI)1097-4652(199602)166:2<387::AID-JCP17>3.0.CO;2-8; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SATTLER MM, 1996, NATURE, V382, P335; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shao NS, 1996, ONCOGENE, V13, P1; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; STOKER M, 1987, NATURE, V327, P238; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao Y, 1996, AM J PATHOL, V149, P1707; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	47	140	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2212	2223		10.1038/sj.onc.1203566	http://dx.doi.org/10.1038/sj.onc.1203566			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822371				2022-12-25	WOS:000086974100006
J	Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD				Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD			Evi27 encodes a novel membrane protein with homology to the IL17 receptor	ONCOGENE			English	Article						insertional mutagenesis; novel cytokine receptor; IL-17R related gene; myeloid leukemia	MYELOPROLIFERATIVE LEUKEMIA-VIRUS; MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; CYTOKINE RECEPTOR; INTEGRATION SITE; CELL-LINES; T-CELL; GENE; MOUSE; EXPRESSION	Evi27 is a common site of retroviral integration in BXH2 murine myeloid leukemias. Here me show that integration at Evi27 occurs in a CpG island similar to 6 kb upstream from a novel gene (designated Evi27) with homology to the IL17 receptor (Il17r) and that proviral integrations result in increased expression of the Evi27 protein on the cell surface. The human EVI27 homology was also cloned and mapped to chromosome 3p21, Multiple Evi27 isoforms were detected at the RNA and protein level in both human and mouse, indicating that Evi27 expression is complex. Some of the isoforms are shown to likely represent secreted soluble forms of the protein produced by intron incorporation or by proteolytic cleavage. In the mouse, highest Evi27 expression occurs in liver and testes with lower expression in kidney and lung, In humans, EVI27 is expressed at high levels in the kidney, with moderate levels in the liver, brain, and testes. Within hematopoietic cells, Evi27 expression is restricted. Northern and Western analysis showed that Evi27 is expressed in selected T-cell B-cell and myeloid cell lines. These results suggest that Evi27 expression is tightly regulated during hematopoietic differentiation. Collectively, these studies identify a nea member of the cytokine receptor family whose increased and uncoordinated expression may lead to myeloid leukemia by altering Evi27's normal ability to control the growth and/or differentiation of hematopoietic cells.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Ctr Canc, Minneapolis, MN 55455 USA; NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA.		Largaespada, David/C-9832-2014					Bagby G.C.J., 1994, MOL BASIS BLOOD DIS, P71; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CHRETIEN S, 1994, BLOOD, V83, P1813; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COPELAND NG, 1999, ANIMAL MODELS CANC P, P53; FLUBACHER MM, 1994, J VIROL, V68, P7709, DOI 10.1128/JVI.68.12.7709-7716.1994; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Johansson B, 1997, LEUKEMIA, V11, P1207, DOI 10.1038/sj.leu.2400718; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liao XB, 1997, ONCOGENE, V14, P1023, DOI 10.1038/sj.onc.1200929; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ogawa S, 1996, ONCOGENE, V13, P183; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P228, DOI 10.1002/(SICI)1098-2264(199708)19:4<228::AID-GCC4>3.0.CO;2-Z; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YOO ZB, 1995, J IMMUNOL, V155, P5483; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	45	56	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2098	2109		10.1038/sj.onc.1203577	http://dx.doi.org/10.1038/sj.onc.1203577			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815801				2022-12-25	WOS:000086728000003
J	Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF				Kasus-Jacobi, A; Bereziat, V; Perdereau, D; Girard, J; Burnol, AF			Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2	ONCOGENE			English	Article						Grb7; SH2 domain; PIR/BPS; signal transduction; adapter protein; insulin receptor	ADAPTER PROTEIN GRB10; TYROSINE KINASE; I RECEPTOR; GROWTH; CLONING; FAMILY; ASSOCIATION; EXPRESSION; SUBSTRATE; REVEALS	The molecular adapter Grb7 is likely to be implicated in the development of certain cancer types. In this study we show that Grb7 binds the insulin receptors, when they are activated and tyrosine phosphorylated. This interaction is documented by two-hybrid experiments, GST pull-down assays and in vivo coimmunoprecipitations. In addition, our results argue in favor of a preferential association between Grb7 and the insulin receptors when compared to other tyrosine kinase receptors like the EGF receptor, the FGF receptor and Ret, Interestingly, Grb7 is not a substrate of the insulin receptor tyrosine kinase activity. Grb7 binds the activated tyrosine kinase loop of the insulin receptors. Two domains of Grb7 are implicated in the insulin receptor binding: the SH2 domain and the PIR (phosphotyrosine interacting region). The role of these two domains in the interaction,vith the insulin receptor was already reported for Grb10 and Grb14, the other members of the Grb7 family of proteins. However, the relative importance of these domains varies, considering the receptor and the Grb protein. These differences should be a determinant of the specificity of the receptor tyrosine kinase-Grbs binding, and thus of the implication of Grb7/10/14 in signal transduction.	CNRS, UPR 1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Burnol, AF (corresponding author), CNRS, UPR 1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Burnol, Anne-Francoise/P-2181-2017; KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; BEREZIAT, Veronique/0000-0002-9795-549X				Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MORRIONE A, 1997, J BIOL CHEM, V272, P26282; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang J, 1999, MOL CELL BIOL, V19, P6217; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	36	45	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2052	2059		10.1038/sj.onc.1203469	http://dx.doi.org/10.1038/sj.onc.1203469			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803466				2022-12-25	WOS:000086613200009
J	Biggar, SR; Crabtree, GR				Biggar, SR; Crabtree, GR			Chemically regulated transcription factors reveal the persistence of repressor-resistant transcription after disrupting activator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; GENE-EXPRESSION; SWI/SNF COMPLEX; HISTONE DEACETYLASE; SERINE RESIDUE; GAL1 PROMOTER; IN-VITRO; YEAST; PROTEIN	Control of gene expression often requires that transcription terminates rapidly after destruction, inactivation, or nuclear export of transcription factors. However, the role of transcription factor inactivation in terminating transcription is unclear. We have developed a means of conducting order of addition and co-occupancy experiments in living cells by rapidly exchanging proteins bound to promoters. Using this approach, we found that, following specific disruption of activator function, transcription from active promoters decayed slowly, persisting through multiple cell divisions. This persistent transcriptional activity raised the question of what mechanisms return promoters to inactive states. By exchanging or directing co-occupancy of protein complexes bound to a promoter, we found that the transcriptional inhibitor, Ssn6-Tup1, lost its effectiveness as a repressor following activator dissociation. Similar experiments with another repressor, the histone deacetylase Sin3-Rpd3, reinforced this distinction between repression in the presence and absence of an activator. These results suggest that although repressors such as Ssn6-Tup1 and Sin3-Rpd3 prevent activation of gene expression, other mechanisms of repression return promoters to inactive states following the dissociation or inactivation of a transcriptional activator.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chow FS, 1997, DRUG METAB DISPOS, V25, P610; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FASSLER JS, 1991, MOL GEN GENET, V230, P310, DOI 10.1007/BF00290682; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLICK JS, 1992, GENETICS, V130, P295; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Redd MJ, 1997, J BIOL CHEM, V272, P11193; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; STAN R, 1994, J BIOL CHEM, V269, P32027; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88	62	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25381	25390		10.1074/jbc.M002991200	http://dx.doi.org/10.1074/jbc.M002991200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10801867	hybrid			2022-12-25	WOS:000088849400046
J	Cavalli, A; Druey, KM; Milligan, G				Cavalli, A; Druey, KM; Milligan, G			The regulator of G protein signaling RGS4 selectively enhances alpha(2A)-adreoreceptor stimulation of the GTPase activity of G(o1)alpha and G(i2)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ALPHA(2A)-ADRENOCEPTOR-G(I1)ALPHA FUSION PROTEIN; ALPHA-SUBUNITS; ACTIVATING PROTEINS; PHOSPHOLIPASE C-BETA-1; G-ALPHA(I) SUBUNITS; RAT-1 FIBROBLASTS; TRANSITION-STATE; POINT-MUTATION; FAMILY MEMBERS	Agonist-stimulated high affinity GTPase activity of fusion proteins between the alpha(2A)-adrenoreceptor and the alpha subunits of forms of the G proteins G(i1), G(i2), G(i3), and G(o1), modified to render them insensitive to the action of pertussis toxin, was measured following transient expression in COS-7 cells. Addition of a recombinant regulator of G protein signaling protein, RGS4, did not significantly affect basal GTPase activity nor agonist stimulation of the fusion proteins containing G alpha(i1) and G alpha(i3) but markedly enhanced agonist-stimulation of the proteins containing G alpha(i2) and G alpha(o1). The effect of RGS4 on the alpha(2A)-adrenoreceptor-G alpha(o1) fusion protein was concentration-dependent with EC50 of 30 +/- 3 nM and the potency of the receptor agonist UK14304 was reduced 3-fold by 100 nM RGS4. Equivalent reconstitution with Asn(88)-Ser RGS4 failed to enhance agonist function on the alpha(2A)-adrenoreceptor-G alpha(o1) or alpha(2A)-adrenoreceptor-G alpha(i2) fusion proteins. Enzyme kinetic analysis of the GTPase activity of the alpha(2A)-adrenoreceptor-G alpha(o1) and alpha(2A)-adrenoreceptor-G alpha(i2) fusion proteins demonstrated that RGS4 both substantially increased GTPase V-max and significantly increased K-m of the fusion proteins for GTP. The increase in K-m for GTP was dependent upon RGS4 amount and is consistent with previously proposed mechanisms of RGS function. Agonist-stimulated GTPase turnover number in the presence of 100 nM RGS4 was substantially higher for alpha(2A)-adrenoreceptor-G alpha(o1) than for alpha(2A)-adrenoreceptor-G alpha(i2). These studies demonstrate that although RGS4 has been described as a generic stimulator of the GTPase activity of G(i)-family G proteins, selectivity of this interaction and quantitative variation in its function can be monitored in the presence of receptor activation of the G proteins.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	University of Glasgow; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dupuis DS, 1999, NEUROPHARMACOLOGY, V38, P1035, DOI 10.1016/S0028-3908(99)00033-7; Fong CW, 1999, BIOCHEM J, V342, P457, DOI 10.1042/0264-6021:3420457; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gold SJ, 1997, J NEUROSCI, V17, P8024; GRASSIE MA, 1995, BIOCHEM J, V306, P525, DOI 10.1042/bj3060525; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; Kellett E, 1999, MOL PHARMACOL, V56, P684; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; Medici R, 1997, EMBO J, V16, P7241, DOI 10.1093/emboj/16.24.7241; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; Seifert R, 1999, EUR J BIOCHEM, V260, P661, DOI 10.1046/j.1432-1327.1999.00161.x; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Ward RJ, 1999, FEBS LETT, V462, P459, DOI 10.1016/S0014-5793(99)01581-1; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; Wise A, 1997, FEBS LETT, V419, P141, DOI 10.1016/S0014-5793(97)01431-2; Woulfe DS, 1999, J BIOL CHEM, V274, P17718, DOI 10.1074/jbc.274.25.17718; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	57	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23693	23699		10.1074/jbc.M910395199	http://dx.doi.org/10.1074/jbc.M910395199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807934	hybrid			2022-12-25	WOS:000088564200041
J	Liu, XQ; Smerdon, MJ				Liu, XQ; Smerdon, MJ			Nucleotide excision repair of the 5 S ribosomal RNA gene assembled into a nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; CORE PARTICLE; PYRIMIDINE DIMERS; CYCLOBUTANE DIMER; UV PHOTOPRODUCT; ACTIVE GENE; IN-VITRO; CHROMATIN; TRANSCRIPTION; BINDING	A-175-base pair fragment containing the Xenopus borealis somatic 5 S ribosomal RNA gene was used as a model system to determine the effect of nucleosome assembly on nucleotide excision repair (NER) of the major UV photoproduct (cyclobutane pyrimidine dimer (CPD)) in DNA. Xenopus oocyte nuclear extracts were used to carry out repair in vitro on reconstituted, positioned 5 S rDNA nucleosomes. Nucleosome structure strongly inhibits NER at many CPD sites in the 5 S rDNA fragment while having little effect at a few sites. The time course of CPD removal at 35 different sites indicates that >85% of the CPDs in the naked DNA fragment have t1/2 values <2 h, whereas <26% of the t1/2 values in nucleosomes are <2 h, and 15% are >8 h. Moreover, removal of histone tails from these mononucleosomes has little effect on the repair rates. Finally, nucleosome inhibition of repair shows no correlation with the rotational setting of a 14-nucleotide-long pyrimidine tract located 30 base pairs from the nucleosome dyed. These results suggest that inhibition of NER by mononucleosomes is not significantly influenced by the rotational orientation of CPDs on the histone surface, and histone tails play little (or no) role in this inhibition.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R37ES002614] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; Chirinos M, 1998, BIOCHEMISTRY-US, V37, P7251, DOI 10.1021/bi9729817; Conconi A, 1999, EMBO J, V18, P1387, DOI 10.1093/emboj/18.5.1387; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; FRIEDBERG EC, 1995, DNA RAPAIR MUTAGENES; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; LAN SY, 1985, BIOCHEMISTRY-US, V24, P7771, DOI 10.1021/bi00347a041; LI S, 2000, IN PRESS METHODS COM; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUTTER LC, 1989, METHOD ENZYMOL, V170, P264; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; NEUBAUER B, 1989, METHOD ENZYMOL, V170, P630; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; PEHRSON JR, 1992, NUCLEIC ACIDS RES, V20, P1321, DOI 10.1093/nar/20.6.1321; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; Smerdon MJ, 1998, CONT CANC RES, P199; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; van Holde KE., 1989, SPRINGER SERIES MOL; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; Wolffe A., 1998, CHROMATIN STRUCTURE; WOLFFE AP, 1994, J CELL SCI, V107, P2055; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	48	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23729	23735		10.1074/jbc.M002206200	http://dx.doi.org/10.1074/jbc.M002206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10821833	hybrid			2022-12-25	WOS:000088564200046
J	Breitschopf, K; Zeiher, AM; Dimmeler, S				Breitschopf, K; Zeiher, AM; Dimmeler, S			Ubiquitin-mediated degradation of the proapoptotic active form of bid - A functional consequence on apoptosis induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; CYTOCHROME-C RELEASE; BCL-X-L; CELL-DEATH; PROTEASOME PATHWAY; STRUCTURAL BASIS; INTERACTS; FAMILY; BAX; MITOCHONDRIA	Under basal conditions, the proapoptotic protein Bid is a long-lived protein. Pro-apoptotic stimuli such as tumor necrosis factor-alpha (TNF alpha) or Fas induce its caspase-8-mediated cleavage into two fragments. The COOH-terminal cleavage fragment of Bid (tBid) becomes localized to mitochondrial membranes and triggers the release of cytochrome c. Here we show that tBid is ubiquitinated and subsequently degraded by the 26 S proteasome. Degradation of tBid is significantly inhibited by the proteasome inhibitors MG-132 and lactacystin. In contrast, caspase-specific or lysosomal inhibitors do not affect tBid stability. Furthermore, mutation of the putative ubiquitin acceptor sites within tBid results in a stabilized protein as assessed by pulse-chase analysis. To address whether tBid degradation might be regulated by interaction with other Bcl-2-like proteins, cotransfection studies were performed. However, neither the presence of proapoptotic Bax nor antiapoptotic Bcl-2 or Bcl-XL affected tBid degradation. Finally, we determined the functional role of tBid degradation. Overexpression of stabilized tBid proteins significantly enhanced cytochrome c release and subsequent apoptosis induction approximately 2-fold compared with wild type tBid. Similarly, tBid-induced apoptosis was considerably amplified by inhibition of tBid degradation using the proteasome-specific inhibitor MG-132. Thus, proteasomal degradation of tBid limits the extent of apoptosis in living cells.	Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 4, Div Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOYD JM, 1995, ONCOGENE, V11, P1921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GAIEWSKI TF, 1996, CELL, V87, P589; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	36	174	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21648	21652		10.1074/jbc.M001083200	http://dx.doi.org/10.1074/jbc.M001083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801801	hybrid			2022-12-25	WOS:000088230600091
J	Schlegel, A; Lisanti, MP				Schlegel, A; Lisanti, MP			A molecular dissection of caveolin-1 membrane attachment and oligomerization - Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; ONCOGENICALLY TRANSFORMED-CELLS; GIRDLE MUSCULAR-DYSTROPHY; MONOCLONAL-ANTIBODY PROBE; SRC TYROSINE KINASES; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; IN-VIVO; HETEROOLIGOMERIC COMPLEX; SUBCELLULAR-DISTRIBUTION	Caveolins form interlocking networks on the cytoplasmic face of caveolae. The cytoplasmically directed N and C termini of caveolins are separated by a central hydrophobic segment, which is believed to form a hairpin within the membrane. Here, we report that the caveolin scaffolding domain (CSD, residues 82-101), and the C terminus (residues 135-178) of caveolin-1 are each sufficient to anchor green fluorescent protein (GFP) to membranes in vivo. We also show that the first 16 residues of the C terminus (i.e. residues 135-150) are necessary and sufficient to attach GFP to membranes. When fused to the caveolin-1 C terminus, GFP co-localizes with two trans-Golgi markers and is excluded from caveolae. In contrast, the CSD targets GFP to caveolae, albeit less efficiently than full-length caveolin-1. Thus, caveolin-1 contains at least two membrane attachment signals: the CSD, dictating caveolar localization, and the C terminus, driving trans-Golgi localization. Additionally, we find that caveolin-1 oligomer/oligomer interactions require the distal third of the caveolin-1 C terminus. Thus, the caveolin-1 C-terminal domain has two separate functions: (i) membrane attachment (proximal third) and (ii) protein/protein interactions (distal third).	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Schlegel, Amnon/0000-0003-4060-2252	NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Joliot A, 1997, DEVELOPMENT, V124, P1865; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Milgram SL, 1997, J CELL SCI, V110, P695; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2000, J CELL SCI, V113, P2103; Reddy PS, 1999, IMMUNOL TODAY, V20, P582, DOI 10.1016/S0167-5699(99)01542-X; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5	76	150	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21605	21617		10.1074/jbc.M002558200	http://dx.doi.org/10.1074/jbc.M002558200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801850	hybrid			2022-12-25	WOS:000088230600086
J	Kishibe, J; Yamada, S; Okada, Y; Sato, J; Ito, A; Miyazaki, K; Sugahara, K				Kishibe, J; Yamada, S; Okada, Y; Sato, J; Ito, A; Miyazaki, K; Sugahara, K			Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; BASEMENT-MEMBRANES; TUBE FORMATION; IN-VITRO; PROTEOGLYCAN; PROTEIN; SURFACE	Tumor-derived adhesion factor/angiomodulin (AGM) is accumulated in tumor blood vessels and on the endothelial cell surface (Akaogi, K., Okabe, Y., Sate, J., Nagashima, Y., Yasumitsu, H., Sugahara, K., and Miyazaki, a (1996, Proc. Natl. Acad Sci. U.S. A. 93, 8384-8389), In cell culture, it promotes cell adhesion and morphological changes to form cord-like structures of the human bladder carcinoma cell line ECV-304. The cord formation is prevented by heparin, which inhibits the binding of AGM to ECV-304 cells. This observation suggests that AGM interacts with cell surface heparan sulfate (HS) proteoglycans. In this study, HS glycosaminoglycans and core proteins of integral transmembrane proteoglycans, syndecan-1 and -4, were identified by immunocytochemistry on ECV-304 cells, and the structural requirements for the interaction of HS with AGM, were characterized. Inhibition experiments with sulfated polysaccharides and chemically modified heparin derivatives indicated that sulfate groups were essential for both AGM-HS binding and cord-like structure formation and that the rank order of the different sulfate groups in terms of their contribution was N-sulfate > 6-O-sulfate > 2-O-sulfate. The minimum size of heparin, a chemical analog of HS, required for the binding to AGM was a dodecasaccharide as determined by competition experiments using size-defined heparin oligosaccharides. Thus, a specific sulfation pattern in the HS of cell surface syndecans of ECV-304 cells is required for AGM binding and the morphological changes.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Yokohama, Kanagawa 2440813, Japan	Kobe Pharmaceutical University; Yokohama City University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp						AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; DAVID G, 1993, DEVELOPMENT, V119, P841; Dhanabal M, 1999, CANCER RES, V59, P189; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; KURE S, 1986, J IMMUNOL, V137, P3900; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; LORIES V, 1989, J BIOL CHEM, V264, P7009; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LYON M, 1994, J BIOL CHEM, V269, P11208; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; UEOKA C, 1997, 4 BIAS JAP AM PHARM; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; WINTERBOURNE DJ, 1978, J BIOL CHEM, V253, P5109; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591; Zimmermann P, 1999, FASEB J, V13, pS91	50	34	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15321	15329		10.1074/jbc.275.20.15321	http://dx.doi.org/10.1074/jbc.275.20.15321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809767	hybrid			2022-12-25	WOS:000087128300074
J	Medina, DL; Toro, MJ; Santisteban, P				Medina, DL; Toro, MJ; Santisteban, P			Somatostatin interferes with thyrotropin-induced G(1)-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase - Involvement of RhoA and cyclin E-cyclin-dependent kinase 2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-THYROID CELLS; GROWTH-FACTOR-I; FRTL-5 CELLS; SIGNALING PATHWAY; ADENYLATE-CYCLASE; DNA-SYNTHESIS; STIMULATED PROLIFERATION; INHIBITOR P27(KIP1); PHORBOL ESTER; S-PHASE	cAMP-mediated cell proliferation is a complex process that involves multiple pathways. Using a cAMP-dependent cell system, FRTL-5 thyroid cells, we have previously demonstrated the existence of a precise autocrine loop in the control of cell proliferation that involves the positive effector thyrotropin (TSH) and the general inhibitor somatostatin, In search of the regulatory mechanisms responsible for the TSH and somatostatin control of cell proliferation, we analyzed the cell cycle regulatory proteins and the cellular pathways involved in the action of both signals. The results show that specific inhibition of cAMP-dependent protein kinase (PKA) and phosphatidylinositol (PI) 3-kinase blocks independently TS)I-induced FRTL-5 cell proliferation and that somatostatin interferes with both signals. Each pathway activates different proteins required for G(1)/S progression. Thus, PKA is responsible for the TSH-induction of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA levels, RhoA activation, and down-regulation of p27(Kip1). These correlated events are necessary for FRTL-5 cell proliferation after TSH stimulation. Moreover, TSH through PKA pathway increases cyclin-dependent kinase 2 levels, whereas PI 3-kinase signaling increases cyclin E levels. Together, both pathways finally converge, increasing the formation and activation of cyclin E cyclin-dependent kinase 2 complexes and the phosphorylation of the retinoblastoma protein, two important steps in the transition from G(1) to S phase in growth-stimulated cells. Somatostatin exerts its antiproliferative effect inhibiting more upstream the TSH stimulation of PKA and PI 3-kinase, interfering with the TSH-mediated increases of intracellular cAMP levels by inactivation of adenylyl cyclase activity. Together, these results suggest the existence of a PEA-dependent pathway and a new PEA-independent PI 3-kinase pathway in the TSH/cAMP-mediated proliferation of FRTL-5 thyroid cells.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; Univ Alcala de Henares, Dept Bioquim & Biol Mol, Fac Med, E-28871 Alcala De Henares, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universidad de Alcala	Santisteban, P (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid, Spain.	psantisteban@iib.uam.es	Medina, Diego/AAC-9622-2020; Santisteban, Pilar/E-7829-2016; Nozal, M José Toro/AAA-9032-2019	Medina, Diego/0000-0002-7347-2645; Santisteban, Pilar/0000-0002-2758-796X; 				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crespo P, 1996, ONCOGENE, V13, P455; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirai A, 1997, J BIOL CHEM, V272, P13; ISOZAKI O, 1987, MOL ENDOCRINOL, V1, P839, DOI 10.1210/mend-1-11-839; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kimura T, 1999, EUR J ENDOCRINOL, V140, P94, DOI 10.1530/eje.0.1400094; LAMY F, 1993, J BIOL CHEM, V268, P8398; MARCOCCI C, 1987, ACTA ENDOCRINOL-COP, V115, P246; Matowe WC, 1996, THYROID, V6, P53, DOI 10.1089/thy.1996.6.53; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ORTIZ MB, 1995, J CELL PHYSIOL, V162, P139, DOI 10.1002/jcp.1041620117; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Reisine T, 1995, AM J PHYSIOL-GASTR L, V269, pG813, DOI 10.1152/ajpgi.1995.269.6.G813; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TORO MJ, 1988, HORM RES, V29, P59, DOI 10.1159/000180969; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TSUZAKI S, 1990, ENDOCRINOLOGY, V126, P3131, DOI 10.1210/endo-126-6-3131; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt A, 1996, ONCOGENE, V13, P1991; Watanabe SY, 1999, NEUROSCI RES, V33, P71, DOI 10.1016/S0168-0102(98)00113-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; ZEGGARI M, 1994, BIOCHEM J, V15, P441	55	37	38	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15549	15556		10.1074/jbc.275.20.15549	http://dx.doi.org/10.1074/jbc.275.20.15549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809788	hybrid			2022-12-25	WOS:000087128300104
J	Sato, C; Fukuoka, H; Ohta, K; Matsuda, T; Koshino, R; Kobayashi, K; Troy, FA; Kitajima, K				Sato, C; Fukuoka, H; Ohta, K; Matsuda, T; Koshino, R; Kobayashi, K; Troy, FA; Kitajima, K			Frequent occurrence of pre-existing alpha 2 -> 8-linked disialic and oligosialic acids with chain lengths up to 7 Sia residues in mammalian brain glycoproteins - Prevalence revealed by highly sensitive chemical methods and anti-di-, oligo-, and poly-Sia antibodies specific for defined chain lengths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; POLYSIALIC ACID; GROUP-B; MONOCLONAL-ANTIBODY; CARBOHYDRATE UNITS; RAINBOW-TROUT; ADULT-RAT; POLYSACCHARIDE; EXPRESSION	The pre-existence of alpha 2-->8-linked disialic acid (di-Sia) and oligosialic acid (oligo-Sia) structures with up to 7 Sia residues was shown to occur on a large number of brain glycoproteins, including neural cell adhesion molecules (N-CAMs), by two highly sensitive chemical methods (Sato, C., Inoue, S., Matsuda, T., and Kitajima, K. (1998) Anal. Biochem. 261, 191-197; Sate, C., Inoue, S,, Matsuda, T., and Kitajima, K, (1999) Anal Biochem, 266, 102-109). This unexpected finding was also confirmed using a newly developed antibody prepared using a copolymer of alpha 2-->8-linked N-acetylneuraminyl p-vinylbenzylamide and acrylamide as an immunogen and known antibodies whose immunospecificities were determined to be di- and oligo-Sia residues with defined chain lengths. The major significance of the new finding that di- and oligo-Sia chains exist on a large number of brain glycoproteins is 2-fold. First, it reveals a surprising diversity in the number and M-r of proteins distinct from N-CAM that are covalently modified by these short sialyl glycotopes. Second, it suggests that synthesis of di- and/or oligo-Sia units may be catalyzed by alpha 2-->8-sialyltransferase(s) that are distinct from the known polysialyltransferases, STX and PST, which are partially responsible for polysialylation of N-CAM.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Nagoya, Aichi 4648601, Japan; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Nagoya University; Nagoya University; University of California System; University of California Davis	Kitajima, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.	kitajima@agr.nagoya-u.ac.jp	SATO, Chihiro/B-7396-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; ASHWELL G, 1994, ANAL BIOCHEM, V222, P495, DOI 10.1006/abio.1994.1523; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EVANS SV, 1995, BIOCHEMISTRY-US, V34, P6737, DOI 10.1021/bi00020a019; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1977, BIOCHEM BIOPH RES CO, V74, P405, DOI 10.1016/0006-291X(77)90318-7; FINNE J, 1977, EUR J BIOCHEM, V77, P319, DOI 10.1111/j.1432-1033.1977.tb11670.x; Fox GB, 1995, INT J DEV NEUROSCI, V13, P663, DOI 10.1016/0736-5748(95)00067-4; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KIANG WL, 1982, J BIOL CHEM, V257, P1651; Kitajima K, 1999, SIALOBIOLOGY OTHER N, P69; KOBAYASHI K, 1996, POLYM PREP JPN, V45, P2651; KOPITZ J, 1997, GLYCOSCIENCES STATUS, P163; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANDRELL RE, 1982, J IMMUNOL, V129, P2171; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; Nohara K, 1997, BBA-LIPID LIPID MET, V1345, P207, DOI 10.1016/S0005-2760(96)00181-6; ROHR TE, 1980, J BIOL CHEM, V255, P2332; SARFF LD, 1975, LANCET, V1, P1099; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SEVIGNY MB, 1999, SIALOBIOLOGY OTHER N, P171; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; ZUBER C, 1992, J BIOL CHEM, V267, P9965	46	102	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15422	15431		10.1074/jbc.275.20.15422	http://dx.doi.org/10.1074/jbc.275.20.15422			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809778	hybrid			2022-12-25	WOS:000087128300088
J	Jacobsen, RB; Koch, ED; Lange-Malecki, B; Stocker, M; Verhey, J; Van Wagoner, RM; Vyazovkina, A; Olivera, BM; Terlau, H				Jacobsen, RB; Koch, ED; Lange-Malecki, B; Stocker, M; Verhey, J; Van Wagoner, RM; Vyazovkina, A; Olivera, BM; Terlau, H			Single amino acid substitutions in kappa-conotoxin PVIIA disrupt interaction with the Shaker K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; XENOPUS OOCYTES; MUTANT CYCLES; ION-CHANNEL; PEPTIDE; RECEPTOR; TOXIN; CURRENTS; SNAILS; BLOCK	K-Conotoxin PVILA (kappa-PVIIA), a 27-amino acid peptide with three disulfide cross-links, isolated from the venom of Conus purpurascens, is the first conopeptide shown to inhibit the Shaker K+ channel (Terlau, H., Shon, K., Grilley, M., Stocker, Ri., Stuhmer, W., and Olivera, B. M. (1996) Nature 381, 148-151). Recently, two groups independently determined the solution structure for kappa-PVIIA using NMR; although the structures reported were similar, two mutually exclusive models for the interaction of the peptide with the Shaker channel were proposed. We carried out a structure/function analysis of kappa-PVIIA, with alanine substitutions for all amino acids postulated to be key residues by both groups. Our data are consistent with the critical dyad model developed by Menez and co-workers (Dauplais, M., Lecoq, A., Song, J., Cotton, J., Jamin, N., Gilquin, B., Roumestand, C., Vita, C., de Medeiros, C., Rowan, E. G., Harvey, A. L., and Menez, A. (1997) J. Biol. Chem. 272, 4802-4809) for polypeptide antagonists of KC channels. In the case of kappa-PVIIA, Lys(7) and Phe(9) are essential for activity as predicted by Savarin et al. (Savarin, P., Guenneugues, M., Gilquin, B., Lamthanh, H., Gasparini, S., Zinn-Justin, S., and Menez, A. (1998) Biochemistry 37, 5407-5416); these workers also correctly predicted an important role for Lys(25). Thus, although K-conotoxin PVIIA has no obvious sequence homology to polypeptide toxins from other venomous animals that interact with voltage-gated K+ channels, there may be convergent functional features in diverse KC channel polypeptide antagonists.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Max Planck Society	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E 201, Salt Lake City, UT 84112 USA.		Stocker, Martin/C-1844-2008		NIGMS NIH HHS [GM 48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; DAUPLAIS M, 1997, J BIOL CHEM, V272, P4802; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; England LJ, 1998, SCIENCE, V281, P575, DOI 10.1126/science.281.5376.575; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAMMERLAND LG, 1992, EUR J PHARM-MOLEC PH, V226, P239, DOI 10.1016/0922-4106(92)90067-6; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; McIntosh J M, 1999, Methods Enzymol, V294, P605; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; Shon KJ, 1998, J NEUROSCI, V18, P4473; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Terlau H, 1999, J GEN PHYSIOL, V114, P125, DOI 10.1085/jgp.114.1.125; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X	28	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24639	24644		10.1074/jbc.C900990199	http://dx.doi.org/10.1074/jbc.C900990199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818087	hybrid			2022-12-25	WOS:000088683300056
J	Dadke, S; Kusari, J; Chernoff, J				Dadke, S; Kusari, J; Chernoff, J			Down-regulation of insulin signaling by protein-tyrosine phosphatase 1B is mediated by an N-terminal binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RAT ADIPOSE-CELLS; PTP-PEST; STIMULATED TRANSLOCATION; NEGATIVE REGULATOR; KINASE; SUBSTRATE; DOMAIN; ASSOCIATION; P130(CAS)	Protein-tyrosine phosphatases (PTPs) play a major role in regulating insulin signaling. Among the PTPs that regulate this signaling pathway, PTP1B plays an especially prominent role. PTP1B inhibits insulin signaling and has previously been shown to bind to the activated insulin receptor (IR), but neither the mechanism nor the physiological importance of such binding have been established. Here, we show that a previously undefined region in the N-terminal, catalytic half of PTP1B contributes to IR binding. Point mutations within this region of PTP1B disrupt IR binding but do not affect the catalytic activity of this phosphatase. This binding defective mutant of PTP1B does not efficiently dephosphorylate the IR in cells, nor does it effectively inhibit IR signaling. These results suggest that PTP1B targets the IR through a novel binding element and that binding is required for the physiological effects of PTP1B on IR signal transduction.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Mol & Cellular Biol Program, New Orleans, LA 70112 USA	Fox Chase Cancer Center; Tulane University; Tulane University	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01-CA58836, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA058836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; Chen H, 1999, BIOCHEMISTRY-US, V38, P384, DOI 10.1021/bi9816103; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487	45	77	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23642	23647		10.1074/jbc.M001063200	http://dx.doi.org/10.1074/jbc.M001063200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807907	hybrid			2022-12-25	WOS:000088564200034
J	Ding, JT; Wu, Z; Crider, BP; Ma, YM; Li, XJ; Slaughter, C; Gong, LM; Xie, XS				Ding, JT; Wu, Z; Crider, BP; Ma, YM; Li, XJ; Slaughter, C; Gong, LM; Xie, XS			Identification and functional expression of four isoforms of ATPase II, the putative aminophospholipid translocase - Effect of isoform variation on the ATPase activity and phospholipid specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; HUMAN-ERYTHROCYTES; SENSITIVE ATPASE; LIPID ASYMMETRY; PHOSPHATIDYLSERINE; PURIFICATION; MEMBRANES; EXPOSURE; CELLS; SUBFAMILY	ATPaseII, avanadate-sensitiveandphosphatidylserine-dependent Mg2+-ATPase, is a member of a subfamily of P-type ATPase and is presumably responsible for aminophospholipid translocation activity in eukaryotic cells. The aminophospholipid translocation activity plays an important physiological role in the maintenance of membrane phospholipid asymmetry that is observed in the plasma membrane as well as the membranes of certain cellular organelles. While the preparations of ATPase II from different sources share common fundamental properties, such as substrate specificity, inhibitor spectrum, and phospholipid dependence, they are divergent in several characteristics. These include specific ATPase activity and phospholipid selectivity. We report here the identification of four isoforms of ATPase II in bovine brain. These isoforms are formed by a combination of two major variations in their primary sequences and show that the structural variation of these isoforms has functional significance in both ATPase activity and phosholipid selectivity. Furthermore, studies with the phosphoenzyme intermediate of ATPase II and its recombinant isoforms revealed that phosphatidylserine is essential for the dephosphorylation of the intermediate. Without phosphatidylserine, ATPase II would be accumulated as phosphoenzyme in the presence of ATP, resulting in the interruption of its catalytic cycle.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Health Science Center Houston	Xie, XS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Mol Transport, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK R01 33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTIA R, 1992, IMMUNOL LETT, V32, P153, DOI 10.1016/0165-2478(92)90108-Z; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Bevers EM, 1996, LUPUS, V5, P480, DOI 10.1177/096120339600500531; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; CRIBIER S, 1993, BIOCHIM BIOPHYS ACTA, V1148, P85, DOI 10.1016/0005-2736(93)90163-T; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; Mouro I, 1999, BIOCHEM BIOPH RES CO, V257, P333, DOI 10.1006/bbrc.1999.0347; PENG SB, 1994, J BIOL CHEM, V269, P17262; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLEGEL RA, 1988, MOL MECHANISMS MEMBR, P289; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Siegmund A, 1998, J BIOL CHEM, V273, P34399, DOI 10.1074/jbc.273.51.34399; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; XIE XS, 1989, J BIOL CHEM, V264, P1710; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046	27	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23378	23386		10.1074/jbc.M910319199	http://dx.doi.org/10.1074/jbc.M910319199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801890	hybrid			2022-12-25	WOS:000088419400107
J	Galbiati, F; Volonte, D; Brown, AMC; Weinstein, DE; Ben-Ze'ev, A; Pestell, RG; Lisanti, MP				Galbiati, F; Volonte, D; Brown, AMC; Weinstein, DE; Ben-Ze'ev, A; Pestell, RG; Lisanti, MP			Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN BREAST-CANCER; ONCOGENICALLY TRANSFORMED-CELLS; APC TUMOR-SUPPRESSOR; D7S522 LOCUS 7Q31.1; ROUS-SARCOMA VIRUS; PROTEIN-KINASE-A; E-CADHERIN; SUBCELLULAR-DISTRIBUTION; MAP KINASE	Caveolin-1 is a principal component of caveolae membranes. In NIR 3T3 cells, caveolin-1 expression is dramatically up-regulated in confluent cells and localizes at areas of cell-cell contact. However, it remains unknown whether caveolin-1 is involved in cell-cell signaling. Here, we examine the potential role of caveolin-1 in regulating beta-catenin signaling. beta-Catenin plays a dual role in the cell, Linking E-cadherin to the actin cytoskeleton and in Wnt signaling by forming a complex with members of the lymphoid enhancing factor (Lef-1) family of transcription factors. We show that E cadherin, beta-catenin, and gamma-catenin (plakoglobin) are all concentrated in caveolae membranes. Moreover, we demonstrate that activation of beta-catenin/Lef-1 signaling by Wnt-1 or by overexpression of beta-catenin itself is inhibited by caveolin-1 expression. We also show that recombinant expression of caveolin-1 in caveolin-1 negative cells is sufficient to recruit beta-catenin to caveolae membranes, thereby blocking beta-catenin-mediated transactivation. These results suggest that caveolin-1 expression can modulate Wnt/beta-catenin/Lef-1 signaling by regulating the intracellular localization of beta-catenin.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Cornell Univ, Weil Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Weizmann Institute of Science; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Galbiati, Ferruccio/AAF-3527-2020	Lisanti, Michael/0000-0003-2034-1382; ben-ze'ev, avri/0000-0001-6113-3921	NATIONAL CANCER INSTITUTE [R01CA075503, R01CA047207, R01CA070897] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA047207, R01-CA-75503, R01-CA-70897] Funding Source: Medline; NHLBI NIH HHS [P50-HL-56399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; Charpin C, 1999, INT J ONCOL, V15, P285; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Geiger B, 1995, ACTA ANAT, V154, P46; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Howe LR, 1999, CANCER RES, V59, P1572; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2000, J CELL SCI, V113, P2103; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Yang LM, 1997, CANCER RES, V57, P4652; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	95	151	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23368	23377		10.1074/jbc.M002020200	http://dx.doi.org/10.1074/jbc.M002020200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816572	hybrid			2022-12-25	WOS:000088419400106
J	Green, AL; Anderson, EJ; Brooker, RJ				Green, AL; Anderson, EJ; Brooker, RJ			A revised model for the structure and function of the lactose permease - Evidence that a face on transmembrane segment 2 is important for conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; LINKING IN-SITU; CYSTEINE-SCANNING MUTAGENESIS; SUGAR-TRANSPORT PROTEINS; METAL-BINDING SITES; THIOL CROSS-LINKING; ESCHERICHIA-COLI; HELIX-V; DISTANCE DETERMINATION; MONOCLONAL-ANTIBODIES	The lactose permease is an integral membrane protein that cotransports H+ and lactose into the bacterial cytoplasm. Previous work has shown that bulky substitutions at glycine 64, which is found on the cytoplasmic edge of transmembrane segment 2 (TMS-S), cause a substantial decrease in the maximal velocity of lactose uptake without significantly affecting the K-m values (Jessen-Marshall, A. E., Parker, N. J., and Brooker, R. J. (1997) J. Bacteriol. 179, 2616-2622). In the current study, mutagenesis was conducted along the face of TMS-2 that contains glycine-64. Single amino acid substitutions that substantially changed side chain volume at codons 52, 57, 59, 63, and 66 had little or no effect on transport activity, whereas substitutions at codons 49, 53, 56, and 60 were markedly defective and/or had lower levels of expression. According to helical wheel plots, Phe-49, Ser-53, Ser-56, Gln-60, and Gly-64 form a continuous stripe along one face of TMS-2. Several of the TMS-2 mutants (S56Y, S56L, S56Q, Q60A, and Q60V) were used as parental strains to isolate mutants that restore transport activity. These mutations were either first-site mutations or second-site suppressors in TMS-1, TMS-2, TMS-7 or TMS-11. A kinetic analysis showed that the suppressors had a higher rate of lactose transport compared with the corresponding parental strains. Overall, the results of this study are consistent with the notion that a face on TMS-8, containing Phe-49, Ser-53, Ser-56, Gln-60, and Gly-64, plays a critical role in conformational changes associated with lactose transport. We hypothesize that TMS-S slides across TMS-7 and TMS-11 when the lactose permease interconverts between the C1 and C2 conformations. This idea is discussed within the context of a revised model for the structure of the lactose permease.	Univ Minnesota, Gortner Labs 240, BioProc Technol Inst, St Paul, MN 55108 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Brooker, RJ (corresponding author), Univ Minnesota, Gortner Labs 240, BioProc Technol Inst, 1479 Gortner Ave, St Paul, MN 55108 USA.				NIGMS NIH HHS [GM53259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL I, 1975, ENZYME KINETICS, P210; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Voss J, 1995, P NATL ACAD SCI USA, V92, P12295, DOI 10.1073/pnas.92.26.12295; Voss J, 1995, P NATL ACAD SCI USA, V92, P12300, DOI 10.1073/pnas.92.26.12300; Wang QD, 1999, J MOL BIOL, V291, P683, DOI 10.1006/jmbi.1999.2948; Wang QD, 1998, BIOCHEMISTRY-US, V37, P4910, DOI 10.1021/bi972990f; Wang QD, 1999, BIOCHEMISTRY-US, V38, P3120, DOI 10.1021/bi982507g; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; Wu JH, 1998, J MOL BIOL, V282, P959, DOI 10.1006/jmbi.1998.2065; Wu JH, 1996, P NATL ACAD SCI USA, V93, P10123, DOI 10.1073/pnas.93.19.10123; Wu JH, 1998, BIOCHEMISTRY-US, V37, P15785, DOI 10.1021/bi981501o; Wu JH, 1999, BIOCHEMISTRY-US, V38, P2320, DOI 10.1021/bi982288z; Wu JH, 1999, BIOCHEMISTRY-US, V38, P1715, DOI 10.1021/bi982342b	53	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23240	23246		10.1074/jbc.M909202199	http://dx.doi.org/10.1074/jbc.M909202199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807929	hybrid			2022-12-25	WOS:000088419400088
J	Kudla, G; Montessuit, S; Eskes, R; Berrier, C; Martinou, JC; Ghazi, A; Antonsson, B				Kudla, G; Montessuit, S; Eskes, R; Berrier, C; Martinou, JC; Ghazi, A; Antonsson, B			The destabilization of lipid membranes induced by the C-terminal fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; BAX; MITOCHONDRIA; DEATH; BCL-2; RELEASE; BCL-X(L); PROTEINS; DOMAIN; BH3	Bid is a proapoptotic, BH8-domain-only member of the Bcl-2 family. In Fas-induced apoptosis, Bid is activated through cleavage by caspase 8 into a 15,5-kDa C-terminal fragment (t(c)Bid) and a 6.5 kDa N-terminal fragment (t(n)Bid). Following the cleavage, t(c)Bid translocates to the mitochondria and promotes the release of cytochrome c into the cytosol by a mechanism that is not understood. Here we report that recombinant t(c)Bid can act as a membrane destabilizing agent, t(c)Bid induces destabilization and breaking of planar lipid bilayers without appearance of ionic channels; its destabilizing activity is comparable with that of Bax and at least 30-fold higher than that of full-length Bid. Consistently, t(c)Bid, but not full-length Bid, permeabilizes liposomes at physiological pH. The destabilizing effect of t(c)Bid on liposomes and planar bilayers is independent of the BH3 domain. In contrast, mutations in the BH3 domain impair t(c)Bid ability to induce cytochrome c release from mitochondria. The permeabilizing effect of t(c)Bid on planar bilayers, liposomes, and mitochondria can be inhibited by t(c)Bid. In conclusion, our results suggest a dual role for Bid: BH3-independent membrane destabilization and BH3-dependent interaction with other proteins. Moreover, the dissociation of Bid after cleavage by caspase 8 represents an additional step at which apoptosis may be regulated.	Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ Paris Sud, CNRS, UMR 8619, Lab Biomembranes, F-91405 Orsay, France	Merck & Company; Serono International S.A.; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Antonsson, B (corresponding author), Serono Int SA, Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.			Kudla, Grzegorz/0000-0002-7924-2744; martinou, Jean-claude/0000-0002-9847-2051				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Lewis S, 1998, PROTEIN EXPRES PURIF, V13, P120, DOI 10.1006/prep.1997.0871; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	24	107	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22713	22718		10.1074/jbc.M003807200	http://dx.doi.org/10.1074/jbc.M003807200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801880	hybrid			2022-12-25	WOS:000088419400018
J	Brooks, PJ; Wise, DS; Berry, DA; Kosmoski, JV; Smerdon, MJ; Somers, RL; Mackie, H; Spoonde, AY; Ackerman, EJ; Coleman, K; Tarone, RE; Robbins, JH				Brooks, PJ; Wise, DS; Berry, DA; Kosmoski, JV; Smerdon, MJ; Somers, RL; Mackie, H; Spoonde, AY; Ackerman, EJ; Coleman, K; Tarone, RE; Robbins, JH			The oxidative DNA lesion 8,5 '-(S)-cyclo-2 '-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM COMPLEMENTATION GROUP; RADICAL-INDUCED FORMATION; XERODERMA-PIGMENTOSUM; 6-4 PHOTOPRODUCTS; PYRIMIDINE DIMER; RNA-POLYMERASE; FREE-EXTRACTS; PLASMID DNA; BASE DAMAGE; GROUP-F	Xeroderma pigmentosum (XP) patients with inherited defects in nucleotide excision repair (NER) are unable to excise from their DNA bulky photoproducts induced by UV radiation and therefore develop accelerated actinic damage, including cancer, on sun-exposed tissue. Some XP patients also develop a characteristic neurodegeneration believed to result from their inability to repair neuronal DNA damaged by endogenous metabolites since the harmful UV radiation in sunlight does not reach neurons. Free radicals, which are abundant in neurons, induce DNA lesions that, if unrepaired, might cause the XP neurodegeneration. Searching for such a lesion, we developed a synthesis for 8,5'-(S)-cyclo-2'-deoxyadenosine (cyclo-dA), a free radical-induced bulky lesion, and incorporated it into DNA to test its repair in mammalian cell extracts and living cells. Using extracts of normal and mutant Chinese hamster ovary (CHO) cells to test for NER and adult rat brain extracts to test for base excision repair, we found that cyclo-dA is re paired by NER and not by base excision repair. We measured host cell reactivation, which reflects a cell's capacity for NER, by transfecting CHO and XP cells with DNA constructs containing a single cyclo-dA or a cyclobutane thymine dimer at a specific site on the transcribed strand of a luciferase reporter gene. We found that, like the cyclobutane thymine dimer, cyclo-dA is a strong block to gene expression in CHO and human cells. Cyclo-dA was repaired extremely poorly in NER-deficient CHO cells and in cells from patients in XP complementation group A with neurodegeneration. Based on these findings, we propose that cyclo-dA is a candidate for an endogenous DNA lesion that might contribute to neurodegeneration in XP.	NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; Berry Associates Inc, Dexter, MI 48130 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Glen Res Corp, Sterling, VA 20164 USA; Pacific NW Natl Lab, Dept Energy, Richland, WA 99352 USA; NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA; NCI, Biostat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brooks, PJ (corresponding author), NIAAA, Neurogenet Lab, NIH, 12420 Parklawn Dr, Bethesda, MD 20892 USA.			Spunde, Alexander/0000-0001-8805-9100	NIEHS NIH HHS [ES02614, ESO4106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002614, R01ES002614, R01ES004106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000083, Z01AA000083] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Armitage P., 1971, STAT METHODS MED RES, V1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Brooks PJ, 1996, J NEUROSCI, V16, P939; Brooks PJ, 1998, MUTAT RES-DNA REPAIR, V408, P37, DOI 10.1016/S0921-8777(98)00018-4; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; DIZDAROGLU M, 1987, BIOCHEM J, V241, P929, DOI 10.1042/bj2410929; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; GANESAN AK, 1994, SOMAT CELL MOLEC GEN, V20, P233, DOI 10.1007/BF02254762; Guzaev A, 1997, TETRAHEDRON LETT, V38, P3989, DOI 10.1016/S0040-4039(97)00739-9; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; KODADEK T, 1988, BIOCHEMISTRY-US, V27, P3210, DOI 10.1021/bi00409a013; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; KUNKEL T, 1987, OLOGONUCLEOTIDE DIRE, V1; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ljungman M, 1996, ONCOGENE, V13, P823; MATSUDA A, 1976, NUCLEIC ACIDS RES, V3, P3349, DOI 10.1093/nar/3.12.3349; MATSUDA A, 1978, TETRAHEDRON, V34, P2449, DOI 10.1016/0040-4020(78)88371-9; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MITCHELL DL, 1989, PLASMID, V21, P21, DOI 10.1016/0147-619X(89)90083-8; NAKAGAWA I, 1975, TETRAHEDRON LETT, V1, P1409; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; PETINGA RA, 1977, BIOCHIM BIOPHYS ACTA, V479, P400, DOI 10.1016/0005-2787(77)90033-8; PetitFrere C, 1996, MUTAT RES-FUND MOL M, V354, P87, DOI 10.1016/0027-5107(96)00042-5; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; ROBBINS JH, 1991, BRAIN, V114, P1335, DOI 10.1093/brain/114.3.1335; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; Romieu A, 1999, CHEM RES TOXICOL, V12, P412, DOI 10.1021/tx9802668; Romieu A, 1998, J ORG CHEM, V63, P5245, DOI 10.1021/jo980083q; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAKEBE H, 1977, CANCER RES, V37, P490; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; WESTMAN E, 1994, NUCLEIC ACIDS RES, V22, P2430, DOI 10.1093/nar/22.12.2430; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	49	237	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22355	22362		10.1074/jbc.M002259200	http://dx.doi.org/10.1074/jbc.M002259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801836	hybrid			2022-12-25	WOS:000088363800082
J	Toyoda, H; Kinoshita-Toyoda, A; Fox, B; Selleck, SB				Toyoda, H; Kinoshita-Toyoda, A; Fox, B; Selleck, SB			Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE HEPARAN-SULFATE; N-SULFOTRANSFERASE; DROSOPHILA; BIOSYNTHESIS; PROTEOGLYCAN; GENE; EXT1	Mutations that disrupt developmental patterning in Drosophila have provided considerable information about growth factor signaling mechanisms. Three genes recently demonstrated to affect signaling by members of the Wnt, transforming growth factor-beta, Hedgehog, and fibroblast growth factor families in Drosophila encode proteins with homology to vertebrate enzymes involved in glycosaminoglycan synthesis. We report here the biochemical characterization of glycosaminoglycans in Drosophila bearing mutations in sugarless, sulfateless, and tout-velu. We find that mutations in sugarless, which encodes a protein with homology to UDP-glucose dehydrogenase, compromise the synthesis of both chondroitin and heparan sulfate, as would be predicted from a defect in UDP-glucuronate production. Defects in sulfateless, a gene encoding a protein with similarity to vertebrate N-deacetylase/N-sulfotransferases, do not affect chondroitin sulfate levels or composition but dramatically alter the composition of heparin lyase-released disaccharides. N-, 6-O-, and a O-sulfated disaccharides are absent and replaced entirely with an unsulfated disaccharide, A mutation in tout-velu, a gene related to the vertebrate Exostoses 1 heparan sulfate co-polymerase, likewise does not affect chondroitin sulfate synthesis but reduces all forms of heparan sulfate to below the limit of detection. These findings show that sugarless, sulfateless, and tout-velu affect glycosaminoglycan biosynthesis and demonstrate the utility of Dro sophila as a model organism for studying the function and biosynthesis of glycosaminoglycans in vivo.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	University of Arizona; Chiba University	Selleck, SB (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054832, R01GM025243] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-25243, GM-54832] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAKATO H, 1995, DEVELOPMENT, V121, P3687; OCONNOR M, 1999, CELL SURFACE PROTEOG, V6, P169; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	22	129	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21856	21861		10.1074/jbc.M003540200	http://dx.doi.org/10.1074/jbc.M003540200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806213	hybrid			2022-12-25	WOS:000088363800016
J	Steffensky, M; Li, SM; Heide, L				Steffensky, M; Li, SM; Heide, L			Cloning, overexpression, and purification of novobiocic acid synthetase from Streptomyces spheroides NCIMB 11891	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ACYL-COA SYNTHETASE; GYRASE-B; DNA GYRASE; PEPTIDE SYNTHETASES; COUMARIN INHIBITORS; ESCHERICHIA-COLI; LIGASE GENES; BIOSYNTHESIS; EXPRESSION	Novobiocic acid synthetase, a key enzyme in the biosynthesis of the antibiotic novobiocin, was cloned from the novobiocin producer Streptomyces spheroides NCIMB 11891. The enzyme is encoded by the gene novL, which codes for a protein of 527 amino acids with a calculated mass of 56,885 Da. The protein was overexpressed as a His(6) fusion protein in Escherichia coli and purified to apparent homogeneity by affinity chromatography and gel chromatography. The purified enzyme catalyzed the formation of an amide bond between 3-dimethylallyl-4-hydroxybenzoic acid (ring A of novobiocin) and 3-amino-4,7-dihydroxy-8-methyl coumarin (ring B of novobiocin) in an ATP-dependent reaction. NovL shows homology to the superfamily of adenylate-forming enzymes, and indeed the formation of an acyl adenylate from ring A and ATP was demonstrated by an ATP-PPi exchange assay. The purified enzyme exhibited both activation and transferase activity, i.e. it catalyzed both the activation of ring A as acyl adenylate and the subsequent transfer of the acyl group to the amino group of ring B. It is active as a monomer as determined by gel filtration chromatography, The reaction was specific for ATP as nucleotide triphosphate and dependent on the presence of Mg2+ or Mn2+. Apparent K-m values for ring A and ring B were determined as 19 and 131 mu M, respectively. Of several analogues of ring A, only 3-geranyl-4-hydroxybenzoate and to a lesser extent 3-methyl-4-aminobenzoate were accepted as substrates.	Univ Tubingen, Inst Pharmazeut, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Heide, L (corresponding author), Univ Tubingen, Inst Pharmazeut, Morgenstelle 8, D-72076 Tubingen, Germany.			Heide, Lutz/0000-0001-7809-7453				ALTHAUS IW, 1988, J ANTIBIOT, V41, P373, DOI 10.7164/antibiotics.41.373; BATES RW, 1995, TETRAHEDRON, V51, P8199, DOI 10.1016/0040-4020(95)00441-A; BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELIA H, 1994, J MOL BIOL, V236, P618, DOI 10.1006/jmbi.1994.1171; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Ehlting J, 1999, PLANT J, V19, P9, DOI 10.1046/j.1365-313X.1999.00491.x; Ferroud D, 1999, BIOORG MED CHEM LETT, V9, P2881, DOI 10.1016/S0960-894X(99)00493-X; Fulda M, 1997, PLANT MOL BIOL, V33, P911, DOI 10.1023/A:1005780529307; Hopwood D. A., 1985, GENETIC MANIPULATION; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; Khosla C, 1998, COMBINATORIAL CHEMISTRY AND MOLECULAR DIVERSITY IN DRUG DISCOVERY, P401; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; Kominek L A, 1975, Methods Enzymol, V43, P502; KOMINEK LA, 1974, DEV IND MICROBIOL, V15, P60; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2875, DOI 10.1016/S0960-894X(99)00492-8; Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2079, DOI 10.1016/S0960-894X(99)00329-7; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; Li SM, 1998, TETRAHEDRON LETT, V39, P2717, DOI 10.1016/S0040-4039(98)00386-4; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MELZER M, 1994, BBA-LIPID LIPID MET, V1212, P93, DOI 10.1016/0005-2760(94)90193-7; MONTECALVO MA, 1995, ANTIMICROB AGENTS CH, V39, P794, DOI 10.1128/AAC.39.3.794; Mootz HD, 1999, CURR OPIN BIOTECH, V10, P341, DOI 10.1016/S0958-1669(99)80062-7; Raad II, 1998, CANCER, V82, P403, DOI 10.1002/(SICI)1097-0142(19980115)82:2<412::AID-CNCR22>3.0.CO;2-0; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; REUSSER F, 1986, J ANTIBIOT, V39, P272; Sambrook J., 2002, MOL CLONING LAB MANU; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Steffensky M, 1998, FEMS MICROBIOL LETT, V161, P69, DOI 10.1111/j.1574-6968.1998.tb12930.x; Steffensky M, 2000, ANTIMICROB AGENTS CH, V44, P1214, DOI 10.1128/AAC.44.5.1214-1222.2000; Stuible HP, 2000, FEBS LETT, V467, P117, DOI 10.1016/S0014-5793(00)01133-9; Symmank H, 1999, J BIOL CHEM, V274, P21581, DOI 10.1074/jbc.274.31.21581; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WALSH TJ, 1993, ANTIMICROB AGENTS CH, V37, P1334, DOI 10.1128/AAC.37.6.1334; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; ZHAO Y, 1990, NUCLEIC ACIDS RES, V18, P6411	43	61	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21754	21760		10.1074/jbc.M003066200	http://dx.doi.org/10.1074/jbc.M003066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801869	hybrid			2022-12-25	WOS:000088230600104
J	Waite, KA; Vance, DE				Waite, KA; Vance, DE			Why expression of phosphatidylethanolamine N-methyltransferase does not rescue Chinese hamster ovary cells that have an impaired CDP-choline pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; INDEPENDENT PHOSPHOLIPASE A(2); PHOSPHATIDYLCHOLINE SYNTHESIS; P388D(1) MACROPHAGES; RAT HEPATOCYTES; METHYLATION; INHIBITION; MANOALIDE	The mutant Chinese hamster ovary cell line (CHO), MT58, has a temperature-sensitive mutation in CTP: phosphocholine cytidylyltransferase (CT), preventing phosphatidylcholine (PC) synthesis at 40 degrees C which results in apoptosis. Previous studies (Houweling, M., Cui, Z. and Vance, D. E. (1995) J. Biol. Chem. 270, 16277-16282) showed that expression of wild-type CT-alpha rescued the cells at 40 degrees C, whereas expression of phosphatidylethanolamine N-methyltransferase-2 (PEMT2) did not, even though PC levels appeared to be maintained at wild-type levels after 24 h at the restrictive temperature. We report that the failure of PEMT2 to rescue the MT58 cell line is due to inadequate long term PC synthesis. We found that changing the medium every 24 h rescued the PEMT2-expressing MT58 cells grown at 40 degrees C, This was due to the uptake and utilization of lipids in the serum. At 40 degrees C, PC levels in the wild-type CHO cells and CT-expressing MT58 cells increased over time whereas PC levels did not change in both the MT58 and PEMT2-expressing MT58 cell lines. Further investigation found that both the PEMT2-expressing MT58 and MT58 cell lines accumulated triacylglycerol at 40 degrees C. Pulse-chase experiments indicated that lyse-PC accumulated to a higher degree at 40 degrees C in the PEMT2-expressing MT58 cells compared with CT-expressing MT58 cells. Transfection of the PEMT-expressing MT58 cells with additional PEMT2 cDNA partially rescued the growth of these cells at 40 degrees C, Inhibition of PC degradation, by inhibitors of phospholipases, also stimulated PEMT-expressing MT58 cell growth at 40 degrees C, Best results were observed using a calcium-independent phospholipase A, inhibitor, methyl arachidonyl fluorophosphonate. This inhibitor also increased PC mass in the PEMT2-expressing MT58 cells. When the cells are shifted to 40 degrees C, PC degradation by enzymes such as phospholipases is greater than PC synthesis in the mutant PEMT2-expressing MT58 cells. Taken together, these results indicate that PEMT2 expression fails to rescue the mutant cell line at 40 degrees C because it does not maintain PC levels required for cellular replication.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cobb RR, 1996, MOL PHARMACOL, V49, P998; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; ESKO JD, 1981, J BIOL CHEM, V256, P7388; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gomez-Munoz A, 1999, BBA-MOL CELL BIOL L, V1438, P247, DOI 10.1016/S1388-1981(99)00056-6; Grange E, 1998, NEUROCHEM RES, V23, P1251, DOI 10.1023/A:1020788031720; GRATAS C, 1993, ANTICANCER RES, V13, P1239; HOLMEN SL, 1995, IN VITRO CELL DEV-AN, V31, P347; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; JACKOWSKI S, 2000, BIOCHIM BIOPHYS ACTA, V1483, P310; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Soriente A, 1999, CURR MED CHEM, V6, P415; SUNDLER R, 1974, J BIOL CHEM, V249, P5102; SYNDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE JE, 1986, J BIOL CHEM, V261, P4486; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	31	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21197	21202		10.1074/jbc.M003539200	http://dx.doi.org/10.1074/jbc.M003539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801878	hybrid			2022-12-25	WOS:000088230600033
J	Yang, BL; Cao, L; Kiani, C; Lee, V; Zhang, Y; Adams, ME; Yang, BB				Yang, BL; Cao, L; Kiani, C; Lee, V; Zhang, Y; Adams, ME; Yang, BB			Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PG-M; CELL-ADHESION; LINK PROTEIN; CDNA CLONING; AGGRECAN; CHONDROGENESIS; PROLIFERATION; CARTILAGE; BRAIN	The large aggregating chondroitin sulfate proteoglycans, including aggrecan, versican (PG-M), neurocan, and brevican, are characterized by N-terminal and C-terminal globular (or selectin-like) domains known as the G1 and G3 domains, respectively, For this study, we generated a series of expression constructs containing various combinations of chicken versican/PG-M domains and a leading peptide of link protein in order to examine the roles of the G1 and G3 domains in versican function, In transfection studies, we observed that the presence of the G1 domain was sufficient to inhibit product secretion, while the G3 domain enhanced this process, We also demonstrated that the G1 domain inhibited the attachment of glycosaminoglycan chains to the core proteins, while the G3 domain enhanced this process. Further studies revealed that inhibition of secretion by G1 was mediated by its two tandem repeats, while G3's promotion of glycosaminoglycan chain attachment was apparently dependent on G3's complement-binding protein (CBP)-like motif, The modulatory effects of these two molecular domains may contribute to versican's biological activities.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BLOCK JA, 1991, J BONE JOINT SURG AM, V73A, P647, DOI 10.2106/00004623-199173050-00002; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Cao L, 1999, EXP CELL RES, V246, P527, DOI 10.1006/excr.1998.4335; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LI H, 1993, J BIOL CHEM, V268, P23504; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; VERTEL BM, 1993, J CELL SCI, V104, P939; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANG B, 1994, ANAL BIOCHEM, V228, P299; YANG BB, 1997, MATRIX BIOL, V16, P537; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	35	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21255	21261		10.1074/jbc.M001443200	http://dx.doi.org/10.1074/jbc.M001443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801813	hybrid			2022-12-25	WOS:000088230600041
J	Xu, Y; Grindley, NDF; Joyce, CM				Xu, Y; Grindley, NDF; Joyce, CM			Coordination between the polymerase and 5 '-nuclease components of DNA polymerase I of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 RNASE-H; SINGLE-STRANDED-DNA; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; REVERSE-TRANSCRIPTASE; FLAP ENDONUCLEASE; REPLICATION; EXONUCLEASE; COMPLEX; BINDING	The polymerase and 5'-nuclease components of DNA polymerase I must collaborate in vivo so as to generate ligatable structures. Footprinting shows that the polymerase and 5'-nuclease cannot bind simultaneously to a DNA substrate and appear to compete with one another, suggesting that the two active sites are physically separate and operate independently, The desired biological end point, a ligatable nick, results from the substrate specificities of the polymerase and 5'-nuclease. The preferred substrate of the 5'-nuclease is a "double-flap" structure having a frayed base at the primer terminus overlapping the displaced strand that is to be cleaved by the 5'-nuclease. Cleavage of this structure occurs almost exclusively between the first two paired bases of the downstream strand, yielding a ligatable nick. In whole DNA polymerase I, the polymerase and 5'-nuclease activities are coupled such that the majority of molecules cleaved by the 5'-nuclease have also undergone polymerase-catalyzed addition to the primer terminus. This implies that the 5'-nuclease can capture a DNA molecule from the polymerase site more efficiently than from the bulk solution.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.				NIGMS NIH HHS [GM-28550, GM-19025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; KELLY RB, 1969, NATURE, V224, P495, DOI 10.1038/224495a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KLENOW H, 1970, FEBS LETT, V6, P25, DOI 10.1016/0014-5793(70)80032-1; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murali R, 1998, P NATL ACAD SCI USA, V95, P12562, DOI 10.1073/pnas.95.21.12562; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Sambrook J., 2002, MOL CLONING LAB MANU; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SETLOW P, 1972, J BIOL CHEM, V247, P232; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967	38	37	44	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20949	20955		10.1074/jbc.M909135199	http://dx.doi.org/10.1074/jbc.M909135199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10806216	hybrid			2022-12-25	WOS:000088084500102
J	Hotti, A; Jarvinen, K; Siivola, P; Holtta, E				Hotti, A; Jarvinen, K; Siivola, P; Holtta, E			Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases	ONCOGENE			English	Article						apoptosis; ATM (ataxia telangiectasia mutated); caspases; c-Myc; mitochondria; p53	CYCLE CHECKPOINT PATHWAY; ATAXIA-TELANGIECTASIA; CELL-CYCLE; DNA-DAMAGE; IONIZING-RADIATION; CYTOCHROME-C; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS; PROTEIN-KINASE; WILD-TYPE	The mechanism(s) of c-Myc transcription factor-induced apoptosis is still obscure. The activation of c-Myc has been found to lead into the processing/activation of caspases (caspase-3), but the significance of this for the cell demise is debatable, Here we report that several targets of caspases (PKC delta, MDM2, PARP, replication factor C, 70 kDa UlsnRNP, fodrin and lamins) are cleaved during c-Myc-induced apoptosis in Rat-1 MycER(TM) cells, indicating an important role for caspases in the apoptotic process. We further found that the ATM (ataxia telangiectasia mutated) - protein is a novel key substrate of caspases, In in vitro assays, purified recombinant ATM protein was found to be cleaved by the effector caspases 3 and 7, The functional significance of the ATM cleavage is supported by the finding that ectopic expression of ATM protected in part against apoptosis, We also show that c-Myc-induced apoptosis involves loss of mitochondrial transmembrane potential, release of cytochrome c from mitochondria into the cytosol and subsequent processing of caspase-9, The cleavage of caspase-9 is, hone, er, minimal and a much later event than the processing/activation of caspase-3, suggesting that it is not the apical caspase, Evidence is provided that there is, nevertheless, an upstream caspase(s) regulating the functions of caspase-3 and mitochondria, Additionally, it mas found that p53 becomes upregulated, together,vith its transcriptional targets MDM2 and p21, upon c-Myc induction, but this occurs also at a later time than the activation of caspase-3.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki	Holtta, E (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NARVANEN O, 1987, FEBS LETT, V224, P156, DOI 10.1016/0014-5793(87)80440-4; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2354	2362		10.1038/sj.onc.1203567	http://dx.doi.org/10.1038/sj.onc.1203567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822387				2022-12-25	WOS:000086974300011
J	Huynh, QK; Boddupalli, H; Rouw, SA; Koboldt, CM; Hall, T; Sommers, C; Hauser, SD; Pierce, JL; Combs, RG; Reitz, BA; Diaz-Collier, JA; Weinberg, RA; Hood, BL; Kilpatrick, BF; Tripp, CS				Huynh, QK; Boddupalli, H; Rouw, SA; Koboldt, CM; Hall, T; Sommers, C; Hauser, SD; Pierce, JL; Combs, RG; Reitz, BA; Diaz-Collier, JA; Weinberg, RA; Hood, BL; Kilpatrick, BF; Tripp, CS			Characterization of the recombinant IKK1/IKK2 heterodimer - Mechanisms regulating kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; IKK-BETA; KINETIC MECHANISM; ALPHA; COMPLEX; ACTIVATION; PHOSPHORYLATION; SUBUNIT; MICE; SUBSTRATE	Nuclear factor kappa B (NP-kappa B) is a ubiquitous, inducible transcription factor that regulates the initiation and progression of immune and inflammatory stress responses. NF-kappa B activation depends on phosphorylation and degradation of its inhibitor protein, I kappa B, initiated by an I kappa B kinase (IKK) complex. This IKK complex includes a catalytic heterodimer composed of I kappa B kinase 1 (IKK1) and I kappa B kinase 2 (IKK2) as well as a regulatory adaptor subunit, NF-kappa B essential modulator. To better understand the role of IKKs in NF-kappa B activation, we have cloned, expressed, purified, and characterized the physiological isoform, the rhIKK1/rhIKK2 heterodimer. We compared its kinetic properties with those of the homodimers rhIKK1 and rhIKK2 and a constitutively active rhIKK2 (S177E, S181E) mutant. We demonstrate activation of these recombinantly expressed IKKs by phosphorylation during expression in a baculoviral system. The K-m values for ATP and I kappa Ba peptide for the rhIKK1/rhIKK2 heterodimer are 0.63 and 0.60 mu M, respectively, which are comparable to those of the IKK2 homodimer. However, the purified rhIKK1/rhIKK2 heterodimer exhibits the highest catalytic efficiency (k(cat)/K-m) of 47.50 h(-1) mu M-1 using an I kappa B alpha peptide substrate compared with any of the other IKK isoforms, including rhIKK2 (17.44 h(-1) mu M-1), its mutant rhIKK2 (S177E, S181E, 1.18 h(-1) mu M-1), or rhIKK1 (0.02 h(-1) mu M-1). Kinetic analysis also indicates that, although both products of the kinase reaction, ADP and a phosphorylated I kappa B alpha peptide, exhibited competitive inhibitory kinetics, only ADP with the low K-i of 0.77 mu M may play a physiological role in regulation of the enzyme activity.	Monsanto Life Sci Co, Dept Discovery Pharmacol, Searle Discovery Res, GD Searle & Co, St Louis, MO 63167 USA	Monsanto	Huynh, QK (corresponding author), Monsanto Life Sci Co, Dept Discovery Pharmacol, Searle Discovery Res, GD Searle & Co, Mailzone T3M,800 N Lindbergh Blvd, St Louis, MO 63167 USA.	quang.k.huynh@monsanto.com						BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Escoubas JM, 1999, FEBS LETT, V453, P293, DOI 10.1016/S0014-5793(99)00737-1; GHOSH S, 1998, ANNU REV IMMUNOL, V16, P115; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1992, GRAFIT VERSION 4 0; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Traincard F, 1999, J CELL SCI, V112, P3529; Wisniewski D, 1999, ANAL BIOCHEM, V274, P220, DOI 10.1006/abio.1999.4287; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	35	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25883	25891		10.1074/jbc.M000296200	http://dx.doi.org/10.1074/jbc.M000296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10823818	hybrid			2022-12-25	WOS:000088999700002
J	Khoo, KM; Han, MK; Park, JB; Chae, SW; Kim, UH; Lee, HC; Bay, BH; Chang, CF				Khoo, KM; Han, MK; Park, JB; Chae, SW; Kim, UH; Lee, HC; Bay, BH; Chang, CF			Localization of the cyclic ADP-ribose-dependent calcium signaling pathway in hepatocyte nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; TRANSMEMBRANE GLYCOPROTEIN CD38; PANCREATIC ACINAR-CELLS; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; IMMUNOELECTRON MICROSCOPY; CD38/ADP-RIBOSYL CYCLASE; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTORS; INSULIN-SECRETION	CD38 is a type II transmembrane glycoprotein found on both hematopoietic and non-hematopoietic cells. It is known for its involvement in the metabolism of cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate, two nucleotides with calcium mobilizing activity independent of inositol trisphosphate. It is generally believed that CD38 is an integral protein with ectoenzymatic activities found mainly on the plasma membrane. Here we show that enzymatically active CD38 is present intracellularly on the nuclear envelope of rat hepatocytes. CD38 isolated from rat liver nuclei possessed both ADP-ribosyl cyclase and NADase activity. Immunofluorescence studies on rat liver cryosections and isolated nuclei localized CD38 to the nuclear envelope of hepatocytes. Subcellular localization via immunoelectron microscopy showed that CD38 is located on the inner nuclear envelope. The isolated nuclei sequestered calcium in an ATP-dependent manner. cADPR elicited a rapid calcium release from the loaded nuclei, which was independent of inositol trisphosphate and was inhibited by 8-amino-cADPR, a specific antagonist of cADPR, and ryanodine. However, nicotinic acid adenine dinucleotide phosphate failed to elicit any calcium release from the nuclear calcium stores. The nuclear localization of CD38 shown in this study suggests a novel role of CD38 in intracellular calcium signaling for non-hematopoietic cells.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore; Tan Tock Seng Hosp, Clin Res Unit, Singapore 308433, Singapore; Chonbuk Natl Univ, Sch Med, Inst Med Sci, Dept Biochem, Chonju 561182, South Korea; Chonbuk Natl Univ, Sch Med, Cardiovasc Res Inst, Dept Pharmacol, Chonju 561182, South Korea; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 119260, Singapore; Univ Minnesota, Dept Physiol, Minneapolis, MN 55455 USA	National University of Singapore; Tan Tock Seng Hospital; Jeonbuk National University; Jeonbuk National University; National University of Singapore; University of Minnesota System; University of Minnesota Twin Cities	Chang, CF (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, 10 Kent Ridge Crescent, Singapore 119260, Singapore.		Lee, Hon Cheung/C-4329-2009	Han, Myung-Kwan/0000-0003-1931-8898; Kim, Uh-Hyun/0000-0003-3304-7190	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; BAY BH, 1997, J ELECT MICROSC, V47, P359; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chidambaram N, 1999, ARCH BIOCHEM BIOPHYS, V363, P267, DOI 10.1006/abbi.1999.1103; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Cristovao AJ, 1997, CELL SIGNAL, V9, P97, DOI 10.1016/S0898-6568(96)00116-7; da Silva CP, 1998, FEBS LETT, V439, P291, DOI 10.1016/S0014-5793(98)01396-9; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Deaglio S, 1996, J IMMUNOL, V156, P727; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; Dussossoy D, 1999, EUR J BIOCHEM, V263, P377, DOI 10.1046/j.1432-1327.1999.00500.x; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151; Franco L, 1998, FASEB J, V12, P1507; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FUKUSHIMA M, 1976, J BIOCHEM-TOKYO, V80, P167, DOI 10.1093/oxfordjournals.jbchem.a131248; FUNARO A, 1990, J IMMUNOL, V145, P2390; Funaro A, 1998, J IMMUNOL, V160, P2238; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GILLOT I, 1994, CELL CALCIUM, V16, P269, DOI 10.1016/0143-4160(94)90090-6; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GREEN DE, 1955, J BIOL CHEM, V217, P551; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Guihard G, 1997, FEBS LETT, V414, P89, DOI 10.1016/S0014-5793(97)00949-6; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Ikehata F, 1998, J CLIN INVEST, V102, P395, DOI 10.1172/JCI1656; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Khoo KM, 1999, BRAIN RES, V821, P17, DOI 10.1016/S0006-8993(98)01347-X; Khoo KM, 1998, BIOCHEM MOL BIOL INT, V44, P841; Khoo KM, 2000, ARCH BIOCHEM BIOPHYS, V373, P35, DOI 10.1006/abbi.1999.1526; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIRKHAM PA, 1994, IMMUNOLOGY, V83, P513; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; Komazaki S, 1998, CELL TISSUE RES, V294, P467, DOI 10.1007/s004410051198; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANINI L, 1992, J BIOL CHEM, V267, P11548; Lee CH, 1999, ATOMIZATION SPRAY, V9, P193, DOI 10.1615/AtomizSpr.v9.i2.50; LEE CY, 1973, ARCH BIOCHEM BIOPHYS, V157, P83, DOI 10.1016/0003-9861(73)90392-5; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LILLY LB, 1995, AM J PHYSIOL-GASTR L, V268, pG1017, DOI 10.1152/ajpgi.1995.268.6.G1017; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MartinezMerlos T, 1997, INT J BIOCHEM CELL B, V29, P529, DOI 10.1016/S1357-2725(96)00140-9; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MOREAU A, 1988, J HISTOCHEM CYTOCHEM, V36, P87, DOI 10.1177/36.1.3275714; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; OISHI K, 1993, MOL CELL BIOCHEM, V121, P127, DOI 10.1007/BF00925971; OSADA S, 1994, HEPATOLOGY, V19, P514; PAUL E, 1992, J MEMBRANE BIOL, V127, P129; PEKALA PH, 1978, J BIOL CHEM, V253, P7453; Quinton TM, 1996, BIOCHEM BIOPH RES CO, V224, P740, DOI 10.1006/bbrc.1996.1093; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; Santella L, 1997, EUR J BIOCHEM, V246, P602, DOI 10.1111/j.1432-1033.1997.t01-1-00602.x; Sato A, 1999, BIOCHEM J, V337, P491, DOI 10.1042/0264-6021:3370491; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STIRLING JW, 1995, J HISTOCHEM CYTOCHEM, V43, P115, DOI 10.1177/43.2.7529784; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAMULEVICIUS P, 1979, BIOCHEM J, V178, P467, DOI 10.1042/bj1780467; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGER E, 1975, HISTOCHEMISTRY, V43, P73, DOI 10.1007/BF00490156; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLEMER S, 1990, HISTOCHEMISTRY, V93, P319; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	79	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24807	24817		10.1074/jbc.M908231199	http://dx.doi.org/10.1074/jbc.M908231199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818108	hybrid			2022-12-25	WOS:000088683300078
J	Polunovsky, VA; Gingras, AC; Sonenberg, N; Peterson, M; Tan, A; Rubins, JB; Manivel, JC; Bitterman, PB				Polunovsky, VA; Gingras, AC; Sonenberg, N; Peterson, M; Tan, A; Rubins, JB; Manivel, JC; Bitterman, PB			Translational control of the antiapoptotic function of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4G; PROTEIN-SYNTHESIS; INDUCED APOPTOSIS; GROWTH-FACTOR; CELL-GROWTH; PHAS-I; PHOSPHORYLATION; RAPAMYCIN; SURVIVAL; KINASE	Activated Ras has been shown to provide powerful antiapoptotic signals to cells through well defined transcriptional and post- translational pathways, whereas translational control as a mechanism of Ras survival signaling remains unexplored, Here we show a direct relationship between assembly of the cap-dependent translation initiation apparatus and suppression of apoptosis by oncogenic Ras in vitro and in vice. Decreasing protein synthesis with rapamycin, which is known to inhibit cap-dependent translation, increases the susceptibility of Ras-transformed fibroblasts to cytostatic drug-induced apoptosis, In contrast, suppressing global protein synthesis with equipotent concentrations of cycloheximide actually prevents apoptosis. Enforced expression of the cap-dependent translational repressor, the eukaryotic translation initiation factor (eIF) 4E-binding protein (4E-BPI), sensitizes fibroblasts to apoptosis in a manner strictly dependent on its ability to sequester eIF4E from a translationally active complex with eIF4GI and the co-expression of oncogenic Ras, Ectopic expression of 4E-BP1 also promotes apoptosis of Ras-transformed cells injected into immunodeficient mice and markedly diminishes their tumorigenicity, These results establish that eIF4E-dependent protein synthesis is essential for survival of fibroblasts bearing oncogenic Ras and support the concept that activation of cap-dependent translation by extracellular ligands or intrinsic survival signaling molecules suppresses apoptosis, whereas synthesis of proteins mediating apoptosis can occur independently of the cap.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; McGill University	Bitterman, PB (corresponding author), Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.		Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; BITTERMAN, PETER/0000-0002-7995-7117	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50-HL50152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; HULTIN T, 1961, EXP CELL RES, V25, P405, DOI 10.1016/0014-4827(61)90290-7; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Merrick WC., 1996, TRANSLATION CONTROL, P31; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rousseau D, 1996, ONCOGENE, V13, P2415; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	38	91	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24776	24780		10.1074/jbc.M001938200	http://dx.doi.org/10.1074/jbc.M001938200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10811643	hybrid			2022-12-25	WOS:000088683300074
J	Aviel, S; Winberg, G; Massucci, M; Ciechanover, A				Aviel, S; Winberg, G; Massucci, M; Ciechanover, A			Degradation of the Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway - Targeting via ubiquitination of the N-terminal residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE GROWTH TRANSFORMATION; LIGAND-INDUCED INTERNALIZATION; KAPPA-B ACTIVATION; HORMONE RECEPTOR; GENETIC-ANALYSIS; PLASMA-MEMBRANE; CELL-SURFACE; CONJUGATION; SYSTEM; SITE	The latent membrane protein 1 (LMP1) of the Epstein-Barr virus is a constitutively active receptor essential for B lymphocyte transformation by the Epstein-Barr virus. It is a short-lived protein, but the proteolytic pathway involved in its degradation is not known. The ubiquitin pathway is a major system for specific protein degradation in eukaryotes. Most plasma membrane substrates of the pathway are internalized upon ubiquitination and delivered for degradation in the lysosome/vacuole. Here we show that LMP1 is a substrate of the ubiquitin pathway and is ubiquitinated both in vitro and in vivo. However, in contrast to other plasma membrane substrates of the ubiquitin system, it is degraded mostly by the proteasome and not by lysosomes. Degradation is independent of the single Lys residue of the protein; a lysine-less mutant LMP1 is degraded in a ubiquitin- and proteasome-dependent manner similar to the wild type protein, Degradation of both wild type and lysine-less protein is sensitive to fusion of a Myc tag to the N terminus of LMP1, In addition, deletion of as few as 12 N-terminal amino acid residues stabilizes the protein, These findings suggest that the first event in LMP1 degradation is attachment of ubiquitin to the N-terminal residue of the protein. We present evidence suggesting that phosphorylation is also required for degradation of LMP1.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Karolinska Institutet	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	mdaaron@tx.technion.ac.il	Winberg, Gosta/I-5686-2013; Ciechanover, Aaron J/C-9166-2017	Winberg, Gosta/0000-0002-3371-4056				BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Busch LK, 1999, J IMMUNOL, V162, P2555; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOU D, 1994, J BIOL CHEM, V269, P14244; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Korn GA, 1999, NEURAL PROCESS LETT, V9, P107, DOI 10.1023/A:1018665006640; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MELLER G, 1990, VIROLOGY, P563; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	44	134	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23491	23499		10.1074/jbc.M002052200	http://dx.doi.org/10.1074/jbc.M002052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807912	hybrid			2022-12-25	WOS:000088564200014
J	Cheng, Y; Zhizhin, I; Perlman, RL; Mangoura, D				Cheng, Y; Zhizhin, I; Perlman, RL; Mangoura, D			Prolactin-induced cell proliferation in PC12 cells depends on JNK but not ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAMMARY-GLAND DEVELOPMENT; TYROSINE KINASE JAK2; N-TERMINAL KINASE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PRL RECEPTOR; PHOSPHORYLATION; PATHWAYS; RAS	The effects of pituitary and extrapituitary prolactin include cellular proliferation and differentiation. PC12 cells was used as a model to delineate respective signaling of prolactin. Prolactin acted as a mitogen for undifferentiated PC12 cells, as measured by significant increases in bromodeoxyuridine incorporation and in cell numbers, with an efficacy equal to epidermal growth factor. Both the long and short form of the prolactin receptor was expressed, yet only the long isoform was tyrosine-phosphorylated upon agonist binding. Functional prolactin receptor signaling was further demonstrated in the activation of JAK2 and phosphorylation activation of the transcription factors Stat1, -3, and -5a. Surprisingly, prolactin stimulated a sustained activation of Raf-B, without activation of the MAP kinases ERK1 or -2. Instead, in solid phase kinase assays using a glutathione S-transferase-c-Jun fusion protein (amino acids 1-79) as the substrate, a significant activation of the mitogen-activated protein Janus kinase (c-Jun N-terminal kinase; JNK) was observed. The prolactin-induced activation of JNK was prolonged and accompanied by a significant increase in c-Jun mRNA abundance and c-Jun protein synthesis. Moreover, analysis of bromodeoxyuridine incorporation at the single cell level revealed that epidermal growth factor-dependent incorporation was inhibited by PD98059 and independent of SB203580, whereas prolactin-induced incorporation was ERR and mitogen-activated protein kinase p38 independent but was abolished with JNK inhibition by 30 mu M SB203580. Our studies suggest that prolactin may have a role in the growth of PC12 cells, where it stimulates concurrent mitogenic and differentiation-promoting signaling pathways.	Univ Chicago, Comm Neurobiol, Kennedy Ctr, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Comm Cell Physiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Mangoura, D (corresponding author), Univ Chicago, Comm Neurobiol, Kennedy Ctr, Dept Pediat, MC 5058,WCH C-576, Chicago, IL 60637 USA.		Perlman, Robert/GZH-2102-2022					Ali S, 1998, J BIOL CHEM, V273, P7709, DOI 10.1074/jbc.273.13.7709; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHENG Y, 1996, T SOC NEUROSCI, V22, P1212; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DeVito WJ, 1997, ENDOCRINOLOGY, V138, P922, DOI 10.1210/en.138.3.922; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hurel SJ, 1997, J CLIN ENDOCR METAB, V82, P2962, DOI 10.1210/jc.82.9.2962; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Mangoura D, 1998, J NEUROCHEM, V70, P130; Mangoura D, 1997, ADV EXP MED BIOL, V429, P39; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MANGOURA D, 2000, IN PRESS INT J DEV N; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PAVLOVICSURJANCEV B, 1992, J NEUROCHEM, V59, P2134; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHUERMANN M, 1989, CELL, V56, P1507; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SKAPER SD, 1983, J NEUROSCI RES, V10, P303, DOI 10.1002/jnr.490100309; WATERS MJ, 1995, J BIOL CHEM, V270, P5136, DOI 10.1074/jbc.270.10.5136; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamashita H, 1999, J BIOL CHEM, V274, P14699, DOI 10.1074/jbc.274.21.14699; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yu TX, 1998, BBA-MOL CELL RES, V1448, P126, DOI 10.1016/S0167-4889(98)00116-5	47	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23326	23332		10.1074/jbc.M001837200	http://dx.doi.org/10.1074/jbc.M001837200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807911	hybrid			2022-12-25	WOS:000088419400100
J	He, B; Kemppainen, JA; Wilson, EM				He, B; Kemppainen, JA; Wilson, EM			FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGIONS; NUCLEAR RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR TIF2; HISTONE ACETYLTRANSFERASE; PROGESTERONE-RECEPTOR; DEPENDENT INTERACTION; STRUCTURAL BASIS; DNA-BINDING	The nuclear receptor superfamily members of eukaryotic transcriptional regulators contain a highly conserved activation function 2 (AF2) in the hormone binding carboxyl-terminal domain and, for some, an additional activation function 1 in the NH2-terminal region which is not conserved. Recent biochemical and crystallographic studies revealed the molecular basis of AF2 is hormone-dependent recruitment of LXXLL motif-containing coactivators, including the p160 family, to a hydrophobic cleft in the ligand binding domain. Our previous studies demonstrated that AF2 in the androgen receptor (AR) binds only weakly to LXXLL motif-containing coactivators and instead mediates an androgen-dependent interaction with the AR NH2-terminal domain required for its physiological function, Here we demonstrate in a mammalian two-hybrid assay, glutathione S-transferase fusion protein binding studies, and functional assays that two predicted cu-helical regions that are similar, but functionally distinct from the p160 coactivator interaction sequence, mediate the androgen-dependent, NH2- and carboxyl-terminal interaction. FXXLF in the AR NH2-terminal domain with the sequence (23)FQNLF(27) mediates interaction with AF2 and is the predominant androgen-dependent interaction site. This FXXLF sequence and a second NH2-terminal WXYLF sequence (WHTLF437)-W-433 interact with different regions of the ligand binding domain to stabilize the hormone-receptor complex and may compete with AF2 recruitment of LXXLL motif-containing coactivators. The results suggest a unique mechanism for AR-mediated transcriptional activation.	Univ N Carolina, Lab Reprod Biol, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lab Reprod Biol, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Lab Reprod Biol, Dept Biochem & Biophys, CB 7500,Rm 374 Med Sci Res Bldg, Chapel Hill, NC 27599 USA.		Philibert, Pascal/C-6728-2008	Philibert, Pascal/0000-0001-6384-521X	NICHD NIH HHS [HD-16910, U54-HD-35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041, R01HD016910, R37HD016910] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choong CS, 1998, J MOL EVOL, V47, P334, DOI 10.1007/PL00006391; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Ghadessy FJ, 1999, J CLIN INVEST, V103, P1517, DOI 10.1172/JCI4289; Glass CK, 2000, GENE DEV, V14, P121; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeo J, 1999, J BIOL CHEM, V274, P5674, DOI 10.1074/jbc.274.9.5674; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	61	347	353	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22986	22994		10.1074/jbc.M002807200	http://dx.doi.org/10.1074/jbc.M002807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10816582	Green Published, hybrid			2022-12-25	WOS:000088419400053
J	Krause, CD; Lunn, CA; Izotova, LS; Mirochnitchenko, O; Kotenko, SV; Lundell, DJ; Narula, SK; Pestka, S				Krause, CD; Lunn, CA; Izotova, LS; Mirochnitchenko, O; Kotenko, SV; Lundell, DJ; Narula, SK; Pestka, S			Signaling by covalent heterodimers of interferon-gamma - Evidence for one-sided signaling in the active tetrameric receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; TARGETED DISRUPTION; IMMUNE INTERFERON; CELLS; GENE; TRANSCRIPTION; DIMERIZATION; EXPRESSION; SUFFICIENT; ACTIVATION	Interferon-gamma (IFN-gamma) and its receptor complex are dimeric and bilaterally symmetric. We created mutants of IFN-gamma that bind only one IFN-gamma R1 chain per dimer molecule (called a monovalent IFN-gamma) to see if the interaction of IFN-gamma with one-half of the receptor complex is sufficient for bioactivity. Mutating a receptor-binding sequence in either AB loop of a covalent dimer of IFN-gamma yielded two monovalent IFN-gamma s, gamma(m)-gamma and gamma-gamma(m), which cross-link to only a single soluble IFN-gamma R1 molecule in solution and on the cell surface. Monovalent IFN-gamma competes fully with wild type IFN-gamma for binding to U937 cells but only at a greater than 100-fold higher concentration than wild type IFN-gamma. Monovalent IFN-gamma had anti-vesicular stomatitis virus activity and antiproliferative activity, and it induced major histocompatibility complex class I and class II (HLA-DR) expression. In contrast, the maximal levels of activated Stat1 alpha produced by monovalent IFN-gamma s after 15 min were never more than half of those produced by either wild type or covalent IFN-gamma s in human cell lines. These data indicate that while monovalent IFN-gamma activates only one-half of a four-chain receptor complex, this is sufficient for Stat1 alpha activation, major histocompatibility complex class I surface antigen induction, and antiviral and antiproliferative activities. Thus, while interaction with both halves of the receptor complex is required for high affinity binding of IFN-gamma and efficient signal transduction, interaction with only one-half of the receptor complex is sufficient to initiate signal transduction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Sch Biomed Sci, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Schering Plough Corp, Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA; Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Schering Plough Corporation; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Pestka, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Sch Biomed Sci, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450, R01AI043369] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46465] Funding Source: Medline; NIAID NIH HHS [R01 AI43369, R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; COOK JR, 1994, J BIOL CHEM, V269, P7013; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Familletti P C, 1981, Methods Enzymol, V78, P387; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; Green MM, 1998, BIOCHEM BIOPH RES CO, V243, P170, DOI 10.1006/bbrc.1998.8077; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; Klug J, 1997, BIOTECHNIQUES, V22, P212, DOI 10.2144/97222bm02; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUNG HF, 1986, METHOD ENZYMOL, V119, P204; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LUNDELL D, 1994, J BIOL CHEM, V269, P16159; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NGUYEN HT, 1991, J CELL BIOCH S A, V15, P257; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; Randal M, 1998, PROTEIN SCI, V7, P1057; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SZENTE BE, 1994, BIOCHEM BIOPH RES CO, V203, P1645, DOI 10.1006/bbrc.1994.2375; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0	33	19	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22995	23004		10.1074/jbc.M909607199	http://dx.doi.org/10.1074/jbc.M909607199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811814	hybrid			2022-12-25	WOS:000088419400054
J	Morishige, T; Tsujita, T; Yamada, Y; Sato, F				Morishige, T; Tsujita, T; Yamada, Y; Sato, F			Molecular characterization of the S-adenosyl-L-methionine : 3 '-hydroxy-N-methylcoclaurine 4 '-O-methyltransferase involved in isoquinoline alkaloid biosynthesis in Coptis japonica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; BERBERINE BRIDGE ENZYME; CLONING; CELLS; METHYLTRANSFERASES; PURIFICATION; EXPRESSION; CULTURES; PATHWAY; POPPY	S-Adenosyl-L-methionine:3' -hydroxy-N-methylcoclaurine 4'-O-methyltransferase (4'-OMT) catalyzes the conversion of 3'-hydroxy-N-methylcoclaurine to reticuline, an important intermediate in synthesizing isoquinoline alkaloids. In an earlier step in the biosynthetic pathway to reticuline, another O-methyltransferase, S-adenosyl-L-methionine:norcoclaurine 6-O-methyltransferase (6-OMT), catalyzes methylation of the 6-hydroxyl group of norcoclaurine, We isolated two kinds of cDNA clones that correspond to the internal amino acid sequences of a 6-OMT/4'-OMT preparation from cultured Coptis japonica cells. Heterologously expressed proteins had 6-OMT or 4'-OMT activities, indicative that each cDNA encodes a different enzyme. 4'-OMT was purified using recombinant protein, and its enzymological properties were characterized. It had enzymological characteristics similar to those of 6-OMT; the active enzyme was the dimer of the subunit, no divalent cations were required for activity, and there was inhibition by Fe2+ Cu2+, Co2+, Zn2+, or Ni2+, but none by the SH reagent. 4'-OMT clearly had different substrate specificity. It methylated (R,S)-6-O-methylnorlaudanosoline, as well as (R,S)-laudanosoline and (R,S)-norlaudanosoline. Laudanosoline, an N-methylated substrate, was a much better substrate for 4'-OMT than norlaudanosoline. 6-OMT methylated norlaudanosoline and laudanosoline equally. Further characterization of the substrate saturation and product inhibition kinetics indicated that 4'-OMT follows an ordered Bi Bi mechanism, whereas 6-OMT follows a Ping-Pong Bi Bi mechanism. The molecular evolution of these two related O-methyltransferases is discussed.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Sato, F (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan.		Sato, Fumihiko/C-1078-2011	Sato, Fumihiko/0000-0001-9497-4452				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; Dixon M., 1979, ENZYMES, Vthird; Facchini PJ, 1996, PLANT PHYSIOL, V112, P1669, DOI 10.1104/pp.112.4.1669; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3505, DOI 10.1016/0031-9422(90)85265-H; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; Hauschild K, 1998, PLANT MOL BIOL, V36, P473, DOI 10.1023/A:1005917808232; He XZ, 1998, PLANT MOL BIOL, V36, P43, DOI 10.1023/A:1005938121453; Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889; Li LG, 1997, P NATL ACAD SCI USA, V94, P5461, DOI 10.1073/pnas.94.10.5461; MUEMMLER S, 1985, PLANT CELL REP, V4, P36, DOI 10.1007/BF00285501; MULLER MJ, 1992, PLANTA MED, V58, P524, DOI 10.1055/s-2006-961541; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; RUFFER M, 1983, PLANTA MED, V49, P131; SATO F, 1993, PHYTOCHEMISTRY, V32, P659, DOI 10.1016/S0031-9422(00)95151-3; SATO F, 1994, EUR J BIOCHEM, V225, P125, DOI 10.1111/j.1432-1033.1994.00125.x; SATO F, 1984, PHYTOCHEMISTRY, V23, P281, DOI 10.1016/S0031-9422(00)80318-0; STADLER R, 1990, LIEBIGS ANN CHEM, V6, P555; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; WAT CK, 1986, Z NATURFORSCH C, V41, P126; Wu QD, 1997, PLANT MOL BIOL, V35, P551, DOI 10.1023/A:1005836508844; [No title captured]	23	139	161	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23398	23405		10.1074/jbc.M002439200	http://dx.doi.org/10.1074/jbc.M002439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811648	hybrid			2022-12-25	WOS:000088419400109
J	Ortenberg, R; Mevarech, M				Ortenberg, R; Mevarech, M			Evidence for post-translational membrane insertion of the integral membrane protein bacterioopsin expressed in the heterologous halophilic archaeon Haloferax volcanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; SENSORY RHODOPSIN-I; ESCHERICHIA-COLI; POLYPEPTIDE FRAGMENTS; HALOBACTERIUM-VOLCANII; FUNCTIONAL EXPRESSION; BINDING PROTEIN; ANION TRANSPORT; FUSION PROTEIN	The gene coding for the integral membrane protein bacterioopsin (Bop), that is composed of seven transmembrane helices, was expressed in the halophilic archaeon Haloferax volcanii as a fusion protein with the halobacterial enzyme dihydrofolate reductase and with the cellulose binding domain of Clostridium thermocellum cellulosome. In each case, bacterioopsin was present both in the membrane and in the cytoplasmic fractions. Pulse-chase labeling experiments showed that the fusion protein in the cytoplasmic fraction is the precursor of the membrane-bound species. Bacterioopsin mutants that lack the seventh helix (Bop Delta 7) were found to accumulate only in the cytoplasmic fraction, whereas bacterioopsin mutants that lack either helices four and five (Bop Delta 4-5), or helices one and two (Bop Delta 1-2), were found in the cytoplasmic as well as in the membrane fractions. The seventh helix, when expressed alone, could target in trans the insertion of a separately expressed bacterioopsin mutant protein that has only the first six helices. These results support a model in which bacterioopsin is produced in LI, volcanii as a soluble protein and in which its insertion into the membrane occurs post-translationally. According to this model, membrane insertion is directed by the seventh helix.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Mevarech, M (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	mevarech@ccsg.tau.ac.il						BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Brodsky JL, 1998, INT REV CYTOL, V178, P277; Chen GQ, 1996, PROTEIN SCI, V5, P456; CLINE SW, 1989, CAN J MICROBIOL, V35, P148, DOI 10.1139/m89-022; Dale H, 1999, J BIOL CHEM, V274, P22693, DOI 10.1074/jbc.274.32.22693; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P5894, DOI 10.1073/pnas.77.10.5894; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; FERRANDO E, 1993, GENE, V125, P41, DOI 10.1016/0378-1119(93)90743-M; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; GROPP R, 1992, P NATL ACAD SCI USA, V89, P1204, DOI 10.1073/pnas.89.4.1204; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; HOLMES ML, 1991, J BACTERIOL, V173, P3807, DOI 10.1128/JB.173.12.3807-3813.1991; HUANG KS, 1981, J BIOL CHEM, V256, P3802; Koebnik R, 1996, EMBO J, V15, P3529, DOI 10.1002/j.1460-2075.1996.tb00722.x; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; LANYI JK, 1982, J BIOL CHEM, V257, P2674; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Maniatis T., 1982, MOL CLONING LAB MANU; Manoil C, 1995, ANNU REV GENET, V29, P131; Marti T, 1998, J BIOL CHEM, V273, P9312, DOI 10.1074/jbc.273.15.9312; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MEVARECH M, 1985, J BACTERIOL, V162, P461, DOI 10.1128/JB.162.1.461-462.1985; Mingarro I, 1997, J MOL BIOL, V272, P633, DOI 10.1006/jmbi.1997.1276; MORAG E, 1995, APPL ENVIRON MICROB, V61, P1980, DOI 10.1128/AEM.61.5.1980-1986.1995; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nomura S, 1998, FEMS MICROBIOL LETT, V167, P287, DOI 10.1111/j.1574-6968.1998.tb13241.x; Nomura S, 1999, LANGMUIR, V15, P214, DOI 10.1021/la980742u; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; Patenge N, 1999, FEMS MICROBIOL LETT, V171, P27, DOI 10.1016/S0378-1097(98)00583-7; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; PFEIFER F, 1993, MOL GEN GENET, V239, P66, DOI 10.1007/BF00281602; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; Stewart C, 1998, J BIOL CHEM, V273, P28078, DOI 10.1074/jbc.273.43.28078; Turner GJ, 1999, PROTEIN EXPRES PURIF, V17, P324, DOI 10.1006/prep.1999.1111; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Wang L, 1997, J BIOL CHEM, V272, P10631; WOLFER U, 1988, EUR J BIOCHEM, V174, P51, DOI 10.1111/j.1432-1033.1988.tb14061.x; XUI ZJ, 1995, J BIOL CHEM, V270, P24858, DOI 10.1074/jbc.270.42.24858; Zelazny A, 1997, P NATL ACAD SCI USA, V94, P6025, DOI 10.1073/pnas.94.12.6025; ZUSMAN T, 1989, J BIOL CHEM, V264, P18878	55	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22839	22846		10.1074/jbc.M908916199	http://dx.doi.org/10.1074/jbc.M908916199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807928	hybrid			2022-12-25	WOS:000088419400034
J	Cervin, MA; Spiegelman, GB				Cervin, MA; Spiegelman, GB			A role for Asp(75) in domain interactions in the Bacillus subtilis response regulator SpoOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; SPOIIG PROMOTER; STIMULATES TRANSCRIPTION; SIGMA(F) ACTIVITY; DEDUCED PRODUCT; SPO0A PROTEIN; ABRB GENE	Spo0A is a two-domain response regulator required for sporulation initiation in Bacillus subtilis, Studies on response regulators have focused on the activity of each domain, but very little is known about the mechanism by which the regulatory domain inhibits the activator domain. In this study, we created a single amino acid substitution in the regulatory domain, D75S, which resulted in a dramatic decrease in sporulation in vivo, In vitro studies with the purified Spo0AD75S protein demonstrated that phosphorylation and DNA binding were comparable with wild type Spo0A. However, the mutant was unable to stimulate transcription by sigma(A)-RNA polymerase from the Spo0A-dependent spoIIG operon promoter, We suggest that the amino acid Asp(75) and/or the region within which it resides, the alpha 3-beta 4 loop, are involved in the inhibitory interaction between the regulatory and activator domains of Spo0A.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Spiegelman, GB (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	spie@interchange.ubc.ca						Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; Baikalov I, 1998, BIOCHEMISTRY-US, V37, P3665, DOI 10.1021/bi972365a; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BRISSETTE RE, 1991, J BACTERIOL, V173, P3749, DOI 10.1128/JB.173.12.3749-3755.1991; Buckner CM, 1998, J BACTERIOL, V180, P4987, DOI 10.1128/JB.180.18.4987-4990.1998; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Cervin MA, 1999, MOL MICROBIOL, V31, P597, DOI 10.1046/j.1365-2958.1999.01200.x; Da Re S, 1999, MOL MICROBIOL, V34, P504, DOI 10.1046/j.1365-2958.1999.01614.x; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; Errington J, 1996, PHILOS T ROY SOC B, V351, P537, DOI 10.1098/rstb.1996.0052; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; Greene EA, 1996, J BIOL CHEM, V271, P11455, DOI 10.1074/jbc.271.19.11455; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; Hatt JK, 1998, J BACTERIOL, V180, P3584, DOI 10.1128/JB.180.14.3584-3591.1998; Hoch J.A., 1995, 2 COMPONENT SIGNAL T, DOI [10.1128/9781555818319, DOI 10.1128/9781555818319]; HOCH JA, 1985, J BACTERIOL, V161, P552, DOI 10.1128/JB.161.2.552-555.1985; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOCH JA, 1993, ADV MICROB PHYSIOL, V35, P111, DOI 10.1016/S0065-2911(08)60098-3; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Jiang M, 1999, MOL MICROBIOL, V33, P389, DOI 10.1046/j.1365-2958.1999.01481.x; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Madhusudan, 1997, BIOCHEMISTRY-US, V36, P12739, DOI 10.1021/bi971276v; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RODENBURG KW, 1994, PROTEIN ENG, V7, P905, DOI 10.1093/protein/7.7.905; Rowe-Magnus DA, 1998, P NATL ACAD SCI USA, V95, P5305, DOI 10.1073/pnas.95.9.5305; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SATOLA S, 1991, P NATL ACAD SCI USA, V88, P4533, DOI 10.1073/pnas.88.10.4533; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; Schyns G, 1997, J BACTERIOL, V179, P5605, DOI 10.1128/jb.179.17.5605-5608.1997; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; TRACH KA, 1985, P NATL ACAD SCI USA, V82, P7260, DOI 10.1073/pnas.82.21.7260; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996	54	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22025	22030		10.1074/jbc.M000211200	http://dx.doi.org/10.1074/jbc.M000211200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801786	hybrid			2022-12-25	WOS:000088363800040
J	Unk, I; Haracska, L; Johnson, RE; Prakash, S; Prakash, L				Unk, I; Haracska, L; Johnson, RE; Prakash, S; Prakash, L			Apurinic endonuclease activity of yeast Apn2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; APYRIMIDINIC ENDONUCLEASE; GENE; PURIFICATION; SUBSTRATE; HOMOLOG; COMPLEX	Abasic (apurinic/apyrimidinic; AP) sites are generated in vivo through spontaneous base loss and by enzymatic removal of bases damaged by alkylating agents and reactive oxygen species, In Saccharomyces cerevisiae, the APN1 and APN2 genes function in alternate pathways of AP site removal. Apn2-like proteins have been identified in other eukaryotes including humans, and these proteins form a distinct subfamily within the exonuclease III (ExoIII)/Ape1/Apn2 family of proteins. Apn2 and other members of this subfamily contain a carboxyl-terminal extension not present in the ExoIII/Ape1-like proteins. Here, we purify the Apn2 protein from yeast and show that, it is a class II AP endonuclease. Deletion of the carboxyl terminus does not affect the AP endonuclease activity of the protein, but this protein is defective in the removal of AP sites in vivo. The carboxyl terminus may enable Apn2 to complex with other proteins, and such a multiprotein assembly may be necessary for the efficient recognition and cleavage of AP sites in vivo.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA41261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett RAO, 1999, MOL CELL BIOL, V19, P1800; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; KANE CM, 1981, J BIOL CHEM, V256, P3405; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MUELLER JP, 1995, NUCLEIC ACIDS RES, V23, P3457, DOI 10.1093/nar/23.17.3457; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49	22	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22427	22434		10.1074/jbc.M002845200	http://dx.doi.org/10.1074/jbc.M002845200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10806210	hybrid			2022-12-25	WOS:000088363800091
J	Fattori, D; Urbani, A; Brunetti, M; Ingenito, R; Pessi, A; Prendergast, K; Narjes, F; Matassa, VG; De Francesco, R; Steinkuhler, C				Fattori, D; Urbani, A; Brunetti, M; Ingenito, R; Pessi, A; Prendergast, K; Narjes, F; Matassa, VG; De Francesco, R; Steinkuhler, C			Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NS4A COFACTOR PEPTIDE; TERMINAL PROTEINASE DOMAIN; ZINC-BINDING SITE; HCV NS3 PROTEIN; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; FACTOR-XA; IN-VITRO; INHIBITION; DISSOCIATION	A serine protease domain contained within the viral NS3 protein is a key player in the maturational processing of the hepatitis C virus polyprotein and a prime target for the development of antiviral drugs. In the present work, we describe a dansylated hexapeptide inhibitor of this enzyme. Active site occupancy by this compound could be monitored following fluorescence resonance energy transfer between the dansyl fluorophore and protein tryptophan residues and could be used to 1) unambiguously assess active site binding of NS3 protease inhibitors, 2) directly determine equilibrium and pre-steady-state parameters of enzyme-inhibitor complex formation, and 3) dissect, using site-directed mutagenesis, the contribution of single residues of NS3 to inhibitor binding in direct binding assays. The assay was also used to characterize the inhibition of the NS3 protease by its cleavage products. We show that enzyme-product inhibitor complex formation depends on the presence of an NS4A cofactor peptide, Equilibrium and pre-steady-state data support an ordered mechanism of ternary (enzyme-inhibitor-cofactor) complex formation, requiring cofactor complexation prior to inhibitor binding.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy; Merck Res Labs, West Point, PA 19486 USA	Merck & Company; Merck & Company	Steinkuhler, C (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30600, I-00040 Rome, Italy.	Steinbuhler@IRBM.it	Urbani, Andrea/B-2953-2012; De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; Fattori, Daniela/0000-0001-5663-2072; Narjes, Frank/0000-0002-3104-7771; Ingenito, Raffaele/0000-0002-8292-6346				Atherton E., 1990, SOLID PHASE PEPTIDE; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Bianchi E, 1997, BIOCHEMISTRY-US, V36, P7890, DOI 10.1021/bi9631475; Cerretani N, 1999, ANAL BIOCHEM, V266, P192, DOI 10.1006/abio.1998.2948; Cicero DO, 1999, J MOL BIOL, V289, P385, DOI 10.1006/jmbi.1999.2746; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; De Francesco R, 1998, THERAPIES FOR VIRAL HEPATITIS, P235; DeFrancesco R, 1996, BIOCHEMISTRY-US, V35, P13282, DOI 10.1021/bi9616458; EPPS DE, 1989, ANAL BIOCHEM, V181, P172, DOI 10.1016/0003-2697(89)90413-2; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; HIROMI I, 1979, KINETICS FAST ENZYME, P99; Ingallinella P, 1998, BIOCHEMISTRY-US, V37, P8906, DOI 10.1021/bi980314n; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; LaPlante SR, 1999, J BIOL CHEM, V274, P18618, DOI 10.1074/jbc.274.26.18618; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Lohmann V, 1996, J HEPATOL, V24, P11; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; SACHDEV GP, 1975, J BIOL CHEM, V250, P501; Sali DL, 1998, BIOCHEMISTRY-US, V37, P3392, DOI 10.1021/bi972010r; SHAH DO, 1984, J AM CHEM SOC, V106, P4272, DOI 10.1021/ja00327a038; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; SOLE NA, 1992, J ORG CHEM, V57, P5399, DOI 10.1021/jo00046a022; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2611, DOI 10.1021/bi00383a030; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; Steinkuhler C, 1996, J VIROL, V70, P6694; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; Urbani A, 1999, BIOCHEMISTRY-US, V38, P5206, DOI 10.1021/bi982773u; Urbani A, 1997, J BIOL CHEM, V272, P9204; Yan YW, 1998, PROTEIN SCI, V7, P837; Yao N, 1998, ANTIVIR THER, V3, P93; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Zhang RM, 1997, J VIROL, V71, P6208, DOI 10.1128/JVI.71.8.6208-6213.1997	42	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15106	15113		10.1074/jbc.275.20.15106	http://dx.doi.org/10.1074/jbc.275.20.15106			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809747	hybrid			2022-12-25	WOS:000087128300047
J	Fertala, J; Vance, JR; Pourquier, P; Pommier, Y; Bjornsti, MA				Fertala, J; Vance, JR; Pourquier, P; Pommier, Y; Bjornsti, MA			Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN SENSITIVITY; CLEAVABLE COMPLEXES; REPLICATION FORKS; CELLS; RESISTANCE; DRUGS; PHOSPHORYLATION; TOXICITY; POISONS; BINDING	Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA topology and is the cellular target of camptothecin, Recent reports of enzyme structure highlight the importance of conserved amino acids N-terminal to the active site tyrosine and the involvement of Asn-726 in mediating Top1p sensitivity to camptothecin, To investigate the contribution of this residue to enzyme catalysis, we evaluated the effect of substituting His, Asp, or Ser for Asn-726 on yeast Top1p, Top1N726S and Top1N726D mutant proteins were resistant to camptothecin, although the Ser mutant was distinguished by a lack of detectable changes in activity. Thus, a basic residue immediately N-terminal to the active site tyrosine is required for camptothecin cytotoxicity. However, replacing Asn-726 with Asp or His interfered with distinct aspects of the catalytic cycle, resulting in cell lethality. In contrast to camptothecin, which inhibits enzyme-catalyzed religation of DNA, the His substituent enhanced the rate of DNA scission, whereas the Asp mutation diminished the enzyme binding of DNA. Yet, these effects on enzyme catalysis were not mutually exclusive as the His mutant was hypersensitive to camptothecin. These results suggest distinct mechanisms of poisoning DNA topoisomerase I may be explored in the development of antitumor agents capable of targeting different aspects of the Top1p catalytic cycle.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	St Jude Children's Research Hospital; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005	NCI NIH HHS [CA09346, CA09137, CA58755] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058755, T32CA009346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benedetti P, 1998, DRUG RESIST UPDATE, V1, P176, DOI 10.1016/S1368-7646(98)80037-X; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CROW RT, 1992, J MED CHEM, V35, P4160, DOI 10.1021/jm00100a022; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FUJIMORI A, 1995, CANCER RES, V55, P1339; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KAISER C, 1994, METHODS YEAST GENETI, P133; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Takimoto CH, 1998, BBA-GENE STRUCT EXPR, V1400, P107, DOI 10.1016/S0167-4781(98)00130-4; TSAO YP, 1993, CANCER RES, V53, P5908; WALL ME, 1995, CANCER RES, V55, P753; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang XY, 1999, BIOCHEMISTRY-US, V38, P4374, DOI 10.1021/bi982708k	42	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15246	15253		10.1074/jbc.275.20.15246	http://dx.doi.org/10.1074/jbc.275.20.15246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809761	hybrid			2022-12-25	WOS:000087128300065
J	Gutwein, P; Oleszewski, M; Mechtersheimer, S; Agmon-Levin, N; Krauss, K; Altevogt, P				Gutwein, P; Oleszewski, M; Mechtersheimer, S; Agmon-Levin, N; Krauss, K; Altevogt, P			Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA CONVERTING-ENZYME; GROWTH-FACTOR-ALPHA; L-SELECTIN; FAMILY KINASES; TYROSINE PHOSPHORYLATION; SECRETASE CLEAVAGE; NEURITE OUTGROWTH; N-CAM; INTEGRIN	The ectodomain of certain transmembrane molecules can be released by proteolysis, and the solubilized antigens often exert important biological functions. We demonstrated before that the L1 adhesion molecule is shed from the cell surface. Here we show that L1 release in AR breast carcinoma cells is mediated by a member of the disintegrin metalloproteinase (ADAM) family of proteinases, Up-regulation of L1 shedding by phorbol ester or pervanadate involved distinct mechanisms. Pervanadate induced shedding and rounding-up of cells from the substrate, which was blocked by the Src kinase inhibitor PP2. Tyr phosphorylation of the L1 cytoplasmic tail and the Src kinase Fyn was observed following pervanadate treatment. Up-regulation of L1 release and activation of Fyn occurred also when cells were detached by EDTA suggesting that the regulation of L1 shedding by this pathway was linked to cell morphology and adhesion. The phorbol 12-myristate 13-acetate-induced shedding was inhibited by the protein kinase C inhibitor bisindolylnaleimide I and by PD98059, a specific inhibitor of the mitogen-activated protein kinase pathway. Soluble L1 binds to the proteoglycan neurocan and in bound form could support integrin-mediated cell adhesion and migration. We propose that the release of cell-associated adhesion molecules such as L1 may be relevant to promote cell migration.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280,0710, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz-heidelberg.de						Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Beer S, 1999, J CELL SCI, V112, P2667; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; CODONY SJ, 1999, CANCER RES, V59, P1196; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; Heiland PC, 1998, EUR J CELL BIOL, V75, P97, DOI 10.1016/S0171-9335(98)80052-6; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kadmon G, 1997, DIFFERENTIATION, V61, P143, DOI 10.1046/j.1432-0436.1997.6130143.x; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Nath D, 1999, J CELL SCI, V112, P579; Nitsch R M, 1994, J Neural Transm Suppl, V44, P21; Nolte C, 1999, CELL TISSUE RES, V298, P261, DOI 10.1007/s004419900063; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Schlondorff J, 1999, J CELL SCI, V112, P3603; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; Verbeek BS, 1999, EXP CELL RES, V248, P531, DOI 10.1006/excr.1999.4416; Vollmer P, 1999, EUR J BIOCHEM, V263, P438, DOI 10.1046/j.1432-1327.1999.00511.x; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4	57	148	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15490	15497		10.1074/jbc.275.20.15490	http://dx.doi.org/10.1074/jbc.275.20.15490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809781	hybrid			2022-12-25	WOS:000087128300096
J	Koya, RC; Fujita, H; Shimizu, S; Ohtsu, M; Takimoto, M; Tsujimoto, Y; Kuzumaki, N				Koya, RC; Fujita, H; Shimizu, S; Ohtsu, M; Takimoto, M; Tsujimoto, Y; Kuzumaki, N			Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ACTIN-REGULATORY PROTEIN; RAS-TRANSFORMED CELLS; CALCIUM SIGNALS; DEATH; MODULATION; ACTIVATION; BCL-2; BAX; PURIFICATION	Apoptotic cell death, characterized by chromatin condensation, nuclear fragmentation, cell membrane blebbing, and apoptotic body formation, is also accompanied by typical mitochondrial changes. The latter includes enhanced membrane permeability, fall in mitochondrial membrane potential (Delta psi(m)) and release of cytochrome c into the cytosol, Gelsolin, an actin regulatory protein, has been shown. to inhibit apoptosis, but when cleaved by caspase-3, a fragment that is implicated as an effector of apoptosis is generated. The mechanism by which the full-length form of gelsolin inhibits apoptosis is unclear. Here we show that the overexpression of gelsolin inhibits the loss of Delta psi(m), and cytochrome c release from mitochondria resulting in the lack of activation of caspase-3, -8, and -9 in Jurkat cells treated with staurosporine, thapsigargin, and protoporphyrin IX. These effects were corroborated in vitro using recombinant gelsolin protein on isolated rat mitochondria stimulated with Ca2+, atractyloside, or Bax. This protective function of gelsolin, which was not due to simple Ca2+ sequestration, was inhibited by polyphosphoinositide binding. In addition we confirmed that gelsolin, besides its localization in the cytosol, is also present in the mitochondrial fraction of cells. Gelsolin thus acts on an early step in the apoptotic signaling at the level of mitochondria.	Hokkaido Univ, Div Canc Gene Regulat, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Osaka Univ, Sch Med, Dept Med Genet, Ctr Biomed Res, Osaka 5650871, Japan	Hokkaido University; Osaka University	Kuzumaki, N (corresponding author), Hokkaido Univ, Div Canc Gene Regulat, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	kuzumaki@med.hokudai.ac.jp	Takimoto, Masato/D-9653-2012					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH MC, 1984, J BIOL CHEM, V259, P7473; Kuzminova AE, 1998, FEBS LETT, V434, P313, DOI 10.1016/S0014-5793(98)01005-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MULLAUER L, 1993, ONCOGENE, V8, P2531; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SOUA Z, 1985, EUR J BIOCHEM, V153, P275, DOI 10.1111/j.1432-1033.1985.tb09298.x; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TANAKA M, 1995, CANCER RES, V55, P3228; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; YIN HL, 1980, J BIOL CHEM, V255, P9490; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	57	197	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15343	15349		10.1074/jbc.275.20.15343	http://dx.doi.org/10.1074/jbc.275.20.15343			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809769	Green Published, hybrid			2022-12-25	WOS:000087128300077
J	Orzech, E; Cohen, S; Weiss, A; Aroeti, B				Orzech, E; Cohen, S; Weiss, A; Aroeti, B			Interactions between the exocytic and endocytic pathways in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTORS; TRANS-GOLGI NETWORK; LYSOSOMAL MEMBRANE-PROTEINS; BASOLATERAL SORTING SIGNAL; HUMAN TRANSFERRIN RECEPTOR; KINASE-II PHOSPHORYLATION; HIGH-AFFINITY INTERACTION; CLATHRIN-COATED VESICLES; AGGLUTININ BINDING-SITES	The compartments involved in polarized exocytosis of membrane proteins are not well defined. In this study we hypothesized that newly synthesized polymeric immunoglobulin receptors are targeted from the trans-Golgi network to endosomes prior to their appearance on the basolateral cell surface of polarized Madin-Darby canine kidney cells. To examine this hypothesis, we have used an assay designed to measure the meeting of newly synthesized receptors with a selective population of apical or basolateral endosomes loaded with horseradish peroxidase, We found that in the course of basolateral exocytosis, the wild-type polymeric immunoglobulin receptor is targeted from the trans-Golgi network to apical and basolateral endosomes. Phosphorylation of a Ser residue in the cytoplasmic tail of the receptor is implicated in this process. The biosynthetic pathway of apically sorted polymeric immunoglobulin receptor mutants similarly traversed apical endosomes, raising the possibility that apical receptors are segregated from basolateral receptors in apical endosomes. The post-endocytic pathway of transcytosing and recycling receptors also passed through apical endosomes. Together, these observations are consistent with the possibility that the biosynthetic and endocytic routes merge into endosomes and justify a model suggesting that endosomal recycling processes govern polarized trafficking of proteins traveling in both pathways.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; Jerusalem Coll Technol, Dept Elect, IL-91160 Jerusalem, Israel	Hebrew University of Jerusalem	Aroeti, B (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.	aroeti@cc.huji.ac.il						ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; APODACA G, 1993, J BIOL CHEM, V268, P23712; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1993, J BIOL CHEM, V268, P20380; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BALIN BJ, 1988, J NEUROCYTOL, V17, P809, DOI 10.1007/BF01216708; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; Brachet V, 1999, MOL BIOL CELL, V10, P2891, DOI 10.1091/mbc.10.9.2891; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Keller P, 1997, J CELL SCI, V110, P3001; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Menon AK, 1998, TRENDS CELL BIOL, V8, P374, DOI 10.1016/S0962-8924(98)01340-3; Mostov K, 1999, CELL, V99, P121, DOI 10.1016/S0092-8674(00)81643-8; Mostov KE, 1995, COLD SPRING HARB SYM, V60, P775, DOI 10.1101/SQB.1995.060.01.083; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RAUB TJ, 1990, J CELL PHYSIOL, V144, P52, DOI 10.1002/jcp.1041440108; RAUB TJ, 1990, J CELL PHYSIOL, V143, P1, DOI 10.1002/jcp.1041430102; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; Reich V, 1996, J CELL SCI, V109, P2133; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; van Ijzendoorn SCD, 1999, TRENDS CELL BIOL, V9, P144, DOI 10.1016/S0962-8924(99)01512-3; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; WILDE A, 1992, FEBS LETT, V313, P235, DOI 10.1016/0014-5793(92)81199-V	75	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15207	15219		10.1074/jbc.275.20.15207	http://dx.doi.org/10.1074/jbc.275.20.15207			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809756	hybrid			2022-12-25	WOS:000087128300060
J	Szalai, G; Csordas, G; Hantash, BM; Thomas, AP; Hajnoczky, G				Szalai, G; Csordas, G; Hantash, BM; Thomas, AP; Hajnoczky, G			Calcium signal transmission between ryanodine receptors and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT CARDIAC MYOCYTES; SINGLE-RAT CARDIOMYOCYTES; FREE CA2+ CONCENTRATION; MUSCLE-CELL LINE; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; CONTRACTION CYCLE; INTACT-CELLS; IN-SITU	Control of energy metabolism by increases of mitochondrial matrix [Ca2+] ([Ca2+](m)) may represent a fundamental mechanism to meet the ATP demand imposed by heart contractions, but the machinery underlying propagation of [Ca2+] signals from ryanodine receptor Ca2+ release channels (RyR) to the mitochondria remains elusive. Using permeabilized cardiac (H9c2) cells we investigated the cytosolic [Ca2+] ([Ca2+](c)) and [Ca2+](m) signals elicited by activation of RyR, Caffeine, Ca2+, and ryanodine evoked [Ca2+](c) spikes that often appeared as frequency-modulated [Ca2+](c) oscillations in these permeabilized cells. Rapid increases in [Ca2+], and activation of the Ca2+-sensitive mitochondrial dehydrogenases were synchronized to the rising phase of the [Ca2+](c) spikes, The RyR-mediated elevations of global [Ca2+](c) were in the submicromolar range, but the rate of [Ca2+](m) increases was as large as it was in the presence of 30 mu M global [Ca2+](c). Furthermore, RyR-dependent increases of [Ca2+](m) were relatively insensitive to buffering of [Ca2+](c) by EGTA. Therefore, RyR-driven rises of [Ca2+](m) appear to result from large and rapid increases of perimitochondrial [Ca2+]. The falling phase of [Ca2+](c) spikes was followed by a rapid decay of [Ca2+](m). CGP37157 slowed down relaxation of [Ca2+](m) spikes, whereas cyclosporin A had no effect, suggesting that activation of the mitochondrial Ca2+ exchangers accounts for rapid reversal of the [Ca2+](m) response with little contribution from the permeability transition pore. Thus, rapid activation of Ca2+ uptake sites and Ca2+ exchangers evoked by RyR-mediated local [Ca2+](c) signals allow mitochondria to respond rapidly to single [Ca2+](c) spikes in cardiac cells.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Jefferson University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hajnoczky, G (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 253 JAH, Philadelphia, PA 19107 USA.	Gyorgy.Hajnoczky@mail.tju.edu	Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467; Csordas, Gyorgy/0000-0003-3156-1460	NIDDK NIH HHS [DK51526, DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051526, R01DK038422, R29DK038422, R29DK051526] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BERS DM, 1991, EXCITATION CONTRACTI; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Bowser DN, 1998, BIOPHYS J, V75, P2004, DOI 10.1016/S0006-3495(98)77642-8; Brandes R, 1997, CIRC RES, V80, P82, DOI 10.1161/01.RES.80.1.82; Budd SL, 1996, J NEUROCHEM, V67, P2282; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; CROMPTON M, 1990, CALCIUM HEART, P167; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; FRY CH, 1984, PROC R SOC SER B-BIO, V223, P223, DOI 10.1098/rspb.1984.0091; Griffiths EJ, 1997, AM J PHYSIOL-CELL PH, V273, pC37, DOI 10.1152/ajpcell.1997.273.1.C37; Griffiths EJ, 1997, CELL CALCIUM, V21, P321, DOI 10.1016/S0143-4160(97)90120-2; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEJIAALVAREZ R, 1994, J PHYSIOL-LONDON, V478, P315, DOI 10.1113/jphysiol.1994.sp020252; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MORAVEC CS, 1991, AM J PHYSIOL, V260, pH989, DOI 10.1152/ajpheart.1991.260.3.H989; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Ohata H, 1998, J BIOENERG BIOMEMBR, V30, P207, DOI 10.1023/A:1020588618496; Ramesh V, 1998, ANN NY ACAD SCI, V853, P341, DOI 10.1111/j.1749-6632.1998.tb08295.x; Rios E, 1997, ANNU REV BIOPH BIOM, V26, P47, DOI 10.1146/annurev.biophys.26.1.47; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; SIPIDO KR, 1991, CIRC RES, V69, P1487, DOI 10.1161/01.RES.69.6.1487; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tanimura A, 1996, J BIOL CHEM, V271, P30904, DOI 10.1074/jbc.271.48.30904; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; WENDTGALLITELLI MF, 1991, J PHYSIOL-LONDON, V435, P349, DOI 10.1113/jphysiol.1991.sp018514; Zhou Z, 1998, J PHYSIOL-LONDON, V507, P379, DOI 10.1111/j.1469-7793.1998.379bt.x	48	183	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15305	15313		10.1074/jbc.275.20.15305	http://dx.doi.org/10.1074/jbc.275.20.15305			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809765	hybrid			2022-12-25	WOS:000087128300072
J	Yu, CD; Wang, F; Kan, M; Jin, CL; Jones, RB; Weinstein, M; Deng, CX; McKeehan, WL				Yu, CD; Wang, F; Kan, M; Jin, CL; Jones, RB; Weinstein, M; Deng, CX; McKeehan, WL			Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MESSENGER-RNA LEVELS; HMG-COA REDUCTASE; LIVER DEVELOPMENT; NUCLEAR RECEPTOR; OXYSTEROL 7-ALPHA-HYDROXYLASE; COORDINATE REGULATION; HEPARAN-SULFATE; BINDING PROTEIN; FACTOR FAMILY	Heparan sulfate-regulated transmembrane tyrosine kinase receptor FGFR4 is the major FGFR isotype in mature hepatocytes. Fibroblast growth factor has been implicated in the definition of liver from foregut endoderm where FGFR4 is expressed and stimulation of hepatocyte DNA synthesis in vitro, Here we show that livers of mice lacking FGFR4 exhibited normal morphology and regenerated normally in response to partial hepatectomy, However, the FGFR4 (-/-) mice exhibited depleted gallbladders, an elevated bile acid pool and elevated excretion of bile acids. Cholesterol- and bile acid-controlled liver cholesterol 7 alpha-hydroxylase, the limiting enzyme for bile acid synthesis, was elevated, unresponsive to dietary cholesterol, but repressed normally by dietary cholate, Expression pattern and cholate-dependent, cholesterol-induced hepatomegaly in the FGFR4 (-/-) mice suggested that activation of receptor interacting protein 140, a co-repressor of feed-forward activator liver X receptor alpha, may mediate the negative regulation of cholesterol- and bile acid-controlled liver cholesterol 7 alpha-hydroxylase transcription by FCFR4 and cholate, The results demonstrate that transmembrane sensors interface with metabolite-controlled transcription networks and suggest that pericellular matrix-controlled liver FGFR4 in particular may ensure adequate cholesterol for cell structures and signal transduction.	Texas A&M Univ, Inst Biosci & Technol, Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	McKeehan, WL (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	wmckeeha@ibt.tamu.edu	deng, chuxia/N-6713-2016; Yu, C/G-4626-2010		NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, Z01DK056001] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK47039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORKHEM I, 1992, J LIPID RES, V33, P455; BROWN MS, 1980, J LIPID RES, V21, P505; Chiang John Y. L., 1998, Frontiers in Bioscience, V3, pD176; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feingold KR, 1996, J LIPID RES, V37, P223; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Harnish DC, 1998, J BIOL CHEM, V273, P9270, DOI 10.1074/jbc.273.15.9270; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; ITOH T, 1993, BIOCHEM BIOPH RES CO, V192, P1011, DOI 10.1006/bbrc.1993.1517; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN M, 1998, LIVER GROWTH REPAIR, V9, P240; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Massimi M, 1998, HEPATOLOGY, V28, P1064, DOI 10.1002/hep.510280422; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NAKANO K, 1995, EUR SURG RES, V27, P389, DOI 10.1159/000129425; Naski M C, 1998, Front Biosci, V3, pd781; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PORTINCASA P, 1994, AM J GASTROENTEROL, V89, P909; PORTINCASA P, 1995, EUR J CLIN INVEST, V25, P746, DOI 10.1111/j.1365-2362.1995.tb01953.x; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Shneider BL, 1997, PEDIATR RES, V42, P189, DOI 10.1203/00006450-199708000-00010; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; Turley SD, 1996, J CARDIOVASC PHARM, V27, P71, DOI 10.1097/00005344-199601000-00012; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Xu XL, 1998, DEVELOPMENT, V125, P753; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	50	292	315	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15482	15489		10.1074/jbc.275.20.15482	http://dx.doi.org/10.1074/jbc.275.20.15482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809780	hybrid			2022-12-25	WOS:000087128300095
J	Zhu, WD; Zou, YZ; Shiojima, I; Kudoh, S; Aikawa, R; Hayashi, D; Mizukami, M; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I				Zhu, WD; Zou, YZ; Shiojima, I; Kudoh, S; Aikawa, R; Hayashi, D; Mizukami, M; Toko, H; Shibasaki, F; Yazaki, Y; Nagai, R; Komuro, I			Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CARDIAC GENE-EXPRESSION; HEAVY-CHAIN GENE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; MECHANICAL-STRESS; T-LYMPHOCYTES; MUSCLE-CELLS; NF-ATC; MYOCYTES	Endothelin-l (ET-1) induces cardiac hypertrophy, Because Ca2+ is a major second messenger of ET-1, the role of Ca2+ in ET-l-induced hypertrophic responses in cultured cardiac myocytes of neonatal rats was examined. ET-I activated the promoter of the beta-type myosin heavy chain gene (beta-MHC) (-354 to +34 base pairs) by about 4-fold. This activation was inhibited by chelation of Ca2+ and the blocking of protein kinase C activity. Similarly, the beta-MHC promoter was activated by Ca2+ ionophores and a protein kinase C activator. beta-MHC promoter activation induced by ET-I was suppressed by pretreatment with the calmodulin inhibitor, W7, the Ca2+/calmodulin-dependent kinase II (CaMKII) inhibitor, KN62, and the calcineurin inhibitor, cyclosporin A. P-MHC promoter activation by ET-I was also attenuated by overexpression of dominant-negative mutants of CaMKII and calcineurin, ET-1 increased the activity of CaMKII and calcineurin in cardiac myocytes, Pretreatment with KN62 and cyclosporin A strongly suppressed ET-l-induced increases in [H-3]phenylalanine uptake and in cell size. These results suggest that Ca2+ plays a critical role in ET-l-induced cardiomyocyte hypertrophy by activating CaMKII- and calcineurin-dependent pathways.	Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138655, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Komuro, I (corresponding author), Univ Tokyo, Dept Cardiovasc Med, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; GHAFFARI TN, 1999, EUR J IMMUNOL, V29, P132; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasegawa K, 1997, CIRCULATION, V96, P3943; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOMIYAMA M, 1990, J MUSCLE RES CELL M, V11, P419, DOI 10.1007/BF01739762; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; LEITE MF, 1994, AM J PHYSIOL-HEART C, V267, pH2193, DOI 10.1152/ajpheart.1994.267.6.H2193; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wang Y, 1996, MOL CELL BIOL, V16, P5915; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221	37	123	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15239	15245		10.1074/jbc.275.20.15239	http://dx.doi.org/10.1074/jbc.275.20.15239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809760	hybrid			2022-12-25	WOS:000087128300064
J	Gire, V; Marshall, C; Wynford-Thomas, D				Gire, V; Marshall, C; Wynford-Thomas, D			PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS	ONCOGENE			English	Article						RAS; intra-cellular signals; PI-3-kinase; MAP kinase; epithelial; thyroid	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; IN-VITRO; TRANSFORMATION; SUFFICIENT; PATHWAYS; GROWTH; DIFFERENTIATION; EXPRESSION	In contrast to its growth-inhibitory effect on primary mesenchymal cells, RAS oncogene activation induces a proliferative phenotype in normal human thyroid epithelial cells in vitro, consistent with its putative role in tumour initiation. Using this model, we previously showed that activation of the MAP kinase (MAPK) pathway is necessary, but not sufficient for the proliferative response to mutant (V12) H-RAS. Were we extend this work to show that another major RAS effector - phosphatidylinositol-3-kinase (PI-3-K) - while also insufficient alone, is able to synergize with MAPK activation to mimic the effect of mutant RAS, albeit at reduced efficiency. Furthermore we show that PI-3-K is an absolute requirement for the proliferative response to RAS in these cells, acting via suppression of RAS-induced apoptosis. These data extend our understanding of RAS signalling in a clinically-relevant cell context and point to the use of PI-3-K inhibitors as potential therapeutic agents for targetting human cancers induced by RAS mutation.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Ctr Cellular & Mol Biol, Canc Res Campaign, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; Treinies I, 1999, MOL CELL BIOL, V19, P321; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	40	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2269	2276		10.1038/sj.onc.1203544	http://dx.doi.org/10.1038/sj.onc.1203544			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822377				2022-12-25	WOS:000086974300001
J	Murphy, MP; Uljon, SN; Fraser, PE; Fauq, A; Lookingbill, HA; Findlay, KA; Smith, TE; Lewis, PA; McLendon, DC; Wang, R; Golde, TE				Murphy, MP; Uljon, SN; Fraser, PE; Fauq, A; Lookingbill, HA; Findlay, KA; Smith, TE; Lewis, PA; McLendon, DC; Wang, R; Golde, TE			Presenilin 1 regulates pharmacologically distinct gamma-secretase activities - Implications for the role of presenilin in gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-PROTEIN; SIGNALING PATHWAY; ASPARTYL PROTEASE; KINASE-C; CATENIN; NOTCH; GENERATION; DEFICIENCY	Presenilins (PSs) are polytopic membrane proteins that have been implicated as potential therapeutic targets in Alzheimer's disease because of their role in regulating the gamma-secretase cleavage that generates the amyloid beta protein (A beta), It is not clear how PSs regulate gamma-secretase cleavage, but there is evidence that PSs could be either essential cofactors in the gamma-secretase cleavage, gamma-secretase themselves, or regulators of intracellular trafficking that indirectly influence gamma-secretase cleavage. Using presenilin 1 (PS1) mutants that inhibit A beta production in conjunction with transmembrane domain mutants of the amyloid protein precursor that are cleaved by pharmacologically distinct gamma-secretases, we show that PS1 regulates multiple pharmacologically distinct gamma-secretase activities as well as inducible alpha-secretase activity. It is likely that PS1 acts indirectly to regulate these activities (as in a trafficking or chaperone role), because these data indicate that for PS1 to be gamma-secretase it must either have multiple active sites or exist in a variety of catalytically active forms that are altered to an equivalent extent by the mutations we have studied.	Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA; Univ Toronto, Toronto, ON M5S 3H2, Canada	Mayo Clinic; Rockefeller University; University of Toronto	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA.		Lewis, Patrick A./C-3674-2009; Wang, Rong/A-8721-2009	Lewis, Patrick/0000-0003-4537-0489	NIA NIH HHS [AG-16065] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG016065] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 1997, J NEUROCHEM, V69, P2432; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Higaki JN, 1999, J MED CHEM, V42, P3889, DOI 10.1021/jm990009f; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kang DE, 1999, J NEUROSCI, V19, P4229; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Scheper W, 2000, HUM MOL GENET, V9, P303, DOI 10.1093/hmg/9.2.303; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shin JE, 1999, NEUROSCI LETT, V269, P99, DOI 10.1016/S0304-3940(99)00434-6; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vestling M, 1999, BBA-MOL BASIS DIS, V1453, P341, DOI 10.1016/S0925-4439(99)00003-4; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	50	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26277	26284		10.1074/jbc.M002812200	http://dx.doi.org/10.1074/jbc.M002812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10816583	hybrid			2022-12-25	WOS:000088999700055
J	Das, AK; Uhler, MD; Hajra, AK				Das, AK; Uhler, MD; Hajra, AK			Molecular cloning and expression of mammalian peroxisomal trans-2-enoyl-coenzyme A reductase cDNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; DEPENDENT CHAIN ELONGATION; ACYL-COENZYME-A; BETA-OXIDATION; ENDOPLASMIC-RETICULUM; LIVER PEROXISOMES; RAT-LIVER; MITOCHONDRIA; PATHWAY; PROLIFERATION	Chain elongation of fatty acids is an important cellular process and is believed to occur in the endoplasmic reticulum of all eukaroytic cells. Herein we describe the cloning and characterization of a peroxisomal NADPH-specific trans-2-enoyl-CoA reductase, the key enzyme for a proposed peroxisomal chain elongation pathway. The reductase was solubilized and partially purified from guinea pig liver peroxisomes by affinity chromatography. On SDS-polyacrylamide gel electrophoresis, a 40-kDa band was identified as the enzyme, and its partial amino acid sequence (27 amino acids) was determined. A full-length cDNA for the reductase was cloned from a guinea pig liver cDNA library. The open reading frame of this nucleotide sequence encodes a 302-amino acid polypeptide with a calculated molecular mass of 32.5 kDa. Full-length mouse and human cDNA clones encoding homologous proteins have also been isolated, All of these translated polypeptides have the type I peroxisomal targeting signal, AKL, at the carboxyl terminus. The identity of the cloned enoyl-CoA reductase cDNAs was confirmed by expressing the guinea pig and human cDNAs in Escherichia coli. The His-tagged recombinant enzymes were found to have very high NADPH-specific 2-enoyl-CoA reductase activity with similar properties and specificity as the liver peroxisomal reductase. Both the natural and the recombinant enzyme catalyze the reduction of trans-2-enoyl-CoAs of varying chain lengths from 6:1 to 16:1, having maximum activity with 10:1 CoA. Northern blot analysis demonstrated that a single transcript of 1.3 kilobases is present in most mouse tissues, with particularly high concentrations in liver and kidney.	Univ Michigan, Neurosci Lab, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hajra, AK (corresponding author), Univ Michigan, Neurosci Lab, Mental Hlth Res Inst, 1103 E Huron St, Ann Arbor, MI 48104 USA.	akhajra@umich.edu		Das, Arun/0000-0002-0883-1816	NINDS NIH HHS [NS 15747] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; BROUSTAS CG, 1995, J NEUROCHEM, V64, P2345; BURDETT K, 1991, J BIOL CHEM, V266, P12201; Chirala SS, 1997, P NATL ACAD SCI USA, V94, P5588, DOI 10.1073/pnas.94.11.5588; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; CVETANOVIC M, 1985, BIOCHEM J, V227, P9; DATTA SC, 1990, J BIOL CHEM, V265, P8268; DUVE CD, 1971, J CELL BIOL, V50, pD20, DOI 10.1083/jcb.50.1.20d; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fransen M, 1999, BIOCHEM J, V340, P561, DOI 10.1042/0264-6021:3400561; Geisbrecht BV, 1999, J BIOL CHEM, V274, P25814, DOI 10.1074/jbc.274.36.25814; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HAJRA AK, 1998, CELL LAB MANUAL; Hayashi H, 1997, BBA-LIPID LIPID MET, V1346, P38, DOI 10.1016/S0005-2760(97)00020-9; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAUER WM, 1941, J AM CHEM SOC, V63, P1153; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; NADA MA, 1992, ANAL BIOCHEM, V201, P62, DOI 10.1016/0003-2697(92)90174-6; NAGI MN, 1986, ARCH BIOCHEM BIOPHYS, V248, P408, DOI 10.1016/0003-9861(86)90437-6; PODACK ER, 1974, EUR J BIOCHEM, V45, P13, DOI 10.1111/j.1432-1033.1974.tb03524.x; RADIN NS, 1960, J LIPID RES, V1, P250; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; Sprecher H, 1995, J LIPID RES, V36, P2471; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; THOMASON SC, 1968, J CHEM EDUC, V45, P546, DOI 10.1021/ed045p546; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; VOLKL A, 1982, ANN NY ACAD SCI, V386, P504, DOI 10.1111/j.1749-6632.1982.tb21464.x; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WOOD R, 1981, J BIOL CHEM, V256, P2379; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9; Zhang JH, 1999, BBA-PROTEIN STRUCT M, V1435, P184, DOI 10.1016/S0167-4838(99)00218-6	43	45	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24333	24340		10.1074/jbc.M001168200	http://dx.doi.org/10.1074/jbc.M001168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10811639	hybrid			2022-12-25	WOS:000088683300014
J	Molla, G; Porrini, D; Job, V; Motteran, L; Vegezzi, C; Campaner, S; Pilone, MS; Pollegioni, L				Molla, G; Porrini, D; Job, V; Motteran, L; Vegezzi, C; Campaner, S; Pilone, MS; Pollegioni, L			Role of arginine 285 in the active site of Rhodotorula gracilis D-amino acid oxidase - A site-directed mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-SERINE; MECHANISM; ENZYME; SUBSTRATE; FLAVOPROTEINS; COLI	Arg(285), one of the very few conserved residues in the active site of D-amino acid oxidases, has been mutated to lysine, glutamine, aspartate, and alanine in the enzyme from the yeast Rhodotorula gracilis (RgDAAO), The mutated proteins are all catalytically competent. Mutations of Arg(285) result in an increase ( approximate to 300-fold) of K-m for the D-amino acid and in a large decrease (approximate to 500-fold) of turnover number. Stopped-flow analysis shows that the decrease in turnover is paralleled by a similar decrease in the rate of flavin reduction (k(2)), the latter still being the rate-limiting step of the reaction. In agreement with data from the protein crystal structure, loss of the guanidinium group of Arg(285) in the mutated DAAOs drastically reduces the binding of several carboxylic acids (e.g. benzoate). These results highlight the importance of this active site residue in the precise substrate orientation, a main factor in this redox reaction. Furthermore, Arg(285) DAAO mutants have spectral properties similar to those of the wild-type enzyme, but show a low degree of stabilization of the flavin semiquinone and a change in the redox properties of the free enzyme. From this, we can unexpectedly conclude that Arg(285) in the free enzyme form is involved in the stabilization of the negative charge on the N(1)-C(2)=O locus of the isoalloxazine ring of the flavin. We also suggest that the residue undergoes a conformational change in order to bind the carboxylate portion of the substrate/ligand in the complexed enzyme.	Univ Insubria, Dipartimento Biol Strutturale & Funzionale, I-21100 Varese, Italy	University of Insubria	Pollegioni, L (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funzionale, Via JH Dunant 3, I-21100 Varese, Italy.			CAMPANER, Stefano/0000-0003-4547-6849; POLLEGIONI, LOREDANO/0000-0003-1733-7243; Molla, Gianluca/0000-0003-3688-3397				CASALIN P, 1991, EUR J BIOCHEM, V197, P513, DOI 10.1111/j.1432-1033.1991.tb15939.x; Clark W.M., 1960, OXIDATION REDUCTION, P184; CURTI B, 1992, CHEM BIOCH FLAVOENZY, P69; FAOTTO L, 1995, BIOTECHNOL LETT, V17, P193, DOI 10.1007/BF00127987; FERTI C, 1981, EUR J BIOCHEM, V119, P553, DOI 10.1111/j.1432-1033.1981.tb05643.x; FITZPATRICK PF, 1983, J BIOL CHEM, V258, P9700; GADDA G, 1994, J BIOL CHEM, V269, P17809; GIBSON QH, 1964, J BIOL CHEM, V259, P3927; Harris CM, 1999, J BIOL CHEM, V274, P36233, DOI 10.1074/jbc.274.51.36233; HERSH LB, 1975, J BIOL CHEM, V250, P8728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1991, FLAVINS FLAVOPROTEIN, P56; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1997, CURR OPIN STRUC BIOL, V7, P804, DOI 10.1016/S0959-440X(97)80150-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MIURA R, 1988, BIOORG CHEM, V16, P97, DOI 10.1016/0045-2068(88)90039-9; Mizutani H, 1996, J BIOCHEM-TOKYO, V120, P14; Molla G, 1998, PROTEIN EXPRES PURIF, V14, P289, DOI 10.1006/prep.1998.0956; NISHINO T, 1980, J BIOL CHEM, V255, P3610; PILONESIMONETTA M, 1989, EUR J BIOCHEM, V180, P199, DOI 10.1111/j.1432-1033.1989.tb14634.x; POLLEGIONI L, 1992, BIOCHEM J, V286, P389, DOI 10.1042/bj2860389; Pollegioni L, 1997, J BIOL CHEM, V272, P4924, DOI 10.1074/jbc.272.8.4924; Pollegioni L, 1997, J BIOTECHNOL, V58, P115, DOI 10.1016/S0168-1656(97)00142-9; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SA, 1999, J BIOL CHEM, V274, P22289, DOI 10.1074/jbc.274.32.22289; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WALSH CT, 1971, J BIOL CHEM, V246, P6855; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409	34	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24715	24721		10.1074/jbc.M908193199	http://dx.doi.org/10.1074/jbc.M908193199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10821840	hybrid			2022-12-25	WOS:000088683300066
J	Chen, CA; Manning, DR				Chen, CA; Manning, DR			Regulation of G(alpha i) palmitoylation by activation of the 5-hydroxytryptamine-1A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE LOCALIZATION; BETA-ADRENERGIC-RECEPTOR; LIPID MODIFICATIONS; BIOCHEMICAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; SF9 CELLS; RAT-BRAIN	Nearly all alpha subunits of heterotrimeric GTP-binding regulatory proteins (G proteins) are palmitoylated at cysteine residues near the N terminus. A regulated cycle of palmitoylation could provide a mechanism for modulating G protein signaling by affecting protein interactions and localization of the subunit, In the present studies we utilized both [H-3]palmitate incorporation and pulse chase techniques to address the dynamics of alpha(i) palmitoylation in Chinese hamster ovary cells. Both techniques demonstrated a dose- and time-dependent change in [H-3]palmitate labeling of alpha(i) upon activation of stably expressed 5-hydroxytryptamine-1A receptors by the agonist (+/-)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide (DPAT), with an EC50 of similar to 10 nM, For the incorporation assay, DPAT elicited an approximate doubling in labeling at the earliest time point measured. For the pulse-chase assay, DPAT promoted a significant loss of radiolabel almost equally as fast. These data demonstrate that the exchange of palmitate on cui is increased upon stimulation of 5-hydroxytryptamine-1A receptors through the combined processes of depalmitoylation and palmitoylation, These results provide the basis for extending the concept of regulated exchange of palmitate beyond G(s) and provide a framework for exploring the specific functional attributes of the palmitoylated and depalmitoylated forms of subunit.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	manning@pharm.med.upenn.edu			NIGMS NIH HHS [GM53156] Funding Source: Medline; NIMH NIH HHS [MH14654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Cornea A, 1998, ENDOCRINOLOGY, V139, P397, DOI 10.1210/en.139.1.397; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; DUMUIS A, 1988, MOL PHARMACOL, V33, P178; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; Gurdal H, 1997, MOL PHARMACOL, V52, P1064, DOI 10.1124/mol.52.6.1064; HJORTH S, 1982, J NEURAL TRANSM, V55, P169, DOI 10.1007/BF01276574; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KUNG MP, 1995, J PHARMACOL EXP THER, V272, P429; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Song KS, 1997, CELL MOL BIOL, V43, P293; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Stoffel RH, 1998, BIOCHEMISTRY-US, V37, P16053, DOI 10.1021/bi981432d; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wise A, 1997, BIOCHEMISTRY-US, V36, P10620, DOI 10.1021/bi9702997	71	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23516	23522		10.1074/jbc.M003439200	http://dx.doi.org/10.1074/jbc.M003439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10818105	hybrid			2022-12-25	WOS:000088564200017
J	Nassar, A; Simpson, AWM				Nassar, A; Simpson, AWM			Elevation of mitochondrial calcium by ryanodine-sensitive calcium-induced calcium release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; CA2+ CONCENTRATION; INTACT-CELLS; OSCILLATIONS; HEART; CA-2+; STORE; PARTICIPATION	Calcium is an important regulator of mitochondrial function. Since there can be tight coupling between inositol 1,4,5-trisphosphate-sensitive Ca2+ release and elevation of mitochondrial calcium concentration, we have investigated whether a similar relationship exists between the release of Ca2+ from the ryanodine receptor and the elevation of mitochondrial Ca2+. Perfusion of permeabilized A10 cells with inositol 1,4,5-trisphosphate resulted in a large transient elevation of mitochondrial Ca2+ to about 8 mu M. The response was inhibited by heparin but not ryanodine. Perfusion of the cells with Ca2+ buffers in excess of 1 mu M leads to large increases in mitochondrial Ca2+ that are much greater than the perfused Ca2+. These increases, which average around 10 mu M, are enhanced by caffeine and inhibited by ryanodine and depletion of the intracellular stores with either orthovanadate or thapsigargin. We conclude that Ca2+-induced Ca2+ release at the ryanodine receptor generates microdomains of elevated Ca2+ that are sensed by adjacent mitochondria. In addition to ryanodine sensitive stores acting as a source of Ca2+, Ca2+-induced Ca2+ release is required to generate efficient elevation of mitochondrial Ca2+.	Univ Liverpool, New Med Sch, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England	University of Liverpool	Simpson, AWM (corresponding author), Univ Liverpool, New Med Sch, Dept Human Anat & Cell Biol, Ashton St, Liverpool L69 3GE, Merseyside, England.	awms@liv.ac.uk						ALLEN DG, 1979, DETECTION MEASUREMEN, P159; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; CROMPTON M, 1985, CURR TOP MEMBR TRANS, V25, P231; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MCCORMACK JG, 1985, BIOCHEM SOC T, V13, P664, DOI 10.1042/bst0130664; ORITZ A, 1984, BIOCHEM J, V221, P213; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016/S0005-2728(98)00118-2; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SIMPSON AWM, 1989, BIOCHEM BIOPH RES CO, V163, P1223, DOI 10.1016/0006-291X(89)91108-X; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SOMLYO AP, 1982, FED PROC, V41, P2883; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WERTH JL, 1994, J NEUROSCI, V14, P348; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	42	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23661	23665		10.1074/jbc.M000457200	http://dx.doi.org/10.1074/jbc.M000457200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10821828	hybrid			2022-12-25	WOS:000088564200037
J	Tian, M; Alt, FW				Tian, M; Alt, FW			Transcription-induced cleavage of immunoglobulin switch regions by nucleotide excision repair nucleases in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENES; MURINE B-CELLS; CIRCULAR DNA; ENDONUCLEASE ACTIVITY; REPETITIVE SEQUENCES; STRUCTURAL ELEMENTS; RECOMBINATION SITES; COMPLEX-FORMATION; GROWTH FAILURE; XPG PROTEIN	Immunoglobulin (Tg) heavy chain class switch recombination (CSR) mediates isotype switching during B cell development. CSR occurs between switch (S) regions that precede each Ig heavy chain constant region gene. Various studies have demonstrated that transcription plays an essential role in CSR in vivo. In this study, we show that in vitro transcription of S regions in their physiological orientation induces the formation of stable R loops. Furthermore, we show that the nucleotide excision repair nucleases XPF-ERCC1 and XPG can cleave the R loops formed in the S regions. Based on these findings, we propose that CSR is initiated via a mechanism that involves transcription-dependent S region cleavage by DNA structure-specific endonucleases that function in general DNA repair processes. Such a mechanism also may underlie transcription-dependent mutagenic processes such as somatic hypermutation, and contribute to genomic instability in general.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Alt, FW (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.				NIAID NIH HHS [AI-31531] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI031531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BETHELL DR, 1982, AM J PHYSIOL, V243, P262; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOTTARO A, 1997, IGE REGULATION MOL M, P155; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COLLINS JT, 1993, INT IMMUNOL, V5, P885, DOI 10.1093/intimm/5.8.885; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KATAOKA T, 1981, CELL, V23, P357, DOI 10.1016/0092-8674(81)90131-8; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; LANSFORD R, 1996, MOL IMMUNOL, P1; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; MARCU KB, 1982, NATURE, V298, P87, DOI 10.1038/298087a0; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; McCutchen-Maloney SL, 1999, BIOCHEMISTRY-US, V38, P9417, DOI 10.1021/bi990591+; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MOWATT MR, 1986, J IMMUNOL, V136, P2674; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCAPPINO LA, 1991, GENE, V99, P295, DOI 10.1016/0378-1119(91)90142-X; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; STANTON LW, 1982, NUCLEIC ACIDS RES, V10, P5993, DOI 10.1093/nar/10.19.5993; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; Storb U, 1998, IMMUNOL REV, V162, P153; SZUREK P, 1985, J IMMUNOL, V135, P620; Tracy RB, 2000, EMBO J, V19, P1055, DOI 10.1093/emboj/19.5.1055; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; Zelazowski P, 1997, J IMMUNOL, V159, P2559; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	57	164	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24163	24172		10.1074/jbc.M003343200	http://dx.doi.org/10.1074/jbc.M003343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811812	hybrid			2022-12-25	WOS:000088564200102
J	Seshasayee, D; Geiger, JN; Gaines, P; Wojchowski, DM				Seshasayee, D; Geiger, JN; Gaines, P; Wojchowski, DM			Intron 1 elements promote erythroid-specific GATA-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LIGATION-MEDIATED PCR; ERYTHROPOIETIN RECEPTOR; GLOBIN GENE; CELL LINEAGES; STEM-CELLS; MOUSE; DIFFERENTIATION; UPSTREAM; MICE	The zinc finger protein GATA-1 functions in a concentration-dependent fashion to activate the transcription of erythroid and megakaryocytic genes. Less is understood, however, regarding factors that regulate the GATA-1 gene, Presently elements within intron 1 are shown to markedly affect its erythroid-restricted transcription. Within a full-length 6.8-kilobase GATA-1 gene construct (G6.8-Luc) the deletion of a central subdomain of intron 1 inhibited transcription greater than or equal to 10-fold in transiently transfected erythroid SKT6 cells, and likewise inhibited high-level transcription in erythroid FDCW2ER-GATA1 cells. In parental myeloid FDCER cells, however, low-level transcription was largely unaffected by intron I deletions. Within intron 1, repeated GATA and Apl consensus elements in a central region are described which when linked directly to reporter cassettes promote transcription in erythroid SKTG and FDCER-GATA1 cells at high rates. Moreover, GATA-1 activated transcription from this subdomain in 293 cells, and in SKT6 cells this subdomain footprinted in vivo. For stably integrated GFP reporter constructs in erythroid SKTG cells, corroborating results were obtained. Deletion of intronic GATA and Apl motifs abrogated the activity of G6.8 pEGFP; activity was decreased by 43 and 56%, respectively, by the deletion of either motif; and the above 1800-base pair region of intron 1 per se was transcribed at rates uniformly greater than G6.8-pEGFP. Also described is the differential utilization of exons la and Ib among primary erythromegakaryocytic and myeloid cells.	Penn State Univ, Genet Program, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Genet Program, 115 William L Henning Bldg, University Pk, PA 16802 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNET A, 1995, BLOOD, V86, P1202; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; IHLE JN, 1982, J IMMUNOL, V129, P1377; JACKSON CE, 1995, J BIOL CHEM, V270, P28448; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEONARD M, 1993, BLOOD, V82, P1071; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Malyankar UM, 1996, J CELL BIOCHEM, V60, P198, DOI 10.1002/(SICI)1097-4644(19960201)60:2<198::AID-JCB4>3.0.CO;2-S; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Miller CP, 1999, BLOOD, V94, P3381, DOI 10.1182/blood.V94.10.3381.422k25_3381_3387; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muro-Pastor MI, 1999, EMBO J, V18, P1584, DOI 10.1093/emboj/18.6.1584; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; QUELLE FW, 1991, J BIOL CHEM, V266, P609; Ronchi Antonella, 1997, Genes and Function, V1, P245; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SINGH L, 1994, NUCLEIC ACIDS RES, V22, P2289, DOI 10.1093/nar/22.12.2289; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Strauss EC, 1997, METHODS, V11, P164, DOI 10.1006/meth.1996.0402; Sutterluety H, 1998, NUCLEIC ACIDS RES, V26, P4989, DOI 10.1093/nar/26.21.4989; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22969	22977		10.1074/jbc.M002931200	http://dx.doi.org/10.1074/jbc.M002931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811657	hybrid			2022-12-25	WOS:000088419400051
J	Masutomi, K; Kaneko, S; Hayashi, N; Yamashita, T; Shirota, Y; Kobayashi, K; Murakami, S				Masutomi, K; Kaneko, S; Hayashi, N; Yamashita, T; Shirota, Y; Kobayashi, K; Murakami, S			Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT TETRAHYMENA TELOMERASE; CATALYTIC SUBUNIT; EUPLOTES AEDICULATUS; YEAST TELOMERASE; TUMOR-CELLS; IN-VITRO; PROTEIN; RIBONUCLEOPROTEIN; CANCER; IMMORTALIZATION	Telomerase is a specialized reverse transcriptase that catalyzes elongation of the telomeric tandem repeat, TTAGGG, by addition of this sequence to the ends of existing telomeres, Human telomerase reverse transcriptase (hTERT) has been identified as a catalytic enzyme involved in telomere elongation that requires telomerase RNA, human telomerase RNA component (hTR), as an RNA template. We established a new method to express and purify soluble insect-expressed recombinant hTERT, The partially purified FLAG-hTERT retained the catalytic activity of telomerase in a complementation assay in vitro to exhibit telomerase activity in telomerase-negative TIG3 cell extract and in a reconstitution assay with FLAG-hTERT and purified hTR in vitro. FLAG-hTERT (D712A) with a mutation in the VDV motif exhibited no telomerase activity, confirming the authentic catalytic activity of FLAG-hTERT. The reconstituted complex of FLAG-hTERT and hTR in vitro was detected by electrophoretic mobility shift assay, and its activity was stimulated by more than 30-fold by TIG3 cell extract, This suggested that some cellular component(s) in the extract facilitated the reconstituted telomerase activity in vitro. Geldanamycin had no effect on the reconstituted activity but partially reduced the stimulated activity of the reconstituted telomerase by the TIG3 cell extract, suggesting that Hsp90 may contribute to the stimulatory effect of the cellular components.	Kanazawa Univ, Canc Res Inst, Div Mol Oncol, Dept Mol Biol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Sch Med, Dept Internal Med 1, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Oncol, Dept Mol Biol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	semuraka@kenroku.kanazawa-u.ac.jp		Hayashi, Naoyuki/0000-0001-9626-3689; Shirota, Yukihiro/0000-0001-6561-4626				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P388; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Gilley D, 1999, P NATL ACAD SCI USA, V96, P6621, DOI 10.1073/pnas.96.12.6621; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; HANATANI M, 1984, J BIOCHEM-TOKYO, V95, P1349, DOI 10.1093/oxfordjournals.jbchem.a134742; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HILDRETH JEK, 1982, BIOCHEM J, V207, P363, DOI 10.1042/bj2070363; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; Lin Y, 1997, CANCER RES, V57, P5137; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OREILY D, 1992, BACULOVIRUS EXPRESSI; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Riou J F, 1998, Bull Cancer, V85, P115; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; Shay JW, 1996, LEUKEMIA, V10, P1255; Tatematsu K, 1996, ONCOGENE, V13, P2265; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wright WE, 1996, DEV GENET, V18, P173; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	45	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22568	22573		10.1074/jbc.M000622200	http://dx.doi.org/10.1074/jbc.M000622200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811633	Green Submitted, hybrid			2022-12-25	WOS:000088363800110
J	Zhang, JQ; Nicoll, G; Jones, C; Crocker, PR				Zhang, JQ; Nicoll, G; Jones, C; Crocker, PR			Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; SIALOADHESIN FAMILY; INHIBITORY RECEPTOR; MOLECULAR-CLONING; CD33; IDENTIFICATION; ANTIGEN; GLYCOPROTEIN; PROTEIN; CD22	Here we characterize the properties and expression pattern of Siglec-9 (sialic acid-binding Ig-like lectin-9), a new member of the Siglec subgroup of the immunoglobulin superfamily, A full-length cDNA encoding Siglec-9 was isolated from a dibutyryl cAMP-treated HL-60 cell cDNA library. Siglec-9 is predicted to contain three extracellular immunoglobulin-like domains that comprise an N-terminal V-set domain and two C2-set domains, a transmembrane region and a cytoplasmic tail containing two putative tyrosine-based signaling motifs, Overall, Siglec-9 is similar to 80% identical in amino acid sequence to Siglec-7, suggesting that the genes encoding these two proteins arose relatively recently by gene duplication. Binding assays showed that, similar to Siglec-7, Siglec-9 recognized sialic acid in either the alpha 2,3- or alpha 2,6-glycosidic linkage to galactose, Using a specific mAb, Siglec-9 was found to be expressed at high or intermediate levels by monocytes, neutrophils, and a minor population of CD16(+), CD56(-) cells. Weaker expression was observed on similar to 50%, of B cells and NK cells and minor subsets of CD8(+) T cells and CD4(+) T cells. These results show that despite their high degree of sequence similarity, Siglec-7 and Siglec-9 have distinct expression profiles.	Univ Dundee, MSI, Dept Biochem, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Crocker, PR (corresponding author), Univ Dundee, MSI, Dept Biochem, Wellcome Trust Bioctr, WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	p.r.crocker@dundee.ac.uk		Crocker, Paul/0000-0001-6230-0293				BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CROCKER PR, 1998, GLYCOBIOLOGY; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; KANTOR AB, 1997, WEIRS HDB EXPT IMMUN, V2; Karow J, 1996, BIOCHEM J, V318, P489, DOI 10.1042/bj3180489; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; LANIER LL, 1986, J IMMUNOL, V136, P4480; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; MCKENZIE RS, 1992, CANCER RES, V52, P6318; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; Schauer R, 1997, N COMP BIOC B, V29, P243; SIMMONS D, 1988, J IMMUNOL, V141, P2797; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Varki A, 1999, ESSENTIALS GLYCOBIOL, P195; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Yousef GM, 1999, ANTICANCER RES, V19, P2843	32	160	172	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22121	22126		10.1074/jbc.M002788200	http://dx.doi.org/10.1074/jbc.M002788200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801862	hybrid			2022-12-25	WOS:000088363800053
J	Mukhopadhyay, R; Shi, J; Rosen, BP				Mukhopadhyay, R; Shi, J; Rosen, BP			Purification and characterization of Acr2p, the Saccharomyces cerevisiae arsenate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE ENCODES; PROTEIN; GLUTATHIONE; YEAST; THIOREDOXIN; RESISTANCE; CLONING; MUTANT	In Saccharomyces cerevisiae, expression of the ACR2 and ACR3 genes confers arsenical resistance. Acr2p is the first identified eukaryotic arsenate reductase. It reduces arsenate to arsenite, which is then extruded from cells by Acr3p. In this study, we demonstrate that ACR2 complemented the arsenate-sensitive phenotype of an arsC deletion in Escherichia coli. ACR2 was cloned into a bacterial expression vector and expressed in E. coli as a C-terminally histidine-tagged protein that was purified by sequential metal chelate affinity and gel filtration chromatography. Acr2p purified as a homodimer of 34 kDa. The purified protein was shown to catalyze the reduction of arsenate to arsenite. Enzymatic activity as a function of arsenate concentration exhibited an apparent positive cooperativity with an apparent Hill coefficient of 2.7. Activity required GSH and glutaredoxin as the source of reducing equivalents. Thioredoxin was unable to support arsenate reduction. However, glutaredoxins from both S. cerevisiae and E. coli were able to serve as reductants. Analysis of grx mutants lacking one or both cysteine residues in the Cys-Pro-Tyr-Cys active site demonstrated that only the N-terminal cysteine residue is essential for arsenate reductase activity. This suggests that during the catalytic cycle, Acr2p forms a mixed disulfide with GSH before being reduced by glutaredoxin to regenerate the active Acr2p reductase.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; Bhattacharjee H, 1999, SYMP SOC GEN MICROBI, V58, P58; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; BUTTON DK, 1973, J BACTERIOL, V113, P599, DOI 10.1128/JB.113.2.599-611.1973; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; KURGANOV BI, 1988, ALLOSTERIC ENZYMES K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li L, 1999, FEBS LETT, V461, P1, DOI 10.1016/S0014-5793(99)01414-3; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Mukhopadhyay R, 1998, FEMS MICROBIOL LETT, V168, P127, DOI 10.1016/S0378-1097(98)00430-3; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Wysocki R, 1997, J BIOL CHEM, V272, P30061, DOI 10.1074/jbc.272.48.30061	34	171	175	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21149	21157		10.1074/jbc.M910401199	http://dx.doi.org/10.1074/jbc.M910401199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801893	hybrid			2022-12-25	WOS:000088230600027
J	Yakovlev, AG; Wang, GP; Stoica, BA; Boulares, HA; Spoonde, AY; Yoshihara, K; Smulson, ME				Yakovlev, AG; Wang, GP; Stoica, BA; Boulares, HA; Spoonde, AY; Yoshihara, K; Smulson, ME			A role of the Ca2+/Mg2+-dependent endonuclease in apoptosis and its inhibition by poly(ADP-ribose) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DIPHOSPHATE-RIBOSYLATION; CHROMATIN-BOUND ENDONUCLEASE; CASPASE-ACTIVATED DNASE; MG2+-DEPENDENT ENDONUCLEASE; CELL-DEATH; RAT THYMOCYTES; IN-VITRO; FRAGMENTATION; NUCLEASE; IDENTIFICATION	Apoptosis is characterized by various cell morphological and biochemical features, one of which is the internucleosomal degradation of genomic DNA. The role of the human chromatin-bound Ca2+- and Mg2+-dependent endonuclease (CME) DNAS1L3 and its inhibition by poly(ADP-ribosyl)ation in the DNA degradation that accompanies apoptosis was investigated. The nuclear localization of this endonuclease is the unique feature that distinguishes it from other suggested apoptotic nucleases. Purified recombinant DNAS1L3 was shown to cleave nuclear DNA into both high molecular weight and oligonucleosomal fragments in vitro. Furthermore, exposure of mouse skin fibroblasts expressing DNAS1L3 to inducers of apoptosis resulted in oligonucleosomal DNA fragmentation, an effect not observed in cells not expressing this CME, as well as in a decrease in cell viability greater than that apparent in the control cells. Recombinant DNAS1L3 was modified by recombinant human poly(ADP-ribose) polymerase (PARP) in vitro, resulting in a loss of nuclease activity. The DNAS1L3 protein also underwent poly(ADP-ribosyl)ation in transfected mouse skin fibroblasts in response to inducers of apoptosis. The cleavage and inactivation of PARP by a caspase-3-like enzyme late in apoptosis were associated with a decrease in the extent of DNAS1L3 poly(ADP-ribosyl)ation, which likely releases DNAS1L3 from inhibition and allows it to catalyze the degradation of genomic DNA.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Nara Med Univ, Dept Biochem, Kashihara, Nara 634, Japan	Georgetown University; Nara Medical University	Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Rm 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.		STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Spunde, Alexander/0000-0001-8805-9100	NCI NIH HHS [1PO1-CA74175, CA25344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Charriaut-Marlangue C, 1998, BIOMED PHARMACOTHER, V52, P264, DOI 10.1016/S0753-3322(98)80012-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1984, J IMMUNOL, V132, P38; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser MJ, 1996, J CELL SCI, V109, P2343; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; JONES DP, 1989, J BIOL CHEM, V264, P6398; KASID UN, 1989, J BIOL CHEM, V264, P18687; Khodarev NN, 1996, J IMMUNOL, V156, P922; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Liu QY, 1998, BIOCHEMISTRY-US, V37, P10134, DOI 10.1021/bi9800597; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MATSUBARA K, 1994, EXP CELL RES, V213, P412, DOI 10.1006/excr.1994.1217; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Mitamura S, 1998, BIOCHEM BIOPH RES CO, V243, P480, DOI 10.1006/bbrc.1998.8122; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; Rodriguez AM, 1997, GENOMICS, V42, P507, DOI 10.1006/geno.1997.4748; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Shiokawa D, 1997, BIOCHEM J, V326, P675, DOI 10.1042/bj3260675; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; Smulson ME, 1998, CANCER RES, V58, P3495; SOKOLOVA IA, 1995, BBA-MOL CELL RES, V1266, P135, DOI 10.1016/0167-4889(94)00233-5; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THRAVES PJ, 1985, CANCER RES, V45, P386; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; WATSON AJM, 1995, GASTROENTEROLOGY, V109, P472, DOI 10.1016/0016-5085(95)90335-6; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHIHAR.K, 1974, BIOCHEM BIOPH RES CO, V59, P658, DOI 10.1016/S0006-291X(74)80030-6; YOSHIHARA K, 1975, P NATL ACAD SCI USA, V72, P289, DOI 10.1073/pnas.72.1.289; YOSHIHARA K, 1975, J BIOCHEM-TOKYO, V77, pP10; Yoshihara K, 1997, BIOCHEM BIOPH RES CO, V236, P423, DOI 10.1006/bbrc.1997.6968; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778	57	115	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21302	21308		10.1074/jbc.M001087200	http://dx.doi.org/10.1074/jbc.M001087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10807908	hybrid			2022-12-25	WOS:000088230600047
J	Abbott, MB; Gaponenko, V; Abusamhadneh, E; Finley, N; Li, G; Dvoretsky, A; Rance, M; Solaro, RJ; Rosevear, PR				Abbott, MB; Gaponenko, V; Abusamhadneh, E; Finley, N; Li, G; Dvoretsky, A; Rance, M; Solaro, RJ; Rosevear, PR			Regulatory domain conformational exchange and linker region flexibility in cardiac troponin C bound to cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; N-TERMINAL DOMAIN; CENTRAL HELIX; ANGSTROM RESOLUTION; STRUCTURAL DETAILS; MUSCLE-CONTRACTION; NEUTRON-SCATTERING; BACKBONE DYNAMICS; SH3 DOMAIN; X-RAY	Previously, we utilized N-15 transverse relaxation rates to demonstrate significant mobility in the linker region and conformational exchange in the regulatory domain of Ca2+-saturated cardiac troponin C bound to the isolated N-domain of cardiac troponin I (Gaponenko, V,, Abusamhadneh, E., Abbott, M. B., Finley, N., Gasmi-Seabrook, G., Solaro, R.J., Rance, RI., and Rosevear, P.R. (1999) J. Biol. Chem. 274, 16681-16684). Here we show a large decrease in cardiac troponin C linker flexbility, corresponding to residues 85-93, when bound to intact cardiac troponin I. The addition of 2 M urea to the intact cardiac troponin I-troponin C complex significantly increased linker flexibility, Conformational changes in the regulatory domain of cardiac troponin C were monitored in complexes with troponin I-(1-211), troponin I-(33-211), troponin I-(1-80) and bisphosphorylated troponin I-(1-80), The cardiac specific N terminus, residues 1-32, and the C-domain, residues 81-211, of troponin I are both capable of inducing conformational changes in the troponin C regulatory domain. Phosphorylation of the cardiac specific N terminus reversed its effects on the regulatory domain. These studies provide the first evidence that the cardiac specific N terminus can modulate the function of troponin C by altering the conformational equilibrium of the regulatory domain.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rosevear, PR (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		Gaponenko, Vadim/K-9729-2019	Gaponenko, Vadim/0000-0002-7891-9223	NHLBI NIH HHS [HL63377] Funding Source: Medline; NIAMS NIH HHS [AR 44324] Funding Source: Medline; NIGMS NIH HHS [GM 40089] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040089] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott MB, 2000, FEBS LETT, V469, P168, DOI 10.1016/S0014-5793(00)01271-0; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Caflisch A, 1999, STRUCT FOLD DES, V7, P477, DOI 10.1016/S0969-2126(99)80064-1; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; DING XL, 1994, PROTEIN SCI, V3, P2089, DOI 10.1002/pro.5560031122; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; DOTSCH V, 1995, FEBS LETT, V366, P6, DOI 10.1016/0014-5793(95)00459-M; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; HERZBERG O, 1986, CIBA F SYMP, V122, P120; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HIBBARD LS, 1978, BIOCHEMISTRY-US, V17, P5460, DOI 10.1021/bi00618a021; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Konno T, 1997, PROTEIN SCI, V6, P2242; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MOIR AJG, 1980, BIOCHEM J, V185, P505, DOI 10.1042/bj1850505; Mok YK, 1999, J MOL BIOL, V289, P619, DOI 10.1006/jmbi.1999.2769; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Ramakrishnan S, 1995, BIOCHEMISTRY-US, V34, P16789, DOI 10.1021/bi00051a029; Ramakrishnan S, 1996, BIOCHEMISTRY-US, V35, P15515, DOI 10.1021/bi961788u; Rance M, 1999, J MAGN RESON, V136, P92, DOI 10.1006/jmre.1998.1626; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SHENG Z, 1991, J BIOL CHEM, V266, P5711; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WATTANAPERMPOOL J, 1995, AM J PHYSIOL-CELL PH, V268, pC323, DOI 10.1152/ajpcell.1995.268.2.C323; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	44	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20610	20617		10.1074/jbc.M909252199	http://dx.doi.org/10.1074/jbc.M909252199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801883	hybrid			2022-12-25	WOS:000088084500056
J	Cai, YC; Bullard, JM; Thompson, NL; Spremulli, LL				Cai, YC; Bullard, JM; Thompson, NL; Spremulli, LL			Interaction of mitochondrial elongation factor Tu with aminoacyl-tRNA and elongation factor Ts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; ESCHERICHIA-COLI; TERNARY COMPLEX; TRANSFER-RNA; GUANINE-NUCLEOTIDES; CRYSTAL-STRUCTURE; GTP; PURIFICATION	Elongation factor (EF) Tu promotes the binding of aminoacyl-tRNA (aa-tRNA) to the acceptor site of the ribosome, This process requires the formation of a ternary complex (EF-Tu.GTP.aa-tRNA). EF-Tu is released from the ribosome as an EF-Tu GDP complex. Exchange of GDP for GTP is carried out through the formation of a complex with EF-Ts (EF-Tu.Ts). Mammalian mitochondrial EF-Tu (EF-Tu(mt)) differs from the corresponding prokaryotic factors in having a much lower affinity for guanine nucleotides, To further understand the EF-Tu(mt) subcycle, the dissociation constants for the release of aa-tRNA from the ternary complex (K-tRNA) and for the dissociation of the EF-Tu.Ts-mt complex (K-Ts) were investigated. The equilibrium dissociation constant for the ternary complex was 18 +/- 4 nM, which is close to that observed in the prokaryotic system. The kinetic dissociation rate constant for the ternary complex was 7.3 x 10(-4) s(-1), which is essentially equivalent to that observed for the ternary complex in Escherichia coli. The binding of EF-Tu(mt) to EF-Ts-mt is mutually exclusive with the formation of the ternary complex, K-Ts was determined by quantifying the effects of increasing concentrations of EF-Ts-mt on the amount of ternary complex formed with EF-Tu(mt). The value obtained for K-Ts (5.5 +/- 1.3 nM) is comparable to the value K-tRNA.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, J MOL BIOL, V297, P421, DOI 10.1006/jmbi.2000.3564; ANTONSSON B, 1984, EUR J BIOCHEM, V141, P483, DOI 10.1111/j.1432-1033.1984.tb08218.x; ARAI KI, 1978, EUR J BIOCHEM, V92, P509, DOI 10.1111/j.1432-1033.1978.tb12773.x; BENKOWSKI L, 1995, NUCL ACIDS S SER, V33, P163; Blank J, 1996, EUR J BIOCHEM, V236, P222, DOI 10.1111/j.1432-1033.1996.00222.x; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; Bremer H, 1996, ESCHERICHIA COLI SAL; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; CANTATORE P, 1987, FEBS LETT, V213, P144, DOI 10.1016/0014-5793(87)81480-1; ELWELL ML, 1977, BIOCHIM BIOPHYS ACTA, V494, P367, DOI 10.1016/0005-2795(77)90166-0; FURANO AV, 1975, P NATL ACAD SCI USA, V72, P4780, DOI 10.1073/pnas.72.12.4780; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KING MP, 1993, J BIOL CHEM, V268, P10228; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LOUIE A, 1985, BIOCHEMISTRY-US, V24, P6433, DOI 10.1021/bi00344a019; LOUIE A, 1984, J BIOL CHEM, V259, P5010; McKee EE, 1999, BIOCHEM BIOPH RES CO, V257, P466, DOI 10.1006/bbrc.1999.0489; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PINGOUD A, 1977, EUR J BIOCHEM, V78, P403, DOI 10.1111/j.1432-1033.1977.tb11752.x; ROSENTHAL LP, 1987, J BIOL CHEM, V262, P10955; SCHWARTZBACH CJ, 1991, J BIOL CHEM, V266, P16324; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; Woriax VL, 1997, BBA-GENE STRUCT EXPR, V1352, P91, DOI 10.1016/S0167-4781(97)00002-X	32	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20308	20314		10.1074/jbc.M001899200	http://dx.doi.org/10.1074/jbc.M001899200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801827	Green Published, hybrid			2022-12-25	WOS:000088084500015
J	Trumbo, TA; Maurer, MC				Trumbo, TA; Maurer, MC			Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; PLASMA FACTOR-XIII; MYOCARDIAL-INFARCTION; BLOOD-COAGULATION; HUMAN-FIBRINOGEN; THROMBOLYTIC THERAPY; COMMON POLYMORPHISM; VENOUS THROMBOSIS	the blood coagulation cascade, thrombin cleaves fibrinopeptides A and B from fibrinogen revealing sites for fibrin polymerization that lead to insoluble clot formation. Factor XIII stabilizes this clot by catalyzing the formation of intermolecular cross-links in the fibrin network, Thrombin activates the Factor XIII a(2) dimer by cleaving the Factor XIII activation peptide segment at the Arg(37)-Gly(38) peptide bond. Using a high performance liquid chromatography assay, the kinetic constants K-m, k(cat), and k(cat)/K-m mere determined for thrombin hydrolysis of fibrinogen A alpha-(7-20), Factor XIII activation peptide-(28-41), and Factor XIII activation peptide-(28-41) with a Val(34) to Leu substitution. This Val to Leu mutation has been correlated with protection from myocardial infarction, In the absence of fibrin, the Factor XIII activation peptide-(28-41) exhibits a 10-fold lower k(cat)/K-m value than fibrinogen A alpha-(7-20). With the Factor XIII V34L mutation, decreases in K-m and increases in k(cat) produce a 6-fold increase in k(cat)/K-m relative to the wild-type Factor XIII sequence. A review of the x-ray crystal structures of known substrates and inhibitors of thrombin leads to a hypothesis that the new Leu generates a peptide with more extensive interactions with the surface of thrombin. As a result, the Factor XIII V34L is proposed to be susceptible to wasteful conversion of zymogen to activated enzyme. Premature depletion may provide cardioprotective effects.	Univ Louisville, Dept Chem, Louisville, KY 40292 USA	University of Louisville	Maurer, MC (corresponding author), Univ Louisville, Dept Chem, Louisville, KY 40292 USA.							Anwar R, 1999, BRIT J HAEMATOL, V107, P468, DOI 10.1046/j.1365-2141.1999.01648.x; Anwar R, 1999, BLOOD, V93, P897, DOI 10.1182/blood.V93.3.897.403k02_897_905; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Catto AJ, 1998, STROKE, V29, P813, DOI 10.1161/01.STR.29.4.813; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; FEAR JD, 1983, THROMB HAEMOSTASIS, V49, P102; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P676; GREENBERG CS, 1987, BLOOD, V69, P867; HALKIER T, 1991, MECH BLOOD COAGULATI, P3; HORNYAK TJ, 1992, BIOCHEMISTRY-US, V31, P423, DOI 10.1021/bi00117a017; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; Kangsadalampai S, 1998, BLOOD, V92, P2766, DOI 10.1182/blood.V92.8.2766.420k26_2766_2770; Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P862; Kohler HP, 1999, THROMB HAEMOSTASIS, V81, P511; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Kohler HP, 1999, QJM-INT J MED, V92, P67, DOI 10.1093/qjmed/92.2.67; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MARY A, 1988, BIOCHIM BIOPHYS ACTA, V966, P328, DOI 10.1016/0304-4165(88)90082-7; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Maurer MC, 1998, BIOCHEMISTRY-US, V37, P5888, DOI 10.1021/bi972538w; McCormack LJ, 1998, THROMB HAEMOSTASIS, V80, P523; Muszbek L, 1999, THROMB RES, V94, P271, DOI 10.1016/S0049-3848(99)00023-7; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NI F, 1995, J MOL BIOL, V252, P656, DOI 10.1006/jmbi.1995.0527; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1992, BIOCHEMISTRY-US, V31, P11551, DOI 10.1021/bi00161a037; ONUNDARSON PT, 1993, THROMB HAEMOSTASIS, V70, P998; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SCHERAGA HA, 1983, ANN NY ACAD SCI, V408, P330, DOI 10.1111/j.1749-6632.1983.tb23255.x; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; WINZOR DJ, 1964, ARCH BIOCHEM BIOPHYS, V104, P202, DOI 10.1016/S0003-9861(64)80004-7; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	53	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20627	20631		10.1074/jbc.M000209200	http://dx.doi.org/10.1074/jbc.M000209200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801785	hybrid			2022-12-25	WOS:000088084500058
J	Emanuelli, B; Peraldi, P; Filloux, C; Sawka-Verhelle, D; Hilton, D; Van Obberghen, E				Emanuelli, B; Peraldi, P; Filloux, C; Sawka-Verhelle, D; Hilton, D; Van Obberghen, E			SOCS-3 is an insulin-induced negative regulator of insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TRANSCRIPTION FACTOR; 3T3-L1 ADIPOCYTES; TYROSINE KINASE; 2-HYBRID SYSTEM; BOX MOTIF; CYTOKINE; PROTEINS; EXPRESSION; INHIBITION	The SOCS proteins are induced by several cytokines and are involved in negative feedback loops. Here we demonstrate that in 3T3-L1 adipocytes, insulin, a hormone whose receptor does not belong to the cytokine receptor family, induces SOCS-3 expression but not CIS or SOCS-2, Using transfection of COS-7 cells, we show that insulin induction of SOCS-3 is enhanced upon Stat5B expression. Moreover, Stat5B from insulin-stimulated cells binds directly to a Stat element present in the SOCS-3 promoter. Once induced, SOCS-3 inhibits insulin activation of Stat5B without modifying the insulin receptor tyrosine kinase activity. Two pieces of evidence suggest that this negative regulation likely results from competition between SOCS-3 and Stat5B binding to the same insulin receptor motif. First, using a yeast two-hybrid system, we show that SOCS-3 binds to the insulin receptor at phosphotyrosine 960, which is precisely where Stat5B binds. Second, using confocal microscopy, we show that insulin induces translocation of SOCS-3 from an intracellular compartment to the cell membrane, leading to colocalization of SOCS-3 with the insulin receptor. This colocalization is dependent upon phosphorylation of insulin receptor tyrosine 960, Indeed, in cells expressing an insulin receptor mutant ill which tyrosine 960 has been mutated to phenylalanine, insulin does not modify the cellular localization of SOCS-3. We have thus revealed an insulin target gene of which the expression is potentiated upon Stat5B activation. By inhibiting insulin-stimulated Stat5B, SOCS-3 appears to function as a negative regulator of insulin signaling.	Fac Med Nice, INSERM, U145, F-06107 Nice 2, France; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factor, Parkville, Vic 3050, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Walter & Eliza Hall Institute	Peraldi, P (corresponding author), Fac Med Nice, INSERM, U145, IFR-50, F-06107 Nice 2, France.	peraldi@unice.fr	Emanuelli, Brice/M-2097-2016; Peraldi, Pascal/O-4592-2016; Hilton, Douglas J/C-7250-2013	Emanuelli, Brice/0000-0001-5795-5666; Peraldi, Pascal/0000-0003-0205-9252; Hilton, Douglas J/0000-0002-7698-2392				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CARVALHEIRA JBC, 1999, DIABETES; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Coffer PJ, 1997, ONCOGENE, V15, P2529, DOI 10.1038/sj.onc.1201429; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 1999, EMBO J, V18, P904; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORGETTI-PERALDI S, 1995, EUR J BIOCHEM, V234, P656, DOI 10.1111/j.1432-1033.1995.656_b.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LUGER A, 1990, EXP CLIN ENDOCRINOL, V95, P339, DOI 10.1055/s-0029-1210974; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	54	364	389	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15985	15991		10.1074/jbc.275.21.15985	http://dx.doi.org/10.1074/jbc.275.21.15985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821852	hybrid			2022-12-25	WOS:000087291400052
J	Basrur, V; Song, YS; Mazur, SJ; Higashimoto, Y; Turpin, JA; Rice, WG; Inman, JK; Appella, E				Basrur, V; Song, YS; Mazur, SJ; Higashimoto, Y; Turpin, JA; Rice, WG; Inman, JK; Appella, E			Inactivation of HIV-1 nucleocapsid protein P7 by pyridinioalkanoyl thioesters - Characterization of reaction products and proposed mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZINC FINGERS; TYPE-1; RESISTANCE; INHIBITORS; INFECTIVITY; REPLICATION; ZIDOVUDINE; MUTATIONS; PEPTIDES	The synthesis and antiviral properties of pyridinioalkanoyl thioester (PATE) compounds that target nucleocapsid p7 protein (NCp7) of the human immunodeficiency virus type 1 (HIV-1) have been described previously (Turpin, J. A., Song, Y., Inman, J. K., Huang, M., Wallqvist, k, Maynard, A., Covell, D. G,, Rice, W, G., and Appella, E. (1999) J. Med. Chem, 42, 67-86), In the present study, fluorescence and electrospray ionization-mass spectrometry were employed to determine the mechanism of modification of NCp7 by two lead compounds, N-[2-(5-pyridiniovaleroylthio)benzoyl] sulfacetamide bromide and N-12-(5-pyridiniovaleroylthio)benzoyll-4-(4-nitrophenylsulfonyl) aniline bromide (compounds 45 and 47, respectively). Although both compounds exhibit antiviral activity in cell-based assays, we failed to detect appreciable ejection of zinc from NCp7 under conditions in which previously described NCp7-active disulfides readily eject zinc. However, upon "activation" by Ag+, compound 45 reacted with NCp7 resulting in the zinc ejection from both zinc fingers. The reaction followed a two-step mechanism in which zinc was ejected from the carboxyl-terminal zinc finger faster than from the amino-terminal zinc finger. Both compounds covalently modified the protein with pyridinioalkanoyl groups. Compound 45 modified cysteines 36 and 49 of the carboxyl-terminal zinc finger. The results obtained herein demonstrate that FATE compounds can be constructed that selectively target only one of the two zinc fingers of NCp7, thus providing an impetus to pursue development of highly selective zinc finger inhibitors.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Serquest, Antiviral Res Lab, Frederick, MD 21702 USA; Achill Pharmaceut, Frederick, MD 21701 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Appella, E (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.			Higashimoto, Yuichiro/0000-0003-1382-8598	NATIONAL CANCER INSTITUTE [Z01BC009101, ZIABC009101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000786] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BLAKE J, 1981, INT J PEPT PROT RES, V17, P273; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; Chertova EN, 1998, BIOCHEMISTRY-US, V37, P17890, DOI 10.1021/bi980907y; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; EMINI EA, 1994, ARCH VIROL, P11; Hathout Y, 1996, DRUG METAB DISPOS, V24, P1395; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KRAUSSLICH HG, 1995, J VIROL, V69, P3407; Lee BM, 1998, J MOL BIOL, V279, P633, DOI 10.1006/jmbi.1998.1766; Loo JA, 1996, J MED CHEM, V39, P4313, DOI 10.1021/jm960253w; Maynard AT, 1998, P NATL ACAD SCI USA, V95, P11578, DOI 10.1073/pnas.95.20.11578; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; Rice WG, 1997, ANTIMICROB AGENTS CH, V41, P419, DOI 10.1128/AAC.41.2.419; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Sakamoto H, 1996, INT J PEPT PROT RES, V48, P429; Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969; Turpin JA, 1999, J MED CHEM, V42, P67, DOI 10.1021/jm9802517	24	29	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14890	14897		10.1074/jbc.275.20.14890	http://dx.doi.org/10.1074/jbc.275.20.14890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809733	hybrid			2022-12-25	WOS:000087128300018
J	Hunke, S; Mourez, M; Jehanno, M; Dassa, E; Schneider, E				Hunke, S; Mourez, M; Jehanno, M; Dassa, E; Schneider, E			ATP modulates subunit-subunit interactions in an ATP-binding cassette transporter (MalFGK(2)) determined by site-directed chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MEMBRANE-PROTEIN FHUB; ESCHERICHIA-COLI; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; ABC TRANSPORTER; HYDROXAMATE TRANSPORT; MALK SUBUNIT; SYSTEM; GENE	The binding protein-dependent maltose transport system of enterobacteria (MalFGK(2)), a member of the ATP-binding cassette (ABC) transporter superfamily, is composed of two integral membrane proteins, MalF and MalG, and of two copies of an ATPase subunit, MalK, which hydrolyze ATP, thus energizing the translocation process. In addition, an extracellular (periplasmic) substrate-binding protein (MalE) is required for activity. Ligand translocation and ATP hydrolysis are dependent on a signaling mechanism originating from the binding protein and traveling through MalF/MalG, Thus, subunit-subunit interactions in the complex are crucial to the transport process but the chemical nature of residues involved is poorly understood. We have investigated the proximity of residues in a conserved sequence ("EAA" loop) of MalF and MalG to residues in a helical segment of the MalK subunits by means of site-directed chemical cross-linking. To this end, single cysteine residues were introduced into each subunit at several positions and the respective malF and malG alleles were individually co-expressed with each of the malK alleles. Membrane vesicles were prepared from those double mutants that contained a functional transporter in vivo and treated with Cu(1,10-phenanthroline)(2)SO4 or bifunctional cross-linkers. The results suggest that residues Ala-85, Lys-106, Val-114, and Val-117 in the helical segment of MalK, to different extents, participate in constitution of asymmetric interaction sites with the EAA loops of MalF and MalG. Furthermore, both MalK monomers in the complex are in close contact to each other through Ala-85 and Lys-106. These interactions are strongly modulated by MgATP, indicating a structural rearrangement of the subunits during the transport cycle. These data are discussed with respect to current transport models.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Inst Pasteur, CNRS, Unite Programmat Mol & Toxicol Genet, URA 1444, F-75645 Paris 15, France	Humboldt University of Berlin; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.		Hunke, Sabine/B-7169-2011					Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; BAKKER EP, 1981, J BACTERIOL, V147, P820, DOI 10.1128/JB.147.3.820-826.1981; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; DAHL MK, 1989, MOL GEN GENET, V218, P199, DOI 10.1007/BF00331269; DASSA E, 1993, MOL MICROBIOL, V7, P39, DOI 10.1111/j.1365-2958.1993.tb01095.x; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DASSA E, 1990, MOL GEN GENET, V222, P32; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Gruis DB, 1997, BIOCHEMISTRY-US, V36, P7739, DOI 10.1021/bi9701585; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Hunke S, 2000, J BACTERIOL, V182, P1432, DOI 10.1128/JB.182.5.1432-1436.2000; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; KOSTER W, 1992, MOL GEN GENET, V232, P399; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; Mademidis A, 1997, MOL MICROBIOL, V26, P1109, DOI 10.1046/j.1365-2958.1997.6592008.x; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Miller J.H., 1972, EXPT MOL GENETICS; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Sambrook J., 2002, MOL CLONING LAB MANU; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SCHNEIDER E, 1995, J BACTERIOL, V177, P5364, DOI 10.1128/jb.177.18.5364-5367.1995; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; SON J, 1998, BIOCHEMISTRY-US, V37, P8020; WALTER C, 1992, J BIOL CHEM, V267, P8863; WEBB DC, 1992, J BIOL CHEM, V267, P24661; WILKEN S, 1996, MOL MICROBIOL, V22, P555; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099	42	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15526	15534		10.1074/jbc.275.20.15526	http://dx.doi.org/10.1074/jbc.275.20.15526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809785	hybrid			2022-12-25	WOS:000087128300101
J	Merali, S; Vargas, D; Franklin, M; Clarkson, AB				Merali, S; Vargas, D; Franklin, M; Clarkson, AB			S-adenosylmethionine and Pneumocystis carinii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DL-ALPHA-DIFLUOROMETHYLORNITHINE; L-METHIONINE SYNTHETASE; RAT MODEL; SACCHAROMYCES-CEREVISIAE; ORNITHINE DECARBOXYLASE; CONTINUOUS-INFUSION; TRYPANOSOMA-BRUCEI; PNEUMONIA; TRANSPORT; DEFEROXAMINE	We previously reported that S-adenosylmethionine (AdoMet), a key molecule in methylation reactions and polyamine biosynthesis, enhances axenic culture of the AIDS-associated opportunistic fungal pathogen Pneumocystis carinii. Here we report that AdoMet is absolutely required for continuous growth. Two transporters are present, one high affinity, K-m = 4.5 mu M, and one low affinity, K-m = 333 mu M. The physiologically relevant high affinity transporter has a pH optimum of 7.5 and no related natural compounds compete for uptake. Transport is 98% inhibited at 4 degrees C, 24% inhibited by 20 mM sodium azide, and 95% inhibited by the combination of 20 mM sodium azide and 1 mM salicylhydroxamic acid; thus transport is active and dependent on both a cytochrome chain and an alternative oxidase. In vitro, AdoMet is used at a rate of 1.40 x 10(7) molecules cell(-1) min(-1). AdoMet synthetase activity was not detected by a sensitive radiolabel incorporation assay capable of detecting 0.1% of the activity in rat liver. In addition, the AdoMet plasma concentration of rats is inversely correlated with the number of P. carinii in the lungs. These findings demonstrate that P, carinii is an AdoMet auxotroph, The uptake and metabolism of this compound are rational chemotherapeutic targets.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	New York University	Merali, S (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041947, R01AI043757] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43757, R01 AI41947] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Azoulay E, 1999, AM J RESP CRIT CARE, V160, P493, DOI 10.1164/ajrccm.160.2.9901019; BALDESSARINI RJ, 1966, J NEUROCHEM, V13, P769, DOI 10.1111/j.1471-4159.1966.tb09884.x; Bontemps F, 1997, BIOCHEM J, V327, P383, DOI 10.1042/bj3270383; BRAWLEY JV, 1980, J BACTERIOL, V142, P608, DOI 10.1128/JB.142.2.608-614.1980; CHEREST H, 1978, MOL GEN GENET, V163, P153, DOI 10.1007/BF00267406; Chin K, 1996, ANTIMICROB AGENTS CH, V40, P2318, DOI 10.1128/AAC.40.10.2318; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; DUCE AM, 1988, HEPATOLOGY, V8, P65, DOI 10.1002/hep.1840080113; Goldberg B, 1997, FASEB J, V11, P256, DOI 10.1096/fasebj.11.4.9068614; Goldberg B, 1998, BIOCHEM PHARMACOL, V56, P95, DOI 10.1016/S0006-2952(98)00118-X; Le Quesne S A, 1998, Methods Mol Biol, V79, P149; MCINTOSH L, 1994, PLANT PHYSIOL, V105, P781, DOI 10.1104/pp.105.3.781; Merali S, 1999, P NATL ACAD SCI USA, V96, P2402, DOI 10.1073/pnas.96.5.2402; Merali S, 1999, J BIOL CHEM, V274, P21017, DOI 10.1074/jbc.274.30.21017; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; MERALI S, 1995, ANTIMICROB AGENTS CH, V39, P2023, DOI 10.1128/AAC.39.9.2023; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; MERALI S, 1995, ANTIMICROB AGENTS CH, V39, P1442, DOI 10.1128/AAC.39.7.1442; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; Newman EB, 1998, J BACTERIOL, V180, P3614, DOI 10.1128/JB.180.14.3614-3619.1998; PARKS LW, 1957, J BIOL CHEM, V230, P295; PISI E, 1990, DRUGS, V40, P65, DOI 10.2165/00003495-199000403-00007; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; SARIC M, 1994, ANTIMICROB AGENTS CH, V38, P2545, DOI 10.1128/AAC.38.11.2545; SLOAND E, 1993, J EUKARYOT MICROBIOL, V40, P188, DOI 10.1111/j.1550-7408.1993.tb04902.x; Wilkin A, 1999, AM FAM PHYSICIAN, V60, P1713; Wilkin A, 1999, AM FAM PHYSICIAN, V60, P1699; YARLETT N, 1993, BIOCHIM BIOPHYS ACTA, V1181, P68, DOI 10.1016/0925-4439(93)90092-F	29	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14958	14963		10.1074/jbc.275.20.14958	http://dx.doi.org/10.1074/jbc.275.20.14958			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809741	hybrid			2022-12-25	WOS:000087128300027
J	Fognani, C; Rondi, R; Romano, A; Blasi, F				Fognani, C; Rondi, R; Romano, A; Blasi, F			cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain	ONCOGENE			English	Article						MAP kinase; protein-protein interaction; Rel; NF-kappa B transcription factor; signal transduction; transcriptional regulation	NF-KAPPA-B; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-KINASE; V-REL; TRANSCRIPTIONAL ACTIVITY; P65 SUBUNIT; DNA-BINDING; IN-VIVO; ACTIVATION	The activity of transcription factors is often modulated by signal responsive protein kinases, Rel/NF-kappa B transcription factors are regulated by I kappa B inhibitors, the phospharylation of which causes ubiquitination and degradation, resulting in nuclear translocation of NF-kappa B and activation of target genes. Here we report pull-down and immunoprecipitation experiments showing that a mammalian 66 kDa protein kinase binds murine c-Rel, both in vitro and in vitro. This kinase appears to hare at least two binding sites on c-Rel, a proline-directed serine/ threonine substrate specificity similar to MAP kinases and to specifically phosphorylate the C-terminal domain of murine c-Rel at an ERI: consensus site.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, I-20132 Milan, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS European Institute of Oncology (IEO)	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Mol Genet Unit, Via Olgettina 58, I-20132 Milan, Italy.			Blasi, Francesco/0000-0001-9406-1784				Abe MK, 1999, MOL CELL BIOL, V19, P1301; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	48	15	15	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2224	2232		10.1038/sj.onc.1203543	http://dx.doi.org/10.1038/sj.onc.1203543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822372				2022-12-25	WOS:000086974100007
J	Fang, P; Wang, Z; Sachs, MS				Fang, P; Wang, Z; Sachs, MS			Evolutionarily conserved features of the arginine attenuator peptide provide the necessary requirements for its function in translational regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; S-ADENOSYLMETHIONINE DECARBOXYLASE; CARBAMOYL-PHOSPHATE SYNTHETASE; AMINO-ACID AVAILABILITY; IN-VITRO TRANSLATION; NEUROSPORA-CRASSA; MESSENGER-RNA; LEADER PEPTIDE; GENE; EXPRESSION	Neurospora crassa arg-2 mRNA contains an evolutionarily conserved upstream open reading frame (uORF) encoding the Arg attenuator peptide (AAP) that confers negative translational regulation in response to Arg. We examined the regulatory role of the AAP and the RNA encoding it using an N. crassa cell-free translation system. AAPs encoded by uORFs in four fungal mRNAs each conferred negative regulation in response to Arg by causing ribosome stalling at the uORF termination codon. Deleting the AAP non-conserved N terminus did not impair regulation, but deletions extending into the conserved region eliminated it. Introducing many silent mutations into a functional AAP coding region did not eliminate regulation, but a single additional nucleotide change altering the conserved AAP sequence abolished regulation. Therefore, the conserved peptide sequence, but not the mRNA sequence, appeared responsible for regulation. AAP extension at its C terminus resulted in Arg-mediated ribosomal stalling during translational elongation within the extended region and during termination. Comparison of Arg-mediated stalling at a rare or common codon revealed more stalling at the rare codon, These data indicate that the highly evolutionarily conserved peptide core functions within the ribosome to cause stalling; translational events at a potential stall site can influence the extent of stalling there.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Sachs, MS (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.			Sachs, Matthew/0000-0001-9891-9223	NIGMS NIH HHS [GM47498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047498, R01GM047498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderete JP, 1999, J VIROL, V73, P8330, DOI 10.1128/JVI.73.10.8330-8337.1999; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Baek JM, 1998, FUNGAL GENET BIOL, V23, P34, DOI 10.1006/fgbi.1997.1025; Chiba Y, 1999, SCIENCE, V286, P1371, DOI 10.1126/science.286.5443.1371; CHRISTOFFELS VM, 1995, J BIOL CHEM, V270, P24932, DOI 10.1074/jbc.270.42.24932; CROMBIE T, 1992, J MOL BIOL, V228, P7, DOI 10.1016/0022-2836(92)90486-4; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; Freitag M, 1996, GENETICS, V142, P117; GEBALLE AP, 2000, TRANSLATIONAL CONTRO; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; HILL JR, 1993, J BIOL CHEM, V269, P726; Komar AA, 1999, FEBS LETT, V462, P387, DOI 10.1016/S0014-5793(99)01566-5; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Shen WC, 1997, FUNGAL GENET BIOL, V21, P40, DOI 10.1006/fgbi.1997.0958; Tsalkova T, 1999, J MOL BIOL, V286, P71, DOI 10.1006/jmbi.1998.2481; Wang Z, 1997, J BIOL CHEM, V272, P255; Wang Z, 1998, MOL CELL BIOL, V18, P7528, DOI 10.1128/MCB.18.12.7528; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; Wang Z, 1999, J BIOL CHEM, V274, P37565, DOI 10.1074/jbc.274.53.37565; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WERNER M, 1990, POST TRANSCRIPTION H, V49, P337; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000; Yarus M, 1998, J MOL EVOL, V47, P109, DOI 10.1007/PL00006357	39	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26710	26719						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10818103				2022-12-25	WOS:000089144800008
J	Evans, DB; Rank, KB; Bhattacharya, K; Thomsen, DR; Gurney, ME; Sharma, SK				Evans, DB; Rank, KB; Bhattacharya, K; Thomsen, DR; Gurney, ME; Sharma, SK			Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; CYCLIN-DEPENDENT KINASE-5; NEURONAL CDK5 ACTIVATOR; ALZHEIMERS-DISEASE BRAIN; NEUROFIBRILLARY DEGENERATION; CDC2-LIKE KINASE; BOVINE BRAIN; BINDING; SITES; IDENTIFICATION	In Alzheimer's disease, hyperphosphorylated tau is an integral part of the neurofibrillary tangles that form within neuronal cell bodies and fails to promote microtubule assembly, Dysregulation of the brain-specific tau protein kinase II is reported to play an important role in the pathogenesis of Alzheimer's disease (Patrick, G. N., Zukerberg, L., Nikolic, M., De La Monte, S., Dikkes, P., and Tsai, L.-H, (1999) Nature 402, 615-622), We report here that in vitro phosphorylation of human tau by human recombinant tau protein kinase II severely inhibits the ability of tau to promote microtubule assembly as monitored by tubulin polymerization. The ultrastructure of tau-mediated polymerized tubulin was visualized by electron microscopy and compared with phosphorylated tau, Consistent with the observed slower kinetics of tubulin polymerization, phosphorylated tau is compromised in its ability to generate microtubules. Moreover, me show that phosphorylation of microtubule-associated tau results in tau's dissociation from the microtubules and tubulin depolymerization, Mutational studies with human tau indicate that phosphorylation by tau protein kinase II at serine 396 and serine 404 is primarily responsible for the functional loss of tau-mediated tubulin polymerization. These in vitro results suggest a possible role for tau protein kinase II-mediated tau phosphorylation in initiating the destabilization of microtubules.	Pharmacia Corp, Prot Sci, Kalamazoo, MI 49007 USA	Pfizer	Sharma, SK (corresponding author), Pharmacia Corp, Prot Sci, 7240-267-117, Kalamazoo, MI 49007 USA.	satish.k.sharma@am.pnu.com						Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BONDAREFF W, 1990, AM J PATHOL, V137, P711; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Desai A, 1998, BIOESSAYS, V20, P523, DOI 10.1002/(SICI)1521-1878(199807)20:7<523::AID-BIES1>3.0.CO;2-L; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FAN NS, 1995, J BIOL CHEM, V270, P13573; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HOSOI T, 1995, J BIOCHEM, V117, P741, DOI 10.1093/oxfordjournals.jbchem.a124771; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOSIK KS, 1991, TRENDS NEUROSCI, V14, P218, DOI 10.1016/0166-2236(91)90116-C; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LU Q, 1993, J NEUROSCI, V13, P508; Mailliot C, 1998, FEBS LETT, V433, P201, DOI 10.1016/S0014-5793(98)00910-7; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Michel G, 1998, BBA-GEN SUBJECTS, V1380, P177, DOI 10.1016/S0304-4165(97)00139-6; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Probst A, 1996, ACTA NEUROPATHOL, V92, P588, DOI 10.1007/s004010050565; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Roloff EV, 1999, CELL MOL LIFE SCI, V55, P601, DOI 10.1007/s000180050318; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tolnay M, 1997, ACTA NEUROPATHOL, V93, P477, DOI 10.1007/s004010050642; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vincent I, 1997, J NEUROSCI, V17, P3588; Wagner U, 1996, J CELL SCI, V109, P1537; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	58	108	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24977	24983		10.1074/jbc.M000808200	http://dx.doi.org/10.1074/jbc.M000808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10818091	hybrid			2022-12-25	WOS:000088683300099
J	Terada, K; Mori, M				Terada, K; Mori, M			Human DnaJ homologs dj2 and dj3, and bag-1 are positive cochaperones of hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONES; MAMMALIAN-CELLS; IMPORT; HSP70; EXPRESSION; CLONING; CYCLE; LOCALIZATION; BINDING	DnaJ is an essential cochaperone of mammalian heat shock cognate 70 (hsc70) protein. We previously found that dj2 (HSDJ/hdj-2/rdj1), rather than dj1 (hsp40/hdj-1), is a partner DnaJ for the hsc70-based chaperone system. Here, we compared the distribution of dj1, dj2, and the newly found dj3 (cpr3/DNJ3/HIRIP4/rdj2) in cultured cells. Both dj3 as well as dj2 were farnesylated and were ubiquitously expressed. In immunocytochemical and subfractionation studies, these two proteins colocalized with hsc70 under normal conditions, However, dj1 and hsc70 apparently colocalized in the nucleoli after heat shock. Simultaneous depletion of dj2 and dj3 from rabbit reticulocyte lysate markedly reduced mitochondrial import of pre-ornithine transcarbamylase and refolding of guanidine-denatured luciferase. Re-addition of either dj2 or dj3 led to recovery of these reactions. In a reconstituted system, both hsc70-dj2 and hsc70-dj3 were effective in protein refolding. Anti-apoptotic protein bag-1 further stimulated ATP hydrolysis and protein refolding by both pairs. Thus, dj2 and dj3 are the partner DnaJs of hsc70 within the cell, functionally similar and much more efficient than dj1, and bag-1 is a positive cochapcrone of the hsc70-dj2 and hsc70-dj3 systems.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan	Kumamoto University	Terada, K (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Genet, Honjo 2-2-1, Kumamoto 8600811, Japan.							Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Davis AR, 1998, INT J BIOCHEM CELL B, V30, P1203, DOI 10.1016/S1357-2725(98)00091-0; Edwards MC, 1997, GENETICS, V147, P1063; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; HATTORI H, 1993, J CELL SCI, V104, P629; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Muramatsu M, 1978, Methods Cell Biol, V17, P141, DOI 10.1016/S0091-679X(08)61142-5; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Royaux I, 1998, GENOMICS, V53, P415, DOI 10.1006/geno.1998.5501; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; Terada K, 1996, MOL CELL BIOL, V16, P6103; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; WADELIN C, 1953, ANAL CHEM, V25, P1668, DOI 10.1021/ac60083a026; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	35	109	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24728	24734		10.1074/jbc.M002021200	http://dx.doi.org/10.1074/jbc.M002021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10816573	hybrid			2022-12-25	WOS:000088683300068
J	Ansaldi, R; Chaboud, A; Dumas, C				Ansaldi, R; Chaboud, A; Dumas, C			Multiple S gene family members including natural antisense transcripts are differentially expressed during development of maize flowers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; RECEPTOR KINASE GENE; SELF-INCOMPATIBILITY RESPONSE; LOCUS-RELATED GENES; ZEA-MAYS-L; MESSENGER-RNA; PROTEIN-KINASE; C-ELEGANS; ARABIDOPSIS-THALIANA; PLANT-REGENERATION	Within the large Brassica S gene family, SLG (S locus glycoprotein) and SRK (S locus receptor kinase) participate to the control of pollen-stigma self-incompatibility, In the self-compatible species maize, S gene family members are predominantly expressed in vegetative organs but are also expressed to a lesser extent in the stigma (silk), To determine if the expression of any S gene family members correlates with female receptivity, we analyzed their expression in developing maize silks, We show that a large family of maize S transcripts is expressed in developing silks. Surprisingly, we isolated a cDNA complementary to a large portion of the antisense strand of the maize receptor kinase S domain. Rapid amplification of cDNA ends (RACE)-polymerase chain reaction, RNase protection, and Northern hybridization with single-stranded riboprobes confirmed that natural antisense S transcripts exist in leaves and seedling shoots and in all sexual tissues tested except mature pollen. These natural antisense S transcripts co-exist with several less abundant sense S transcripts. The accumulation of sense and antisense S transcripts is differentially regulated during pollen and silk development. Thus, these results support a role for S gene family members in sexual tissue development and/or compatible pollination and reveal a new level of complexity in the regulation and function of the S gene family in maize.	Ecole Normale Super Lyon, UCBLyon 1, INRA, CNRS,UMR 5667, F-69634 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)	Chaboud, A (corresponding author), Ecole Normale Super Lyon, UCBLyon 1, INRA, CNRS,UMR 5667, 46 Allee Italie, F-69634 Lyon 07, France.	Annie.Chaboud@ens-lyon.fr						ALEXANDER MP, 1969, STAIN TECHNOL, V44, P117, DOI 10.3109/10520296909063335; ATKINS D, 1994, BIOL CHEM H-S, V375, P721; BARLOY D, 1989, MAYDICA, V34, P303; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bisseling T, 1999, CURR OPIN PLANT BIOL, V2, P365, DOI 10.1016/S1369-5266(99)00006-0; BOYES DC, 1995, PLANT CELL, V7, P1283, DOI 10.1105/tpc.7.8.1283; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; CELANO P, 1992, J BIOL CHEM, V267, P15092; Charon C, 1999, PLANT CELL, V11, P1953, DOI 10.1105/tpc.11.10.1953; Cock JM, 1997, MOL GEN GENET, V255, P514, DOI 10.1007/s004380050524; COCK JM, 1995, MOL GEN GENET, V248, P151, DOI 10.1007/BF02190796; Cock JM, 2000, ADV BOT RES, V32, P269, DOI 10.1016/S0065-2296(00)32027-4; Conner JA, 1997, PLANT J, V11, P809, DOI 10.1046/j.1365-313X.1997.11040809.x; Counihan VP, 1995, METHOD CELL BIOL, V49, P515, DOI 10.1016/S0091-679X(08)61477-6; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DIEU P, 1986, MAYDICA, V31, P245; DOLFINI S, 1993, MOL GEN GENET, V241, P161, DOI 10.1007/BF00280213; Dubreuil P, 1996, CROP SCI, V36, P790, DOI 10.2135/cropsci1996.0011183X003600030043x; DUMAS C, 1993, PLANT CELL, V5, P1337, DOI 10.1105/tpc.5.10.1337; DUPUIS I, 1990, PLANT SCI, V70, P11, DOI 10.1016/0168-9452(90)90026-K; DWYER KG, 1989, GENOME, V31, P969, DOI 10.1139/g89-169; DWYER KG, 1992, MOL GEN GENET, V231, P442, DOI 10.1007/BF00292714; DWYER KG, 1994, PLANT CELL, V6, P1829, DOI 10.1105/tpc.6.12.1829; FARRELL CM, 1995, J BIOL CHEM, V270, P3400, DOI 10.1074/jbc.270.7.3400; Gagliardi D, 1995, PLANT MOL BIOL, V29, P841, DOI 10.1007/BF00041173; GAILLARD A, 1991, PLANT CELL REP, V10, P55, DOI 10.1007/BF00236456; GURR SJ, 1991, PCR PRACTICAL APPROA, P147; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Joanin P, 1997, PLANT MOL BIOL, V33, P23, DOI 10.1023/A:1005790129668; Jorgensen RA, 1999, TRENDS GENET, V15, P11, DOI 10.1016/S0168-9525(98)01651-5; KERHOAS C, 1987, PLANTA, V171, P1, DOI 10.1007/BF00395062; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; Kowyama Y, 1996, PLANT CELL PHYSIOL, V37, P681, DOI 10.1093/oxfordjournals.pcp.a028998; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li AW, 1996, BIOCHEM BIOPH RES CO, V223, P19, DOI 10.1006/bbrc.1996.0839; Li AW, 1996, MOL CELL ENDOCRINOL, V118, P113, DOI 10.1016/0303-7207(96)03772-0; LUEHRSEN KR, 1994, PLANT CELL REP, V13, P454, DOI 10.1007/BF00231966; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Luu DT, 1999, PLANT CELL, V11, P251; Marx J, 1996, SCIENCE, V273, P1338, DOI 10.1126/science.273.5280.1338; McCarty DR, 1986, MAIZE GEN COOP NEWSL, V60, P61; McCormick S, 1998, CURR OPIN PLANT BIOL, V1, P18, DOI 10.1016/S1369-5266(98)80122-2; MOL JNM, 1990, FEBS LETT, V268, P427, DOI 10.1016/0014-5793(90)81298-3; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Morino K, 1999, PLANT J, V17, P275, DOI 10.1046/j.1365-313X.1999.00373.x; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Pastuglia M, 1997, PLANT CELL, V9, P49, DOI 10.1105/tpc.9.1.49; ROGERS JC, 1988, PLANT MOL BIOL, V11, P125, DOI 10.1007/BF00015665; Rogers S.O., 1988, PLANT MOL BIOL MANUA, pA6/1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE MP, 1995, DEV DYNAM, V202, P343, DOI 10.1002/aja.1002020404; SCHMITZ G, 1992, MOL GEN GENET, V233, P269, DOI 10.1007/BF00587588; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SUZUKI G, 1995, PLANT CELL PHYSIOL, V36, P1273; Suzuki G, 1999, GENETICS, V153, P391; Takasaki T, 1999, PLANT MOL BIOL, V40, P659, DOI 10.1023/A:1006274525421; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2000, P NATL ACAD SCI USA, V97, P3765, DOI 10.1073/pnas.040580797; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; Tobias CM, 1996, PLANT J, V10, P523, DOI 10.1046/j.1365-313X.1996.10030523.x; vandeSande K, 1996, SCIENCE, V273, P370, DOI 10.1126/science.273.5273.370; VANDUIN M, 1989, MOL CELL BIOL, V9, P1794, DOI 10.1128/MCB.9.4.1794; VANENGELEN FA, 1993, PLANT J, V4, P855, DOI 10.1046/j.1365-313X.1993.04050855.x; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; ZHANG R, 1993, PLANT MOL BIOL, V21, P1171, DOI 10.1007/BF00023612; ZHAO Y, 1994, PLANT MOL BIOL, V26, P791, DOI 10.1007/BF00028849	85	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24146	24155		10.1074/jbc.M003047200	http://dx.doi.org/10.1074/jbc.M003047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10821836	Green Published, hybrid			2022-12-25	WOS:000088564200100
J	Paushkin, S; Charroux, B; Abel, L; Perkinson, RA; Pellizzoni, L; Dreyfuss, G				Paushkin, S; Charroux, B; Abel, L; Perkinson, RA; Pellizzoni, L; Dreyfuss, G			The survival motor neuron protein of Schizosacharomyces pombe - Conservation of survival motor neuron interaction domains in divergent organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; YEAST SCHIZOSACCHAROMYCES-POMBE; DISEASE GENE-PRODUCT; SNRNP PROTEINS; FISSION YEAST; SMN; RNA; COMPLEX; BINDING; IDENTIFICATION	Spinal muscular atrophy is a common often lethal neurodegenerative disease resulting from deletions or mutations in the survival motor neuron gene (SMN). SMN is ubiquitously expressed in metazoan cells and plays a role in small nuclear ribonucleoprotein assembly and pre-mRNA splicing. Here we characterize the Schizosacharomyces pombe orthologue of SMN (yeast SMN (ySMN)). We report that the ySMN protein is essential for viability and localizes in both the cytoplasm and the nucleus. Like human SMN, we show that ySMN can oligomerize. Remarkably, ySMN interacts directly with human SMN and Sm proteins, The highly conserved carboxyl-terminal domain of ySMN is necessary for the evolutionarily conserved interactions of SMN and required for cell viability. We also demonstrate that the conserved amino-terminal region of ySMN is not required for SMN and Sm binding but is critical for the housekeeping function of SMN.	Univ Penn, Sch Med, Dept Biochem & Biophys, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774; Pellizzoni, Livio/0000-0002-9168-5628				BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; HAGAN IM, 1988, J CELL SCI, V89, P343; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Jablonka S, 2000, HUM MOL GENET, V9, P341, DOI 10.1093/hmg/9.3.341; KEENEY JB, 1994, GENETICS, V136, P849; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; Ling MF, 1995, NUCLEIC ACIDS RES, V23, P4924, DOI 10.1093/nar/23.23.4924; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; McNabb DS, 1997, BIOTECHNIQUES, V22, P1134, DOI 10.2144/97226rr01; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PEARN J, 1978, J NEUROL SCI, V38, P263, DOI 10.1016/0022-510X(78)90072-2; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497	41	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23841	23846		10.1074/jbc.M001441200	http://dx.doi.org/10.1074/jbc.M001441200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816558	Green Submitted, hybrid			2022-12-25	WOS:000088564200060
J	Philipp, S; Trost, C; Warnat, J; Rautmann, J; Himmerkus, N; Schroth, G; Kretz, O; Nastainczyk, W; Cavalie, A; Hoth, M; Flockerzi, V				Philipp, S; Trost, C; Warnat, J; Rautmann, J; Himmerkus, N; Schroth, G; Kretz, O; Nastainczyk, W; Cavalie, A; Hoth, M; Flockerzi, V			TRP4 (CCE1) protein is part of native calcium release-activated Ca2+-like channels in adrenal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; OPERATED HTRP3 CHANNELS; DIFFUSIBLE MESSENGER; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; XENOPUS OOCYTES; DROSOPHILA TRP; I-CRAC; ENTRY; EXPRESSION	Mammalian TRP proteins have been implicated to function as ion channel subunits responsible for agonist-induced Ca2+ entry. To date, TRP proteins have been extensively studied by heterologous expression giving rise to diverse channel properties and activation mechanisms including store-operated mechanisms. However, the molecular structure and the functional properties of native TRP channels still remain elusive. Here we analyze the properties of TRP4 (CCE1) channels in their native environment and characterize TRP expression patterns and store-operated calcium currents that are endogenous to bovine adrenal cells. We show by Northern blot analysis, immunoblots, and immunohistochemistry that TRP4 transcripts and TRP4 protein are present in the adrenal cortex but absent in the medulla, Correspondingly, bovine adrenal cortex cells express TRP4 abundantly. The only other TRP transcript found at considerable levels was TRP1, whereas TRP2, TRP3, TRP5(CCE2), and TRP6 were not detectable. Depletion of calcium stores with inositol 1,4,5-trisphosphate or thapsigargin activates store operated ion channels in adrenal cells. These channels closely resemble calcium release-activated Ca2+ (CRAC) channels. Expression of trp4(CCE1) cDNA in antisense orientation significantly reduces both, the endogenous CRAC-like currents and the amount of native TRP4 protein. These results demonstrate that TRP4 contributes essentially to the formation of native CRAC-like channels in adrenal cells.	Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarland, Inst Anat, D-66421 Homburg, Germany; Univ Saarland, Inst Med Biochem, D-66421 Homburg, Germany; Univ Saarland, Inst Physiol, D-66421 Homburg, Germany	Saarland University; Saarland University; Saarland University; Saarland University	Philipp, S (corresponding author), Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.	stephan.philipp@med-rz.uni-sb.de	Philipp, Stephan/AAR-7519-2020	Hoth, Markus/0000-0001-7080-4643; Himmerkus, Nina/0000-0002-2910-6728; Philipp, Stephan/0000-0003-1959-9167; Kretz, Oliver/0000-0003-1152-5956				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Freichel M, 1998, FEBS LETT, V422, P354, DOI 10.1016/S0014-5793(98)00041-6; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Philipp S, 2000, CRC METH SIG TRANS, P321; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Qian F, 1999, BIOPHYS J, V76, pA210; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHAEFER M, 1999, NAUNYNSCHMIEDEBER S1, V359, pR69; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang Z, 1999, BIOPHYS J, V76, pA210; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	165	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23965	23972		10.1074/jbc.M003408200	http://dx.doi.org/10.1074/jbc.M003408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816590	hybrid			2022-12-25	WOS:000088564200077
J	Semenov, AY; Vassiliev, IR; van der Est, A; Mamedov, MD; Zybailov, B; Shen, GZ; Stehlik, D; Diner, BA; Chitnis, PR; Golbeck, JH				Semenov, AY; Vassiliev, IR; van der Est, A; Mamedov, MD; Zybailov, B; Shen, GZ; Stehlik, D; Diner, BA; Chitnis, PR; Golbeck, JH			Recruitment of a foreign quinone into the A(1) site of photosystem I - Altered kinetics of electron transfer in phylloquinone biosynthetic pathway mutants studied by time-resolved optical, EPR, and electrometric techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; PHOTOSYNTHETIC REACTION CENTERS; CLUSTER F-B; RESONANCE SPECTROSCOPY; PARAMAGNETIC-RESONANCE; SPIN POLARIZATION; ROOM-TEMPERATURE; 2 PHYLLOQUINONES; TRANSIENT EPR; ACCEPTOR	Interruption of the menA or menB gene in Synechocystis sp, PCC 6803 results in the incorporation of a foreign quinone, termed Q, into the A, site of photosystem I with a number of experimental indicators identifying Q as plastoquinone-9, A global multiexponential analysis of time-resolved optical spectra in the blue region shows the following three kinetic components: 1) a 3-ms lifetime in the absence of methyl viologen that represents charge recombination between P700(+) and an FeS- cluster; 2) a 750-mu s lifetime that represents electron donation from an FeS- cluster to methyl viologen; and 3) an similar to 15-mu s lifetime that represents an electrochromic shift of a carotenoid pigment. Room temperature direct detection transient EPR studies of forward electron trans fer show a spectrum of P700(+) Q(-) during the lifetime of the spin polarization and give no evidence of a significant population of P700(+) FeS- for t less than or equal to 2-3 mu s. The UV difference spectrum measured 5 mu s after a flash shows a maximum at 315 nm, a crossover at 280 nm, and a minimum at 255 nm as well as a shoulder at 290-295 nm, all of which are characteristic of the plastoquinone-9 anion radical, Kinetic measurements that monitor Q at 315 nm show a major phase of forward electron transfer to the FeS clusters with a lifetime of similar to 15 mu s, which matches the electrochromic shift at 485 nm of the carotenoid, as well as an minor phase with a lifetime of similar to 250 mu s. Electrometric measurements show similar biphasic kinetics, The slower kinetic phase can be detected using time-resolved EPR spectroscopy and has a spectrum characteristic of a semiquinone anion radical. We estimate the redox potential of plastoquinone-9 in the A(1) site to be more oxidizing than phylloquinone so that electron transfer from Q(-) to F-X is thermodynamically unfavorable in the menA and menB mutants.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; DuPont Co Inc, Expt Stn, Cent Res & Dev, Wilmington, DE 19980 USA; Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Lomonosov Moscow State University; Brock University; Free University of Berlin; DuPont; Iowa State University	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	JHG5@psu.edu	Mamedov, Mahir/X-7600-2018; Semenov, Alexey Yu/G-2759-2014	Semenov, Alexey Yu/0000-0003-1035-0381; Zybailov, Boris/0000-0003-2432-9145				BENASSON R, 1973, BIOCHIM BIOPHYS ACTA, V325, P175; BIGGINS J, 1990, BIOCHEMISTRY-US, V29, P7259, DOI 10.1021/bi00483a014; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; Diner BA, 1998, METHOD ENZYMOL, V297, P337; Franke JE, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P75; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GUTMANN V, 1976, COORDIN CHEM REV, V18, P225, DOI 10.1016/S0010-8545(00)82045-7; IWAKI M, 1994, PLANT CELL PHYSIOL, V35, P983; JAWORSKI JS, 1979, J ELECTROANAL CHEM, V105, P329, DOI 10.1016/S0022-0728(79)80126-6; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; Mamedov MD, 1996, J BIOENERG BIOMEMBR, V28, P517, DOI 10.1007/BF02110441; Mamedova AA, 1999, FEBS LETT, V462, P421, DOI 10.1016/S0014-5793(99)01570-7; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PRINCE RC, 1986, METHOD ENZYMOL, V125, P109; PRINCE RC, 1983, FEBS LETT, V160, P273, DOI 10.1016/0014-5793(83)80981-8; RUSTANDI RR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P311, DOI 10.1016/0005-2728(92)90087-I; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; SETIF P, 1990, CURRENT RES PHOTOSYN, V2, P539; Shinkarev VP, 2000, BIOPHYS J, V78, P363, DOI 10.1016/S0006-3495(00)76599-4; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; van der Est A, 1998, BBA-BIOENERGETICS, V1409, P87, DOI 10.1016/S0005-2728(98)00152-2; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; VANGORKOM HJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P439, DOI 10.1016/0005-2728(74)90081-4; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; VOS MH, 1988, BIOCHIM BIOPHYS ACTA, V934, P293, DOI 10.1016/0005-2728(88)90089-8; VOS MH, 1990, BIOPHYS J, V58, P1547, DOI 10.1016/S0006-3495(90)82499-1; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	40	77	85	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23429	23438		10.1074/jbc.M000508200	http://dx.doi.org/10.1074/jbc.M000508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801789	hybrid			2022-12-25	WOS:000088564200006
J	Zhuang, Y; Wendt, C; Gick, G				Zhuang, Y; Wendt, C; Gick, G			Regulation of Na,K-ATPase beta 1 subunit gene transcription by low external potassium in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; TISSUE-SPECIFIC EXPRESSION; DEPENDENT PROTEIN-KINASE; PRETRANSLATIONAL REGULATION; SODIUM-TRANSPORT; MESSENGER-RNAS; ALPHA-SUBUNIT; H-3 OUABAIN; CELLS; IDENTIFICATION	Expression of Na,K-ATPase activity is up-regulated in cells incubated for extended intervals in the presence of low external K+. Our previous data showed that exposure of cardiac myocytes to low K+ increased the steady-state abundance of Na,K-ATPase beta 1 subunit mRNk In the present study we determined that incubation of primary cultures of neonatal rat cardiac myocytes with low K+ augmented Na,K-ATPase beta 1 gene expression at a transcriptional level and that this effect required extracellular Ca2+. The stimulatory effect of low K+ on Na,K-ATPase beta 1 gene transcription was not dependent on increased contractile activity of cardiac myocytes, Na,KATPase beta 1 5'-flanking region deletion plasmids used in transient transfection analysis demonstrated that the region between nucleotides -62 to -42 of the beta 1 pro meter contained a low K+ response element. Site-directed mutagenesis of a potential GC box core motif GCG in the -58/-56 region of the beta 1 promoter decreased basal and low K+-mediated transcription. Mutation of the core sequence of a putative GC box element located between nucleotides -101 and -99 further decreased the low K+ effect on beta 1 gene transcription. Electrophoretic mobility shift assays using oligonucleotides spanning the proximal and distal GC box elements of the beta 1 promoter showed enhanced binding of two complexes in response to low K+. The inclusion of a consensus GC box sequence as a competitor in gel shift analysis reduced factor binding to the low K+ response elements. Antibodies to transcription factors Sp1 and Sp3 interacted with components of both DNA-binding complexes and binding of nuclear factors was abolished in gel shift studies using GC box mutants. Together these data indicate that enhanced binding. of Sp1 and Sp3 to two GC box elements in the rat Na,K-ATPase beta 1 subunit gene promoter mediates beta 1 gene transcription up-regulation in neonatal rat cardiac myocytes exposed to low external K+.	SUNY Hlth Sci Ctr, Dept Biochem, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Ctr Cardiovasc & Muscle Res, Brooklyn, NY 11203 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Gick, G (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	gickg11@bklynhsc.edu	Wendt, Chris/C-6823-2012					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; Arystarkhova E, 1997, J BIOL CHEM, V272, P22405, DOI 10.1074/jbc.272.36.22405; AZUMA KK, 1991, AM J PHYSIOL, V29, pC958; BAGROV AY, 1991, CARDIOVASC RES, V25, P371, DOI 10.1093/cvr/25.5.371; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; BLUSCHKE V, 1976, EUR J PHARMACOL, V37, P189, DOI 10.1016/0014-2999(76)90021-2; BOARDMAN LJ, 1972, J PHYSIOL-LONDON, V225, P619, DOI 10.1113/jphysiol.1972.sp009960; BOWEN JW, 1987, AM J PHYSIOL, V252, pC179, DOI 10.1152/ajpcell.1987.252.2.C179; CUMBERBATCH M, 1981, BRIT J CLIN PHARMACO, V11, P565, DOI 10.1111/j.1365-2125.1981.tb01172.x; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Eble DM, 1998, J MOL CELL CARDIOL, V30, P55, DOI 10.1006/jmcc.1997.0571; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FISONE G, 1994, J BIOL CHEM, V269, P9368; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FORD AR, 1979, BRIT J CLIN PHARMACO, V8, P135, DOI 10.1111/j.1365-2125.1979.tb05811.x; GONICK HC, 1993, AM J HYPERTENS, V6, P680, DOI 10.1093/ajh/6.8.680; GRAVES SW, 1995, AM J HYPERTENS, V8, P5, DOI 10.1016/0895-7061(94)00167-A; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KENNEDY DG, 1990, BIOCHIM BIOPHYS ACTA, V1027, P218, DOI 10.1016/0005-2736(90)90310-K; KIM D, 1984, J CLIN INVEST, V74, P1481, DOI 10.1172/JCI111561; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE CO, 1985, AM J PHYSIOL, V249, pC367, DOI 10.1152/ajpcell.1985.249.5.C367; LI PWC, 1993, INT J CARDIOL, V40, P95; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; Malik N, 1996, J BIOL CHEM, V271, P22754, DOI 10.1074/jbc.271.37.22754; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; Netticadan T, 1997, BIOCHEM BIOPH RES CO, V238, P544, DOI 10.1006/bbrc.1997.7305; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PRESSLEY TA, 1988, AM J PHYSIOL, V255, pC252, DOI 10.1152/ajpcell.1988.255.2.C252; QIN X, 1994, AM J HYPERTENS, V7, P96, DOI 10.1093/ajh/7.1.96; RAYSON BM, 1991, J BIOL CHEM, V266, P21335; RAYSON BM, 1993, J BIOL CHEM, V268, P8851; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; TANG MJ, 1992, AM J PHYSIOL, V263, pC436, DOI 10.1152/ajpcell.1992.263.2.C436; TAORMINO JP, 1990, J BIOL CHEM, V265, P4116; Wendt CH, 1998, AM J PHYSIOL-CELL PH, V274, pC356, DOI 10.1152/ajpcell.1998.274.2.C356; WHITTAKER J, 1983, LIFE SCI, V32, P747, DOI 10.1016/0024-3205(83)90308-9; YAMAMOTO K, 1993, J CLIN INVEST, V92, P1889, DOI 10.1172/JCI116781; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101; ZEIDEL ML, 1991, AM J PHYSIOL, V261, pF1013, DOI 10.1152/ajprenal.1991.261.6.F1013	47	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24173	24184		10.1074/jbc.M002953200	http://dx.doi.org/10.1074/jbc.M002953200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811658	hybrid			2022-12-25	WOS:000088564200103
J	Sahin-Toth, M				Sahin-Toth, M			Human cationic trypsinogen - Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SERINE PROTEINASE-INHIBITOR; GENE; MUTATIONS; ECOTIN; SPECIFICITY	Mutation Asn-21 --> Ile in human cationic trypsinogen (Tg-l) has been associated with hereditary pancreatitis. Recent studies with rat anionic Tg (Tg-2) indicated that the analogous Thr-21 --> Ile mutation stabilizes the zymogen against autoactivation, whereas it has no effect on catalytic properties or autolytic stability of trypsin (Sahin-Toth, M. (1999) J. Biol. Chem. 274, 29899-29704). In the present paper, human cationic Tg (Asn-81-Tg) and mutants Asn-21 --> Ile (Ile-21-Tg) and Asn-21 --> Thr (Thr-21-Tg) were expressed in Escherichia coli, and zymogen activation, zymogen degradation, and trypsin autolysis were studied. Enterokinase activated Asn-21-Tg approximately 2-fold better than Ile-21-Tg or Thr-21-Tg, and catalytic parameters of trypsins were comparable. At 37 degrees C, in 5 mM Ca2+, all three trypsins were highly stable. In the absence of Ca2+, Asn-21- and Ile-21-trypsins suffered autolysis in an indistinguishable manner, whereas Thr-21-trypsin exhibited significantly increased stability. In sharp contrast to observations with the rat proenzyme, at pH 8.0, 37 degrees C, autoactivation kinetics of Asn-21-Tg and Ile-21-Tg were identical; however, at pH 5.0, Ile-21-Tg autoactivated at an enhanced rate relative to Asn-a1-Tg. Remarkably, at both pH values, Thr-21-Tg showed markedly higher autoactivation rates than the two other zymogens, Finally, autocatalytic proteolysis of human zymogens was limited to cleavage at Arg-117, and no digestion at Lys-188 was detected. The observations indicate that zymogen stabilization by Ile-21 as observed in rat Tg-2 is not characteristic of human Tg-1, Instead, an increased propensity to autoactivation under acidic conditions might be relevant to the pathomechanism of the Asn-21 --> Ile mutation in hereditary pancreatitis, In the same context, faster autoactivation and increased trypsin stability caused by the Asn-21 --> Thr mutation in human Tg-1 might provide a rationale for the evolutionary divergence from Thr-al found in other mammalian trypsinogens.	Univ Calif Los Angeles, Dept Physiol, HHMI, MacDonald Res Labs 5748, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sahin-Toth, M (corresponding author), Univ Calif Los Angeles, Dept Physiol, HHMI, MacDonald Res Labs 5748, Box 951662, Los Angeles, CA 90095 USA.							Chen JM, 2000, HUM GENET, V106, P125, DOI 10.1007/s004390051019; COLOMB E, 1979, BIOCHIM BIOPHYS ACTA, V570, P397, DOI 10.1016/0005-2744(79)90159-1; Creighton J, 1999, LANCET, V354, P42, DOI 10.1016/S0140-6736(99)01814-0; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; Gates LK, 1999, SURG CLIN N AM, V79, P711, DOI 10.1016/S0039-6109(05)70037-2; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GREENBAUM LM, 1959, J BIOL CHEM, V234, P2885; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; LI XF, 1988, BIOCHEM BIOPH RES CO, V250, P235; MAROUX S, 1969, BIOCHIM BIOPHYS ACTA, V181, P59, DOI 10.1016/0005-2795(69)90227-X; Nishimori I, 1999, GUT, V44, P259, DOI 10.1136/gut.44.2.259; Pal G, 1996, FEBS LETT, V385, P165, DOI 10.1016/0014-5793(96)00376-6; PAL G, 1994, FEBS LETT, V342, P57, DOI 10.1016/0014-5793(94)80584-9; PERRAULT J, 1994, GASTROENTEROL CLIN N, V23, P743; RINDERKNECHT H, 1988, INT J PANCREATOL, V3, P33; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; Sahin-Toth M, 1999, BIOCHEM BIOPH RES CO, V264, P505, DOI 10.1006/bbrc.1999.1565; Sahin-Toth M, 1999, J BIOL CHEM, V274, P29699, DOI 10.1074/jbc.274.42.29699; Steer ML, 1998, PANCREAS, V17, P31, DOI 10.1097/00006676-199807000-00003; Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; Whitcomb DC, 1999, GUT, V45, P317, DOI 10.1136/gut.45.3.317; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Whitcomb DC, 1999, GASTROENTEROL CLIN N, V28, P525, DOI 10.1016/S0889-8553(05)70071-6; White CR, 1999, SEMIN CUTAN MED SURG, V18, P1, DOI 10.1016/S1085-5629(99)80002-9	30	125	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22750	22755		10.1074/jbc.M002943200	http://dx.doi.org/10.1074/jbc.M002943200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801865	hybrid			2022-12-25	WOS:000088419400023
J	Drees, B; Friederich, E; Fradelizi, J; Louvard, D; Beckerle, MC; Grolsteyn, RM				Drees, B; Friederich, E; Fradelizi, J; Louvard, D; Beckerle, MC; Grolsteyn, RM			Characterization of the interaction between zyxin and members of the ena/vasodilator-stimulated phosphoprotein family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; HOST-CELL ACTIN; PROLINE-RICH REGION; LISTERIA-MONOCYTOGENES; FOCAL-ADHESION; CYTOSKELETAL DYNAMICS; OWN CYTOSKELETON; MAMMALIAN-CELLS; SURFACE PROTEIN; ENA/VASP FAMILY	Zyxin contains a proline-rich N-terminal domain that is similar to the C-terminal domain in the ActA protein of the bacteria, Listeria monocytogenes. We screened the entire amino acid sequence of human zyxin for Mena-interacting peptides and found that, as with ActA, proline-rich sequences were the sole zyxin sequences capable of binding to Ena/vasodilator-stimulated phosphoprotein (VASP) family members in vitro. From this information, we tested zyxin mutants in which the proline-rich sequences were altered. The reduction in Mena/VASP binding was confirmed by peptide tests, immunoprecipitation, and ectopic expression of zyxin variants at the surface of mitochondria. By transfection assays we showed that zyxin interaction with Mena/VASP in vivo enhances the production of actin-rich structures at the apical surface of cells. Microinjection into cells of peptides corresponding to the first proline-rich sequence of zyxin caused the loss of Mena/VASP from focal contacts. Furthermore, these peptides reduced the degree of spreading of cells replated after trypsinization, We conclude that zyxin and proteins that harbor similar proline-rich repeats contribute to the positioning of Mena/VASP proteins. The positioning of Ena/VASP family members appears to be important when the actin cytoskeleton is reorganized, such as during spreading.	Univ Utah, Dept Biol, Huntsman Canc Inst, Salt Lake City, UT 84103 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Grolsteyn, RM (corresponding author), Inst Curie, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris 05, France.	golsteyn@curie.fr						Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; ASHAR HR, 1995, CELL, V82, P57; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BEREITERHAHN J, 1990, J CELL SCI, V96, P171; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Fradelizi J, 1999, BIOTECHNIQUES, V26, P484; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Golsteyn RM, 1997, J CELL SCI, V110, P1893; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MATTHIAS PD, 1982, EMBO J, V1, P1207, DOI 10.1002/j.1460-2075.1982.tb00014.x; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Sechi AS, 1997, J CELL BIOL, V137, P155, DOI 10.1083/jcb.137.1.155; SMALL JV, 1978, NATURE, V272, P638, DOI 10.1038/272638a0; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1992, J CELL BIOL, V118, P71, DOI 10.1083/jcb.118.1.71; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; Zeile WL, 1998, P NATL ACAD SCI USA, V95, P13917, DOI 10.1073/pnas.95.23.13917; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	61	133	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22503	22511		10.1074/jbc.M001698200	http://dx.doi.org/10.1074/jbc.M001698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801818	hybrid			2022-12-25	WOS:000088363800100
J	Gibson, RM; Schiemann, WP; Prichard, LB; Reno, JM; Ericsson, LH; Nathanson, NM				Gibson, RM; Schiemann, WP; Prichard, LB; Reno, JM; Ericsson, LH; Nathanson, NM			Phosphorylation of human gp130 at Ser-782 adjacent to the di-leucine internalization motif - Effects on expression and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; ACTIVATED PROTEIN-KINASE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; LIGAND-INDUCED ENDOCYTOSIS; FACTOR-II RECEPTOR; T-CELL RECEPTOR; CYTOPLASMIC DOMAIN; TRANSDUCER GP130; DOWN-REGULATION; GROWTH-FACTOR	The receptor for leukemia inhibitory factor (LIF) consists of two polypeptides, the LIF receptor and gp130. Agonist stimulation has been shown previously to cause phosphorylation of gp130 on serine, threonine, and tyrosine residues. We found that gp130 fusion proteins were phosphorylated exclusively on Ser-782 by LIF- and growth factor-stimulated 3T3-L1 cell extracts. Ser-780 was required for phosphorylation of Ser-782 but was not itself phosphorylated. Ser-782 is located immediately N-terminal to the di-leucine motif of gp130, which regulates internalization of the receptor. Transient expression of chimeric granulocyte colony-stimulating factor receptor (G-CSFR)-gp130(S782A) receptors resulted in increased cell surface expression in COS-7 cells and increased ability to induce vasoactive intestinal peptide gene expression in IMR-32 neuroblastoma cells when compared with expression of chimeric receptors containing wild-type gp130 cytoplasmic domains. These results identify Ser-782 as the major phosphorylated serine residue in human gp130 and indicate that this site regulates cell surface expression of the receptor polypeptide.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.		Gibson, Robin/A-6841-2009		NIGMS NIH HHS [TM32-GM07750] Funding Source: Medline; NINDS NIH HHS [F32-NS10585, T32-NS07332] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010585, T32NS007332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BOWER J, 1995, J CELL PHYSIOL, V164, P93, DOI 10.1002/jcp.1041640112; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; DiStefano PS, 1996, J BIOL CHEM, V271, P22839, DOI 10.1074/jbc.271.37.22839; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GERHARTZ C, 1994, EUR J BIOCHEM, V223, P265, DOI 10.1111/j.1432-1033.1994.tb18991.x; Goldman PS, 1996, J BIOL CHEM, V271, P4215; HAFT CR, 1994, J BIOL CHEM, V269, P26286; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Levy W P, 1981, Methods Enzymol, V79, P27; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Rosoff ML, 1999, CELL MOL NEUROBIOL, V19, P289, DOI 10.1023/A:1006937413310; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHWABE M, 1994, J CLIN INVEST, V94, P2317, DOI 10.1172/JCI117596; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; Taga T, 1996, J NEUROCHEM, V67, P1; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Wang XJ, 1998, BLOOD, V91, P3308, DOI 10.1182/blood.V91.9.3308.3308_3308_3314; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	57	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22574	22582		10.1074/jbc.M907658199	http://dx.doi.org/10.1074/jbc.M907658199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10811661	hybrid			2022-12-25	WOS:000088363800111
J	Osthus, RC; Shim, H; Kim, S; Li, Q; Reddy, R; Mukherjee, M; Xu, Y; Wonsey, D; Lee, LA; Dang, CV				Osthus, RC; Shim, H; Kim, S; Li, Q; Reddy, R; Mukherjee, M; Xu, Y; Wonsey, D; Lee, LA; Dang, CV			Accelerated publication - Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; PYRUVATE-KINASE GENE; CANCER-CELLS; TRANSCRIPTIONAL REGULATION; RAT FIBROBLASTS; MESSENGER-RNA; TARGET GENES; BINDING; OVEREXPRESSION; METABOLISM	Unlike normal mammalian cells, which use oxygen to generate energy, cancer cells rely on glycolysis for energy and are therefore less dependent on oxygen. We previously observed that the c-Myc oncogenic transcription factor regulates lactate dehydrogenase A and induces lactate overproduction. We, therefore, sought to determine whether c-Myc controls other genes regulating glucose metabolism. In Rat1a fibroblasts and murine livers overexpressing c-Myc, the mRNA levels of the glucose transporter GLUT1, phosphoglucose isomerase, phosphofructokinase, glyceraldehyde-3-phosphate de hydrogenase, phosphoglycerate kinase, and enolase were elevated. c-Myc directly transactivates genes encoding GLUT1, phosphofructokinase, and enolase and increases glucose uptake in Rat1 fibroblasts, Nuclear run-on studies confirmed that the GLUT1 transcriptional rate is elevated by c-Myc. Our findings suggest that overexpression of the c-Myc oncoprotein deregulates glycolysis through the activation of several components of the glucose metabolic pathway.	Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dang, CV (corresponding author), Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Ross Res Bldg,Room 1025,720 Rutland Ave, Baltimore, MD 21205 USA.		Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA 51497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051497, R01CA051497, R29CA051497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Barr LF, 2000, CANCER RES, V60, P143; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; Choi Jong-Whan, 1995, Yonsei Medical Journal, V36, P480; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Elend M, 1999, CURR BIOL, V9, pR936, DOI 10.1016/S0960-9822(00)80109-8; Fell DA, 1998, BIOTECHNOL BIOENG, V58, P121, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<121::AID-BIT2>3.3.CO;2-F; Ferry N, 1998, HUM GENE THER, V9, P1975, DOI 10.1089/hum.1998.9.14-1975; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GODWIN AK, 1991, MOL CARCINOGEN, V4, P275, DOI 10.1002/mc.2940040406; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEMLINGER G, 1997, NAT MED, V3, P177; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Younes M, 1996, CLIN CANCER RES, V2, P1151; Younes M, 1996, CANCER RES, V56, P1164; YU NC, 1995, MOL PHARMACOL, V48, P550	46	595	613	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21797	21800		10.1074/jbc.C000023200	http://dx.doi.org/10.1074/jbc.C000023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10823814	hybrid			2022-12-25	WOS:000088363800006
J	Onorato, JM; Jenkins, AJ; Thorpe, SR; Baynes, JW				Onorato, JM; Jenkins, AJ; Thorpe, SR; Baynes, JW			Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions - Mechanism of action of pyridoxamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPID HYDROPEROXIDE; MAILLARD-REACTION; STRUCTURE ELUCIDATION; END-PRODUCTS; POST-AMADORI; IN-VITRO; PROTEIN; ACID; PEROXIDATION	Maillard or browning reactions lead to formation of advanced glycation end products (AGEs) on protein and contribute to the increase in chemical modification of proteins during aging and in diabetes. AGE inhibitors such as aminoguanidine and pyridoxamine (PM) have proven effective in animal model and clinical studies as inhibitors of AGE formation and development of diabetic complications. We report here that PM also inhibits the chemical modification of proteins during lipid peroxidation (lipoxidation) reactions in vitro, and we show that it traps reactive intermediates formed during lipid peroxidation. In reactions of arachidonate with the model protein RNase, PM prevented modification of lysine residues and formation of the advanced lipoxidation end products (ALEs) N-epsilon-(carboxymethyl)lysine, N-epsilon-(carboxyethyl)lysine, malondialdehyde-lysine, and 4-hydroxynonenal-lysine. PM also inhibited lysine modification and formation of ALEs during copper-catalyzed oxidation of low density lipoprotein. Hexanoic acid amide and nonanedioic acid monoamide derivatives of PM were identified as major products formed during oxidation of linoleic acid in the presence of PM. We propose a mechanism for formation of these products from the 9- and 13-oxo-decadienoic acid intermediates formed during peroxidation of linoleic acid. PM, as a potent inhibitor of both AGE and ALE formation, may prove useful for limiting the increased chemical modification of tissue proteins and associated pathology in aging and chronic diseases, including both diabetes and atherosclerosis.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.			Jenkins, Alicia/0000-0003-0583-3717	NIDDK NIH HHS [DK-19971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BAYNES JW, 2000, IN PRESS FREE RADIC; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BULL AW, 1990, CARCINOGENESIS, V11, P1699, DOI 10.1093/carcin/11.10.1699; Bull AW, 1996, LIFE SCI, V58, P2355, DOI 10.1016/0024-3205(96)00236-6; D'Alelio GF, 1937, J AM CHEM SOC, V59, P111, DOI 10.1021/ja01280a026; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GARDNER HW, 1977, LIPIDS, V12, P655, DOI 10.1007/BF02533760; Kato Y, 1999, J BIOL CHEM, V274, P20406, DOI 10.1074/jbc.274.29.20406; Kato Y, 1997, J LIPID RES, V38, P1334; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1990, ARCH BIOCHEM BIOPHYS, V279, P218, DOI 10.1016/0003-9861(90)90484-G; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; ONORATO JM, 1999, THESIS U S CAROLINA; PICARD S, 1992, P NATL ACAD SCI USA, V89, P6876, DOI 10.1073/pnas.89.15.6876; Requena J R, 1992, Diabetes Res, V20, P43; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; SAWICKI E, 1963, ANAL CHEM, V35, P199, DOI 10.1021/ac60195a026; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shoda H, 1997, ENDOCRINOLOGY, V138, P1886, DOI 10.1210/en.138.5.1886; SPADARO AC, 1979, ANAL BIOCHEM, V96, P317, DOI 10.1016/0003-2697(79)90587-6; Spiteller G, 1998, CHEM PHYS LIPIDS, V95, P105, DOI 10.1016/S0009-3084(98)00091-7; Spiteller P, 1998, BBA-LIPID LIPID MET, V1392, P23, DOI 10.1016/S0005-2760(97)00209-9; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001	31	205	216	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21177	21184		10.1074/jbc.M003263200	http://dx.doi.org/10.1074/jbc.M003263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801874	hybrid			2022-12-25	WOS:000088230600030
J	Pando, MP; Verma, IM				Pando, MP; Verma, IM			Signal-dependent and -independent degradation of free and NF-kappa B-bound I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DNA-BINDING PROTEINS; CASEIN KINASE-II; INDUCIBLE DEGRADATION; CONSTITUTIVE PHOSPHORYLATION; TRANSCRIPTION FACTOR; TERMINAL SEQUENCES; ACTIVATION; COMPLEX; VIVO	A family of inhibitory I kappa B molecules regulates the activation of the transcription factor NF-kappa B. One member of the I kappa B family, I kappa B alpha, plays a major role in the rapid signal-induced activation of NF-kappa B. I kappa B alpha itself is transcriptionally regulated by NF-kappa B allowing for a tight autoregulatory loop that is both sensitive to and rapidly influenced by NF-kappa B activating stimuli. For this pathway to remain primed both for rapid activation of NF-kappa B in the presence of signal and then to suppress NF-kappa B activation once that signal is removed, I kappa B alpha must be exquisitely regulated. The regulation of I kappa B alpha is mainly accomplished through phosphorylation, ubiquitination, and subsequent degradation. The mechanism(s) that regulate I kappa B alpha degradation needs to be able to target I kappa B alpha for degradation in both its NF-kappa B bound and free states in the cell. In this study, we utilize a full-length I kappa B alpha mutant that is unable to associate to RelA/p65. We show that the signal-induced I kappa B kinase (IKK) phosphorylation sites on I kappa B alpha can only significantly influence the regulation of signal-dependent but not signal-independent turnover of I kappa B alpha. We also demonstrate that the constitutive carboxyl-terminal casein kinase II phosphorylation sites are necessary for the proper regulation of both signal-dependent and -independent turnover of I kappa B alpha. These findings further elucidate how the phosphorylation of I kappa B alpha influences the complex regulatory mechanisms involved in maintaining a sensitive NF-kappa B pathway.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	verma@salk.edu						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aoki T, 1996, ONCOGENE, V12, P1159; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALTIMORE D, 1995, NATURE, V373, P287, DOI 10.1038/373287a0; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Traenckner EBM, 1995, J CELL SCI, P79; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	57	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21278	21286		10.1074/jbc.M002532200	http://dx.doi.org/10.1074/jbc.M002532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801847	hybrid			2022-12-25	WOS:000088230600044
J	Murata, H; Hruz, PW; Mueckler, M				Murata, H; Hruz, PW; Mueckler, M			The mechanism of insulin resistance caused by HIV protease inhibitor therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; RAT ADIPOSE-CELLS; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; TRANSGENIC MICE; APPARENT TRANSLOCATION; POTENTIAL MECHANISM; GLUT4; SURFACE	Retroviral protease inhibitors used as therapy for HIV-1 infection have been causally associated with serious metabolic side effects, including peripheral lipodystrophy, hyperlipidemia, insulin resistance, and in some cases, overt type 2 diabetes. The etiology of this characteristic clinical syndrome remains unknown. We demonstrate that the HIV protease inhibitor, indinavir, dramatically inhibits insulin-stimulated glucose uptake in 3T3-L1 adipocytes in a dose-dependent manner (63% inhibition observed with 100 mu M indinavir). Indinavir treatment did not affect early insulin signaling events or the translocation of intracellular Glut1 or Glut4 glucose transporters to the cell surface. To determine whether indinavir may be directly affecting the intrinsic transport activity of glucose transporters, the Glut1 and Glut4 isoforms were heterologously expressed and analyzed in Xenopus laevis oocytes, Indinavir at 100 ECM had no effect on Glut1 transport activity in Xenopus oocytes, whereas Glut4 activity was significantly inhibited (45% inhibition). Similar effects on glucose transport were observed for other HIV protease inhibitors. We conclude that HIV protease inhibitors as a class are capable of selectively inhibiting the transport function of Glut4 and that this effect may be responsible for a major iatrogenic complication frequently observed in HIV patients.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012	Hruz, Paul/0000-0002-1478-3355	NIDDK NIH HHS [DK38495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behrens G, 1999, AIDS, V13, pF63, DOI 10.1097/00002030-199907090-00001; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KELLER K, 1989, J BIOL CHEM, V264, P18884; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER MM, 1995, NEWS PHYSIOL SCI, V10, P22; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; PARK CR, 1955, AM J PHYSIOL, V182, P17, DOI 10.1152/ajplegacy.1955.182.1.17; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1991, AM J PHYSIOL, V260, P570; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1993, J BIOL CHEM, V268, P16113; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; Wentworth JM, 2000, J ENDOCRINOL, V164, pR7, DOI 10.1677/joe.0.164R007; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	44	425	441	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20251	20254		10.1074/jbc.C000228200	http://dx.doi.org/10.1074/jbc.C000228200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10806189	hybrid			2022-12-25	WOS:000088084500006
J	Darling, RJ; Ruddon, RW; Perini, F; Bedows, E				Darling, RJ; Ruddon, RW; Perini, F; Bedows, E			Cystine knot mutations affect the folding of the glycoprotein hormone alpha-subunit - Differential secretion and assembly of partially folded intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HAMSTER OVARY CELLS; PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE BOND FORMATION; BETA-SUBUNIT; GROWTH-FACTOR; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; QUALITY-CONTROL	The common glycoprotein hormone alpha-subunit (GPH-alpha) contains five intramolecular disulfide bonds, three of which form a cystine knot motif (10-60, 28-82, and 32-84), By converting each pair of cysteine residues of a given disulfide bond to alanine, we have studied the role of individual disulfide bonds in GPH-alpha folding and have related folding ability to secretion and assembly with the human chorionic gonadotropin beta-subunit (hCG-beta). Mutation of non-cystine knot disulfide bond 7-31, bond 59-87, or both (leaving only the cystine knot) resulted in an efficiently secreted folding form that was indistinguishable from wild type. Conversely, the cystine knot mutants were inefficiently secreted (<25%), Furthermore, mutation of the cystine knot disulfide bonds resulted in multiple folding intermediates containing 1, 2, or 4 disulfide bonds. High performance liquid chromatographic separation of intracellular and secreted forms of the folding intermediates demonstrated that the most folded forms were preferentially secreted and combined with hCG-beta, From these studies we conclude that: (1) the cystine knot of GPH-alpha is necessary and sufficient for folding and (ii) there is a direct correlation between the extent of GPH-alpha folding, its ability to be secreted, and its ability to heterodimerize with hCG-beta.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Obstet & Gynecol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Bedows, E (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, 600 S 42nd St, Omaha, NE 68198 USA.				NCI NIH HHS [P 30 CA36727, CA32949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032949, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BEEBE JS, 1990, J BIOL CHEM, V265, P312; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; Erbel PJA, 1999, EUR J BIOCHEM, V260, P490, DOI 10.1046/j.1432-1327.1999.00188.x; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; Furuhashi M, 1996, ENDOCRINOLOGY, V137, P4196, DOI 10.1210/en.137.10.4196; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETERS BP, 1989, ENDOCRINOLOGY, V124, P1602, DOI 10.1210/endo-124-4-1602; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATO A, 1997, J BIOL CHEM, V272, P18093; SCHUBACK DE, 1995, HUM MUTAT, V5, P285, DOI 10.1002/humu.1380050403; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	36	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15413	15421		10.1074/jbc.275.20.15413	http://dx.doi.org/10.1074/jbc.275.20.15413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809777	hybrid			2022-12-25	WOS:000087128300087
J	Luders, J; Demand, J; Papp, O; Hohfeld, J				Luders, J; Demand, J; Papp, O; Hohfeld, J			Distinct isoforms of the cofactor BAG-1 differentially affect Hsc70 chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; ALTERNATIVE TRANSLATION INITIATION; HEAT-SHOCK PROTEINS; CANCER-CELLS; NEGATIVE REGULATOR; RECEPTOR; DEATH; HSP70/HSC70; LINES; RAP46	In the mammalian cytosol and nucleus the activity of the molecular chaperone Hsc70 is regulated by chaperone cofactors that modulate ATP binding and hydrolysis by Hsc70. Among such cofactors is the anti-apoptotic protein BAG-1. Remarkably, BAG-1 is expressed as multiple isoforms, which are distinguished by their amino termini. We investigated whether distinct isoforms differ with respect to their Hsc70-regulating activity. By comparing the mainly cytosolic isoforms BAG-1M and BAG-1S, opposite effects of the two isoforms were observed in chaperone-assisted folding reactions. Whereas BAG-1M was found to inhibit the Hsc70-mediated refolding of nonnative polypeptide substrates, the BAG-1S isoform stimulated Hsc70 chaperone activity. The opposite effects are not due to differences in the regulation of the ATPase activity of Hsc70 by the two isoforms. Both isoforms stimulated ATP hydrolysis by Hsc70 in an Hsp40-dependent manner through an acceleration of ADP-ATP exchange. Our results reveal that the different amino termini of the distinct BAG-1 isoforms determine the outcome of an Hsc70-mediated folding event, most likely by transiently interacting with the polypeptide substrate. Employing isoforms of a cofactor with different substrate binding properties appears to provide the means to influence the chaperone function of Hsc70 in addition to modulating its ATPase cycle.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Hohfeld, J (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Lüders, Jens/H-2812-2015	Lüders, Jens/0000-0002-9018-7977				Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hohfeld J, 1998, BIOL CHEM, V379, P269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Mayer MP, 1998, BIOL CHEM, V379, P261; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	34	75	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14817	14823		10.1074/jbc.275.20.14817	http://dx.doi.org/10.1074/jbc.275.20.14817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809723	hybrid			2022-12-25	WOS:000087128300008
J	Nasim, MT; Jaenecke, S; Belduz, A; Kollmus, H; Flohe, L; McCarthy, JEG				Nasim, MT; Jaenecke, S; Belduz, A; Kollmus, H; Flohe, L; McCarthy, JEG			Eukaryotic selenocysteine incorporation follows a nonprocessive mechanism that competes with translational termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; INSERTION-SEQUENCE ELEMENT; MESSENGER-RNA STABILITY; SELENOPROTEIN SYNTHESIS; COTRANSLATIONAL INCORPORATION; FUNCTIONAL-CHARACTERIZATION; ESCHERICHIA-COLI; BINDING PROTEIN; XENOPUS-LAEVIS; AMINO-ACID	The synthesis of eukaryotic selenoproteins involves the recoding of an internal UGA codon as a site for selenocysteine incorporation. This recoding event is directed by a selenocysteine insertion sequence in the 3'-untranslated region. Because UGA also functions as a signal for peptidyl-tRNA hydrolysis, we have investigated how the rates of translational termination and selenocysteine incorporation relate to cia-acting elements in the mRNA as well as to trans-acting factors in the cytoplasm, We used cia-elements from the phospholipid glutathione peroxidase gene as the basis for this work because of its relatively high efficiency of selenocysteine incorporation. The last two codons preceding the UGA were found to exert a far greater influence on selenocysteine incorporation than nucleotides downstream of it, The efficiency of selenocysteine incorporation was generally much less than 100% but could be partially enhanced by concomitant overexpression of the tRNA(Sec) gene. The combination of two or three UGA codons in one reading frame led to a dramatic reduction in the yield of full-length protein. It is therefore unlikely that multiple incorporations of selenocysteine are processive with respect to the mode of action of the ribosomal complex binding to the UGA site. These observations are discussed in terms of the mechanism of selenoprotein synthesis and its ability to compete with termination at UGA codons.	Univ Manchester, Dept Biomol Sci, Postranscript Control Grp, Manchester M60 1QD, Lancs, England; Tech Univ Carolo Wilhelmina Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany	University of Manchester; Braunschweig University of Technology	McCarthy, JEG (corresponding author), Univ Manchester, Dept Biomol Sci, Postranscript Control Grp, POB 88, Manchester M60 1QD, Lancs, England.	J.McCarthy@umist.ac.uk	BELDUZ, Ali Osman/A-1642-2018	BELDUZ, Ali Osman/0000-0003-2240-7568; Nasim, Talat/0000-0003-1968-5663				BARON C, 1993, P NATL ACAD SCI USA, V90, P4181, DOI 10.1073/pnas.90.9.4181; Bermano G, 1996, FEBS LETT, V387, P157, DOI 10.1016/0014-5793(96)00493-0; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HILL KE, 1991, J BIOL CHEM, V266, P10050; Hubert N, 1996, NUCLEIC ACIDS RES, V24, P464, DOI 10.1093/nar/24.3.464; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Maquat LE, 1996, AM J HUM GENET, V59, P279; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Moustafa ME, 1998, RNA, V4, P1436, DOI 10.1017/S1355838298981043; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Sambrook J., 1989, MOL CLONING, pA1; Shen QC, 1998, J BIOL CHEM, V273, P5443, DOI 10.1074/jbc.273.10.5443; Shen QC, 1995, J BIOL CHEM, V270, P30448, DOI 10.1074/jbc.270.51.30448; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Suppmann S, 1999, EMBO J, V18, P2284, DOI 10.1093/emboj/18.8.2284; TASSAN JP, 1993, MOL CELL BIOL, V13, P2815, DOI 10.1128/MCB.13.5.2815; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walczak R, 1998, RNA, V4, P74; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; YAMADA K, 1994, FEBS LETT, V347, P137, DOI 10.1016/0014-5793(94)00523-0; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	41	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14846	14852		10.1074/jbc.275.20.14846	http://dx.doi.org/10.1074/jbc.275.20.14846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809727	hybrid			2022-12-25	WOS:000087128300012
J	Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B				Davezac, N; Baldin, V; Gabrielli, B; Forrest, A; Theis-Febvre, N; Yashida, M; Ducommun, B			Regulation of CDC25B phosphatases subcellular localization	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinases; CDC25B; localization; nuclear export sequence	NUCLEAR EXPORT; FISSION YEAST; TRANSCRIPTION FACTOR; MITOTIC INDUCER; PROTEIN-KINASE; CDK REGULATION; DNA-DAMAGE; MITOSIS; SIGNAL; TRIGGERS	The CDC25B dual specificity phosphatase is involved in the control of the G2/M transition of the cell cycle. Subcellular localization might represent an important aspect of the regulation of its activity, We have examined in transiently transfected asynchronous HeLa cells the localization of HA-tagged CDC25B proteins and found that they are nuclear or cytoplasmic suggesting the existence of an active shuttling. Accordingly, localization analysis of deletion and truncation proteins indicates that CDC25B contains a putative nuclear localization signal located between residues 335 and 353. We also demonstrated that a short 58 residues deletion of the amino-terminus end of CDC25B is sufficient to retain it to the nucleus, Mutational analysis indicates that a nuclear export sequence is located between residues 28 and 40. In addition, treatment of the cells with the exportin inhibitor, Leptomycin B, has the same effect, The mutation of Ser-323, a residue that is essential for the interaction with 14-3-3 proteins, also abolishes cytoplasmic staining. The subcellular localization of CDC25B is therefore dependent on the combined effects of a nuclear localization signal, a nuclear export signal and on the interaction with 14-3-3 proteins.	Univ Toulouse 3, LBCMCP, CNRS UMR5088, F-31062 Toulouse, France; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Tokyo	Ducommun, B (corresponding author), Univ Toulouse 3, LBCMCP, CNRS UMR5088, 118 Route Narbonne, F-31062 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; Forrest, Alistair/A-6597-2008; BALDIN, Véronique/Y-8397-2019; Gabrielli, Brian G/B-3655-2011	Forrest, Alistair/0000-0003-4543-1675; BALDIN, Véronique/0000-0001-8523-0494; Gabrielli, Brian G/0000-0003-3933-1651; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	31	88	91	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2179	2185		10.1038/sj.onc.1203545	http://dx.doi.org/10.1038/sj.onc.1203545			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822367				2022-12-25	WOS:000086974100002
J	Bennett, TA; Maestas, DC; Prossnitz, ER				Bennett, TA; Maestas, DC; Prossnitz, ER			Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; PHOSPHORYLATION; ACTIVATION; DESENSITIZATION; MODEL; INTERNALIZATION; ENDOCYTOSIS; MECHANISMS; RHODOPSIN; KINASES	Following activation by ligand, the N-formyl peptide receptor (FPR) undergoes processing events initiated by phosphorylation that lead to receptor desensitization and internalization. Our previous results have shown that FPR internalization can occur in the absence of receptor desensitization, suggesting that FPR desensitization and internalization are controlled by distinct mechanisms. More recently, we have provided evidence that internalization of the FPR occurs via a mechanism that is independent of the actions of arrestin, dynamin, and clathrin. In the present report, we demonstrate that stimulation of the FPR with agonist leads to a significant translocation of arrestin-2 from the cytosol to the membrane. Fluorescence microscopy revealed that the translocated arrestin-2 is highly colocalized with the Ligand-bound FPR, A D71A mutant FPR, which does not undergo activation or phosphorylation in response to ligand, did not colocalize with arrestin-2. Surprisingly, an R123G mutant FPR, which does not bind G protein but does become phosphorylated and subsequently internalized, also did not bind arrestin, These results indicate that arrestin binding is not required for FPR internalization and demonstrate for the first time that a common motif, the conserved "DRY" domain of G protein-coupled receptors, is essential for phosphorylation-dependent arrestin binding, as well as G protein activation.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.		Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302; 	NIAID NIH HHS [AI36357, AI43932] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043932, R29AI036357, R01AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Gilbert TL, 1999, J RECEPT SIGNAL TR R, V19, P327, DOI 10.3109/10799899909036655; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	28	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24590	24594		10.1074/jbc.C000314200	http://dx.doi.org/10.1074/jbc.C000314200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823817	hybrid			2022-12-25	WOS:000088683300049
J	Kanungo, J; Potapova, I; Malbon, CC; Wang, HY				Kanungo, J; Potapova, I; Malbon, CC; Wang, HY			MEKK4 mediates differentiation in response to retinoic acid via activation of c-Jun N-terminal kinase in rat embryonal carcinoma P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; PRIMITIVE ENDODERM; STEM-CELLS; G(I-ALPHA-2); EXPRESSION; ADIPOCYTES; DISEASE	Differentiation of pie embryonal carcinoma cells in response to the morphogen retinoic acid is regulated by G alpha(12/13) and is associated with activation of c-Jun N-terminal kinase. The role of MEKK1 and MEKK4 up-stream of the c-Jun N-terminal kinase was investigated in P19 cells. P19 clones stably expressing constitutively active and dominant negative mutants of MEKK1 and MEKK4 were created and characterized. Expression of the constitutively active form of either MEKK1 or MEKK4 mimicked the action of retinoic acid, inducing these embryonal carcinoma cells to primitive endoderm. Expression of the dominant negative form of MEKK1 had no influence on the ability of retinoic acid to induce either JNK activation or primitive endoderm formation in P19 stern cells. Expression of the dominant negative form of MEKK4, in contrast, effectively blocks both morphogen-induced activation of JNK and cellular differentiation. These data identify MEKK4 as upstream of c-Jun N-terminal kinase in the pathway mediating differentiation of P19 stem cells to primitive endoderm.	SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Univ Med Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Univ Med Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Dept Mol Pharmacol, Univ Med Ctr, Stony Brook, NY 11794 USA.	craig@pharm.som.sunysb.edu	malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FANGER BO, 1991, REGUL PEPTIDES, V32, P241, DOI 10.1016/0167-0115(91)90018-C; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GAO P, 1995, AM J PHYSIOL-CELL PH, V268, pC1460, DOI 10.1152/ajpcell.1995.268.6.C1460; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRAHAM CF, 1979, DIFFERENTIATION, V13, P29, DOI 10.1111/j.1432-0436.1979.tb01611.x; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; OTTE AP, 1992, DEVELOPMENT, V116, P141; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Spiegel AM, 1997, J INHERIT METAB DIS, V20, P113, DOI 10.1023/A:1005393501786; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1991, J CELL SCI, P27; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; YAN MH, 1994, NATURE, V372, P798	30	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24032	24039		10.1074/jbc.M002747200	http://dx.doi.org/10.1074/jbc.M002747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807916	hybrid			2022-12-25	WOS:000088564200086
J	Mandal, D; Woolf, TB; Rao, R				Mandal, D; Woolf, TB; Rao, R			Manganese selectivity of Pmr1, the yeast secretory pathway ion pump, is defined by residue Gln(783) in transmembrane segment 6 - Residue Asp(778) is essential for cation transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; CALCIUM PUMPS; MEMBRANE; CA2+; CA2+-ATPASE; DOMAIN; PROTEINS; GOLGI	We have solubilized and purified the histidine-tagged yeast secretory pathway/Golgi ion pump Pmr1 to near homogeneity in one step, using nickel affinity chromatography, The purified pump demonstrates both Ca2+- and Mn2+-dependent ATP hydrolysis and phosphoenzyme intermediate formation in forward (ATP) and reverse (P-i) directions. This preparation has allowed us to examine, in detail, the properties of mutations D778A and Q783A in transmembrane segment M6 of Pmr1, In phenotypic screens of Ca2+ chelator and Mn2+ toxicity reported separately (Wei, Y,, Chen, J,, Rosas, G., Tompkins, D.A., Holt, P.A., and Rao, R. (2000) J. Biol. Chem. 275, XXXX-XXXX), D778A was a loss-of-function mutant apparently defective for transport of both Ca2+ and Mn2+, whereas mutant Q783A displayed a differential sensitivity consistent with the selective loss of Mn2+ transport. We show that mutant D778A is devoid of cation-dependent ATP hydrolytic activity and phosphoenzyme formation from ATP, However, reverse phosphorylation from P-i is preserved but is insensitive to inhibition by Ca2+ or Mn2+ ions, which is evidence for a specific inability to bind cations in this mutant. We also show that Ca2+ can activate ATP hydrolysis in the purified Q783A mutant, with a half-maximal concentration of 0.06 mu M, essentially identical to that of wild type (0.07 mu M). Mn2+ activation of ATP hydrolysis was half-maximal at 0.02 mu M in wild type, establishing a normal selectivity profile of Mn2+ > Ca2+, Strikingly, Mn2+-ATPase in the Q783A mutant was nearly abolished, even at concentrations of up to 10 mu M. These results were confirmed in assays of phosphoenzyme intermediates. Molecular modeling of the packing between helices M4 and M6 suggests that residue Gln(783) in M6 may form a critical hydrophobic interaction with Val(335) in M4, such that the Ala substitution modifies the packing or tilt of the helices and thus the ion pore. The data emphasize the critical role of transmembrane segment M6 in defiing the cation binding pocket of P-type ATPases.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rrao@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Fu DX, 1997, J BIOL CHEM, V272, P2129; GHOSH J, 1990, J BIOL CHEM, V265, P11345; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HAWKINS C, 1994, BBA-BIOMEMBRANES, V1191, P231, DOI 10.1016/0005-2736(94)90174-0; KAWASAKI H, 1986, J BIOCHEM-TOKYO, V99, P1409, DOI 10.1093/oxfordjournals.jbchem.a135610; Keller C H, 1980, Ann N Y Acad Sci, V356, P205, DOI 10.1111/j.1749-6632.1980.tb29612.x; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LAWRENCE GD, 1978, COORDIN CHEM REV, V27, P173, DOI 10.1016/S0010-8545(00)80358-6; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Loneragan J.F., 1988, MANGANESE SOILS PLAN, P113; LOUKIN S, 1995, J CELL BIOL, V131, P1025, DOI 10.1083/jcb.131.4.1025; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Osterberg R, 1974, MET IONS BIOL SYST, V3, P45; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Reed G.H., 1986, MANGANESE METABOLISM, P313; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Sachs JN, 2000, BIOPHYS J, V78, p159A; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; Sorin A, 1997, J BIOL CHEM, V272, P9895; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; WEBER K, 1969, J BIOL CHEM, V244, P4406; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; WILLIAMS RJP, 1982, FEBS LETT, V140, P3, DOI 10.1016/0014-5793(82)80508-5; WILSON SP, 1983, J BIOL CHEM, V258, P4994; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	41	95	102	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23933	23938		10.1074/jbc.M002619200	http://dx.doi.org/10.1074/jbc.M002619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801856	hybrid			2022-12-25	WOS:000088564200073
J	Mu, XM; Liu, YX; Collins, LL; Kim, E; Chang, CS				Mu, XM; Liu, YX; Collins, LL; Kim, E; Chang, CS			The p53/retinoblastoma-mediated repression of testicular orphan receptor-2 in the rhesus monkey with cryptorchidism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; GERM-CELL APOPTOSIS; STEROID-RECEPTOR; RETINOBLASTOMA PROTEIN; DIFFERENTIAL REGULATION; MOLECULAR-CLONING; RESPONSE ELEMENT; P53 PROTEIN; RAT TESTIS; GENE	Whereas the linkage of infertility to cryptorchidism, the failure of the testis to descend into the scrotum at birth, has been well documented, the detailed molecular mechanism remains unclear. Here we report that the testicular orphan receptor-2 (TR2) expression, which modulates many signal pathways, was completely repressed in the surgery-induced cryptorchidism of the rhesus monkey. Further studies link TR2 repression to the induction of p53 and results suggest that induced p53 could repress TR2 expression via the p53 --> p21 --> CDK --> Rb --> E2F signal pathway. In return, TR2 could also control the expression of p53 and Rb through the regulation of human papillomavirus 16 E6/E7 genes, Together, our data suggest a feedback control mechanism between TR2 and p53/Rb tumor suppressors, which might play important roles in male infertility associated with cryptorchidism.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; Chinese Acad Sci, Inst Zool, Beijing 100080, Peoples R China	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Chinese Academy of Sciences; Institute of Zoology, CAS	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOWDHURY AK, 1970, J REPROD FERTIL, V22, P205, DOI 10.1530/jrf.0.0220205; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CordonCardo C, 1997, CANCER RES, V57, P1217; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DAVIS LG, 1986, BASIC METHODS MOL BI, P322; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FRANKENHUIS MT, 1979, FERTIL STERIL, V31, P428; FUKUI N, 1923, JPN MED WORLD, V3, P160; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo CX, 1999, BIOCHEM BIOPH RES CO, V258, P401, DOI 10.1006/bbrc.1999.0654; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; JACKS T, 1992, NATURE, V359, P285; JENSEN TK, 1995, CLIN CHEM, V41, P1896; Lee CH, 1999, BIOCHEMISTRY-US, V38, P8820, DOI 10.1021/bi9903547; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee HJ, 1999, MOL CELL BIOCHEM, V194, P199, DOI 10.1023/A:1006903202089; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1999, J BIOL CHEM, V274, P16198, DOI 10.1074/jbc.274.23.16198; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE RJ, 1990, NEW ENGL J MED, V323, P12, DOI 10.1056/NEJM199007053230103; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Mu XM, 1998, ENDOCRINE, V9, P27, DOI 10.1385/ENDO:9:1:27; MUNGER K, 1989, J VIROL, V63, P4417; NISHIMUNE Y, 1986, ARCH ANDROLOGY, V16, P89, DOI 10.3109/01485018608986927; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Poluha W, 1996, MOL CELL BIOL, V16, P1335; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHIKONE T, 1994, BIOL REPROD, V51, P865, DOI 10.1095/biolreprod51.5.865; SIGMAN M, 1992, CAMPBELLS UROLOGY, P681; UEMURA H, 1995, J BIOL CHEM, V270, P5427, DOI 10.1074/jbc.270.10.5427; VILLUMSEN AL, 1966, ARCH DIS CHILD, V41, P198, DOI 10.1136/adc.41.216.198; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAVETZ H, 1992, ANDROLOGIA, V24, P293; Yin YZ, 1998, BIOL REPROD, V58, P492, DOI 10.1095/biolreprod58.2.492; Yin YZ, 1997, J ANDROL, V18, P159; Young WJ, 1998, J BIOL CHEM, V273, P20877, DOI 10.1074/jbc.273.33.20877; Yu XM, 1997, J VIROL, V71, P9366, DOI 10.1128/JVI.71.12.9366-9374.1997	64	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23877	23883		10.1074/jbc.M910158199	http://dx.doi.org/10.1074/jbc.M910158199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10811662	hybrid			2022-12-25	WOS:000088564200065
J	Schroeder, BC; Hechenberger, M; Weinreich, F; Kubisch, C; Jentsch, TJ				Schroeder, BC; Hechenberger, M; Weinreich, F; Kubisch, C; Jentsch, TJ			KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; IDIOPATHIC EPILEPSY; CARDIAC-ARRHYTHMIAS; K+ CHANNELS; KVLQT1; GENE; LINOPIRDINE; MUTATION; CELLS; INACTIVATION	KCNQ2 and KCNQ3, both of which are mutated in a type of human neonatal epilepsy, form heteromeric potassium channels that are expressed in broad regions of the brain. The associated current may be identical to the M-current, an important regulator of neuronal excitability. We now show that the RNA encoding the novel KCNQ5 channel is: also expressed in brain and in sympathetic ganglia where it overlaps largely with KCNQ2 and KCNQ3. In addition, it is expressed in skeletal muscle, KCNQ5 yields currents that activate slowly with depolarization and can form heteromeric channels with KCNQ3, Currents expressed from KCNQ5 have voltage dependences and inhibitor sensitivities in common with M-currents. They are also inhibited by M1 muscarinic receptor activation. A KCNQ5 splice variant found in skeletal muscle displays altered gating kinetics. This indicates a molecular diversity of channels yielding M-type currents and suggests a role for KCNQ5 in the regulation of neuronal excitability.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; Jentsch, Thomas/0000-0002-3509-2553				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1989, J PHYSIOL-LONDON, V413, P469, DOI 10.1113/jphysiol.1989.sp017664; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; BUSCH AE, 1994, MOL PHARMACOL, V46, P750; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Cloues R, 1996, BIOPHYS J, V70, P806, DOI 10.1016/S0006-3495(96)79620-0; Costa AMN, 1997, NEUROPHARMACOLOGY, V36, P1747, DOI 10.1016/S0028-3908(97)00155-X; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Kharkovets T, 2000, P NATL ACAD SCI USA, V97, P4333, DOI 10.1073/pnas.97.8.4333; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lamas JA, 1997, EUR J NEUROSCI, V9, P605, DOI 10.1111/j.1460-9568.1997.tb01637.x; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Marrion NV, 1997, TRENDS NEUROSCI, V20, P243; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Meves H, 1999, BRIT J PHARMACOL, V127, P1213, DOI 10.1038/sj.bjp.0702642; Nakamura M, 1998, RECEPTOR CHANNEL, V5, P255; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Pusch M, 1998, BIOPHYS J, V75, P785, DOI 10.1016/S0006-3495(98)77568-X; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; Selyanko AA, 2000, J PHYSIOL-LONDON, V522, P349, DOI 10.1111/j.1469-7793.2000.t01-2-00349.x; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; Selyanko AA, 1999, J NEUROSCI, V19, P7742; Shapiro MS, 2000, J NEUROSCI, V20, P1710; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Stansfeld C, 1997, TRENDS NEUROSCI, V20, P13, DOI 10.1016/S0166-2236(96)20058-X; STANSFELD CE, 1993, NEURON, V10, P639, DOI 10.1016/0896-6273(93)90166-O; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tinel N, 1998, FEBS LETT, V438, P171, DOI 10.1016/S0014-5793(98)01296-4; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; TSAI MC, 1992, NEUROPHARMACOLOGY, V31, P89, DOI 10.1016/0028-3908(92)90166-M; VILLARROEL A, 1994, J NEUROSCI, V14, P7053; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419; Zaczek R, 1998, J PHARMACOL EXP THER, V285, P724	43	304	326	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24089	24095		10.1074/jbc.M003245200	http://dx.doi.org/10.1074/jbc.M003245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816588	hybrid			2022-12-25	WOS:000088564200093
J	Li, LW; Cousart, S; Hu, J; McCall, CE				Li, LW; Cousart, S; Hu, J; McCall, CE			Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; ADAPTER PROTEIN; LIPOPOLYSACCHARIDE; IRAK; MICE; SEPSIS; MYD88; GENE; EXPRESSION; FAMILY	Interleukin-1 receptor-associated kinase (IRAK), a signal transducer for interleukin-1, has also been suggested to participate in the Toll-like receptor-mediated innate immune response to bacterial endotoxin Lipopolysaccharide (LPS). Using the human promonocytic THP-1 cell line, we demonstrated that the endogenous IRAK is quickly activated in response to bacterial LPS stimulation, as measured by its in vitro kinase activity toward myelin basic protein. LPS also triggers the association of IRAK with MyD88, the adaptor protein linking IRAK to the Toll-like receptor/interleukin-1 beta receptor intracellular domain. Macrophage cells with prolonged LPS treatment become tolerant to additional dose of LPS and no longer express inflammatory cytokines, Endotoxin tolerance is a common phenomenon observed in blood from sepsis patients. We observed for the first time that the quantity of IRAK is greatly reduced in LPS-tolerant THP-1 cells, and its activity no longer responds to further LPS challenge. In addition, IRAK does not associate with MyD88 in the tolerant cells. Furthermore, application of AG126, a putative tyrosine kinase inhibitor, can substantially alleviate the LPS-induced cytokine gene expression and can also decrease IRAK level and activity. Our study indicates that IRAK is essential for LPS-mediated signaling and that cells may develop endotoxin tolerance by down-regulating IRAK.	Wake Forest Univ, Sch Med, Dept Med, Infect Dis Sect, Winston Salem, NC 27157 USA	Wake Forest University	Li, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Med, Infect Dis Sect, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.			Li, Liwu/0000-0001-8870-5299	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009169, R21AI009169] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09169] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dushay MS, 1998, AM J HUM GENET, V62, P10, DOI 10.1086/301694; Hoshino K, 1999, J IMMUNOL, V162, P3749; Inoue M, 1999, BIOCHEM BIOPH RES CO, V264, P276, DOI 10.1006/bbrc.1999.1515; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; Thomas JA, 1999, J IMMUNOL, V163, P978; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	25	210	235	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23340	23345		10.1074/jbc.M001950200	http://dx.doi.org/10.1074/jbc.M001950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10811644	hybrid			2022-12-25	WOS:000088419400102
J	Dai, J; Zhu, HF; Shi, JY; Woldegiorgis, G				Dai, J; Zhu, HF; Shi, JY; Woldegiorgis, G			Identification by mutagenesis of conserved arginine and tryptophan residues in rat liver carnitine palmitoyltransferase I important for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MALONYL-COA; CHEMICAL MODIFICATION; HEART; BINDING; ACETYLTRANSFERASE; EXPRESSION; ISOFORM; PROTEIN; ALANINE	Carnitine palmitoyltransferase I catalyzes the conversion of long-chain acyl-CoA to acylcarnitines in the presence of L-carnitine. To determine the role of the conserved arginine and tryptophan residues on catalytic activity in the liver isoform of carnitine palmitoyltransferase I (L-CPTI), we separately mutated five conserved arginines and two tryptophans to alanine. Substitution of arginine residues 388, 451, and 606 with alanine resulted in loss of 88, 82, and 93% of L-CPTI activity, respectively, Mutants R601A and R655A showed less than 2% of the wild type L-CPTI activity. A change of tryptophan 391 and 452 to alanine resulted in 50 and 93% loss in carnitine palmitoyltransferase activity, respectively. The mutations caused decreases in catalytic efficiency of 80-98%. The residual activity in the mutant L-CPTIs was sensitive to malonyl-CoA inhibition. Mutants R388A, R451A, R606A, W391A, and W452A had no effect on the K-m values for carnitine or palmitoyl-Cok However, these mutations decreased the V-max values for both substrates by 10-40-fold, suggesting that the main effect of the mutations was to decrease the stability of the enzyme-substrate complex. We suggest that conserved arginine and tryptophan residues in L-CPTI contribute to the stabilization of the enzyme-substrate complex by charge neutralization and hydrophobic interactions. The predicted secondary structure of the 100-amino acid residue region of L-CPTI, containing arginines 388 and 451 and tryptophans 391 and 452, consists of four alpha-helices similar to the known three-dimensional structure of the acyl-CoA-binding protein. We predict that this 100-amino acid residue region constitutes the putative palmitoyl-CoA-binding site in L-CPTI.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA		Woldegiorgis, G (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	gwoldeg@bmb.ogi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bonnefont JP, 1996, AM J HUM GENET, V58, P971; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P19157; CORR PB, 1995, HERZ, V20, P156; Cronin CN, 1997, EUR J BIOCHEM, V247, P1029, DOI 10.1111/j.1432-1033.1997.01029.x; DAY PJ, 1992, J BIOL CHEM, V267, P5122; Delomenie C, 1997, BIOCHEM J, V323, P207, DOI 10.1042/bj3230207; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Knudsen J, 2000, J NUTR, V130, p294S, DOI 10.1093/jn/130.2.294S; KRAELUND BB, 1999, BIOCHEMISTRY-US, V38, P2386; KRAELUND BB, 1993, J MOL BIOL, V230, P1260; Kragelund BB, 1999, NAT STRUCT BIOL, V6, P594; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; SHANMUGASUNDARAM T, 1989, BIOCHEMISTRY-US, V28, P7112, DOI 10.1021/bi00443a049; SHANMUGASUNDARAM T, 1988, BIOCHEMISTRY-US, V27, P6499, DOI 10.1021/bi00417a045; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Taggart RT, 1999, HUM MUTAT, V13, P210; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; Woldegiorgis G, 2000, J NUTR, V130, p310S, DOI 10.1093/jn/130.2.310S; WU DH, 1995, J BIOL CHEM, V270, P29111, DOI 10.1074/jbc.270.49.29111; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	31	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22020	22024		10.1074/jbc.M002118200	http://dx.doi.org/10.1074/jbc.M002118200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801831	hybrid			2022-12-25	WOS:000088363800039
J	Hirosaki, T; Mizushima, H; Tsubota, Y; Moriyama, K; Miyazaki, K				Hirosaki, T; Mizushima, H; Tsubota, Y; Moriyama, K; Miyazaki, K			Structural requirement of carboxyl-terminal globular domains of laminin alpha 3 chain for promotion of rapid cell adhesion and migration by laminin-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; GASTRIC-CARCINOMA CELLS; BASEMENT-MEMBRANES; PLASMINOGEN-ACTIVATOR; EPIDERMAL JUNCTION; EPITHELIAL-CELLS; HEPARIN-BINDING; SCATTER FACTOR; GAMMA-2 CHAIN; HUMAN TISSUES	The basement membrane protein laminin-5, a heterotrimer of laminin alpha 3, beta 3, and gamma 2 chains, potently promotes cellular adhesion and motility, It has been supposed that the carboxyl-terminal globular region of the alpha 3 chain consisting of five distinct domains (G1 to G5) is important for its interaction with integrins, To clarify the function of each G domain, we transfected cDNAs for the full-length (wild type (WT)) and five deletion derivatives (Delta Gs) of the a3 chain into human fibrosarcoma cell line HT1080, which expressed and secreted the laminin beta 3 and gamma 2 chains but not the alpha 3 chain. The transfectants with the alpha 3 chain cDNAs lacking G5 (Delta G(5)), G4-5 (Delta G(4-5)), G3-5 (Delta G(3-5)), and G2-5 (Delta G(2-5)) secreted laminin-5 variants at levels comparable to that with WT cDNA However, the transfectant with the cDNA without any G domains (Delta G(1-5)) secreted little laminin-5, suggesting that the G domains are essential for the efficient assembly and secretion of the heterotrimer alpha 3 beta 3 gamma 2, The transfectants with WT, Delta G(5), and Delta G(4-5) cDNAs survived in serum-free medium longer than those with Delta G(3-5), Delta G(2-5), and Delta G(1-5) cDNAs, The transfectants with WT, Delta G(5), and Delta G(4-5) cDNAs secreted apparently the same size of laminin-5, which lacked G4 and G5 due to proteolytic cleavage between G3 and G4, and these laminin-5 forms potently promoted integrin alpha(3)beta(1)-dependent cell adhesion and migration, However, the laminin-5 forms of Delta G(3-5) and Delta G(2-5) hardly promoted the cell adhesion and motility, These findings demonstrate that the G3 domain, but not the G4 and G5 domains, of the alpha 3 chain is essential for the potent promotion of cell adhesion and motility bg laminin-5.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 642-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.							ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Aumailley M, 1999, MATRIX BIOL, V18, P19, DOI 10.1016/S0945-053X(98)00004-3; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; GEE SH, 1993, J BIOL CHEM, V268, P14972; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; GRORGESLABOUESS.E, 1996, NAT GENET, V13, P370; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Koshikawa N, 1999, CANCER RES, V59, P5596; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Pattaramalai S, 1996, EXP CELL RES, V222, P281, DOI 10.1006/excr.1996.0036; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; PYKE C, 1995, CANCER RES, V55, P4132; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1988, BIOCHIM BIOPHYS ACTA, V942, P45, DOI 10.1016/0005-2736(88)90273-8; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	37	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22495	22502		10.1074/jbc.M001326200	http://dx.doi.org/10.1074/jbc.M001326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10801807	hybrid			2022-12-25	WOS:000088363800099
J	Emmerich, NPN; Nussbaum, AK; Stevanovic, S; Priemer, M; Toes, REM; Rammensee, HG; Schild, H				Emmerich, NPN; Nussbaum, AK; Stevanovic, S; Priemer, M; Toes, REM; Rammensee, HG; Schild, H			The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ANTIGEN PRESENTATION; ORNITHINE DECARBOXYLASE; ENDOPLASMIC-RETICULUM; REGULATORY PARTICLE; DISULFIDE-ISOMERASE; BETA-SUBUNITS; CELL-PROTEINS; C-FOS; DEGRADATION	Intracellular protein degradation is a major source of short antigenic peptides that can be presented on the cell surface in the context of major histocompatibility class I molecules for recognition by cytotoxic T lymphocytes. The capacity of the most important cytosolic protease, the 20 S proteasome, to generate peptide fragments with an average length of 7-8 amino acid residues has been thoroughly investigated. It has been shown that the cleavage products are not randomly generated, but originate from the commitment of the catalytically active subunits to complex recognition motifs in the primary amino acid sequence. The role of the even larger 26 S proteasome is less well defined, however. It has been demonstrated that the 26 S proteasome can bind and degrade ubiquitin-tagged proteins and minigene translation products in vivo and in vitro, but the nature of the degradation products remains elusive. In this study, we present the first analysis of cleavage products from in vitro digestion of the unmodified model substrate beta-casein with both the 26 S and 20 S proteasome. The data we obtained show that 26 S and 20 S proteasomes generate overlapping, but at the same time substantially different, sets of fragments by following very similar instructions.	Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Leiden Univ, Med Ctr, Dept Immunohematol & Bloodbank, NL-2300 RC Leiden, Netherlands	Eberhard Karls University of Tubingen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Schild, H (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.			Toes, Rene/0000-0002-9618-6414				Anton LC, 1998, J IMMUNOL, V160, P4859; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BenShahar S, 1997, J BIOL CHEM, V272, P21060, DOI 10.1074/jbc.272.34.21060; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; COX JH, 1995, J IMMUNOL, V154, P511; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; Dick TP, 1998, EUR J IMMUNOL, V28, P2478, DOI 10.1002/(SICI)1521-4141(199808)28:08<2478::AID-IMMU2478>3.3.CO;2-L; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; KUEHN L, 1989, BIOCHIM BIOPHYS ACTA, V991, P263, DOI 10.1016/0304-4165(89)90114-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammert E, 1997, EUR J IMMUNOL, V27, P1685, DOI 10.1002/eji.1830270714; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; RAMMENSEE H, 1999, MHC LIGANDS PEPTIDE; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; Tobery T, 1999, J IMMUNOL, V162, P639; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; [No title captured]	48	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21140	21148		10.1074/jbc.M000740200	http://dx.doi.org/10.1074/jbc.M000740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801794	hybrid			2022-12-25	WOS:000088230600026
J	Choi, Y; Asada, S; Uesugi, M				Choi, Y; Asada, S; Uesugi, M			Divergent hTAF(II)31-binding motifs hidden in activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE TAFS; TRANSCRIPTIONAL ACTIVATION; DNA-DAMAGE; DROSOPHILA-TRITHORAX; REGULATORY DOMAIN; ACUTE LEUKEMIAS; IN-VIVO; P53; PROTEIN; PHOSPHORYLATION	Activation domains are functional modules that enable DNA-binding proteins to stimulate transcription. Characterization of these essential modules in transcription factors has been hampered by their low sequence homology. Here we delineate the peptide sequences that are required for transactivation and interaction with hTAF(II)31, a classical target of the acidic class of activation domains. Our analyses indicate that hTAF(II)31 recognizes a diverse set of sequences for transactivation. This information enabled the identification of hTAF(II) 31-binding sequences that are critical for the activity of the activation domains of five human transcription factors: NFAT1, ALL1, NF-IL6, ESX, and HSF-1. The interaction surfaces are localized in short peptide segments of activation domains. The brevity and heterogeneity of the motifs may explain the low sequence homology among acidic activation domains.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Uesugi, M (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.		Uesugi, Motonari/AAM-9777-2020					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15912	15916		10.1074/jbc.275.21.15912	http://dx.doi.org/10.1074/jbc.275.21.15912			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821850	hybrid			2022-12-25	WOS:000087291400042
J	Gao, GF; Willcox, BE; Wyer, JR; Boulter, JM; O'Callaghan, CA; Maenaka, K; Stuart, DI; Jones, EY; Van Der Merwe, PA; Bell, JI; Jakobsen, BK				Gao, GF; Willcox, BE; Wyer, JR; Boulter, JM; O'Callaghan, CA; Maenaka, K; Stuart, DI; Jones, EY; Van Der Merwe, PA; Bell, JI; Jakobsen, BK			Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8 alpha alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; CYTOTOXIC LYMPHOCYTES-T; MHC CLASS-I; HLA-G; ALPHA-3 DOMAIN; CRYSTAL-STRUCTURE; NEGATIVE SELECTION; NK CELLS; CD8; PEPTIDE	The cell surface molecules CD4 and CD8 greatly enhance the sensitivity of T-cell antigen recognition, acting as "co-receptors" by binding to the same major histocompatibility complex (MHC) molecules as the T-cell receptor (TCR), Here we use surface plasmon resonance to study the binding of CD8 alpha alpha to class I MHC molecules. CD8 alpha alpha bound the classical MHC molecules HLA-A*0201, -A*1101, -B*3501, and -C*0702 with dissociation constants (K-d) of 90-220 mu M, a range of affinities distinctly lower than that of TCR/peptide-MHC interaction. We suggest such affinities apply to most CD8 alpha alpha/classical class I MHC interactions and may be optimal for T-cell recognition. In contrast, CD8 alpha alpha bound both HLA-A*6801 and B*4801 with a significantly lower affinity (greater than or equal to 1 mM), consistent with the finding that interactions with these alleles are unable to mediate cell-cell adhesion. Interestingly, CD8 alpha alpha bound normally to the nonclassical MHC molecule HLA-G (K-d similar to 150 mu M), but only weakly to the natural killer cell receptor ligand HLA-E (K-d greater than or equal to 1 mM). Site-directed mutagenesis experiments revealed that variation in CD8 alpha alpha binding affinity can be explained by amino acid differences within the alpha 3 domain. Taken together with crystallographic studies, these results indicate that subtle conformational changes in the solvent exposed alpha 3 domain loop (residues 223-229) can account for the differential ability of both classical and nonclassical class I MHC molecules to bind CD8.	John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, MRC, Oxford OX3 9DS, England; Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DS, England; Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; Howard Hughes Medical Institute; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Jakobsen, BK (corresponding author), John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, MRC, Oxford OX3 9DS, England.		van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/J-2293-2016; Gao, George Fu/ABD-5229-2021; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; CHUMBLEY G, 1994, CELL IMMUNOL, V155, P312, DOI 10.1006/cimm.1994.1125; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DENIZ G, 1994, J IMMUNOL, V152, P4255; Diehl M, 1996, CURR BIOL, V6, P305, DOI 10.1016/S0960-9822(02)00481-5; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Gao GF, 1998, PROTEIN SCI, V7, P1245, DOI 10.1002/pro.5560070520; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MartinezNaves E, 1997, TISSUE ANTIGENS, V50, P258, DOI 10.1111/j.1399-0039.1997.tb02869.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOEBIUS U, 1991, EUR J IMMUNOL, V21, P1793, DOI 10.1002/eji.1830210803; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; O'Callaghan CA, 1998, PROTEIN SCI, V7, P1264, DOI 10.1002/pro.5560070525; O'Callaghan CA, 1998, MOL CELL, V1, P531, DOI 10.1016/S1097-2765(00)80053-2; O'Callaghan CA, 1998, IMMUNOL REV, V163, P129, DOI 10.1111/j.1600-065X.1998.tb01192.x; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SANDERS SK, 1991, J EXP MED, V174, P737, DOI 10.1084/jem.174.3.737; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; Soderstrom K, 1997, J IMMUNOL, V159, P1072; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vessey SJR, 1997, EUR J IMMUNOL, V27, P879; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Zuniga-Pflucker J C, 1991, Semin Immunol, V3, P167	37	116	122	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15232	15238		10.1074/jbc.275.20.15232	http://dx.doi.org/10.1074/jbc.275.20.15232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809759	hybrid			2022-12-25	WOS:000087128300063
J	Millet, I; Phillips, RJ; Sherwin, RS; Ghosh, S; Voll, RE; Flavell, RA; Vignery, A; Rincon, M				Millet, I; Phillips, RJ; Sherwin, RS; Ghosh, S; Voll, RE; Flavell, RA; Vignery, A; Rincon, M			Inhibition of NF-kappa B activity and enhancement of apoptosis by the neuropeptide calcitonin gene-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; FETAL-RAT OSTEOBLASTS; T-CELL PROLIFERATION; TRANSCRIPTION FACTORS; MICE LACKING; TNF-ALPHA; TARGETED EXPRESSION; IKK-ALPHA; ACTIVATION; RECEPTOR	Calcitonin gene-related peptide (CGRP) is a neuropeptide produced by the central and peripheral nervous systems and by endocrine cells. CORP exerts diverse biological effects on the cardiovascular, gastrointestinal, respiratory, central nervous and immune systems. Little is known, however, about the molecular mechanisms that mediate CORP effects. Using the NF kappa B-luciferase reporter transgenic mice, here we show that CGRP selectively inhibits NF-kappa B-mediated transcription in thymocytes in vitro and in vivo. In contrast, CGRP does not affect transcription mediated by the AP-1 and NFAT transcription factors. CORP inhibits the accumulation of NF-kappa B complexes in the nucleus by preventing phosphorylation and degradation of the NF-kappa B inhibitor I kappa B. Inhibition of NF-kappa B activity is associated with the induction of apoptosis by CORP in thymocytes. Together these results demonstrate for the first time the selective implication of the NF-kappa B signaling pathway in the regulatory function of the neuropeptide CGRP. Our study suggests a potential molecular mechanism by which CGRP can induce cell death in thymocytes.	Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT 05405 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA	University of Vermont; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Rincon, M (corresponding author), Univ Vermont, Dept Med, Immunobiol Program, Given Med Bldg C305, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R55AR041965] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42138] Funding Source: Medline; NIAMS NIH HHS [AR41965, AR41942] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aiyar N, 1999, MOL CELL BIOCHEM, V197, P179, DOI 10.1023/A:1006962221332; Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ASAHINA A, 1995, J IMMUNOL, V154, P3056; Bakker TR, 1999, J IMMUNOL, V162, P3456; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Ballica R, 1999, J BONE MINER RES, V14, P1067, DOI 10.1359/jbmr.1999.14.7.1067; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERNARD GW, 1990, PEPTIDES, V11, P625, DOI 10.1016/0196-9781(90)90171-Z; BOUDARD F, 1991, J NEUROSCI RES, V29, P29, DOI 10.1002/jnr.490290104; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Bulloch K, 1998, ANN NY ACAD SCI, V840, P551, DOI 10.1111/j.1749-6632.1998.tb09594.x; BULLOCH K, 1991, ANN NY ACAD SCI, V621, P218; BULLOCH K, 1994, ANN NY ACAD SCI, V741, P129; Bulloch K, 1991, PROG NEURENDOCRINIMM, V4, P186; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; Esslinger CW, 1997, J IMMUNOL, V158, P5075; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOODMAN EC, 1986, LIFE SCI, V38, P2169, DOI 10.1016/0024-3205(86)90568-0; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Kanno T, 1996, J IMMUNOL, V157, P5277; Khachatryan A, 1997, J IMMUNOL, V158, P1409; KRUGER L, 1989, J COMP NEUROL, V280, P291, DOI 10.1002/cne.902800210; KURZ B, 1995, PEPTIDES, V16, P1497, DOI 10.1016/0196-9781(95)02042-X; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Marie JC, 1999, J IMMUNOL, V162, P2103; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; MCGILLIS JP, 1995, CAN J PHYSIOL PHARM, V73, P1057, DOI 10.1139/y95-150; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Millet I, 1997, CYTOKINE, V9, P999, DOI 10.1006/cyto.1997.0245; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; QUIRION R, 1992, ANN NY ACAD SCI, V657, P88, DOI 10.1111/j.1749-6632.1992.tb22759.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rincon M, 1996, MOL CELL BIOL, V16, P1074; Rincon Mercedes, 1997, Genes and Function, V1, P51; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; ROSENFELD MG, 1991, ANN NY ACAD SCI, V621, P1; Sakuta H, 1996, J NEUROIMMUNOL, V67, P103; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Teresi S, 1996, IMMUNOL LETT, V50, P105, DOI 10.1016/0165-2478(96)02524-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UMEDA Y, 1988, BIOCHEM BIOPH RES CO, V154, P227, DOI 10.1016/0006-291X(88)90674-2; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verastegui C, 1997, EUR J HISTOCHEM, V41, P119; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG F, 1992, J BIOL CHEM, V267, P21052; Wang W, 1999, J IMMUNOL, V162, P314; Wang X, 1999, J NEUROIMMUNOL, V94, P95, DOI 10.1016/S0165-5728(98)00230-6; WEIHE E, 1989, NEUROSCI LETT, V100, P77, DOI 10.1016/0304-3940(89)90663-0; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	69	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15114	15121		10.1074/jbc.275.20.15114	http://dx.doi.org/10.1074/jbc.275.20.15114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809748	hybrid			2022-12-25	WOS:000087128300048
J	Schmitz, C; Gotthardt, M; Hinderlich, S; Leheste, JR; Gross, V; Vorum, H; Christensen, EI; Luft, FC; Takahashi, S; Willnow, TE				Schmitz, C; Gotthardt, M; Hinderlich, S; Leheste, JR; Gross, V; Vorum, H; Christensen, EI; Luft, FC; Takahashi, S; Willnow, TE			Normal blood pressure and plasma renin activity in mice lacking the renin-binding protein, a cellular renin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE KIDNEY; MOLECULAR-CLONING; GENE; RNBP; IDENTIFICATION; EXPRESSION; PRORENIN; SEQUENCE	In renal extracts, some renin is present as "high molecular weight renin," a heterodimeric complex of renin with the 46-kDa renin-binding protein (RnBP), also known as N-acyl-D-glucosamine a-epimerase. Because RnBP specifically inhibits renin activity, the protein was proposed to play an important role in the regulation of the renin-angiotensin system (RAS), Using gene targeting, we have generated mice lacking RnBP and tested this hypothesis in vivo. In particular, we analyzed biosynthesis, secretion, and activity of renin and other components of the RAS in mice lacking RnBP, Despite extensive investigations, we were unable to detect any major effects of RnBP deficiency on the plasma and renal RAS or on blood pressure regulation. Contrary to previous hypotheses, we conclude that RnBP does not play a significant role in the regulation of renin activity in plasma or kidney, However, RnBP knockout mice excrete an abnormal pattern of carbohydrates in the urine, indicating a role of the protein in renal carbohydrate metabolism.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Free Univ Berlin, Dept Mol Biol & Biochem, D-13125 Berlin, Germany; Humboldt Univ, Franz Volhardt Clin, D-13125 Berlin, Germany; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus C, Denmark; Akita Res Inst Food & Brewing, Akita 0101623, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Aarhus University; Aarhus University	Schmitz, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	cschmitz@mdc-berlin.de	Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Willnow, Thomas/0000-0001-9515-7921; Luft, Friedrich/0000-0002-8635-1199				Bohlender J, 1998, AM J PHYSIOL-HEART C, V274, pH1450, DOI 10.1152/ajpheart.1998.274.5.H1450; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Clausmeyer S, 1999, CIRC RES, V84, P337, DOI 10.1161/01.RES.84.3.337; Gomez R. Ariel, 1995, P1637; Gorg A, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P386; Gross V, 1999, J AM SOC NEPHROL, V10, P1430; IKEMOTO F, 1982, CLIN SCI, V62, P157, DOI 10.1042/cs0620157; INOUE H, 1992, J BIOCHEM-TOKYO, V111, P407, DOI 10.1093/oxfordjournals.jbchem.a123770; INOUE H, 1990, J BIOL CHEM, V265, P6556; INOUE H, 1991, J BIOL CHEM, V266, P11896; Katz Stephen A., 1995, P1489; Knoll A, 1997, HUM MOL GENET, V6, P1527, DOI 10.1093/hmg/6.9.1527; Lee-Kirsch MA, 1999, CIRC RES, V84, P240, DOI 10.1161/01.RES.84.2.240; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; Reudelhuber Timothy L., 1995, P1621; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; Smithies O, 1997, HYPERTENSION, V30, P1318, DOI 10.1161/01.HYP.30.6.1318; TADA M, 1992, J BIOCHEM, V112, P175, DOI 10.1093/oxfordjournals.jbchem.a123874; TAKAHASHI S, 1992, J BIOL CHEM, V267, P13007; TAKAHASHI S, 1983, J BIOCHEM-TOKYO, V93, P265, DOI 10.1093/oxfordjournals.jbchem.a134162; WEISS P, 1989, J BIOL CHEM, V264, P17635	21	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15357	15362		10.1074/jbc.275.20.15357	http://dx.doi.org/10.1074/jbc.275.20.15357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809771	hybrid			2022-12-25	WOS:000087128300079
J	Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C				Hacki, J; Egger, L; Monney, L; Conus, S; Rosse, T; Fellay, I; Borner, C			Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2	ONCOGENE			English	Article						apoptosis; cytochrome c; caspases; Bcl-2; ER stress; BFA	PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NF-KAPPA-B; BREFELDIN-A; FAMILY PROTEINS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; X-L; ACTIVATION; CERAMIDE	Apoptosis involves mitochondrial steps such as the release of the apoptogenic factor cytochrome c which are effectively blocked by Bcl-2, Although Bcl-2 may have a direct action on the mitochondrial membrane, it also resides and functions on the endoplasmic reticulum (ER), and there is increasing evidence for a role of the ER in apoptosis regulation as well. Here we uncover a hitherto unrecognized, apoptotic crosstalk between the ER and mitochondria that is controlled by Bcl-2, After triggering massive ER dilation due to an inhibition of secretion, the drug brefeldin A (BFA) induces the release of cytochrome c from mitochondria in a caspase-8- and Bid-independent manner. This is followed by caspase-3 activation and DNA/nuclear fragmentation. Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5), Similar findings were obtained with tunicamycin, an agent interfering with IV-linked glycosylations in the secretory system, Thus, apoptotic agents perturbing ER functions induce a novel crosstalk between the ER and mitochondria that can be interrupted by ER-based Bcl-2.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.		Egger, Charlotte/T-6517-2019	Egger, Charlotte/0000-0001-6501-5703				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chandra NC, 1998, J BIOL CHEM, V273, P19715, DOI 10.1074/jbc.273.31.19715; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	60	270	277	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2000	19	19					2286	2295		10.1038/sj.onc.1203592	http://dx.doi.org/10.1038/sj.onc.1203592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822379				2022-12-25	WOS:000086974300003
J	Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M				Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M			Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release	ONCOGENE			English	Article						CD95; hyperthermia; cytochrome c; glioma; mitochondria	HUMAN-MALIGNANT GLIOMA; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CD95L-INDUCED APOPTOSIS; GENE-TRANSFER; FUNCTIONS DOWNSTREAM; CASPASE ACTIVATION; DEATH RECEPTORS; LETHAL WEAPON; MITOCHONDRIA	CD95L-induced apoptosis involves caspase activation and is facilitated when RNA and protein synthesis are inhibited. Here, we report that hyperthermia sensitizes malignant glioma cells to CD95L- and APO2L-induced apoptosis in the absence, but not in the presence, of inhibitors of RNA and protein synthesis. Hyperthermia does not alter CD95 expression at the cell surface and does not modulate the morphology of CD95-mediated cell death on electron microscopy, Bcl-2 gene transfer inhibits apoptosis and abrogates the sensitization mediated by hyperthermia, Hyperthermia does not overcome resistance to apoptosis conferred by the viral caspase inhibitor, crm-A, indicating the absolute requirement for the activation of crm-A-sensitive caspases, probably caspase 8, for apoptosis, CD95L-evoked DEVD-amc-cleaving caspase activity is enhanced by hyperthermia, suggesting that hyperthermia operates up-stream of caspase processing to promote apoptosis, There is no uniformly enhanced processing of three caspase 3 substrate, poly-ADP ribose polymerase (PARP), protein kinase C (PKC) delta and DNA fragmentation factor (DFF) 45, Yet, hyperthermia promotes CD95L-evoked DNA fragmentation, Interestingly, hyperthermia enhances the CD95L-evoked release of cytochrome c in the absence, but not in the presence, of CHX. In contrast, the reduction of the mitochondrial membrane potential is enhanced by hyperthermia both in the absence and presence of CHX, and enhanced cytochrome c release is not associated with significantly enhanced caspase 9 processing. The potentiation of cytochrome c release at hyperthermic conditions in the absence of CHX is abrogated by Bcl-2, Thus, either hyperthermia or inhibition of protein synthesis by CHX potentiate cytotoxic cytokine-induced apoptosis, These pathways show no synergy, but rather redundance, indicating that CHX may function to promote apoptosis in response to cytotoxic cytokines by inhibiting the synthesis of specific proteins whose synthesis, function or degradation is temperature-sensitive.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KLOSTERGAARD J, 1992, CANCER RES, V52, P5271; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; WATANABE N, 1988, CANCER RES, V48, P650; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yount GL, 1998, CANCER RES, V58, P3819	37	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2338	2345		10.1038/sj.onc.1203554	http://dx.doi.org/10.1038/sj.onc.1203554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822385				2022-12-25	WOS:000086974300009
J	Vatamaniuk, OK; Mari, S; Lu, YP; Rea, PA				Vatamaniuk, OK; Mari, S; Lu, YP; Rea, PA			Mechanism of heavy metal ion activation of phytochelatin (PC) synthase - Blocked thiols are sufficient for PC synthase-catalyzed transpeptidation of glutathione and related thiol peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADMIUM-BINDING PEPTIDES; HUMAN L-ARGININE; GLYCINE AMIDINOTRANSFERASE; YEAST; ARABIDOPSIS; TRANSPORT; PLANTS; SEQUESTRATION; TOLERANCE; PROTEASES	The dependence of phytochelatin synthase (gamma-glutamylcysteine dipeptidyltranspeptidase (PCS), EC 2.3.2.15) on heavy metals for activity has invariably been interpreted in terms of direct metal binding to the enzyme. Here we show, through analyses of immunopurified, recombinant PCS1 from Arabidopsis thaliana (AtPCS1), that free metal ions are not essential for catalysis. Although AtPCS1 appears to be primarily activated posttranslationally in the intact plant and purified AtPCS1 is able to bind heavy metals directly, metal binding per se is not responsible for catalytic activation. As exemplified by Cd2+- and Zn2+-dependent AtPCS1-mediated catalysis, the kinetics of PC synthesis approximate a substituted enzyme mechanism in which micromolar heavy metal glutathione thiolate (e.g. Cd.GS(2) or Zn GS,) and free glutathione act as gamma-Glu-Cys acceptor and donor. Further, as demonstrated by the facility of AtPCS1 for the net synthesis of S-alkyl-PCs from S-alkyl-glutathiones with biphasic kinetics, consistent with the sufficiency of S-alkyl-glutathiones as both gamma-Glu-Cys donors and accepters in media devoid of metals, even heavy metal thiolates are dispensable. It is concluded that the dependence of AtPCS1 on the provision of heavy metal ions for activity in media containing glutathione and other thiol peptides is a reflection of this enzyme's requirement for glutathione-like peptides containing blocked thiol groups for activity.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEAH E, 1993, PROTEIN ENG, V6, P575, DOI 10.1093/protein/6.6.575; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 1999, TRENDS PLANT SCI, V4, P335, DOI 10.1016/S1360-1385(99)01465-X; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRILL E, 1989, P NATL ACAD SCI USA, V89, P6338; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; Humm A, 1997, BIOCHEM J, V322, P771, DOI 10.1042/bj3220771; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Inze Dirk, 1995, Current Opinion in Biotechnology, V6, P153, DOI 10.1016/0958-1669(95)80024-7; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KONDO N, 1984, TETRAHEDRON LETT, V25, P3869, DOI 10.1016/S0040-4039(01)91190-6; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LOEFFLER S, 1989, FEBS LETT, V258, P42, DOI 10.1016/0014-5793(89)81611-4; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Martell A.E., 1976, CRITICAL STABILITY C, V4; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; RAUSER WE, 1990, ANNU REV BIOCHEM, V59, P61, DOI 10.1146/annurev.bi.59.070190.000425; SALT DE, 1995, PLANT PHYSIOL, V107, P1293, DOI 10.1104/pp.107.4.1293; Smith RM, 1974, CRITICAL STABILITY C, V1-6; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	29	284	297	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31451	31459		10.1074/jbc.M002997200	http://dx.doi.org/10.1074/jbc.M002997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10807919	hybrid			2022-12-25	WOS:000089762700099
J	Qian, YM; Devi, LA; Mzhavia, N; Munzer, S; Seidah, NG; Fricker, LD				Qian, YM; Devi, LA; Mzhavia, N; Munzer, S; Seidah, NG; Fricker, LD			The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE FAT/FAT MICE; SECRETORY PATHWAY; ATT-20 CELLS; IN-VITRO; METALLOCARBOXYPEPTIDASE-D; RECOMBINANT BACULOVIRUS; PROPROTEIN CONVERTASES; PITUITARY POLYPEPTIDE; PRECURSOR PROTEINS; ENZYMATIC-ACTIVITY	ProSAAS is a recently discovered 26-kDa neuroendocrine protein that was previously found to inhibit prohormone convertase (PC) 1 and not PC2, In the present study, the specificity of proSAAS toward other members of the prohormone convertase family was determined. Two mu M proSAAS selectively inhibits PC1 but not furin, PACE4, PC5A, or PC7. The PC1 inhibitory region of proSAAS was mapped to an 8-12-residue region near the C terminus that includes a critical Lys-Arg sequence. Synthetic peptides corresponding to this region are competitive inhibitors of PC1 with apparent K-i values of 14-40 nM. The inhibition becomes more effective with incubation time, indicating that the inhibitor is slow binding. A fusion protein containing the inhibitory region of proSAAS linked to the C terminus of glutathione S-transferase binds the 71-kDa form but not the 85-kDa form of PC1. This binding, which occurs at pH 5.5 and not at pH 7.4, is stable to incubation at room temperature for 1 h in the presence or absence of 0.5% Triton X-100 and/or 0.5 M NaCl. The removal of Ca2+ with chelating agents partially releases the bound PC1. High concentrations of the inhibitory peptide quantitatively release the bound PC1, Taken together, these data support the proposal that proSAAS functions as an endogenous inhibitor of PC1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Yeshiva University; Albert Einstein College of Medicine; New York University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Seidah, Nabil/I-3596-2013; Devi P, Lakshmi/GXM-5982-2022	Seidah, Nabil/0000-0001-6503-9342; Devi P, Lakshmi/0000-0001-9274-4776; Mzhavia, Nino/0000-0001-8602-9987	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04494, K02-DA00194] Funding Source: Medline; NINDS NIH HHS [R01-NS26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PAQUET L, 1994, J BIOL CHEM, V269, P19279; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1998, J CELL SCI, V111, P877; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	32	81	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23596	23601		10.1074/jbc.M001583200	http://dx.doi.org/10.1074/jbc.M001583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10816562	hybrid			2022-12-25	WOS:000088564200027
J	Zhou, H; Lin, AN; Gu, ZN; Chen, S; Park, NH; Chiu, R				Zhou, H; Lin, AN; Gu, ZN; Chen, S; Park, NH; Chiu, R			12-O-tetradecanoylphorbol-13-acetate (TPA)-induced c-Jun N-terminal kinase (JNK) phosphatase renders immortalized or transformed epithelial cells refractory to TPA-inducible JNK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DUAL-SPECIFICITY PHOSPHATASE; MAP KINASE; TYROSINE-PHOSPHATASE; IN-VIVO; DIFFERENTIAL ACTIVATION; MOLECULAR-CLONING; MAMMALIAN-CELLS; GENE-PRODUCT; HEAT-SHOCK	c-Jun N-terminal kinase (JNK) regulates gene expression in response to various extracellular stimuli. JNK can be activated by the tumor promoting agent, 12-O-tetradecanoylphorbol-13-acetate (TPA) in normal human oral keratinocytes but not in human keratinocytes that have been immortalized (HOK-16B and HaCaT) or transformed (HOK-16B-Bap-T) nor in a cervical carcinoma cell line (HeLa). The refractory JNK activation response to TPA is not due a defect in the JNR pathway, because JNK can be activated by other stimuli, e.g. UV irradiation and an alkylating agent N-methyl-N'-nitrosoguanidine in these immortalized or transformed cells. More importantly, the refractory JNR and JNKK activation response to TPA can be restored by treatment of the cells with a combination of TPA and a protein-tyrosine phosphatase inhibitor, sodium orthovanadate. Furthermore, pretreatment of cells with TPA partially inhibited UV- or N-methyl-N'-nitrosoguanidine-induced JNK activity. These results suggest that a TPA-inducible, orthovanadate sensitive protein-tyrosine phosphatase may specifically down-regulate JNK signaling pathway in these immortalized/transformed epithelial cells. In contrast, ERK and p38/Mpk2 are not regulated by this TPA-induced phosphatase. This putative protein-tyrosine phosphatase appears to be JNK pathway-specific.	Univ Calif Los Angeles, Sch Dent, Dept Oral Biol & Med, Inst Dent Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Surg Oncol, Los Angeles, CA 90095 USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of Chicago	Chiu, R (corresponding author), Univ Calif Los Angeles, Sch Dent, Dept Oral Biol & Med, Inst Dent Res, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA66746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1993, ONCOGENE, V8, P2015; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kanai M, 1998, P NATL ACAD SCI USA, V95, P178, DOI 10.1073/pnas.95.1.178; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KIM MS, 1993, CANCER RES, V53, P4811; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee HY, 1999, MOL CELL BIOL, V19, P1973; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARK NH, 1995, ONCOGENE, V10, P2145; POSNER BI, 1994, J BIOL CHEM, V269, P4596; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	56	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22868	22875		10.1074/jbc.M909273199	http://dx.doi.org/10.1074/jbc.M909273199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10807930	hybrid			2022-12-25	WOS:000088419400038
J	Chow, JYC; Uribe, JM; Barrett, KE				Chow, JYC; Uribe, JM; Barrett, KE			A role for protein kinase C epsilon in the inhibitory effect of epidermal growth factor on calcium-stimulated chloride secretion in human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE-C; PKC-EPSILON; ACTIVATION; WORTMANNIN; LINE; ENDOCYTOSIS; ISOENZYMES	Epidermal growth factor (EGF) inhibits carbachol-induced chloride secretion in T-84 colonic epithelial cells and has been shown to activate phosphatidylinositol (PI) 3-kinase, leading to inhibition of a basolateral potassium conductance. We asked whether the inhibitory effect of EGF on secretion is due to activation of specific isoforms of protein kinase C (PKC) by PI 3-kinase. Western analysis revealed that PKC alpha, gamma, epsilon, eta, mu, lambda/iota, and zeta were expressed in T-84 cells. Ro318220 (an inhibitor active against PKC epsilon, 10 mu M) but not Go6983 (an inhibitor active against PKC zeta; 10 mu M) reversed the inhibitory effect of EGF (100 ng/ml) on carbachol-stimulated chloride secretion. EGF induced the rapid translocation of PKC epsilon from the cytoplasm to the membrane. Wortmannin (50 mu M) and LY294002 (20 nM), which are PI 3-kinase inhibitors that by themselves had no effect on PKC epsilon activity, significantly suppressed PKC epsilon translocation activated by EGF. LY294002 also reversed the inhibitory action of EGF on chloride secretion. PI (3,4)P-2 increased membrane-associated PKC epsilon and reduced carbachol-induced Rb-86(+) efflux. Antisense oligonucleotides against PKC epsilon decreased PKC epsilon mass and prevented the inhibitory effect of EGF on carbachol-induced Rb-86(+) afflux. Thus, the inhibitory effect of EGF on carbachol-induced chloride secretion involves the activation of PKC epsilon mediated by PI 3-kinase. Our findings contribute to the understanding of the cellular mechanisms that control chloride secretion.	Univ Calif San Diego, Med Ctr, Sch Med, Dept Med,Div Gastroenterol, San Diego, CA 92103 USA	University of California System; University of California San Diego	Barrett, KE (corresponding author), Univ Calif San Diego, Med Ctr, Sch Med, Dept Med,Div Gastroenterol, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.		Barrett, Kim Elaine/AAE-7762-2019; Barrett, Kim/AAE-2794-2022	Barrett, Kim Elaine/0000-0002-6704-998X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202, R01DK028305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305, DK07202] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett K.E.., 1999, ELECTROLYTE SECRETIO; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Boland LM, 1999, AM J PHYSIOL-CELL PH, V277, pC100, DOI 10.1152/ajpcell.1999.277.1.C100; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CLARKE LL, 1993, PHARM RESP TRACT, P505; COURAGE C, 1995, BRIT J CANCER, V71, P697, DOI 10.1038/bjc.1995.137; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DECOY DL, 1995, J CLIN INVEST, V95, P2749, DOI 10.1172/JCI117978; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, P204; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; JOHNSON MS, 1993, FEBS LETT, V333, P67, DOI 10.1016/0014-5793(93)80376-6; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; Kang-Park S, 1998, J HEPATOL, V28, P250, DOI 10.1016/0168-8278(88)80012-6; Liedtke CM, 1998, AM J PHYSIOL-CELL PH, V275, pC1357, DOI 10.1152/ajpcell.1998.275.5.C1357; Liedtke CM, 1997, AM J PHYSIOL-CELL PH, V273, pC937, DOI 10.1152/ajpcell.1997.273.3.C937; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; REENSTRA WW, 1993, AM J PHYSIOL, V264, pC161, DOI 10.1152/ajpcell.1993.264.1.C161; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Song JC, 1999, AM J PHYSIOL-CELL PH, V277, pC1239, DOI 10.1152/ajpcell.1999.277.6.C1239; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; TOKER A, 1994, J BIOL CHEM, V269, P32358; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; YANO H, 1993, J BIOL CHEM, V268, P25846; Zhang Y, 1998, CURR EYE RES, V17, P294, DOI 10.1076/ceyr.17.3.294.5223	38	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21169	21176		10.1074/jbc.M002160200	http://dx.doi.org/10.1074/jbc.M002160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801833	hybrid			2022-12-25	WOS:000088230600029
J	Nakano, K; Yamauchi, J; Nakagawa, K; Itoh, H; Kitamura, N				Nakano, K; Yamauchi, J; Nakagawa, K; Itoh, H; Kitamura, N			NESK, a member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is expressed during the late stages of embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-RELATED PROTEIN-KINASE; KAPPA-B; SIGNALING PATHWAY; BETA-GAMMA; JNK; CLONING; CASCADE; DOMAIN; HPK1; NIK	The c-Jun N-terminal kinase (JNK) signaling pathway plays a crucial role in cellular responses stimulated by stress-inducing agents and proinflammatory cytokines. The group I germinal center kinase family members selectively activate the JNK pathway. In this study, we have isolated a mouse cDNA encoding a protein kinase homologous to Nck-interacting kinase (MK), a member of the group I germinal center kinase family. This protein kinase is expressed during the late stages of embryogenesis, but not in adult tissues, and thus named NESK (NIK-like embryo-specific kinase). NESK selectively activated the JNK pathway when overexpressed in HEK 293 cells but did not stimulate the p38 kinase or extracellular signal-regulated kinase (ERK) pathways. NESK-induced JNK activation was inhibited by the dominant negative mutants of MEKK1 and MKK4. Tumor necrosis factor (TNF)-alpha or TNF receptor-associated factor 2 (TRAF2) stimulated the NESK activity. Furthermore, the dominant negative NESK mutant inhibited the JNK activation induced by TNF-alpha or TRAF2. These results suggest that NESK, a novel activator of the JNK pathway, functions in coupling TRAF2 to the MEKK1 --> MKK4 --> JNK kinase cascade during the late stages of mammalian embryogenesis.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp						Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; HATZ P, 1994, J BIOL CHEM, V269, P16802; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kanai-Azuma M, 1999, MECH DEVELOP, V89, P155, DOI 10.1016/S0925-4773(99)00193-8; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kurioka K, 1998, BBA-GENE STRUCT EXPR, V1443, P275, DOI 10.1016/S0167-4781(98)00224-3; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	26	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20533	20539		10.1074/jbc.M001009200	http://dx.doi.org/10.1074/jbc.M001009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10801798	hybrid			2022-12-25	WOS:000088084500045
J	Liu, YF; Dorow, D; Marshall, J				Liu, YF; Dorow, D; Marshall, J			Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE-2; INTRANUCLEAR INCLUSIONS; CELLULAR-LOCALIZATION; STRIATAL NEURONS; PROTEIN-KINASE; DISEASE; EXPRESSION; APOPTOSIS; PATHWAY; JNK	We previously reported that expression of polyglutamine expanded huntingtin induces apoptosis via c-Jun amino-terminal kinase (JNK) activation in HN33 cells (Liu, Y. F. (1998) J. Biol. Chem. 273, 28873-28822), Extending this study, we now demonstrate a role of mixed-lineage kinase 2 (MLK2), a JNK activator, in polyglutamine-expanded huntingtin-mediated neuronal toxicity. We find that normal huntingtin interacts with MLK2, whereas the polyglutamine expansion interferes with this interaction. Similar to the expression of polyglutamine-expanded huntingtin, expression of MLK2 also induces JNK activation and apoptosis in HN33 cells. Go-expression of dominant negative MLK2 significantly attenuates neuronal apoptosis induced by the mutated huntingtin, Furthermore, over-expression of the N terminus of normal huntingtin partially rescues the neuronal toxicity induced by MLK2, Our results suggest that activation of MLK2-mediated signaling cascades may be partially involved in neuronal death induced by polyglutamine-expanded huntingtin.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Peter MacCallum Canc Inst, Trecowthick Res Ctr, Melbourne, Vic 3000, Australia; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Northeastern University; Peter Maccallum Cancer Center; Brown University	Liu, YF (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, 312 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.							DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Eilers A, 1998, J NEUROSCI, V18, P1713; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; Fusco FR, 1999, J NEUROSCI, V19, P1189; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Phelan DR, 1999, MOL REPROD DEV, V52, P135, DOI 10.1002/(SICI)1098-2795(199902)52:2&lt;135::AID-MRD3&gt;3.0.CO;2-N; SANCHEZ I, 1994, NATURE, V380, P75; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104	26	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	2000	275	25					19035	19040		10.1074/jbc.C000180200	http://dx.doi.org/10.1074/jbc.C000180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327VZ	10801775	hybrid			2022-12-25	WOS:000087815900056
J	Lee, D; Long, SA; Adams, JL; Chan, G; Vaidya, KS; Francis, TA; Kikly, K; Winkler, JD; Sung, CM; Debouck, C; Richardson, S; Levy, MA; DeWolf, WE; Keller, PM; Tomaszek, T; Head, MS; Ryan, MD; Haltiwanger, RC; Liang, PH; Janson, CA; McDevitt, PJ; Johanson, K; Concha, NO; Chan, W; Abdel-Meguid, SS; Badger, AM; Lark, MW; Nadeau, DP; Suva, LJ; Gowen, M; Nuttall, ME				Lee, D; Long, SA; Adams, JL; Chan, G; Vaidya, KS; Francis, TA; Kikly, K; Winkler, JD; Sung, CM; Debouck, C; Richardson, S; Levy, MA; DeWolf, WE; Keller, PM; Tomaszek, T; Head, MS; Ryan, MD; Haltiwanger, RC; Liang, PH; Janson, CA; McDevitt, PJ; Johanson, K; Concha, NO; Chan, W; Abdel-Meguid, SS; Badger, AM; Lark, MW; Nadeau, DP; Suva, LJ; Gowen, M; Nuttall, ME			Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE APOPTOSIS; GENE-EXPRESSION; II COLLAGEN; IN-VIVO; OSTEOARTHRITIS; MICE; PEPTIDE; CARTILAGE; PROTEASE; DEGENERATION	Caspases have been strongly implicated to play an essential role in apoptosis, A critical question regarding the role(s) of these proteases is whether selective inhibition of an effector caspase(s) will prevent cell death. We have identified potent and selective non-peptide inhibitors of the effector caspases 3 and 7, The inhibition of apoptosis and maintenance of cell functionality with a caspase 3/7-selective inhibitor is demonstrated for the first time, and suggests that targeting these two caspases alone is sufficient for blocking apoptosis, Furthermore, an x-ray co-crystal structure of the complex between recombinant human caspase 3 and an isatin sulfonamide inhibitor has been solved to 2.8-Angstrom resolution, In contrast to previously reported peptide-based caspase inhibitors, the isatin sulfonamides derive their selectivity for caspases 3 and 7 by interacting primarily with the S-2, subsite, and do not bind in the caspase primary aspartic acid binding pocket (S-1), These inhibitors blocked apoptosis in murine bone marrow neutrophils and human chondrocytes, Furthermore, in camptothecin-induced chondrocyte apoptosis, cell functionality as measured by type II collagen promoter activity is maintained, an activity considered essential for cartilage homeostasis. These data suggest that inhibiting chondrocyte cell death with a caspase 3/7-selective inhibitor may provide a novel therapeutic approach for the prevention and treatment of osteoarthritis, or other disease states characterized by excessive apoptosis.	SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biomol Discovery, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunopharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Recognit, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Lee, D (corresponding author), Sunesis Pharmaceut, 3696 Haven Ave,Suite C, Redwood City, CA 94063 USA.	denlee@sunesis-pharma.com; mark_e_nuttall@sbphrd.com	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Suva, Larry/0000-0002-2892-9757				Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1992, XPLOR VERSION 3 1 SY; Cryns V. L., 1998, CELLS DIE COMPREHENS, P177; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERLACHER L, 1995, J RHEUMATOL, V22, P926; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAMERMAN D, 1993, J AM GERIATR SOC, V41, P760, DOI 10.1111/j.1532-5415.1993.tb07469.x; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; Hollander AP, 1995, J CLIN INVEST, V96, P2859, DOI 10.1172/JCI118357; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karaplis AC, 1997, CURR OPIN NEPHROL HY, V6, P308; Kaufmann S. H., 1997, ADV PHARM, V41; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lockshin RA, 1998, CELLS DIE; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; MARTINEZ F, 1990, SYNTHETIC MET, V39, P195, DOI 10.1016/0379-6779(90)90184-M; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nuttall ME, 1999, PROG INFLAM RES, P163; NUTTALL ME, 2000, IN PRESS J ORTHOP RE; PARKINSON A, 1996, CASARETT DOULLS TOXI, P120; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Vaishnaw AK, 1997, ARTHRITIS RHEUM, V40, P1917, DOI 10.1002/art.1780401102; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VIGNON E, 1974, CLIN ORTHOP RELAT R, P269; Von Tacconi G., 1973, J PRAKT CHEM, V315, P339; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Webber SE, 1996, J MED CHEM, V39, P5072, DOI 10.1021/jm960603e; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang CL, 1997, EXP CELL RES, V235, P370, DOI 10.1006/excr.1997.3692	50	208	219	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16007	16014		10.1074/jbc.275.21.16007	http://dx.doi.org/10.1074/jbc.275.21.16007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821855	hybrid			2022-12-25	WOS:000087291400055
J	Razzini, G; Brancaccio, A; Lemmon, MA; Guarnieri, S; Falasca, M				Razzini, G; Brancaccio, A; Lemmon, MA; Guarnieri, S; Falasca, M			The role of the pleckstrin homology domain in membrane targeting and activation of phospholipase C beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC-AMINO-ACIDS; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PHOSPHOINOSITIDE 3-KINASES; SIGNAL-TRANSDUCTION; AKT PROTOONCOGENE; C ISOZYMES; KINASE; PATHWAY; BINDING	Current studies involve an investigation of the role of the pleckstrin homology (PH) domain in membrane targeting and activation of phospholipase C beta(1) (PLC beta(1)). Here we report studies on the membrane localization of the isolated PH domain from the amino terminus of PLC beta(1) (PLC beta(1)-PH) using fluorescence microscopy of a green fluorescent protein fusion protein. Whereas PLC beta(1)-PH does not localize to the plasma membrane in serum-starved cells, it undergoes a rapid but transient migration to the plasma membrane upon stimulation of cells with serum or lysophosphatidic acid (LPA). Regulation of the plasma membrane localization of PLC beta(1)-PH by phosphoinositides was also investigated. PLC beta(1)-PH was found to bind phosphatidylinositol 3-phosphate most strongly, whereas other phosphoinositides were bound with lower affinity. The plasma membrane localization of PLC beta(1)-PH induced by serum and LPA was blocked by wortmannin pretreatment and by LY294002. In parallel, activation of PLC beta by LPA was inhibited by wortmannin, by LY294002, or by the overexpression of PLC beta(1)-PH. Microinjection of beta gamma subunits of G proteins in serum-starved cells induced the translocation of PLC beta(1)-PH to the plasma membrane. These results demonstrate that a cooperative mechanism involving phosphatidylinositol 3-phosphate and the G beta gamma subunit regulates the plasma membrane localization and activation of PLC beta(1)-PH.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Unit Physiopathol Cell Signalling, I-66030 Santa Maria Imbaro, CH, Italy; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ G DAnnunzio, Dept Pharmacol Sci, Lab Cellular Physiol, I-66013 Chieti, Italy; Fdn Caripe, Mol Oncol Lab, I-65100 Pescara, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Pennsylvania; G d'Annunzio University of Chieti-Pescara	Falasca, M (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Unit Physiopathol Cell Signalling, I-66030 Santa Maria Imbaro, CH, Italy.		Guarnieri, Simone/AAA-5921-2020; Falasca, Marco/S-4020-2016	Guarnieri, Simone/0000-0002-2916-2965; Falasca, Marco/0000-0002-9801-7235; Lemmon, Mark/0000-0002-3379-5319	NIGMS NIH HHS [R01 GM056846, GM56846] Funding Source: Medline; Fondazione Telethon Funding Source: Custom; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Fondazione Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARK DG, 1993, J BIOL CHEM, V268, P3710; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; WU D, 1993, J BIOL CHEM, V268, P2704; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	42	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14873	14881		10.1074/jbc.275.20.14873	http://dx.doi.org/10.1074/jbc.275.20.14873			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809731	hybrid			2022-12-25	WOS:000087128300016
J	Subbaramaiah, K; Hart, JC; Norton, L; Dannenberg, AJ				Subbaramaiah, K; Hart, JC; Norton, L; Dannenberg, AJ			Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2 - Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN COLON-CANCER; N-TERMINAL KINASE; PROSTAGLANDIN-H SYNTHASE-2; SQUAMOUS CARCINOMA-CELLS; GROWTH-FACTOR-ALPHA; PHORBOL ESTER; GENE-EXPRESSION; CHEMOPREVENTIVE ACTIVITY; BREAST-CANCER	We investigated whether microtubule-interfering agents (MIAs: taxol, colchicine, nocodazole, vinblastine, vincristine, 17-beta-estradiol, 2-methoxyestradiol) altered cyclooxygenase-a (COX-2) expression in human mammary epithelial cells. MIAs enhanced prostaglandin E-2 synthesis and increased levels of COX-2 protein and mRNA Nuclear run-off assays revealed increased rates of COX-2 transcription after treatment with MIAs. Calphostin C, an inhibitor of protein kinase C, blocked the induction of COX-2 by MIAs. The stimulation of COX-2 promoter activity by MIAs was inhibited by overexpressing dominant negative forms of Rho and Raf-l. MIAs stimulated ERR, JNK, and p38 mitogen-activated protein kinases (MAPK); pharmacological inhibitors of MAPK kinase and p38 MAPK blocked the induction of COX-2 by MIAs. Overexpressing dominant negative forms of ERK1 or p38 MAPK inhibited MIA-mediated activation of the COX-2 promoter. MIAs stimulated the binding of the activator protein-1 transcription factor complex to the cyclic AMP response element in the COX-2 promoter. A dominant negative form of c-Jun inhibited the activation of the COX-2 promoter by MIAs. Additionally, cytochalasin D, an agent that inhibits actin polymerization, stimulated COX-2 transcription by the same signaling pathway as MIAs. Thus, microtubule or actin-interfering agents stimulated MAPK signaling and activator protein-1 activity. This led, in turn, to induction of COX-2 gene expression via the cyclic AMP response element site in the COX-2 promoter.	Cornell Univ, New York Presbyterian Hosp, Div Gastroenterol & Hepatol, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Strang Canc Prevent Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Subbaramaiah, K (corresponding author), Cornell Univ, New York Presbyterian Hosp, Div Gastroenterol & Hepatol, Dept Med, Rm F-203,1300 York Ave, New York, NY 10021 USA.			Norton, Larry/0000-0003-3701-9250	NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER; NCI NIH HHS [S/G 2P01 CA68425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZUYOKOTA E, 1994, CARCINOGENESIS, V15, P1875, DOI 10.1093/carcin/15.9.1875; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; BERG D, 1983, ACTA ENDOCRINOL-COP, V103, P282, DOI 10.1530/acta.0.1030282; Chan G, 1999, CANCER RES, V59, P991; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P1654; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; GEMSA D, 1980, J IMMUNOL, V124, P376; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; Howe LR, 1999, CANCER RES, V59, P1572; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lipsky PE, 1997, J RHEUMATOL, V24, P9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Moos PJ, 1999, J IMMUNOL, V162, P467; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARETT ML, 1997, INT J ONCOL, V10, P503; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H., 1998, AM J PHYSIOL, V274, P1061; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YEH CK, 1987, BIOCHIM BIOPHYS ACTA, V927, P315, DOI 10.1016/0167-4889(87)90095-4; ZHAI YF, 1993, CANCER RES, V53, P2272	62	276	288	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14838	14845		10.1074/jbc.275.20.14838	http://dx.doi.org/10.1074/jbc.275.20.14838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809726	hybrid			2022-12-25	WOS:000087128300011
J	Mirmira, RG; Watada, H; German, MS				Mirmira, RG; Watada, H; German, MS			beta-cell differentiation factor Nkx6.1 contains distinct DNA binding interference and transcriptional repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEINS; INSULIN GENE; PANCREATIC DEVELOPMENT; ENGRAILED HOMEODOMAIN; SEQUENCE RECOGNITION; CRYSTAL-STRUCTURE; ISLET CELLS; SPECIFICITY; COMPLEX; IDENTIFICATION	beta-Cell differentiation factor Nkx6.1 is a homeodomain protein expressed in developing and mature beta-cells in the pancreatic islets of Langerhans, To understand how it contributes to beta-cell development and function, we characterized its DNA binding and transactivation properties. A single copy of the homeodomain of Nkx6.1 binds to a strictly conserved 8-base pair DNA consensus sequence, TTAATTAC; even minor variations to this consensus reduce DNA binding affinity significantly. Full-length Nkx6.1, however, has markedly reduced DNA binding affinity due to an acidic domain at the carboxyl end of the molecule that functions as a mobile binding interference domain capable of interrupting the interaction between DNA and DNA binding domains of the helix-turn-helix type. When expressed in fibroblast cell. lines, Nkx6.1 represses transcription through isolated Nkx6.1 binding sites; in beta-cell lines, Nkx6.1 specifically represses the intact insulin promoter through TAAT-containing sequences. In Gal4 one-hybrid fusion studies, transcriptional repression maps to a discreet region within the amino terminus. Our findings suggest a model in which Nkx6.1, regulated by interactions through its carboxyl terminus, directs the repression of specific genes in developing and mature beta-cells.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075; Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [R01 DK021344, DK21344] Funding Source: Medline; PHS HHS [K08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK021344, R37DK021344, R01DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Awatramani R, 1997, J NEUROSCI, V17, P6657; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Draganescu A, 1998, J MOL BIOL, V276, P529, DOI 10.1006/jmbi.1997.1567; DRAGANESCU A, 1995, J MOL BIOL, V250, P595, DOI 10.1006/jmbi.1995.0401; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gruschus JM, 1997, BIOCHEMISTRY-US, V36, P5372, DOI 10.1021/bi9620060; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; Ogbourne S, 1998, BIOCHEM J, V331, P1; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANDER M, 1998, KEYST S VERT DEV STE; Smith SB, 1999, MOL CELL BIOL, V19, P8272; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TREISMAN J, 1989, CELL, V59, P553; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263	47	50	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14743	14751		10.1074/jbc.275.19.14743	http://dx.doi.org/10.1074/jbc.275.19.14743			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10799563	hybrid			2022-12-25	WOS:000087006900098
J	Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S				Preudhomme, C; Roumier, C; Hildebrand, MP; Dallery-Prudhomme, E; Lantoine, D; Lai, JL; Daudignon, A; Adenis, C; Bauters, F; Fenaux, P; Kerckaert, JP; Galiegue-Zouitina, S			Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma	ONCOGENE			English	Article						non Hodgkin's lymphoma; translocation; RhoH/TTF; small G protein; LAZ3/BCL6	GERMINAL-CENTER FORMATION; CHROMOSOMAL TRANSLOCATIONS; RAS TRANSFORMATION; LAZ3/BCL6 ONCOPROTEIN; B-CELLS; EXPRESSION; BCL-6; RHO; DOMAIN; LAZ3	We recently isolated the RhoH/TTF gene by its fusion to the LAZ3/BCL6 gene, in a non-Hodgkin's lymphoma (NHL) cell line, which bore a t(3;4)(q27;p11-13) translocation, This gene encodes a novel Rho GTP-binding protein and is specifically expressed in hematopoietic tissues. We made its precise mapping at band 4p13, and described its partial genomic structure, Using fluorescence ill situ hybridization and molecular analyses, we report here on the rearrangement of the RhoH/TTF gene, at band 4p13, in four cases of NHL with t(3;4)(q27;p13) translocation and its fusion to the LAZ3/BCL6 gene at band 3q27, in three of these cases. RT-PCR analysis of two cases allowed the detection of variable fusion transcripts emerging from the rearranged alleles, and in one case, a deregulated expression of both RhoH/TTF and LAZ3/BCL6 genes, by promoter substitution, was observed, We also show here another rearrangement of the RhoH/TTF gene in a patient with multiple myeloma slid t(4;14)(p13;q32) translocation, with breakage within the IGH gene. It is the first report which describes the recurrent chromosomal alteration of a GTP-binding protein encoding gene, in patients with hematopoietic malignancies.	Inst Rech Canc, INSERM U524, F-59045 Lille, France; CHU Lille, Lab Hematol A, F-59037 Lille, France; CHU Lille, Lab Cytogenet, F-59037 Lille, France; CHG Valenciennes, Dept Hematol & Cytogenet, Valenciennes, France; Ctr Oscar Lambret, Lab Cytogenet, F-59020 Lille, France; CHU Lille, Serv Malad Sang, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; CH de Valenciennes; UNICANCER; Centre Oscar Lambret; Universite de Lille - ISITE; CHU Lille	Galiegue-Zouitina, S (corresponding author), Inst Rech Canc, INSERM U524, Pl Verdun, F-59045 Lille, France.		Preudhomme, Claude/T-8553-2018	Preudhomme, Claude/0000-0002-1267-9546				Akasaka T, 1997, CANCER RES, V57, P7; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; BASTARD C, 1994, BLOOD, V83, P2423; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; CalletBauchu E, 1996, GENE CHROMOSOME CANC, V17, P185, DOI 10.1002/(SICI)1098-2264(199611)17:3<185::AID-GCC7>3.0.CO;2-0; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLERY E, 1995, ONCOGENE, V10, P2171; DalleryPrudhomme E, 1997, GENOMICS, V43, P89, DOI 10.1006/geno.1997.4788; Daudignon A, 1999, CANCER GENET CYTOGEN, V111, P157, DOI 10.1016/S0165-4608(98)00239-8; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MITELMAN F, 1991, GUIDELINES CANC CY S; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; STORSKI T, 1998, P NATL ACAD SCI USA, V95, P11858; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zandecki M, 1996, BRIT J HAEMATOL, V94, P217	39	87	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2023	2032		10.1038/sj.onc.1203521	http://dx.doi.org/10.1038/sj.onc.1203521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803463				2022-12-25	WOS:000086613200006
J	Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T				Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T			Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity	ONCOGENE			English	Article						Rb; BRCT; BRCA1; cell cycle checkpoint; DNA damage sensor	LARGE T-ANTIGEN; REPLICATION CHECKPOINT CONTROL; FISSION YEAST; GENE-PRODUCT; DAMAGE; REPAIR; DOMAIN; MICE; P53; APOPTOSIS	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene I product), is ubiquitous in several proteins that participate in cell cycle checkpoints and DNA repair. We have previously shown that the BRCT regions pf TopBP1 (DNA topoisomerase II binding protein 1) and BRCA1 bound DNA breaks. A BRCT-related region, BRCT-W1, in the retinoblastoma susceptibility gene product (Rb) also could bind DNA fragments, independently of DNA sequences. Five BRCT-W regions were found in the Rb family. All BRCT-Ws of Rb bound DNA fragments. Electron microscopy and treatment with an exonuclease showed that BRCT-Ws bound double-strand DIVA breaks. Since some BRCTs are exceptional common relating elements in tumor suppression, our findings reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo; RIKEN	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan.							Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wang J, 1997, CANCER RES, V57, P351; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					1982	1991		10.1038/sj.onc.1203528	http://dx.doi.org/10.1038/sj.onc.1203528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803459				2022-12-25	WOS:000086613200002
J	Xie, P; Browning, DD; Hay, N; Mackman, N; Ye, RD				Xie, P; Browning, DD; Hay, N; Mackman, N; Ye, RD			Activation of NF-kappa B by bradykinin through a G alpha(q)-and G beta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN EPITHELIAL-CELLS; SERUM RESPONSE FACTOR; GENE-EXPRESSION; IKK-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; THROMBIN RECEPTOR; RGS PROTEINS; P115 RHOGEF; KINASE IKK	Recent work has suggested a role for the serine/threonine kinase Akt and I kappa B kinases (IKKs) in nuclear factor (NF)-kappa B activation. In this study, the involvement of these components in NF-kappa B activation through a G protein-coupled pathway was examined using transfected HeLa cells that express the BE-type bradykinin (BK) receptor. The function of IKK2, and to a lesser extent, IKK1, was suggested by BK-induced activation of their kinase activities and by the ability of their dominant negative mutants to inhibit BK-induced NF-kappa B activation. BK-induced NF-kappa B activation and IKK2 activity were markedly inhibited by RGS3T, a regulator of G protein signaling that inhibits G alpha(q), and by two G beta gamma scavengers. Go-expression of G alpha q potentiated BK-induced NF-kappa B activation, whereas co-expression of either an activated G alpha q(Q209L) or G beta(1)gamma(2) induced IKK2 activity and NF-kappa B activation without BK stimulation. BK-induced NF-kappa B activation was partially blocked by LY294002 and by a dominant negative mutant of phosphoinositide 3-kinase (PI3K), suggesting that PI3K is a downstream effector of G alpha(q) and G beta(1)gamma(2) for NF-kappa B activation. Furthermore, BK could activate the PI8K downstream kinase Akt, whereas a catalytically inactive mutant of Akt inhibited BK-induced NF-kappa B activation. Taken together, these findings suggest that BK utilizes a signaling pathway that involves G alpha(q), G beta(1)gamma(2), PI3K1 Akt, and IKK for NF-kappa B activation.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 So Wolcott Ave,MC868, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hsu MH, 1999, BLOOD, V93, P3241, DOI 10.1182/blood.V93.10.3241.410k02_3241_3249; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; Lieb K, 1997, J IMMUNOL, V159, P4952; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MARI B, 1994, J BIOL CHEM, V269, P8517; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rahman A, 1999, J IMMUNOL, V162, P5466; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Todisco A, 1999, BIOCHEM BIOPH RES CO, V261, P877, DOI 10.1006/bbrc.1999.1141; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; Ye RD, 1996, GENE EXPRESSION, V5, P205; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	62	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24907	24914		10.1074/jbc.M001051200	http://dx.doi.org/10.1074/jbc.M001051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10801799	hybrid			2022-12-25	WOS:000088683300090
J	Booden, MA; Sakaguchi, DS; Buss, JE				Booden, MA; Sakaguchi, DS; Buss, JE			Mutation of Ha-Ras C terminus changes effector pathway utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; PLASMA-MEMBRANE LOCALIZATION; PHOSPHOINOSITIDE 3-KINASE; PC12 CELLS; INCREASING COMPLEXITY; ACTIN ORGANIZATION; POLYBASIC DOMAIN; ACTIVATE RAF-1; ZINC-FINGER	In PC12 cells, Ha-Ras modulates multiple effector proteins that induce neuronal differentiation. To regulate these pathways Ha-nas must be located at the plasma membrane, a process normally requiring attachment of farnesyl and palmitate lipids to the C terminus. Ext61L, a constitutively activated and palmitoylated Ha-Res that lacks a farnesyl group, induced neurites with more actin cytoskeletal changes and lamellipodia than were induced by farnesylated Ha-Ras61L, Ext61L-triggered neurite outgrowth was prevented easily by co-expressing inhibitory Rho, Cdc42, or p21-activated kinase but required increased amounts of inhibitory Rac, Compared with Ha-Ras61L, Ext61L caused a-fold greater Rac GTP binding and phosphatidylinositol 3-kinase activity in membranes, a hyperactivation that explained the numerous lamellipodia and ineffectiveness of Rac(N17), In contrast, Ext61L activated B-Raf kinase and ERK phosphorylation more poorly than Ha-Ras61L, Thus, accentuated differentiation by Ext61L apparently results from heightened activation of one Ras effector (phosphatidylinositol 3-kinase) and suboptimal activation of another (B-Raf). This surprising unbalanced effector activation, without changes in the designated Res effector domain, indicates the Ext61L C-terminal alternations are a new way to influence Ha-Res-effector utilization and suggest a broader role of the lipidated C terminus in Ha-Res biological functions.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Iowa State Univ Sci & Technol, Dept Zool Genet, Ames, IA 50011 USA; Iowa State Univ Sci & Technol, Signal Transduct Training Grp, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University	Buss, JE (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, 3212 Mol Biol Bldg, Ames, IA 50011 USA.	jbuss@iastate.edu		Buss, Janice/0000-0002-8086-265X; Sakaguchi, Donald/0000-0003-4537-0972				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Coats SG, 1999, BIOCHEMISTRY-US, V38, P12926, DOI 10.1021/bi9909290; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Okada T, 1999, MOL CELL BIOL, V19, P6057; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23559	23568		10.1074/jbc.M001368200	http://dx.doi.org/10.1074/jbc.M001368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10801808	hybrid			2022-12-25	WOS:000088564200022
J	Nyaga, SG; Lloyd, RS				Nyaga, SG; Lloyd, RS			Two glycosylase/abasic lyases from Neisseria mucosa that initiate DNA repair at sites of UV-induced photoproducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; T4 ENDONUCLEASE-V; CATALYTIC MECHANISM; MICROCOCCUS-LUTEUS; BETA-ELIMINATION; ABASIC LYASE; CIS-SYN; T4-ENDONUCLEASE-V; VIRUS; BACTERIOPHAGE-T4	Diverse organisms ranging from Escherichia coli to humans contain a variety of DNA repair proteins that function in the removal of damage caused by shortwave UV light. This study reports the identification, purification, and biochemical characterization of two DNA glycosylases with associated abasic lyase activity from Neisseria mucosa. These enzymes, pyrimidine dimer glycosylase I and II Nmu-pdg I and (Nmu-pdg II), were purified 30,000- and 10,000-fold, respectively. SDS-polyacrylamide gel electrophoresis analysis indicated that Nmu-pdg I is approximately 30 kDa, whereas Nmu-pdg II is approximately 19 kDa, The N-terminal amino acid sequence of Nmu-pdg II exhibits 64 and 66% identity with E, coli and Hemophilus parinfluenzae endonuclease III, respectively. Both Nmu-pdg I and Nmu-pdg II were found to have broad substrate specificities, as evidenced by their ability to incise DNA containing many types of UV and some types of oxidative damage. Consistent with other glycosylase/abasic lyases, the existence of a covalent enzyme-DNA complex could be demonstrated for both Nmu-pdg I and II when reactions were carried out in the presence of sodium borohydride. These data indicate the involvement of an amino group in the catalytic reaction mechanism of both enzymes.	Univ Texas, Med Branch, Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Ctr Mol Sci, 5 142 Med Res Bldg, Galveston, TX 77555 USA.			Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, P30ES006676] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04091, ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; CUNNINGHAM RP, 1994, ANN NY ACAD SCI, V726, P215, DOI 10.1111/j.1749-6632.1994.tb52818.x; Dizdaroglu M, 1996, MUTAT RES-DNA REPAIR, V362, P1, DOI 10.1016/0921-8777(95)00025-9; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furuta M, 1997, APPL ENVIRON MICROB, V63, P1551, DOI 10.1128/AEM.63.4.1551-1556.1997; Garvish JF, 2000, J MOL BIOL, V295, P479, DOI 10.1006/jmbi.1999.3369; Garvish JF, 1999, J BIOL CHEM, V274, P9786, DOI 10.1074/jbc.274.14.9786; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HAMILTON RW, 1989, J BIOL CHEM, V264, P17422; HIGGINS KM, 1987, MUTAT RES, V183, P117, DOI 10.1016/0167-8817(87)90053-8; LIU FT, 1978, BIOCHEMISTRY-US, V17, P4865, DOI 10.1021/bi00616a003; Lloyd RS, 1999, PROG NUCLEIC ACID RE, V62, P155; Lloyd RS, 1998, MUTAT RES-DNA REPAIR, V408, P159, DOI 10.1016/S0921-8777(98)00032-9; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MATSUNAGA T, 1991, PHOTOCHEM PHOTOBIOL, V54, P403, DOI 10.1111/j.1751-1097.1991.tb02034.x; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x	32	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23569	23576		10.1074/jbc.M000628200	http://dx.doi.org/10.1074/jbc.M000628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10807906	hybrid			2022-12-25	WOS:000088564200023
J	Busso, D; Keriel, A; Sandrock, B; Poterszman, A; Gileadi, O; Egly, JM				Busso, D; Keriel, A; Sandrock, B; Poterszman, A; Gileadi, O; Egly, JM			Distinct regions of MAT1 regulate cdk7 kinase and TFIIH transcription activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; RING FINGER PROTEIN; PRE-MESSENGER-RNA; CAK ASSEMBLY FACTOR; ACTIVATING KINASE; CTD KINASE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; HELA-CELLS	The transcription/DNA repair factor TFIIM may be resolved into at least two subcomplexes: the core TFIIH and the cdk-activating kinase (CAR) complex. The CAK complex, which is also found free in the cell, is composed of cdk7, cyclin H, and MAT1. In the present work, we found that the C terminus of MAT1 binds to the cdk7 cyclin Ii complex and activates the cdk7 kinase activity. The median portion of MAT1, which contains a coiled-coil motif, allows the binding of CAK to the TFIIH core through interactions with both XPD and XPB helicases. Furthermore, using recombinant TFIIH complexes, it is demonstrated that the N-terminal RING finger domain of MAT1 is crucial for transcription activation and participates to the phosphorylation of the C-terminal domain of the largest subunit of the RNA polymerase II.	Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Weizmann Institute of Science	Egly, JM (corresponding author), Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, Boite Postale 163, F-67404 Illkirch, France.		Keriel, Anne/N-3753-2017; Gileadi, Opher/F-1105-2013	Keriel, Anne/0000-0003-3340-299X; Gileadi, Opher/0000-0001-6886-898X; POTERSZMAN, Arnaud/0000-0002-6702-5777				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Besse Sylvie, 1995, Gene Expression, V4, P143; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rickert P, 1996, ONCOGENE, V12, P2631; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SANDROCK B, 2000, METHODS MOL BIOL 2 H; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YEE A, 1995, CANCER RES, V55, P6058; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	53	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22815	22823		10.1074/jbc.M002578200	http://dx.doi.org/10.1074/jbc.M002578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801852	hybrid			2022-12-25	WOS:000088419400031
J	Leach, TJ; Mazzeo, M; Chotkowski, HL; Madigan, JP; Wotring, MG; Glaser, RL				Leach, TJ; Mazzeo, M; Chotkowski, HL; Madigan, JP; Wotring, MG; Glaser, RL			Histone H2A.Z is widely but nonrandomly distributed in chromosomes of Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; TETRAHYMENA-THERMOPHILA; NUCLEOSOME STRUCTURE; CHROMATIN STRUCTURE; CENP-A; VARIANT; PROTEIN; DNA; PHOSPHORYLATION	Variant histones that differ in amino acid sequence from S-phase histones are widespread in eukaryotes, yet the structural changes they cause to nucleosomes and how those changes affect relevant cellular processes have not been determined. H2A.F/Z is a highly conserved family of H2A variants. H2Av, the H2A.F/Z variant of Drosophila melanogaster, was localized in polytene chromosomes by indirect immunofluorescence and in diploid chromosomes by chromatin immunoprecipitation. H2Av was widely distributed in the genome and not limited to sites of active transcription. H2Av was present in thousands of euchromatic bands and the heterochromatic chromocenter of polytene chromosomes, and the H2Av antibody precipitated both transcribed and nontranscribed genes as well as noncoding euchromatic and heterochromatic sequences. The distribution of H2Av was not uniform. The complex banding pattern of H2Av in polytene chromosomes did not parallel the concentration of DNA, as did the pattern of immunofluorescence using H2A antibodies, and the density of H2Av measured by immunoprecipitation varied between different sequences. Of the sequences assayed, H2Av was least abundant on 1.688 satellite sequences and most abundant on the hsp70 genes. Finally, transcription caused, to an equivalent extent, both H2Av and H2A to be less tightly associated with DNA.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Glaser, RL (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, POB 22002, Albany, NY 12201 USA.				NIGMS NIH HHS [GM53476] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; CARR AM, 1994, MOL GEN GENET, V245, P628, DOI 10.1007/BF00282226; CHAMPLIN DT, 1991, GENE DEV, V5, P1611, DOI 10.1101/gad.5.9.1611; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Doenecke D, 1997, ADV EXP MED BIOL, V424, P37; DONAHUE PR, 1986, P NATL ACAD SCI USA, V83, P6878, DOI 10.1073/pnas.83.18.6878; GILMOUR DS, 1985, MOL CELL BIOL, V5, P2009, DOI 10.1128/MCB.5.8.2009; GLASER RL, 1994, NUCLEIC ACIDS RES, V22, P5068, DOI 10.1093/nar/22.23.5068; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Jackson JD, 1996, TRENDS BIOCHEM SCI, V21, P466, DOI 10.1016/S0968-0004(96)20028-3; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Jiang WP, 1998, BIOCHEM BIOPH RES CO, V245, P613, DOI 10.1006/bbrc.1998.8495; KURTH PD, 1978, J CELL BIOL, V78, P910, DOI 10.1083/jcb.78.3.910; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; ORRWEAVER TL, 1986, MOL CELL BIOL, V6, P4624, DOI 10.1128/MCB.6.12.4624; PALMER D, 1980, P NATL ACAD SCI-BIOL, V77, P2671, DOI 10.1073/pnas.77.5.2671; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PINA B, 1987, DEV BIOL, V123, P51, DOI 10.1016/0012-1606(87)90426-X; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; THONGLAIROAM V, 1994, THESIS U ADELAIDE AD; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zweidler A, 1984, HISTONE GENES STRUCT, P339	41	105	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23267	23272		10.1074/jbc.M910206199	http://dx.doi.org/10.1074/jbc.M910206199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801889	hybrid			2022-12-25	WOS:000088419400092
J	O'Neill, T; Dwyer, AJ; Ziv, Y; Chan, DW; Lees-Miller, SP; Abraham, RH; Lai, JH; Hill, D; Shiloh, Y; Cantley, LC; Rathbun, GA				O'Neill, T; Dwyer, AJ; Ziv, Y; Chan, DW; Lees-Miller, SP; Abraham, RH; Lai, JH; Hill, D; Shiloh, Y; Cantley, LC; Rathbun, GA			Utilization of oriented peptide libraries to identify substrate motifs selected by ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA GENE; NIJMEGEN BREAKAGE SYNDROME; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; 3-KINASE RELATED KINASES; DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; V(D)J RECOMBINATION; IONIZING-RADIATION	The ataxia telangiectasia mutated (ATM) gene encodes a serine/threonine protein kinase that plays a critical role in genomic surveillance and development. Here, we use a peptide library approach to define the in vitro substrate specificity of ATM kinase activity. The peptide library analysis identified an optimal sequence with a central core motif of LSQE that is preferentially phosphorylated by ATM. The contributions of the amino acids surrounding serine in the LSQE motif were assessed by utilizing specific peptide libraries or individual peptide substrates. All amino acids comprising the LSQE sequence were critical for maximum peptide substrate suitability for ATM. The DNA-dependent protein kinase (DNA-PK), a Ser/Thr kinase related to ATM and important in DNA repair, was compared with ATM in terms of peptide substrate selectivity. DNA-PK was found to be unique in its preference of neighboring amino acids to the phosphorylated serine. Peptide library analyses defined a preferred amino acid motif for ATM that permits clear distinctions between ATM and DNA-PK kinase activity. Data base searches using the library-derived ATM sequence identified previously characterized substrates of ATM, as well as novel candidate substrate targets that may function downstream in ATM-directed signaling pathways.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, Boston, MA 02115 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Biol Chem, Calgary, AB T2N 1N4, Canada; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Beth Israel Deaconess Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Oncogene Sci Inc, Cambridge, MA 02142 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Tel Aviv University; Sackler Faculty of Medicine; University of Calgary; University of Calgary; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rathbun, GA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Lees-Miller, Susan/0000-0001-5809-2516	NIGMS NIH HHS [GM57018, GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203, R01GM057018] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chapman CR, 1999, MOL BIOL CELL, V10, P3223, DOI 10.1091/mbc.10.10.3223; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Mayo LD, 1997, CANCER RES, V57, P5013; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	65	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22719	22727		10.1074/jbc.M001002200	http://dx.doi.org/10.1074/jbc.M001002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801797	hybrid			2022-12-25	WOS:000088419400019
J	Simpson, KJ; Ranganathan, S; Fisher, JA; Janssens, PA; Shaw, DC; Nicholas, KR				Simpson, KJ; Ranganathan, S; Fisher, JA; Janssens, PA; Shaw, DC; Nicholas, KR			The gene for a novel member of the whey acidic protein family encodes three four-disulfide core domains and is asynchronously expressed during lactation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALLABY MACROPUS-EUGENII; LINKED KALLMANN SYNDROME; TAMMAR WALLABY; MAMMARY-GLAND; MOLECULAR-CLONING; DEPENDENT EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; CASEIN GENE; MILK WHEY	Secretion of whey acidic protein (WAP) in milk throughout lactation has previously been reported for a limited number of species, including the mouse, rat, rabbit, camel, and pig. We report here the isolation of WAP from the milk of a marsupial, the tammar wallaby (Macropus eugenii). Tammar WAP (tWAP) was isolated by reverse-phase HPLC and migrates in SDS-polyacrylamide gel electrophoresis at 29.9 kDa. tWAP is the major whey protein, but in contrast to eutherians, secretion is asynchronous and occurs only from approximately days 130 through 240 of lactation. The full-length cDNA codes for a mature protein of 191 amino acids, which is comprised of three four-disulfide core domains, contrasting with the two four-disulfide core domain arrangement in all other known WAPs. A three dimensional model for tWAP has been constructed and suggests that the three domains have Little interaction and could function independently. Analysis of the amino acid sequence suggests the protein belongs to a family of protease inhibitors; however, the predicted active site of these domains is dissimilar to the confirmed active site for known protease inhibitors. This suggests that any putative protease ligand may be unique to either the mammary gland, milk, or gut of the pouch young. Examination of the endocrine regulation of the tWAP gene showed consistently that the gene is prolactin-responsive but that the endocrine requirements for induction and maintenance of tWAP gene expression are different during lactation.	Victorian Inst Anim Sci, Attwood, Vic 3049, Australia; La Trobe Univ, Sch Agr Sci, Bundoora, Vic 3083, Australia; Univ Sydney, Australian Genom Informat Ctr, Sydney, NSW 2006, Australia; Australian Natl Univ, Div Biochem & Mol Biochem, Canberra, ACT 2602, Australia; Australian Natl Univ, John Curtin Sch Med Res, Prot Biochem Grp, Canberra, ACT 2601, Australia	Victorian Department of Environment & Primary Industries; La Trobe University; University of Sydney; Australian National University; Australian National University; John Curtin School of Medical Research	Simpson, KJ (corresponding author), Victorian Inst Anim Sci, 475 Mickleham Rd, Attwood, Vic 3049, Australia.	k.simpson@biochemistry.unimelb.edu.au		Simpson, Kaylene/0000-0001-9136-1781; Ranganathan, Shoba/0000-0002-8290-813X				BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; BIRD PH, 1994, J MOL ENDOCRINOL, V13, P117, DOI 10.1677/jme.0.0130117; BURDON T, 1991, MECH DEVELOP, V36, P67, DOI 10.1016/0925-4773(91)90073-F; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CECHOVA D, 1971, COLLECT CZECH CHEM C, V36, P3342; CHOMCZYNSKI P, 1984, SCIENCE, V226, P1326, DOI 10.1126/science.6390680; COLLET C, 1991, J MOL ENDOCRINOL, V6, P9, DOI 10.1677/jme.0.0060009; COUTO MA, 1993, INFECT IMMUN, V61, P2991, DOI 10.1128/IAI.61.7.2991-2994.1993; DANDEKAR AM, 1982, P NATL ACAD SCI-BIOL, V79, P3987, DOI 10.1073/pnas.79.13.3987; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DEVINOY E, 1988, REPROD NUTR DEV, V28, P1145, DOI 10.1051/rnd:19880711; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; FARMER SJ, 1990, MOL ENDOCRINOL, V4, P1095, DOI 10.1210/mend-4-8-1095; FINDLAY L, 1982, J REPROD FERTIL, V65, P59, DOI 10.1530/jrf.0.0650059; Garczynski MA, 1997, BIOL REPROD, V57, P856, DOI 10.1095/biolreprod57.4.856; Green B., 1984, Symposia of the Zoological Society of London, P369; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; KATO I, 1979, FED PROC, V38, P832; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen M, 1998, J BIOL CHEM, V273, P4574, DOI 10.1074/jbc.273.8.4574; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEGOUIS R, 1993, GENOMICS, V17, P516, DOI 10.1006/geno.1993.1360; LINCOLN DW, 1981, J REPROD FERTIL, V63, P193, DOI 10.1530/jrf.0.0630193; May ACW, 1995, PROTEIN ENG, V8, P873, DOI 10.1093/protein/8.9.873; MCKNIGHT RA, 1991, GENES ONCOGENES HORM; MORRISON BW, 1994, ONCOGENE, V9, P3417; Nicholas K, 1997, J MAMMARY GLAND BIOL, V2, P299, DOI 10.1023/A:1026392623090; NICHOLAS KR, 1987, BIOCHEM J, V241, P899, DOI 10.1042/bj2410899; NICHOLAS KR, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P153; NICHOLAS KR, 1988, BIOCHEM BIOPH RES CO, V154, P529, DOI 10.1016/0006-291X(88)90172-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Piotte CP, 1996, ARCH BIOCHEM BIOPHYS, V330, P59, DOI 10.1006/abbi.1996.0225; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; PUISSANT C, 1991, CELL BIOL INT REP, V15, P121, DOI 10.1016/0309-1651(91)90103-P; Ranganathan S, 1999, J MOL GRAPH MODEL, V17, P106, DOI 10.1016/S1093-3263(99)00023-6; RENFREE MB, 1981, BIOL NEONATE, V40, P29, DOI 10.1159/000241469; RENFREE MB, 1994, MARSHALLS PHYSL REPR, V3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shamay Avi, 1992, Transgenic Research, V1, P124, DOI 10.1007/BF02528777; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; Simpson K, 1998, COMP BIOCHEM PHYS B, V120, P535, DOI 10.1016/S0305-0491(98)10040-8; Simpson KJ, 1998, J MOL ENDOCRINOL, V20, P27, DOI 10.1677/jme.0.0200027; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; TEAHAN CG, 1991, COMP BIOCHEM PHYS B, V99, P99, DOI 10.1016/0305-0491(91)90014-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyndale-Biscoe CH, 1988, DEV MARSUPIAL; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; WESSEL GM, 1995, DEV BIOL, V167, P388, DOI 10.1006/dbio.1995.1033; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WILLIAMS K, 1992, TODAYS LIFE SCI, V4, P50; Xu WD, 1996, ARCH ANDROLOGY, V37, P135, DOI 10.3109/01485019608988514; Zitnik RJ, 1997, BIOCHEM BIOPH RES CO, V232, P687, DOI 10.1006/bbrc.1997.6358	59	66	68	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23074	23081		10.1074/jbc.M002161200	http://dx.doi.org/10.1074/jbc.M002161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10801834	hybrid			2022-12-25	WOS:000088419400064
J	Miyake, JH; Wang, SL; Davis, RA				Miyake, JH; Wang, SL; Davis, RA			Accelerated publication - Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY GENE INDUCTION; MESSENGER-RNA; NUCLEAR RECEPTOR; ATHEROGENIC DIET; PRIMARY CULTURES; RAT HEPATOCYTES; CELLS; MICE; BIOSYNTHESIS; CLONING	In the studies reported herein, we show that two complementary experimental models: inbred strains of mice (i.e. C57BL/6 and C3H/HeJ), and a differentiated line of rat hepatoma cells (i.e. L35 cells), require the activation of cytokines by monocyte/macrophages to display bile acid negative feedback repression of cholesterol 7 alpha-hydroxylase (CYP7A1), Feeding a bile acid-containing atherogenic diet for 3 weeks to C57BL/6 mice led to a 70% reduction in the expression of hepatic CYP7A1 mRNA whereas no reduction was observed in C3H/HeJ mice. The strain-specific response to repression of CYP7A1 paralleled the activation of hepatic cytokine expression. Studies using cultured THP-1 monocyte/macrophages showed that the hydrophobic bile acid chenodeoxycholate, a well established potent repressor of CYP7A1, induced the expression of mRNAs encoding interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF alpha), In contrast, the hydrophilic bile acid ursodeoxycholate, which does not repress CYP7A1, did not induce cytokine mRNA expression by THP-1 cells. Chenodeoxycholate activation of cytokines by THP-1 cells was blocked by the peroxisome proliferator-activated receptor gamma agonist rosiglitazone. The expression of cytokines (e.g. IL-1 and TNF alpha) by THP-1 cells paralleled with the ability of these cells to produce conditioned medium that when added to rat L35 hepatoma cells, repressed CYP7A1. Moreover, rosiglitazone, which blocks cytokine activation by macrophages, also blocked the repression of CYP7A1 normally exhibited by C57BL/6 mice fed the bile acid-containing atherogenic diet. The combined data indicate that the activation of cytokines may mediate CYP7A1 repression caused by feeding mice an atherogenic diet containing bile acids.	San Diego State Univ, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA	California State University System; San Diego State University	Davis, RA (corresponding author), San Diego State Univ, Mammalian Cell & Mol Biol Lab, Life Sci Bldg LS307,5500 Campanile Dr, San Diego, CA 92182 USA.	rdavis@sunstroke.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGSTROM S, 1958, ACTA PHYSIOL SCAND, V43, P1, DOI 10.1111/j.1748-1716.1958.tb01572.x; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; Crestani M, 1998, J LIPID RES, V39, P2192; DUELAND S, 1993, J LIPID RES, V34, P923; Dueland S, 1997, J LIPID RES, V38, P1445; EDWARDS PA, 1996, N COMP BIOC, V31, P341; Feingold KR, 1996, J LIPID RES, V37, P223; Gutierrez-Ruiz MC, 1999, TOXICOLOGY, V134, P197, DOI 10.1016/S0300-483X(99)00044-X; HEUMAN DM, 1989, J LIPID RES, V30, P1161; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LI YC, 1990, J BIOL CHEM, V265, P12012; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Machleder D, 1997, J CLIN INVEST, V99, P1406, DOI 10.1172/JCI119300; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SHEFER S, 1969, J LIPID RES, V10, P646; SHEFFER S, 1970, J LIPID RES, V11, P404; Spady DK, 1996, J BIOL CHEM, V271, P18623, DOI 10.1074/jbc.271.31.18623; Stonans I, 1999, CYTOKINE, V11, P151, DOI 10.1006/cyto.1998.0366; STRAVITZ RT, 1995, J LIPID RES, V36, P1359; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; Trawick JD, 1997, J BIOL CHEM, V272, P3099, DOI 10.1074/jbc.272.5.3099; Trawick JD, 1996, J LIPID RES, V37, P588; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2	33	129	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21805	21808		10.1074/jbc.C000275200	http://dx.doi.org/10.1074/jbc.C000275200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10823815	hybrid			2022-12-25	WOS:000088363800008
J	Goese, M; Eisenreich, W; Kupfer, E; Weber, W; Bacher, A				Goese, M; Eisenreich, W; Kupfer, E; Weber, W; Bacher, A			Biosynthetic origin of hydrogen atoms in the lipase inhibitor lipstatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; STREPTOMYCES-TOXYTRICINI; PANCREATIC LIPASE; PYRUVATE-KINASE; STEREOCHEMISTRY; EPIMERIZATION; PROTON	The lipase inhibitor lipstatin is biosynthesized in Streptomyces toxytricini via condensation of a C-14 precursor and a C-8 precursor, which are both obtained from fatty acid catabolism. To study the mechanism of this reaction in more detail, S. toxytricini was grown in medium containing a mixture of U-C-13,U-H-2-lipids and unlabeled sunflower oil or in a medium containing 70% D2O. Lipstatin was isolated and analyzed by H-1,H-2 and C-13 NMR spectroscopy. Hydrogen atoms at C-2, C-3, and C-4 of lipstatin were found to be derived from solvent protons. The formation of the lipstatin precursor 3-hydroxy-Delta(5,8)-tetradecadienoyl-CoA by beta oxidation of linoleic acid explains the incorporation of solvent hydrogen into the 4 position of lipstatin. The hydrogen in position 3 of lipstatin is most probably introduced from solvent by proton/deuterium exchange of a redox cofactor involved in the reduction of the keto group in the branched chain beta keto acid arising by a decarboxylative condensation. The incorporation of solvent hydrogen at position 2 can be explained by epimerization of a chiral intermediate at C-2 and C-3. Epimerization may involve a dehydration-rehydration mechanism.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Hoffmann La Roche AG, Dept Biotechnol, Pharma Preclin Res, CH-4070 Basel, Switzerland	Technical University of Munich; Roche Holding	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	adelbert.bacher@ch.tum.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ALBERTS AW, 1964, BIOCHEMISTRY-US, V3, P1563, DOI 10.1021/bi00898a030; CANE DE, 1986, J AM CHEM SOC, V108, P4957, DOI 10.1021/ja00276a042; Eisenreich W, 1997, J BIOL CHEM, V272, P867, DOI 10.1074/jbc.272.2.867; Goese M, 1999, EUR J BIOCHEM, V263, P447, DOI 10.1046/j.1432-1327.1999.00518.x; HOCHULI E, 1987, J ANTIBIOT, V40, P1086, DOI 10.7164/antibiotics.40.1086; JIN SJ, 1992, J BIOL CHEM, V267, P119; LUTHIPENG QQ, 1992, FEBS LETT, V299, P111, DOI 10.1016/0014-5793(92)80112-T; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; ROBINSON JL, 1972, J BIOL CHEM, V247, P1096; ROSE IA, 1989, BIOCHEMISTRY-US, V28, P9579, DOI 10.1021/bi00451a005; SAITO K, 1980, BIOCHIM BIOPHYS ACTA, V618, P202; SMELAND TE, 1991, J BIOL CHEM, V266, P23904; WEIBEL EK, 1987, J ANTIBIOT, V40, P1081, DOI 10.7164/antibiotics.40.1081; Weissman KJ, 1997, BIOCHEMISTRY-US, V36, P13849, DOI 10.1021/bi971566b	14	16	17	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21192	21196		10.1074/jbc.M003094200	http://dx.doi.org/10.1074/jbc.M003094200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801870	hybrid			2022-12-25	WOS:000088230600032
J	van Tiel, CM; Westerman, J; Paasman, M; Wirtz, KWA; Snoek, GT				van Tiel, CM; Westerman, J; Paasman, M; Wirtz, KWA; Snoek, GT			The protein kinase C-dependent phosphorylation of serine 166 is controlled by the phospholipid species bound to the phosphatidylinositol transfer protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI NETWORK; RAT-BRAIN; CELLS; TRANSPORT; 3-KINASE; VESICLES; BINDING; ISOFORM	The charge isomers of bovine brain PI-TP alpha (i.e. PI-TP alpha I containing a phosphatidylinositol (PI) molecule and PI-TP alpha II containing a phosphatidylcholine (PC) molecule) were phosphorylated in vitro by rat brain protein kinase C (PKC) at different rates. From the double-reciprocal plot, it was estimated that the V-max values for PI-TP alpha I and II were 2.0 and 6.0 nmol/min, respectively; the K-m values for both charge isomers were about equal, i.e. 0.7 mu M. Phosphorylation of charge isomers of recombinant mouse PI-TP alpha confirmed that the PC-containing isomer was the better substrate. Phosphoamino acid analysis of in vitro and in vivo P-32-labeled PI-TP alpha s showed that serine was the major site of phosphorylation, Degradation of P-32-labeled PI-TP alpha by cyanogen bromide followed by high pressure liquid chromatography and sequence analysis yielded one P-32-labeled peptide (amino acids 104-190), This peptide contained Ser-148, Ser-152, and the consensus PKC phosphorylation site Ser-166. Replacement of Ser-166 with an alanine residue confirmed that indeed this residue was the site of phosphorylation. This mutation completely abolished PI and PC transfer activity. This was also observed when Ser-166 was replaced with Asp, implying that this is a key amino acid residue in regulating the function of PI-TP alpha, Stimulation of NIH3T3 fibroblasts by phorbol ester or platelet-derived growth factor induced the rapid relocalization of PI-TP alpha to perinuclear Golgi structures concomitant with a 2-3-fold increase in lysophosphatidylinositol levels. This relocalization was also observed for Myc-tagged wtPI-TP alpha expressed in NIH3T3 cells. In contrast, the distribution of Myc-tagged PI-TP alpha(S166A) and Myc-tagged PI-TP alpha(S166D) were not affected by phorbol ester, suggesting that phosphorylation of Ser-166 was a prerequisite for the relocalization to the Golgi, A model is proposed in which the PKC-dependent phosphorylation of PI-TP alpha is linked to the degradation of PI.	Univ Utrecht, Inst Biomembranes, Dept Lipid Biochem, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Snoek, GT (corresponding author), Univ Utrecht, Inst Biomembranes, Dept Lipid Biochem, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	g.t.snoek@chem.uu.nl						ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cockcroft S, 1997, FEBS LETT, V410, P44, DOI 10.1016/S0014-5793(97)00414-6; Cockcroft S, 1997, BIOCHEM SOC T, V25, P1125, DOI 10.1042/bst0251125; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; Falasca M, 1996, EUR J BIOCHEM, V241, P386, DOI 10.1111/j.1432-1033.1996.00386.x; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; Monaco ME, 1998, BIOCHEM J, V335, P175, DOI 10.1042/bj3350175; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Paul KS, 1998, FEBS LETT, V431, P91, DOI 10.1016/S0014-5793(98)00722-4; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; SNOEK GT, 1993, BIOCHEM J, V291, P649, DOI 10.1042/bj2910649; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TIMMERMANSHEREIJGERS JLPM, 1995, J BIOL CHEM, V270, P14263, DOI 10.1074/jbc.270.24.14263; van Tiel CM, 2000, BIOCHEM J, V346, P537, DOI 10.1042/0264-6021:3460537; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; Voziyan PA, 1997, BIOCHEMISTRY-US, V36, P10082, DOI 10.1021/bi970829z; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353	32	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2000	275	28					21532	21538		10.1074/jbc.M002203200	http://dx.doi.org/10.1074/jbc.M002203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	335EM	10801835	hybrid			2022-12-25	WOS:000088230600077
J	Irihimovitch, V; Shapira, M				Irihimovitch, V; Shapira, M			Glutathione redox potential modulated by reactive oxygen species regulates translation of Rubisco large subunit in the chloroplast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; II D1 PROTEIN; CHLAMYDOMONAS-REINHARDTII; PHOTOSYSTEM-II; ACTIVE OXYGEN; BIOLOGICAL SAMPLES; SALICYLIC-ACID; MESSENGER-RNA; LIGHT STRESS; EXPRESSION	Previous work showed a transient but dramatic arrest in the synthesis of Rubisco large subunit (LSU) upon transfer of Chlamydomonas reinhardtii cells from low light (LL) to high light (HL), Using dichlorofluorescin, a short-term increase in reactive oxygen species (ROS) was demonstrated, suggesting that their excessive formation could signal LSU down-regulation. A decrease in LSU synthesis occurred at LL in the presence of methyl viologen and was prevented at HL by ascorbate. Interfering with D1 function by mutations or by incubation with DCMU prevented the increase in ROS formation at HL and the concomitant down-regulation of LSU synthesis, If the electron transport was blocked further downstream, by mutation in the cytochrome b(6)/f or by incubation with 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone, ROS formation increased, and LSU synthesis ceased. The elevation of ROS occurred concurrently with a change in the redox state of the glutathione pool, which shifted toward its oxidized form immediately after the transfer to HL and returned to its original value after 6 h, The decrease in the reduced/oxidized glutathione ratio at HL was prevented by ascorbate and could be induced at LL by methyl viologen. We suggest that excess ROS mediate a decrease in the reduced/oxidized glutathione ratio that in turn signals the translational arrest of the rbcL transcript.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Shapira, M (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.			Shapira, Michal/0000-0002-6164-7874				ALCHER RG, 1997, PHYSIOL PLANTARUM, V100, P224; Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; ANDERSON JM, 1987, SHADE SUN RESPONSES, P1; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARRACLOUGH R, 1979, EUR J BIOCHEM, V94, P165, DOI 10.1111/j.1432-1033.1979.tb12883.x; Bei Yong-Mei, 1995, Plant Journal, V8, P235; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Chamnongpol S, 1996, PLANT J, V10, P491, DOI 10.1046/j.1365-313X.1996.10030491.x; CHEN ZX, 1995, P NATL ACAD SCI USA, V92, P4134, DOI 10.1073/pnas.92.10.4134; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; FALKOWSKI PG, 1991, J PHYCOL, V27, P8, DOI 10.1111/j.0022-3646.1991.00008.x; FOYER CH, 1994, PHYSIOL PLANTARUM, V92, P696, DOI 10.1111/j.1399-3054.1994.tb03042.x; FOYER CH, 1995, PLANT PHYSIOL, V109, P1047, DOI 10.1104/pp.109.3.1047; GONG HS, 1995, BBA-BIOENERGETICS, V1228, P181, DOI 10.1016/0005-2728(94)00170-A; GREEN R, 1995, PLANT CELL, V7, P203, DOI 10.1105/tpc.7.2.203; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; HARRIS EH, 1989, GENETICS, V123, P281; HARTEL H, 1992, J PHOTOCH PHOTOBIO B, V12, P375, DOI 10.1016/1011-1344(92)85042-S; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; Ishida H, 1997, PLANT CELL PHYSIOL, V38, P471, DOI 10.1093/oxfordjournals.pcp.a029191; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Khrebtukova I, 1996, P NATL ACAD SCI USA, V93, P13689, DOI 10.1073/pnas.93.24.13689; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Lardans A, 1997, J BIOL CHEM, V272, P210; LERS A, 1992, J BIOL CHEM, V267, P17494; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; MORENO J, 1995, PLANT PHYSIOL BIOCH, V33, P121; Okada K, 1996, BBA-BIOENERGETICS, V1274, P73, DOI 10.1016/0005-2728(96)00015-1; Osmond CB, 1994, PHOTOINHIBITION PHOT, P1; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Rodermel S, 1996, P NATL ACAD SCI USA, V93, P3881, DOI 10.1073/pnas.93.9.3881; SCHMIDT GW, 1983, P NATL ACAD SCI-BIOL, V80, P2632, DOI 10.1073/pnas.80.9.2632; SCHMIDT RJ, 1985, MOL CELL BIOL, V5, P1093, DOI 10.1128/MCB.5.5.1093; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Shapira M, 1997, PLANT MOL BIOL, V33, P1001, DOI 10.1023/A:1005814800641; Spreitzer R.J., 1993, ANNU REV PLANT PHYS, V44, P1; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206	45	65	74	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16289	16295		10.1074/jbc.275.21.16289	http://dx.doi.org/10.1074/jbc.275.21.16289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10821870	hybrid			2022-12-25	WOS:000087291400092
J	Chen, SC; Cui, JF; Nakamura, K; Ribeiro, RCJ; West, BL; Gardner, DG				Chen, SC; Cui, JF; Nakamura, K; Ribeiro, RCJ; West, BL; Gardner, DG			Coactivator-vitamin D receptor interactions mediate inhibition of the atrial natriuretic peptide promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; 1,25-DIHYDROXYVITAMIN D-3 RECEPTOR; TRANSCRIPTION FACTOR-TFIIB; LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; NUCLEAR-RECEPTOR; NEGATIVE REGULATION; GENE-EXPRESSION; STEROID-RECEPTORS; FACTOR-IIB	We have discovered a role for coactivators binding to the AF-2 surface of the vitamin D receptor (VDR) in its negative effects on gene transcription. We tested nine amino acid residues (Ser(235), Ile(242), Lys(246), Asp(253), Ile(260), Leu(263), Leu(417), Leu(419), and Glu(420)) in, human VDR which, based on homology to the human thyroid hormone receptor, would be predicted to lie in or near the coactivator-binding site. Mutation of six of these residues in VDR resulted in loss of both the activation (assessed with a transfected DR3 TK luciferase reporter) and inhibition (assessed with an hANPCAT reporter) functions of the receptor when tested in cultured neonatal rat atrial myocytes and HeLa cells. Collectively, these mutations also suppressed association of VDR with the coactivators GRIP1 and steroid receptor coactivator 1 in vitro but had little or no effect on ligand binding, heterodimerization with the retinoid X receptor, or association with a VDR-specific DNA recognition element. Co-transfection with GRIP1 or steroid receptor coactivator 1 amplified both the positive and negative responses to wild type VDR but had little or no effect on the functionally impaired mutants described above. The interaction between VDR and GRIP1 proved to be heavily dependent upon the integrity of nuclear box III in the latter protein. Mutations in this region of GRIP1 impaired its ability to associate with VDR in vitro and to amplify VDR activity in intact cells. These studies establish a role for coactivators recruited to the same receptor surface in both the activating and inhibitory activity of the liganded receptor.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Gardner, DG (corresponding author), Univ Calif San Francisco, Metab Res Unit, 1109 HSW, San Francisco, CA 94143 USA.	gardner@itsa.ucsf.edu		West, Brian/0000-0002-5320-3691	NHLBI NIH HHS [HL-35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BAUER RF, 1976, IN VITRO CELL DEV B, V12, P558; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen SC, 1998, HYPERTENSION, V31, P1338, DOI 10.1161/01.HYP.31.6.1338; Chen SC, 1999, J BIOL CHEM, V274, P11260, DOI 10.1074/jbc.274.16.11260; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jimenez-Lara AM, 1999, J BIOL CHEM, V274, P13503, DOI 10.1074/jbc.274.19.13503; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kovacic B, 1998, J BIOL CHEM, V273, P35185; LI Q, 1994, J BIOL CHEM, V269, P4934; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norman AW, 1999, J CELL BIOCHEM, V74, P323, DOI 10.1002/(SICI)1097-4644(19990901)74:3<323::AID-JCB2>3.0.CO;2-V; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; WU JP, 1989, J BIOL CHEM, V264, P6472; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	41	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15039	15048		10.1074/jbc.275.20.15039	http://dx.doi.org/10.1074/jbc.275.20.15039			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809746	hybrid			2022-12-25	WOS:000087128300039
J	Hao, MM; Maxfield, FR				Hao, MM; Maxfield, FR			Characterization of rapid membrane internalization and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; EARLY ENDOSOMES; HEP2 CELLS; PATHWAY; COMPARTMENTS; FIBROBLASTS	Lipids and other membrane constituents recycle between the plasma membrane and intracellular endocytic compartments. In CHO cells, approximately half of the internalized C-6-NBD-SM, a fluorescent lipid analogue widely used as a membrane maker, recycles via the endocytic recycling compartment with a t(1/2) of similar to 12 min (Mayor, S., Presley, J. F,, and Maxfield, F. R, (1993) J, Cell Biol. 121, 1257-1269), Surprisingly, the rest returns to the plasma membrane very quickly. A detailed kinetic study presented in this paper indicates that after a brief internalization pulse, 42-62% of the internalized C-6-NBD-SM returns to the plasma membrane with a t1/2 of 1-2 min. Similar results are obtained using HEp2 and nonpolarized Madin-Darby canine kidney cells. Using FM dyes of different hydrophobicity, we show that rapid recycling involves passage through an endocytic organelle that was subsequently identified as the sorting endosome by co-localization with internalized transferrin and low density lipoprotein, These results imply that the membrane internalization rate is much higher than previously estimated, with a t(1/2) as short as 5-10 min. Rapid internalization and recycling would facilitate processes such as nutrient uptake and cholesterol afflux.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	frmaxfie@med.cornell.edu	Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027083, R01DK027083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BIRN H, 1993, AM J PHYSIOL, V264, pF239, DOI 10.1152/ajprenal.1993.264.2.F239; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GHOSH RN, 1994, J CELL SCI, V107, P2177; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HUANG ZJ, 1991, BIOCHEM BIOPH RES CO, V181, P166, DOI 10.1016/S0006-291X(05)81396-8; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P40; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Vidal M, 1997, J CELL SCI, V110, P1867; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	34	193	195	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					15279	15286		10.1074/jbc.275.20.15279	http://dx.doi.org/10.1074/jbc.275.20.15279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809763	hybrid			2022-12-25	WOS:000087128300069
J	Nandi, A; Estess, P; Siegelman, MH				Nandi, A; Estess, P; Siegelman, MH			Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PRIMARY ADHESION; IN-VITRO; IMMUNOMODULATORY FUNCTIONS; ALLOGRAFT-REJECTION; BINDING PROTEINS; DISEASE-ACTIVITY; GROWTH-FACTOR; LYMPH-NODE; E-SELECTIN	CD44 on lymphocytes binding to its carbohydrate ligand hyaluronan can mediate primary adhesion (rolling interactions) of lymphocytes on vascular endothelial cells. This adhesion pathway is utilized in the extravasation of activated T cells from the blood into sites of inflammation and therefore influences patterns of lymphocyte homing and inflammation. Hyaluronan is a glycosaminoglycan found in the extracellular matrix and is involved in a number of biological processes. We have shown that the expression of hyaluronan on the surface of endothelial cells is inducible by proinflammatory cytokines. However, the manner through which hyaluronan is anchored to the endothelial cell surface so that it can resist shear forces and the mechanism of the regulation of the level of hyaluronan on the cell surface has not been investigated. In order to characterize potential hyaluronan receptors on endothelial cells, we performed analyses of cell surface staining by flow cytometry on intact endothelial cells and ligand blotting assays using membrane fractions, Hyaluronan binding activity was detected as a major species corresponding to the size of CD44, and this was confirmed to be the same by Western blotting and immunoprecipitation. Moreover, alterations in the surface level of hyaluronan after tumor necrosis factor-cu stimulation is regulated primarily by changes in the cell surface levels of the hyaluronan-binding form of CD44. In laminar flow assays, lymphoid cells specifically rob on hyaluronan anchored by purified CD44 coated on glass tubes, indicating that the avidity of the endothelial CD44/hyaluronan interaction is sufficient to support rolling adhesions under conditions mimicking physiologic shear forces. Together these studies show that CD44 serves to anchor hyaluronan on endothelial cell surfaces, that activation of CD44 is a major regulator of endothelial surface hyaluronan expression, and that the non-covalent interaction between CD44 and hyaluronan is sufficient to provide resistance to shear under physiologic conditions and thereby support the initial steps of lymphocyte extravasation.	Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Siegelman, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	siegelman@utsw.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056746] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57571] Funding Source: Medline; NHLBI NIH HHS [HL56746] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBASSI O, 1991, J IMMUNOL, V147, P2107; ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AUSPRUNK DH, 1986, AM J ANAT, V177, P313, DOI 10.1002/aja.1001770304; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERNARD O, 1978, J EXP MED, V148, P580, DOI 10.1084/jem.148.2.580; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; Ermak G, 1996, CANCER RES, V56, P1037; Estess P, 1999, J EXP MED, V190, P9, DOI 10.1084/jem.190.1.9; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; GREEN SJ, 1988, J CELL SCI, V90, P145; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HATHCOCK KS, 1993, J IMMUNOL, V151, P6712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; Jacoboni I, 1999, J STRUCT BIOL, V126, P52, DOI 10.1006/jsbi.1999.4090; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1989, J IMMUNOL, V142, P3050; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P423; KING SR, 1991, SURGERY, V109, P76; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; Knoflach A, 1999, TRANSPLANTATION, V67, P909, DOI 10.1097/00007890-199903270-00020; Knoflach A, 1999, J AM SOC NEPHROL, V10, P1059; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, CIBA F SYMP, V124, P9; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LAWRENCE MB, 1987, BLOOD, V70, P1284; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; OCONNELL KA, 1990, J IMMUNOL, V144, P521; OKSALA O, 1995, J HISTOCHEM CYTOCHEM, V43, P125, DOI 10.1177/43.2.7529785; PAPAKONSTANTINOU E, 1995, P NATL ACAD SCI USA, V92, P9881, DOI 10.1073/pnas.92.21.9881; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Roden L, 1989, CIBA F SYMP, P76; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TAMMI R, 1994, ARCH DERMATOL RES, V286, P21, DOI 10.1007/BF00375839; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; UNDERHILL CB, 1980, J BIOL CHEM, V255, P4544; VERDRENGH M, 1995, SCAND J IMMUNOL, V42, P353, DOI 10.1111/j.1365-3083.1995.tb03667.x; VISWESWARIAH SS, 1994, EUR J BIOCHEM, V219, P727, DOI 10.1111/j.1432-1033.1994.tb18551.x; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055	86	153	156	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14939	14948		10.1074/jbc.275.20.14939	http://dx.doi.org/10.1074/jbc.275.20.14939			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10809739	hybrid			2022-12-25	WOS:000087128300025
J	Kao, SY; Lemoine, FJ; Marriott, SJ				Kao, SY; Lemoine, FJ; Marriott, SJ			HTLV-1 Tax protein sensitizes cells to apoptotic cell death induced by DNA damaging agents	ONCOGENE			English	Article						HTLV-1; Tax; apoptosis; nucleotide excision repair; DNA damage	VIRUS TYPE-I; NF-KAPPA-B; TRANSFORMS RAT FIBROBLASTS; LEUKEMIA-VIRUS; INDUCTION; GENE; ACTIVATION; EXPRESSION; TRANSACTIVATOR; INTEGRATION	Transient HTLV-1 Tax expression suppresses cellular nucleotide excision repair, and this effect correlates with Tax transactivation of the proliferating cell nuclear antigen promoter. The inability to repair DNA damage typically induces apoptotic cell death, Therefore, we in investigated the effect of Tax-mediated suppression of DIVA repair on apoptosis in stable Tax-expressing cells. Constitutive Tax expression reduced cellular nucleotide excision repair activity compared with parental and control cells. Tax-expressing cells were also more sensitive to apoptosis induced by DNA damaging agents than control cells. Even though Tax-expressing cells displayed reduced DNA repair, they showed increased DNA replication following UV damage. These results suggest that Tax suppresses the cell's ability to repair DNA damage and stimulates DIVA replication even in the presence of damage. The inability to repair DNA damage is likely to stimulate apoptotic cell death in the majority of Tax-expressing cells while the ability to promote DNA replication may also allow the survival of a small population of cells. We propose that together these effects contribute to the monoclonal nature and low efficiency of HTLV-1 transformation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER; NCI NIH HHS [CA09197, CA-77371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJITA M, 1995, ONCOGENE, V11, P15; GESSAIN A, 1985, LANCET, V2, P407; Hall AP, 1998, J PATHOL, V186, P209; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KELLAND LR, 1993, CRIT REV ONCOL HEMAT, V15, P191, DOI 10.1016/1040-8428(93)90042-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitajima I, 1996, J BONE MINER RES, V11, P200; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; Los M, 1998, J IMMUNOL, V161, P3050; Lydy SL, 1998, VIROLOGY, V250, P60, DOI 10.1006/viro.1998.9378; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; POIESZ BJ, 1980, J VIROL, V64, P5682; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SANDBERG AA, 1991, CHROMOSOMES HUMAN CA; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2240	2248		10.1038/sj.onc.1203559	http://dx.doi.org/10.1038/sj.onc.1203559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822374				2022-12-25	WOS:000086974100009
